<SEC-DOCUMENT>0001126234-17-000107.txt : 20171103
<SEC-HEADER>0001126234-17-000107.hdr.sgml : 20171103
<ACCEPTANCE-DATETIME>20171103124705
ACCESSION NUMBER:		0001126234-17-000107
CONFORMED SUBMISSION TYPE:	10-Q
PUBLIC DOCUMENT COUNT:		53
CONFORMED PERIOD OF REPORT:	20170930
FILED AS OF DATE:		20171103
DATE AS OF CHANGE:		20171103

FILER:

	COMPANY DATA:	
		COMPANY CONFORMED NAME:			NEWLINK GENETICS CORP
		CENTRAL INDEX KEY:			0001126234
		STANDARD INDUSTRIAL CLASSIFICATION:	PHARMACEUTICAL PREPARATIONS [2834]
		IRS NUMBER:				421491350
		FISCAL YEAR END:			1231

	FILING VALUES:
		FORM TYPE:		10-Q
		SEC ACT:		1934 Act
		SEC FILE NUMBER:	001-35342
		FILM NUMBER:		171175515

	BUSINESS ADDRESS:	
		STREET 1:		2503 SOUTH LOOP DRIVE
		STREET 2:		SUITE 5100
		CITY:			AMES
		STATE:			IA
		ZIP:			50010
		BUSINESS PHONE:		515-296-5555

	MAIL ADDRESS:	
		STREET 1:		2503 SOUTH LOOP DRIVE
		STREET 2:		SUITE 5100
		CITY:			AMES
		STATE:			IA
		ZIP:			50010
</SEC-HEADER>
<DOCUMENT>
<TYPE>10-Q
<SEQUENCE>1
<FILENAME>nlnk-20170930x10q.htm
<DESCRIPTION>10-Q THIRD QUARTER 2017
<TEXT>
<!DOCTYPE html PUBLIC "-//W3C//DTD HTML 4.01 Transitional//EN" "http://www.w3.org/TR/html4/loose.dtd">
<html>
	<head>
		<!-- Document created using Wdesk 1 -->
		<!-- Copyright 2017 Workiva -->
		<title>Document</title>
	</head>
	<body style="font-family:Times New Roman;font-size:10pt;">
<div><a name="sBCDF241F2E09565AB99C57F787154AE9"></a></div><div><div style="line-height:120%;text-align:left;font-size:8pt;"><a style="font-family:inherit;font-size:8pt;" href="#sD088029191DD5EB99A130DC52B3A6E1B"><font style="font-family:inherit;font-size:8pt;">Table of Contents</font></a></div></div><div><br></div><div style="line-height:120%;text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#32;&#32;&#32;</font><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="1"></td></tr><tr><td style="width:100%;"></td></tr><tr><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:2px solid #000000;"><div style="overflow:hidden;height:5px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr></table></div></div><div style="line-height:120%;text-align:center;font-size:18pt;"><font style="font-family:inherit;font-size:18pt;font-weight:bold;">UNITED STATES</font></div><div style="line-height:120%;text-align:center;font-size:18pt;"><font style="font-family:inherit;font-size:18pt;font-weight:bold;">SECURITIES AND EXCHANGE COMMISSION</font></div><div style="line-height:120%;text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Washington, D.C. 20549</font></div><div style="line-height:120%;padding-bottom:4px;padding-top:4px;text-align:center;font-size:18pt;"><font style="font-family:inherit;font-size:18pt;font-weight:bold;">FORM&#160;10-Q</font></div><div style="line-height:120%;padding-bottom:4px;padding-top:4px;text-align:center;font-size:18pt;"><font style="font-family:inherit;font-size:18pt;"><br></font></div><div style="line-height:120%;text-align:center;padding-left:24px;font-size:12pt;"><font style="font-family:Wingdings;font-size:12pt;">&#253; </font><font style="font-family:inherit;font-size:12pt;font-weight:bold;">Quarterly report pursuant to Section&#160;13 or 15(d)&#160;of the Securities Exchange Act of 1934.</font></div><div style="line-height:120%;text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">For the quarterly period ended September 30, 2017.</font></div><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:12pt;padding-left:24px;"><font style="font-family:Wingdings;font-size:12pt;">o</font><font style="font-family:inherit;font-size:12pt;">&#160;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:center;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;font-weight:bold;">Transition report pursuant to Section&#160;13 or 15(d)&#160;of the Securities Exchange Act of 1934.</font></div></td></tr></table><div style="line-height:120%;text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">For the transition period from &#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;to &#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;.</font></div><div style="line-height:120%;text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Commission File Number</font></div><div style="line-height:120%;text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">001-35342</font></div><div style="line-height:120%;text-align:center;font-size:14pt;"><font style="font-family:inherit;font-size:14pt;"><br></font></div><div style="line-height:120%;text-align:center;font-size:18pt;"><font style="font-family:inherit;font-size:18pt;font-weight:bold;">NEWLINK GENETICS CORPORATION</font></div><div style="line-height:120%;text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(Exact name of Registrant as specified in Its Charter)</font></div><div style="line-height:120%;text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="3"></td></tr><tr><td style="width:48%;"></td><td style="width:4%;"></td><td style="width:48%;"></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Delaware</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:1pt;"><font style="font-family:inherit;font-size:1pt;font-weight:bold;">&#160;</font></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">42-1491350</font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(State or other jurisdiction of incorporation or organization)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:1pt;"><font style="font-family:inherit;font-size:1pt;">&#160;</font></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(I.R.S. Employer Identification No.)</font></div></td></tr></table></div></div><div style="line-height:120%;text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">2503 South Loop Drive</font></div><div style="line-height:120%;text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Ames,&#160;Iowa 50010</font></div><div style="line-height:120%;text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">(515) 296-5555</font></div><div style="line-height:120%;text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(Address, including zip code, and telephone number, including area code, of principal executive offices)</font></div><div style="line-height:120%;text-align:center;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;"><br></font></div><div style="line-height:120%;text-align:justify;text-indent:18px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Indicate by check mark whether the registrant (1) has filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that the registrant was required to file such reports), and (2) has been subject to such filing requirements for the past 90 days. &#160;&#160;Yes&#160;</font><font style="font-family:Wingdings;font-size:10pt;">&#253;</font><font style="font-family:inherit;font-size:10pt;">&#160;&#160;&#160;&#160;No&#160;</font><font style="font-family:Wingdings;font-size:10pt;">o</font></div><div style="line-height:120%;text-align:justify;text-indent:18px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:justify;text-indent:18px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Indicate by check mark whether the registrant has submitted electronically and posted on its corporate Web site, if any, every Interactive Data File required to be submitted and posted pursuant to Rule&#160;405 of Regulation S-T (&#167;232.405 of this chapter) during the preceding 12 months (or for such shorter period that the registrant was required to submit and post such files). Yes&#160;</font><font style="font-family:Wingdings;font-size:10pt;">&#253;</font><font style="font-family:inherit;font-size:10pt;">&#160;&#160;&#160;&#160;No&#160;</font><font style="font-family:Wingdings;font-size:10pt;">o</font></div><div style="line-height:120%;text-indent:24px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-indent:24px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer, a smaller reporting company or an emerging growth company. See the definitions of &#8220;large accelerated filer,&#8221; &#8220;accelerated filer,&#8221; &#8220;smaller reporting company&#8221; and "emerging growth company" in Rule&#160;12b-2 of the Exchange Act. (Check one):</font></div><div style="line-height:120%;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="3"></td></tr><tr><td style="width:48%;"></td><td style="width:4%;"></td><td style="width:48%;"></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Large accelerated filer&#160;</font><font style="font-family:Wingdings;font-size:10pt;">o  </font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:1pt;"><font style="font-family:inherit;font-size:1pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Accelerated filer</font><font style="font-family:Wingdings;font-size:10pt;">&#160;x</font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Non-accelerated filer&#160;</font><font style="font-family:Wingdings;font-size:10pt;">o</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:1pt;"><font style="font-family:inherit;font-size:1pt;">&#160;</font></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(Do not check if a smaller reporting company)</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:1pt;"><font style="font-family:inherit;font-size:1pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Smaller reporting company&#160;</font><font style="font-family:Wingdings;font-size:10pt;">o</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:6px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:6px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:6px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Emerging growth company&#160;</font><font style="font-family:Wingdings;font-size:10pt;">o</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td colspan="3" style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. </font><font style="font-family:Wingdings;font-size:10pt;">o</font></div></td></tr></table></div></div><div style="line-height:120%;text-indent:24px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-indent:24px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Indicate by check mark whether the registrant is a shell company (as defined in Rule&#160;12b-2 of the Exchange Act).&#160;&#160;Yes&#160;</font><font style="font-family:Wingdings;font-size:10pt;">o</font><font style="font-family:inherit;font-size:10pt;">&#160;&#160;&#160;&#160;No&#160;</font><font style="font-family:Wingdings;font-size:10pt;">&#253;</font></div><div style="line-height:120%;text-indent:24px;font-size:10pt;"><font style="font-family:Wingdings;font-size:10pt;"><br></font></div><div style="line-height:120%;text-indent:24px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">As of </font><font style="font-family:inherit;font-size:10pt;">October&#160;31, 2017</font><font style="font-family:inherit;font-size:10pt;">, there were </font><font style="font-family:inherit;font-size:10pt;">37,077,159</font><font style="font-family:inherit;font-size:10pt;">&#32;shares of the registrant&#8217;s Common Stock, par value $0.01&#160;per share, outstanding.</font></div><div style="line-height:120%;text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div><br></div><hr style="page-break-after:always"><div><a name="sD088029191DD5EB99A130DC52B3A6E1B"></a></div><div><div style="line-height:120%;text-align:left;font-size:8pt;"><a style="font-family:inherit;font-size:8pt;" href="#sD088029191DD5EB99A130DC52B3A6E1B"><font style="font-family:inherit;font-size:8pt;">Table of Contents</font></a></div></div><div><br></div><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;padding-bottom:12px;text-align:center;"><img src="newlinklogorgbwtaga01a01a09.jpg" alt="newlinklogorgbwtaga01a01a09.jpg" style="height:138px;width:277px;"></div><div style="line-height:120%;padding-bottom:12px;text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;padding-bottom:12px;text-align:center;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;font-weight:bold;">NewLink Genetics Corporation</font></div><div style="line-height:120%;padding-bottom:12px;text-align:center;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;font-weight:bold;">FORM 10-Q</font></div><div style="line-height:120%;padding-bottom:12px;text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Table of Contents</font></div><div style="line-height:120%;padding-bottom:20px;text-align:center;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="3"></td></tr><tr><td style="width:8%;"></td><td style="width:84%;"></td><td style="width:8%;"></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:middle;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">Page</font></div></td></tr><tr><td colspan="3" style="vertical-align:middle;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><a style="font-family:inherit;font-size:9pt;font-weight:bold;color:#000000;text-decoration:none;" href="#sE15B2ED01C125FAC8B1BF6D12C97240F"><font style="font-family:inherit;font-size:9pt;font-weight:bold;color:#000000;text-decoration:none;">PART&#160;I &#8211; FINANCIAL INFORMATION</font></a></div></td></tr><tr><td style="vertical-align:middle;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><a style="font-family:inherit;font-size:9pt;color:#000000;text-decoration:none;" href="#s4EE54C6AACCB519584D300C805FE625A"><font style="font-family:inherit;font-size:9pt;color:#000000;text-decoration:none;">ITEM 1.</font></a></div></td><td style="vertical-align:middle;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><a style="font-family:inherit;font-size:9pt;color:#000000;text-decoration:none;" href="#s4EE54C6AACCB519584D300C805FE625A"><font style="font-family:inherit;font-size:9pt;color:#000000;text-decoration:none;">Condensed Consolidated Financial Statements (unaudited)</font></a></div></td><td style="vertical-align:middle;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:9pt;"><a style="font-family:inherit;font-size:9pt;color:#000000;text-decoration:none;" href="#s4EE54C6AACCB519584D300C805FE625A">3</a></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:middle;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><a style="font-family:inherit;font-size:9pt;color:#000000;text-decoration:none;" href="#sA9F10412986B5BCD8CE0F769EB820ED9"><font style="font-family:inherit;font-size:9pt;color:#000000;text-decoration:none;">Condensed Consolidated Balance Sheets as of September 30, 2017 and December 31, 2016</font></a></div></td><td style="vertical-align:middle;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:9pt;"><a style="font-family:inherit;font-size:9pt;color:#000000;text-decoration:none;" href="#sA9F10412986B5BCD8CE0F769EB820ED9">3</a></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:middle;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><a style="font-family:inherit;font-size:9pt;color:#000000;text-decoration:none;" href="#sD5E06358B5BB58549FFC39F28A0905A5"><font style="font-family:inherit;font-size:9pt;color:#000000;text-decoration:none;">Condensed Consolidated Statements of Operations for the Three and Nine Months Ended September 30, 2017 and 2016</font></a></div></td><td style="vertical-align:middle;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:9pt;"><a style="font-family:inherit;font-size:9pt;color:#000000;text-decoration:none;" href="#sD5E06358B5BB58549FFC39F28A0905A5">4</a></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:middle;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><a style="font-family:inherit;font-size:9pt;color:#000000;text-decoration:none;" href="#sF213105590145DFAB5F20685F9618AD2"><font style="font-family:inherit;font-size:9pt;color:#000000;text-decoration:none;">Condensed Consolidated Statement of Stockholders&#8217; Equity for the Nine Months Ended September 30, 2017</font></a></div></td><td style="vertical-align:middle;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:9pt;"><a style="font-family:inherit;font-size:9pt;color:#000000;text-decoration:none;" href="#sF213105590145DFAB5F20685F9618AD2">5</a></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:middle;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><a style="font-family:inherit;font-size:9pt;color:#000000;text-decoration:none;" href="#s909FAAB5D80C5E959C51DA27FAB6C988"><font style="font-family:inherit;font-size:9pt;color:#000000;text-decoration:none;">Condensed Consolidated Statements of Cash Flows for the Nine Months Ended September 30, 2017 and 2016</font></a></div></td><td style="vertical-align:middle;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:9pt;"><a style="font-family:inherit;font-size:9pt;color:#000000;text-decoration:none;" href="#s909FAAB5D80C5E959C51DA27FAB6C988">6</a></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:middle;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><a style="font-family:inherit;font-size:9pt;color:#000000;text-decoration:none;" href="#s56BF158E146D5F2582F930BD3DC5F5A2"><font style="font-family:inherit;font-size:9pt;color:#000000;text-decoration:none;">Notes to Condensed Consolidated Financial Statements</font></a></div></td><td style="vertical-align:middle;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:9pt;"><a style="font-family:inherit;font-size:9pt;color:#000000;text-decoration:none;" href="#s56BF158E146D5F2582F930BD3DC5F5A2">7</a></div></td></tr><tr><td style="vertical-align:middle;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><a style="font-family:inherit;font-size:9pt;color:#000000;text-decoration:none;" href="#s0F1BEB42835457E4BE551138D7B7D00C"><font style="font-family:inherit;font-size:9pt;color:#000000;text-decoration:none;">ITEM 2.</font></a></div></td><td style="vertical-align:middle;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><a style="font-family:inherit;font-size:9pt;color:#000000;text-decoration:none;" href="#s0F1BEB42835457E4BE551138D7B7D00C"><font style="font-family:inherit;font-size:9pt;color:#000000;text-decoration:none;">Management's Discussion and Analysis of Financial Condition and Results of Operations</font></a></div></td><td style="vertical-align:middle;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:9pt;"><a style="font-family:inherit;font-size:9pt;color:#000000;text-decoration:none;" href="#s0F1BEB42835457E4BE551138D7B7D00C">16</a></div></td></tr><tr><td style="vertical-align:middle;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><a style="font-family:inherit;font-size:9pt;color:#000000;text-decoration:none;" href="#s621F22E950965CF3884FA22C5688A2E7"><font style="font-family:inherit;font-size:9pt;color:#000000;text-decoration:none;">ITEM 3</font></a><font style="font-family:inherit;font-size:9pt;">.</font></div></td><td style="vertical-align:middle;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><a style="font-family:inherit;font-size:9pt;color:#000000;text-decoration:none;" href="#s621F22E950965CF3884FA22C5688A2E7"><font style="font-family:inherit;font-size:9pt;color:#000000;text-decoration:none;">Quantitative and Qualitative Disclosures about Market Risk</font></a></div></td><td style="vertical-align:middle;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:9pt;"><a style="font-family:inherit;font-size:9pt;color:#000000;text-decoration:none;" href="#s621F22E950965CF3884FA22C5688A2E7">23</a></div></td></tr><tr><td style="vertical-align:middle;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><a style="font-family:inherit;font-size:9pt;color:#000000;text-decoration:none;" href="#s77EBCE2628965F1C9C60403C5C78DDDD"><font style="font-family:inherit;font-size:9pt;color:#000000;text-decoration:none;">ITEM 4.</font></a></div></td><td style="vertical-align:middle;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><a style="font-family:inherit;font-size:9pt;color:#000000;text-decoration:none;" href="#s77EBCE2628965F1C9C60403C5C78DDDD"><font style="font-family:inherit;font-size:9pt;color:#000000;text-decoration:none;">Controls and Procedures</font></a></div></td><td style="vertical-align:middle;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:9pt;"><a style="font-family:inherit;font-size:9pt;color:#000000;text-decoration:none;" href="#s77EBCE2628965F1C9C60403C5C78DDDD">23</a></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:21px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:21px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:21px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td colspan="2" style="vertical-align:middle;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><a style="font-family:inherit;font-size:9pt;font-weight:bold;color:#000000;text-decoration:none;" href="#s43669D29A3FB5270A7EBABDFD65CF907"><font style="font-family:inherit;font-size:9pt;font-weight:bold;color:#000000;text-decoration:none;">PART II - OTHER INFORMATION</font></a></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:middle;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><a style="font-family:inherit;font-size:9pt;color:#000000;text-decoration:none;" href="#s45AACAB2722D5BB9A90DF79CA7CA0B61"><font style="font-family:inherit;font-size:9pt;color:#000000;text-decoration:none;">ITEM 1A.</font></a></div></td><td style="vertical-align:middle;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="font-size:9pt;"><a style="font-family:inherit;font-size:9pt;color:#000000;text-decoration:none;" href="#s45AACAB2722D5BB9A90DF79CA7CA0B61"><font style="font-family:inherit;font-size:9pt;color:#000000;text-decoration:none;">Risk Factors</font></a></div></td><td style="vertical-align:middle;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:9pt;"><a style="font-family:inherit;font-size:9pt;color:#000000;text-decoration:none;" href="#s45AACAB2722D5BB9A90DF79CA7CA0B61">24</a></div></td></tr><tr><td style="vertical-align:middle;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><a style="font-family:inherit;font-size:9pt;color:#000000;text-decoration:none;" href="#s9DA6F2ADA0075A91ABCAAC4FE1CE5D9D"><font style="font-family:inherit;font-size:9pt;color:#000000;text-decoration:none;">ITEM 1.</font></a></div></td><td style="vertical-align:middle;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="font-size:9pt;"><a style="font-family:inherit;font-size:9pt;color:#000000;text-decoration:none;" href="#s9DA6F2ADA0075A91ABCAAC4FE1CE5D9D"><font style="font-family:inherit;font-size:9pt;color:#000000;text-decoration:none;">Legal Proceedings</font></a></div></td><td style="vertical-align:middle;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:9pt;"><a style="font-family:inherit;font-size:9pt;color:#000000;text-decoration:none;" href="#s9DA6F2ADA0075A91ABCAAC4FE1CE5D9D">50</a></div></td></tr><tr><td style="vertical-align:middle;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><a style="font-family:inherit;font-size:9pt;color:#000000;text-decoration:none;" href="#s34A27F43F6F15C849871E7BC98D02B30"><font style="font-family:inherit;font-size:9pt;color:#000000;text-decoration:none;">ITEM 2.</font></a></div></td><td style="vertical-align:middle;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="font-size:9pt;"><a style="font-family:inherit;font-size:9pt;color:#000000;text-decoration:none;" href="#s34A27F43F6F15C849871E7BC98D02B30"><font style="font-family:inherit;font-size:9pt;color:#000000;text-decoration:none;">Unregistered Sales of Equity Securities and Use of Proceeds</font></a></div></td><td style="vertical-align:middle;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:9pt;"><a style="font-family:inherit;font-size:9pt;color:#000000;text-decoration:none;" href="#s34A27F43F6F15C849871E7BC98D02B30">50</a></div></td></tr><tr><td style="vertical-align:middle;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><a style="font-family:inherit;font-size:9pt;color:#000000;text-decoration:none;" href="#s430D12B702C0521BB1AEEBD0FC27339E"><font style="font-family:inherit;font-size:9pt;color:#000000;text-decoration:none;">ITEM 3.</font></a></div></td><td style="vertical-align:middle;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="font-size:9pt;"><a style="font-family:inherit;font-size:9pt;color:#000000;text-decoration:none;" href="#s78F69C13DEE25A33AA333DCCCD2E8709"><font style="font-family:inherit;font-size:9pt;color:#000000;text-decoration:none;">Defaults Upon Senior Securities</font></a></div></td><td style="vertical-align:middle;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:9pt;"><a style="font-family:inherit;font-size:9pt;color:#000000;text-decoration:none;" href="#s78F69C13DEE25A33AA333DCCCD2E8709">50</a></div></td></tr><tr><td style="vertical-align:middle;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><a style="font-family:inherit;font-size:9pt;color:#000000;text-decoration:none;" href="#sAAAA9EB571685726A26F377BBCED6599"><font style="font-family:inherit;font-size:9pt;color:#000000;text-decoration:none;">ITEM 4.</font></a></div></td><td style="vertical-align:middle;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="font-size:9pt;"><a style="font-family:inherit;font-size:9pt;color:#000000;text-decoration:none;" href="#sAAAA9EB571685726A26F377BBCED6599"><font style="font-family:inherit;font-size:9pt;color:#000000;text-decoration:none;">Mine Safety Disclosures</font></a></div></td><td style="vertical-align:middle;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:9pt;"><a style="font-family:inherit;font-size:9pt;color:#000000;text-decoration:none;" href="#sAAAA9EB571685726A26F377BBCED6599">51</a></div></td></tr><tr><td style="vertical-align:middle;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><a style="font-family:inherit;font-size:9pt;color:#000000;text-decoration:none;" href="#sE7E34FB816E656DBB3A9CDB32CA46FBB"><font style="font-family:inherit;font-size:9pt;color:#000000;text-decoration:none;">ITEM 5</font></a><font style="font-family:inherit;font-size:9pt;">.</font></div></td><td style="vertical-align:middle;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="font-size:9pt;"><a style="font-family:inherit;font-size:9pt;color:#000000;text-decoration:none;" href="#sE7E34FB816E656DBB3A9CDB32CA46FBB"><font style="font-family:inherit;font-size:9pt;color:#000000;text-decoration:none;">Other Information</font></a></div></td><td style="vertical-align:middle;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:9pt;"><a style="font-family:inherit;font-size:9pt;color:#000000;text-decoration:none;" href="#sE7E34FB816E656DBB3A9CDB32CA46FBB">51</a></div></td></tr><tr><td style="vertical-align:middle;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><a style="font-family:inherit;font-size:9pt;color:#000000;text-decoration:none;" href="#s2F7E6DC7B29C53758635C14BC677D37A"><font style="font-family:inherit;font-size:9pt;color:#000000;text-decoration:none;">ITEM 6.</font></a></div></td><td style="vertical-align:middle;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="font-size:9pt;"><a style="font-family:inherit;font-size:9pt;color:#000000;text-decoration:none;" href="#s2F7E6DC7B29C53758635C14BC677D37A"><font style="font-family:inherit;font-size:9pt;color:#000000;text-decoration:none;">Exhibits</font></a></div></td><td style="vertical-align:middle;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:9pt;"><a style="font-family:inherit;font-size:9pt;color:#000000;text-decoration:none;" href="#s2F7E6DC7B29C53758635C14BC677D37A">51</a></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:21px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:21px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:21px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td colspan="2" style="vertical-align:middle;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="font-size:9pt;"><a style="font-family:inherit;font-size:9pt;color:#000000;text-decoration:none;" href="#s74D629AC887B5B61B575859B5EFE4A9D"><font style="font-family:inherit;font-size:9pt;color:#000000;text-decoration:none;">SIGNATURES</font></a></div></td><td style="vertical-align:middle;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:9pt;"><a style="font-family:inherit;font-size:9pt;color:#000000;text-decoration:none;" href="#s74D629AC887B5B61B575859B5EFE4A9D">52</a></div></td></tr><tr><td colspan="2" style="vertical-align:middle;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="font-size:9pt;"><a style="font-family:inherit;font-size:9pt;color:#000000;text-decoration:none;" href="#s1B1852E2B0445560A16AA92D64688214"><font style="font-family:inherit;font-size:9pt;color:#000000;text-decoration:none;">INDEX OF EXHIBITS</font></a></div></td><td style="vertical-align:middle;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:9pt;"><a style="font-family:inherit;font-size:9pt;color:#000000;text-decoration:none;" href="#s1B1852E2B0445560A16AA92D64688214">53</a></div></td></tr></table></div></div><div style="line-height:120%;padding-bottom:20px;text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div><br></div><div style="text-align:center;"><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">2</font></div></div><hr style="page-break-after:always"><div><a name="sE15B2ED01C125FAC8B1BF6D12C97240F"></a></div><div><div style="line-height:120%;text-align:left;font-size:8pt;"><a style="font-family:inherit;font-size:8pt;" href="#sD088029191DD5EB99A130DC52B3A6E1B"><font style="font-family:inherit;font-size:8pt;">Table of Contents</font></a></div></div><div><br></div><div style="line-height:120%;text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">PART&#160;I</font></div><div><a name="s4EE54C6AACCB519584D300C805FE625A"></a></div><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div><a name="sA9F10412986B5BCD8CE0F769EB820ED9"></a></div><div style="line-height:120%;text-align:center;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:93.67816091954023%;border-collapse:collapse;text-align:left;"><tr><td colspan="9" style="padding-top:4px;padding-bottom:4px;"><div style="line-height:120%;text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">NewLink Genetics Corporation</font></div><div style="line-height:120%;text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">and Subsidiaries&#160;</font></div><div style="line-height:120%;text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Condensed Consolidated Balance Sheets</font></div><div style="line-height:120%;text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">(unaudited)</font></div><div style="line-height:120%;text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">(In thousands, except share data)</font></div></td></tr><tr><td style="width:71%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:11%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:12%;"></td><td style="width:1%;"></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:center;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;font-weight:bold;">September&#160;30,</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;font-weight:bold;">December&#160;31,</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-top:2px;padding-bottom:2px;"><div style="text-align:center;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;font-weight:bold;">2017</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;font-weight:bold;">2016</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Assets</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Current assets:</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Cash and cash equivalents</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:12px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">120,702</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">131,490</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Prepaid expenses and other current assets</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:12px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">2,701</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">5,921</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Income tax receivable</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:12px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">114</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">5,975</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Other receivables</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">10,670</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">24,526</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Total current assets</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">134,187</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">167,912</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Property and equipment, net</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:44px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">5,527</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:44px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">6,835</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Total assets</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">139,714</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">174,747</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Liabilities and Stockholders' Equity</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:3px double #000000;"><div style="text-align:right;font-size:1pt;"><font style="font-family:inherit;font-size:1pt;font-weight:bold;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:3px double #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:3px double #000000;"><div style="text-align:right;font-size:1pt;"><font style="font-family:inherit;font-size:1pt;font-weight:bold;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:3px double #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Current liabilities:</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:1pt;"><font style="font-family:inherit;font-size:1pt;">&#160;</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:1pt;"><font style="font-family:inherit;font-size:1pt;">&#160;</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Accounts payable</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">11,860</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">22,883</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Accrued expenses</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:12px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">13,832</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">14,309</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Current portion of unearned revenue</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:12px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">112</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">391</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Current portion of deferred rent</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:12px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">93</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">90</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Current portion of notes payable and obligations under capital leases</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">194</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">232</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Total current liabilities</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">26,091</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">37,905</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Long-term liabilities:</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:1pt;"><font style="font-family:inherit;font-size:1pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:1pt;"><font style="font-family:inherit;font-size:1pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Royalty obligation payable to Iowa Economic Development Authority</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">6,000</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">6,000</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Notes payable and obligations under capital leases</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">138</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">285</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Deferred rent</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">1,021</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">1,091</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Total long-term liabilities</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">7,159</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">7,376</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Total liabilities</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">33,250</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">45,281</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Stockholders' equity:</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Blank check preferred stock, $0.01 par value: Authorized shares&#160;&#8212; 5,000,000 at September 30, 2017 and December 31, 2016; issued and outstanding shares&#160;&#8212; 0 at September 30, 2017 and December 31, 2016</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Common stock, $0.01 par value: Authorized shares&#160;&#8212; 75,000,000 at September 30, 2017 and December 31, 2016;  issued 31,375,528 and 29,193,718 at September 30, 2017 and December 31, 2016, respectively, and outstanding 31,319,751 and 29,163,673 at September 30, 2017 and December 31, 2016, respectively</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">314</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">292</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Additional paid-in capital</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">331,036</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">295,535</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Treasury stock, at cost: 55,777 and 30,045 shares at September 30, 2017 and December 31, 2016, respectively</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(1,113</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(853</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Accumulated deficit</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(223,773</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(165,508</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Total stockholders' equity</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">106,464</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">129,466</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Total liabilities and stockholders' equity</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">139,714</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">174,747</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td colspan="9" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">See accompanying notes to condensed consolidated financial statements.</font></div></td></tr></table></div></div><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div><br></div><div style="text-align:center;"><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">3</font></div></div><hr style="page-break-after:always"><div><a name="sD5E06358B5BB58549FFC39F28A0905A5"></a></div><div><div style="line-height:120%;text-align:left;font-size:8pt;"><a style="font-family:inherit;font-size:8pt;" href="#sD088029191DD5EB99A130DC52B3A6E1B"><font style="font-family:inherit;font-size:8pt;">Table of Contents</font></a></div></div><div><br></div><div style="line-height:120%;text-align:center;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:85.15625%;border-collapse:collapse;text-align:left;"><tr><td colspan="18" style="padding-top:4px;padding-bottom:4px;"><div style="line-height:120%;text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">NewLink Genetics Corporation</font></div><div style="line-height:120%;text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">and Subsidiaries</font></div><div style="line-height:120%;text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Condensed Consolidated Statements of Operations</font></div><div style="line-height:120%;text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">(unaudited)</font></div><div style="line-height:120%;text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">(In thousands, except share and per share data)</font></div></td></tr><tr><td style="width:36%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:12%;"></td><td style="width:1%;"></td><td style="width:2%;"></td><td style="width:1%;"></td><td style="width:12%;"></td><td style="width:1%;"></td><td style="width:2%;"></td><td style="width:1%;"></td><td style="width:12%;"></td><td style="width:1%;"></td><td style="width:2%;"></td><td style="width:1%;"></td><td style="width:11%;"></td><td style="width:1%;"></td><td style="width:2%;"></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:17px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:17px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:17px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:17px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:17px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:17px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:17px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:17px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:17px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:17px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:17px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:17px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:17px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:17px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:17px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:17px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:17px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:17px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:17px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:17px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="7" rowspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:center;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;font-weight:bold;">Three Months Ended September 30, </font></div></td><td rowspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="7" rowspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:center;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;font-weight:bold;">Nine Months Ended September 30, </font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:17px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:17px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:17px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;font-weight:bold;">2017</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;font-weight:bold;">2016</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;font-weight:bold;">2017</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;font-weight:bold;">2016</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Grant revenue</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">5,379</font></div></td><td style="vertical-align:bottom;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">14,457</font></div></td><td style="vertical-align:bottom;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">18,279</font></div></td><td style="vertical-align:bottom;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">20,057</font></div></td><td style="vertical-align:bottom;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Licensing and collaboration revenue</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">103</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">888</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">334</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">3,008</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:28px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Total operating revenues</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">5,482</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">15,345</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">18,613</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">23,065</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Operating expenses:</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:1pt;"><font style="font-family:inherit;font-size:1pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:1pt;"><font style="font-family:inherit;font-size:1pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:1pt;"><font style="font-family:inherit;font-size:1pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Research and development</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">18,480</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">24,463</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">52,405</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">73,810</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">General and administrative</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">7,907</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">7,749</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">25,038</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">26,043</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:28px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Total operating expenses</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">26,387</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">32,212</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">77,443</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">99,853</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Loss from operations</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(20,905</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(16,867</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(58,830</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(76,788</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Other income and expense:</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:1pt;"><font style="font-family:inherit;font-size:1pt;">&#160;</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:1pt;"><font style="font-family:inherit;font-size:1pt;">&#160;</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:1pt;"><font style="font-family:inherit;font-size:1pt;">&#160;</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Miscellaneous income (expense)</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">12</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(44</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(101</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(44</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Interest income</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">151</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">68</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">353</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">180</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Interest expense</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(3</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(5</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(116</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(18</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Other income, net</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">160</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">19</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">136</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">118</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Net loss before taxes</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(20,745</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(16,848</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(58,694</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(76,670</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Income tax benefit</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">119</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">1,308</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">429</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">5,021</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Net loss</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(20,626</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(15,540</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(58,265</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(71,649</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:20px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:20px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:20px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:20px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:20px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:20px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:20px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:20px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:20px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:20px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Basic and diluted loss per share</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(0.69</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(0.54</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(1.98</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(2.48</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:20px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:20px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:20px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:20px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:20px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:20px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:3px double #000000;"><div style="overflow:hidden;height:20px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:20px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:20px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:20px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Basic and diluted average shares outstanding</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">29,939,823</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">28,983,561</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">29,462,226</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">28,911,042</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td colspan="18" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">See accompanying notes to condensed consolidated financial statements.</font></div></td></tr></table></div></div><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div><br></div><div style="text-align:center;"><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">4</font></div></div><hr style="page-break-after:always"><div><a name="sF213105590145DFAB5F20685F9618AD2"></a></div><div><div style="line-height:120%;text-align:left;font-size:8pt;"><a style="font-family:inherit;font-size:8pt;" href="#sD088029191DD5EB99A130DC52B3A6E1B"><font style="font-family:inherit;font-size:8pt;">Table of Contents</font></a></div></div><div><br></div><div style="line-height:120%;padding-top:4px;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:center;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:89.6484375%;border-collapse:collapse;text-align:left;"><tr><td colspan="24" style="padding-top:4px;padding-bottom:4px;"><div style="line-height:120%;text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">NewLink Genetics Corporation</font></div><div style="line-height:120%;text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">and Subsidiaries</font></div><div style="line-height:120%;text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Condensed&#160;Consolidated Statement of Stockholders' Equity</font></div><div style="line-height:120%;text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">(unaudited)</font></div><div style="line-height:120%;text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">(In thousands, except share data)</font></div></td></tr><tr><td style="width:41%;"></td><td style="width:1%;"></td><td style="width:9%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:6%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:6%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:5%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:8%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:8%;"></td><td style="width:1%;"></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:16px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:16px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:16px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:16px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:16px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:16px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:16px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:16px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:16px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td rowspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:16px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:16px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:16px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:16px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:16px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:16px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:16px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:16px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:16px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:16px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:16px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:16px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:16px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:16px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:16px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:16px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;vertical-align:middle;font-size:7pt;"><font style="font-family:inherit;font-size:7pt;font-weight:bold;text-align:center;vertical-align:middle;">Number of</font></div><div style="text-align:center;vertical-align:middle;font-size:7pt;"><font style="font-family:inherit;font-size:7pt;font-weight:bold;text-align:center;vertical-align:middle;">Common</font></div><div style="text-align:center;vertical-align:middle;font-size:7pt;"><font style="font-family:inherit;font-size:7pt;font-weight:bold;text-align:center;vertical-align:middle;">Shares</font></div><div style="text-align:center;vertical-align:middle;font-size:7pt;"><font style="font-family:inherit;font-size:7pt;font-weight:bold;text-align:center;vertical-align:middle;">Outstanding</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;vertical-align:middle;font-size:7pt;"><font style="font-family:inherit;font-size:7pt;font-weight:bold;text-align:center;vertical-align:middle;">Common</font></div><div style="text-align:center;vertical-align:middle;font-size:7pt;"><font style="font-family:inherit;font-size:7pt;font-weight:bold;text-align:center;vertical-align:middle;">Stock</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;vertical-align:middle;font-size:7pt;"><font style="font-family:inherit;font-size:7pt;font-weight:bold;text-align:center;vertical-align:middle;">Additional</font></div><div style="text-align:center;vertical-align:middle;font-size:7pt;"><font style="font-family:inherit;font-size:7pt;font-weight:bold;text-align:center;vertical-align:middle;">Paid-in</font></div><div style="text-align:center;vertical-align:middle;font-size:7pt;"><font style="font-family:inherit;font-size:7pt;font-weight:bold;text-align:center;vertical-align:middle;">Capital</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:7pt;"><font style="font-family:inherit;font-size:7pt;font-weight:bold;">Treasury Stock</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:7pt;"><font style="font-family:inherit;font-size:7pt;font-weight:bold;">Accumulated Deficit</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:7pt;"><font style="font-family:inherit;font-size:7pt;font-weight:bold;">Total</font></div><div style="text-align:center;font-size:7pt;"><font style="font-family:inherit;font-size:7pt;font-weight:bold;">Stockholders' Equity</font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">Balance at December 31, 2016</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">29,163,673</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">292</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">295,535</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">(853</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">)</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">(165,508</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">)</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">129,466</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">Share-based compensation</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">&#8212;</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">&#8212;</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">14,938</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">&#8212;</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">&#8212;</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">14,938</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">Exercise of stock options and restricted stock vested</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">189,155</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">2</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">923</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">&#8212;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">&#8212;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">925</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">Sales of shares under stock purchase plan</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">51,999</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">1</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">325</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">&#8212;</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">&#8212;</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">326</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">Repurchase of common stock</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">(25,732</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">)</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">&#8212;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">&#8212;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">(260</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">)</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">&#8212;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">(260</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">)</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">Issuance of common stock under the ATM Offering (net of offering costs of $561)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">1,940,656</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">19</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">19,315</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">19,334</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">Net loss</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">&#8212;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">&#8212;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">&#8212;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">&#8212;</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">(58,265</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">)</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">(58,265</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">)</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">Balance at September 30, 2017</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">31,319,751</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">314</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">331,036</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">(1,113</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">(223,773</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">106,464</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr></table></div></div><div style="line-height:120%;text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;padding-bottom:10px;padding-top:10px;text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">See accompanying notes to condensed consolidated financial statements.</font></div><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div><br></div><div style="text-align:center;"><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">5</font></div></div><hr style="page-break-after:always"><div><a name="s909FAAB5D80C5E959C51DA27FAB6C988"></a></div><div><div style="line-height:120%;text-align:left;font-size:8pt;"><a style="font-family:inherit;font-size:8pt;" href="#sD088029191DD5EB99A130DC52B3A6E1B"><font style="font-family:inherit;font-size:8pt;">Table of Contents</font></a></div></div><div><br></div><div style="line-height:120%;text-align:center;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:92.20272904483431%;border-collapse:collapse;text-align:left;"><tr><td colspan="9" style="padding-top:4px;padding-bottom:4px;"><div style="line-height:120%;text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">NewLink Genetics Corporation</font></div><div style="line-height:120%;text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">and Subsidiaries </font></div><div style="line-height:120%;text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Condensed Consolidated Statements of Cash Flows</font></div><div style="line-height:120%;text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">(unaudited)</font></div><div style="line-height:120%;text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">(In thousands)</font></div></td></tr><tr><td style="width:66%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:14%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:14%;"></td><td style="width:1%;"></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="7" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:center;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;font-weight:bold;">Nine Months Ended September 30, </font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;font-weight:bold;">2017</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;font-weight:bold;">2016</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;font-weight:bold;">Cash Flows From Operating Activities</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">Net loss</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">(58,265</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">)</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">(71,649</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">)</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;font-weight:bold;">Adjustments to reconcile net loss to net cash used in operating activities:</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">Share-based compensation</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">14,938</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">13,119</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">Depreciation and amortization</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">1,064</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">1,536</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">Forgiveness of debt</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">&#8212;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">(397</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">)</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">Tax shortfall associated with employee stock plans</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:middle;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">&#8212;</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:middle;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">(640</font></div></td><td style="vertical-align:middle;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">)</font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">Impairment of fixed assets</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">&#8212;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">3,976</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">Loss on sale of fixed assets</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">102</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">&#8212;</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">Changes in operating assets and liabilities:</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">Prepaid expenses and other current assets</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">3,220</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">(5,734</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">)</font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">Other receivables</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">13,856</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">(9,607</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">)</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">Accounts payable and accrued expenses</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">(11,500</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">27,204</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">Income taxes receivable</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">5,861</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">(6,056</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">)</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">Unearned revenue</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">(279</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">(606</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">)</font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">Deferred rent</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">(67</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">)</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">(79</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">)</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:28px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">Net cash used in operating activities</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">(31,070</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">(48,933</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">)</font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;font-weight:bold;">Cash Flows From Investing Activities</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">Maturity of certificates of deposit</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">&#8212;</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">2,180</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">Purchase of equipment</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">(43</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">)</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">(2,069</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">)</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">Proceeds on sale of equipment</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">185</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">&#8212;</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:28px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">Net cash provided by investing activities</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">142</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">111</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;font-weight:bold;">Cash Flows From Financing Activities</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">Issuance of common stock, net of offering costs</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:12px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">20,585</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">1,686</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">Repurchase of common stock</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:12px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">(260</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:12px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">(13</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">)</font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">Payments under capital lease obligations and principal payments on notes payable</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">(185</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">)</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">(195</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">)</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:28px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">Net cash provided by financing activities</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">20,140</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">1,478</font></div></td><td style="vertical-align:bottom;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:28px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">Net decrease in cash and cash equivalents</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">(10,788</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">)</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">(47,344</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">)</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">Cash and cash equivalents at beginning of period</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">131,490</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">195,620</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">Cash and cash equivalents at end of period</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">120,702</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">148,276</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">Supplemental disclosure of cash flows information:</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">Cash paid for interest</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">11</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">18</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">Cash (refunds received) paid for taxes, net</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">(6,261</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">1,022</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">Noncash financing and investing activities:</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">Equipment acquired by capital lease</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">&#8212;</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">231</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">Forgiveness of debt</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">&#8212;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">397</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr></table></div></div><div style="line-height:120%;padding-bottom:10px;padding-top:10px;text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">See accompanying notes to condensed consolidated financial statements.</font></div><div><br></div><div style="text-align:center;"><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">6</font></div></div><hr style="page-break-after:always"><div><a name="s56BF158E146D5F2582F930BD3DC5F5A2"></a></div><div><div style="line-height:120%;font-size:8pt;"><a style="font-family:inherit;font-size:8pt;" href="#sD088029191DD5EB99A130DC52B3A6E1B"><font style="font-family:inherit;font-size:8pt;">Table of Contents</font></a></div><div style="line-height:120%;text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">NewLink Genetics Corporation and Subsidiaries</font></div><div style="line-height:120%;text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Notes to Condensed Consolidated Financial Statements</font></div><div style="line-height:120%;text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">(unaudited)</font></div><div style="line-height:120%;text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></div><div><br></div><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div><a name="s18FBECC59D7B50A7BF4B0891DD64BA83"></a></div><div style="line-height:120%;padding-bottom:12px;padding-top:12px;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">1.&#160;&#160;&#160;&#160;&#160;D</font><font style="font-family:inherit;font-size:10pt;background-color:#ffffff;font-weight:bold;">escription of Business</font></div><div style="line-height:120%;padding-bottom:12px;padding-top:12px;text-align:justify;text-indent:32px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">On June&#160;4, 1999, NewLink Genetics Corporation (NewLink) was incorporated as a Delaware corporation. NewLink was formed for the purpose of developing treatments for patients with cancer and other diseases. NewLink initiated operations in April 2000. </font></div><div style="line-height:120%;padding-bottom:12px;padding-top:12px;text-align:justify;text-indent:32px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">NewLink and its subsidiaries (the Company) are devoting substantially all of their efforts toward research and development. The Company has never earned revenue from commercial sales of its drugs. The Company incurred a net loss of </font><font style="font-family:inherit;font-size:10pt;">$20.6 million</font><font style="font-family:inherit;font-size:10pt;">&#32;and </font><font style="font-family:inherit;font-size:10pt;">$58.3 million</font><font style="font-family:inherit;font-size:10pt;">&#32;for the </font><font style="font-family:inherit;font-size:10pt;">three and nine months ended</font><font style="font-family:inherit;font-size:10pt;">&#32;</font><font style="font-family:inherit;font-size:10pt;">September&#160;30, 2017</font><font style="font-family:inherit;font-size:10pt;">. </font></div><div style="line-height:120%;padding-bottom:12px;padding-top:12px;text-align:justify;text-indent:32px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">In July 2017, the Company&#160;undertook an organizational realignment to refocus its clinical development efforts and align the Company's resources to focus on the Company's highest value opportunities. The Company's restructuring activities included a reduction of its workforce by approximately </font><font style="font-family:inherit;font-size:10pt;">50%</font><font style="font-family:inherit;font-size:10pt;">, which consisted primarily of clinical and research and development staff, as well as stopping additional research on the Zika virus. Refer to Note 9 for more information.</font></div><div style="line-height:120%;padding-bottom:12px;padding-top:12px;text-align:justify;text-indent:32px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">The accompanying condensed consolidated financial statements as of </font><font style="font-family:inherit;font-size:10pt;">September&#160;30, 2017</font><font style="font-family:inherit;font-size:10pt;">&#32;and for the </font><font style="font-family:inherit;font-size:10pt;">three and nine months ended</font><font style="font-family:inherit;font-size:10pt;">&#32;have been prepared assuming the Company will continue as a going concern. The Company successfully raised net proceeds of </font><font style="font-family:inherit;font-size:10pt;">$37.6 million</font><font style="font-family:inherit;font-size:10pt;">&#32;from its IPO, completed a follow-on offering of its common stock raising net proceeds of </font><font style="font-family:inherit;font-size:10pt;">$49.0 million</font><font style="font-family:inherit;font-size:10pt;">, and raised an additional </font><font style="font-family:inherit;font-size:10pt;">$58.7 million</font><font style="font-family:inherit;font-size:10pt;">&#32;in net proceeds from an at the market (ATM) offering completed in 2015.</font></div><div style="line-height:120%;padding-bottom:12px;padding-top:12px;text-align:justify;text-indent:32px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">On November 29, 2016, the Company entered into a Sales Agreement with Cantor Fitzgerald &amp; Co. (Cantor) under which the Company may sell up to </font><font style="font-family:inherit;font-size:10pt;">$40.0 million</font><font style="font-family:inherit;font-size:10pt;">&#32;of its common stock in one or more placements at prevailing market prices in an ATM offering. The Company launched this ATM offering in June 2017. During the </font><font style="font-family:inherit;font-size:10pt;">three months ended</font><font style="font-family:inherit;font-size:10pt;">&#32;</font><font style="font-family:inherit;font-size:10pt;">September&#160;30, 2017</font><font style="font-family:inherit;font-size:10pt;">, </font><font style="font-family:inherit;font-size:10pt;">1,940,656</font><font style="font-family:inherit;font-size:10pt;">&#32;shares of the Company's common stock were sold under this ATM, with aggregate net proceeds of </font><font style="font-family:inherit;font-size:10pt;">$19.3 million</font><font style="font-family:inherit;font-size:10pt;">&#32;after commissions of </font><font style="font-family:inherit;font-size:10pt;">$398,000</font><font style="font-family:inherit;font-size:10pt;">&#32;paid to Cantor as the placement agent, and other costs of </font><font style="font-family:inherit;font-size:10pt;">$163,000</font><font style="font-family:inherit;font-size:10pt;">&#32;. </font></div><div style="line-height:120%;padding-bottom:12px;padding-top:12px;text-align:justify;text-indent:32px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Subsequent to </font><font style="font-family:inherit;font-size:10pt;">September&#160;30, 2017</font><font style="font-family:inherit;font-size:10pt;">, the Company sold </font><font style="font-family:inherit;font-size:10pt;">5,750,000</font><font style="font-family:inherit;font-size:10pt;">&#32;of its shares of common stock in a public offering for aggregate net proceeds of </font><font style="font-family:inherit;font-size:10pt;">$55.2 million</font><font style="font-family:inherit;font-size:10pt;">&#32;after underwriters' discounts, commissions and other expenses of </font><font style="font-family:inherit;font-size:10pt;">$3.7 million</font><font style="font-family:inherit;font-size:10pt;">.</font></div><div style="line-height:120%;padding-bottom:12px;padding-top:12px;text-align:justify;text-indent:32px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">In connection with </font><font style="font-family:inherit;font-size:10pt;">two</font><font style="font-family:inherit;font-size:10pt;">&#32;license and collaboration agreements the Company entered into during 2014, the Company received a nonrefundable upfront cash payment of </font><font style="font-family:inherit;font-size:10pt;">$150.0 million</font><font style="font-family:inherit;font-size:10pt;">&#32;from Genentech Inc., a member of the Roche Group, or Genentech, in 2014, and a nonrefundable upfront cash payment of </font><font style="font-family:inherit;font-size:10pt;">$30.0 million</font><font style="font-family:inherit;font-size:10pt;">&#32;from Merck, Sharpe and Dohme Corp., or Merck, in 2014, as well as a milestone payment of </font><font style="font-family:inherit;font-size:10pt;">$20.0 million</font><font style="font-family:inherit;font-size:10pt;">&#32;from Merck in February 2015. </font></div><div style="line-height:120%;padding-bottom:12px;padding-top:12px;text-align:justify;text-indent:32px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">The Company's cash and cash equivalents after these agreements and the offerings are expected to be adequate to satisfy the Company's liquidity requirements into the second quarter of 2020. If available liquidity becomes insufficient to meet the Company&#8217;s operating obligations as they come due, the Company's plans include pursuing alternative funding arrangements and/or reducing expenditures as necessary to meet the Company&#8217;s cash requirements. However, there is no assurance that, if required, the Company will be able to raise additional capital or reduce discretionary spending to provide the required liquidity. Failure by the Company to successfully execute its plans or otherwise address its liquidity needs may have a material adverse effect on its business and financial position, and may materially affect the Company&#8217;s ability to continue as a going concern.</font></div><div><a name="sD01907C9E8605F6696B7C684EC914ED2"></a></div><table cellpadding="0" cellspacing="0" style="padding-top:12px;padding-bottom:12px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:30px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:0px;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">2.</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Basis of Presentation</font></div></td></tr></table><div style="line-height:120%;padding-bottom:12px;padding-top:12px;text-align:justify;text-indent:29px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">The accompanying unaudited condensed consolidated financial statements have been prepared and presented by the Company in accordance with U.S. generally accepted accounting principles (U.S.&#160;GAAP) and the rules&#160;and regulations of the U.S. Securities and Exchange Commission (the SEC), and, in management&#8217;s opinion, reflect all adjustments necessary to present fairly the Company&#8217;s interim condensed financial information.</font></div><div style="line-height:120%;padding-bottom:12px;padding-top:12px;text-align:justify;text-indent:29px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Certain information and footnote disclosures normally included in the Company&#8217;s annual financial statements prepared in accordance with U.S. GAAP have been condensed or omitted. The accompanying unaudited condensed consolidated financial statements should be read in conjunction with the audited consolidated financial statements for the year ended </font><font style="font-family:inherit;font-size:10pt;">December&#160;31, 2016</font><font style="font-family:inherit;font-size:10pt;">, included in the Company&#8217;s Annual Report on Form 10-K. There were no significant changes in the Company&#8217;s accounting policies since the end of fiscal </font><font style="font-family:inherit;font-size:10pt;">2016</font><font style="font-family:inherit;font-size:10pt;">. The financial results for any interim period are not necessarily indicative of financial results for the full year.</font></div><div><br></div><div style="text-align:center;"><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">7</font></div></div><hr style="page-break-after:always"><div><a name="s2A00299768B559E99D50DBAC0C63FEA6"></a></div><div><div style="line-height:120%;font-size:8pt;"><a style="font-family:inherit;font-size:8pt;" href="#sD088029191DD5EB99A130DC52B3A6E1B"><font style="font-family:inherit;font-size:8pt;">Table of Contents</font></a></div><div style="line-height:120%;text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">NewLink Genetics Corporation and Subsidiaries</font></div><div style="line-height:120%;text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Notes to Condensed Consolidated Financial Statements</font></div><div style="line-height:120%;text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">(unaudited)</font></div><div style="line-height:120%;text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></div><div><br></div><div style="line-height:120%;padding-bottom:12px;padding-top:12px;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">3.&#160;&#160;&#160;&#160;&#160;Significant Accounting Policies</font></div><div style="line-height:120%;padding-bottom:12px;padding-top:12px;text-align:justify;text-indent:18px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;">Use of Estimates</font></div><div style="line-height:120%;padding-bottom:12px;padding-top:12px;text-align:justify;text-indent:32px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">The preparation of the condensed consolidated financial statements in conformity with U.S.&#160;GAAP requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the condensed consolidated financial statements and the reported amounts of revenues and expenses during the reporting period. Actual results could differ from those estimates.</font></div><div style="line-height:120%;padding-bottom:12px;padding-top:12px;text-align:justify;text-indent:18px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;">Principles of Consolidation</font></div><div style="line-height:120%;padding-bottom:12px;padding-top:12px;text-align:justify;text-indent:32px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">The condensed consolidated financial statements include the financial statements of NewLink and its wholly owned subsidiaries.  All significant intercompany balances and transactions have been eliminated in consolidation.</font></div><div style="line-height:120%;padding-bottom:12px;padding-top:12px;text-align:justify;text-indent:18px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;">Financial Instruments and Concentrations of Credit Risk</font></div><div style="line-height:120%;padding-bottom:12px;padding-top:12px;text-align:justify;text-indent:30px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Cash and cash equivalents, receivables, and accounts payable are recorded at cost, which approximates fair value based on the short-term nature of these financial instruments. The carrying value of notes payable and capital lease obligations was </font><font style="font-family:inherit;font-size:10pt;">$332,000</font><font style="font-family:inherit;font-size:10pt;">&#32;and </font><font style="font-family:inherit;font-size:10pt;">$517,000</font><font style="font-family:inherit;font-size:10pt;">&#32;as of </font><font style="font-family:inherit;font-size:10pt;">September&#160;30, 2017</font><font style="font-family:inherit;font-size:10pt;">&#32;and </font><font style="font-family:inherit;font-size:10pt;">December&#160;31, 2016</font><font style="font-family:inherit;font-size:10pt;">, respectively, which approximate fair value using Level 2 inputs (computed in accordance with ASC 820). The Company is unable to estimate the fair value of the royalty obligation based on future product sales, as the timing of payments, if any, is uncertain.  </font></div><div style="line-height:120%;padding-bottom:12px;padding-top:12px;text-align:justify;text-indent:30px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Financial instruments that potentially subject the Company to concentrations of credit risk consist primarily of cash and cash equivalents. Cash and cash equivalents are held by financial institutions and are federally insured up to certain limits. At times, the Company&#8217;s cash and cash equivalents balance exceeds the federally insured limits. To limit the credit risk, the Company invests its excess cash primarily in high-quality securities such as certificates of deposit and money market funds.</font></div><div style="line-height:120%;padding-bottom:12px;padding-top:12px;text-align:justify;text-indent:18px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;">Property and equipment</font></div><div style="line-height:120%;padding-bottom:12px;padding-top:12px;text-align:justify;text-indent:30px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Property and equipment are capitalized as the Company believes they have alternative future uses and are stated at cost, less accumulated depreciation of </font><font style="font-family:inherit;font-size:10pt;">$6.7 million</font><font style="font-family:inherit;font-size:10pt;">&#32;and </font><font style="font-family:inherit;font-size:10pt;">$5.7 million</font><font style="font-family:inherit;font-size:10pt;">&#32;as of </font><font style="font-family:inherit;font-size:10pt;">September&#160;30, 2017</font><font style="font-family:inherit;font-size:10pt;">&#32;and </font><font style="font-family:inherit;font-size:10pt;">December&#160;31, 2016</font><font style="font-family:inherit;font-size:10pt;">, respectively. Equipment under capital leases is stated at the present value of minimum lease payments. Depreciation on all property and equipment is calculated on the straight-line method over the shorter of the lease term or estimated useful life of the asset. Computer equipment has useful lives of </font><font style="font-family:inherit;font-size:10pt;">three</font><font style="font-family:inherit;font-size:10pt;">&#32;to </font><font style="font-family:inherit;font-size:10pt;">five</font><font style="font-family:inherit;font-size:10pt;">&#32;years, lab equipment has a useful life of </font><font style="font-family:inherit;font-size:10pt;">five</font><font style="font-family:inherit;font-size:10pt;">&#32;years and contract manufacturing organization equipment has a useful life of </font><font style="font-family:inherit;font-size:10pt;">five</font><font style="font-family:inherit;font-size:10pt;">&#32;years. </font></div><div style="line-height:120%;padding-bottom:12px;padding-top:12px;text-align:justify;text-indent:18px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;">Revenue Recognition</font></div><div style="line-height:120%;padding-bottom:12px;padding-top:12px;text-align:justify;text-indent:30px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">The Company receives payments from government entities under its grants and contracts with the Department of Defense and the United States Department of Health and Human Services. These agreements provide the Company cost reimbursement plus a percentage for certain types of expenditures in return for research and development activities over a contractually defined period. Grant revenues are recognized in the period during which the related costs are incurred, provided that the conditions under which the costs submitted or to be submitted for reimbursement have been met and the Company has only perfunctory obligations outstanding. </font></div><div style="line-height:120%;padding-bottom:12px;padding-top:12px;text-align:justify;text-indent:30px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">The Company had&#160;</font><font style="font-family:inherit;font-size:10pt;">$10.1 million</font><font style="font-family:inherit;font-size:10pt;">&#32;and </font><font style="font-family:inherit;font-size:10pt;">$23.9 million</font><font style="font-family:inherit;font-size:10pt;">&#32;of receivables from the government contracts recorded in other receivables and </font><font style="font-family:inherit;font-size:10pt;">$1.5 million</font><font style="font-family:inherit;font-size:10pt;">&#32;and </font><font style="font-family:inherit;font-size:10pt;">$4.3 million</font><font style="font-family:inherit;font-size:10pt;">&#32;of unbilled expenses relating to the government contracts recorded in prepaid expenses and other current assets on the balance sheet as of </font><font style="font-family:inherit;font-size:10pt;">September&#160;30, 2017</font><font style="font-family:inherit;font-size:10pt;">&#32;and </font><font style="font-family:inherit;font-size:10pt;">December&#160;31, 2016</font><font style="font-family:inherit;font-size:10pt;">, respectively. The Company had </font><font style="font-family:inherit;font-size:10pt;">$1.4 million</font><font style="font-family:inherit;font-size:10pt;">&#32;and </font><font style="font-family:inherit;font-size:10pt;">$2.9 million</font><font style="font-family:inherit;font-size:10pt;">&#32;of accrued expenses for subcontractor fees incurred under the government contracts as of </font><font style="font-family:inherit;font-size:10pt;">September&#160;30, 2017</font><font style="font-family:inherit;font-size:10pt;">&#32;and </font><font style="font-family:inherit;font-size:10pt;">December&#160;31, 2016</font><font style="font-family:inherit;font-size:10pt;">, respectively. </font></div><div style="line-height:120%;padding-bottom:12px;padding-top:12px;text-align:justify;text-indent:18px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;">Recent Accounting Pronouncements</font></div><div style="line-height:120%;text-align:justify;text-indent:30px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">On May 28, 2014, the FASB issued ASU No. 2014-09, Revenue from Contracts with Customers, which requires an entity to recognize the amount of revenue to which it expects to be entitled for the transfer of promised goods or services to customers. The ASU will replace most existing revenue recognition guidance in U.S. GAAP when it becomes effective. The new standard is effective for the Company on January 1, 2018. The standard permits the use of either the retrospective or cumulative effect transition method. The Company plans to adopt the standard on a modified retrospective basis at January 1, 2018, with an adjustment for the cumulative effect of all changes recognized in beginning retained earnings.  The Company does not expect to record any </font></div><div><br></div><div style="text-align:center;"><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">8</font></div></div><hr style="page-break-after:always"><div><div style="line-height:120%;font-size:8pt;"><a style="font-family:inherit;font-size:8pt;" href="#sD088029191DD5EB99A130DC52B3A6E1B"><font style="font-family:inherit;font-size:8pt;">Table of Contents</font></a></div><div style="line-height:120%;text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">NewLink Genetics Corporation and Subsidiaries</font></div><div style="line-height:120%;text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Notes to Condensed Consolidated Financial Statements</font></div><div style="line-height:120%;text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">(unaudited)</font></div><div style="line-height:120%;text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></div><div><br></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">adjustment relating to the Company&#8217;s licensing and collaboration agreements. The Company continues to assess the impact adoption will have on the government grant revenue contracts. </font></div><div><a name="s6DEC4C1DC58D51D2AA9230F7B5FD555A"></a></div><div style="line-height:120%;padding-bottom:12px;padding-top:12px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">4.&#160;&#160;&#160;&#160;&#160;Long-Term Debt </font></div><div style="line-height:120%;padding-bottom:12px;padding-top:12px;text-indent:30px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;">March 2010 City of Ames Forgivable Loan</font></div><div style="line-height:120%;padding-bottom:12px;padding-top:12px;text-align:justify;text-indent:30px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">In March 2010, the Company entered into a </font><font style="font-family:inherit;font-size:10pt;">$400,000</font><font style="font-family:inherit;font-size:10pt;">&#32;forgivable loan agreement with the City of Ames, Iowa and the Ames Chamber of Commerce, jointly, as lenders. The project provided the Company with financial assistance to construct new facilities within the Ames city limits. </font></div><div style="line-height:120%;padding-bottom:12px;padding-top:12px;text-align:justify;text-indent:30px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">The project required the Company to create or retain at least </font><font style="font-family:inherit;font-size:10pt;">150</font><font style="font-family:inherit;font-size:10pt;">&#32;full-time positions located in Ames, Iowa by March&#160;10, 2016. The agreement required the Company to enter into a </font><font style="font-family:inherit;font-size:10pt;">five</font><font style="font-family:inherit;font-size:10pt;">-year building lease with the option for extension for an additional </font><font style="font-family:inherit;font-size:10pt;">five</font><font style="font-family:inherit;font-size:10pt;">&#32;years of not less than </font><font style="font-family:inherit;font-size:10pt;">20,000</font><font style="font-family:inherit;font-size:10pt;">&#32;square feet within the corporate limits of the City of Ames by March&#160;10, 2015, which requirement was met prior to the deadline of March 10, 2015. As of March&#160;10, 2016, the Company had satisfactorily fulfilled all of the above terms of the loan agreement and the loan was forgiven. Accordingly, the entire outstanding loan amount of </font><font style="font-family:inherit;font-size:10pt;">$397,000</font><font style="font-family:inherit;font-size:10pt;">&#32;was derecognized with a corresponding amount recorded in grant revenue for the three months ended March 31, 2016.</font></div><div><a name="sD095F3CD4EF050D2878CAF0A6E8337EE"></a></div><div style="line-height:120%;padding-bottom:12px;padding-top:12px;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">5.&#160;&#160;&#160;License and Research Collaboration Agreements</font></div><div style="line-height:120%;padding-bottom:12px;padding-top:12px;text-align:left;text-indent:30px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;">Genentech, a Member of the Roche Group</font></div><div style="line-height:120%;padding-bottom:12px;padding-top:12px;text-align:justify;text-indent:30px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">In October 2014, the Company entered into an exclusive worldwide collaboration and license agreement with Genentech, or the Genentech Agreement, for the development and commercialization of navoximod (GDC-0919), one of the Company's clinical stage IDO pathway inhibitors. The parties also entered into a research collaboration for the discovery of next generation IDO and TDO pathway inhibitors to be developed and commercialized under this agreement.  Under the terms of the Genentech Agreement, the Company received a nonrefundable upfront cash payment of </font><font style="font-family:inherit;font-size:10pt;">$150.0 million</font><font style="font-family:inherit;font-size:10pt;">&#32;from Genentech in 2014 and is eligible to receive additional milestone payments of up to </font><font style="font-family:inherit;font-size:10pt;">$561.0 million</font><font style="font-family:inherit;font-size:10pt;">&#32;upon achieving certain Next Generation Product Development regulatory development, international patent acceptance, country marketing approval, and sales-based milestones. The Company retains the right to exercise an option to co-promote any products for the U.S. market and is also eligible to receive escalating  royalty payments on potential commercial sales of products by Genentech. </font></div><div style="line-height:120%;padding-bottom:12px;padding-top:12px;text-align:justify;text-indent:30px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">On June 6, 2017, the Company received a formal notice of Genentech&#8217;s intent to terminate the Genentech Agreement with respect to navoximod with such termination to be effective no later than December 6, 2017.  Discussions regarding the termination are ongoing.  The Genentech Agreement continues with regards to any Next Generation Products as defined under the Genentech Agreement.</font></div><div style="line-height:120%;padding-bottom:12px;padding-top:12px;text-align:justify;text-indent:30px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">For the </font><font style="font-family:inherit;font-size:10pt;">three and nine months ended</font><font style="font-family:inherit;font-size:10pt;">&#32;</font><font style="font-family:inherit;font-size:10pt;">September&#160;30, 2017</font><font style="font-family:inherit;font-size:10pt;">, the Company recognized license and collaboration revenue under the Genentech Agreement of </font><font style="font-family:inherit;font-size:10pt;">$56,000</font><font style="font-family:inherit;font-size:10pt;">&#32;and </font><font style="font-family:inherit;font-size:10pt;">$279,000</font><font style="font-family:inherit;font-size:10pt;">, respectively, for providing an alliance manager.  For the </font><font style="font-family:inherit;font-size:10pt;">three months ended</font><font style="font-family:inherit;font-size:10pt;">&#32;</font><font style="font-family:inherit;font-size:10pt;">September&#160;30, 2016</font><font style="font-family:inherit;font-size:10pt;">, the Company recognized license and collaboration revenue under the Genentech Agreement of </font><font style="font-family:inherit;font-size:10pt;">$687,000</font><font style="font-family:inherit;font-size:10pt;">, including </font><font style="font-family:inherit;font-size:10pt;">$486,000</font><font style="font-family:inherit;font-size:10pt;">&#32;for amounts received as reimbursement for the Company's employees working on the project, and </font><font style="font-family:inherit;font-size:10pt;">$201,000</font><font style="font-family:inherit;font-size:10pt;">&#32;for providing an alliance manager. For the </font><font style="font-family:inherit;font-size:10pt;">nine months ended</font><font style="font-family:inherit;font-size:10pt;">&#32;</font><font style="font-family:inherit;font-size:10pt;">September&#160;30, 2016</font><font style="font-family:inherit;font-size:10pt;">, the Company recognized license and collaboration revenue under the Genentech Agreement of </font><font style="font-family:inherit;font-size:10pt;">$2.2 million</font><font style="font-family:inherit;font-size:10pt;">, including </font><font style="font-family:inherit;font-size:10pt;">$1.6 million</font><font style="font-family:inherit;font-size:10pt;">&#32;for amounts received as reimbursement for the Company's employees working on the project, </font><font style="font-family:inherit;font-size:10pt;">$502,000</font><font style="font-family:inherit;font-size:10pt;">&#32;for providing an alliance manager, and </font><font style="font-family:inherit;font-size:10pt;">$101,000</font><font style="font-family:inherit;font-size:10pt;">&#32;for participation in the joint research committee. In accordance with the Company&#8217;s continuing performance obligation, </font><font style="font-family:inherit;font-size:10pt;">$112,000</font><font style="font-family:inherit;font-size:10pt;">&#32;of the </font><font style="font-family:inherit;font-size:10pt;">$150.0 million</font><font style="font-family:inherit;font-size:10pt;">&#32;upfront payment remains deferred as of </font><font style="font-family:inherit;font-size:10pt;">September&#160;30, 2017</font><font style="font-family:inherit;font-size:10pt;">&#32;and will be recognized during the remainder of 2017. The upfront payment provides no general right of return for any non-contingent deliverable and no portion of any revenue recognized is refundable.</font></div><div><br></div><div style="text-align:center;"><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">9</font></div></div><hr style="page-break-after:always"><div><div style="line-height:120%;font-size:8pt;"><a style="font-family:inherit;font-size:8pt;" href="#sD088029191DD5EB99A130DC52B3A6E1B"><font style="font-family:inherit;font-size:8pt;">Table of Contents</font></a></div><div style="line-height:120%;text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">NewLink Genetics Corporation and Subsidiaries</font></div><div style="line-height:120%;text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Notes to Condensed Consolidated Financial Statements</font></div><div style="line-height:120%;text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">(unaudited)</font></div><div style="line-height:120%;text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></div><div><br></div><div style="line-height:120%;padding-bottom:12px;padding-top:12px;text-align:left;text-indent:30px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;">Merck Sharp &amp; Dohme Corp. </font></div><div style="line-height:120%;padding-bottom:12px;padding-top:12px;text-align:justify;text-indent:30px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">In November 2014, the Company entered into a licensing and collaboration agreement with Merck, or the Merck Agreement, to develop, manufacture and commercialize rVSV-ZEBOV GP, an Ebola vaccine the Company licensed from the Public Health Agency of Canada, or PHAC.  Under the terms of the Merck Agreement, the Company granted Merck an exclusive, royalty bearing license to rVSV-ZEBOV GP and related technology. Under the Merck Agreement, the Company received a </font><font style="font-family:inherit;font-size:10pt;">$30.0 million</font><font style="font-family:inherit;font-size:10pt;">&#32;non-refundable, upfront payment in December 2014, and a one-time </font><font style="font-family:inherit;font-size:10pt;">$20.0 million</font><font style="font-family:inherit;font-size:10pt;">&#32;non-refundable milestone payment in February 2015 upon the initiation of the pivotal clinical trial using the current rVSV-ZEBOV GP vaccine product as one arm of the trial. In addition, the Company can receive escalating royalties on potential commercial sales by Merck of the current product candidate ranging from single digit to double digits on the rVSV-ZEBOV GP license agreement product sales and escalating royalties on potential commercial sales by Merck of products other than current products within the Company&#8217;s patent rights ranging from low to high single digit, on increasing levels of annual net sales worldwide. Merck will lead the development of rVSV-ZEBOV GP and any other rVSV-based viral hemorrhagic fever vaccine product candidates in order to create a marketable product safe for human use.</font></div><div style="line-height:120%;padding-bottom:12px;padding-top:12px;text-align:justify;text-indent:30px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">The Company completed all deliverables under the Merck Agreement in their entirety during the year ended </font><font style="font-family:inherit;font-size:10pt;">December&#160;31, 2016</font><font style="font-family:inherit;font-size:10pt;">. For the </font><font style="font-family:inherit;font-size:10pt;">three months ended</font><font style="font-family:inherit;font-size:10pt;">&#32;</font><font style="font-family:inherit;font-size:10pt;">September&#160;30, 2016</font><font style="font-family:inherit;font-size:10pt;">, the Company recognized </font><font style="font-family:inherit;font-size:10pt;">no</font><font style="font-family:inherit;font-size:10pt;">&#32;revenues under the Merck Agreement. For the </font><font style="font-family:inherit;font-size:10pt;">nine months ended</font><font style="font-family:inherit;font-size:10pt;">&#32;</font><font style="font-family:inherit;font-size:10pt;">September&#160;30, 2016</font><font style="font-family:inherit;font-size:10pt;">, the Company recognized license and collaboration revenues under the Merck Agreement of </font><font style="font-family:inherit;font-size:10pt;">$764,000</font><font style="font-family:inherit;font-size:10pt;">, for the reimbursement of costs not covered under government contracts.</font></div><div><a name="s563BF748546557DC936AB3768752DF2D"></a></div><div style="line-height:120%;padding-bottom:12px;padding-top:12px;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">6.&#160;&#160;&#160;Common Stock Equity Incentive Plan</font></div><div style="line-height:120%;padding-bottom:12px;padding-top:12px;text-indent:30px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;">2009 Equity Incentive Plan</font></div><div style="line-height:120%;padding-bottom:12px;padding-top:12px;text-align:justify;text-indent:32px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">In April 2000, the stockholders approved the Company's 2000 Equity Incentive Plan, or the 2000 Plan, and in July 2009, the stockholders approved the Company's 2009 Equity Incentive Plan, or the 2009 Plan. Following the approval of the 2009 Plan, all options outstanding under the 2000 Plan are effectively included under the 2009 Plan. Under the provisions of the 2009 Plan, the Company may grant the following types of common stock awards:</font></div><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:24px;"><font style="font-family:inherit;font-size:10pt;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Incentive Stock Options</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:24px;"><font style="font-family:inherit;font-size:10pt;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Nonstatutory Stock Options</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:24px;"><font style="font-family:inherit;font-size:10pt;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Restricted Stock Awards</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:24px;"><font style="font-family:inherit;font-size:10pt;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Stock Appreciation Rights</font></div></td></tr></table><div style="line-height:120%;padding-bottom:12px;padding-top:12px;text-align:justify;text-indent:32px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Awards under the 2009 Plan, as amended, may be made to officers, employees, members of the Board of Directors, advisors, and consultants to the Company.  As of </font><font style="font-family:inherit;font-size:10pt;">September&#160;30, 2017</font><font style="font-family:inherit;font-size:10pt;">, there were </font><font style="font-family:inherit;font-size:10pt;">10,238,220</font><font style="font-family:inherit;font-size:10pt;">&#32;shares of common stock authorized for the 2009 Plan and </font><font style="font-family:inherit;font-size:10pt;">1,094,264</font><font style="font-family:inherit;font-size:10pt;">&#32;shares remained available for issuance.</font></div><div style="line-height:120%;padding-bottom:12px;padding-top:12px;text-align:justify;text-indent:32px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">The following table summarizes the authorized increases of common stock under the 2009 Plan:</font></div><div style="line-height:120%;padding-bottom:12px;padding-top:12px;text-align:center;text-indent:32px;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:57.421875%;border-collapse:collapse;text-align:left;"><tr><td colspan="4"></td></tr><tr><td style="width:43%;"></td><td style="width:1%;"></td><td style="width:55%;"></td><td style="width:1%;"></td></tr><tr><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;font-weight:bold;">Date Authorized</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;font-weight:bold;">Authorized Shares Added</font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">May 15, 2010</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">1,238,095</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">January 7, 2011</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">714,286</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">January 1, 2013</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">838,375</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">January 1, 2014</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">1,066,340</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">January 1, 2015</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">1,119,255</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">January 1, 2016</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">1,152,565</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">January 1, 2017</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">1,166,546</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr></table></div></div><div><br></div><div style="text-align:center;"><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">10</font></div></div><hr style="page-break-after:always"><div><div style="line-height:120%;font-size:8pt;"><a style="font-family:inherit;font-size:8pt;" href="#sD088029191DD5EB99A130DC52B3A6E1B"><font style="font-family:inherit;font-size:8pt;">Table of Contents</font></a></div><div style="line-height:120%;text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">NewLink Genetics Corporation and Subsidiaries</font></div><div style="line-height:120%;text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Notes to Condensed Consolidated Financial Statements</font></div><div style="line-height:120%;text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">(unaudited)</font></div><div style="line-height:120%;text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></div><div><br></div><div style="line-height:120%;padding-bottom:12px;padding-top:12px;text-align:justify;text-indent:32px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">The increases in the authorized shares of common stock under the 2009 Plan in 2010 and 2011 were approved by the Company&#8217;s stockholders. The increases in the authorized shares of common stock under the 2009 Plan in 2012 through 2017 were made pursuant to an &#8220;evergreen provision,&#8221; in accordance with which, on January 1 of each year, from 2012 to (and including) 2019, a number of shares of common stock in an amount equal to </font><font style="font-family:inherit;font-size:10pt;">4%</font><font style="font-family:inherit;font-size:10pt;">&#32;of the total number of shares of common stock outstanding on December 31 of the preceding calendar year, or such lesser amount of shares (or no shares) approved by the Company's Board of Directors, was added or will be added to the shares reserved under the 2009 Plan. </font></div><div style="line-height:120%;padding-bottom:12px;padding-top:12px;text-align:justify;text-indent:32px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;">2010 Non-Employee Directors' Stock Award Plan</font></div><div style="line-height:120%;padding-bottom:12px;padding-top:12px;text-align:justify;text-indent:32px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Under the terms of the Company&#8217;s 2010 Non-Employee Directors&#8217; Stock Award Plan, or the Directors&#8217; Plan, which became effective on November 10, 2011, </font><font style="font-family:inherit;font-size:10pt;">238,095</font><font style="font-family:inherit;font-size:10pt;">&#32;shares of common stock were reserved for future issuance. On </font><font style="font-family:inherit;font-size:10pt;">May&#160;9, 2013</font><font style="font-family:inherit;font-size:10pt;">, an additional </font><font style="font-family:inherit;font-size:10pt;">161,905</font><font style="font-family:inherit;font-size:10pt;">&#32;shares of common stock were added to the shares reserved for future issuance under the Directors' Plan.  As of </font><font style="font-family:inherit;font-size:10pt;">September&#160;30, 2017</font><font style="font-family:inherit;font-size:10pt;">, </font><font style="font-family:inherit;font-size:10pt;">no</font><font style="font-family:inherit;font-size:10pt;">&#32;shares remained available for issuance under the Directors' Plan.</font></div><div style="line-height:120%;padding-bottom:12px;padding-top:12px;text-align:justify;text-indent:32px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;">2010 Employee Stock Purchase Plan</font></div><div style="line-height:120%;padding-bottom:12px;padding-top:12px;text-align:justify;text-indent:32px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Under the terms of the Company&#8217;s 2010 Employee Stock Purchase Plan, or the 2010 Purchase Plan, which became effective on November 10, 2011, </font><font style="font-family:inherit;font-size:10pt;">214,285</font><font style="font-family:inherit;font-size:10pt;">&#32;shares of common stock were reserved for future issuance. On </font><font style="font-family:inherit;font-size:10pt;">May&#160;9, 2013</font><font style="font-family:inherit;font-size:10pt;">, an additional </font><font style="font-family:inherit;font-size:10pt;">185,715</font><font style="font-family:inherit;font-size:10pt;">&#32;shares of common stock were added to the shares reserved for future issuance under the 2010 Purchase Plan. As of </font><font style="font-family:inherit;font-size:10pt;">September&#160;30, 2017</font><font style="font-family:inherit;font-size:10pt;">, </font><font style="font-family:inherit;font-size:10pt;">120,784</font><font style="font-family:inherit;font-size:10pt;">&#32;shares remained available for issuance under the 2010 Purchase Plan.</font></div><div style="line-height:120%;padding-bottom:12px;padding-top:12px;text-align:justify;text-indent:32px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;">Share-based Compensation</font></div><div style="line-height:120%;padding-bottom:12px;padding-top:12px;text-align:justify;text-indent:32px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Share-based compensation expense for the </font><font style="font-family:inherit;font-size:10pt;">three months ended</font><font style="font-family:inherit;font-size:10pt;">&#32;</font><font style="font-family:inherit;font-size:10pt;">September&#160;30, 2017</font><font style="font-family:inherit;font-size:10pt;">&#32;and </font><font style="font-family:inherit;font-size:10pt;">2016</font><font style="font-family:inherit;font-size:10pt;">&#32;was </font><font style="font-family:inherit;font-size:10pt;">$4.4 million</font><font style="font-family:inherit;font-size:10pt;">&#32;and </font><font style="font-family:inherit;font-size:10pt;">$3.9 million</font><font style="font-family:inherit;font-size:10pt;">, respectively, and was </font><font style="font-family:inherit;font-size:10pt;">$14.9 million</font><font style="font-family:inherit;font-size:10pt;">&#32;and </font><font style="font-family:inherit;font-size:10pt;">$13.1 million</font><font style="font-family:inherit;font-size:10pt;">, respectively, for </font><font style="font-family:inherit;font-size:10pt;">nine months ended</font><font style="font-family:inherit;font-size:10pt;">&#32;</font><font style="font-family:inherit;font-size:10pt;">September&#160;30, 2017</font><font style="font-family:inherit;font-size:10pt;">&#32;and </font><font style="font-family:inherit;font-size:10pt;">2016</font><font style="font-family:inherit;font-size:10pt;">.  Share-based compensation expense is allocated between research and development and general and administrative expenses within the condensed consolidated statements of operations. </font></div><div style="line-height:120%;padding-bottom:12px;padding-top:12px;text-align:justify;text-indent:32px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">As of </font><font style="font-family:inherit;font-size:10pt;">September&#160;30, 2017</font><font style="font-family:inherit;font-size:10pt;">, the total compensation cost related to nonvested option awards not yet recognized was </font><font style="font-family:inherit;font-size:10pt;">$19.9 million</font><font style="font-family:inherit;font-size:10pt;">&#32;and the weighted-average period over which it is expected to be recognized is </font><font style="font-family:inherit;font-size:10pt;">2.1 years</font><font style="font-family:inherit;font-size:10pt;">.</font></div><div style="line-height:120%;padding-bottom:12px;padding-top:12px;text-align:justify;text-indent:32px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;">Stock Options and Performance Stock Options</font></div><div style="line-height:120%;padding-bottom:12px;padding-top:12px;text-align:justify;text-indent:32px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">The following table summarizes the stock option activity, including options with performance conditions, for the </font><font style="font-family:inherit;font-size:10pt;">nine months ended</font><font style="font-family:inherit;font-size:10pt;">&#32;</font><font style="font-family:inherit;font-size:10pt;">September&#160;30, 2017</font><font style="font-family:inherit;font-size:10pt;">:</font></div><div style="line-height:120%;padding-bottom:12px;padding-top:12px;text-align:center;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:551px;border-collapse:collapse;text-align:left;"><tr><td colspan="10"></td></tr><tr><td style="width:226px;"></td><td style="width:5px;"></td><td style="width:94px;"></td><td style="width:4px;"></td><td style="width:5px;"></td><td style="width:9px;"></td><td style="width:83px;"></td><td style="width:4px;"></td><td style="width:5px;"></td><td style="width:114px;"></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">Number</font></div><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">of options</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">Weighted</font></div><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">average</font></div><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">exercise</font></div><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">price</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">Weighted average</font></div><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">remaining contractual</font></div><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">term (years)</font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Outstanding at beginning of period</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">6,278,542</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">14.93</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">5.8</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Options granted</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">1,439,287</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">11.78</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Options exercised</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(108,775</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">8.51</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Options forfeited</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(277,443</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">20.13</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Options expired</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(17,605</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">42.00</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Outstanding at end of period</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">7,314,006</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">14.15</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">5.5</font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Options exercisable at end of period</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:3px double #000000;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">5,456,602</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:3px double #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">12.65</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">4.4</font></div></td></tr></table></div></div><div style="line-height:120%;padding-bottom:12px;text-align:justify;text-indent:36px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">The Company estimates the fair value of each stock option grant on the date of grant using a Black-Scholes option pricing model. For stock option grants issued with a market condition, the Company used a Monte Carlo simulation valuation model to determine the grant date fair value. </font></div><div><br></div><div style="text-align:center;"><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">11</font></div></div><hr style="page-break-after:always"><div><div style="line-height:120%;font-size:8pt;"><a style="font-family:inherit;font-size:8pt;" href="#sD088029191DD5EB99A130DC52B3A6E1B"><font style="font-family:inherit;font-size:8pt;">Table of Contents</font></a></div><div style="line-height:120%;text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">NewLink Genetics Corporation and Subsidiaries</font></div><div style="line-height:120%;text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Notes to Condensed Consolidated Financial Statements</font></div><div style="line-height:120%;text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">(unaudited)</font></div><div style="line-height:120%;text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></div><div><br></div><div style="line-height:120%;padding-bottom:12px;text-align:justify;text-indent:36px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">The following table summarizes the range of assumptions used to estimate the fair value of stock options granted, including those options granted with a market condition, during the </font><font style="font-family:inherit;font-size:10pt;">nine months ended</font><font style="font-family:inherit;font-size:10pt;">&#32;</font><font style="font-family:inherit;font-size:10pt;">September&#160;30, 2017</font><font style="font-family:inherit;font-size:10pt;">:</font></div><div style="line-height:120%;padding-bottom:12px;padding-top:12px;text-align:center;text-indent:32px;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:63.0859375%;border-collapse:collapse;text-align:left;"><tr><td colspan="3"></td></tr><tr><td style="width:68%;"></td><td style="width:1%;"></td><td style="width:31%;"></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Risk-free interest rate</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">1.9% to 2.2%</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Expected dividend yield</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8212;%</font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Expected volatility</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">68.9% to 73.2%</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Expected term (in years)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">6.5 to 7.8</font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Weighted-average grant-date fair value per share</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$7.81</font></div></td></tr></table></div></div><div style="line-height:120%;padding-bottom:12px;padding-top:12px;text-align:justify;text-indent:32px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">The intrinsic value of options exercised during the </font><font style="font-family:inherit;font-size:10pt;">nine months ended</font><font style="font-family:inherit;font-size:10pt;">&#32;</font><font style="font-family:inherit;font-size:10pt;">September&#160;30, 2017</font><font style="font-family:inherit;font-size:10pt;">&#32;was </font><font style="font-family:inherit;font-size:10pt;">$924,164</font><font style="font-family:inherit;font-size:10pt;">. The fair value of awards vested during the </font><font style="font-family:inherit;font-size:10pt;">nine months ended</font><font style="font-family:inherit;font-size:10pt;">&#32;</font><font style="font-family:inherit;font-size:10pt;">September&#160;30, 2017</font><font style="font-family:inherit;font-size:10pt;">&#32;was </font><font style="font-family:inherit;font-size:10pt;">$12.4 million</font><font style="font-family:inherit;font-size:10pt;">. </font></div><div style="line-height:120%;padding-bottom:12px;padding-top:12px;text-align:justify;text-indent:32px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">During the </font><font style="font-family:inherit;font-size:10pt;">nine months ended</font><font style="font-family:inherit;font-size:10pt;">&#32;</font><font style="font-family:inherit;font-size:10pt;">September&#160;30, 2017</font><font style="font-family:inherit;font-size:10pt;">, the Company&#8217;s Board of Directors approved and granted </font><font style="font-family:inherit;font-size:10pt;">388,144</font><font style="font-family:inherit;font-size:10pt;">&#32;shares of compensation and equity awards to certain executives with either market or performance conditions. The compensation and equity awards had a weighted average grant date fair value per share of $</font><font style="font-family:inherit;font-size:10pt;">6.73</font><font style="font-family:inherit;font-size:10pt;">.   The compensation and equity awards will vest upon the achievement of certain performance conditions. During the </font><font style="font-family:inherit;font-size:10pt;">nine months ended</font><font style="font-family:inherit;font-size:10pt;">&#32;</font><font style="font-family:inherit;font-size:10pt;">September&#160;30, 2017</font><font style="font-family:inherit;font-size:10pt;">, certain conditions were met which resulted in the vesting of </font><font style="font-family:inherit;font-size:10pt;">194,070</font><font style="font-family:inherit;font-size:10pt;">&#32;shares and the recognition of </font><font style="font-family:inherit;font-size:10pt;">$1.2 million</font><font style="font-family:inherit;font-size:10pt;">&#32;in stock compensation expense.</font></div><div style="line-height:120%;padding-bottom:12px;padding-top:12px;text-align:justify;text-indent:32px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;">Restricted Stock and Performance Restricted Stock</font></div><div style="line-height:120%;padding-bottom:12px;padding-top:12px;text-align:justify;text-indent:32px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Restricted stock is common stock that is subject to restrictions, including risks of forfeiture, determined by the plan committee of the Board of Directors in its sole discretion, for as long as such common stock remains subject to any such restrictions.  A holder of restricted stock has all rights of a stockholder with respect to such stock, including the right to vote and to receive dividends thereon, except as otherwise provided in the award agreement relating to such award.  Restricted stock awards are classified as equity within the consolidated balance sheets.  The fair value of each restricted stock grant is estimated on the date of grant using the closing price of the Company's common stock on the NASDAQ Stock Market on the date of grant.</font></div><div style="line-height:120%;padding-bottom:12px;padding-top:12px;text-align:justify;text-indent:30px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">A summary of the Company's unvested restricted stock, including restricted stock with performance conditions, at </font><font style="font-family:inherit;font-size:10pt;">September&#160;30, 2017</font><font style="font-family:inherit;font-size:10pt;">&#32;and changes during the </font><font style="font-family:inherit;font-size:10pt;">nine months ended</font><font style="font-family:inherit;font-size:10pt;">&#32;</font><font style="font-family:inherit;font-size:10pt;">September&#160;30, 2017</font><font style="font-family:inherit;font-size:10pt;">&#32;are as follows:</font></div><div style="line-height:120%;padding-bottom:12px;padding-top:12px;text-align:center;text-indent:30px;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:64.84375%;border-collapse:collapse;text-align:left;"><tr><td colspan="11"></td></tr><tr><td style="width:57%;"></td><td style="width:1%;"></td><td style="width:19%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:16%;"></td><td style="width:1%;"></td><td style="width:1%;"></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">Number of restricted stock shares</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="5" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">Weighted average grant date fair value</font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Unvested at beginning of period</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">288,964</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">34.94</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Granted</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Vested</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(80,380</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">35.04</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Forfeited/cancelled</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(27,248</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">33.84</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Unvested at end of period</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">181,336</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">35.05</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr></table></div></div><div style="line-height:120%;padding-bottom:12px;padding-top:12px;text-align:justify;text-indent:30px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">As of </font><font style="font-family:inherit;font-size:10pt;">September&#160;30, 2017</font><font style="font-family:inherit;font-size:10pt;">, the total remaining unrecognized compensation cost related to restricted stock was approximately </font><font style="font-family:inherit;font-size:10pt;">$4.4 million</font><font style="font-family:inherit;font-size:10pt;">&#32;and is expected to be recognized over a weighted-average period of </font><font style="font-family:inherit;font-size:10pt;">1.8 years</font><font style="font-family:inherit;font-size:10pt;">. As of </font><font style="font-family:inherit;font-size:10pt;">September&#160;30, 2017</font><font style="font-family:inherit;font-size:10pt;">, there remains approximately </font><font style="font-family:inherit;font-size:10pt;">$6.4 million</font><font style="font-family:inherit;font-size:10pt;">&#32;of unrecognized compensation cost related to the issuance of performance restricted stock. The fair value of awards vested during the </font><font style="font-family:inherit;font-size:10pt;">nine months ended</font><font style="font-family:inherit;font-size:10pt;">&#32;</font><font style="font-family:inherit;font-size:10pt;">September&#160;30, 2017</font><font style="font-family:inherit;font-size:10pt;">&#32;was </font><font style="font-family:inherit;font-size:10pt;">$814,000</font><font style="font-family:inherit;font-size:10pt;">.</font></div><div style="line-height:120%;padding-bottom:12px;padding-top:12px;text-align:justify;text-indent:30px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">The Company does not have a formal policy regarding the source of shares issued upon exercise of stock options or issuance of restricted stock. The Company expects shares issued to be issued from treasury shares or new shares.</font></div><div><a name="s6B54648E2A9059B6A4DDA7B14398E544"></a></div><div style="line-height:120%;padding-bottom:12px;padding-top:12px;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">7.&#160;&#160;&#160;Income Taxes</font></div><div style="line-height:120%;padding-bottom:12px;padding-top:12px;text-align:justify;text-indent:32px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">For the </font><font style="font-family:inherit;font-size:10pt;">three and nine months ended</font><font style="font-family:inherit;font-size:10pt;">&#32;</font><font style="font-family:inherit;font-size:10pt;">September&#160;30, 2017</font><font style="font-family:inherit;font-size:10pt;">, the Company recorded an income tax benefit of </font><font style="font-family:inherit;font-size:10pt;">$119,000</font><font style="font-family:inherit;font-size:10pt;">&#32;and </font><font style="font-family:inherit;font-size:10pt;">$429,000</font><font style="font-family:inherit;font-size:10pt;">, respectively.  For the </font><font style="font-family:inherit;font-size:10pt;">three and nine months ended</font><font style="font-family:inherit;font-size:10pt;">&#32;</font><font style="font-family:inherit;font-size:10pt;">September&#160;30, 2016</font><font style="font-family:inherit;font-size:10pt;">, the Company recorded an income tax benefit of </font><font style="font-family:inherit;font-size:10pt;">$1.3 million</font><font style="font-family:inherit;font-size:10pt;">&#32;and </font><font style="font-family:inherit;font-size:10pt;">$5.0 million</font><font style="font-family:inherit;font-size:10pt;">, respectively. The income tax benefit for the </font><font style="font-family:inherit;font-size:10pt;">three and nine months ended</font><font style="font-family:inherit;font-size:10pt;">&#32;</font><font style="font-family:inherit;font-size:10pt;">September&#160;30, 2017</font><font style="font-family:inherit;font-size:10pt;">&#32;differs from the amount that would be expected after applying the statutory U.S. federal income tax rate primarily due to the limited potential to carry back losses to 2015 and the net loss generated by NewLink's foreign subsidiary. Income tax benefit for the </font><font style="font-family:inherit;font-size:10pt;">three and nine months ended</font><font style="font-family:inherit;font-size:10pt;">&#32;</font><font style="font-family:inherit;font-size:10pt;">September&#160;30, 2016</font><font style="font-family:inherit;font-size:10pt;">&#32;differs from the amount that would be expected after applying the statutory U.S. </font></div><div><br></div><div style="text-align:center;"><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">12</font></div></div><hr style="page-break-after:always"><div><div style="line-height:120%;font-size:8pt;"><a style="font-family:inherit;font-size:8pt;" href="#sD088029191DD5EB99A130DC52B3A6E1B"><font style="font-family:inherit;font-size:8pt;">Table of Contents</font></a></div><div style="line-height:120%;text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">NewLink Genetics Corporation and Subsidiaries</font></div><div style="line-height:120%;text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Notes to Condensed Consolidated Financial Statements</font></div><div style="line-height:120%;text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">(unaudited)</font></div><div style="line-height:120%;text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></div><div><br></div><div style="line-height:120%;padding-bottom:12px;padding-top:12px;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">federal income tax rate primarily due to the ability to carry back losses to 2014 and the net loss generated by the NewLink's foreign subsidiary. </font></div><div style="line-height:120%;padding-bottom:12px;padding-top:12px;text-align:justify;text-indent:32px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">In assessing the realizability of deferred tax assets, management considers whether it is more likely than not that some portion or all of the deferred tax assets will not be realized. The ultimate realization of deferred tax assets is dependent upon the generation of future taxable income during the periods in which those temporary differences become deductible. Management considers the scheduled reversal of deferred tax liabilities, projected taxable income, and tax planning strategies in making this assessment. Valuation allowances have been established for the entire amount of the net deferred tax assets as of </font><font style="font-family:inherit;font-size:10pt;">September&#160;30, 2017</font><font style="font-family:inherit;font-size:10pt;">&#32;and </font><font style="font-family:inherit;font-size:10pt;">December&#160;31, 2016</font><font style="font-family:inherit;font-size:10pt;">, respectively, due to the uncertainty of future recoverability.</font></div><div style="line-height:120%;padding-bottom:12px;padding-top:12px;text-align:justify;text-indent:32px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">The Company has a reserve for uncertain tax positions related to state tax matters of </font><font style="font-family:inherit;font-size:10pt;">$843,000</font><font style="font-family:inherit;font-size:10pt;">&#32;as of </font><font style="font-family:inherit;font-size:10pt;">September&#160;30, 2017</font><font style="font-family:inherit;font-size:10pt;">&#32;recorded within Accrued Expenses in the condensed consolidated balance sheet, which includes the accrual of interest and penalties. The Company does not expect the amount to change significantly within the next 12 months.</font></div><div><a name="s51511EDF6F9759CB8DDCF240E523BDA0"></a></div><div style="line-height:120%;padding-bottom:12px;padding-top:12px;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">8.&#160;&#160;&#160;Net Loss per Common Share</font></div><div style="line-height:120%;padding-bottom:12px;padding-top:12px;text-align:justify;text-indent:30px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Basic loss per share is based upon the weighted-average number of common shares outstanding during the period, without consideration of common stock equivalents. Diluted loss per share is based upon the weighted-average number of common shares outstanding during the period plus additional weighted-average potentially dilutive common stock equivalents during the period when the effect is dilutive.</font></div><div style="line-height:120%;text-align:justify;text-indent:30px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">The following table presents the computation of basic and diluted loss per common share (in thousands, except share and per share data):</font></div><div style="line-height:120%;text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#32;</font><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:639px;border-collapse:collapse;text-align:left;"><tr><td colspan="18"></td></tr><tr><td style="width:292px;"></td><td style="width:5px;"></td><td style="width:9px;"></td><td style="width:66px;"></td><td style="width:4px;"></td><td style="width:5px;"></td><td style="width:9px;"></td><td style="width:66px;"></td><td style="width:4px;"></td><td style="width:8px;"></td><td style="width:9px;"></td><td style="width:64px;"></td><td style="width:4px;"></td><td style="width:9px;"></td><td style="width:9px;"></td><td style="width:66px;"></td><td style="width:4px;"></td><td style="width:5px;"></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="7" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:center;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;font-weight:bold;">Three Months Ended September 30, </font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="7" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:center;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;font-weight:bold;">Nine Months Ended September 30, </font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:bottom;background-color:;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;font-weight:bold;">2017</font></div></td><td style="vertical-align:bottom;background-color:;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;font-weight:bold;">2016</font></div></td><td style="vertical-align:bottom;background-color:;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:center;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;font-weight:bold;">2017</font></div></td><td style="vertical-align:bottom;background-color:;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:center;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;font-weight:bold;">2016</font></div></td><td style="vertical-align:bottom;background-color:;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:middle;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Loss attributable to common stockholders</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(20,626</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(15,540</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(58,265</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(71,649</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:bottom;background-color:;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Basic and diluted weighted-average shares outstanding</font></div></td><td style="vertical-align:bottom;background-color:;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:3px double #000000;background-color:;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">29,939,823</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:3px double #000000;background-color:;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">28,983,561</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:3px double #000000;background-color:;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">29,462,226</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:3px double #000000;background-color:;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">28,911,042</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:8px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:8px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:8px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:8px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:8px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:8px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:8px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:8px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:8px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:8px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Basic and diluted loss per share</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(0.69</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(0.54</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(1.98</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(2.48</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr></table></div></div><div style="line-height:120%;padding-bottom:10px;text-align:justify;text-indent:24px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:justify;text-indent:24px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">All common stock equivalents are excluded from the computation of diluted loss per share during periods in which losses are reported since the result would be anti-dilutive. As of </font><font style="font-family:inherit;font-size:10pt;">September&#160;30, 2017</font><font style="font-family:inherit;font-size:10pt;">, anti-dilutive stock options and restricted stock awards excluded from our calculation totaled </font><font style="font-family:inherit;font-size:10pt;">7,314,006</font><font style="font-family:inherit;font-size:10pt;">&#32;and </font><font style="font-family:inherit;font-size:10pt;">181,336</font><font style="font-family:inherit;font-size:10pt;">, respectively.  As of </font><font style="font-family:inherit;font-size:10pt;">September 30,</font><font style="font-family:inherit;font-size:10pt;">&#32;</font><font style="font-family:inherit;font-size:10pt;">2016</font><font style="font-family:inherit;font-size:10pt;">, anti-dilutive stock options and restricted stock awards excluded from our calculation totaled </font><font style="font-family:inherit;font-size:10pt;">6,453,331</font><font style="font-family:inherit;font-size:10pt;">&#32;and </font><font style="font-family:inherit;font-size:10pt;">307,079</font><font style="font-family:inherit;font-size:10pt;">, respectively. </font></div><div style="line-height:120%;text-indent:24px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div><a name="sBE4993B152715540A31674D8A5E3100C"></a></div><table cellpadding="0" cellspacing="0" style="padding-top:12px;padding-bottom:12px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:30px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:0px;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">9.</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Restructuring Charges</font></div></td></tr></table><div style="line-height:120%;padding-bottom:12px;padding-top:12px;text-align:justify;text-indent:30px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">The Company records liabilities for costs associated with exit or disposal activities in the period in which the liability is incurred. Employee severance costs are accrued when the&#160;restructuring&#160;actions are probable and estimable. Costs for one-time termination benefits in which the employee is required to render service until termination in order to receive the benefits are recognized ratably over the future service period. The Company also records costs incurred with contract terminations associated with restructuring&#160;activities. </font></div><div style="line-height:120%;padding-bottom:12px;padding-top:12px;text-align:justify;text-indent:30px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">In July 2017, the Company&#160;undertook an organizational realignment to refocus its clinical development efforts and align the Company's resources to focus on the Company's highest value opportunities. The Company's restructuring activities included a reduction of its workforce by approximately </font><font style="font-family:inherit;font-size:10pt;">50%</font><font style="font-family:inherit;font-size:10pt;">, which consisted primarily of clinical and research and development staff, as well as stopping additional research on the Zika virus.  Restructuring charges recorded during the </font><font style="font-family:inherit;font-size:10pt;">three and nine months ended</font><font style="font-family:inherit;font-size:10pt;">&#32;</font><font style="font-family:inherit;font-size:10pt;">September&#160;30, 2017</font><font style="font-family:inherit;font-size:10pt;">&#32;included </font><font style="font-family:inherit;font-size:10pt;">$1.7 million</font><font style="font-family:inherit;font-size:10pt;">&#32;in employee severance cost, which is comprised of one-time employee termination benefits and certain expenses related to contractual termination benefits for employees with pre-existing severance arrangements.  </font></div><div style="line-height:120%;text-align:justify;text-indent:30px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">In May 2016, the Company announced that its Phase 3 clinical trial Immunotherapy for Pancreatic RESectable cancer Study, or IMPRESS, of algenpantucel-L for patients with resected pancreatic cancer did not achieve its primary endpoint and in order to </font></div><div><br></div><div style="text-align:center;"><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">13</font></div></div><hr style="page-break-after:always"><div><div style="line-height:120%;font-size:8pt;"><a style="font-family:inherit;font-size:8pt;" href="#sD088029191DD5EB99A130DC52B3A6E1B"><font style="font-family:inherit;font-size:8pt;">Table of Contents</font></a></div><div style="line-height:120%;text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">NewLink Genetics Corporation and Subsidiaries</font></div><div style="line-height:120%;text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Notes to Condensed Consolidated Financial Statements</font></div><div style="line-height:120%;text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">(unaudited)</font></div><div style="line-height:120%;text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></div><div><br></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">reduce costs associated with algenpantucel-L and the HyperAcute&#174; Cellular Immunotherapy platform technology, the Company's management adopted a restructuring plan in May 2016 which included a reduction in the Company's workforce; the exit or reduction of certain leased facilities; and the renegotiation or termination of contracts with certain third parties. As a result of the restructuring, the Company also impaired fixed assets which management determined had no or limited future use. The fair value of impaired fixed assets was determined based on management&#8217;s estimate of market resale value. Restructuring charges recorded during 2016 were </font><font style="font-family:inherit;font-size:10pt;">$12.3 million</font><font style="font-family:inherit;font-size:10pt;">, of which </font><font style="font-family:inherit;font-size:10pt;">$500,000</font><font style="font-family:inherit;font-size:10pt;">&#32;is included within general and administrative expenses and </font><font style="font-family:inherit;font-size:10pt;">$11.8 million</font><font style="font-family:inherit;font-size:10pt;">&#32;is included within the research and development expenses in the condensed consolidated statement of operations. Included in the </font><font style="font-family:inherit;font-size:10pt;">$12.3 million</font><font style="font-family:inherit;font-size:10pt;">&#32;of charges is non-cash asset impairment charges of </font><font style="font-family:inherit;font-size:10pt;">$4.0 million</font><font style="font-family:inherit;font-size:10pt;">.  </font><font style="font-family:inherit;font-size:10pt;">No</font><font style="font-family:inherit;font-size:10pt;">&#32;additional charges related to the 2016 restructuring were recorded during the </font><font style="font-family:inherit;font-size:10pt;">three and nine months ended</font><font style="font-family:inherit;font-size:10pt;">&#32;</font><font style="font-family:inherit;font-size:10pt;">September&#160;30, 2017</font><font style="font-family:inherit;font-size:10pt;">&#32;and all amounts accrued as of December 31, 2016 were paid by the end of the first quarter of 2017.</font></div><div style="line-height:120%;padding-bottom:12px;padding-top:12px;text-align:justify;text-indent:32px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">The following table shows the amount accrued for restructuring activities which is recorded within Accrued Expenses in the condensed consolidated balance sheet:</font></div><div style="line-height:120%;padding-bottom:12px;padding-top:12px;text-align:center;text-indent:32px;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:428px;border-collapse:collapse;text-align:left;"><tr><td colspan="9"></td></tr><tr><td style="width:200px;"></td><td style="width:6px;"></td><td style="width:9px;"></td><td style="width:92px;"></td><td style="width:4px;"></td><td style="width:6px;"></td><td style="width:9px;"></td><td style="width:95px;"></td><td style="width:4px;"></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;font-weight:bold;">Employee Severance Cost</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;font-weight:bold;">Total</font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Balance as of December 31, 2016</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">42</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">42</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Expensed</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">1,695</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">1,695</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Cash Payments</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">1,085</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">1,085</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Balance as of September 30, 2017</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">652</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">652</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr></table></div></div><div style="line-height:120%;padding-bottom:12px;padding-top:12px;text-align:justify;text-indent:30px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">The majority of the charges are expected to be paid by the end of the year. &#160;&#160;&#160;&#160;</font></div><div><a name="sEA05B716E92F59E7BC7CE42E70831B1C"></a></div><table cellpadding="0" cellspacing="0" style="padding-top:12px;padding-bottom:12px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:30px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:0px;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">10.</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Commitments and Contingencies </font></div></td></tr></table><div style="line-height:120%;padding-bottom:12px;padding-top:12px;text-align:justify;text-indent:30px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">From time to time, claims are asserted against the Company arising in the ordinary course of business. In the opinion of management, liabilities, if any, arising from existing claims are not expected to have a material effect on the Company's earnings, financial position, or liquidity.</font></div><div style="line-height:120%;padding-bottom:12px;text-align:justify;text-indent:30px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">On or about May 12, 2016, Trevor Abramson filed a putative securities class action lawsuit in the United States District Court for the Southern District of New York, or the Court, captioned Abramson v. NewLink Genetics Corp., et al., Case 1:16-cv-3545, or the Securities Action. &#160;Subsequently, the Court appointed Michael and Kelly Nguyen as lead plaintiffs and approved their selection of Kahn, Swick &amp; Foti, LLC as lead counsel in the Securities Action.&#160;&#160;On October 31, 2016, the lead plaintiffs filed an amended complaint which asserts claims under the federal securities laws against the Company, the Company&#8217;s Chief Executive Officer Charles J. Link, Jr., and the Company&#8217;s Chief Medical Officer and President Nicholas Vahanian, or collectively, the Defendants.&#160; The amended complaint alleges the Defendants made material false and/or misleading statements that caused losses to the Company&#8217;s investors. In particular, the lead plaintiffs allege that the Defendants made material misstatements or omissions related to the Phase II and III trials and efficacy of the product candidate algenpantucel-L. The lead plaintiffs do not quantify any alleged damages in the amended complaint but, in addition to attorneys&#8217; fees and costs, they seek to recover damages on behalf of themselves and other persons who purchased or otherwise acquired the Company&#8217;s stock during the putative class period of September 17, 2013 through May 9, 2016, inclusive, at allegedly inflated prices and purportedly suffered financial harm as a result.  On April 27, 2017, the Court granted the parties&#8217; request for leave to brief a motion to dismiss the amended complaint, and ordered the parties to file a stipulation and proposed order setting forth a schedule for the briefing of that motion. &#160;On May 15, 2017, the Court ordered the following briefing schedule: motion to dismiss due July 14, 2017, opposition due September 12, 2017, and reply due September 26, 2017.&#160; The Defendants filed a motion to dismiss on July 14, 2017. The lead plaintiffs filed an opposition to the motion to dismiss on September 12, 2017. The Defendants filed a reply in support of the motion to dismiss on September 26, 2017. Oral argument was held on October 19, 2017, after which the Court reserved decision. The Company disputes the claims in the Securities Action and intends to defend against them vigorously.</font></div><div style="line-height:120%;text-align:justify;text-indent:30px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">On or about April 26, 2017, Ronald Morrow filed a shareholder derivative lawsuit on behalf of the Company in the United States District Court for the Southern District of New York, or the Court, against the Company&#8217;s Chief Executive Officer Charles J. Link, Jr., the Company&#8217;s Chief Medical Officer and President Nicholas Vahanian, and Company directors Thomas A. Raffin, Joseph Saluri, Ernest J. Talarico, III, Paul R. Edick, Paolo Pucci, and Lota S. Zoth, or collectively, the Morrow Defendants, captioned Morrow v. Link., et al., Case 1:17-cv-03039, or the Morrow Action.&#160; The complaint alleges that the Morrow Defendants caused the Company to issue false statements in its 2016 proxy statement regarding risk management and compensation matters in violation </font></div><div><br></div><div style="text-align:center;"><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">14</font></div></div><hr style="page-break-after:always"><div><div style="line-height:120%;font-size:8pt;"><a style="font-family:inherit;font-size:8pt;" href="#sD088029191DD5EB99A130DC52B3A6E1B"><font style="font-family:inherit;font-size:8pt;">Table of Contents</font></a></div><div style="line-height:120%;text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">NewLink Genetics Corporation and Subsidiaries</font></div><div style="line-height:120%;text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Notes to Condensed Consolidated Financial Statements</font></div><div style="line-height:120%;text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">(unaudited)</font></div><div style="line-height:120%;text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></div><div><br></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">of federal securities law.&#160; The complaint also asserts state law claims against the Morrow Defendants for breaches of fiduciary duties, unjust enrichment, abuse of control, insider trading, gross mismanagement, and corporate waste, alleging that the Morrow Defendants made material misstatements or omissions related to the Phase II and III trials and efficacy of the product candidate algenpantucel-L, awarded themselves excessive compensation, engaged in illegal insider trading, and grossly mismanaged the Company.&#160; The plaintiff does not quantify any alleged damages in the complaint but seeks restitution for damages to the Company, attorneys&#8217; fees, costs, and expenses, as well as an order directing that proposals for strengthening board oversight be put to a vote of the Company&#8217;s shareholders. &#160;The language for such proposals is not specified in the complaint.&#160; The plaintiff also contemporaneously filed a statement of relatedness, informing the Court that the Morrow Action is related to Abramson v. NewLink Genetics Corp., et al., Case 1:16-cv-3545.&#160; On May 19, 2017, the plaintiff dismissed the Morrow Action without prejudice.&#160; Also on May 19, 2017, plaintiffs&#8217; counsel in the Morrow Action filed a new shareholder derivative complaint that is substantively identical to the Morrow Action, except that the plaintiff is Rickey Ely.&#160; The latter action is captioned Ely v. Link, et al., Case 17-cv-3799, or the Ely Action.&#160; By agreement of the parties and order dated June 26, 2017, the Court temporarily stayed the Ely Action until the Securities Action is dismissed or otherwise resolved.&#160; Under the terms of the stay, the plaintiff in the Ely Action will be provided with any discovery that is provided in the Securities Action, and given an opportunity to participate in any mediation or settlement efforts in the Securities Action.&#160; The Company disputes the claims in the Ely Action and intends to defend against them vigorously.</font></div><div><a name="sEE4FF83EED0A552993BAA4A452533C20"></a></div><table cellpadding="0" cellspacing="0" style="padding-top:12px;padding-bottom:12px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:30px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:0px;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">11.</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Subsequent Events</font></div></td></tr></table><div style="line-height:120%;padding-bottom:12px;padding-top:12px;text-align:justify;text-indent:30px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">On October 6, 2017, the Company sold </font><font style="font-family:inherit;font-size:10pt;">5,750,000</font><font style="font-family:inherit;font-size:10pt;">&#32;shares of its common stock for total proceeds of </font><font style="font-family:inherit;font-size:10pt;">$55.2 million</font><font style="font-family:inherit;font-size:10pt;">, net of offering expenses of </font><font style="font-family:inherit;font-size:10pt;">$3.7 million</font><font style="font-family:inherit;font-size:10pt;">. Net proceeds from the offering will be used to further advance its pipeline of product candidates, including the continued clinical development of indoximod, and for working capital and other general corporate purposes.  </font></div><div style="line-height:120%;padding-bottom:12px;padding-top:12px;text-align:justify;text-indent:30px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;padding-bottom:12px;padding-top:12px;text-align:justify;text-indent:30px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div><br></div><div style="text-align:center;"><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">15</font></div></div><hr style="page-break-after:always"><div><a name="s0F1BEB42835457E4BE551138D7B7D00C"></a></div><div><div style="line-height:120%;text-align:left;font-size:8pt;"><a style="font-family:inherit;font-size:8pt;" href="#sD088029191DD5EB99A130DC52B3A6E1B"><font style="font-family:inherit;font-size:8pt;">Table of Contents</font></a></div></div><div><br></div><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">ITEM 2.&#160;&#160;&#160;&#160;MANAGEMENT&#8217;S DISCUSSION AND ANALYSIS OF FINANCIAL CONDITION AND RESULTS OF OPERATIONS</font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;">This Quarterly Report on Form&#160;10-Q</font><font style="font-family:inherit;font-size:10pt;">&#32;</font><font style="font-family:inherit;font-size:10pt;font-style:italic;">contains</font><font style="font-family:inherit;font-size:10pt;">&#32;</font><font style="font-family:inherit;font-size:10pt;font-style:italic;">forward-looking statements</font><font style="font-family:inherit;font-size:10pt;">&#32;</font><font style="font-family:inherit;font-size:10pt;font-style:italic;">within the meaning of Section&#160;27A of the Securities Act of 1933, as amended, Section&#160;21E of the Securities Exchange Act of 1934, as amended, and the Private Securities Litigation Reform Act of 1995, and such statements are subject to the</font><font style="font-family:inherit;font-size:10pt;">&#32;</font><font style="font-family:inherit;font-size:10pt;font-style:italic;">&#8220;safe harbor&#8221;</font><font style="font-family:inherit;font-size:10pt;">&#32;</font><font style="font-family:inherit;font-size:10pt;font-style:italic;">created by those sections. &#160;Forward-looking statements are based on our management&#8217;s beliefs and assumptions and on information available to our management</font><font style="font-family:inherit;font-size:10pt;">&#32;</font><font style="font-family:inherit;font-size:10pt;font-style:italic;">as of the date hereof. In some cases, you can identify forward-looking statements by terms such as &#8220;may,&#8221; &#8220;will,&#8221; &#8220;should,&#8221; &#8220;could,&#8221; &#8220;would,&#8221; &#8220;expect,&#8221; &#8220;plans,&#8221; &#8220;anticipates,&#8221; &#8220;believes,&#8221; &#8220;estimates,&#8221; &#8220;projects,&#8221; &#8220;predicts,&#8221; &#8220;potential&#8221; and similar expressions intended to identify forward-looking statements. Examples of these statements include, but are not limited to, statements regarding: our ongoing and planned preclinical studies and clinical trials; the timing of the release of the results of data from ongoing clinical studies; the timing of and our ability to obtain and maintain regulatory approvals for our product candidates; the clinical utility of our product candidates; our plans to leverage our existing technologies to discover and develop additional product candidates; our ability to quickly and efficiently identify and develop product candidates; our intellectual property position; the potential benefits of strategic collaboration agreements and our ability to enter into strategic arrangements; our estimates regarding expenses, future revenues, capital requirements and needs for additional financing; plans to develop, commercialize, market and manufacture our product candidates; and other risks and uncertainties, including those</font><font style="font-family:inherit;font-size:10pt;">&#32;</font><font style="font-family:inherit;font-size:10pt;font-style:italic;">described in Part&#160;II,&#160;Item&#160;1A,</font><font style="font-family:inherit;font-size:10pt;">&#32;</font><font style="font-family:inherit;font-size:10pt;font-style:italic;">&#8220;Risk Factors&#8221;</font><font style="font-family:inherit;font-size:10pt;">&#32;</font><font style="font-family:inherit;font-size:10pt;font-style:italic;">of this Quarterly Report and in our other periodic reports filed from time to time with the Securities and Exchange Commission, or SEC, including our Annual Report on Form 10-K for the year ended December 31, 2016.&#160;</font><font style="font-family:inherit;font-size:10pt;">&#32;</font><font style="font-family:inherit;font-size:10pt;font-style:italic;">Our actual results could differ materially from those discussed in our forward-looking statements for many reasons, including those risks. You should not place undue reliance on these forward-looking statements, which apply only as of the date of this Quarterly Report on Form&#160;10-Q. You should read this Quarterly Report on Form&#160;10-Q completely. Except as required by law, we assume no obligation to update these forward-looking statements publicly, or to update the reasons actual results could differ materially from those anticipated in these forward-looking statements, even if new information becomes available in the future.</font></div><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;">The following discussion and analysis should be read in conjunction with the unaudited financial statements and notes thereto included in Part&#160;I,&#160;Item&#160;1 of this Quarterly Report on Form&#160;10-Q.</font></div><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div><a name="sD630AB3F2DBE50A79B0B16F1BEDB2835"></a></div><div style="line-height:120%;padding-bottom:12px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Overview</font></div><div style="line-height:120%;padding-bottom:12px;text-align:justify;text-indent:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">We are a late clinical-stage immuno-oncology company focused on discovering and developing novel immunotherapeutic products for the treatment of patients with cancer. We are committed to developing our pipeline of small-molecule and biologic immuno-oncology product candidates intended to treat a wide range of oncology indications. Our leading small-molecule product candidates currently in clinical development target the indoleamine-2, 3-dioxygenase, or IDO, pathway, which is one of the key pathways for cancer immune escape. These product candidates, indoximod, NLG802 and navoximod (formerly GDC-0919), are IDO pathway inhibitors with mechanisms of action that center around breaking the immune system&#8217;s tolerance to cancer. Additional clinical-stage product candidates in our pipeline include two product candidates that utilize our HyperAcute&#174; Cellular Immunotherapy technology and two small molecules we acquired in 2017 from Cerulean Pharmaceuticals. The HyperAcute candidates, tergenpumatucel-L and dorgenmeltucel-L, are in Phase 2 clinical trials for patients with advanced lung cancer and melanoma, respectively. The two small molecules, CRLX101 and CRLX301, are being evaluated in early clinical development for patients with advanced solid malignancies. Additional clinical trials with these product candidates are under consideration, pending the outcome of the current studies and the availability of resources.&#160;</font></div><div style="line-height:120%;padding-bottom:16px;text-align:justify;text-indent:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">We believe that immune system failure is a fundamental reason for the inability of the human body to successfully fight cancer cells. Research into the inability of the immune system to respond to cancerous tumors indicates that tumors can induce the human immune system to tolerate the existence of the tumor. This immune tolerance and suppression represents a major barrier to successful treatment of cancer and is a significant target for new therapeutics.</font></div><div style="line-height:120%;padding-bottom:16px;text-align:justify;text-indent:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Scientific understanding of the process leading to immune tolerance, while moving rapidly, is still in its early stages. We believe IDO is part of a system that may be used by some tumors as a mechanism to evade the immune system.</font></div><div style="line-height:120%;padding-bottom:16px;text-align:justify;text-indent:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">In cancer, the IDO pathway regulates immune response by suppressing T-cell activation, which enables local tumors to avoid immune response. The IDO pathway is expressed in many cancers, both within tumor cells as a direct defense against T-cell attack, and also within antigen presenting cells in tumor-draining lymph nodes, whereby this pathway promotes peripheral tolerance to tumor associated antigens, or TAAs. When hijacked by developing cancers in this manner, the IDO pathway may facilitate the survival, growth, invasion and metastasis of malignant cells whose expression of TAAs might otherwise be recognized and attacked by the immune system. </font></div><div><br></div><div style="text-align:center;"><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">16</font></div></div><hr style="page-break-after:always"><div><div style="line-height:120%;text-align:left;font-size:8pt;"><a style="font-family:inherit;font-size:8pt;" href="#sD088029191DD5EB99A130DC52B3A6E1B"><font style="font-family:inherit;font-size:8pt;">Table of Contents</font></a></div></div><div><br></div><div style="line-height:120%;text-align:justify;text-indent:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">The IDO pathway refers to a series of reactions initiated by IDO that result in the reduction of the amino acid tryptophan in the local tumor environment.  We believe the local presence of tryptophan in adequate concentrations promotes antitumor T-cells, and the local reduction of tryptophan combined with the presence of the break-down product of tryptophan metabolism, kynurenine, is understood to suppress the activation of T-cells. Direct enzymatic inhibitors such as navoximod and peer molecules of other companies inhibit the IDO enzyme directly and thereby prevents the metabolism of tryptophan into kynurenine. We believe that indoximod has a different mechanism of action from such direct enzymatic inhibitors and acts in part directly on T-cells bypassing the effects of IDO activity. Indoximod may also &#8220;mimic&#8221; tryptophan and signal the activation of antitumor T-cells in a local microenvironment where IDO is active.  Indoximod is therefore understood to return the immune system to a more active state. </font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;padding-bottom:12px;text-align:justify;text-indent:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">While traditional chemotherapy places substantial stress on tumor-induced immune tolerance, this effect often dissipates following the end of chemotherapy treatment. Cytotoxic chemotherapy appears to mitigate immune tolerance in several ways: (1)&#160;dying tumor cells release waves of TAAs for processing and presentation, (2)&#160;many chemotherapeutic regimens induce a period of transient lymphopenia and homeostatic recovery during which T-cells may become more susceptible to breaking tolerance, and (3)&#160;certain regimens can transiently deplete or inactivate tumor-protective T-regulatory cells. However, most chemotherapeutic agents do not appear to trigger a protective immune response against established tumors, as many tumors rapidly re-establish tolerance following each cycle of chemotherapy. We believe a potential portion of this mechanism underlying these phenomena is IDO expression by APCs in tumor-draining lymph nodes, which triggers an immunosuppression and immune tolerance to cancer. Preclinical and, increasingly, clinical data suggest that IDO pathway inhibitors may enhance the anti-tumor effects of other immunotherapies, chemotherapies and radiation, when used in combination.  </font></div><div style="line-height:120%;padding-bottom:12px;text-align:justify;text-indent:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">The ability to eliminate the protective IDO mechanism by administering IDO pathway inhibitor drugs may provide a therapeutic window in which to break tolerance in some tumors and reverse the inhibition of immune cells. </font></div><div style="line-height:120%;padding-bottom:12px;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">IDO Pathway Inhibitor Clinical Development </font></div><div style="line-height:120%;padding-bottom:12px;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;">Indoximod</font></div><div style="line-height:120%;padding-bottom:12px;text-align:justify;text-indent:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Indoximod, our lead IDO pathway inhibitor, has a differentiated mechanism of action from other drugs in the class of IDO inhibitors and is currently in Phase 2 clinical development in combination with other cancer therapeutics for patients with melanoma, pancreatic cancer and acute myeloid leukemia. We intend to launch a pivotal Phase 3 clinical trial in the first quarter of 2018 for patients with advanced melanoma, and we expect to substantially complete enrollment by the end of 2018. Indoximod has been studied in more than 700 patients to date and has been generally well-tolerated, both as a single agent and in combination with PD-1 checkpoint inhibitors, various chemotherapy agents and a cancer vaccine. Primary tumor types being explored in clinical trials include melanoma, pancreatic cancer and acute myeloid leukemia. We believe there may be additional opportunities for a broad set of cancer indications. We expect data from our Phase 2 trial for patients with pancreatic cancer in the first half of 2018, completion of our Phase 2 trial for patients with acute myeloid leukemia in the second half of 2018 and completion of our Phase 2 trial for patients with advanced melanoma in 2018. A summary of these key trials is set forth in the table below.</font></div><div style="line-height:120%;padding-bottom:12px;text-align:center;"><img src="nlnkidoclinicalprioritiesa01.jpg" alt="nlnkidoclinicalprioritiesa01.jpg" style="height:334px;width:597px;"></div><div><br></div><div style="text-align:center;"><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">17</font></div></div><hr style="page-break-after:always"><div><div style="line-height:120%;text-align:left;font-size:8pt;"><a style="font-family:inherit;font-size:8pt;" href="#sD088029191DD5EB99A130DC52B3A6E1B"><font style="font-family:inherit;font-size:8pt;">Table of Contents</font></a></div></div><div><br></div><div style="line-height:120%;padding-bottom:12px;text-align:justify;text-indent:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Our planned pivotal clinical trial in advanced melanoma is a Phase 3 investigation of indoximod in combination with a checkpoint inhibitor for advanced unresectable and metastatic melanoma compared to the checkpoint inhibitor alone. The trial will have a 1:1 randomized, double blind, placebo controlled design. Participating investigators will be allowed to prescribe either of the U.S. Food and Drug Administration, or FDA, approved PD-1 checkpoint inhibitors, KEYTRUDA&#174; (pembrolizumab) or OPDIVO&#174; (nivolumab), and patients will then be randomized to receive indoximod or placebo in conjunction with the checkpoint inhibitor. The trial will have co-primary endpoints by Response Evaluation in Solid Tumors, or RECIST, criteria of progression free survival and overall survival. The planned enrollment is approximately 600 patients.</font></div><div style="line-height:120%;padding-bottom:12px;text-align:justify;text-indent:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">A U.S. patent covering salt and prodrug formulations of indoximod was issued to us on August 15, 2017 providing exclusivity into 2036. We are pursuing international patent coverage for these formulations. We intend to use the improved salt formulation of indoximod in our planned Phase 3 clinical trial. The required clinical safety testing for this new formulation is being addressed in an ongoing trial in patients with acute myeloid leukemia and will also be addressed in the pivotal Phase 3 clinical trial in patients with advanced melanoma. This plan was discussed with the FDA during a Type B meeting, and the FDA agreed that the plan would likely satisfy the requirement for a clinical bridge.&#160; If the results of any of these clinical trials raise meaningful concerns about clinical safety, the time and expense required to initiate and complete our Phase 3 clinical trial would likely increase.&#160;</font></div><div style="line-height:120%;padding-bottom:12px;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;">NLG802</font></div><div style="line-height:120%;padding-bottom:12px;text-align:justify;text-indent:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">NLG802 is a prodrug of indoximod. NLG802 is intended to increase bioavailability and exposure to indoximod above the levels currently achievable by direct oral administration of the original formulation of indoximod. We filed an Investigational New Drug application, or IND, with the FDA in the first quarter of 2017 and the first patient was dosed with NLG802 in a Phase 1 clinical trial in July 2017. The purpose of this Phase 1 trial is to assess preliminary safety and to determine the recommended dose for subsequent Phase 2 evaluations. NLG802 is a new chemical entity with patent coverage into 2036. We are also pursuing international patent coverage for NLG802.</font></div><div style="line-height:120%;padding-bottom:12px;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;">Navoximod (formerly GDC-0919)</font></div><div style="line-height:120%;padding-bottom:12px;text-align:justify;text-indent:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Navoximod, a direct enzymatic inhibitor, was previously in clinical development as part of our collaboration with Genentech, Inc., a member of the Roche Group, or Genentech. In October 2014, we entered into an exclusive worldwide license and collaboration agreement with Genentech, or the Genentech Agreement. The Genentech Agreement provided for the development and commercialization of navoximod. In addition, under the Genentech Agreement, we conducted a two-year pre-clinical research program with Genentech to discover novel next generation IDO/TDO (tryptophan-2, 3-dioxygenase) inhibitors. The research program ended in November 2016, but our collaboration with Genentech continues with respect to next generation IDO/TDO inhibitors identified through the research program.</font></div><div style="line-height:120%;padding-bottom:12px;text-align:justify;text-indent:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">On&#160;June 6, 2017, we received a formal notice of Genentech&#8217;s intent to terminate the Genentech Agreement with respect to navoximod with such termination to be effective no later than December 6, 2017. Discussions regarding the termination are ongoing. The Genentech Agreement will continue with regards to any Next Generation Products and/or Subsequent Products as defined under the Genentech Agreement.</font></div><div style="line-height:120%;padding-bottom:12px;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;">PTEN</font><font style="font-family:inherit;font-size:10pt;">&#160;&#160;&#160;&#160;</font></div><div style="line-height:120%;padding-bottom:12px;text-align:justify;text-indent:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">We also have an early discovery program focused on Phosphatase and Tensin Homolog in Chromosome 10, or PTEN. Recent advances in the characterization of the IDO pathway have suggested that IDO activates a subset of PD-1-dependent regulatory T-cells, or Tregs, that are potently immunosuppressive. Evidence suggests these Treg cells mediate systemic immunosuppression against tumor-associated antigens and that the function of PTEN may be important to maintaining the suppressive character of these cells. Based on data from preclinical animal models, we believe that the efficacy of PTEN inhibitors might be enhanced when combined with different standard-of-care therapeutic approaches such as chemotherapy and radiotherapy, as well as with IDO pathway inhibitors such as indoximod.</font></div><div style="line-height:120%;padding-bottom:12px;text-align:justify;text-indent:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">In March 2016, we entered into an exclusive, worldwide license agreement with Augusta University Research Institute, or AURI, related to PTEN inhibitor products. Under the terms of such agreement, or the AURI PTEN License Agreement, we paid an upfront payment to AURI of $1.0 million and we are obligated to pay AURI potential milestone payments in an aggregate amount up to approximately $4.3 million and royalties at a single-digit or less percentage of net sales of royalty-bearing products, or PTEN inhibitor products that are covered by licensed patents or certain of our patents or that were researched or developed using licensed technology. In addition, if we grant a sublicense under the license granted by AURI or we grant a license to certain of our patents that cover royalty-bearing products, we must pay to AURI a percentage of certain specified consideration that we receive from the sublicensee or licensee.</font></div><div style="line-height:120%;padding-bottom:12px;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Ebola Vaccine Candidate</font></div><div><br></div><div style="text-align:center;"><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">18</font></div></div><hr style="page-break-after:always"><div><div style="line-height:120%;text-align:left;font-size:8pt;"><a style="font-family:inherit;font-size:8pt;" href="#sD088029191DD5EB99A130DC52B3A6E1B"><font style="font-family:inherit;font-size:8pt;">Table of Contents</font></a></div></div><div><br></div><div style="line-height:120%;padding-bottom:12px;text-align:justify;text-indent:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">In November 2014, we entered into an exclusive, worldwide license and collaboration agreement, or the Merck Agreement, with Merck, Sharp and Dohme Corp., or Merck, to develop and potentially commercialize our rVSV&#8710;G-ZEBOV GP vaccine product candidate and other aspects of our vaccine technology. The rVSV&#8710;G-ZEBOV GP vaccine product candidate was originally developed by the Public Health Agency of Canada, or PHAC, and is designed to utilize the rVSV vector to induce immunity against Ebola virus when replacing the VSV glycoprotein with corresponding glycoproteins from filoviruses. Under the Merck Agreement, we received an upfront payment of $30.0 million in October 2014, and in February 2015 we received a milestone payment of $20.0 million. We have the potential to earn royalties on sales of the vaccine in certain countries, if the vaccine is approved and if Merck successfully commercializes it. rVSV&#8710;G-ZEBOV GP is also eligible to receive a priority review voucher and we are entitled to a portion of the value of the voucher if it is granted. In addition to milestone payments from Merck, we were awarded contracts for development of the rVSV&#8710;G-ZEBOV GP from the U.S. BioMedical Advanced Research &amp; Development Authority and the Defense Threat Reduction Agency totaling $52.1 million during 2016 and $67.0 million during 2014 and 2015, for total awards of $119.1 million.&#160;</font></div><div style="line-height:120%;padding-bottom:12px;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Recent Developments</font></div><div style="line-height:120%;padding-bottom:12px;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;">Collaboration with AstraZeneca</font></div><div style="line-height:120%;padding-bottom:12px;text-align:justify;text-indent:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">On September 25, 2017, we announced that we have entered into a clinical collaboration agreement with&#160;AstraZeneca&#160;to evaluate the combination of indoximod and durvalumab, AstraZeneca's anti-PD-L1 monoclonal antibody, along with standard of care chemotherapy for patients with metastatic pancreatic cancer. We and AstraZeneca have agreed to initiate a randomized, placebo-controlled, Phase 2 clinical trial with the primary objective to evaluate the efficacy and safety of the immuno-oncology-based indoximod/durvalumab combination compared to gemcitabine/ABRAXANE alone. Some patients will be enrolled into a smaller cohort evaluating the combination of durvalumab with gemcitabine/ABRAXANE. From the date of our agreement with AstraZeneca and for 90 days after the completion of such combination study, we may not conduct a clinical trial involving the combination of indoximod and any compound that targets PD-1 or PD-L1 (other than durvalumab) for the metastatic pancreatic cancer indication, and AstraZeneca may not conduct a clinical trial involving the combination of durvalumab and any IDO pathway inhibitor (other than indoximod) for the metastatic pancreatic cancer indication. The Phase 2 clinical trial will be funded equally by both companies, with&#160;us serving as the study sponsor. Our share of the aggregate expense of the trial is not expected to have a material effect on our financial position. We expect to begin enrolling patients in the first quarter of 2018.</font></div><div style="line-height:120%;padding-bottom:12px;text-align:justify;text-indent:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">The market opportunity for the treatment of pancreatic cancer is substantial. Approximately 54,000 new cases of pancreatic cancer in the United States will be diagnosed in 2017 according to the&#160;National Cancer Institute, or&#160;NCI, and a little over 43,000 people will die of the disease this year. Pancreatic cancer is difficult to detect in its early stages and approximately 52% of all pancreatic cancers are metastatic, or advanced, in nature and are associated with a poor prognosis. The 5-year survival rate for pancreatic cancer overall is only 8.2%, and drops to a low of 2.7% for individuals whose pancreatic cancer has metastasized to farther regions of the body.</font></div><div style="line-height:120%;padding-bottom:12px;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;">Updated Phase 2 Data for Patients with Advanced Melanoma</font></div><div style="line-height:120%;padding-bottom:12px;text-align:justify;text-indent:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">On September 7, 2017, we announced updated data from the ongoing Phase 2 NLG2103 trial of indoximod in combination with the PD-1 pathway inhibitor, KEYTRUDA (pembrolizumab). These data were highlighted in an oral presentation at the&#160;Third International Cancer Immunotherapy conference&#160;in&#160;Frankfurt/Mainz,&#160;Germany, on&#160;September 9, 2017&#160;by&#160;Yousef Zakharia, M.D., Assistant Professor of Medicine,&#160;Division of Hematology, Oncology and Blood &amp; Marrow Transplantation at the&#160;University of Iowa&#160;and&#160;Holden Comprehensive Cancer Center.</font></div><div style="line-height:120%;padding-bottom:12px;text-align:justify;text-indent:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">NLG2103 is a Phase 2 trial evaluating the addition of indoximod to the standard of care checkpoint inhibitors approved for patients with advanced melanoma (pembrolizumab, ipilimumab, or nivolumab). The interim data represent a cohort of approximately 60 evaluable patients who received indoximod in combination with pembrolizumab. Evaluable patients were defined as those having at least one on-treatment imaging study. The primary outcome measure of the trial is objective response rate, or ORR, and secondary outcome measures include disease control rate and evaluation of safety and tolerability.</font></div><div style="line-height:120%;padding-bottom:12px;text-align:justify;text-indent:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">The&#160;data presented showed an improvement over previously reported results for the same 51 patients with cutaneous, mucosal and melanoma of unknown primary origin first presented at the American Association for Cancer Research Annual Meeting 2017 for both the complete response rate, or CR, and the ORR for patients&#160;who received indoximod in combination with pembrolizumab. The data showed improvement in CR to 20% (10/51 patients) compared to the previously reported CR of 12% (6/51 patients). The Progression-Free Survival, or PFS, by RECIST criteria was 56% at one year with median PFS of 12.9 months.</font></div><div style="line-height:120%;padding-bottom:16px;padding-top:16px;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Restructuring Charges</font></div><div style="line-height:120%;padding-bottom:12px;padding-top:16px;text-align:justify;text-indent:32px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">In July 2017, we&#160;undertook an organizational realignment to refocus our clinical development efforts and align our resources to focus on our highest value opportunities. The restructuring activities included a reduction of our workforce by approximately </font></div><div><br></div><div style="text-align:center;"><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">19</font></div></div><hr style="page-break-after:always"><div><div style="line-height:120%;text-align:left;font-size:8pt;"><a style="font-family:inherit;font-size:8pt;" href="#sD088029191DD5EB99A130DC52B3A6E1B"><font style="font-family:inherit;font-size:8pt;">Table of Contents</font></a></div></div><div><br></div><div style="line-height:120%;padding-bottom:12px;padding-top:16px;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">50%, which consisted primarily of clinical and research and development staff, as well as stopping additional research on the Zika virus. Refer to Note 9 for more information.</font></div><div style="line-height:120%;padding-bottom:16px;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Corporate Information</font></div><div style="line-height:120%;padding-bottom:12px;text-align:justify;text-indent:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Founded in 1999, our principal executive office is located in Ames, Iowa, with an additional office located in Austin, Texas.  We have a clinical, research and development team dedicated to our pipeline of product candidates for patients with cancer and other diseases. </font></div><div style="line-height:120%;text-indent:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">We incurred a net loss of </font><font style="font-family:inherit;font-size:10pt;">$58.3 million</font><font style="font-family:inherit;font-size:10pt;">&#32;for the </font><font style="font-family:inherit;font-size:10pt;">nine months ended</font><font style="font-family:inherit;font-size:10pt;">&#32;</font><font style="font-family:inherit;font-size:10pt;">September&#160;30, 2017</font><font style="font-family:inherit;font-size:10pt;">.  We expect to continue to incur losses over the next several years as we incur expenses to complete our clinical trial programs for our product candidates, develop our pipeline and pursue regulatory approval of our product candidates.</font></div><div><a name="sAAD28AD42568549183235A5A6E32FD7E"></a></div><div style="line-height:120%;padding-top:12px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Critical Accounting Policies and Significant Judgments and Estimates</font></div><div style="line-height:120%;padding-top:12px;text-align:justify;text-indent:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">We have prepared our financial statements in accordance with U.S. GAAP which requires us to make estimates, assumptions and judgments that affect the reported amount of assets, liabilities, expenses and related disclosures at the date of the financial statements, as well as revenues and expenses during the reporting periods. As such, to understand our financial statements, it is important to understand our critical accounting policies.  A critical accounting policy is one that is both important to the portrayal of our financial condition and results of operation and requires management&#8217;s most difficult, subjective or complex judgments, often as a result of the need to make estimates about the effect of matters that are inherently uncertain. Actual results could therefore differ materially from these estimates under different assumptions or conditions.</font></div><div style="line-height:120%;padding-bottom:12px;padding-top:12px;text-align:justify;text-indent:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Our Annual Report on Form 10-K for the year ended </font><font style="font-family:inherit;font-size:10pt;">December&#160;31, 2016</font><font style="font-family:inherit;font-size:10pt;">, discusses our most critical accounting policies. Since </font><font style="font-family:inherit;font-size:10pt;">December&#160;31, 2016</font><font style="font-family:inherit;font-size:10pt;">, there have been no material changes in the critical accounting policies discussed in our 2016 Annual Report.</font></div><div style="line-height:120%;padding-bottom:12px;padding-top:12px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Recent Accounting Pronouncements</font></div><div style="line-height:120%;text-align:left;text-indent:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">We do not believe that any recently issued effective pronouncements, or pronouncements issued but not yet effective, if adopted, would have a material effect on the accompanying financial statements.</font></div><div><a name="s5F05C977605057B3AD3F65D7973E89D6"></a></div><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Results of Operations</font></div><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;">Comparison of the Three Months Ended </font><font style="font-family:inherit;font-size:10pt;color:#000000;font-style:italic;font-weight:bold;text-decoration:none;">September&#160;30, 2017</font><font style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;">&#32;and </font><font style="font-family:inherit;font-size:10pt;color:#000000;font-style:italic;font-weight:bold;text-decoration:none;">2016</font></div><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:justify;text-indent:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;">Revenues.</font><font style="font-family:inherit;font-size:10pt;">&#32;Revenues for the </font><font style="font-family:inherit;font-size:10pt;">three months ended</font><font style="font-family:inherit;font-size:10pt;">&#32;</font><font style="font-family:inherit;font-size:10pt;">September&#160;30, 2017</font><font style="font-family:inherit;font-size:10pt;">&#32;were </font><font style="font-family:inherit;font-size:10pt;">$5.5 million</font><font style="font-family:inherit;font-size:10pt;">, a </font><font style="font-family:inherit;font-size:10pt;">decrease</font><font style="font-family:inherit;font-size:10pt;">&#32;of </font><font style="font-family:inherit;font-size:10pt;">$9.8 million</font><font style="font-family:inherit;font-size:10pt;">&#32;from </font><font style="font-family:inherit;font-size:10pt;">$15.3 million</font><font style="font-family:inherit;font-size:10pt;">&#32;for the same period in </font><font style="font-family:inherit;font-size:10pt;">2016</font><font style="font-family:inherit;font-size:10pt;">. The </font><font style="font-family:inherit;font-size:10pt;">decrease</font><font style="font-family:inherit;font-size:10pt;">&#32;in revenue was due to a </font><font style="font-family:inherit;font-size:10pt;">decrease</font><font style="font-family:inherit;font-size:10pt;">&#32;in grant revenue of </font><font style="font-family:inherit;font-size:10pt;">$9.1 million</font><font style="font-family:inherit;font-size:10pt;">, primarily due to a decrease in billings under the government grant contracts, and a </font><font style="font-family:inherit;font-size:10pt;">decrease</font><font style="font-family:inherit;font-size:10pt;">&#32;of </font><font style="font-family:inherit;font-size:10pt;">$785,000</font><font style="font-family:inherit;font-size:10pt;">&#32;in licensing revenue. Licensing revenues declined due to lower revenues recognized under the Genentech Agreement in the </font><font style="font-family:inherit;font-size:10pt;">three months ended</font><font style="font-family:inherit;font-size:10pt;">&#32;</font><font style="font-family:inherit;font-size:10pt;">September&#160;30, 2017</font><font style="font-family:inherit;font-size:10pt;">.  For the </font><font style="font-family:inherit;font-size:10pt;">three months ended</font><font style="font-family:inherit;font-size:10pt;">&#32;</font><font style="font-family:inherit;font-size:10pt;">September&#160;30, 2017</font><font style="font-family:inherit;font-size:10pt;">&#32;and </font><font style="font-family:inherit;font-size:10pt;">2016</font><font style="font-family:inherit;font-size:10pt;">, revenues recognized under the Genentech Agreement were </font><font style="font-family:inherit;font-size:10pt;">$56,000</font><font style="font-family:inherit;font-size:10pt;">&#32;and </font><font style="font-family:inherit;font-size:10pt;">$687,000</font><font style="font-family:inherit;font-size:10pt;">, respectively. </font></div><div style="line-height:120%;text-align:justify;text-indent:29px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:justify;text-indent:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;">Research and Development Expenses.</font><font style="font-family:inherit;font-size:10pt;">&#32;Research and development expenses for the </font><font style="font-family:inherit;font-size:10pt;">three months ended</font><font style="font-family:inherit;font-size:10pt;">&#32;</font><font style="font-family:inherit;font-size:10pt;">September&#160;30, 2017</font><font style="font-family:inherit;font-size:10pt;">&#32;were </font><font style="font-family:inherit;font-size:10pt;">$18.5 million</font><font style="font-family:inherit;font-size:10pt;">, a </font><font style="font-family:inherit;font-size:10pt;">decrease</font><font style="font-family:inherit;font-size:10pt;">&#32;of </font><font style="font-family:inherit;font-size:10pt;">$6.0 million</font><font style="font-family:inherit;font-size:10pt;">&#32;from </font><font style="font-family:inherit;font-size:10pt;">$24.5 million</font><font style="font-family:inherit;font-size:10pt;">&#32;for the same period in </font><font style="font-family:inherit;font-size:10pt;">2016</font><font style="font-family:inherit;font-size:10pt;">.  The </font><font style="font-family:inherit;font-size:10pt;">decrease</font><font style="font-family:inherit;font-size:10pt;">&#32;was due primarily to&#160;a&#160;$6.2 million decline in contract research and manufacturing spend, a $500,000 decrease in personnel-related spend, and a $530,000 decline in clinical trial and other supplies, offset by an increase of $630,000 in one-time restructuring expense incurred for employee severance during the third quarter of 2017, an increase of $370,000 in legal and consulting spend, and an increase of $230,000 in stock compensation expense.</font></div><div style="line-height:120%;padding-bottom:10px;padding-top:10px;text-align:justify;text-indent:48px;font-size:11pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;">General and Administrative Expenses.</font><font style="font-family:inherit;font-size:10pt;">&#32;General and administrative expenses for the </font><font style="font-family:inherit;font-size:10pt;">three months ended</font><font style="font-family:inherit;font-size:10pt;">&#32;</font><font style="font-family:inherit;font-size:10pt;">September&#160;30, 2017</font><font style="font-family:inherit;font-size:10pt;">&#32;were </font><font style="font-family:inherit;font-size:10pt;">$7.9 million</font><font style="font-family:inherit;font-size:10pt;">, an </font><font style="font-family:inherit;font-size:10pt;">increase</font><font style="font-family:inherit;font-size:10pt;">&#32;of $200,000 from </font><font style="font-family:inherit;font-size:10pt;">$7.7 million</font><font style="font-family:inherit;font-size:10pt;">&#32;for the same period in </font><font style="font-family:inherit;font-size:10pt;">2016</font><font style="font-family:inherit;font-size:10pt;">.  The </font><font style="font-family:inherit;font-size:10pt;">increase</font><font style="font-family:inherit;font-size:10pt;">&#32;</font><font style="font-family:inherit;font-size:11pt;">w</font><font style="font-family:inherit;font-size:10pt;">as due to a one-time restructuring expense incurred for employee severance during the third quarter of 2017 of $1.1 million, an increase of $370,000 for supplies and other expenses, and an increase in stock compensation expense of $260,000 offset by a decline of&#160;$1.1 million in personnel-related spend, and a decline of $430,000 in consulting and legal fees.</font></div><div style="line-height:120%;padding-bottom:10px;padding-top:10px;text-align:justify;text-indent:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;">Income Tax Benefit.  </font><font style="font-family:inherit;font-size:10pt;">The income tax benefit for the </font><font style="font-family:inherit;font-size:10pt;">three months ended</font><font style="font-family:inherit;font-size:10pt;">&#32;</font><font style="font-family:inherit;font-size:10pt;">September&#160;30, 2017</font><font style="font-family:inherit;font-size:10pt;">&#32;was </font><font style="font-family:inherit;font-size:10pt;">$119,000</font><font style="font-family:inherit;font-size:10pt;">, compared to an income tax benefit of </font><font style="font-family:inherit;font-size:10pt;">$1.3 million</font><font style="font-family:inherit;font-size:10pt;">&#32;for the same period in 2016.  The change of </font><font style="font-family:inherit;font-size:10pt;">$1.2 million</font><font style="font-family:inherit;font-size:10pt;">&#32;is primarily due to the limited ability to carry 2017 losses back to 2015 compared to the larger benefit generated by the ability to carry 2016 losses back to 2014. The effective tax rate differs between periods primarily due to the change in the net loss generated by our foreign subsidiary and </font></div><div><br></div><div style="text-align:center;"><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">20</font></div></div><hr style="page-break-after:always"><div><div style="line-height:120%;text-align:left;font-size:8pt;"><a style="font-family:inherit;font-size:8pt;" href="#sD088029191DD5EB99A130DC52B3A6E1B"><font style="font-family:inherit;font-size:8pt;">Table of Contents</font></a></div></div><div><br></div><div style="line-height:120%;padding-bottom:10px;padding-top:10px;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">the ability to carry losses from 2017 and 2016 back to prior years. The full benefit in 2017 to be carried back to prior years is limited to the loss available in 2015.</font></div><div style="line-height:120%;padding-bottom:12px;text-align:justify;text-indent:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;">Net Loss.  </font><font style="font-family:inherit;font-size:10pt;">The n</font><font style="font-family:inherit;font-size:10pt;color:#222222;">et loss for the </font><font style="font-family:inherit;font-size:10pt;">three months ended</font><font style="font-family:inherit;font-size:10pt;color:#222222;">&#32;</font><font style="font-family:inherit;font-size:10pt;">September&#160;30, 2017</font><font style="font-family:inherit;font-size:10pt;color:#222222;">&#32;was </font><font style="font-family:inherit;font-size:10pt;color:#222222;">$20.6 million</font><font style="font-family:inherit;font-size:10pt;">&#32;compared to net loss of </font><font style="font-family:inherit;font-size:10pt;color:#222222;">$15.5 million</font><font style="font-family:inherit;font-size:10pt;color:#222222;">&#32;for the same period in </font><font style="font-family:inherit;font-size:10pt;color:#222222;">2016</font><font style="font-family:inherit;font-size:10pt;color:#222222;">.  The basic and diluted weighted average common shares outstanding for the </font><font style="font-family:inherit;font-size:10pt;">three months ended</font><font style="font-family:inherit;font-size:10pt;">&#32;</font><font style="font-family:inherit;font-size:10pt;">September&#160;30, 2017</font><font style="font-family:inherit;font-size:10pt;color:#222222;">&#32;were </font><font style="font-family:inherit;font-size:10pt;color:#222222;">29,939,823</font><font style="font-family:inherit;font-size:10pt;color:#222222;">, resulting in a basic and diluted loss per share of </font><font style="font-family:inherit;font-size:10pt;color:#222222;">$0.69</font><font style="font-family:inherit;font-size:10pt;color:#222222;">.  For the </font><font style="font-family:inherit;font-size:10pt;">three months ended</font><font style="font-family:inherit;font-size:10pt;">&#32;</font><font style="font-family:inherit;font-size:10pt;color:#222222;">September&#160;30, 2016</font><font style="font-family:inherit;font-size:10pt;color:#222222;">, the basic and diluted weighted average common shares outstanding were </font><font style="font-family:inherit;font-size:10pt;color:#222222;">28,983,561</font><font style="font-family:inherit;font-size:10pt;color:#222222;">, resulting in basic and diluted loss per share of </font><font style="font-family:inherit;font-size:10pt;color:#222222;">$0.54</font><font style="font-family:inherit;font-size:10pt;color:#222222;">.</font></div><div style="line-height:120%;padding-bottom:12px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;">Comparison of the Nine Months Ended </font><font style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;">September&#160;30, 2017</font><font style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;">&#32;and </font><font style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;">2016</font></div><div style="line-height:120%;padding-bottom:12px;text-align:justify;text-indent:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;">Revenues.</font><font style="font-family:inherit;font-size:10pt;">&#32;Revenues for the </font><font style="font-family:inherit;font-size:10pt;">nine months ended</font><font style="font-family:inherit;font-size:10pt;">&#32;</font><font style="font-family:inherit;font-size:10pt;">September&#160;30, 2017</font><font style="font-family:inherit;font-size:10pt;">&#32;were </font><font style="font-family:inherit;font-size:10pt;">$18.6 million</font><font style="font-family:inherit;font-size:10pt;">, a </font><font style="font-family:inherit;font-size:10pt;">decrease</font><font style="font-family:inherit;font-size:10pt;">&#32;of </font><font style="font-family:inherit;font-size:10pt;">$4.5 million</font><font style="font-family:inherit;font-size:10pt;">&#32;from </font><font style="font-family:inherit;font-size:10pt;">$23.1 million</font><font style="font-family:inherit;font-size:10pt;">&#32;for the same period in </font><font style="font-family:inherit;font-size:10pt;">2016</font><font style="font-family:inherit;font-size:10pt;">. The </font><font style="font-family:inherit;font-size:10pt;">decrease</font><font style="font-family:inherit;font-size:10pt;">&#32;in revenue was due to a </font><font style="font-family:inherit;font-size:10pt;">decrease</font><font style="font-family:inherit;font-size:10pt;">&#32;in grant revenue of </font><font style="font-family:inherit;font-size:10pt;">$1.8 million</font><font style="font-family:inherit;font-size:10pt;">, primarily due to a decrease in billings under the government grant contracts, and a </font><font style="font-family:inherit;font-size:10pt;">decrease</font><font style="font-family:inherit;font-size:10pt;">&#32;of </font><font style="font-family:inherit;font-size:10pt;">$2.7 million</font><font style="font-family:inherit;font-size:10pt;">&#32;in licensing revenue. Licensing revenues declined primarily due to lower revenues recognized under the Genentech and Merck Agreements in the </font><font style="font-family:inherit;font-size:10pt;">nine months ended</font><font style="font-family:inherit;font-size:10pt;">&#32;</font><font style="font-family:inherit;font-size:10pt;">September&#160;30, 2017</font><font style="font-family:inherit;font-size:10pt;">.  For the </font><font style="font-family:inherit;font-size:10pt;">nine months ended</font><font style="font-family:inherit;font-size:10pt;">&#32;</font><font style="font-family:inherit;font-size:10pt;">September&#160;30, 2017</font><font style="font-family:inherit;font-size:10pt;">&#32;and </font><font style="font-family:inherit;font-size:10pt;">2016</font><font style="font-family:inherit;font-size:10pt;">, revenues recognized under the Genentech Agreement were </font><font style="font-family:inherit;font-size:10pt;">$279,000</font><font style="font-family:inherit;font-size:10pt;">&#32;and </font><font style="font-family:inherit;font-size:10pt;">$2.2 million</font><font style="font-family:inherit;font-size:10pt;">, respectively. No revenues were recognized under the Merck Agreement for the </font><font style="font-family:inherit;font-size:10pt;">nine months ended</font><font style="font-family:inherit;font-size:10pt;">&#32;</font><font style="font-family:inherit;font-size:10pt;">September&#160;30, 2017</font><font style="font-family:inherit;font-size:10pt;">&#32;compared to revenues of </font><font style="font-family:inherit;font-size:10pt;">$764,000</font><font style="font-family:inherit;font-size:10pt;">&#32;for the </font><font style="font-family:inherit;font-size:10pt;">nine months ended</font><font style="font-family:inherit;font-size:10pt;">&#32;</font><font style="font-family:inherit;font-size:10pt;">September&#160;30, 2016</font><font style="font-family:inherit;font-size:10pt;">. </font></div><div style="line-height:120%;padding-bottom:12px;text-align:justify;text-indent:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;">Research and Development Expenses.</font><font style="font-family:inherit;font-size:10pt;">&#32;Research and development expenses for the </font><font style="font-family:inherit;font-size:10pt;">nine months ended</font><font style="font-family:inherit;font-size:10pt;">&#32;</font><font style="font-family:inherit;font-size:10pt;">September&#160;30, 2017</font><font style="font-family:inherit;font-size:10pt;">&#32;were </font><font style="font-family:inherit;font-size:10pt;">$52.4 million</font><font style="font-family:inherit;font-size:10pt;">, a </font><font style="font-family:inherit;font-size:10pt;">decrease</font><font style="font-family:inherit;font-size:10pt;">&#32;of </font><font style="font-family:inherit;font-size:10pt;">$21.4 million</font><font style="font-family:inherit;font-size:10pt;">&#32;from </font><font style="font-family:inherit;font-size:10pt;">$73.8 million</font><font style="font-family:inherit;font-size:10pt;">&#32;for the same period in </font><font style="font-family:inherit;font-size:10pt;">2016</font><font style="font-family:inherit;font-size:10pt;">.  The </font><font style="font-family:inherit;font-size:10pt;">decrease</font><font style="font-family:inherit;font-size:10pt;">&#32;was primarily due to a decrease of $11.2 million in restructuring charges.  During the nine months ended September 30, 2017 we incurred restructuring charges of $630,000 for employee severance costs compared to restructuring charges of $11.8 million for contract termination fees of $6.5 million, a fixed asset impairment charge of $4.0 million and employee severance of $1.3 million during the comparable period in 2016.  The remainder of the change year over year is due to a decline in clinical trial spend of $4.9 million, a decrease in supplies and other expenses of $3.5 million, a decrease in personnel-related expense of $2.9 million, and a decrease in licensing fees of $600,000. These reductions in spend were offset by an increase in stock compensation expense of $1.1 million, an increase in manufacturing spend of $310,000, and an increase in legal and consulting fees of $300,000.</font></div><div style="line-height:120%;padding-bottom:12px;text-align:justify;text-indent:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;">General and Administrative Expenses.</font><font style="font-family:inherit;font-size:10pt;">&#32;General and administrative expenses for the </font><font style="font-family:inherit;font-size:10pt;">nine months ended</font><font style="font-family:inherit;font-size:10pt;">&#32;</font><font style="font-family:inherit;font-size:10pt;">September&#160;30, 2017</font><font style="font-family:inherit;font-size:10pt;">&#32;were </font><font style="font-family:inherit;font-size:10pt;">$25.0 million</font><font style="font-family:inherit;font-size:10pt;">, a </font><font style="font-family:inherit;font-size:10pt;">decrease</font><font style="font-family:inherit;font-size:10pt;">&#32;of </font><font style="font-family:inherit;font-size:10pt;">$1.0 million</font><font style="font-family:inherit;font-size:10pt;">&#32;from </font><font style="font-family:inherit;font-size:10pt;">$26.0 million</font><font style="font-family:inherit;font-size:10pt;">&#32;for the same period in </font><font style="font-family:inherit;font-size:10pt;">2016</font><font style="font-family:inherit;font-size:10pt;">.  The </font><font style="font-family:inherit;font-size:10pt;">decrease</font><font style="font-family:inherit;font-size:10pt;">&#32;was due primarily to a reduction in personnel-related spend of $2.3 million and a reduction in legal and consulting of $680,000. These decreases were offset by an increase in stock compensation expense of $760,000, an increase in supplies and other expenses of $650,000, and an increase in restructuring charges of $570,000 for employee severance costs. </font></div><div style="line-height:120%;padding-bottom:12px;text-align:justify;text-indent:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;">Income Tax Benefit.  </font><font style="font-family:inherit;font-size:10pt;">The income tax benefit for the </font><font style="font-family:inherit;font-size:10pt;">nine months ended</font><font style="font-family:inherit;font-size:10pt;">&#32;</font><font style="font-family:inherit;font-size:10pt;">September&#160;30, 2017</font><font style="font-family:inherit;font-size:10pt;">&#32;was </font><font style="font-family:inherit;font-size:10pt;">$429,000</font><font style="font-family:inherit;font-size:10pt;">, compared to income tax benefit of </font><font style="font-family:inherit;font-size:10pt;">$5.0 million</font><font style="font-family:inherit;font-size:10pt;">&#32;for the same period in 2016.  The change of </font><font style="font-family:inherit;font-size:10pt;">$4.6 million</font><font style="font-family:inherit;font-size:10pt;">&#32;is primarily due to the limited ability to carry 2017 losses back to 2015 compared to the larger benefit generated by the ability to carry 2016 losses back to 2014. The effective tax rate differs between periods primarily due to the change in the net loss generated by our foreign subsidiary and the ability to carry losses from 2017 and 2016 back to prior years and limitations on the amount available to be used in prior years. </font></div><div style="line-height:120%;padding-bottom:12px;text-align:justify;text-indent:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;">Net Loss.  </font><font style="font-family:inherit;font-size:10pt;">The n</font><font style="font-family:inherit;font-size:10pt;color:#222222;">et loss for the </font><font style="font-family:inherit;font-size:10pt;">nine months ended</font><font style="font-family:inherit;font-size:10pt;color:#222222;">&#32;</font><font style="font-family:inherit;font-size:10pt;">September&#160;30, 2017</font><font style="font-family:inherit;font-size:10pt;color:#222222;">&#32;was </font><font style="font-family:inherit;font-size:10pt;color:#222222;">$58.3 million</font><font style="font-family:inherit;font-size:10pt;">&#32;compared to net loss of </font><font style="font-family:inherit;font-size:10pt;">$71.6 million</font><font style="font-family:inherit;font-size:10pt;color:#222222;">&#32;for the same period in </font><font style="font-family:inherit;font-size:10pt;color:#222222;">2016</font><font style="font-family:inherit;font-size:10pt;color:#222222;">.  The basic and diluted weighted average common shares outstanding for the </font><font style="font-family:inherit;font-size:10pt;">nine months ended</font><font style="font-family:inherit;font-size:10pt;">&#32;</font><font style="font-family:inherit;font-size:10pt;">September&#160;30, 2017</font><font style="font-family:inherit;font-size:10pt;color:#222222;">&#32;were </font><font style="font-family:inherit;font-size:10pt;color:#222222;">29,462,226</font><font style="font-family:inherit;font-size:10pt;color:#222222;">, resulting in a basic and diluted loss per share of </font><font style="font-family:inherit;font-size:10pt;color:#222222;">$1.98</font><font style="font-family:inherit;font-size:10pt;color:#222222;">.  For the </font><font style="font-family:inherit;font-size:10pt;">nine months ended</font><font style="font-family:inherit;font-size:10pt;">&#32;</font><font style="font-family:inherit;font-size:10pt;color:#222222;">September&#160;30, 2016</font><font style="font-family:inherit;font-size:10pt;color:#222222;">, the basic and diluted weighted average common shares outstanding were </font><font style="font-family:inherit;font-size:10pt;color:#222222;">28,911,042</font><font style="font-family:inherit;font-size:10pt;color:#222222;">, resulting in basic and diluted loss per share of </font><font style="font-family:inherit;font-size:10pt;color:#222222;">$2.48</font><font style="font-family:inherit;font-size:10pt;color:#222222;">.</font></div><div><a name="s72AF2ED2157855D18D03845F0A5D3923"></a></div><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Liquidity and Capital Resources</font></div><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:justify;text-indent:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">As of </font><font style="font-family:inherit;font-size:10pt;">September&#160;30, 2017</font><font style="font-family:inherit;font-size:10pt;">, we had cash and cash equivalents of </font><font style="font-family:inherit;font-size:10pt;">$120.7 million</font><font style="font-family:inherit;font-size:10pt;">. We have funded our operations principally through the private placement of equity securities and public offerings of common stock. To date, we have raised aggregate proceeds, net of offering costs, of $76.3 million from the issuance of convertible preferred stock prior to our IPO, and $145.3 million in net proceeds through our IPO and other public follow-on offerings. Additionally, on November 29, 2016, we entered into a Sales Agreement with Cantor Fitzgerald &amp; Co., or Cantor, under which we may sell up to </font><font style="font-family:inherit;font-size:10pt;">$40.0 million</font><font style="font-family:inherit;font-size:10pt;">&#32;of our common stock in one or more placements at prevailing market prices in an ATM offering. We launched this ATM in June 2017.  During the </font><font style="font-family:inherit;font-size:10pt;">three months ended</font><font style="font-family:inherit;font-size:10pt;">&#32;</font><font style="font-family:inherit;font-size:10pt;">September&#160;30, 2017</font><font style="font-family:inherit;font-size:10pt;">, we sold </font><font style="font-family:inherit;font-size:10pt;">1,940,656</font><font style="font-family:inherit;font-size:10pt;">&#32;shares of common stock under this ATM, with aggregate net proceeds of </font><font style="font-family:inherit;font-size:10pt;">$19.3 million</font><font style="font-family:inherit;font-size:10pt;">&#32;after commissions of </font><font style="font-family:inherit;font-size:10pt;">$398,000</font><font style="font-family:inherit;font-size:10pt;">&#32;paid to Cantor as the placement agent and other expenses of </font><font style="font-family:inherit;font-size:10pt;">$163,000</font><font style="font-family:inherit;font-size:10pt;">. Also subsequent to </font><font style="font-family:inherit;font-size:10pt;">September&#160;30, 2017</font><font style="font-family:inherit;font-size:10pt;">, we sold </font><font style="font-family:inherit;font-size:10pt;">5,750,000</font><font style="font-family:inherit;font-size:10pt;">&#32;shares of common stock in a public offering for aggregate net proceeds of </font><font style="font-family:inherit;font-size:10pt;">$55.2 million</font><font style="font-family:inherit;font-size:10pt;">&#32;after underwriters' discounts, commissions and other expenses of </font><font style="font-family:inherit;font-size:10pt;">$3.7 million</font><font style="font-family:inherit;font-size:10pt;">. </font></div><div style="line-height:120%;text-align:justify;text-indent:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div><br></div><div style="text-align:center;"><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">21</font></div></div><hr style="page-break-after:always"><div><div style="line-height:120%;text-align:left;font-size:8pt;"><a style="font-family:inherit;font-size:8pt;" href="#sD088029191DD5EB99A130DC52B3A6E1B"><font style="font-family:inherit;font-size:8pt;">Table of Contents</font></a></div></div><div><br></div><div style="line-height:120%;text-align:justify;text-indent:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">With the exception of the 2014 fiscal year, we have incurred operating losses and an accumulated deficit as a result of ongoing research and development spending since inception. We anticipate that we will continue to generate operating losses as we incur expenses to complete our clinical trial programs for our product candidates, develop our pipeline and pursue regulatory approval of our product candidates. </font></div><div style="line-height:120%;padding-bottom:10px;padding-top:10px;text-align:justify;text-indent:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">We may seek to sell additional equity or debt securities or obtain a credit facility if our available cash and cash equivalents are insufficient to satisfy our liquidity requirements or if we develop additional opportunities to do so. The sale of additional equity and debt securities may result in additional dilution to our stockholders. If we raise additional funds through the issuance of debt securities or preferred stock, these securities could have rights senior to those of our common stock and could contain covenants that would restrict our operations. We may require additional capital beyond our currently forecasted amounts. Any such required additional capital may not be available on reasonable terms, if at all. If we were unable to obtain additional financing, we may be required to reduce the scope of, delay or eliminate some or all of our planned research and development activities, which could harm our business.</font></div><div style="line-height:120%;padding-bottom:10px;padding-top:10px;text-align:justify;text-indent:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Because of the numerous risks and uncertainties associated with the research and development of biopharmaceutical products, we are unable to estimate the exact amounts of our working capital requirements. Our future funding requirements will depend on many factors, including, but not limited to:</font></div><table cellpadding="0" cellspacing="0" style="padding-top:4px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:72px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:48px;"><font style="font-family:inherit;font-size:10pt;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">the scope, progress, results and costs of clinical trials for our product candidates, and discovery and development activities related to new product candidates;</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:4px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:72px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:48px;"><font style="font-family:inherit;font-size:10pt;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">the timing of, and the costs involved in, obtaining regulatory approvals for our product candidates;</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:4px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:72px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:48px;"><font style="font-family:inherit;font-size:10pt;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">the cost of commercialization activities if any of our product candidates are approved for sale, including marketing, sales, facilities, and distribution costs;</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:4px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:72px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:48px;"><font style="font-family:inherit;font-size:10pt;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">the cost of manufacturing our product candidates and any products we commercialize;</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:4px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:72px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:48px;"><font style="font-family:inherit;font-size:10pt;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">our ability to establish and maintain strategic collaborations, licensing or other arrangements and the financial terms of such agreements;</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:4px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:72px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:48px;"><font style="font-family:inherit;font-size:10pt;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">whether, and to what extent, we are required to repay our outstanding government provided loans;</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:4px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:72px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:48px;"><font style="font-family:inherit;font-size:10pt;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">the costs involved in preparing, filing, prosecuting, maintaining, defending and enforcing patent claims, including litigation costs and the outcome of such litigation; and</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:4px;padding-bottom:16px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:72px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:48px;"><font style="font-family:inherit;font-size:10pt;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">the timing, receipt and amount of sales of, or royalties on, our future products, if any.</font></div></td></tr></table><div style="line-height:120%;text-align:justify;text-indent:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">We believe that our cash and cash equivalents on hand and the proceeds from our recent public offering will be sufficient to fund our planned operations into the second quarter of 2020.</font></div><div style="line-height:120%;padding-bottom:10px;padding-top:10px;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;">Cash Flows</font></div><div style="line-height:120%;padding-bottom:4px;padding-top:10px;text-align:justify;text-indent:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">The following table sets forth the primary sources and uses of cash for each of the periods set forth below:</font></div><div style="line-height:120%;text-align:center;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:73.6328125%;border-collapse:collapse;text-align:left;"><tr><td colspan="10" style="padding-top:4px;padding-bottom:4px;"><div style="line-height:120%;text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Sources and Uses of Cash and Cash Equivalents</font></div><div style="line-height:120%;text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">(in thousands)</font></div></td></tr><tr><td style="width:1%;"></td><td style="width:59%;"></td><td style="width:1%;"></td><td style="width:17%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:17%;"></td><td style="width:1%;"></td><td style="width:1%;"></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="7" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:center;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;font-weight:bold;">Nine Months Ended September 30, </font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:1pt;"><font style="font-family:inherit;font-size:1pt;font-weight:bold;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">2017</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">2016</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Net cash used in operating activities</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(31,070</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(48,933</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Net cash provided by investing activities</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">142</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">111</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Net cash provided by financing activities</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">20,140</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">1,478</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Net decrease in cash and cash equivalents</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(10,788</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(47,344</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr></table></div><font style="font-family:inherit;font-size:10pt;">&#32;</font></div><div style="line-height:120%;text-indent:29px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:justify;text-indent:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">For the </font><font style="font-family:inherit;font-size:10pt;">nine months ended</font><font style="font-family:inherit;font-size:10pt;">&#32;</font><font style="font-family:inherit;font-size:10pt;">September&#160;30, 2017</font><font style="font-family:inherit;font-size:10pt;">&#32;and </font><font style="font-family:inherit;font-size:10pt;">2016</font><font style="font-family:inherit;font-size:10pt;">, we used cash of </font><font style="font-family:inherit;font-size:10pt;">$31.1 million</font><font style="font-family:inherit;font-size:10pt;">&#32;and </font><font style="font-family:inherit;font-size:10pt;">$48.9 million</font><font style="font-family:inherit;font-size:10pt;">, respectively, for our operating activities. For the </font><font style="font-family:inherit;font-size:10pt;">nine months ended</font><font style="font-family:inherit;font-size:10pt;">&#32;</font><font style="font-family:inherit;font-size:10pt;">September&#160;30, 2017</font><font style="font-family:inherit;font-size:10pt;">, the sources and uses of cash in this period primarily resulted from our net loss adjusted for non-cash items and changes in operating assets and liabilities. The decrease in cash used in operating activities was primarily due to the decrease in research and development activity offset by changes in working capital and a decrease in revenues for the </font><font style="font-family:inherit;font-size:10pt;">nine months ended</font><font style="font-family:inherit;font-size:10pt;">&#32;</font><font style="font-family:inherit;font-size:10pt;">September&#160;30, 2017</font><font style="font-family:inherit;font-size:10pt;">&#32;as compared to revenues for the </font><font style="font-family:inherit;font-size:10pt;">nine months ended</font><font style="font-family:inherit;font-size:10pt;">&#32;</font><font style="font-family:inherit;font-size:10pt;">September&#160;30, 2016</font><font style="font-family:inherit;font-size:10pt;">.</font></div><div style="line-height:120%;padding-bottom:10px;padding-top:10px;text-align:justify;text-indent:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">For the </font><font style="font-family:inherit;font-size:10pt;">nine months ended</font><font style="font-family:inherit;font-size:10pt;">&#32;</font><font style="font-family:inherit;font-size:10pt;">September&#160;30, 2017</font><font style="font-family:inherit;font-size:10pt;">&#32;and </font><font style="font-family:inherit;font-size:10pt;">2016</font><font style="font-family:inherit;font-size:10pt;">, our investing activities provided cash of </font><font style="font-family:inherit;font-size:10pt;">$142,000</font><font style="font-family:inherit;font-size:10pt;">&#32;and </font><font style="font-family:inherit;font-size:10pt;">$111,000</font><font style="font-family:inherit;font-size:10pt;">, respectively. The cash provided by investing activities during the </font><font style="font-family:inherit;font-size:10pt;">nine months ended</font><font style="font-family:inherit;font-size:10pt;">&#32;</font><font style="font-family:inherit;font-size:10pt;">September&#160;30, 2017</font><font style="font-family:inherit;font-size:10pt;">&#32;was due to proceeds received from sales of property and equipment of $185,000 offset by $43,000 in purchases of property and equipment. The cash </font></div><div><br></div><div style="text-align:center;"><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">22</font></div></div><hr style="page-break-after:always"><div><div style="line-height:120%;text-align:left;font-size:8pt;"><a style="font-family:inherit;font-size:8pt;" href="#sD088029191DD5EB99A130DC52B3A6E1B"><font style="font-family:inherit;font-size:8pt;">Table of Contents</font></a></div></div><div><br></div><div style="line-height:120%;padding-bottom:10px;padding-top:10px;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">provided by investing activities during the </font><font style="font-family:inherit;font-size:10pt;">nine months ended</font><font style="font-family:inherit;font-size:10pt;">&#32;</font><font style="font-family:inherit;font-size:10pt;">September&#160;30, 2016</font><font style="font-family:inherit;font-size:10pt;">&#32;was due to maturity of certificates of deposit for $2.2 million offset by $2.1 million in purchases of property and equipment. </font></div><div style="line-height:120%;padding-bottom:10px;padding-top:10px;text-align:justify;text-indent:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">For the </font><font style="font-family:inherit;font-size:10pt;">nine months ended</font><font style="font-family:inherit;font-size:10pt;">&#32;</font><font style="font-family:inherit;font-size:10pt;">September&#160;30, 2017</font><font style="font-family:inherit;font-size:10pt;">&#32;and </font><font style="font-family:inherit;font-size:10pt;">2016</font><font style="font-family:inherit;font-size:10pt;">, our financing activities provided cash of </font><font style="font-family:inherit;font-size:10pt;">$20.1 million</font><font style="font-family:inherit;font-size:10pt;">&#32;and </font><font style="font-family:inherit;font-size:10pt;">$1.5 million</font><font style="font-family:inherit;font-size:10pt;">, respectively. The cash provided by financing activities in the </font><font style="font-family:inherit;font-size:10pt;">nine months ended</font><font style="font-family:inherit;font-size:10pt;">&#32;</font><font style="font-family:inherit;font-size:10pt;">September&#160;30, 2017</font><font style="font-family:inherit;font-size:10pt;">&#32;was due to the issuance of common stock for net proceeds of $20.6 million offset by net payments on long-term obligations and notes payable of $185,000 and repurchases of common stock of $260,000. The cash provided by financing activities in the </font><font style="font-family:inherit;font-size:10pt;">nine months ended</font><font style="font-family:inherit;font-size:10pt;">&#32;</font><font style="font-family:inherit;font-size:10pt;">September&#160;30, 2016</font><font style="font-family:inherit;font-size:10pt;">&#32;was primarily due to the sale and issuance of common stock for net proceeds of $1.7 million, offset by net payments on long-term obligations and notes payable of $197,000, and repurchase of common stock of $13,000. </font></div><div style="line-height:120%;padding-bottom:12px;padding-top:12px;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;">Contractual Obligations and Commitments</font></div><div style="line-height:120%;padding-bottom:12px;padding-top:12px;text-align:justify;text-indent:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">There are no material changes to our contractual obligations as disclosed in our Annual Report on Form 10-K for the year ended December 31, 2016.</font></div><div><a name="s14F09522F1EF5154AC45FBDE63EA3EA5"></a></div><div style="line-height:120%;padding-top:16px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Off-Balance Sheet Arrangements</font></div><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:justify;text-indent:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">We did not have during the periods presented, and we do not currently have, any off-balance sheet arrangements, as defined under SEC rules.</font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div><a name="s621F22E950965CF3884FA22C5688A2E7"></a></div><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">ITEM 3.&#160;&#160;&#160;&#160;QUANTITATIVE AND QUALITATIVE DISCLOSURES ABOUT MARKET RISK</font></div><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:justify;text-indent:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">We are exposed to market risk related to changes in interest rates. As of </font><font style="font-family:inherit;font-size:10pt;">September&#160;30, 2017</font><font style="font-family:inherit;font-size:10pt;">&#32;and </font><font style="font-family:inherit;font-size:10pt;">December&#160;31, 2016</font><font style="font-family:inherit;font-size:10pt;">, we had cash and cash equivalents and certificates of deposit of </font><font style="font-family:inherit;font-size:10pt;">$120.7 million</font><font style="font-family:inherit;font-size:10pt;">&#32;and </font><font style="font-family:inherit;font-size:10pt;">$131.5 million</font><font style="font-family:inherit;font-size:10pt;">, respectively, consisting primarily of money market funds. Our primary exposure to market risk is interest rate sensitivity, which is affected by changes in the general level of United States interest rates. Due to the short-term duration of our investment portfolio and the low risk profile of our investments, an immediate 10% change in interest rates would not have a material effect on the fair market value of our portfolio. </font></div><div style="line-height:120%;text-align:justify;text-indent:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:justify;text-indent:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Our long-term debt and our capital lease obligations bear interest at fixed rates. Any change in interest rates would have an immaterial impact on our financial statements.</font></div><div><a name="s77EBCE2628965F1C9C60403C5C78DDDD"></a></div><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">ITEM 4.&#160;&#160;&#160;&#160;CONTROLS AND PROCEDURES</font></div><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-indent:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;">Evaluation of Disclosure Controls and Procedures</font></div><div style="line-height:120%;text-indent:29px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:justify;text-indent:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">We carried out an evaluation required by the Securities Exchange Act of 1934, as amended, or the Exchange Act, under the supervision and with the participation of our chief executive officer and chief financial officer, of the effectiveness of the design and operation of our disclosure controls and procedures, as defined in Rule 13a-15(e) of the Exchange Act, as of </font><font style="font-family:inherit;font-size:10pt;">September&#160;30, 2017</font><font style="font-family:inherit;font-size:10pt;">.  Based on this evaluation, our chief executive officer and chief financial officer concluded that, as of </font><font style="font-family:inherit;font-size:10pt;">September&#160;30, 2017</font><font style="font-family:inherit;font-size:10pt;">, our disclosure controls and procedures were effective to provide reasonable assurance that information required to be disclosed by us in the reports that we file or submit under the Exchange Act is recorded, processed, summarized, and reported within the time periods specified in the rules and forms of the SEC and to provide reasonable assurance that such information is accumulated and communicated to our management, including our chief executive officer and chief financial officer, as appropriate to allow timely decisions regarding required disclosures.</font></div><div style="line-height:120%;padding-bottom:16px;padding-top:16px;text-align:left;text-indent:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;">Changes in Internal Control over Financial Reporting</font></div><div style="line-height:120%;padding-bottom:16px;text-align:justify;text-indent:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">There were no changes in our internal control over financial reporting during the period covered by this Quarterly Report on Form 10-Q that have materially affected, or are reasonably likely to materially affect, our internal control over financial reporting.</font></div><div><br></div><div style="text-align:center;"><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">23</font></div></div><hr style="page-break-after:always"><div><a name="s43669D29A3FB5270A7EBABDFD65CF907"></a></div><div><div style="line-height:120%;text-align:left;font-size:8pt;"><a style="font-family:inherit;font-size:8pt;" href="#sD088029191DD5EB99A130DC52B3A6E1B"><font style="font-family:inherit;font-size:8pt;">Table of Contents</font></a></div></div><div><br></div><div style="line-height:120%;text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">PART&#160;II. OTHER INFORMATION</font></div><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div><a name="s45AACAB2722D5BB9A90DF79CA7CA0B61"></a></div><div style="line-height:120%;padding-bottom:16px;text-align:left;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;font-weight:bold;">Item 1A. &#160;&#160;&#160;&#160;RISK FACTORS</font></div><div style="line-height:120%;text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">RISK FACTORS</font></div><div style="line-height:120%;padding-top:16px;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;">Investing in our common stock involves significant risks, some of which are described below. In evaluating our business, investors should carefully consider the following risk factors. These risk factors contain, in addition to historical information, forward-looking statements that involve substantial risks and uncertainties. Our actual results could differ materially from the results discussed in the forward-looking statements. Factors that could cause or contribute to such differences include, but are not limited to, those discussed below. The order in which the following risks are presented is not intended to reflect the magnitude of the risks described. The occurrence of any of the following risks could have a material adverse effect on our business, financial condition, results of operations and prospects. In that case, the trading price of our common stock could decline, and you may lose all or part of your investment.</font></div><div style="line-height:120%;padding-top:16px;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Business Risks </font></div><div style="line-height:120%;padding-top:16px;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Risks Relating to Clinical Development and Commercialization of Our Product Candidates</font></div><div style="line-height:120%;padding-top:16px;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;">If our product candidates do not meet safety and efficacy endpoints in clinical trials, they will not receive regulatory approval, and we will be unable to market them. We have not completed testing of any of our product candidates in controlled clinical trials.</font></div><div style="line-height:120%;padding-top:16px;text-align:justify;text-indent:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">The clinical development and regulatory approval process is expensive and time-consuming. The timing of any future product approval cannot be accurately predicted. If we fail to obtain regulatory approval for our current or future product candidates, we will be unable to market and sell them and therefore we may never be profitable.</font></div><div style="line-height:120%;padding-top:16px;text-align:justify;text-indent:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">As part of the regulatory process, we must conduct clinical trials for each product candidate to demonstrate safety and efficacy to the satisfaction of the FDA and other regulatory authorities abroad. The number and design of clinical trials that will be required varies depending on the product candidate, the condition being evaluated, the trial results and regulations applicable to any particular product candidate. Any inability to successfully complete preclinical and clinical development could result in additional costs to us.</font></div><div style="line-height:120%;padding-top:16px;text-align:justify;text-indent:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Prior clinical trial program designs and results are not necessarily predictive of future clinical trial designs or results. Initial results may not be confirmed upon full analysis of the detailed results of a trial. Product candidates in later-stage clinical trials may fail to show the desired safety and efficacy despite having progressed through initial clinical trials with acceptable endpoints. A number of companies in the biopharmaceutical industry have suffered significant setbacks in advanced clinical trials due to lack of efficacy or unacceptable safety issues, notwithstanding promising results in earlier trials. Most product candidates that commence clinical trials are never approved as products.</font></div><div style="line-height:120%;padding-top:16px;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;">We are heavily dependent on the success of the clinical development of indoximod, and if we fail to complete clinical trials, fail to demonstrate safety and efficacy in those clinical trials, fail to obtain regulatory approval or fail to successfully commercialize indoximod, our business, financial condition and results of operations would be harmed.</font></div><div style="line-height:120%;padding-top:16px;text-align:justify;text-indent:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">The indoximod clinical development program currently encompasses a number of Phase 1 and 2 combination trials across multiple cancer indications. In addition, we have announced that we intend to begin a large-scale randomized pivotal Phase 3 clinical trial of Indoximod in combination with PD-1 antibody for patients with advanced melanoma designed to support a new drug application. If we fail to complete any of these trials or fail to obtain regulatory approval, our ability to commercialize indoximod will be materially and adversely affected and our business, financial condition and results of operations would be harmed. </font></div><div style="line-height:120%;padding-top:16px;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;">If we make changes to any of our product candidates, additional clinical trials may be required resulting in additional costs and delays.&#160;</font></div><div style="line-height:120%;padding-top:16px;text-align:justify;text-indent:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">We have an ongoing research program to investigate potential opportunities to improve the potency, efficacy and/or safety profile of some of our product candidates through modifications to their formulations or chemical compositions. &#160;These efforts may not be successful.&#160; If a new formulation or composition appears promising, we may decide to undertake clinical development of such formulation or composition even if an existing product candidate has shown acceptable safety and efficacy in clinical </font></div><div><br></div><div style="text-align:center;"><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">24</font></div></div><hr style="page-break-after:always"><div><div style="line-height:120%;text-align:left;font-size:8pt;"><a style="font-family:inherit;font-size:8pt;" href="#sD088029191DD5EB99A130DC52B3A6E1B"><font style="font-family:inherit;font-size:8pt;">Table of Contents</font></a></div></div><div><br></div><div style="line-height:120%;padding-top:16px;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">trials.&#160; The nature and extent of additional clinical trials that might be required for a new formulation or composition would depend on many factors.&#160; If we were to decide to pursue clinical development of a new formulation or composition, we would incur additional costs and the timeline for potential commercialization would be delayed.&#160; There can be no assurance that any new formulation or composition would prove to be safe or effective or superior to an existing product candidate.&#160; Any delay in commercialization of a new formulation or composition may adversely affect our competitive position.</font></div><div style="line-height:120%;padding-top:16px;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;">We may expend our limited resources to pursue a particular product candidate or indication and fail to capitalize on product candidates or indications that may be more profitable or for which there is a greater likelihood of success.</font></div><div style="line-height:120%;padding-top:16px;text-align:justify;text-indent:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Because we have limited financial and managerial resources, we must focus on research programs and product candidates for the specific indications that we believe are the most scientifically and commercially promising. As a result, we have in the past determined to let certain of our development projects remain idle, including by allowing Investigational New Drug applications to lapse into inactive status, and we may in the future decide to forego or delay pursuit of opportunities with other product candidates or other indications that later prove to have greater scientific or commercial potential. Our resource allocation decisions may cause us to fail to capitalize on viable scientific or commercial products or profitable market opportunities. In addition, we may spend valuable time and managerial and financial resources on research programs and product candidates for specific indications that ultimately do not yield any scientifically or commercially viable products. Furthermore, our resource allocation decisions and our decisions about whether and how to develop or commercialize any particular product candidate may be based on evaluations of the scientific and commercial potential or target market for the product candidate that later prove to be materially inaccurate. If we enter into collaborations, licensing or other royalty arrangements to develop or commercialize a particular product candidate, we may relinquish valuable rights to that product candidate in situations where it would have been more advantageous for us to retain sole rights to development and commercialization.</font></div><div style="line-height:120%;padding-top:16px;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;">We may face delays in completing our clinical trials, or we may not be able to complete them at all.</font></div><div style="line-height:120%;padding-top:16px;text-align:justify;text-indent:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">We have not completed all of the clinical trials necessary to support an application with the FDA for approval to market any of our product candidates. Our current and future clinical trials may be delayed or terminated as a result of many factors, including:</font></div><div style="line-height:120%;text-align:justify;text-indent:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;&#160;&#160;&#160;</font></div><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:96px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:60px;"><font style="font-family:inherit;font-size:10pt;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">we may experience delays or failure in reaching agreement on acceptable clinical trial contracts or clinical trial protocols with prospective sites;</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:96px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:60px;"><font style="font-family:inherit;font-size:10pt;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">regulators or institutional review boards may not authorize us to commence a clinical trial;</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:96px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:60px;"><font style="font-family:inherit;font-size:10pt;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">regulators or institutional review boards may suspend or terminate clinical research for various reasons, including noncompliance with regulatory requirements or concerns about patient safety;</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:96px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:60px;"><font style="font-family:inherit;font-size:10pt;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">we may suspend or terminate our clinical trials if we believe that they expose the participating patients to unacceptable health risks;</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:96px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:60px;"><font style="font-family:inherit;font-size:10pt;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">we may need to reformulate or change the dosing of our product candidates;</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:96px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:60px;"><font style="font-family:inherit;font-size:10pt;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">our clinical trials may have slower than expected patient enrollment or lack of a sufficient number of patients that meet their enrollment criteria;</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:96px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:60px;"><font style="font-family:inherit;font-size:10pt;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">patients may not complete clinical trials due to safety issues, side effects, dissatisfaction with the product candidate, or other reasons;</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:96px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:60px;"><font style="font-family:inherit;font-size:10pt;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">we may experience difficulty in maintaining contact with patients after treatment, preventing us from collecting the data required by our clinical trial protocol;</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:96px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:60px;"><font style="font-family:inherit;font-size:10pt;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">product candidates may demonstrate a lack of efficacy during clinical trials;</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:96px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:60px;"><font style="font-family:inherit;font-size:10pt;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">our third-party contractors, including those manufacturing our product candidates or components of ingredients thereof or conducting clinical trials on our behalf, may fail to comply with regulatory requirements or meet their contractual obligations to us in a timely manner or at all;</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:96px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:60px;"><font style="font-family:inherit;font-size:10pt;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">the supply or quality of raw materials or manufactured product candidates or other materials necessary to conduct clinical trials of our product candidates may be insufficient, inadequate or not available at an acceptable cost, or we may experience interruptions in supply;</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:96px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:60px;"><font style="font-family:inherit;font-size:10pt;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">we may experience governmental or regulatory delays, failure to obtain regulatory approval or changes in regulatory requirements, policy and guidelines;</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:96px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:60px;"><font style="font-family:inherit;font-size:10pt;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">enrollment in and conduct of our clinical trials may be adversely affected by the regulatory approval of competing agents in this class, competition with ongoing clinical trials or scheduling conflicts with participating clinicians; and</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:96px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:60px;"><font style="font-family:inherit;font-size:10pt;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">we may experience delays in achieving clinical trial endpoints and completing data analysis for a trial.</font></div></td></tr></table><div style="line-height:120%;padding-top:16px;text-align:justify;text-indent:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">In addition, we rely on academic institutions, physician practices and clinical research organizations to conduct, supervise or monitor some or all aspects of clinical trials involving our product candidates. We have less control over the timing and other </font></div><div><br></div><div style="text-align:center;"><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">25</font></div></div><hr style="page-break-after:always"><div><div style="line-height:120%;text-align:left;font-size:8pt;"><a style="font-family:inherit;font-size:8pt;" href="#sD088029191DD5EB99A130DC52B3A6E1B"><font style="font-family:inherit;font-size:8pt;">Table of Contents</font></a></div></div><div><br></div><div style="line-height:120%;padding-top:16px;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">aspects of these clinical trials than if we conducted the monitoring and supervision entirely on our own. Third parties may not perform their responsibilities for our clinical trials on our anticipated schedule or consistent with a clinical trial protocol or applicable regulations. We also may rely on clinical research organizations to perform our data management and analysis. They may not provide these services as required or in a timely or compliant manner.</font></div><div style="line-height:120%;padding-top:16px;text-align:justify;text-indent:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Moreover, our development costs will increase if we are required to complete additional or larger clinical trials for our product candidates prior to FDA approval. If the delays or costs are significant, our financial results and ability to commercialize our product candidates will be adversely affected.</font></div><div style="line-height:120%;padding-top:16px;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;">If we encounter difficulties enrolling patients in our clinical trials, our clinical trials could be delayed or otherwise adversely affected.</font></div><div style="line-height:120%;padding-top:16px;text-align:justify;text-indent:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Clinical trials for our product candidates require us to identify and enroll a large number of patients with the disease under investigation, or healthy volunteers willing to participate in certain trials. We may not be able to enroll a sufficient number of patients, or those with required or desired characteristics to achieve diversity in a clinical trial, to complete our clinical trials in a timely manner. Patient enrollment is affected by factors including:</font></div><div style="line-height:120%;padding-left:0px;padding-bottom:8px;padding-top:16px;text-align:justify;text-indent:60px;"><font style="padding-bottom:8px;padding-top:16px;text-align:justify;font-family:inherit;font-size:10pt;padding-right:36px;">&#8226;</font><font style="font-family:inherit;font-size:10pt;">severity of the disease under investigation;</font></div><table cellpadding="0" cellspacing="0" style="padding-bottom:8px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:96px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:60px;"><font style="font-family:inherit;font-size:10pt;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">design of the trial protocol;</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-bottom:8px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:96px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:60px;"><font style="font-family:inherit;font-size:10pt;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">size of the patient population;</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-bottom:8px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:96px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:60px;"><font style="font-family:inherit;font-size:10pt;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">eligibility criteria for the clinical trial in question;</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-bottom:8px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:96px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:60px;"><font style="font-family:inherit;font-size:10pt;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">perceived risks and benefits of the product candidate under study;</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-bottom:8px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:96px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:60px;"><font style="font-family:inherit;font-size:10pt;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">changes in the standard of care that make the trial as designed less attractive to clinicians and patients;</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-bottom:8px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:96px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:60px;"><font style="font-family:inherit;font-size:10pt;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">availability of competing therapies and clinical trials, including announced Phase 3 clinical trials evaluating potentially competing IDO pathway inhibitors in clinical settings similar to our clinical trials;</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-bottom:8px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:96px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:60px;"><font style="font-family:inherit;font-size:10pt;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">efforts to facilitate timely enrollment in clinical trials;</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-bottom:8px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:96px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:60px;"><font style="font-family:inherit;font-size:10pt;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">patient referral practices of physicians;</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-bottom:8px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:96px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:60px;"><font style="font-family:inherit;font-size:10pt;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">ability to monitor patients adequately during and after treatment; and</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-bottom:8px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:96px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:60px;"><font style="font-family:inherit;font-size:10pt;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">proximity and availability of clinical trial sites for prospective patients.</font></div></td></tr></table><div style="line-height:120%;padding-top:16px;text-align:justify;text-indent:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">We have experienced difficulties enrolling patients in certain of our smaller clinical trials due to lack of referrals and may experience similar difficulties in the future. If we have difficulty enrolling a sufficient number or diversity of patients to conduct our clinical trials as planned, we may need to delay or terminate ongoing or planned clinical trials, either of which would have an adverse effect on our business.</font></div><div style="line-height:120%;padding-top:16px;text-align:justify;text-indent:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">In addition, the inclusion of critically ill patients in our clinical trials may result in deaths or other adverse medical events for reasons that may not be related to the product candidate we are testing or, in those trials where our product candidate is being tested in combination with one or more other therapies, for reasons that may be attributable to such other therapies, but which can nevertheless negatively affect clinical trial results. </font></div><div style="line-height:120%;padding-top:16px;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;">Regulatory authorities may not approve our product candidates even if they meet safety and efficacy endpoints in clinical trials.</font></div><div style="line-height:120%;padding-top:16px;text-align:justify;text-indent:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">We have discussions with and obtain guidance from regulatory authorities regarding certain aspects of our clinical development activities. These discussions are not binding commitments on the part of regulatory authorities. Under certain circumstances, regulatory authorities may revise or retract previous guidance during the course of our clinical activities or after the completion of our clinical trials. A regulatory authority may also disqualify a clinical trial in whole or in part from consideration in support of approval of a potential product for commercial sale or otherwise deny approval of that product. Prior to regulatory approval, a regulatory authority may elect to obtain advice from outside experts regarding scientific issues and/or marketing applications under a regulatory authority review. In the United States, these outside experts are convened through the FDA&#8217;s Advisory Committee process, which would report to the FDA and make recommendations that may differ from the views of the FDA. The FDA is not bound by the recommendations of an Advisory Committee, but it typically follows such recommendations.  In addition, should an Advisory Committee be convened, it would be expected to lengthen the time for obtaining regulatory approval, if such approval is obtained at all.</font></div><div><br></div><div style="text-align:center;"><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">26</font></div></div><hr style="page-break-after:always"><div><div style="line-height:120%;text-align:left;font-size:8pt;"><a style="font-family:inherit;font-size:8pt;" href="#sD088029191DD5EB99A130DC52B3A6E1B"><font style="font-family:inherit;font-size:8pt;">Table of Contents</font></a></div></div><div><br></div><div style="line-height:120%;padding-bottom:8px;padding-top:16px;text-align:justify;text-indent:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">The FDA and other foreign regulatory agencies can delay, limit or deny marketing approval for many reasons, including:</font></div><table cellpadding="0" cellspacing="0" style="padding-bottom:8px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:96px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:58px;"><font style="font-family:inherit;font-size:10pt;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">a product candidate may not be considered safe or effective;</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-bottom:8px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:96px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:58px;"><font style="font-family:inherit;font-size:10pt;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">our manufacturing processes or facilities may not meet the applicable requirements; and</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-bottom:8px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:96px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:58px;"><font style="font-family:inherit;font-size:10pt;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">changes in their approval policies or adoption of new regulations may require additional work on our part.</font></div></td></tr></table><div style="line-height:120%;padding-top:16px;text-align:justify;text-indent:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Any delay in, or failure to receive or maintain, approval for any of our product candidates could prevent us from ever generating meaningful revenues or achieving profitability in future years.</font></div><div style="line-height:120%;padding-top:16px;text-align:justify;text-indent:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Our product candidates may not be approved even if they achieve their endpoints in clinical trials. Regulatory agencies, including the FDA, or their advisors may disagree with our trial design and our interpretations of data from preclinical studies and clinical trials. Regulatory agencies may change requirements for approval even after a clinical trial design has been approved. Regulatory agencies also may approve a product candidate for fewer or more limited indications than requested or may grant approval subject to the performance of post-marketing studies. In addition, regulatory agencies may not approve the labeling claims that are necessary or desirable for the successful commercialization of our product candidates.</font></div><div style="line-height:120%;padding-top:16px;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;">Under the Merck Agreement, we have ongoing obligations related to the development of our Ebola vaccine product candidate, which may result in greater costs and a longer timeframe for regulatory approval than we estimate, yet we will receive limited revenues, if any, from any future sales of our Ebola vaccine product candidate. </font></div><div style="line-height:120%;padding-top:16px;text-align:justify;text-indent:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Under the Merck Agreement, we have ongoing obligations related to the development of our Ebola vaccine product candidate, including obligations related to clinical trials, government contracting and licensing of the vaccine technology, which may cause us to incur costs or losses materially larger than we expect. However, because we have exclusively licensed the right to research, develop, manufacture and distribute our Ebola vaccine product candidate to Merck and we are only entitled to certain royalty and other payments under the Merck Agreement, we will receive limited revenues, if any, even if we or Merck are successful in developing and commercializing our Ebola vaccine product candidate. </font></div><div style="line-height:120%;padding-top:16px;text-align:justify;text-indent:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">The time and cost of product development and the timeframe for regulatory approval of any Ebola vaccine product candidate are uncertain and may be longer and more costly than we estimate. Our Ebola vaccine product candidate is a live virus based on vesicular stomatitis virus, or VSV. There are no commercial vaccines based upon this virus, and unforeseen problems related to the use of our live virus vaccine may prevent or materially increase costs and delays of further development or approval of our Ebola vaccine product candidate. There may be unknown safety risks associated with the vaccine, and regulatory agencies such as the FDA may require us to conduct extensive safety testing prior to approval to demonstrate a low risk of rare and severe adverse events caused by the vaccine. </font></div><div style="line-height:120%;padding-top:16px;text-align:justify;text-indent:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Public perception of vaccine safety issues, including adoption of novel vaccines based upon VSV, may adversely influence willingness of subjects to participate in clinical trials, or if approved, of physicians to prescribe, and of patients to receive, novel vaccines. For example, our Ebola vaccine product candidate is currently being developed for prevention of, and may later be developed for treatment of patients infected with, Ebola, and public aversion to vaccines for Ebola or vaccines in general may adversely influence later-stage clinical trials of this product candidate or, if approved, its commercial success. </font></div><div style="line-height:120%;padding-top:16px;text-align:justify;text-indent:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Even if approved, a number of factors may adversely affect commercial sales. Lack of familiarity with the viral vaccine and potential adverse events associated with vaccination may adversely affect physician and patient perception and uptake of our potential product. Furthermore, there are no assurances that the vaccine will be approved for inclusion in government stockpile programs, which may be material to the commercial success of the product candidate, either in the United States or abroad. If our Ebola vaccine product candidate eventually is approved and sold commercially, we will receive limited revenues under the Merck Agreement. Finally, in certain cases, our obligations to pay royalties to PHAC may exceed the royalties we receive from Merck. </font></div><div style="line-height:120%;padding-top:16px;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;">We may be required to suspend, repeat or terminate our clinical trials if they are not conducted in accordance with regulatory requirements, the results are negative or inconclusive or the trials are not well designed.</font></div><div style="line-height:120%;padding-top:16px;text-align:justify;text-indent:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Clinical trials must be conducted in accordance with the FDA&#8217;s Good Clinical Practice, or GCP, requirements, or other applicable foreign government guidelines and are subject to oversight by the FDA, other foreign governmental agencies and Institutional Review Boards at the medical institutions where the clinical trials are conducted. In addition, clinical trials must be conducted with product candidates produced under current Good Manufacturing Practice, or cGMP, requirements and may require large numbers of test subjects. Clinical trials may be suspended by the FDA, other foreign governmental agencies, or us for various reasons, including:</font></div><div><br></div><div style="text-align:center;"><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">27</font></div></div><hr style="page-break-after:always"><div><div style="line-height:120%;text-align:left;font-size:8pt;"><a style="font-family:inherit;font-size:8pt;" href="#sD088029191DD5EB99A130DC52B3A6E1B"><font style="font-family:inherit;font-size:8pt;">Table of Contents</font></a></div></div><div><br></div><table cellpadding="0" cellspacing="0" style="padding-top:16px;padding-bottom:8px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:96px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:60px;"><font style="font-family:inherit;font-size:10pt;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">deficiencies in the conduct of the clinical trials, including failure to conduct the clinical trial in accordance with regulatory requirements or clinical protocols;</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-bottom:8px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:96px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:60px;"><font style="font-family:inherit;font-size:10pt;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">inspection of the clinical trial operations or trial sites by the FDA or other regulatory authorities resulting in the imposition of a clinical hold;</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-bottom:8px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:96px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:60px;"><font style="font-family:inherit;font-size:10pt;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">the product candidate may have unforeseen adverse side effects;</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-bottom:8px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:96px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:60px;"><font style="font-family:inherit;font-size:10pt;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">the time required to determine whether the product candidate is effective may be longer than expected;</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-bottom:8px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:96px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:60px;"><font style="font-family:inherit;font-size:10pt;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">fatalities or other adverse events arising during a clinical trial due to medical problems that may not be related to clinical trial treatments;</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-bottom:8px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:96px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:60px;"><font style="font-family:inherit;font-size:10pt;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">failure to demonstrate a benefit from using a drug;</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-bottom:8px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:96px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:60px;"><font style="font-family:inherit;font-size:10pt;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">the quality or stability of the product candidate may fall below acceptable standards; or</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-bottom:8px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:96px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:60px;"><font style="font-family:inherit;font-size:10pt;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">insufficient quantities of the product candidate to complete the trials.</font></div></td></tr></table><div style="line-height:120%;padding-bottom:16px;text-align:justify;text-indent:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">In addition, changes in regulatory requirements and guidance may occur and we may need to amend clinical trial protocols to reflect these changes. Amendments may require us to resubmit our clinical trial protocols to Institutional Review Boards for reexamination, which may impact the costs, timing or successful completion of a clinical trial. Due to these and other factors indoximod, NLG802, navoximod, and other product candidates could take significantly longer to gain regulatory approval than we expect or we may never gain approval for additional indications, which could reduce our revenue by delaying or terminating their commercialization.</font></div><div style="line-height:120%;padding-bottom:16px;padding-top:16px;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;">Some of our product candidates have been studied, or in the future may be studied, in clinical trials co-sponsored by organizations or agencies other than us, or in investigator-initiated clinical trials, which means we have little control over the conduct of such trials.</font></div><div style="line-height:120%;padding-bottom:16px;text-align:justify;text-indent:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">We are currently supplying indoximod, our lead IDO pathway inhibitor product candidate, in support of a Phase 2 investigator-initiated clinical trial, and we provided clinical supply of dorgenmeltucel-L in support of a Phase&#160;2 investigator-initiated clinical trial. Our Ebola vaccine product candidate was studied in clinical trials in West Africa.</font><font style="font-family:inherit;font-size:10pt;"><sup style="vertical-align:top;line-height:120%;font-size:7pt"> </sup></font><font style="font-family:inherit;font-size:10pt;">We may continue to supply and otherwise support similar trials in the future. However, because we are not the sponsors of these trials, we do not control the protocols, administration or conduct of these trials, including follow-up with patients and ongoing collection of data after treatment, and, as a result, are subject to risks associated with the way these types of trials are conducted, in particular should any problems arise. These risks include difficulties or delays in communicating with investigators or administrators, procedural delays and other timing issues and difficulties or differences in interpreting data.</font></div><div style="line-height:120%;padding-top:16px;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;">If we cannot demonstrate the safety of our product candidates in preclinical and/or other non-clinical studies, we will not be able to initiate or continue clinical trials or obtain approval for our product candidates.</font></div><div style="line-height:120%;padding-top:16px;text-align:justify;text-indent:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">In order to move a product candidate not yet being tested in humans into a clinical trial, we must first demonstrate in preclinical testing that the product candidate is safe. Furthermore, in order to obtain approval, we must also demonstrate safety in various preclinical and non-clinical tests. We may not have conducted or may not conduct in the future the types of preclinical and other non-clinical testing ultimately required by regulatory authorities, or future preclinical tests may indicate that our product candidates are not safe for use in humans. Preclinical testing is expensive, can take many years and can have an uncertain outcome. In addition, success in initial preclinical testing does not ensure that later preclinical testing will be successful. We may experience numerous unforeseen events during, or as a result of, the preclinical testing process, which could delay or prevent our ability to develop or commercialize our product candidates, including:</font></div><table cellpadding="0" cellspacing="0" style="padding-top:16px;padding-bottom:8px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:96px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:60px;"><font style="font-family:inherit;font-size:10pt;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">our preclinical testing may produce inconclusive or negative safety results, which may require us to conduct additional preclinical testing or to abandon product candidates that we believed to be promising;</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-bottom:8px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:96px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:58px;"><font style="font-family:inherit;font-size:10pt;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">our product candidates may have unfavorable pharmacology, toxicology or carcinogenicity;</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-bottom:8px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:96px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:58px;"><font style="font-family:inherit;font-size:10pt;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">our product candidates may cause undesirable side effects; and</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-bottom:8px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:96px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:58px;"><font style="font-family:inherit;font-size:10pt;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">the FDA or other regulatory authorities may determine that additional safety testing is required.</font></div></td></tr></table><div style="line-height:120%;padding-top:16px;text-align:justify;text-indent:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Any such events would increase our costs and could delay or prevent our ability to commercialize our product candidates, which could adversely impact our business, financial condition and results of operations.</font></div><div><br></div><div style="text-align:center;"><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">28</font></div></div><hr style="page-break-after:always"><div><div style="line-height:120%;text-align:left;font-size:8pt;"><a style="font-family:inherit;font-size:8pt;" href="#sD088029191DD5EB99A130DC52B3A6E1B"><font style="font-family:inherit;font-size:8pt;">Table of Contents</font></a></div></div><div><br></div><div style="line-height:120%;padding-top:16px;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;">Even if ultimately approved, indoximod, navoximod, NLG802, our Ebola vaccine product candidate or any other potential product we or our collaborators may commercialize and market may be later withdrawn from the market or subject to promotional limitations.</font></div><div style="line-height:120%;padding-top:16px;text-align:justify;text-indent:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">We or our collaborators may not be able to obtain the labeling claims necessary or desirable for the promotion of any potential future products. We or our collaborators may also be required to undertake post-marketing clinical trials. If the results of such post-marketing studies are not satisfactory, the FDA or a comparable agency in a foreign country may withdraw marketing authorization or may condition continued marketing on commitments from us or our collaborators that may be expensive and/or time consuming to fulfill. In addition, if we or others identify adverse side effects after any of our potential products are on the market, or if manufacturing problems occur, regulatory approval may be withdrawn and reformulation of our potential products, additional clinical trials, changes in labeling of our potential products and/or additional marketing applications may be required. Any reformulation or labeling changes may limit the marketability of our potential products.</font></div><div style="line-height:120%;padding-top:16px;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;">We will need to develop or acquire additional capabilities in order to commercialize any product candidates that obtain FDA approval, and we may encounter unexpected costs or difficulties in doing so</font><font style="font-family:inherit;font-size:10pt;font-weight:bold;">.</font></div><div style="line-height:120%;padding-top:16px;text-align:justify;text-indent:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">We will need to acquire additional capabilities and effectively manage our operations and facilities to successfully pursue and complete future research, development and commercialization efforts. Currently, we have limited experience in preparing applications for marketing approval, commercial-scale manufacturing, managing large-scale information technology systems or managing a large-scale distribution system. We will need to add personnel and expand our capabilities, which may strain our existing managerial, operational, regulatory compliance, financial and other resources. </font></div><div style="line-height:120%;padding-top:16px;text-align:justify;text-indent:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">To do this effectively, we must:</font></div><table cellpadding="0" cellspacing="0" style="padding-top:16px;padding-bottom:8px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:96px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:60px;"><font style="font-family:inherit;font-size:10pt;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">train, manage and motivate a growing employee base; </font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-bottom:8px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:96px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:58px;"><font style="font-family:inherit;font-size:10pt;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">accurately forecast demand for our products; and</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-bottom:8px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:96px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:58px;"><font style="font-family:inherit;font-size:10pt;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">expand existing operational, financial and management information systems.</font></div></td></tr></table><div style="line-height:120%;padding-top:16px;text-align:justify;text-indent:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">We will need to increase our manufacturing capacity, which may include negotiating and entering into additional third-party agreements to meet our commercial manufacturing requirements. </font></div><div style="line-height:120%;padding-top:16px;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;">If we are unable to establish sales and marketing capabilities or enter into agreements with third parties to market and sell our product candidates, we may be unable to generate significant product revenue.</font></div><div style="line-height:120%;padding-top:12px;text-align:justify;text-indent:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">We do not have a sales organization and have no experience in the sales and distribution of pharmaceutical products. There are risks involved with establishing our own sales capabilities and increasing our marketing capabilities, as well as entering into arrangements with third parties to perform these services. Developing an internal sales force is expensive and time consuming and could delay any product launch. On the other hand, if we enter into arrangements with third parties to perform sales, marketing and distribution services, our product revenues or the profitability of these product revenues to us could potentially be lower than if we market and sell these products ourselves.</font></div><div style="line-height:120%;padding-top:12px;text-align:justify;text-indent:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">We entered into the Merck Agreement in November 2014 for the research, development, manufacture and distribution of our Ebola vaccine product candidate. Even if our Ebola vaccine product candidate are approved by regulators for marketing and sale, Merck may be unsuccessful in its efforts to commercialize our Ebola vaccine product candidate, respectively, or may devote fewer resources to such efforts than we would consider optimal.</font></div><div style="line-height:120%;padding-top:16px;text-align:justify;text-indent:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">We may establish our own specialty sales force and/or engage other biopharmaceutical or other healthcare companies with established sales, marketing and distribution capabilities to sell, market and distribute any future products, including to co-promote next generation IDO/TDO inhibitors in the United States, under the Genentech Agreement. We may not be able to establish a specialty sales force or establish sales, marketing or distribution relationships on acceptable terms. Factors that may inhibit our efforts to commercialize any future products without strategic collaborators or licensees include:</font></div><table cellpadding="0" cellspacing="0" style="padding-top:16px;padding-bottom:8px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:96px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:60px;"><font style="font-family:inherit;font-size:10pt;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">our inability to recruit and retain adequate numbers of effective sales and marketing personnel;</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-bottom:8px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:96px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:60px;"><font style="font-family:inherit;font-size:10pt;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">the inability of sales personnel to obtain access to or persuade adequate numbers of physicians to prescribe any future products;</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-bottom:8px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:96px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:60px;"><font style="font-family:inherit;font-size:10pt;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">the lack of complementary products to be offered by sales personnel, which may put us at a competitive disadvantage relative to companies with more extensive product lines; and</font></div></td></tr></table><div><br></div><div style="text-align:center;"><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">29</font></div></div><hr style="page-break-after:always"><div><div style="line-height:120%;text-align:left;font-size:8pt;"><a style="font-family:inherit;font-size:8pt;" href="#sD088029191DD5EB99A130DC52B3A6E1B"><font style="font-family:inherit;font-size:8pt;">Table of Contents</font></a></div></div><div><br></div><table cellpadding="0" cellspacing="0" style="padding-bottom:8px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:96px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:60px;"><font style="font-family:inherit;font-size:10pt;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">unforeseen costs and expenses associated with creating an independent sales and marketing organization.</font></div></td></tr></table><div style="line-height:120%;padding-top:16px;text-align:justify;text-indent:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Because the establishment of sales, marketing and distribution capabilities depends on the progress toward commercialization of our product candidates, and because of the numerous risks and uncertainties involved with establishing those capabilities, we are unable to predict when, if ever, we will establish our own sales, marketing and distribution capabilities. If we are not able to collaborate with third parties and are unsuccessful in recruiting sales, marketing and distribution personnel or in building the necessary infrastructure, we will have difficulty commercializing our product candidates, which would adversely affect our business and financial condition.</font></div><div style="line-height:120%;padding-top:16px;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;">Failure to attract and retain key personnel could impede our ability to develop our products and to obtain new collaborations or other sources of funding.</font></div><div style="line-height:120%;padding-top:16px;text-align:justify;text-indent:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Because of the specialized scientific nature of our business, our success is highly dependent upon our ability to attract and retain qualified scientific and technical personnel, consultants and advisors. We are highly dependent on the principal members of our scientific and management staff. On July 28, 2017, we announced that Dr. Nicholas N. Vahanian will be on a temporary leave of absence and that during his absence, other members of the management team will assume his duties. The long-term loss of services of key executives might significantly delay or prevent the achievement of our research, development, and business objectives. We do not maintain key-man life insurance with respect to any of our employees, nor do we intend to secure such insurance.</font></div><div style="line-height:120%;padding-top:16px;text-align:justify;text-indent:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">We will need to recruit additional personnel in order to achieve our operating goals. In order to pursue product development and marketing and sales activities, if any, we will need to hire additional qualified scientific personnel to perform research and development, as well as personnel with expertise in clinical testing, government regulation, manufacturing, marketing and sales. We also rely on consultants and advisors to assist in formulating our research and development strategy and adhering to complex regulatory requirements. We face competition for qualified individuals from numerous pharmaceutical and biotechnology companies, universities and other research institutions. There can be no assurance that we will be able to attract and retain such individuals on acceptable terms, if at all. Additionally, our only significant facility is located in Iowa, which may make attracting and retaining qualified scientific and technical personnel from outside of Iowa difficult. The failure to attract and retain qualified personnel, consultants and advisors could have a material adverse effect on our business, financial condition and results of operations.</font></div><div style="line-height:120%;padding-top:16px;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Risks Relating to Manufacturing Activities </font></div><div style="line-height:120%;padding-top:16px;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;">We rely on third-party manufacturers to produce our preclinical and clinical product candidate supplies and we intend to rely on third parties to produce commercial supplies of any product candidates that may be approved in the future. Any failure by a third-party manufacturer to produce supplies for us may delay or impair our ability to complete our clinical trials or commercialize our product candidates.</font></div><div style="line-height:120%;padding-top:16px;text-align:justify;text-indent:48px;font-size:12pt;"><font style="font-family:inherit;font-size:10pt;">We do not possess all of the capabilities to fully commercialize any of our product candidates on our own. If we are unable to arrange for third-party manufacturing sources, or to do so on commercially reasonable terms, we may not be able to complete development of such product candidates or market them. In addition, we currently rely on our partner Merck for the supply of our Ebola vaccine product candidate and other third party manufacturers for our supply of indoximod, navoximod and NLG802 for preclinical and clinical studies. Problems with any of our facilities or processes, or our contract manufacturers&#8217; facilities or processes, could prevent or delay the production of adequate supplies of indoximod, navoximod, NLG802, our Ebola vaccine product candidate or other finished products.</font><font style="font-family:inherit;font-size:12pt;">&#32;</font></div><div style="line-height:120%;padding-top:16px;text-align:justify;text-indent:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Any prolonged delay or interruption in the operations of our current or future contract manufacturers&#8217; facilities could result in cancellation of shipments, loss of components in the process of being manufactured or a shortfall in availability of a product. A number of factors could cause interruptions, including the inability of a supplier to provide raw materials, equipment malfunctions or failures, damage to a facility due to natural disasters, changes in international or U.S. regulatory requirements or standards that require modifications to our manufacturing processes, action by regulatory authorities or by us that results in the halting or slowdown of production of components or finished product due to regulatory issues, a contract manufacturer going out of business or failing to produce product as contractually required or other similar factors. Because manufacturing processes are highly complex and are subject to a lengthy regulatory approval process, alternative qualified production capacity and sufficiently trained or qualified personnel may not be available on a timely or cost-effective basis or at all. Difficulties or delays in our contract manufacturers&#8217; production of product candidates could delay our clinical trials, increase our costs, damage our reputation and cause us to lose revenue and market share if we are unable to meet market demand for any products that are approved for sale on a timely basis.</font></div><div><br></div><div style="text-align:center;"><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">30</font></div></div><hr style="page-break-after:always"><div><div style="line-height:120%;text-align:left;font-size:8pt;"><a style="font-family:inherit;font-size:8pt;" href="#sD088029191DD5EB99A130DC52B3A6E1B"><font style="font-family:inherit;font-size:8pt;">Table of Contents</font></a></div></div><div><br></div><div style="line-height:120%;padding-top:16px;text-align:justify;text-indent:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Reliance on third-party manufacturers entails risks to which we would not be subject if we manufactured product candidates ourselves, including reliance on the third party for regulatory compliance and quality assurance, the possibility of breach of the manufacturing agreement by the third party because of factors beyond our control, failure of the third party to accept orders for supply of drug substance or drug product and the possibility of termination or nonrenewal of the agreement by the third-party based on its own business priorities and at a time that is costly or damaging to us. In addition, the FDA and other regulatory authorities require that our product candidates be manufactured according to cGMP and similar foreign standards. Any failure by our third-party manufacturers to comply with cGMP or failure to scale-up manufacturing processes as needed, including any failure to deliver sufficient quantities of product candidates in a timely manner, could lead to a delay in, or failure to obtain, regulatory approval of any of our product candidates. In addition, such failure could be the basis for action by the FDA to withdraw approvals for product candidates that may have been granted to us and for other regulatory action, including recall or seizure, fines, imposition of operating restrictions, total or partial suspension of production or injunctions.</font></div><div style="line-height:120%;padding-top:16px;text-align:justify;text-indent:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">We rely on our manufacturers to purchase from third-party suppliers the materials necessary to produce our product candidates for our clinical studies. There are a small number of suppliers for certain capital equipment and raw materials that are used to&#160;manufacture&#160;our product candidates. Such suppliers may not sell this capital equipment or these raw materials to our manufacturers at the times we need them or on commercially reasonable terms. We do not have any control over the process or timing of the acquisition of this capital equipment or these raw materials by our manufacturers. Moreover, we currently do not have any agreements for the commercial production of these raw materials. Any significant delay in the supply of a product candidate or the raw material components thereof for an ongoing clinical trial due to the need to replace a third-party manufacturer could considerably delay completion of our clinical studies, product testing and potential regulatory approval of our product candidates. If our manufacturers or we are unable to purchase these raw materials after regulatory approval has been obtained for our product candidates, the commercial launch of our product candidates would be delayed or there would be a shortage in supply, which would impair our ability to generate revenues from the sale of our product candidates.</font></div><div style="line-height:120%;padding-top:16px;text-align:justify;text-indent:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Because of the complex nature of many of our early stage compounds and product candidates, our manufacturers may not be able to&#160;manufacture&#160;such compounds and product candidates at a cost or in quantities or in a timely manner necessary to develop and commercialize related products. If we successfully commercialize any of our product candidates, we may be required to establish or access large-scale commercial manufacturing capabilities. In addition, as our drug development pipeline increases and matures, we will have a greater need for clinical trial and commercial manufacturing capacity. To meet our projected needs for commercial manufacturing in the event that one or more of our product candidates gains marketing approval, third parties with whom we currently work will need to increase their scale of production or we will need to secure alternate suppliers.</font></div><div style="line-height:120%;padding-top:16px;text-align:justify;text-indent:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Furthermore, we do not currently have experience with the management of relationships related to commercial-scale contract manufacturing, and we may incur substantial costs to develop the capability to negotiate and enter into relationships with third-party contract manufacturers.</font></div><div style="line-height:120%;padding-top:16px;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;">We and our contract manufacturers are subject to significant regulation with respect to manufacturing of our products.</font></div><div style="line-height:120%;padding-top:16px;text-align:justify;text-indent:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">All entities involved in the preparation of a therapeutic drug for clinical trials or commercial sale, including our Company, our existing contract manufacturers and those we may engage in the future, and Merck in its capacity as our licensee, are subject to extensive regulation. Components of a finished therapeutic product approved for commercial sale or used in late-stage clinical trials must be manufactured in accordance with cGMP regulations. These regulations govern manufacturing processes and procedures (including record keeping) and the implementation and operation of quality systems to control and assure the quality of investigational products and products approved for sale. Our facilities and quality systems and the facilities and quality systems of some or all of our third party contractors must pass a pre-approval inspection for compliance with the applicable regulations as a condition of regulatory approval of any of our product candidates. In addition, the regulatory authorities may, at any time, audit or inspect a manufacturing facility involved with the preparation of any of our product candidates or the associated quality systems for compliance with the regulations applicable to the activities being conducted. If any such inspection or audit identifies a failure to comply with applicable regulations or if a violation of our product specifications or applicable regulations occurs independent of such an inspection or audit, we or the relevant regulatory authority may require remedial measures that may be costly and/or time consuming for us or a third party to implement and that may include the temporary or permanent suspension of a clinical trial or commercial sales or the temporary or permanent closure of a facility. Any such remedial measures imposed upon us or third parties with whom we contract could materially harm our business. In addition, to the extent that we rely on foreign contract manufacturers, as we do currently for our Ebola vaccine product candidate, we are or will be subject to additional risks including the need to comply with export and import regulations.</font></div><div style="line-height:120%;padding-top:16px;text-align:justify;text-indent:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">If our current or future contract manufacturers are not in compliance with regulatory requirements at any stage, including post-marketing approval, we may be fined, forced to remove a product from the market and/or experience other adverse consequences, including delays, which could materially harm our business.</font></div><div><br></div><div style="text-align:center;"><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">31</font></div></div><hr style="page-break-after:always"><div><div style="line-height:120%;text-align:left;font-size:8pt;"><a style="font-family:inherit;font-size:8pt;" href="#sD088029191DD5EB99A130DC52B3A6E1B"><font style="font-family:inherit;font-size:8pt;">Table of Contents</font></a></div></div><div><br></div><div style="line-height:120%;padding-top:16px;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;">Our costs for the manufacture and clinical development of our Ebola vaccine product candidate may exceed our current or any future funding for development efforts of our Ebola vaccine product candidate.</font></div><div style="line-height:120%;padding-top:16px;text-align:justify;text-indent:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">We have entered into certain manufacturing and clinical trial management agreements for our Ebola vaccine product candidate, and we expect to enter into additional agreements and incur additional costs related to our obligations under the Merck Agreement and our agreements with government agencies that are providing funding to us for the development of our Ebola vaccine product candidate. The total costs that we are likely to incur to fulfill our contractual obligations under agreements with third parties for the development of our Ebola vaccine product candidate may exceed our total amount of funding from all sources for such activities. In addition, we are likely to incur operating expenses related to our Ebola vaccine product candidate in addition to our direct contractual costs of administering clinical and other studies.&#160; Our failure to obtain sufficient grants or other funding for our Ebola vaccine development efforts will not relieve us of our obligations under our current or future contract manufacturing and other agreements for the Ebola vaccine product candidate.</font></div><div style="line-height:120%;padding-top:16px;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;">Our facility is located in areas where floods and tornados are known to occur, and the occurrence of a flood, tornado or other catastrophic disaster could damage our facilities and equipment, which could cause us to curtail or cease operations.</font></div><div style="line-height:120%;padding-top:16px;text-align:justify;text-indent:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Our primary facility is located in Ames, Iowa, which is susceptible to floods and tornados, and our facility is therefore vulnerable to damage or disruption from floods and tornados. We are also vulnerable to damage from other types of disasters, such as power loss, fire and similar events. If any disaster were to occur, our ability to operate our business could be seriously impaired. We currently carry business insurance (real, personal and business income) of nearly $12.1 million in the aggregate, but this policy does not cover disasters such as floods and earthquakes. We may not have adequate insurance to cover our losses resulting from disasters or other similar significant business interruptions, and we do not plan to purchase additional insurance to cover such losses due to the cost of obtaining such coverage. Any significant losses that are not recoverable under our insurance policies could seriously impair our business and financial condition.</font></div><div style="line-height:120%;padding-top:16px;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;">Significant disruptions of information technology systems or breaches of data security could adversely affect our business.</font></div><div style="line-height:120%;padding-top:16px;text-align:justify;text-indent:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">We are increasingly dependent on information technology systems and infrastructure, including mobile technologies, to operate our business. In the ordinary course of our business, we collect, store and transmit large amounts of confidential information, including intellectual property, proprietary business information and personal information. It is critical that we do so in a secure manner to maintain the confidentiality and integrity of such confidential information. We have also outsourced elements of our information technology infrastructure, and as a result we manage a number of third-party vendors who may or could have access to our confidential information. The size and complexity of our information technology systems, and those of third-party vendors with whom we contract, make such systems potentially vulnerable to breakdown, malicious intrusion, security breaches and other cyber-attacks. In addition, the prevalent use of mobile devices that access confidential information increases the risk of data security breaches, which could lead to the loss of confidential information, trade secrets or other intellectual property. While we have implemented security measures to protect our data security and information technology systems, such measures may not prevent the adverse effect of such events. Significant disruptions of our information technology systems or breaches of data security could adversely affect our business.</font></div><div style="line-height:120%;padding-top:16px;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Risks Relating to Regulation of Our Industry</font></div><div style="line-height:120%;padding-top:16px;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;">The industry within which we operate and our business are subject to extensive regulation, which is costly and time consuming and which may subject us to unanticipated delays.</font></div><div style="line-height:120%;padding-top:16px;text-align:justify;text-indent:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">The research, development, testing, manufacturing, labeling, packaging, marketing, distribution, promotion and advertising of biologic and pharmaceutical products such as our product candidates are subject to extensive regulation by governmental regulatory authorities in the United States and other countries. The drug development and approval process is generally lengthy, expensive and subject to unanticipated delays. Data obtained from preclinical and clinical testing are subject to varying interpretations that could delay, limit or prevent regulatory approval. In addition, delays or rejections may be encountered based upon changes in regulatory policy for product approval during the period of development and regulatory review of each submitted application for approval. To obtain approval for a product candidate, we must demonstrate to the satisfaction of the regulatory authorities that the product candidate is safe and effective in the case of a small-molecule pharmaceutical product, or is safe, pure and potent in the case of a biologic, which typically takes several years or more depending upon the type, complexity and novelty of the product and requires the expenditure of substantial resources. There can be no assurance that we will not encounter problems in clinical trials that would cause us or the regulatory authorities to delay or suspend clinical trials. Any such delay or suspension could have a material adverse effect on our business, financial condition and results of operations.</font></div><div><br></div><div style="text-align:center;"><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">32</font></div></div><hr style="page-break-after:always"><div><div style="line-height:120%;text-align:left;font-size:8pt;"><a style="font-family:inherit;font-size:8pt;" href="#sD088029191DD5EB99A130DC52B3A6E1B"><font style="font-family:inherit;font-size:8pt;">Table of Contents</font></a></div></div><div><br></div><div style="line-height:120%;padding-top:16px;text-align:justify;text-indent:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">There can be no assurance that clinical trials for any of our product candidates currently under development will be completed successfully or within any specified time period, if at all. Further, there can also be no assurance that such testing will show any product to be safe, pure, potent or effective. We cannot predict when, if ever, we might submit for regulatory review our product candidates currently under development. In addition, regardless of how much time and resources we devote to development of a product candidate, there can be no assurance that regulatory approval will be obtained for that product candidate. </font></div><div style="line-height:120%;padding-top:16px;text-align:justify;text-indent:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Even if such regulatory approval is obtained, we, our products and any contract manufacturers or commercial collaborators of ours will be subject to continual regulatory review in both the United States and other countries. Later discovery of previously unknown problems with regard to a product, distributor or manufacturer may result in restrictions, including withdrawal of the product from the market and/or disqualification or decertification of the distributor or manufacturer. If we, our product candidates or the manufacturing facilities for our product candidates fail to comply with regulatory requirements of the FDA and/or non-U.S. regulatory authorities, we could be subject to administrative or judicially imposed sanctions, including:</font></div><div style="line-height:120%;padding-left:0px;padding-bottom:8px;padding-top:16px;text-align:justify;text-indent:60px;"><font style="padding-bottom:8px;padding-top:16px;text-align:justify;font-family:inherit;font-size:10pt;padding-right:36px;">&#8226;</font><font style="font-family:inherit;font-size:10pt;">warning letters;</font></div><table cellpadding="0" cellspacing="0" style="padding-bottom:8px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:96px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:60px;"><font style="font-family:inherit;font-size:10pt;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">civil or criminal penalties;</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-bottom:8px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:96px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:60px;"><font style="font-family:inherit;font-size:10pt;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">injunctions;</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-bottom:8px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:96px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:60px;"><font style="font-family:inherit;font-size:10pt;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">suspension of or withdrawal of regulatory approval;</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-bottom:8px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:96px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:60px;"><font style="font-family:inherit;font-size:10pt;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">total or partial suspension of any ongoing clinical trials or of production;</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-bottom:8px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:96px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:60px;"><font style="font-family:inherit;font-size:10pt;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">voluntary or mandatory product recalls and publicity requirements; </font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-bottom:8px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:96px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:60px;"><font style="font-family:inherit;font-size:10pt;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">refusal to approve pending applications for marketing approval of new products or supplements to approved applications filed by us;</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-bottom:8px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:96px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:60px;"><font style="font-family:inherit;font-size:10pt;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">restrictions on operations, including costly new manufacturing requirements; or</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-bottom:8px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:96px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:60px;"><font style="font-family:inherit;font-size:10pt;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">seizure or detention of our products or import bans.</font></div></td></tr></table><div style="line-height:120%;padding-top:16px;text-align:justify;text-indent:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#32;The FDA and comparable agencies in foreign countries impose substantial requirements on the introduction of new biologic and pharmaceutical products through lengthy and detailed preclinical and clinical testing procedures, sampling activities and other costly and time-consuming compliance procedures. Clinical trials are vigorously regulated and must meet requirements for FDA review and oversight and requirements under GCP guidelines. A new drug may not be marketed in the United States until the FDA has approved it. There can be no assurance that we will not encounter delays or rejections or that the FDA will not make policy changes during the period of product development and FDA regulatory review of each submitted BLA and NDA. A delay in obtaining, or failure to obtain, such approvals would have a material adverse effect on our business, financial condition and results of operations. Even if regulatory approval were obtained, it would be limited as to the indicated uses for which the product may be promoted or marketed. A marketed product, its manufacturer and the facilities in which it is manufactured are subject to continual review and periodic inspections. If marketing approval is granted, we would be required to comply with FDA requirements for manufacturing, labeling, advertising, record-keeping and reporting of adverse experiences and other information. In addition, we would be required to comply with federal and state anti-kickback and other healthcare fraud and abuse laws that pertain to the marketing of pharmaceuticals. Failure to comply with regulatory requirements and other factors could subject us to regulatory or judicial enforcement actions, including product recalls or seizures, injunctions, withdrawal of the product from the market, civil penalties, criminal prosecution, refusals to approve new products and withdrawals of existing approvals, as well as enhanced product liability exposure, any of which could have a material adverse effect on our business, financial condition and results of operations. Sales of our products outside the United States will be subject to foreign regulatory requirements governing clinical trials, marketing approval, manufacturing and pricing. Noncompliance with these requirements could result in enforcement actions or penalties or could delay introduction of our products in certain countries.</font></div><div style="line-height:120%;padding-top:16px;text-align:justify;text-indent:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">The requirements governing the conduct of clinical trials, product licensing, pricing and reimbursement outside the United States vary greatly from country to country. The time required to obtain approvals outside the United States may differ from that required to obtain FDA approval. We may not obtain foreign regulatory approvals on a timely basis, or at all. Approval by the FDA does not ensure approval by regulatory authorities in other countries, and approval by one foreign regulatory authority does not ensure approval by regulatory authorities in other countries or by the FDA. Foreign regulatory authorities could also require additional testing. Failure to comply with these regulatory requirements or obtain required approvals could impair our ability to develop foreign markets for our products and may have a material adverse effect on our results of operations and financial condition.</font></div><div style="line-height:120%;padding-top:16px;text-align:justify;text-indent:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">We are also subject to laws generally applicable to businesses including, but not limited to, federal, state and local regulations relating to wage and hour matters, employee classification, mandatory healthcare benefits, unlawful workplace discrimination and whistleblowing. Any actual or alleged failure to comply with any regulation applicable to our business or any </font></div><div><br></div><div style="text-align:center;"><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">33</font></div></div><hr style="page-break-after:always"><div><div style="line-height:120%;text-align:left;font-size:8pt;"><a style="font-family:inherit;font-size:8pt;" href="#sD088029191DD5EB99A130DC52B3A6E1B"><font style="font-family:inherit;font-size:8pt;">Table of Contents</font></a></div></div><div><br></div><div style="line-height:120%;padding-top:16px;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">whistleblowing claim, even if without merit, could result in costly litigation or regulatory action or otherwise harm our business, results of operations, financial condition, cash flow and future prospects.</font></div><div style="line-height:120%;padding-top:16px;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;">The availability of coverage and amount of reimbursement for our product candidates, if approved, and the manner in which government and private payers may reimburse for our potential products, are uncertain.</font></div><div style="line-height:120%;padding-top:16px;text-align:justify;text-indent:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">In both the United States and foreign markets, sales of our proposed products will depend in part on the availability of coverage and reimbursement from third-party payers such as government health administration authorities, private health insurers and other organizations. Our future levels of revenues and profitability may be affected by the continuing efforts of governmental and third-party payers to contain or reduce the costs of health care. We cannot predict the effect that private sector or governmental health care reforms may have on our business, and there can be no assurance that any such reforms will not have a material adverse effect on our business, financial condition and results of operations.</font></div><div style="line-height:120%;padding-top:16px;text-align:justify;text-indent:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">In addition, in both the United States and elsewhere, sales of prescription drugs are dependent in part on the availability of coverage and reimbursement to the consumer from third-party payers, such as government and private insurance plans. In the United States, there is no uniform policy for coverage and reimbursement among third party payers. In addition, the process for determining whether a third party payer will provide coverage for a pharmaceutical typically is separate from the process for setting the price of such product or for establishing the reimbursement rate that the payer will pay for the product once coverage is approved. Third-party payers are increasingly challenging the price and cost-effectiveness of medical products and services. Significant uncertainty exists as to the reimbursement status of newly approved health care products. There can be no assurance that our proposed products will be considered cost-effective or that adequate third-party reimbursement will be available to enable us to maintain price levels sufficient to realize an appropriate return on our investment in product development. Legislation and regulations affecting the pricing of pharmaceuticals may change before any of our proposed products are approved for marketing. Adoption of such legislation could further limit reimbursement for medical products and services. As a result, we may elect not to market future products in certain markets.</font></div><div style="line-height:120%;padding-top:16px;text-align:justify;text-indent:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Moreover, while we are in clinical trials, we will not be reimbursed for any of our materials used during the clinical trials.</font></div><div style="line-height:120%;padding-top:16px;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;">The biopharmaceutical industry is subject to significant regulation and oversight in the United States, in addition to approval of products for sale and marketing; our failure to comply with these laws could harm our results of operations and financial condition.</font></div><div style="line-height:120%;padding-top:8px;text-align:justify;text-indent:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">In addition to FDA restrictions on marketing of biopharmaceutical products, our operations may be directly, or indirectly through our customers and third-party payers, subject to various federal and state fraud and abuse laws, including, without limitation, the federal Anti-Kickback Statute. These laws may impact, among other things, our proposed sales, marketing and education programs, and these laws have been applied to restrict certain marketing practices in the biopharmaceutical industry. In addition, we may be subject to patient privacy regulation by both the U.S. federal government and the states in which we conduct our business. The laws that may affect our ability to operate include the following:</font></div><table cellpadding="0" cellspacing="0" style="padding-top:8px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:96px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:60px;"><font style="font-family:inherit;font-size:10pt;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">The federal Anti-Kickback Statute prohibits, among other things, knowingly and willfully offering, paying, soliciting, or receiving remuneration to induce or in return for purchasing, leasing, ordering, or arranging for the purchase, lease, or order of any health care item or service reimbursable under Medicare, Medicaid, or other federally financed healthcare programs. This statute has been interpreted to apply to arrangements between pharmaceutical manufacturers on the one hand and prescribers, purchasers and formulary managers on the other. Although there are a number of statutory exemptions and regulatory safe harbors protecting certain common activities from prosecution, the exemptions and safe harbors are drawn narrowly. Practices that involve remuneration that may be alleged to be intended to induce prescribing, purchases or recommendations may be subject to scrutiny if they do not qualify for an exemption or safe harbor. Our practices may not in all cases meet all of the criteria for safe harbor protection from anti-kickback liability. In addition, a person or entity does not need to have actual knowledge of the statute or specific intent to violate it in order to have committed a violation. Moreover, a claim including items or services resulting from a violation of the federal Anti-Kickback Statute constitutes a false or fraudulent claim for purposes of the federal civil False Claims Act.</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:8px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:96px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:60px;"><font style="font-family:inherit;font-size:10pt;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">The federal False Claims Act prohibits any person or entity from knowingly presenting, or causing to be presented, to the federal government a claim for payment or approval that is false or fraudulent or from knowingly making a false statement to avoid, decrease or conceal an obligation to pay money to the federal government. Several pharmaceutical and other health-care companies have been prosecuted under these laws for allegedly providing free product to customers with the expectation that the customers would bill federal programs for the product. Other companies have been prosecuted for causing false claims to be submitted because of off-label promotion. </font></div></td></tr></table><div><br></div><div style="text-align:center;"><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">34</font></div></div><hr style="page-break-after:always"><div><div style="line-height:120%;text-align:left;font-size:8pt;"><a style="font-family:inherit;font-size:8pt;" href="#sD088029191DD5EB99A130DC52B3A6E1B"><font style="font-family:inherit;font-size:8pt;">Table of Contents</font></a></div></div><div><br></div><div style="line-height:120%;padding-left:96px;padding-top:8px;text-align:justify;"><font style="font-family:inherit;font-size:10pt;">Private parties may initiate qui tam whistleblower lawsuits against any person or entity under the False Claims Act in the name of the government and share in the proceeds of the lawsuit.</font></div><table cellpadding="0" cellspacing="0" style="padding-top:8px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:96px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:60px;"><font style="font-family:inherit;font-size:10pt;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">The federal Health Insurance Portability and Accountability Act of 1996, or HIPAA, imposes criminal and civil liability for knowingly and willfully executing, or attempting to execute, a scheme to defraud any healthcare benefit program, or knowingly and willfully falsifying, concealing or covering up a material fact or making any materially false statement in connection with the delivery of, or payment for, healthcare benefits, items or services; similar to the federal Anti- Kickback Statute, a person or entity does not need to have actual knowledge of the statute or specific intent to violate it in order to have committed a violation.&#160;&#160;&#160;&#160;</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:8px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:96px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:60px;"><font style="font-family:inherit;font-size:10pt;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">HIPAA, as amended by the Health Information Technology for Economic and Clinical Health Act of 2009, or HITECH, and its implementing regulations imposes certain obligations, including mandatory contractual terms, with respect to safeguarding the privacy, security and transmission of individually identifiable health information without appropriate authorization on covered entities, such as health plans, healthcare clearinghouses and healthcare providers as well as their business associates that perform certain services involving the use or disclosure of individually identifiable health information.</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:8px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:96px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:60px;"><font style="font-family:inherit;font-size:10pt;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">The federal Food, Drug and Cosmetic Act, or FDCA, prohibits, among other things, the adulteration or misbranding of drugs and medical devices.</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:8px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:96px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:60px;"><font style="font-family:inherit;font-size:10pt;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">The federal Physician Payments Sunshine Act, and its implementing regulations require manufacturers of drugs, devices, biologics and medical supplies that are reimbursable under Medicare, Medicaid, or the Children&#8217;s Health Insurance Program to report annually to the Centers for Medicare and Medicaid Services information related to payments and other transfers of value to physicians, other healthcare providers, and teaching hospitals, as well as ownership and investment interests held by physicians and other healthcare providers and their immediate family members.</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:8px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:96px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:60px;"><font style="font-family:inherit;font-size:10pt;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Analogous state laws and regulations include: state anti-kickback and false claims laws, which may apply to our business practices, including but not limited to, research, distribution, sales and marketing arrangements and claims involving healthcare items or services reimbursed by any third-party payer, including private insurers; state laws that require pharmaceutical companies to comply with the pharmaceutical industry&#8217;s voluntary compliance guidelines and the relevant compliance guidance promulgated by the U.S. federal government, or otherwise restrict payments that may be made to healthcare providers and other potential referral sources; state laws and regulations that require drug manufacturers to file reports relating to pricing and marketing information and that require tracking gifts and other remuneration and items of value provided to healthcare professionals and entities; and state laws governing the privacy and security of health information in certain circumstances, many of which differ from each other in significant ways and often are not preempted by HIPAA, thus complicating compliance efforts.</font></div></td></tr></table><div style="line-height:120%;padding-top:16px;text-align:justify;text-indent:48px;font-size:12pt;"><font style="font-family:inherit;font-size:10pt;">Ensuring that our future business arrangements with third parties comply with applicable healthcare laws and regulations could involve substantial costs. If our operations are found to be in violation of any of the laws described above or any other governmental laws and regulations that may apply to us, we may be subject to significant penalties, including civil, criminal and administrative penalties, damages, fines, disgorgement, individual imprisonment, exclusion from government-funded healthcare programs, such as Medicare and Medicaid,</font><font style="font-family:inherit;font-size:12pt;">&#32;</font><font style="font-family:inherit;font-size:10pt;">additional reporting obligations and oversight if we become subject to a corporate integrity agreement or other agreement to resolve allegations of non-compliance with these laws, and the curtailment or restructuring of our operations. It is possible that some of our business activities could be subject to challenge under one or more of these laws, which could have a material adverse effect on our business, financial condition and results of operations.</font></div><div style="line-height:120%;padding-top:16px;text-align:justify;text-indent:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">We cannot predict the likelihood, nature or extent of government regulation that may arise from future legislation or administrative or executive action, either in the United States or abroad. For example, certain policies of the Trump administration may impact our business and industry. Namely, the Trump administration has taken several executive actions, including the issuance of a number of Executive Orders, that could impose significant burdens on, or otherwise materially delay, FDA&#8217;s ability to engage in routine regulatory and oversight activities such as implementing statutes through rulemaking, issuance of guidance, and review and approval of marketing applications. Notably, on January&#160;30, 2017, President Trump issued an Executive Order, applicable to all executive agencies, including the FDA, that requires that for each notice of proposed rulemaking or final regulation to be issued in fiscal year 2017, the agency shall identify at least two existing regulations to be repealed, unless prohibited by law. These requirements are referred to as the &#8220;two-for-one&#8221; provisions. This Executive Order includes a budget neutrality provision that requires the total incremental cost of all new regulations in the 2017 fiscal year, including repealed regulations, to be no greater than zero, except in limited circumstances. For fiscal years 2018 and beyond, the Executive Order requires agencies to identify regulations to offset any incremental cost of a new regulation and approximate the total costs or savings associated with each new regulation or repealed regulation. In interim guidance issued by the Office of Information and Regulatory Affairs within OMB on </font></div><div><br></div><div style="text-align:center;"><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">35</font></div></div><hr style="page-break-after:always"><div><div style="line-height:120%;text-align:left;font-size:8pt;"><a style="font-family:inherit;font-size:8pt;" href="#sD088029191DD5EB99A130DC52B3A6E1B"><font style="font-family:inherit;font-size:8pt;">Table of Contents</font></a></div></div><div><br></div><div style="line-height:120%;padding-top:16px;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">February&#160;2, 2017, the administration indicates that the &#8220;two-for-one&#8221; provisions may apply not only to agency regulations, but also to significant agency guidance documents. Further, on February&#160;24, 2017, President Trump issued an Executive Order requiring each agency to designate a regulatory reform officer and create a regulatory reform task force to evaluate existing regulations and make recommendations regarding their repeal, replacement, or modification. It is difficult to predict how these requirements will be implemented, and the extent to which they will impact the FDA&#8217;s ability to exercise its regulatory authority. If these executive actions impose constraints on FDA&#8217;s ability to engage in oversight and implementation activities in the normal course, our business may be negatively impacted.</font></div><div style="line-height:120%;padding-top:16px;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;">Healthcare legislative reform measures may have a material adverse effect on our business and results of operations.</font></div><div style="line-height:120%;padding-top:16px;text-align:justify;text-indent:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">The U.S. and some foreign jurisdictions are considering or have enacted a number of additional legislative and regulatory proposals to change the healthcare system in ways that could affect our ability to sell our products profitably. Among policy makers and payors in the United States and elsewhere, there is significant interest in promoting changes in healthcare systems with the stated goals of containing healthcare costs, improving quality and/or expanding access. For example, in the United States, the pharmaceutical industry has been affected by the passage of the Patient Protection and Affordable Care Act, or the ACA, which, among other things, imposed new fees on entities that manufacture or import certain branded prescription drugs and expanded pharmaceutical manufacturer obligations to provide discounts and rebates to certain government programs. There have been judicial and congressional challenges to certain aspects of the ACA. In January 2017, President Trump signed an Executive Order directing federal agencies with authorities and responsibilities under the ACA to waive, defer, grant exemptions from, or delay the implementation of any provision of the ACA that would impose a fiscal or regulatory burden on states, individuals, healthcare providers, health insurers, or manufacturers of pharmaceuticals or medical devices. The U.S. House of Representatives passed legislation known as the American Health Care Act of 2017 in May 2017. More recently, the Senate Republicans proposed multiple bills to repeal or repeal and replace portions of the ACA. Although none of these measure has successfully passed Congress to date, Congress may consider other legislation to repeal and replace elements of the ACA. In addition, there has been particular and increasing legislative and enforcement interest in the United States with respect to specialty drug pricing practices in recent years, particularly with respect to drugs that have been subject to relatively large price increases over relatively short time periods.  There have been several recent U.S. Congressional inquiries and proposed bills designed to, among other things, bring more transparency to drug pricing, review the relationship between pricing and manufacturer patient programs, and reform government program reimbursement methodologies for drugs.  In the future, there will likely continue to be proposals relating to the reform of the U.S. healthcare system, some of which could further limit coverage and reimbursement of drug products, including our product candidates. Any reduction in reimbursement from Medicare or other government programs may result in a similar reduction in payments from private payors. The implementation of cost containment measures or other healthcare reforms may prevent us from being able to generate revenue, attain profitability or commercialize our products.</font></div><div style="line-height:120%;padding-top:16px;text-align:justify;text-indent:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">We cannot predict the likelihood, nature or extent of government regulation that may arise from future legislative or administrative action, either in the United States or abroad.</font></div><div style="line-height:120%;padding-top:16px;text-align:justify;text-indent:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Individual states have become increasingly aggressive in passing legislation and implementing regulations designed to control pharmaceutical and biological product pricing, including price or patient reimbursement constraints, discounts, restrictions on certain product access, and marketing cost disclosure and transparency measures and to encourage importation from other countries and bulk purchasing. Legally mandated price controls on payment amounts by third-party payers or other restrictions could harm our business, results of operations, financial condition and prospects. In addition, regional healthcare authorities and individual hospitals are increasingly using bidding procedures to determine which pharmaceutical products and suppliers will be included in their prescription drug and other healthcare programs. This could reduce ultimate demand for our products or put pressure on our product pricing, which could negatively affect our business, results of operations, financial condition and prospects.</font></div><div style="line-height:120%;padding-top:16px;text-align:justify;text-indent:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">In addition, given recent federal and state government initiatives directed at lowering the total cost of health care, Congress and state legislatures will likely continue to focus on healthcare reform, the cost of prescription drugs and biologics and the reform of the Medicare and Medicaid programs. While we cannot predict the full outcome of any such legislation, it may result in decreased reimbursement for drugs and biologics, which may further exacerbate industry-wide pressure to reduce prescription drug prices. This could harm our ability to generate revenues. In addition, legislation has been introduced in Congress that, if enacted, would permit more widespread importation or re-importation of pharmaceutical products from foreign countries into the United States, including from countries where the products are sold at lower prices than in the United States. Such legislation, or similar regulatory changes, could put competitive pressure on our ability to profitably price our products, which, in turn, could adversely affect our business, results of operations, financial condition and prospects. Alternatively, in response to legislation such as this, we might elect not to seek approval for or market our products in foreign jurisdictions in order to minimize the risk of re-importation, which could also reduce the revenue we generate from our product sales. It is also possible that other legislative proposals having similar effects will be adopted.  </font></div><div><br></div><div style="text-align:center;"><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">36</font></div></div><hr style="page-break-after:always"><div><div style="line-height:120%;text-align:left;font-size:8pt;"><a style="font-family:inherit;font-size:8pt;" href="#sD088029191DD5EB99A130DC52B3A6E1B"><font style="font-family:inherit;font-size:8pt;">Table of Contents</font></a></div></div><div><br></div><div style="line-height:120%;padding-top:16px;text-align:justify;text-indent:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Furthermore, regulatory authorities&#8217; assessment of the data and results required to demonstrate safety and efficacy can change over time and can be affected by many factors, such as the emergence of new information, including on other products, changing policies and agency funding, staffing and leadership. We cannot be sure whether future changes to the regulatory environment will be favorable or unfavorable to our business prospects. For example, average review times at the FDA for marketing approval applications have fluctuated over the last 10 years, and we cannot predict the review time for any of our submissions with any regulatory authorities. In addition, review times can be affected by a variety of factors, including budget and funding levels and statutory, regulatory and policy changes.</font></div><div style="line-height:120%;padding-top:16px;text-align:justify;text-indent:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;">We use hazardous materials in our business and must comply with environmental laws and regulations, which can be expensive.</font></div><div style="line-height:120%;padding-top:16px;text-align:justify;text-indent:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Our research and development involves the controlled use of hazardous materials, chemicals, various active microorganisms and volatile organic compounds, and we may incur significant costs as a result of the need to comply with numerous laws and regulations. We are subject to laws and regulations enforced by the FDA, the Drug Enforcement Agency, foreign health authorities and other regulatory requirements, including the Occupational Safety and Health Act, the Environmental Protection Act, the Toxic Substances Control Act, the Food, Drug and Cosmetic Act, the Resource Conservation and Recovery Act, and other current and potential federal, state, local and foreign laws and regulations governing the use, manufacture, storage, handling and disposal of our products, materials used to develop and manufacture our product candidates, and resulting waste products. Although we believe that our safety procedures for handling and disposing of such materials, and for killing any unused microorganisms before disposing of them, comply with the standards prescribed by state and federal regulations, the risk of accidental contamination or injury from these materials cannot be completely eliminated. In the event of such an accident, we could be held liable for any damages that result and any such liability could exceed our resources.</font></div><div style="line-height:120%;padding-top:16px;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Financial Risks</font></div><div style="line-height:120%;padding-top:16px;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;">Despite our profitable fiscal year ended December 31, 2014, we have a history of net losses. We incurred a net loss for the years ended </font><font style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;">December&#160;31, 2015</font><font style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;">&#32;and </font><font style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;">2016</font><font style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;">&#32;and expect to continue to incur net losses for the foreseeable future, and we may never achieve or maintain profitability in the future.</font></div><div style="line-height:120%;padding-top:16px;text-align:justify;text-indent:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">We were profitable in the year ended December 31, 2014, primarily as a result of upfront payments under the Genentech Agreement and the Merck Agreement. We are not entitled to receive any additional upfront payments under these licensing or collaboration agreements. Any future milestone payments under the Genentech Agreement depend on our achievement of specific milestones, and any royalties depend on successful commercialization of licensed products. The potential milestone and royalty payments under the Genentech Agreement are highly uncertain and dependent on many factors outside of our control related to possible future clinical trials and commercialization. We do not expect any milestone or royalty payments under these or other agreements, if any, to be sufficient to make us profitable in future years. As a result of these and other factors, we incurred a net loss of $85.2 million for the year ended </font><font style="font-family:inherit;font-size:10pt;">December&#160;31, 2016</font><font style="font-family:inherit;font-size:10pt;">&#32;and we do not expect to be profitable for the foreseeable future. If we had not received the upfront payments under the Genentech Agreement and the Merck Agreement, we would have incurred a net loss for the year ended December 31, 2014. We anticipate that we will continue to incur operating losses over the next several years as we expand both our commercialization activities and our discovery and research activities.</font></div><div style="line-height:120%;padding-top:16px;text-align:justify;text-indent:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Because of the numerous risks and uncertainties associated with biopharmaceutical product development and commercialization, we are unable to accurately predict the timing or amount of future expenses or when, or if, we will be able to achieve or maintain profitability. Currently, we have no products approved for commercial sale, and to date we have not generated any product revenue. We have financed our operations primarily through the sale of equity securities, government grants, economic development loans and capital lease and equipment financing. The size of our future net losses will depend, in part, on the rate of growth or contraction of our expenses and the level and rate of growth, if any, of our revenues. Our ability to achieve profitability in future years is dependent on our ability, alone or with others, to complete the development of our products successfully, obtain the required regulatory approvals, manufacture and market our proposed products successfully or have such products manufactured and marketed by others and gain market acceptance for such products. There can be no assurance as to whether or when we will achieve profitability. </font></div><div style="line-height:120%;padding-top:16px;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;">We may require substantial additional capital in the future. If additional capital is not available, we will have to delay, reduce or cease operations.</font></div><div style="line-height:120%;padding-top:16px;text-align:justify;text-indent:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Development of our product candidates will require substantial additional funds to conduct research, development and clinical trials necessary to bring such product candidates to market and to establish manufacturing, marketing and distribution capabilities, either internally or through collaborations with third parties. Our future capital requirements will depend on many factors, including, among others:</font></div><div><br></div><div style="text-align:center;"><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">37</font></div></div><hr style="page-break-after:always"><div><div style="line-height:120%;text-align:left;font-size:8pt;"><a style="font-family:inherit;font-size:8pt;" href="#sD088029191DD5EB99A130DC52B3A6E1B"><font style="font-family:inherit;font-size:8pt;">Table of Contents</font></a></div></div><div><br></div><table cellpadding="0" cellspacing="0" style="padding-top:16px;padding-bottom:8px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:96px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:60px;"><font style="font-family:inherit;font-size:10pt;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">the scope, rate of progress, results and costs of our preclinical studies, clinical trials and other research and development activities;</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-bottom:8px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:96px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:60px;"><font style="font-family:inherit;font-size:10pt;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">the scope, rate of progress and costs of our manufacturing development and commercial manufacturing activities;</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-bottom:8px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:96px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:60px;"><font style="font-family:inherit;font-size:10pt;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">the cost, timing and outcomes of regulatory proceedings (including FDA review of any BLA or NDA we file);</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-bottom:8px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:96px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:60px;"><font style="font-family:inherit;font-size:10pt;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">payments required with respect to development milestones we achieve under our in-licensing agreements;</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-bottom:8px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:96px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:60px;"><font style="font-family:inherit;font-size:10pt;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">the costs involved in preparing, filing, prosecuting, maintaining and enforcing patent claims, including litigation costs and the outcome of such litigation;</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-bottom:8px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:96px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:60px;"><font style="font-family:inherit;font-size:10pt;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">the costs associated with commercializing our product candidates, if they receive regulatory approval;</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-bottom:8px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:96px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:60px;"><font style="font-family:inherit;font-size:10pt;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">the cost of manufacturing our product candidates and any products we commercialize;</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-bottom:8px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:96px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:60px;"><font style="font-family:inherit;font-size:10pt;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">the cost and timing of developing our ability to establish sales and marketing capabilities;</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-bottom:8px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:96px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:60px;"><font style="font-family:inherit;font-size:10pt;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">the potential requirement to repay our outstanding government provided loans;</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-bottom:8px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:96px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:60px;"><font style="font-family:inherit;font-size:10pt;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">competing technological efforts and market developments;</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-bottom:8px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:96px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:60px;"><font style="font-family:inherit;font-size:10pt;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">changes in our existing research relationships;</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-bottom:8px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:96px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:60px;"><font style="font-family:inherit;font-size:10pt;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">our ability to establish and maintain strategic collaborations, licensing or other arrangements and the financial terms of such arrangements;</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-bottom:8px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:96px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:60px;"><font style="font-family:inherit;font-size:10pt;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">the timing and receipt of revenues from existing or future products, if any; and</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-bottom:8px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:96px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:60px;"><font style="font-family:inherit;font-size:10pt;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">payments received under any future strategic collaborations.</font></div></td></tr></table><div style="line-height:120%;padding-top:16px;text-align:justify;text-indent:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">We anticipate that we will continue to generate significant losses in the future as we incur expenses to complete our clinical trial programs for our product candidates, develop our pipeline and pursue regulatory approval of our product candidates. We believe that our existing cash and cash equivalents will allow us to fund our operating plan into the second quarter of 2020. However, our operating plan may change as a result of factors currently unknown to us.</font></div><div style="line-height:120%;padding-top:16px;text-align:justify;text-indent:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">There can be no assurance that our revenue and expense forecasts will prove to be accurate, and any change in the foregoing assumptions could require us to obtain additional financing earlier than anticipated. There is a risk of delay or failure at any stage of developing a product candidate, and the time required and costs involved in successfully accomplishing our objectives cannot be accurately predicted. Actual drug research and development costs could substantially exceed budgeted amounts, which could force us to delay, reduce the scope of or eliminate one or more of our research or development programs.</font></div><div style="line-height:120%;padding-top:16px;text-align:justify;text-indent:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">We are party to license agreements with various parties pursuant to which we have obtained licenses to certain patents, patent applications and other intellectual property related to our product candidates and product development efforts. Pursuant to most of these license agreements, we are obligated to make aggregate payments ranging from approximately $200,000 to $4.3&#160;million under our license agreements (and in some cases, for each product candidate in such license) upon achievement of development and regulatory approval milestones specified in the applicable license. The timing of our achievement of these events and corresponding milestone payments to our licensors is subject to factors relating to the clinical and regulatory development and commercialization of our product candidates, many of which are beyond our control. We may become obligated to make a milestone payment when we do not have the cash on hand to make such payment, which could require us to delay our clinical trials, curtail our operations, scale back our commercialization or marketing efforts or seek funds to meet these obligations on terms unfavorable to us.</font></div><div style="line-height:120%;padding-top:16px;text-align:justify;text-indent:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">We may never be able to generate a sufficient amount of product revenue to cover our expenses. Until we do, we expect to seek additional funding through public or private equity or debt financings, collaborative relationships, capital lease transactions or other available financing transactions. However, there can be no assurance that additional financing will be available on acceptable terms, if at all, and such financings could be dilutive to existing stockholders. Moreover, in the event that additional funds are obtained through arrangements with collaborators, such arrangements may require us to relinquish rights to certain of our technologies, product candidates or products that we would otherwise seek to develop or commercialize ourselves.</font></div><div style="line-height:120%;padding-top:16px;text-align:justify;text-indent:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">If adequate funds are not available, we may be required to delay, reduce the scope of or eliminate one or more of our research or development programs. Our failure to obtain adequate financing when needed and on acceptable terms would have a material adverse effect on our business, financial condition and results of operations.</font></div><div><br></div><div style="text-align:center;"><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">38</font></div></div><hr style="page-break-after:always"><div><div style="line-height:120%;text-align:left;font-size:8pt;"><a style="font-family:inherit;font-size:8pt;" href="#sD088029191DD5EB99A130DC52B3A6E1B"><font style="font-family:inherit;font-size:8pt;">Table of Contents</font></a></div></div><div><br></div><div style="line-height:120%;padding-top:16px;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;">Even though we have received governmental support in the past, we may not continue to receive support at the same level or at all.</font></div><div style="line-height:120%;padding-top:16px;text-align:justify;text-indent:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">We have received significant financial assistance, primarily in the form of forgivable loans, from state and local governments. We have also received significant financial assistance, primarily in the form of grants and contracts, from federal agencies to support our infectious disease research. There can be no assurance that we will continue to receive the same level of assistance from these or other government agencies, if at all.</font></div><div style="line-height:120%;padding-top:16px;text-align:justify;text-indent:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Through our subsidiary, BioProtection Systems Corporation, or BPS, we have received funding from multiple government agencies for our Ebola vaccine product candidate development efforts. There is no guarantee that we will receive sufficient, or any, future grant funding to meet our obligations related to our Ebola vaccine development or that we or Merck will succeed in developing an Ebola vaccine. The termination of a United States government grant, contract or relationship as a result of our failure to satisfy any of our obligations under the grants or contracts would have a negative impact on our operations and harm our reputation and ability to procure government contracts. Additionally, there can be no assurance that we will secure comparable contracts with, or grants from, the United States government in the future.</font></div><div style="line-height:120%;padding-top:16px;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;">Changes in our effective income tax rate could adversely affect our results of operations in the future.</font></div><div style="line-height:120%;padding-top:16px;text-align:justify;text-indent:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">For the </font><font style="font-family:inherit;font-size:10pt;">nine months ended</font><font style="font-family:inherit;font-size:10pt;">&#32;</font><font style="font-family:inherit;font-size:10pt;">September&#160;30, 2017</font><font style="font-family:inherit;font-size:10pt;">&#32;we have a tax benefit due to our ability to carry net operating losses back to the year ended December 31, 2015 which was subject to federal income taxes in the United States. Our effective income tax rate, as well as our relative domestic and international tax liabilities, will depend in part on the allocation of any future income among different jurisdictions. In addition, various factors may have favorable or unfavorable effects on our effective income tax rate in individual jurisdictions or in the aggregate. These factors include whether tax authorities agree with our interpretations of existing tax laws, any required accounting for stock options and other share-based compensation, changes in tax laws and rates, our future levels of research and development spending, changes in accounting standards, changes in the mix of any future earnings in the various tax jurisdictions in which we may operate, the outcome of any examinations by the U.S. Internal Revenue Service or other tax authorities, the accuracy of our estimates for unrecognized tax benefits and realization of deferred tax assets and changes in overall levels of pre-tax earnings. The effect on our income tax liabilities resulting from the above-mentioned factors or other factors could have a material adverse effect on our results of operations.</font></div><div style="line-height:120%;padding-top:16px;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Risks Relating to Competition </font></div><div style="line-height:120%;padding-top:16px;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;">We compete in an industry characterized by extensive research and development efforts and rapid technological progress. New discoveries or commercial developments by our competitors could render our potential products obsolete or non-competitive.</font></div><div style="line-height:120%;padding-top:16px;text-align:justify;text-indent:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">New developments occur and are expected to continue to occur at a rapid pace, and there can be no assurance that discoveries or commercial developments by our competitors will not render some or all of our potential products obsolete or non-competitive, which would have a material adverse effect on our business, financial condition and results of operations.</font></div><div style="line-height:120%;padding-top:16px;text-align:justify;text-indent:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">We expect to compete with fully integrated and well-established pharmaceutical and biotechnology companies in the near and long term. Most of these companies have substantially greater financial, research and development, manufacturing and marketing experience and resources than we do and represent substantial long-term competition for us. Such companies may succeed in discovering and developing pharmaceutical products more rapidly than we do or pharmaceutical products that are safer, more effective or less costly than any that we may develop. Such companies also may be more successful than we are in production and marketing. Smaller companies may also prove to be significant competitors, particularly through collaborative arrangements with large pharmaceutical and established biotechnology companies. Academic institutions, governmental agencies and other public and private research organizations also conduct clinical trials, seek patent protection and establish collaborative arrangements for the development of oncology products.</font></div><div style="line-height:120%;padding-top:16px;text-align:justify;text-indent:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">We may face competition based on product efficacy and safety, the timing and scope of regulatory approvals, availability of supply, marketing and sales capabilities, reimbursement coverage, price and patent position. There can be no assurance that our competitors will not develop safer and more effective products, commercialize products earlier than we do, or obtain patent protection or intellectual property rights that limit our ability to commercialize our products.</font></div><div style="line-height:120%;padding-top:16px;text-align:justify;text-indent:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">There can be no assurance that our issued patents or pending patent applications, if issued, will not be challenged, invalidated or circumvented or that the rights granted thereunder will provide us with proprietary protection or a competitive advantage.</font></div><div><br></div><div style="text-align:center;"><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">39</font></div></div><hr style="page-break-after:always"><div><div style="line-height:120%;text-align:left;font-size:8pt;"><a style="font-family:inherit;font-size:8pt;" href="#sD088029191DD5EB99A130DC52B3A6E1B"><font style="font-family:inherit;font-size:8pt;">Table of Contents</font></a></div></div><div><br></div><div style="line-height:120%;padding-top:16px;text-align:justify;text-indent:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">The biotechnology and pharmaceutical industries are intensely competitive and subject to rapid and significant technological change. Many of the products that we are attempting to develop and commercialize will be competing with existing therapies. In addition, a number of companies are pursuing the development of pharmaceuticals that target the same diseases and conditions that we are targeting. We face competition from pharmaceutical and biotechnology companies both in the United States and abroad. Our competitors may utilize discovery technologies and techniques or collaborate with third parties in order to develop products more rapidly or successfully than we or our collaborators are able to do. Many of our competitors, particularly large pharmaceutical companies, have substantially greater financial, technical and human resources than we do. In addition, academic institutions, government agencies and other public and private organizations conducting research may seek patent protection with respect to potentially competitive products or technologies and may establish exclusive collaborative or licensing relationships with our competitors.</font></div><div style="line-height:120%;padding-top:16px;text-align:justify;text-indent:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">We face intense competition in our development activities. We face competition from many companies in the United States and abroad, including a number of large pharmaceutical companies, firms specialized in the development and production of vaccines, checkpoint inhibitors, and other immunotherapies, and major universities and research institutions. Many companies have entered into the field of immuno-oncology and are developing or commercializing products in areas that we have targeted for product development. Some of these products use therapeutic approaches that may compete directly with our product candidates. Most of our competitors possess substantially greater financial, technical and human resources than we possess. In addition, many of our competitors have significantly greater experience than we have in conducting preclinical and nonclinical testing and human clinical trials of product candidates, scaling up manufacturing operations and obtaining regulatory approvals of drugs and manufacturing facilities. Accordingly, our competitors may succeed in obtaining regulatory approval for drugs more rapidly than we do. We may also be adversely effected by the clinical trial results of our competitors. For example, if a competitor announces inconclusive or negative clinical trial results with respect to an IDO pathway inhibitor, expectations about IDO pathway inhibitors may be generally impacted and we may experience difficulty in enrolling patients in our indoximod trials. If we obtain regulatory approval and launch commercial sales of our product candidates, we also will compete with respect to manufacturing efficiency and sales and marketing capabilities, areas in which we currently have limited experience.</font></div><div style="line-height:120%;padding-top:16px;text-align:justify;text-indent:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">We also face competition from pharmaceutical and biotechnology companies, academic institutions, government agencies and private research organizations in recruiting and retaining highly qualified scientific personnel and consultants and in the development and acquisition of technologies. Moreover, technology controlled by third parties that may be advantageous to our business may be acquired or licensed by our competitors, thereby preventing us from obtaining technology on commercially reasonable terms, if at all. We will also compete for the services of third parties that may have already developed or acquired internal biotechnology capabilities or made commercial arrangements with other biopharmaceutical companies to target the diseases on which we have focused both inside and outside of the United States.</font></div><div style="line-height:120%;padding-top:16px;text-align:justify;text-indent:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Our competitive position will also depend upon our ability to attract and retain qualified personnel, obtain patent protection or otherwise develop proprietary products or processes and secure sufficient capital resources for the often lengthy period between technological conception and commercial sales. We will require substantial capital resources to complete development of some or all of our products, obtain the necessary regulatory approvals and successfully manufacture and market our products. In order to secure capital resources, we may elect to sell additional capital stock, which would dilute the holdings of existing stockholders. We may also attempt to obtain funds through research grants and agreements with commercial collaborators. However, these types of financings are uncertain because they are at the discretion of the organizations and companies that control the funds. Accordingly, we may not receive any additional funds from grants or collaborations.</font></div><div style="line-height:120%;padding-top:16px;text-align:justify;text-indent:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Research and discoveries by others may result in breakthroughs that render indoximod, navoximod, HyperAcute Cellular Immunotherapy product candidates, or our other potential products obsolete even before they begin to generate any revenue. If the FDA approves the commercial sale of any of our product candidates, we will also be competing with respect to marketing capabilities and manufacturing efficiency, areas in which we have limited or no experience. We expect that competition among products approved for sale will be based, among other things, on product efficacy, price, safety, reliability, availability, patent protection, and sales, marketing and distribution capabilities. Our profitability and financial position will suffer if our products receive regulatory approval but cannot compete effectively in the marketplace.</font></div><div style="line-height:120%;padding-top:16px;text-align:justify;text-indent:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Our infectious disease product candidates face significant competition for United States government funding for both development and procurement of vaccines against infectious diseases, medical countermeasures for biological, chemical and nuclear threats, diagnostic testing systems and other emergency preparedness countermeasures. Public and private biopharmaceutical companies, academic institutions, government agencies, private research organizations and public research organizations are conducting research and filing patents toward commercialization of products. </font></div><div><br></div><div style="text-align:center;"><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">40</font></div></div><hr style="page-break-after:always"><div><div style="line-height:120%;text-align:left;font-size:8pt;"><a style="font-family:inherit;font-size:8pt;" href="#sD088029191DD5EB99A130DC52B3A6E1B"><font style="font-family:inherit;font-size:8pt;">Table of Contents</font></a></div></div><div><br></div><div style="line-height:120%;padding-top:16px;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;">Our future products, if any, may not be accepted in the marketplace and therefore, we may not be able to generate significant revenue, or any revenue.</font></div><div style="line-height:120%;padding-top:16px;text-align:justify;text-indent:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Even if our potential products are approved for sale, physicians and the medical community may not ultimately use them or may use them only in applications more restricted than we expect. Our future products, if successfully developed, will compete with a number of traditional immuno-oncology products manufactured and marketed by major pharmaceutical and other biotechnology companies. Our products will also compete with new products currently under development by such companies and others. Physicians will prescribe a product only if they determine, based on experience, clinical data, side effect profiles and other factors, that it is beneficial as compared to other products currently in use. Many other factors influence the adoption of new products, including marketing and distribution restrictions, course of treatment, adverse publicity, product pricing, the views of thought leaders in the medical community and reimbursement by government and private third-party payers.</font></div><div style="line-height:120%;padding-top:16px;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Risks Relating to Our Arrangements with Third Parties </font></div><div style="line-height:120%;padding-top:16px;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;">We rely on third parties to conduct our preclinical studies and our clinical trials. If these third parties do not perform as contractually required or expected, we may not be able to obtain regulatory approval for our product candidates, or we may be delayed in doing so.</font></div><div style="line-height:120%;padding-top:16px;text-align:justify;text-indent:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">We do not have the ability to conduct preclinical studies or clinical trials independently for our product candidates. We must rely on third parties, such as contract research organizations, medical institutions, academic institutions, clinical investigators and contract laboratories, as well as our strategic collaborators and the third parties that they may use, to conduct our preclinical studies and clinical trials. Other than to the extent that Merck is responsible for clinical trials of our Ebola vaccine product candidate and Genentech is responsible for clinical trials that it conducted on navoximod prior to terminating its rights to navoximod and for any clinical trials that it may conduct on next generation IDO/TDO inhibitor products, we are responsible for confirming that our studies are conducted in accordance with applicable regulations and that each of our clinical trials is conducted in accordance with its general investigational plan and protocol. The FDA requires us to comply with GLP for conducting and recording the results of our preclinical studies and with GCP for conducting, monitoring, recording and reporting the results of clinical trials, to assure that data and reported results are accurate and that the clinical trial participants are adequately protected. Our reliance on third parties does not relieve us of these responsibilities. If the third parties conducting our clinical trials do not perform their contractual duties or obligations, do not meet expected deadlines, fail to comply with GCP, do not adhere to our clinical trial protocols or otherwise fail to generate reliable clinical data, we may need to enter into new arrangements with alternative third parties and our clinical trials may be more costly than expected or budgeted, be extended, delayed or terminated or may need to be repeated, and we may not be able to obtain regulatory approval for or to commercialize the product candidate being tested in such trials, or may be delayed in doing so.</font></div><div style="line-height:120%;padding-top:16px;text-align:justify;text-indent:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Further, if our contract manufacturers are not in compliance with regulatory requirements at any stage, including post-marketing approval, we may be fined, forced to remove a product from the market and/or experience other adverse consequences, including delays, which could materially harm our business.</font></div><div style="line-height:120%;padding-top:16px;text-align:justify;text-indent:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">We are also dependent on Genentech and Merck for the development of the product candidates that are the subject of the Genentech Agreement and the Merck Agreement. If either company does not succeed in advancing any product candidate to final approval, or decides to discontinue its collaboration with us, such failure or decision, could materially harm our business.</font></div><div style="line-height:120%;padding-top:16px;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;">If we fail to enter into any needed collaboration agreements for our product candidates, or if we enter into collaborations that are ultimately unsuccessful, we may be unable to commercialize any potential product effectively or at all.</font></div><div style="line-height:120%;padding-top:16px;text-align:justify;text-indent:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">To successfully commercialize any potential product, we will need substantial financial resources as well as expertise and physical resources and systems. We may elect to develop some or all of these physical resources and systems and expertise ourselves or we may seek to collaborate with another company that can provide some or all of such physical resources and systems as well as financial resources and expertise, as we did in the case of the Genentech Agreement and the Merck Agreement. Such collaborations are complex, and any potential discussions may not result in a definitive agreement for many reasons. For example, whether we reach a definitive agreement for a collaboration will depend, among other things, upon our assessment of the collaborator&#8217;s resources and expertise, the terms and conditions of the proposed collaboration, and the proposed collaborator&#8217;s evaluation of a number of factors. Those factors may include the design or results of our clinical trials, the potential market for the subject product candidates, the costs and complexities of manufacturing and delivering the potential product to patients, the potential of competing products, the existence of uncertainty with respect to ownership or the coverage of our technology, which can exist if there is a challenge to such ownership without regard to the merits of the challenge and industry and market conditions generally. If we were to determine that a collaboration for a potential product is necessary or beneficial and were unable to enter into such a collaboration on acceptable terms, we might elect to delay or scale back the commercialization of the potential product </font></div><div><br></div><div style="text-align:center;"><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">41</font></div></div><hr style="page-break-after:always"><div><div style="line-height:120%;text-align:left;font-size:8pt;"><a style="font-family:inherit;font-size:8pt;" href="#sD088029191DD5EB99A130DC52B3A6E1B"><font style="font-family:inherit;font-size:8pt;">Table of Contents</font></a></div></div><div><br></div><div style="line-height:120%;padding-top:16px;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">in order to preserve our financial resources or to allow us adequate time to develop the required physical resources and systems and expertise ourselves.</font></div><div style="line-height:120%;padding-top:16px;text-align:justify;text-indent:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">If we enter into a collaboration agreement we consider acceptable, including the Genentech Agreement to develop and commercialize next generation IDO/TDO inhibitors and the Merck Agreement to commercialize our Ebola vaccine product candidate, the collaboration may not proceed as quickly, smoothly or successfully as we plan. The risks in a collaboration agreement include the following:</font></div><table cellpadding="0" cellspacing="0" style="padding-top:16px;padding-bottom:8px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:96px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:60px;"><font style="font-family:inherit;font-size:10pt;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">the collaborator may not apply the expected financial resources, efforts or required expertise in developing the physical resources and systems necessary to successfully commercialize the subject potential product;</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-bottom:8px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:96px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:60px;"><font style="font-family:inherit;font-size:10pt;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">the collaborator may not invest in the development of a sales and marketing force and the related infrastructure at levels that ensure that sales of the potential product reach their full potential;</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-bottom:8px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:96px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:60px;"><font style="font-family:inherit;font-size:10pt;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">disputes may arise between us and a collaborator that delay the commercialization or adversely affect its sales or profitability of the potential product; or</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-bottom:8px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:96px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:60px;"><font style="font-family:inherit;font-size:10pt;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">the collaborator may independently develop, or develop with third parties, products that could compete with the potential product.</font></div></td></tr></table><div style="line-height:120%;padding-top:16px;text-align:justify;text-indent:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Under the Genentech Agreement, the Merck Agreement and any other collaboration for our product candidates, we will be dependent on our collaborators&#8217; performance of their responsibilities and their cooperation with us. Our collaborators may not perform their obligations under our agreements with them or otherwise cooperate with us. We cannot control whether our collaborators will devote the necessary resources to the activities contemplated by our collaborative agreements, nor can we control the timing of their performance. Our collaborators may choose to pursue existing or alternative technologies in preference to those being developed in collaboration with us. Disputes may arise between us and our collaborators that delay the development and commercialization of our product candidates, and such disputes may be difficult and costly to resolve or may not be resolved. In addition, a collaborator for the potential product may have the right to terminate the collaboration at its discretion, or to discontinue development of a particular product candidate. For example, in June 2017, Genentech gave notice that it is terminating the Genentech Agreement with respect to navoximod. Further, Genentech has the right to terminate the remainder of the Genentech Agreement for any reason, and Merck has the right to terminate the Merck Agreement for any reason, in each case, after a specified advance notice period. Any termination may require us to seek a new collaborator, which we may not be able to do on a timely basis, if at all, or may require us to delay or scale back the development or commercialization efforts. The occurrence of any of these events could adversely affect the development or commercialization of the potential product and materially harm our business and stock price by delaying the sale of any product that may be approved by the FDA in the future, by slowing the growth of such sales, by reducing the profitability of the product and/or by adversely affecting the reputation of the product.</font></div><div style="line-height:120%;padding-top:16px;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;">We may explore strategic collaborations that may never materialize or may fail.</font></div><div style="line-height:120%;padding-bottom:16px;padding-top:16px;text-align:justify;text-indent:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">We may, in the future, periodically explore a variety of possible strategic collaborations in an effort to gain access to additional product candidates or resources. At the current time, we cannot predict what form such a strategic collaboration might take. We are likely to face significant competition in the process of seeking appropriate strategic collaborators, and such collaborations can be complicated and time consuming to negotiate and document. We may not be able to negotiate strategic collaborations on acceptable terms, or at all. We are unable to predict when, if ever, we will enter into any additional strategic collaborations because of the numerous risks and uncertainties associated with establishing them.</font></div><div style="line-height:120%;padding-top:16px;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;">We are required under the AstraZeneca Agreement, Genentech Agreement and the Merck Agreement, and we may be required under other collaborations, to relinquish important rights to and control over the development of our product candidates to our collaborators or otherwise be subject to unfavorable terms.</font></div><div style="line-height:120%;padding-top:16px;text-align:justify;text-indent:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Our collaborations, including any future strategic collaborations we enter into, could subject us to a number of risks, including:</font></div><table cellpadding="0" cellspacing="0" style="padding-top:8px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:96px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:60px;"><font style="font-family:inherit;font-size:10pt;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">we may be required to undertake the expenditure of substantial operational, financial and management resources;</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:8px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:96px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:60px;"><font style="font-family:inherit;font-size:10pt;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">other than under the AstraZeneca Agreement, Genentech Agreement and the Merck Agreement, we may be required to issue equity securities that would dilute our existing stockholders&#8217; percentage ownership;</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:8px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:96px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:60px;"><font style="font-family:inherit;font-size:10pt;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">we may be required to assume substantial actual or contingent liabilities;</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:8px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:96px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:60px;"><font style="font-family:inherit;font-size:10pt;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">we may not be able to control the amount and timing of resources that our strategic collaborators devote to the development or commercialization of our product candidates;</font></div></td></tr></table><div><br></div><div style="text-align:center;"><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">42</font></div></div><hr style="page-break-after:always"><div><div style="line-height:120%;text-align:left;font-size:8pt;"><a style="font-family:inherit;font-size:8pt;" href="#sD088029191DD5EB99A130DC52B3A6E1B"><font style="font-family:inherit;font-size:8pt;">Table of Contents</font></a></div></div><div><br></div><table cellpadding="0" cellspacing="0" style="padding-top:8px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:96px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:60px;"><font style="font-family:inherit;font-size:10pt;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">strategic collaborators may delay clinical trials, provide insufficient funding, terminate a clinical trial or abandon a product candidate, repeat or conduct new clinical trials or require a new version of a product candidate for clinical testing;</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:8px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:96px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:60px;"><font style="font-family:inherit;font-size:10pt;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">strategic collaborators may not pursue further development and commercialization of products resulting from the strategic collaboration arrangement or may elect to discontinue research and development programs;</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:8px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:96px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:60px;"><font style="font-family:inherit;font-size:10pt;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">strategic collaborators may not commit adequate resources to the marketing and distribution of our product candidates, limiting our potential revenues from these products;</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:8px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:96px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:60px;"><font style="font-family:inherit;font-size:10pt;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">disputes may arise between us and our strategic collaborators that result in the delay or termination of the research, development or commercialization of our product candidates or that result in costly litigation or arbitration that diverts management&#8217;s attention and consumes resources;</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:8px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:96px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:60px;"><font style="font-family:inherit;font-size:10pt;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">strategic collaborators may experience financial difficulties;</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:8px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:96px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:60px;"><font style="font-family:inherit;font-size:10pt;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">strategic collaborators may not properly maintain or defend our intellectual property rights or may use our proprietary information in a manner that could jeopardize or invalidate our proprietary information or expose us to potential litigation;</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:8px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:96px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:60px;"><font style="font-family:inherit;font-size:10pt;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">business combinations or significant changes in a strategic collaborator&#8217;s business strategy may also adversely affect a strategic collaborator&#8217;s willingness or ability to complete its obligations under any arrangement;</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:8px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:96px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:60px;"><font style="font-family:inherit;font-size:10pt;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">strategic collaborators could decide to move forward with a competing product candidate developed either independently or in collaboration with others, including our competitors; and</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:8px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:96px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:60px;"><font style="font-family:inherit;font-size:10pt;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">strategic collaborators could terminate the arrangement or allow it to expire, which would delay the development and may increase the cost of developing our product candidates.</font></div></td></tr></table><div style="line-height:120%;padding-top:16px;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Risks Relating to Protecting Our Intellectual Property</font></div><div style="line-height:120%;padding-top:16px;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;">If we are unable to protect our proprietary rights or to defend against infringement claims, we may not be able to compete effectively or operate profitably.</font></div><div style="line-height:120%;padding-top:16px;text-align:justify;text-indent:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Our success will depend, in part, on our ability to obtain patents, operate without infringing the proprietary rights of others and maintain trade secrets, both in the United States and other countries. Patent matters in the biotechnology and pharmaceutical industries can be highly uncertain and involve complex legal and factual questions. Accordingly, the validity, breadth, and enforceability of our patents and the existence of potentially blocking patent rights of others cannot be predicted, either in the United States or in other countries.</font></div><div style="line-height:120%;padding-top:16px;text-align:justify;text-indent:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">There can be no assurance that we will discover or develop patentable products or processes, or that patents will issue from any of the currently pending patent applications or that claims granted on issued patents will be sufficient to protect our technology or adequately cover the products we may actually sell. Potential competitors or other researchers in the field may have filed patent applications, been issued patents, published articles or otherwise created prior art that could restrict or block our efforts to obtain additional patents. There also can be no assurance that our issued patents or pending patent applications, if issued, will not be challenged, invalidated, rendered unenforceable or circumvented or that the rights granted thereunder will provide us with proprietary protection or competitive advantages. Our patent rights also depend on our compliance with technology and patent licenses upon which our patent rights are based and upon the validity of assignments of patent rights from consultants and other inventors that were, or are, not employed by us.</font></div><div style="line-height:120%;padding-top:16px;text-align:justify;text-indent:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">In addition, competitors may manufacture and sell our potential products in those foreign countries where we have not filed for patent protection or where patent protection may be unavailable, not obtainable or ultimately not enforceable. In addition, even where patent protection is obtained, third-party competitors may challenge our patent claims in the various patent offices, for example via opposition in the European Patent Office or reexamination or interference proceedings in the United States Patent and Trademark Office, or USPTO. The ability of such competitors to sell such products in the United States or in foreign countries where we have obtained patents is usually governed by the patent laws of the countries in which the product is sold.</font></div><div style="line-height:120%;padding-top:16px;text-align:justify;text-indent:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">We will incur significant ongoing expenses in maintaining our patent portfolio. Should we lack the funds to maintain our patent portfolio or to enforce our rights against infringers, we could be adversely impacted. Even if claims of infringement are without merit, any such action could divert the time and attention of management and impair our ability to access additional capital and/or cost us significant funds to defend.</font></div><div><br></div><div style="text-align:center;"><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">43</font></div></div><hr style="page-break-after:always"><div><div style="line-height:120%;text-align:left;font-size:8pt;"><a style="font-family:inherit;font-size:8pt;" href="#sD088029191DD5EB99A130DC52B3A6E1B"><font style="font-family:inherit;font-size:8pt;">Table of Contents</font></a></div></div><div><br></div><div style="line-height:120%;padding-top:16px;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;">Patent reform legislation could increase the uncertainties and costs surrounding the prosecution of our patent applications and the enforcement or defense of our issued patents.</font></div><div style="line-height:120%;padding-top:16px;text-align:justify;text-indent:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">On September&#160;16, 2011, the Leahy-Smith America Invents Act, or the Leahy-Smith Act, was signed into law. The Leahy-Smith Act includes a number of significant changes to United States patent law. These include provisions that affect the way patent applications will be prosecuted and may also affect patent litigation. The United States Patent and Trademark Office has developed regulations and procedures to govern administration of the Leahy-Smith Act, but many of the substantive changes to patent law associated with the Leahy-Smith Act, particularly the first-inventor-to-file provisions, only became effective 18&#160;months after its enactment. Accordingly, it is not clear what, if any, impact the Leahy-Smith Act will have on the operation of our business. However, the Leahy-Smith Act and its implementation could increase the uncertainties and costs surrounding the prosecution of our patent applications and the enforcement or defense of our issued patents, all of which could have a material adverse effect on our business and financial condition.</font></div><div style="line-height:120%;padding-top:16px;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;">We may be subject to litigation with respect to the ownership and use of intellectual property that will be costly to defend or pursue and uncertain in its outcome.</font></div><div style="line-height:120%;padding-top:16px;text-align:justify;text-indent:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Our success also will depend, in part, on our refraining from infringing patents or otherwise violating intellectual property owned or controlled by others. Pharmaceutical companies, biotechnology companies, universities, research institutions, and others may have filed patent applications or have received, or may obtain, issued patents in the United States or elsewhere relating to aspects of our technology. It is uncertain whether the issuance of any third-party patents will require us to alter our products or processes, obtain licenses, or cease certain activities. Some third-party applications or patents may conflict with our issued patents or pending applications. Any such conflict could result in a significant reduction of the scope or value of our issued or licensed patents.</font></div><div style="line-height:120%;padding-top:16px;text-align:justify;text-indent:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">In addition, if patents issued to other companies contain blocking, dominating or conflicting claims and such claims are ultimately determined to be valid, we may be required to obtain licenses to these patents or to develop or obtain alternative non-infringing technology and cease practicing those activities, including potentially manufacturing or selling any products deemed to infringe those patents. If any licenses are required, there can be no assurance that we will be able to obtain any such licenses on commercially favorable terms, if at all, and if these licenses are not obtained, we might be prevented from pursuing the development and commercialization of certain of our potential products. Our failure to obtain a license to any technology that we may require to commercialize our products on favorable terms may have a material adverse impact on our business, financial condition and results of operations.</font></div><div style="line-height:120%;padding-top:16px;text-align:justify;text-indent:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Litigation, which could result in substantial costs to us (even if determined in our favor), may also be necessary to enforce any patents issued or licensed to us or to determine the scope and validity of the proprietary rights of others. There can be no assurance that our issued or licensed patents would be held valid by a court of competent jurisdiction or that any third party would be found to infringe our patents.</font></div><div style="line-height:120%;padding-top:16px;text-align:justify;text-indent:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">In addition, if our competitors filed patent applications in the United States that claim technology also claimed by us, and such applications were filed before the Leahy-Smith Act took effect, we may have to participate in interference proceedings to determine priority of invention. These proceedings, if initiated by the USPTO, could result in substantial cost to us, even if the eventual outcome is favorable to us. Such proceedings can be lengthy; are costly to defend and involve complex questions of law and fact, the outcomes of which are difficult to predict. An adverse outcome with respect to a third party claim or in an interference proceeding could subject us to significant liabilities, require us to license disputed rights from third parties, or require us to cease using such technology, any of which could have a material adverse effect on our business, financial condition and results of operations.</font></div><div style="line-height:120%;padding-top:16px;text-align:justify;text-indent:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">We also rely on trade secrets to protect technology, especially where patent protection is not believed to be appropriate or obtainable or where patents have not issued. We attempt to protect our proprietary technology and processes, in part, with confidentiality agreements and assignment of invention agreements with our employees and confidentiality agreements with our consultants and certain contractors. There can be no assurance that these agreements will not be breached, that we would have adequate remedies for any breach, or that our trade secrets will not otherwise become known or be independently discovered by competitors. We may fail in certain circumstances to obtain the necessary confidentiality agreements, or their scope or term may not be sufficiently broad to protect our interests.</font></div><div style="line-height:120%;padding-top:16px;text-align:justify;text-indent:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">If our trade secrets or other intellectual property becomes known to our competitors, it could result in a material adverse effect on our business, financial condition and results of operations. To the extent that we or our consultants or research collaborators use intellectual property owned by others in work for us, disputes may also arise as to the rights to related or resulting know-how and inventions.</font></div><div><br></div><div style="text-align:center;"><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">44</font></div></div><hr style="page-break-after:always"><div><div style="line-height:120%;text-align:left;font-size:8pt;"><a style="font-family:inherit;font-size:8pt;" href="#sD088029191DD5EB99A130DC52B3A6E1B"><font style="font-family:inherit;font-size:8pt;">Table of Contents</font></a></div></div><div><br></div><div style="line-height:120%;padding-top:16px;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Risks Relating to Our Exposure to Litigation </font></div><div style="line-height:120%;padding-top:16px;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;">We are exposed to potential product liability or similar claims, and insurance against these claims may not be available to us at a reasonable rate in the future.</font></div><div style="line-height:120%;padding-top:16px;text-align:justify;text-indent:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Our business exposes us to potential liability risks that are inherent in the testing, manufacturing, marketing and commercial sale of human therapeutic products. Clinical trials involve the testing of product candidates on human subjects or volunteers under a research plan and carry a risk of liability for personal injury or death to patients due to unforeseen adverse side effects, improper administration of the product candidate, or other factors. Many of these patients are already seriously ill and are therefore particularly vulnerable to further illness or death. In addition, healthy volunteers in our indoximod clinical trial or our Ebola vaccine product candidate clinical trial may suffer, or perceive themselves to suffer, personal injury or death related to the Ebola vaccine product candidates and may initiate legal action against us.</font></div><div style="line-height:120%;padding-top:16px;text-align:justify;text-indent:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">We currently carry clinical trial liability insurance in the amount of $5.0 million in the aggregate for claims related to our product candidates other than our Ebola vaccine product candidate. We currently carry clinical trial liability insurance in the amount of $10.0 million in the aggregate for claims related to our Ebola vaccine product candidate. We additionally currently carry clinical trial coverage in lower aggregate amounts in local markets where our clinical trials are conducted on a selective, trial by trial basis. There can be no assurance that we will be able to maintain such insurance or that the amount of such insurance will be adequate to cover claims. We could be materially and adversely affected if we were required to pay damages or incur defense costs in connection with a claim outside the scope of indemnity or insurance coverage, if the indemnity is not performed or enforced in accordance with its terms, or if our liability exceeds the amount of applicable insurance. In addition, there can be no assurance that insurance will continue to be available on terms acceptable to us, if at all, or that if obtained, the insurance coverage will be sufficient to cover any potential claims or liabilities. Similar risks would exist upon the commercialization or marketing of any future products by us or our collaborators.</font></div><div style="line-height:120%;padding-top:16px;text-align:justify;text-indent:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">On December 9, 2014, the United States Department of Health and Human Services declared our Ebola vaccine product candidate covered under the Public Readiness and Emergency Preparedness Act. This declaration provides immunity under U.S. law against legal claims related to the manufacturing, testing, development, distribution and administration of our vaccine candidate. It does not generally provide immunity for a claim brought in a court outside the United States.</font></div><div style="line-height:120%;padding-top:16px;text-align:justify;text-indent:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Regardless of their merit or eventual outcome, product liability claims may result in:</font></div><table cellpadding="0" cellspacing="0" style="padding-top:8px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:96px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:60px;"><font style="font-family:inherit;font-size:10pt;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">decreased demand for our product;</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:8px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:96px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:60px;"><font style="font-family:inherit;font-size:10pt;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">injury to our reputation and significant negative media attention;</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:8px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:96px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:60px;"><font style="font-family:inherit;font-size:10pt;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">withdrawal of clinical trial volunteers;</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:8px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:96px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:60px;"><font style="font-family:inherit;font-size:10pt;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">costs of litigation;</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:8px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:96px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:60px;"><font style="font-family:inherit;font-size:10pt;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">distraction of management; and</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:8px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:96px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:60px;"><font style="font-family:inherit;font-size:10pt;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">substantial monetary awards to plaintiffs.</font></div></td></tr></table><div style="line-height:120%;padding-top:16px;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;">We are involved in a securities class-action litigation and are at risk of additional similar litigation in the future that could divert management&#8217;s attention and adversely affect our business and could subject us to significant liabilities.</font></div><div style="line-height:120%;padding-top:16px;text-align:justify;text-indent:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">In the past, securities class action litigation has often been brought against a company following periods of volatility in the market price of securities. We are a party to the securities class action litigation described in Part II, Item 1 of this Quarterly Report on Form 10-Q under the heading &#8220;Legal Proceedings.&#8221; The defense of this litigation may increase our expenses and divert our management&#8217;s attention and resources and any unfavorable outcome could have a material adverse effect on our business and results of operations. Any adverse determination in this litigation, or any amounts paid to settle this litigation could require that we make significant payments. In addition, we may in the future be the target of other securities class actions or similar litigation.</font></div><div style="line-height:120%;padding-top:16px;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Risks Related to Ownership of Our Common Stock</font></div><div style="line-height:120%;padding-top:16px;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;">The market price of our common stock may be highly volatile, and could decline significantly.</font></div><div style="line-height:120%;padding-top:16px;text-align:justify;text-indent:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;"></font><font style="font-family:inherit;font-size:10pt;">The trading price of our common stock is likely to be highly volatile and could be subject to wide fluctuations in price in response to various factors, many of which are beyond our control, including those described elsewhere in this &#8220;Risk Factors&#8221; section of this Quarterly Report on Form 10-Q and the following:</font></div><div><br></div><div style="text-align:center;"><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">45</font></div></div><hr style="page-break-after:always"><div><div style="line-height:120%;text-align:left;font-size:8pt;"><a style="font-family:inherit;font-size:8pt;" href="#sD088029191DD5EB99A130DC52B3A6E1B"><font style="font-family:inherit;font-size:8pt;">Table of Contents</font></a></div></div><div><br></div><table cellpadding="0" cellspacing="0" style="padding-top:8px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:96px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:60px;"><font style="font-family:inherit;font-size:10pt;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">new products, product candidates or new uses for existing products introduced or announced by our strategic collaborators, or our competitors, and the timing of these introductions or announcements;</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:8px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:96px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:60px;"><font style="font-family:inherit;font-size:10pt;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">actual or anticipated results from and any delays in our clinical trials, as well as results of regulatory reviews relating to the approval of our product candidates;</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:8px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:96px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:60px;"><font style="font-family:inherit;font-size:10pt;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">variations in the level of expenses related to any of our product candidates or clinical development programs, including those relating to the timing of invoices from, and other billing practices of, our clinical research organizations and clinical trial sites;</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:8px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:96px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:60px;"><font style="font-family:inherit;font-size:10pt;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">expenses related to, or our ability or perceived ability to secure, an adequate supply of any future products approved for commercial sale;</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:8px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:96px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:60px;"><font style="font-family:inherit;font-size:10pt;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">the results of our efforts to discover, develop, acquire or in-license additional product candidates or products;</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:8px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:96px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:60px;"><font style="font-family:inherit;font-size:10pt;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">disputes or other developments relating to proprietary rights, including patents, litigation matters and our ability to obtain patent protection for our technologies;</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:8px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:96px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:60px;"><font style="font-family:inherit;font-size:10pt;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">announcements by us or our competitors of significant acquisitions, strategic collaborations, joint ventures and capital commitments;</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:8px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:96px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:60px;"><font style="font-family:inherit;font-size:10pt;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">the commercial or clinical success or failure, or perceived success or failure, of our collaborators, including Genentech, Merck and AstraZeneca;</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:8px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:96px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:60px;"><font style="font-family:inherit;font-size:10pt;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">additions or departures of key scientific or management personnel;</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:8px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:96px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:60px;"><font style="font-family:inherit;font-size:10pt;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">conditions or trends in the biotechnology and biopharmaceutical industries;</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:8px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:96px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:60px;"><font style="font-family:inherit;font-size:10pt;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">media attention, or changes in media attention, given to cancer and cancer treatment, the recent Ebola epidemic and efforts to develop treatments and vaccines for Ebola, or any other condition or disease that our product candidates are being developed to treat;</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:8px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:96px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:60px;"><font style="font-family:inherit;font-size:10pt;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">actual or anticipated changes in earnings estimates, development timelines or recommendations by securities analysts;</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:8px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:96px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:60px;"><font style="font-family:inherit;font-size:10pt;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">actual and anticipated fluctuations in our quarterly operating results;</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:8px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:96px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:60px;"><font style="font-family:inherit;font-size:10pt;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">the financial projections we may provide to the public, and any changes in these projections or our failure to meet these projections;</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:8px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:96px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:60px;"><font style="font-family:inherit;font-size:10pt;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">deviations from securities analysts&#8217; estimates or the impact of other analyst rating downgrades by any securities analysts who follow our common stock;</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:8px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:96px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:60px;"><font style="font-family:inherit;font-size:10pt;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">other events or factors, including those resulting from political uncertainty, war, incidents of terrorism, natural disasters or responses to these events;</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:8px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:96px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:60px;"><font style="font-family:inherit;font-size:10pt;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">changes in accounting principles;</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:8px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:96px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:60px;"><font style="font-family:inherit;font-size:10pt;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">discussion of us or our stock price by the financial and scientific press and in online investor communities;</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:8px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:96px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:60px;"><font style="font-family:inherit;font-size:10pt;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">general economic and market conditions and other factors that may be unrelated to our operating performance or the operating performance of our competitors, including changes in market valuations of similar companies; and</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:8px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:96px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:60px;"><font style="font-family:inherit;font-size:10pt;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">sales of common stock by us or our stockholders in the future, as well as the overall trading volume of our common stock.</font></div></td></tr></table><div style="line-height:120%;padding-top:16px;text-align:justify;text-indent:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">In addition, the stock market in general and the market for biotechnology and biopharmaceutical companies in particular have experienced extreme price and volume fluctuations that have often been unrelated or disproportionate to the operating performance of those companies. These broad market and industry factors may seriously harm the market price of our common stock, regardless of our operating performance. In the past, following periods of volatility in the market, securities class-action litigation has often been instituted against companies. We are currently party to the securities class action litigation described in Part II, Item 1 of this Quarterly Report on Form 10-Q under the heading &#8220;Legal Proceedings.&#8221; This litigation and others like it that could be brought against us in the future could result in substantial costs and diversion of management&#8217;s attention and resources, which could materially and adversely affect our business and financial condition.</font></div><div><br></div><div style="text-align:center;"><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">46</font></div></div><hr style="page-break-after:always"><div><div style="line-height:120%;text-align:left;font-size:8pt;"><a style="font-family:inherit;font-size:8pt;" href="#sD088029191DD5EB99A130DC52B3A6E1B"><font style="font-family:inherit;font-size:8pt;">Table of Contents</font></a></div></div><div><br></div><div style="line-height:120%;padding-top:16px;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;">Our principal stockholders and management own a significant percentage of our stock and will be able to exercise significant influence over matters subject to stockholder approval.</font></div><div style="line-height:120%;padding-top:16px;text-align:justify;text-indent:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">As of </font><font style="font-family:inherit;font-size:10pt;">September&#160;30, 2017</font><font style="font-family:inherit;font-size:10pt;">, our executive officers, directors and principal stockholders, together with their respective affiliates, owned approximately 56.2% of our common stock, including shares subject to outstanding options that are exercisable within 60&#160;days after </font><font style="font-family:inherit;font-size:10pt;">September&#160;30, 2017</font><font style="font-family:inherit;font-size:10pt;">. These stockholders will be able to exert a significant degree of influence over our management and affairs and over matters requiring stockholder approval, including the election of our Board of Directors, future issuances of our common stock or other securities, declarations of dividends on our common stock and approval of other significant corporate transactions. This concentration of ownership could have the effect of delaying or preventing a change in our control or otherwise discouraging a potential acquirer from attempting to obtain control of us, which in turn could have a material and adverse effect on the fair market value of our common stock. In addition, sales of shares beneficially owned by executive officers and directors and their affiliates could be viewed negatively by third parties and have a negative impact on our stock price. Moreover, we cannot assure you as to how these shares may be distributed and subsequently voted.</font></div><div style="line-height:120%;padding-top:16px;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;">We incur significant costs as a result of operating as a public company, and our management is required to devote substantial time to meet compliance obligations.</font></div><div style="line-height:120%;padding-top:16px;text-align:justify;text-indent:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">As a public company, we incur significant legal, accounting and other expenses to comply with reporting requirements of the Securities Exchange Act of 1934, or the Exchange Act, the Sarbanes-Oxley Act of 2002, or the Sarbanes-Oxley Act, as well as rules subsequently implemented by the SEC and The NASDAQ Global Market. Meeting the requirements of these rules and regulations entails significant legal and financial compliance costs, makes some activities more difficult, time-consuming or costly and may also place undue strain on our personnel, systems and resources. Our management and other personnel devote a substantial amount of time to these compliance requirements. In addition, these rules and regulations may make it more difficult and more expensive for us to obtain director and officer liability insurance, and we may be required to accept reduced policy limits and coverage or incur substantially higher costs to obtain the same or similar coverage. As a result, it may be more difficult for us to attract and retain qualified people to serve on our Board of Directors, our board committees or as executive officers.</font></div><div style="line-height:120%;padding-top:16px;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;">Failure to achieve and maintain effective internal controls in accordance with Section&#160;404 of the Sarbanes-Oxley Act could have a material adverse effect on our ability to produce accurate financial statements and on our stock price.</font></div><div style="line-height:120%;padding-top:16px;text-align:justify;text-indent:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Pursuant to Section&#160;404 of the Sarbanes-Oxley Act, we are required to publish a report by our management on our internal control over financial reporting. To achieve compliance with Section&#160;404, we have engaged in a process to document and evaluate our internal control over financial reporting, which has been both costly and challenging. To maintain compliance on an ongoing basis, we will need to dedicate internal resources, engage outside consultants and adopt a detailed work plan. Despite our effort, there is a risk that neither we nor our independent registered public accounting firm will be able to conclude that our internal control over financial reporting is effective as required by Section&#160;404. This could result in an adverse reaction in the financial markets due to a loss of confidence in the reliability of our financial statements.</font></div><div style="line-height:120%;padding-top:16px;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;">We do not expect to pay any cash dividends for the foreseeable future. Investors may never obtain a return on their investment.</font></div><div style="line-height:120%;padding-top:16px;text-align:justify;text-indent:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">You should not rely on an investment in our common stock to provide dividend income. We do not anticipate that we will pay any cash dividends to holders of our common stock in the foreseeable future. Instead, we plan to retain any earnings to maintain and expand our existing operations. In addition, any future debt financing arrangement may contain terms prohibiting or limiting the amount of dividends that may be declared or paid on our common stock. Accordingly, investors must rely on sales of their common stock after price appreciation, which may never occur, as the only way to realize any return on their investment. As a result, investors seeking only cash dividends should not purchase our common stock.</font></div><div style="line-height:120%;padding-top:16px;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;">Provisions in our certificate of incorporation, our by-laws or Delaware law might discourage, delay or prevent a change in control of our company or changes in our management and, therefore, depress the trading price of our common stock.</font></div><div style="line-height:120%;padding-top:16px;text-align:justify;text-indent:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Provisions of our certificate of incorporation, our by-laws or Delaware law may have the effect of deterring unsolicited takeovers or delaying or preventing a change in control of our company or changes in our management, including transactions in which our stockholders might otherwise receive a premium for their shares over then current market prices. In addition, these provisions may limit the ability of stockholders to approve transactions that they may deem to be in their best interest. These provisions include:</font></div><table cellpadding="0" cellspacing="0" style="padding-top:16px;padding-bottom:8px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:96px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:60px;"><font style="font-family:inherit;font-size:10pt;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">the division of our Board of Directors into three classes with staggered, three-year terms;</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-bottom:8px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:96px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:60px;"><font style="font-family:inherit;font-size:10pt;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">advance notice requirements for stockholder proposals and nominations;</font></div></td></tr></table><div><br></div><div style="text-align:center;"><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">47</font></div></div><hr style="page-break-after:always"><div><div style="line-height:120%;text-align:left;font-size:8pt;"><a style="font-family:inherit;font-size:8pt;" href="#sD088029191DD5EB99A130DC52B3A6E1B"><font style="font-family:inherit;font-size:8pt;">Table of Contents</font></a></div></div><div><br></div><table cellpadding="0" cellspacing="0" style="padding-bottom:8px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:96px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:60px;"><font style="font-family:inherit;font-size:10pt;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">the inability of stockholders to call special meetings;</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-bottom:8px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:96px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:60px;"><font style="font-family:inherit;font-size:10pt;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">limitations on the ability of stockholders to remove directors or amend our by-laws; and</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-bottom:8px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:96px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:60px;"><font style="font-family:inherit;font-size:10pt;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">the ability of our Board of Directors to designate the terms of and issue new series of preferred stock without stockholder approval, which could include the right to approve an acquisition or other change in our control or could be used to institute a rights plan, also known as a poison pill, that would work to dilute the stock ownership of a potential hostile acquirer, likely preventing acquisitions that have not been approved by our Board of Directors.</font></div></td></tr></table><div style="line-height:120%;padding-top:16px;text-align:justify;text-indent:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">In addition, Section&#160;203 of the Delaware General Corporation Law prohibits a publicly-held Delaware corporation from engaging in a business combination with an interested stockholder, generally a person that together with its affiliates owns, or within the last three years has owned, 15% of our voting stock, for a period of three years after the date of the transaction in which the person became an interested stockholder, unless the business combination is approved in a prescribed manner.</font></div><div style="line-height:120%;padding-top:16px;text-align:justify;text-indent:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">The existence of the foregoing provisions and anti-takeover measures could limit the price that investors might be willing to pay in the future for shares of our common stock. They could also deter potential acquirers of our company, thereby reducing the likelihood that you could receive a premium for your common stock in an acquisition.</font></div><div style="line-height:120%;padding-top:16px;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;">The holdings of our stockholders may be diluted, and the prices of our securities may decrease, by the exercise of outstanding stock options or by future issuances of securities by us.</font></div><div style="line-height:120%;padding-top:16px;text-align:justify;text-indent:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">We may issue additional common stock, preferred stock, restricted stock units, or securities convertible into or exchangeable for our common stock. Furthermore, substantially all shares of common stock for which our outstanding stock options are exercisable are, once they have been purchased, eligible for immediate sale in the public market. The issuance of additional common stock, preferred stock, restricted stock units, or securities convertible into or exchangeable for our common stock or the exercise of stock options would dilute existing investors and could adversely affect the price of our securities. In addition, such securities may have rights senior to the rights of securities held by existing investors.</font></div><div style="line-height:120%;padding-top:16px;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;">Our ability to use our net operating loss carryforwards and certain other tax attributes is limited by Sections&#160;382 and 383 of the Internal Revenue Code.</font></div><div style="line-height:120%;padding-top:16px;text-align:justify;text-indent:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Sections&#160;382 and 383 of the Internal Revenue Code limit a corporation&#8217;s ability to utilize its net operating loss carryforwards and certain other tax attributes (including research credits) to offset any future taxable income or tax if the corporation experiences a cumulative ownership change of more than 50% over any rolling three-year period. State net operating loss carryforwards (and certain other tax attributes) may be similarly limited. A Section 382 ownership change can therefore result in significantly greater tax liabilities than a corporation would incur in the absence of such a change, and any increased liabilities could adversely affect the corporation&#8217;s business, results of operations, financial condition and cash flow.</font></div><div style="line-height:120%;padding-top:16px;text-align:justify;text-indent:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Based on Section 382 ownership change analyses, we believe that, from our inception through December 31, 2016, we experienced Section&#160;382 ownership changes in September 2001 and March 2003, and BPS experienced Section 382 ownership changes in January 2006 and January 2011. These ownership changes limited our ability to utilize federal net operating loss carryforwards and certain other tax attributes that accrued prior to the respective ownership changes of us and our subsidiaries and may continue to limit our ability to utilize such attributes in the future.</font></div><div style="line-height:120%;padding-top:16px;text-align:justify;text-indent:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Additional ownership changes may occur in the future as a result of events over which we will have little or no control, including purchases and sales of our equity by our 5% stockholders, the emergence of new 5% stockholders, additional equity offerings or redemptions of our stock or certain changes in the ownership of any of our 5% stockholders.</font></div><div style="line-height:120%;padding-top:16px;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;">Accounting pronouncements may impact our reported results of operations and financial position.</font></div><div style="line-height:120%;padding-top:16px;text-align:justify;text-indent:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">U.S. GAAP and related implementation guidelines and interpretations can be highly complex and involve subjective judgments. Changes in these rules or their interpretation, the adoption of new pronouncements or the application of existing pronouncements to changes in our business could significantly alter our reported financial statements and results of operations.</font></div><div><br></div><div style="text-align:center;"><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">48</font></div></div><hr style="page-break-after:always"><div><div style="line-height:120%;text-align:left;font-size:8pt;"><a style="font-family:inherit;font-size:8pt;" href="#sD088029191DD5EB99A130DC52B3A6E1B"><font style="font-family:inherit;font-size:8pt;">Table of Contents</font></a></div></div><div><br></div><div style="line-height:120%;padding-top:16px;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;">If securities or industry analysts do not publish research or publish inaccurate or unfavorable research about our business, our stock price and trading volume could decline.</font></div><div style="line-height:120%;padding-top:16px;text-align:justify;text-indent:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">The trading market for our common stock will depend in part on the research and reports that securities or industry analysts publish about us or our business. If one or more of the analysts who covers us downgrades our stock or publishes inaccurate or unfavorable research about our business, our stock price would likely decline. If one or more of these analysts ceases coverage of us or fails to publish reports on us regularly, demand for our stock could decrease, which could cause our stock price and trading volume to decline.</font></div><div><br></div><div style="text-align:center;"><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">49</font></div></div><hr style="page-break-after:always"><div><a name="s9DA6F2ADA0075A91ABCAAC4FE1CE5D9D"></a></div><div><div style="line-height:120%;text-align:left;font-size:8pt;"><a style="font-family:inherit;font-size:8pt;" href="#sD088029191DD5EB99A130DC52B3A6E1B"><font style="font-family:inherit;font-size:8pt;">Table of Contents</font></a></div></div><div><br></div><div style="line-height:120%;padding-bottom:12px;padding-top:12px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">ITEM 1.&#160;&#160;&#160;&#160;LEGAL PROCEEDINGS</font></div><div style="line-height:120%;padding-bottom:12px;padding-top:12px;text-align:justify;text-indent:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">On or about May 12, 2016, Trevor Abramson filed a putative securities class action lawsuit in the United States District Court for the Southern District of New York, or the Court, captioned Abramson v. NewLink Genetics Corp., et al., Case 1:16-cv-3545, or the Securities Action. &#160;Subsequently, the Court appointed Michael and Kelly Nguyen as lead plaintiffs and approved their selection of Kahn, Swick &amp; Foti, LLC as lead counsel in the Securities Action.&#160;&#160;On October 31, 2016, the lead plaintiffs filed an amended complaint which asserts claims under the federal securities laws against the Company, the Company&#8217;s Chief Executive Officer Charles J. Link, Jr., and the Company&#8217;s Chief Medical Officer and President Nicholas Vahanian, or collectively, the Defendants.&#160; The amended complaint alleges the Defendants made material false and/or misleading statements that caused losses to the Company&#8217;s investors. In particular, the lead plaintiffs allege that the Defendants made material misstatements or omissions related to the Phase II and III trials and efficacy of the product candidate algenpantucel-L. The lead plaintiffs do not quantify any alleged damages in the amended complaint but, in addition to attorneys&#8217; fees and costs, they seek to recover damages on behalf of themselves and other persons who purchased or otherwise acquired the Company&#8217;s stock during the putative class period of September 17, 2013 through May 9, 2016, inclusive, at allegedly inflated prices and purportedly suffered financial harm as a result.  On April 27, 2017, the Court granted the parties&#8217; request for leave to brief a motion to dismiss the amended complaint, and ordered the parties to file a stipulation and proposed order setting forth a schedule for the briefing of that motion. On May 15, 2017, the Court ordered the following briefing schedule: motion to dismiss due July 14, 2017, opposition due September 12, 2017, and reply due September 26, 2017.&#160; The Defendants filed a motion to dismiss on July 14, 2017.</font><font style="font-family:Arial;font-size:10pt;">&#32;</font><font style="font-family:inherit;font-size:10pt;">The lead plaintiffs filed an opposition to the motion to dismiss on September 12, 2017. The Defendants filed a reply in support of the motion to dismiss on September 26, 2017. Oral argument was held on October 19, 2017, after which the Court reserved decision. The Company disputes the claims in the Securities Action and intends to defend against them vigorously.</font></div><div style="line-height:120%;padding-bottom:12px;text-align:justify;text-indent:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">On or about April 26, 2017, Ronald Morrow filed a shareholder derivative lawsuit on behalf of the Company in the United States District Court for the Southern District of New York, or the Court, against the Company&#8217;s Chief Executive Officer Charles J. Link, Jr., the Company&#8217;s Chief Medical Officer and President Nicholas Vahanian, and Company directors Thomas A. Raffin, Joseph Saluri, Ernest J. Talarico, III, Paul R. Edick, Paolo Pucci, and Lota S. Zoth, or collectively, the Morrow Defendants, captioned Morrow v. Link., et al., Case 1:17-cv-03039, or the Morrow Action.&#160; The complaint alleges that the Morrow Defendants caused the Company to issue false statements in its 2016 proxy statement regarding risk management and compensation matters in violation of federal securities law.&#160; The complaint also asserts state law claims against the Morrow Defendants for breaches of fiduciary duties, unjust enrichment, abuse of control, insider trading, gross mismanagement, and corporate waste, alleging that the Morrow Defendants made material misstatements or omissions related to the Phase II and III trials and efficacy of the product candidate algenpantucel-L, awarded themselves excessive compensation, engaged in illegal insider trading, and grossly mismanaged the Company.&#160; The plaintiff does not quantify any alleged damages in the complaint but seeks restitution for damages to the Company, attorneys&#8217; fees, costs, and expenses, as well as an order directing that proposals for strengthening board oversight be put to a vote of the Company&#8217;s shareholders. &#160;The language for such proposals is not specified in the complaint.&#160; The plaintiff also contemporaneously filed a statement of relatedness, informing the Court that the Morrow Action is related to Abramson v. NewLink Genetics Corp., et al., Case 1:16-cv-3545.&#160; On May 19, 2017, the plaintiff dismissed the Morrow Action without prejudice.&#160; Also on May 19, 2017, plaintiffs&#8217; counsel in the Morrow Action filed a new shareholder derivative complaint that is substantively identical to the Morrow Action, except that the plaintiff is Rickey Ely.&#160; The latter action is captioned Ely v. Link, et al., Case 17-cv-3799, or the Ely Action.&#160; By agreement of the parties and order dated June 26, 2017, the Court temporarily stayed the Ely Action until the Securities Action is dismissed or otherwise resolved.&#160; Under the terms of the stay, the plaintiff in the Ely Action will be provided with any discovery that is provided in the Securities Action, and given an opportunity to participate in any mediation or settlement efforts in the Securities Action.  The Company disputes the claims in the Ely Action and intends to defend against them vigorously.</font></div><div><a name="s34A27F43F6F15C849871E7BC98D02B30"></a></div><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">ITEM 2.&#160;&#160;&#160;&#160;UNREGISTERED SALES OF EQUITY SECURITIES AND USE OF PROCEEDS</font></div><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Recent Sales of Unregistered Securities</font></div><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-indent:30px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">None.</font></div><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Use of Proceeds</font></div><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-indent:30px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Not applicable.</font></div><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div><a name="s78F69C13DEE25A33AA333DCCCD2E8709"></a></div><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div><br></div><div style="text-align:center;"><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">50</font></div></div><hr style="page-break-after:always"><div><div style="line-height:120%;text-align:left;font-size:8pt;"><a style="font-family:inherit;font-size:8pt;" href="#sD088029191DD5EB99A130DC52B3A6E1B"><font style="font-family:inherit;font-size:8pt;">Table of Contents</font></a></div></div><div><br></div><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">ITEM 3.&#160;&#160;&#160;&#160;DEFAULTS UPON SENIOR SECURITIES</font></div><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">None.</font></div><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div><a name="sAAAA9EB571685726A26F377BBCED6599"></a></div><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">ITEM 4.&#160;&#160;&#160;&#160;MINE SAFETY DISCLOSURES</font></div><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Not applicable. </font><font style="font-family:inherit;font-size:10pt;font-weight:bold;">&#32;</font></div><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div><a name="sE7E34FB816E656DBB3A9CDB32CA46FBB"></a></div><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">ITEM 5.&#160;&#160;&#160;&#160;OTHER INFORMATION</font></div><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">None.</font></div><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div><a name="s2F7E6DC7B29C53758635C14BC677D37A"></a></div><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">ITEM 6.&#160;&#160;&#160;&#160;EXHIBITS</font></div><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-indent:30px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">The exhibits listed in the Index to Exhibits (following the signatures page&#160;of this Quarterly Report) are filed with, or incorporated by reference in, this Quarterly Report.</font></div><div><br></div><div style="text-align:center;"><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">51</font></div></div><hr style="page-break-after:always"><div><a name="s74D629AC887B5B61B575859B5EFE4A9D"></a></div><div><div style="line-height:120%;text-align:left;font-size:8pt;"><a style="font-family:inherit;font-size:8pt;" href="#sD088029191DD5EB99A130DC52B3A6E1B"><font style="font-family:inherit;font-size:8pt;">Table of Contents</font></a></div></div><div><br></div><div style="line-height:120%;text-align:center;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;font-weight:bold;">SIGNATURES</font></div><div style="line-height:120%;text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:justify;text-indent:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Pursuant to the requirements of the Securities Exchange Act of 1934, the Registrant has duly caused this Report to be signed on its behalf by the undersigned thereunto duly authorized.</font></div><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:right;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;text-align:-moz-right;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:53.3203125%;border-collapse:collapse;text-align:left;margin-left:auto;margin-right:0;"><tr><td colspan="2"></td></tr><tr><td style="width:11%;"></td><td style="width:89%;"></td></tr><tr><td colspan="2" style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">NEWLINK GENETICS CORPORATION</font></div></td></tr><tr><td colspan="2" style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">By:</font></div></td><td style="vertical-align:top;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">/s/ Charles J. Link,&#160;Jr.</font></div></td></tr><tr><td colspan="2" style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Charles J. Link,&#160;Jr.</font></div></td></tr><tr><td colspan="2" style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Chief Executive Officer</font></div></td></tr><tr><td colspan="2" style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(Principal Executive Officer)</font></div></td></tr><tr><td colspan="2" style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;background-color:#ffffff;">Date: November 3, 2017</font></div></td></tr><tr><td colspan="2" style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">By:</font></div></td><td style="vertical-align:top;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">/s/ John B. Henneman, III</font></div></td></tr><tr><td colspan="2" style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">John B. Henneman, III</font></div></td></tr><tr><td colspan="2" style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Chief Financial Officer and Secretary</font></div></td></tr><tr><td colspan="2" style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(Principal Financial Officer)</font></div></td></tr><tr><td colspan="2" style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;background-color:#ffffff;">Date: November 3, 2017</font></div></td></tr></table></div></div><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div><br></div><div style="text-align:center;"><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">52</font></div></div><hr style="page-break-after:always"><div><a name="s1B1852E2B0445560A16AA92D64688214"></a></div><div><div style="line-height:120%;text-align:left;font-size:8pt;"><a style="font-family:inherit;font-size:8pt;" href="#sD088029191DD5EB99A130DC52B3A6E1B"><font style="font-family:inherit;font-size:8pt;">Table of Contents</font></a></div></div><div><br></div><div style="line-height:120%;padding-bottom:16px;text-align:left;text-indent:24px;-sec-extract:summary;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">The following exhibits are filed with this form 10-Q or incorporated herein by reference to the document set forth next to the exhibit listed below.  Where so indicated, exhibits that were previously filed are incorporated by reference.</font></div><div style="line-height:120%;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="7"></td></tr><tr><td style="width:10%;"></td><td style="width:3%;"></td><td style="width:53%;"></td><td style="width:7%;"></td><td style="width:11%;"></td><td style="width:7%;"></td><td style="width:9%;"></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:middle;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;font-weight:bold;">Incorporated By Reference</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:middle;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;font-weight:bold;">Exhibit Number</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:middle;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;font-weight:bold;">Description</font></div></td><td style="vertical-align:middle;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;font-weight:bold;">Form</font></div></td><td style="vertical-align:middle;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;font-weight:bold;">Filing Date</font></div></td><td style="vertical-align:middle;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;font-weight:bold;">Number</font></div></td><td style="vertical-align:middle;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;font-weight:bold;">Filed Herewith</font></div></td></tr><tr><td style="vertical-align:middle;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">3.1</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:middle;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">Amended and Restated Certificate of Incorporation filed on November&#160;16, 2011</font></div></td><td style="vertical-align:middle;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">8-K</font></div></td><td style="vertical-align:middle;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">11/18/2011</font></div></td><td style="vertical-align:middle;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">3.1</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:middle;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">3.2</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:middle;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">Certificate of Amendment to Restated Certificate of Incorporation filed on May 10, 2013</font></div></td><td style="vertical-align:middle;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">8-K</font></div></td><td style="vertical-align:middle;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">5/14/2013</font></div></td><td style="vertical-align:middle;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">3.1</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:middle;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">3.3</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:middle;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">Amended and Restated Bylaws</font></div></td><td style="vertical-align:middle;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">8-K</font></div></td><td style="vertical-align:middle;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">11/18/2011</font></div></td><td style="vertical-align:middle;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">3.2</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:middle;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">4.1</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:middle;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">Form of the Registrant&#8217;s Common Stock Certificate</font></div></td><td style="vertical-align:middle;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">S-1/A</font></div></td><td style="vertical-align:middle;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">10/26/2011</font></div></td><td style="vertical-align:middle;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">4.1</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:middle;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">4.2</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:middle;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">Reference is made to Exhibits&#160;3.1, 3.2 and 3.3 hereof</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:middle;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">4.3</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:middle;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">Amended and Restated Investor Rights Agreement by and between the Company and certain holders of the Company&#8217;s capital stock dated as of December 1, 2010</font></div></td><td style="vertical-align:middle;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">10-Q</font></div></td><td style="vertical-align:middle;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">5/10/2012</font></div></td><td style="vertical-align:middle;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">4.3</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:middle;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">31.1</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:middle;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="font-size:9pt;"><a style="text-decoration:none;color:#000000;-sec-extract:exhibit;" href="nlnk-20170930xex311.htm"><font style="font-family:inherit;font-size:9pt;color:#000000;text-decoration:none;">Certification of principal executive officer required by Rule 13a-14(a) / 15d-14(a)</font></a></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:middle;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">X</font></div></td></tr><tr><td style="vertical-align:middle;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">31.2</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:middle;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="font-size:9pt;"><a style="text-decoration:none;color:#000000;-sec-extract:exhibit;" href="nlnk-20170930xex312.htm"><font style="font-family:inherit;font-size:9pt;color:#000000;text-decoration:none;">Certification of principal financial officer required by Rule 13a-14(a) / 15d-14(a)</font></a></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:middle;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">X</font></div></td></tr><tr><td style="vertical-align:middle;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">32.1</font></div></td><td style="vertical-align:middle;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">#</font></div></td><td style="vertical-align:middle;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="font-size:9pt;"><a style="text-decoration:none;color:#000000;-sec-extract:exhibit;" href="nlnk-20170930xex321.htm"><font style="font-family:inherit;font-size:9pt;color:#000000;text-decoration:none;">Section&#160;1350 Certification</font></a></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:middle;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">X</font></div></td></tr><tr><td style="vertical-align:middle;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">101.INS</font></div></td><td style="vertical-align:middle;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">&#8225;</font></div></td><td style="vertical-align:middle;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">XBRL Instance Document</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:middle;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">X</font></div></td></tr><tr><td style="vertical-align:middle;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">101.SCH</font></div></td><td style="vertical-align:middle;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">&#160;&#8225;</font></div></td><td style="vertical-align:middle;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="font-size:9pt;"><a style="text-decoration:none;color:#000000;-sec-extract:exhibit;" href="nlnk-20170930.xml"><font style="font-family:inherit;font-size:9pt;color:#000000;text-decoration:none;">XBRL Taxonomy Extension Schema Document</font></a></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:middle;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">X</font></div></td></tr><tr><td style="vertical-align:middle;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">101.CAL</font></div></td><td style="vertical-align:middle;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">&#160;&#8225;</font></div></td><td style="vertical-align:middle;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="font-size:9pt;"><a style="text-decoration:none;color:#000000;-sec-extract:exhibit;" href="nlnk-20170930_cal.xml"><font style="font-family:inherit;font-size:9pt;color:#000000;text-decoration:none;">XBRL Taxonomy Extension Calculation Linkbase Document </font></a></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:middle;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">X</font></div></td></tr><tr><td style="vertical-align:middle;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">101.DEF</font></div></td><td style="vertical-align:middle;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">&#160;&#8225;</font></div></td><td style="vertical-align:middle;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="font-size:9pt;"><a style="text-decoration:none;color:#000000;-sec-extract:exhibit;" href="nlnk-20170930_def.xml"><font style="font-family:inherit;font-size:9pt;color:#000000;text-decoration:none;">XBRL Taxonomy Extension Definition Linkbase Document</font></a></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:middle;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">X</font></div></td></tr><tr><td style="vertical-align:middle;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">101.LAB</font></div></td><td style="vertical-align:middle;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">&#160;&#8225;</font></div></td><td style="vertical-align:middle;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="font-size:9pt;"><a style="text-decoration:none;color:#000000;-sec-extract:exhibit;" href="nlnk-20170930_lab.xml"><font style="font-family:inherit;font-size:9pt;color:#000000;text-decoration:none;">XBRL Taxonomy Extension Label Linkbase Document </font></a></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:middle;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">X</font></div></td></tr><tr><td style="vertical-align:middle;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">101.PRE</font></div></td><td style="vertical-align:middle;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">&#160;&#8225;</font></div></td><td style="vertical-align:middle;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="font-size:9pt;"><a style="text-decoration:none;color:#000000;-sec-extract:exhibit;" href="nlnk-20170930_pre.xml"><font style="font-family:inherit;font-size:9pt;color:#000000;text-decoration:none;">XBRL Taxonomy Extension Presentation Linkbase Document </font></a></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:middle;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">X</font></div></td></tr></table></div></div><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">____________________</font></div><div style="line-height:120%;text-align:center;font-size:9pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:92.7734375%;border-collapse:collapse;text-align:left;"><tr><td colspan="2"></td></tr><tr><td style="width:4%;"></td><td style="width:96%;"></td></tr><tr><td style="vertical-align:middle;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">#</font></div></td><td style="vertical-align:middle;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">The certifications attached as Exhibit 32.1 that accompany this Quarterly Report on Form 10-Q are not deemed filed with the Securities and Exchange Commission and are not to be incorporated by reference into any filing of NewLink Genetics Corporation under the Securities Act of 1933, as amended, or the Securities Exchange Act of 1934, as amended, whether made before or after the date of this Form 10-Q, irrespective of any general incorporation language contained in such filing.</font></div></td></tr><tr><td style="vertical-align:middle;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">&#8225;</font></div></td><td style="vertical-align:middle;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">Filed herewith electronically.</font></div></td></tr></table></div></div><div><br></div><div style="text-align:center;"><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">53</font></div></div>	</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-31.1
<SEQUENCE>2
<FILENAME>nlnk-20170930xex311.htm
<DESCRIPTION>CEO CERTIFICATION
<TEXT>
<!DOCTYPE html PUBLIC "-//W3C//DTD HTML 4.01 Transitional//EN" "http://www.w3.org/TR/html4/loose.dtd">
<html>
	<head>
		<!-- Document created using Wdesk 1 -->
		<!-- Copyright 2017 Workiva -->
		<title>Exhibit</title>
	</head>
	<body style="font-family:Times New Roman;font-size:10pt;">
<div><a name="sA83C560C4E5D5227BBC54EF74A748DEC"></a></div><div><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></div><div><br></div><div style="line-height:120%;text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">EXHIBIT 31.1</font></div><div style="line-height:120%;text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">CERTIFICATION</font></div><div style="line-height:120%;text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">I, Charles J. Link, Jr., certify that:</font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><table cellpadding="0" cellspacing="0" style="padding-bottom:12px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:0px;"><font style="font-family:inherit;font-size:10pt;">1.</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">I have reviewed this quarterly report on Form 10-Q of NewLink Genetics Corporation;</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-bottom:12px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:0px;"><font style="font-family:inherit;font-size:10pt;">2.</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements were made, not misleading with respect to the period covered by this report;</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-bottom:12px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:0px;"><font style="font-family:inherit;font-size:10pt;">3.</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Based on my knowledge, the financial statements, and other financial information included in this report, fairly present in all material respects the financial condition, results of operations and cash flows of the registrant as of, and for, the periods presented in this report;</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-bottom:12px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:0px;"><font style="font-family:inherit;font-size:10pt;">4.</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">The registrant's other certifying officer(s) and I are responsible for establishing and maintaining disclosure controls and procedures (as defined in Exchange Act Rules 13a-15(e) and 15d-15(e)) and internal control over financial reporting (as defined in Exchange Act Rules 13a-15(f) and 15d-15(f)) for the registrant and have:</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-bottom:12px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:24px;"><font style="font-family:inherit;font-size:10pt;">a.</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Designed such disclosure controls and procedures, or caused such disclosure controls and procedures to be designed under our supervision, to ensure that material information relating to the registrant, including its consolidated subsidiaries, is made known to us by others within those entities, particularly during the period in which this report is being prepared;</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-bottom:12px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:24px;"><font style="font-family:inherit;font-size:10pt;">b.</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Designed such internal control over financial reporting, or caused such internal control over financial reporting to be designed under our supervision, to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with generally accepted accounting principles</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-bottom:12px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:24px;"><font style="font-family:inherit;font-size:10pt;">c.</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Evaluated the effectiveness of the registrant's disclosure controls and procedures and presented in this report our conclusions about the effectiveness of the disclosure controls and procedures, as of the end of the period covered by this report based on such evaluation; and</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-bottom:12px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:24px;"><font style="font-family:inherit;font-size:10pt;">d.</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Disclosed in this report any change in the registrant's internal control over financial reporting that occurred during the registrant's most recent fiscal quarter (the registrant's fourth fiscal quarter in the case of an annual report) that has materially affected, or is reasonably likely to materially affect, the registrant's internal control over financial reporting; and</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-bottom:12px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:0px;"><font style="font-family:inherit;font-size:10pt;">5.</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">The registrant's other certifying officer(s) and I have disclosed, based on our most recent evaluation of internal control over financial reporting, to the registrant's auditors and the audit committee of the registrant's board of directors (or persons performing the equivalent functions):</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-bottom:12px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:24px;"><font style="font-family:inherit;font-size:10pt;">a.</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">All significant deficiencies and material weaknesses in the design or operation of internal control over financial reporting which are reasonably likely to adversely affect the registrant's ability to record, process, summarize and report financial information; and</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-bottom:12px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:24px;"><font style="font-family:inherit;font-size:10pt;">b.</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Any fraud, whether or not material, that involves management or other employees who have a significant role in the registrant's internal control over financial reporting.</font></div></td></tr></table><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Date: November 3, 2017</font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:right;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;text-align:-moz-right;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:46.484375%;border-collapse:collapse;text-align:left;margin-left:auto;margin-right:0;"><tr><td colspan="2"></td></tr><tr><td style="width:9%;"></td><td style="width:91%;"></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">By:</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">/s/ Charles J. Link, Jr.</font></div></td></tr><tr><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Charles J. Link, Jr.</font></div></td></tr><tr><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Chief Executive Officer</font></div></td></tr><tr><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(Principal Executive Officer)</font></div></td></tr></table></div></div><div><br></div><div style="text-align:center;"><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></div>	</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-31.2
<SEQUENCE>3
<FILENAME>nlnk-20170930xex312.htm
<DESCRIPTION>CFO CERTIFICATION
<TEXT>
<!DOCTYPE html PUBLIC "-//W3C//DTD HTML 4.01 Transitional//EN" "http://www.w3.org/TR/html4/loose.dtd">
<html>
	<head>
		<!-- Document created using Wdesk 1 -->
		<!-- Copyright 2017 Workiva -->
		<title>Exhibit</title>
	</head>
	<body style="font-family:Times New Roman;font-size:10pt;">
<div><a name="s7DF628F486E6519C91B8812A5BE5C0BD"></a></div><div><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></div><div><br></div><div style="line-height:120%;text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">EXHIBIT 31.2</font></div><div style="line-height:120%;text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">CERTIFICATION</font></div><div style="line-height:120%;text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">I, John B. Henneman III, certify that:</font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><table cellpadding="0" cellspacing="0" style="padding-bottom:12px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:0px;"><font style="font-family:inherit;font-size:10pt;">1.</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">I have reviewed this quarterly report on Form 10-Q of NewLink Genetics Corporation;</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-bottom:12px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:0px;"><font style="font-family:inherit;font-size:10pt;">2.</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements were made, not misleading with respect to the period covered by this report;</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-bottom:12px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:0px;"><font style="font-family:inherit;font-size:10pt;">3.</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Based on my knowledge, the financial statements, and other financial information included in this report, fairly present in all material respects the financial condition, results of operations and cash flows of the registrant as of, and for, the periods presented in this report;</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-bottom:12px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:0px;"><font style="font-family:inherit;font-size:10pt;">4.</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">The registrant's other certifying officer(s) and I are responsible for establishing and maintaining disclosure controls and procedures (as defined in Exchange Act Rules 13a-15(e) and 15d-15(e)) and internal control over financial reporting (as defined in Exchange Act Rules 13a-15(f) and 15d-15(f)) for the registrant and have:</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-bottom:12px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:24px;"><font style="font-family:inherit;font-size:10pt;">a.</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Designed such disclosure controls and procedures, or caused such disclosure controls and procedures to be designed under our supervision, to ensure that material information relating to the registrant, including its consolidated subsidiaries, is made known to us by others within those entities, particularly during the period in which this report is being prepared;</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-bottom:12px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:24px;"><font style="font-family:inherit;font-size:10pt;">b.</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Designed such internal control over financial reporting, or caused such internal control over financial reporting to be designed under our supervision, to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with generally accepted accounting principles;</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-bottom:12px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:24px;"><font style="font-family:inherit;font-size:10pt;">c.</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Evaluated the effectiveness of the registrant's disclosure controls and procedures and presented in this report our conclusions about the effectiveness of the disclosure controls and procedures, as of the end of the period covered by this report based on such evaluation; and</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-bottom:12px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:24px;"><font style="font-family:inherit;font-size:10pt;">d.</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Disclosed in this report any change in the registrant's internal control over financial reporting that occurred during the registrant's most recent fiscal quarter (the registrant's fourth fiscal quarter in the case of an annual report) that has materially affected, or is reasonably likely to materially affect, the registrant's internal control over financial reporting; and</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-bottom:12px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:0px;"><font style="font-family:inherit;font-size:10pt;">5.</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">The registrant's other certifying officer(s) and I have disclosed, based on our most recent evaluation of internal control over financial reporting, to the registrant's auditors and the audit committee of the registrant's board of directors (or persons performing the equivalent functions):</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-bottom:12px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:24px;"><font style="font-family:inherit;font-size:10pt;">a.</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">All significant deficiencies and material weaknesses in the design or operation of internal control over financial reporting which are reasonably likely to adversely affect the registrant's ability to record, process, summarize and report financial information; and</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-bottom:12px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:24px;"><font style="font-family:inherit;font-size:10pt;">b.</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Any fraud, whether or not material, that involves management or other employees who have a significant role in the registrant's internal control over financial reporting.</font></div></td></tr></table><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Date: November 3, 2017</font></div><div style="line-height:120%;text-align:right;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;text-align:-moz-right;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:46.484375%;border-collapse:collapse;text-align:left;margin-left:auto;margin-right:0;"><tr><td colspan="2"></td></tr><tr><td style="width:9%;"></td><td style="width:91%;"></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">By:</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">/s/ John B Henneman III</font></div></td></tr><tr><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">John B. Henneman III</font></div></td></tr><tr><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Chief Financial Officer and Secretary</font></div></td></tr><tr><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(Principal Financial Officer)</font></div></td></tr></table></div></div><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div><br></div><div style="text-align:center;"><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></div>	</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-32.1
<SEQUENCE>4
<FILENAME>nlnk-20170930xex321.htm
<DESCRIPTION>SECTION 1350 CERTIFICATION
<TEXT>
<!DOCTYPE html PUBLIC "-//W3C//DTD HTML 4.01 Transitional//EN" "http://www.w3.org/TR/html4/loose.dtd">
<html>
	<head>
		<!-- Document created using Wdesk 1 -->
		<!-- Copyright 2017 Workiva -->
		<title>Exhibit</title>
	</head>
	<body style="font-family:Times New Roman;font-size:10pt;">
<div><a name="s01C47669C00956B59B00BC168E74CE72"></a></div><div><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></div><div><br></div><div style="line-height:120%;text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">EXHIBIT 32.1</font></div><div style="line-height:120%;text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">CERTIFICATION</font></div><div style="line-height:120%;text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Pursuant to the requirements set forth in Rule 13a-14(b) of the Securities Exchange Act of 1934, as amended (the &#8220;Exchange Act&#8221;), and Section 1350 of Chapter 63 of Title 18 of the United States Code (18 U.S.C. &#167; 1350), Charles J. Link, Jr., Chief Executive Officer of NewLink Genetics Corporation (the &#8220;Company&#8221;), and John B. Henneman III, Chief Financial Officer and Secretary of the Company, each hereby certifies that, to the best of his knowledge:</font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:0px;"><font style="font-family:inherit;font-size:10pt;">1.</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">The Company&#8217;s Quarterly Report on Form 10-Q for the period ended September 30, 2017, to which this Certification is attached as Exhibit 32.1 (the &#8220;Periodic Report&#8221;), fully complies with the requirements of Section 13(a) or Section 15(d) of the Exchange Act; and</font></div></td></tr></table><div style="line-height:120%;text-align:left;padding-left:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:0px;"><font style="font-family:inherit;font-size:10pt;">2.</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">The information contained in the Periodic Report fairly presents, in all material respects, the financial condition and results of operations of the Company.</font></div></td></tr></table><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Dated: November 3, 2017</font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:right;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;text-align:-moz-right;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:46.484375%;border-collapse:collapse;text-align:left;margin-left:auto;margin-right:0;"><tr><td colspan="2"></td></tr><tr><td style="width:9%;"></td><td style="width:91%;"></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">By:</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">/s/ Charles J. Link, Jr.</font></div></td></tr><tr><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Charles J. Link, Jr.</font></div></td></tr><tr><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Chief Executive Officer</font></div></td></tr><tr><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(Principal Executive Officer)</font></div></td></tr></table></div></div><div style="line-height:120%;text-align:right;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;text-align:-moz-right;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:46.484375%;border-collapse:collapse;text-align:left;margin-left:auto;margin-right:0;"><tr><td colspan="2"></td></tr><tr><td style="width:9%;"></td><td style="width:91%;"></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">By:</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">/s/ John B. Henneman III</font></div></td></tr><tr><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">John B. Henneman III</font></div></td></tr><tr><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Chief Financial Officer and Secretary</font></div></td></tr><tr><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(Principal Financial Officer)</font></div></td></tr></table></div></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">A signed original of this written statement has been provided to the Company and will be retained by the Company and furnished to the Securities and Exchange Commission or its Staff upon request. This certification &#8220;accompanies&#8221; the </font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Form 10-Q to which it relates, is not deemed filed with the Securities and Exchange Commission and is not to be incorporated by reference into any filing of the Company under the Securities Act of 1933, as amended, or the Securities Exchange Act of 1934, as amended (whether made before or after the date of the Form 10-Q), irrespective of any general incorporation language contained in such filing.</font></div><div><br></div><div style="text-align:center;"><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></div>	</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.INS
<SEQUENCE>5
<FILENAME>nlnk-20170930.xml
<DESCRIPTION>XBRL INSTANCE DOCUMENT
<TEXT>
<XBRL>
<?xml version="1.0" encoding="US-ASCII"?>
<!--XBRL Document Created with Wdesk from Workiva-->
<!--p:44D47D50B60A51A69EBEC5D9283E1F18,x:939f84b4820141aeaf959e1bc2aa7748-->
<xbrli:xbrl xmlns:country="http://xbrl.sec.gov/country/2017-01-31" xmlns:currency="http://xbrl.sec.gov/currency/2017-01-31" xmlns:dei="http://xbrl.sec.gov/dei/2014-01-31" xmlns:exch="http://xbrl.sec.gov/exch/2017-01-31" xmlns:invest="http://xbrl.sec.gov/invest/2013-01-31" xmlns:iso4217="http://www.xbrl.org/2003/iso4217" xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:naics="http://xbrl.sec.gov/naics/2017-01-31" xmlns:nlnk="http://www.linkp.com/20170930" xmlns:nonnum="http://www.xbrl.org/dtr/type/non-numeric" xmlns:num="http://www.xbrl.org/dtr/type/numeric" xmlns:ref="http://www.xbrl.org/2006/ref" xmlns:sic="http://xbrl.sec.gov/sic/2011-01-31" xmlns:stpr="http://xbrl.sec.gov/stpr/2011-01-31" xmlns:us-gaap="http://fasb.org/us-gaap/2017-01-31" xmlns:us-roles="http://fasb.org/us-roles/2017-01-31" xmlns:us-types="http://fasb.org/us-types/2017-01-31" xmlns:utreg="http://www.xbrl.org/2009/utr" xmlns:xbrldi="http://xbrl.org/2006/xbrldi" xmlns:xbrldt="http://xbrl.org/2005/xbrldt" xmlns:xbrli="http://www.xbrl.org/2003/instance" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsd="http://www.w3.org/2001/XMLSchema" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance">
	<link:schemaRef xlink:href="nlnk-20170930.xsd" xlink:type="simple" />
	<xbrli:context id="FD2017Q3YTD">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001126234</xbrli:identifier>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2017-01-01</xbrli:startDate>
			<xbrli:endDate>2017-09-30</xbrli:endDate>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="I2017Q4Oct31">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001126234</xbrli:identifier>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2017-10-31</xbrli:instant>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FI2017Q3">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001126234</xbrli:identifier>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2017-09-30</xbrli:instant>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FI2016Q4">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001126234</xbrli:identifier>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2016-12-31</xbrli:instant>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FD2017Q3QTD">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001126234</xbrli:identifier>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2017-07-01</xbrli:startDate>
			<xbrli:endDate>2017-09-30</xbrli:endDate>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FD2016Q3QTD">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001126234</xbrli:identifier>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2016-07-01</xbrli:startDate>
			<xbrli:endDate>2016-09-30</xbrli:endDate>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FD2016Q3YTD">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001126234</xbrli:identifier>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2016-01-01</xbrli:startDate>
			<xbrli:endDate>2016-09-30</xbrli:endDate>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FD2017Q3YTD_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001126234</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2017-01-01</xbrli:startDate>
			<xbrli:endDate>2017-09-30</xbrli:endDate>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FI2017Q3_us-gaap_StatementEquityComponentsAxis_us-gaap_TreasuryStockMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001126234</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:TreasuryStockMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2017-09-30</xbrli:instant>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FD2017Q3YTD_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001126234</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2017-01-01</xbrli:startDate>
			<xbrli:endDate>2017-09-30</xbrli:endDate>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FI2016Q4_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001126234</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2016-12-31</xbrli:instant>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FD2017Q3YTD_us-gaap_StatementEquityComponentsAxis_us-gaap_TreasuryStockMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001126234</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:TreasuryStockMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2017-01-01</xbrli:startDate>
			<xbrli:endDate>2017-09-30</xbrli:endDate>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FI2016Q4_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001126234</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2016-12-31</xbrli:instant>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FI2017Q3_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001126234</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2017-09-30</xbrli:instant>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FD2017Q3YTD_us-gaap_StatementEquityComponentsAxis_us-gaap_RetainedEarningsMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001126234</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2017-01-01</xbrli:startDate>
			<xbrli:endDate>2017-09-30</xbrli:endDate>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FI2016Q4_us-gaap_StatementEquityComponentsAxis_us-gaap_TreasuryStockMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001126234</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:TreasuryStockMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2016-12-31</xbrli:instant>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FI2016Q4_us-gaap_StatementEquityComponentsAxis_us-gaap_RetainedEarningsMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001126234</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2016-12-31</xbrli:instant>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FI2017Q3_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001126234</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2017-09-30</xbrli:instant>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FI2017Q3_us-gaap_StatementEquityComponentsAxis_us-gaap_RetainedEarningsMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001126234</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2017-09-30</xbrli:instant>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FI2016Q3">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001126234</xbrli:identifier>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2016-09-30</xbrli:instant>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FI2015Q4">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001126234</xbrli:identifier>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2015-12-31</xbrli:instant>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FD2015Q4YTD_us-gaap_SubsidiarySaleOfStockAxis_us-gaap_IPOMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001126234</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">us-gaap:IPOMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2015-01-01</xbrli:startDate>
			<xbrli:endDate>2015-12-31</xbrli:endDate>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="D2016Q4SD_us-gaap_SubsidiarySaleOfStockAxis_nlnk_ATMOfferingMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001126234</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">nlnk:ATMOfferingMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2016-11-29</xbrli:startDate>
			<xbrli:endDate>2016-11-29</xbrli:endDate>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="D2017Q3SD_us-gaap_SubsidiarySaleOfStockAxis_nlnk_ATMOfferingMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001126234</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">nlnk:ATMOfferingMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2017-07-01</xbrli:startDate>
			<xbrli:endDate>2017-08-02</xbrli:endDate>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FD2015Q4YTD_us-gaap_SubsidiarySaleOfStockAxis_nlnk_ATMOfferingMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001126234</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">nlnk:ATMOfferingMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2015-01-01</xbrli:startDate>
			<xbrli:endDate>2015-12-31</xbrli:endDate>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="D2017Q3July1-31">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001126234</xbrli:identifier>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2017-07-01</xbrli:startDate>
			<xbrli:endDate>2017-07-31</xbrli:endDate>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FD2014Q4YTD">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001126234</xbrli:identifier>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2014-01-01</xbrli:startDate>
			<xbrli:endDate>2014-12-31</xbrli:endDate>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="D2017Q4Oct6_us-gaap_SubsequentEventTypeAxis_us-gaap_SubsequentEventMember_us-gaap_SubsidiarySaleOfStockAxis_nlnk_PublicOfferingMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001126234</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis">us-gaap:SubsequentEventMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">nlnk:PublicOfferingMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2017-10-06</xbrli:startDate>
			<xbrli:endDate>2017-10-06</xbrli:endDate>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FD2014Q4YTD_dei_LegalEntityAxis_nlnk_GenentechInc.Member_us-gaap_TypeOfArrangementAxis_us-gaap_CollaborativeArrangementMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001126234</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="dei:LegalEntityAxis">nlnk:GenentechInc.Member</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">us-gaap:CollaborativeArrangementMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2014-01-01</xbrli:startDate>
			<xbrli:endDate>2014-12-31</xbrli:endDate>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FD2014Q4YTD_dei_LegalEntityAxis_nlnk_MerckSharpeandDohmeCorpMember_us-gaap_TypeOfArrangementAxis_us-gaap_CollaborativeArrangementMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001126234</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="dei:LegalEntityAxis">nlnk:MerckSharpeandDohmeCorpMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">us-gaap:CollaborativeArrangementMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2014-01-01</xbrli:startDate>
			<xbrli:endDate>2014-12-31</xbrli:endDate>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FD2015Q4YTD_us-gaap_SubsidiarySaleOfStockAxis_nlnk_FollowOnOfferingMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001126234</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">nlnk:FollowOnOfferingMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2015-01-01</xbrli:startDate>
			<xbrli:endDate>2015-12-31</xbrli:endDate>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="D2015Q1Feb1-28_dei_LegalEntityAxis_nlnk_MerckSharpeandDohmeCorpMember_us-gaap_TypeOfArrangementAxis_us-gaap_CollaborativeArrangementMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001126234</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="dei:LegalEntityAxis">nlnk:MerckSharpeandDohmeCorpMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">us-gaap:CollaborativeArrangementMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2015-02-01</xbrli:startDate>
			<xbrli:endDate>2015-02-28</xbrli:endDate>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FD2017Q3YTD_us-gaap_PropertyPlantAndEquipmentByTypeAxis_us-gaap_ComputerEquipmentMember_us-gaap_RangeAxis_us-gaap_MaximumMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001126234</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:ComputerEquipmentMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:RangeAxis">us-gaap:MaximumMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2017-01-01</xbrli:startDate>
			<xbrli:endDate>2017-09-30</xbrli:endDate>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FD2017Q3YTD_us-gaap_PropertyPlantAndEquipmentByTypeAxis_nlnk_ContractManufacturingOrganizationEquipmentMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001126234</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">nlnk:ContractManufacturingOrganizationEquipmentMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2017-01-01</xbrli:startDate>
			<xbrli:endDate>2017-09-30</xbrli:endDate>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FD2017Q3YTD_us-gaap_PropertyPlantAndEquipmentByTypeAxis_us-gaap_ComputerEquipmentMember_us-gaap_RangeAxis_us-gaap_MinimumMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001126234</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:ComputerEquipmentMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:RangeAxis">us-gaap:MinimumMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2017-01-01</xbrli:startDate>
			<xbrli:endDate>2017-09-30</xbrli:endDate>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FD2017Q3YTD_us-gaap_PropertyPlantAndEquipmentByTypeAxis_us-gaap_EquipmentMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001126234</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:EquipmentMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2017-01-01</xbrli:startDate>
			<xbrli:endDate>2017-09-30</xbrli:endDate>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FD2016Q1QTD_us-gaap_DebtInstrumentAxis_nlnk_CityOfAmesForgivableLoan2010Member">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001126234</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">nlnk:CityOfAmesForgivableLoan2010Member</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2016-01-01</xbrli:startDate>
			<xbrli:endDate>2016-03-31</xbrli:endDate>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="D2010Q1Mar1-31_us-gaap_DebtInstrumentAxis_nlnk_CityOfAmesForgivableLoan2010Member_us-gaap_LongtermDebtTypeAxis_us-gaap_LoansPayableMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001126234</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">nlnk:CityOfAmesForgivableLoan2010Member</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:LoansPayableMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2010-03-01</xbrli:startDate>
			<xbrli:endDate>2010-03-31</xbrli:endDate>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="I2010Q1_us-gaap_DebtInstrumentAxis_nlnk_CityOfAmesForgivableLoan2010Member_us-gaap_LongtermDebtTypeAxis_us-gaap_LoansPayableMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001126234</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">nlnk:CityOfAmesForgivableLoan2010Member</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:LoansPayableMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2010-03-31</xbrli:instant>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FI2017Q3_us-gaap_DebtInstrumentAxis_nlnk_CityOfAmesForgivableLoan2010Member_us-gaap_LongtermDebtTypeAxis_us-gaap_LoansPayableMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001126234</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">nlnk:CityOfAmesForgivableLoan2010Member</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:LoansPayableMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2017-09-30</xbrli:instant>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FD2017Q3YTD_dei_LegalEntityAxis_nlnk_GenentechInc.Member_us-gaap_TypeOfArrangementAxis_us-gaap_CollaborativeArrangementMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001126234</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="dei:LegalEntityAxis">nlnk:GenentechInc.Member</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">us-gaap:CollaborativeArrangementMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2017-01-01</xbrli:startDate>
			<xbrli:endDate>2017-09-30</xbrli:endDate>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FI2017Q3_dei_LegalEntityAxis_nlnk_GenentechInc.Member_us-gaap_TypeOfArrangementAxis_us-gaap_CollaborativeArrangementMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001126234</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="dei:LegalEntityAxis">nlnk:GenentechInc.Member</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">us-gaap:CollaborativeArrangementMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2017-09-30</xbrli:instant>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FD2016Q3YTD_dei_LegalEntityAxis_nlnk_GenentechInc.Member_us-gaap_TypeOfArrangementAxis_us-gaap_CollaborativeArrangementMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001126234</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="dei:LegalEntityAxis">nlnk:GenentechInc.Member</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">us-gaap:CollaborativeArrangementMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2016-01-01</xbrli:startDate>
			<xbrli:endDate>2016-09-30</xbrli:endDate>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FD2016Q3QTD_dei_LegalEntityAxis_nlnk_GenentechInc.Member_us-gaap_TypeOfArrangementAxis_us-gaap_CollaborativeArrangementMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001126234</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="dei:LegalEntityAxis">nlnk:GenentechInc.Member</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">us-gaap:CollaborativeArrangementMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2016-07-01</xbrli:startDate>
			<xbrli:endDate>2016-09-30</xbrli:endDate>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FD2016Q3QTD_dei_LegalEntityAxis_nlnk_MerckSharpeandDohmeCorpMember_us-gaap_TypeOfArrangementAxis_us-gaap_CollaborativeArrangementMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001126234</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="dei:LegalEntityAxis">nlnk:MerckSharpeandDohmeCorpMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">us-gaap:CollaborativeArrangementMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2016-07-01</xbrli:startDate>
			<xbrli:endDate>2016-09-30</xbrli:endDate>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FD2016Q3YTD_dei_LegalEntityAxis_nlnk_MerckSharpeandDohmeCorpMember_us-gaap_TypeOfArrangementAxis_us-gaap_CollaborativeArrangementMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001126234</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="dei:LegalEntityAxis">nlnk:MerckSharpeandDohmeCorpMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">us-gaap:CollaborativeArrangementMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2016-01-01</xbrli:startDate>
			<xbrli:endDate>2016-09-30</xbrli:endDate>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FD2017Q3QTD_dei_LegalEntityAxis_nlnk_GenentechInc.Member_us-gaap_TypeOfArrangementAxis_us-gaap_CollaborativeArrangementMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001126234</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="dei:LegalEntityAxis">nlnk:GenentechInc.Member</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">us-gaap:CollaborativeArrangementMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2017-07-01</xbrli:startDate>
			<xbrli:endDate>2017-09-30</xbrli:endDate>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FD2017Q3YTD_us-gaap_AwardTypeAxis_us-gaap_RestrictedStockMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001126234</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2017-01-01</xbrli:startDate>
			<xbrli:endDate>2017-09-30</xbrli:endDate>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FI2017Q3_us-gaap_AwardTypeAxis_us-gaap_RestrictedStockMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001126234</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2017-09-30</xbrli:instant>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FI2016Q4_us-gaap_AwardTypeAxis_us-gaap_RestrictedStockMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001126234</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2016-12-31</xbrli:instant>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FD2017Q3YTD_us-gaap_AwardTypeAxis_us-gaap_EmployeeStockOptionMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001126234</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2017-01-01</xbrli:startDate>
			<xbrli:endDate>2017-09-30</xbrli:endDate>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FI2016Q4_us-gaap_AwardTypeAxis_us-gaap_EmployeeStockOptionMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001126234</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2016-12-31</xbrli:instant>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FI2017Q3_us-gaap_AwardTypeAxis_us-gaap_EmployeeStockOptionMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001126234</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2017-09-30</xbrli:instant>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FD2016Q4YTD_us-gaap_AwardTypeAxis_us-gaap_EmployeeStockOptionMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001126234</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2016-01-01</xbrli:startDate>
			<xbrli:endDate>2016-12-31</xbrli:endDate>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FD2017Q3YTD_us-gaap_AwardTypeAxis_nlnk_PerformanceRestrictedStockMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001126234</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">nlnk:PerformanceRestrictedStockMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2017-01-01</xbrli:startDate>
			<xbrli:endDate>2017-09-30</xbrli:endDate>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="D2013Q2May9_us-gaap_PlanNameAxis_nlnk_A2010NonEmployeeDirectorsStockOptionPlanMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001126234</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">nlnk:A2010NonEmployeeDirectorsStockOptionPlanMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2013-05-09</xbrli:startDate>
			<xbrli:endDate>2013-05-09</xbrli:endDate>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FD2017Q3YTD_us-gaap_AwardTypeAxis_us-gaap_PerformanceSharesMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001126234</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:PerformanceSharesMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2017-01-01</xbrli:startDate>
			<xbrli:endDate>2017-09-30</xbrli:endDate>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FI2017Q3_us-gaap_PlanNameAxis_nlnk_A2009EquityIncentivePlanMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001126234</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">nlnk:A2009EquityIncentivePlanMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2017-09-30</xbrli:instant>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FD2017Q3YTD_us-gaap_PlanNameAxis_nlnk_A2009EquityIncentivePlanMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001126234</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">nlnk:A2009EquityIncentivePlanMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2017-01-01</xbrli:startDate>
			<xbrli:endDate>2017-09-30</xbrli:endDate>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="I2011Q4SD2_us-gaap_PlanNameAxis_nlnk_A2010EmployeeStockPurchasePlanMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001126234</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">nlnk:A2010EmployeeStockPurchasePlanMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2011-11-10</xbrli:instant>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FI2017Q3_us-gaap_AwardTypeAxis_nlnk_PerformanceRestrictedStockMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001126234</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">nlnk:PerformanceRestrictedStockMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2017-09-30</xbrli:instant>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FI2017Q3_us-gaap_PlanNameAxis_nlnk_A2010NonEmployeeDirectorsStockOptionPlanMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001126234</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">nlnk:A2010NonEmployeeDirectorsStockOptionPlanMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2017-09-30</xbrli:instant>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="I2011Q4SD2_us-gaap_PlanNameAxis_nlnk_A2010NonEmployeeDirectorsStockOptionPlanMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001126234</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">nlnk:A2010NonEmployeeDirectorsStockOptionPlanMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2011-11-10</xbrli:instant>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="D2013Q2May9_us-gaap_PlanNameAxis_nlnk_A2010EmployeeStockPurchasePlanMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001126234</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">nlnk:A2010EmployeeStockPurchasePlanMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2013-05-09</xbrli:startDate>
			<xbrli:endDate>2013-05-09</xbrli:endDate>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FI2017Q3_us-gaap_PlanNameAxis_nlnk_A2010EmployeeStockPurchasePlanMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001126234</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">nlnk:A2010EmployeeStockPurchasePlanMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2017-09-30</xbrli:instant>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="D2017Q1Jan1_us-gaap_PlanNameAxis_nlnk_A2009EquityIncentivePlanMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001126234</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">nlnk:A2009EquityIncentivePlanMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2017-01-01</xbrli:startDate>
			<xbrli:endDate>2017-01-01</xbrli:endDate>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="D2010Q2May15_us-gaap_PlanNameAxis_nlnk_A2009EquityIncentivePlanMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001126234</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">nlnk:A2009EquityIncentivePlanMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2010-05-15</xbrli:startDate>
			<xbrli:endDate>2010-05-15</xbrli:endDate>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="D2011Q1Jan7_us-gaap_PlanNameAxis_nlnk_A2009EquityIncentivePlanMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001126234</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">nlnk:A2009EquityIncentivePlanMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2011-01-07</xbrli:startDate>
			<xbrli:endDate>2011-01-07</xbrli:endDate>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="D2013Q1Jan1_us-gaap_PlanNameAxis_nlnk_A2009EquityIncentivePlanMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001126234</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">nlnk:A2009EquityIncentivePlanMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2013-01-01</xbrli:startDate>
			<xbrli:endDate>2013-01-01</xbrli:endDate>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="D2014Q1Jan1_us-gaap_PlanNameAxis_nlnk_A2009EquityIncentivePlanMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001126234</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">nlnk:A2009EquityIncentivePlanMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2014-01-01</xbrli:startDate>
			<xbrli:endDate>2014-01-01</xbrli:endDate>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="D2015Q1Jan1_us-gaap_PlanNameAxis_nlnk_A2009EquityIncentivePlanMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001126234</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">nlnk:A2009EquityIncentivePlanMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2015-01-01</xbrli:startDate>
			<xbrli:endDate>2015-01-01</xbrli:endDate>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="D2016Q1Jan1_us-gaap_PlanNameAxis_nlnk_A2009EquityIncentivePlanMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001126234</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">nlnk:A2009EquityIncentivePlanMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2016-01-01</xbrli:startDate>
			<xbrli:endDate>2016-01-01</xbrli:endDate>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FD2017Q3YTD_us-gaap_AwardTypeAxis_us-gaap_EmployeeStockOptionMember_us-gaap_RangeAxis_us-gaap_MinimumMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001126234</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:RangeAxis">us-gaap:MinimumMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2017-01-01</xbrli:startDate>
			<xbrli:endDate>2017-09-30</xbrli:endDate>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FD2017Q3YTD_us-gaap_AwardTypeAxis_us-gaap_EmployeeStockOptionMember_us-gaap_RangeAxis_us-gaap_MaximumMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001126234</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:RangeAxis">us-gaap:MaximumMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2017-01-01</xbrli:startDate>
			<xbrli:endDate>2017-09-30</xbrli:endDate>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FD2017Q3QTD_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_us-gaap_RestrictedStockMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001126234</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:RestrictedStockMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2017-07-01</xbrli:startDate>
			<xbrli:endDate>2017-09-30</xbrli:endDate>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FD2017Q3QTD_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_us-gaap_EmployeeStockOptionMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001126234</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2017-07-01</xbrli:startDate>
			<xbrli:endDate>2017-09-30</xbrli:endDate>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FD2016Q3QTD_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_us-gaap_EmployeeStockOptionMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001126234</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2016-07-01</xbrli:startDate>
			<xbrli:endDate>2016-09-30</xbrli:endDate>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FD2016Q3QTD_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_us-gaap_RestrictedStockMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001126234</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:RestrictedStockMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2016-07-01</xbrli:startDate>
			<xbrli:endDate>2016-09-30</xbrli:endDate>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FI2017Q3_us-gaap_RestructuringCostAndReserveAxis_us-gaap_EmployeeSeveranceMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001126234</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:RestructuringCostAndReserveAxis">us-gaap:EmployeeSeveranceMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2017-09-30</xbrli:instant>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FD2017Q3YTD_us-gaap_RestructuringCostAndReserveAxis_us-gaap_EmployeeSeveranceMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001126234</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:RestructuringCostAndReserveAxis">us-gaap:EmployeeSeveranceMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2017-01-01</xbrli:startDate>
			<xbrli:endDate>2017-09-30</xbrli:endDate>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FI2016Q4_us-gaap_RestructuringCostAndReserveAxis_us-gaap_EmployeeSeveranceMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001126234</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:RestructuringCostAndReserveAxis">us-gaap:EmployeeSeveranceMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2016-12-31</xbrli:instant>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FD2017Q3QTD_us-gaap_RestructuringPlanAxis_nlnk_TwoThousandSixteenRestructuringPlanMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001126234</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:RestructuringPlanAxis">nlnk:TwoThousandSixteenRestructuringPlanMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2017-07-01</xbrli:startDate>
			<xbrli:endDate>2017-09-30</xbrli:endDate>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FD2016Q4YTD_us-gaap_IncomeStatementLocationAxis_us-gaap_GeneralAndAdministrativeExpenseMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001126234</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:GeneralAndAdministrativeExpenseMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2016-01-01</xbrli:startDate>
			<xbrli:endDate>2016-12-31</xbrli:endDate>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FD2016Q4YTD_us-gaap_IncomeStatementLocationAxis_us-gaap_ResearchAndDevelopmentExpenseMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001126234</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:ResearchAndDevelopmentExpenseMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2016-01-01</xbrli:startDate>
			<xbrli:endDate>2016-12-31</xbrli:endDate>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FD2016Q4YTD">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001126234</xbrli:identifier>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2016-01-01</xbrli:startDate>
			<xbrli:endDate>2016-12-31</xbrli:endDate>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FD2017Q3QTD_us-gaap_RestructuringCostAndReserveAxis_us-gaap_EmployeeSeveranceMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001126234</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:RestructuringCostAndReserveAxis">us-gaap:EmployeeSeveranceMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2017-07-01</xbrli:startDate>
			<xbrli:endDate>2017-09-30</xbrli:endDate>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FD2017Q3YTD_us-gaap_RestructuringPlanAxis_nlnk_TwoThousandSixteenRestructuringPlanMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001126234</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:RestructuringPlanAxis">nlnk:TwoThousandSixteenRestructuringPlanMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2017-01-01</xbrli:startDate>
			<xbrli:endDate>2017-09-30</xbrli:endDate>
		</xbrli:period>
	</xbrli:context>
	<xbrli:unit id="usdPerShare">
		<xbrli:divide>
			<xbrli:unitNumerator>
				<xbrli:measure>iso4217:USD</xbrli:measure>
			</xbrli:unitNumerator>
			<xbrli:unitDenominator>
				<xbrli:measure>xbrli:shares</xbrli:measure>
			</xbrli:unitDenominator>
		</xbrli:divide>
	</xbrli:unit>
	<xbrli:unit id="arrangement">
		<xbrli:measure>nlnk:arrangement</xbrli:measure>
	</xbrli:unit>
	<xbrli:unit id="number">
		<xbrli:measure>xbrli:pure</xbrli:measure>
	</xbrli:unit>
	<xbrli:unit id="sqft">
		<xbrli:measure>utreg:sqft</xbrli:measure>
	</xbrli:unit>
	<xbrli:unit id="shares">
		<xbrli:measure>xbrli:shares</xbrli:measure>
	</xbrli:unit>
	<xbrli:unit id="usd">
		<xbrli:measure>iso4217:USD</xbrli:measure>
	</xbrli:unit>
	<xbrli:unit id="position">
		<xbrli:measure>nlnk:position</xbrli:measure>
	</xbrli:unit>
	<dei:AmendmentFlag contextRef="FD2017Q3YTD" id="Fact-46A0B5DD1F865C25A713BBC44308D1FD">false</dei:AmendmentFlag>
	<dei:CurrentFiscalYearEndDate contextRef="FD2017Q3YTD" id="Fact-55731757FB9D5FDEB3CC7366975C7A87">--12-31</dei:CurrentFiscalYearEndDate>
	<dei:DocumentFiscalPeriodFocus contextRef="FD2017Q3YTD" id="Fact-31B7BBF99D5F5CE1AB07830844727665">Q3</dei:DocumentFiscalPeriodFocus>
	<dei:DocumentFiscalYearFocus contextRef="FD2017Q3YTD" id="Fact-60F417C4597A59CB9B76C89125729B56">2017</dei:DocumentFiscalYearFocus>
	<dei:DocumentPeriodEndDate contextRef="FD2017Q3YTD" id="Fact-A696505043D95CA6941822065A0C7494">2017-09-30</dei:DocumentPeriodEndDate>
	<dei:DocumentType contextRef="FD2017Q3YTD" id="Fact-CB17D827A7A15EE584525F47E5EDEDB0">10-Q</dei:DocumentType>
	<dei:EntityCentralIndexKey contextRef="FD2017Q3YTD" id="Fact-BDD3E97B51A5572090C391EACBEBA954">0001126234</dei:EntityCentralIndexKey>
	<dei:EntityCommonStockSharesOutstanding contextRef="I2017Q4Oct31" decimals="INF" id="Fact-5CC3238B42F056C4A0A520176B5B031D" unitRef="shares">37077159</dei:EntityCommonStockSharesOutstanding>
	<dei:EntityFilerCategory contextRef="FD2017Q3YTD" id="Fact-3649A94BCC86548889D1E248BC862E91">Accelerated Filer</dei:EntityFilerCategory>
	<dei:EntityRegistrantName contextRef="FD2017Q3YTD" id="Fact-74547A7E1A2258539B04B8C3DC09D985">NEWLINK GENETICS CORP</dei:EntityRegistrantName>
	<nlnk:CollaborativeArrangementNumberofArrangements contextRef="FD2014Q4YTD" decimals="INF" id="Fact-36EF669950625708BE4A3DE84EFC28EE" unitRef="arrangement">2</nlnk:CollaborativeArrangementNumberofArrangements>
	<nlnk:DebtInstrumentCovenantRequiredMinimumLeaseArea contextRef="FI2017Q3_us-gaap_DebtInstrumentAxis_nlnk_CityOfAmesForgivableLoan2010Member_us-gaap_LongtermDebtTypeAxis_us-gaap_LoansPayableMember" decimals="0" id="Fact-377DA13543655EE6B119F2920A98B9A5" unitRef="sqft">20000</nlnk:DebtInstrumentCovenantRequiredMinimumLeaseArea>
	<nlnk:DebtInstrumentCovenantRequiredNumberofPositionsCreationandRetention contextRef="FI2017Q3_us-gaap_DebtInstrumentAxis_nlnk_CityOfAmesForgivableLoan2010Member_us-gaap_LongtermDebtTypeAxis_us-gaap_LoansPayableMember" decimals="INF" id="Fact-0036711CEED3554BBF678D74743495F8" unitRef="position">150</nlnk:DebtInstrumentCovenantRequiredNumberofPositionsCreationandRetention>
	<nlnk:DeferredGovernmentGrantsObligationsNoncurrent contextRef="FI2016Q4" decimals="-3" id="Fact-A775A8294A7E58D7B03C9EF3427588FC" unitRef="usd">6000000</nlnk:DeferredGovernmentGrantsObligationsNoncurrent>
	<nlnk:DeferredGovernmentGrantsObligationsNoncurrent contextRef="FI2017Q3" decimals="-3" id="Fact-4E86A82FF4E25BF39C21BAD68330A0A1" unitRef="usd">6000000</nlnk:DeferredGovernmentGrantsObligationsNoncurrent>
	<nlnk:GovernmentContractAccruedSubcontractorFees contextRef="FI2016Q4" decimals="-5" id="Fact-B5DB38EA264354FF8C867EF7BA091DA1" unitRef="usd">2900000</nlnk:GovernmentContractAccruedSubcontractorFees>
	<nlnk:GovernmentContractAccruedSubcontractorFees contextRef="FI2017Q3" decimals="-5" id="Fact-0188870FE8DB5869A43480914A50C467" unitRef="usd">1400000</nlnk:GovernmentContractAccruedSubcontractorFees>
	<nlnk:LicenseRevenueCommitteeLabor contextRef="FD2016Q3YTD_dei_LegalEntityAxis_nlnk_GenentechInc.Member_us-gaap_TypeOfArrangementAxis_us-gaap_CollaborativeArrangementMember" decimals="0" id="Fact-4D16D1CB5EBC59C4B93A0DB73217DE87" unitRef="usd">101000</nlnk:LicenseRevenueCommitteeLabor>
	<nlnk:LicenseRevenueEmployeeLabor contextRef="FD2016Q3QTD_dei_LegalEntityAxis_nlnk_GenentechInc.Member_us-gaap_TypeOfArrangementAxis_us-gaap_CollaborativeArrangementMember" decimals="0" id="Fact-7718817C8B165F31A833636A91F87711" unitRef="usd">486000</nlnk:LicenseRevenueEmployeeLabor>
	<nlnk:LicenseRevenueEmployeeLabor contextRef="FD2016Q3YTD_dei_LegalEntityAxis_nlnk_GenentechInc.Member_us-gaap_TypeOfArrangementAxis_us-gaap_CollaborativeArrangementMember" decimals="-5" id="Fact-DCE3099C3F6E556A82848E8DA390D490" unitRef="usd">1600000</nlnk:LicenseRevenueEmployeeLabor>
	<nlnk:LicenseRevenueManagerLabor contextRef="FD2016Q3QTD_dei_LegalEntityAxis_nlnk_GenentechInc.Member_us-gaap_TypeOfArrangementAxis_us-gaap_CollaborativeArrangementMember" decimals="0" id="Fact-098B83E30023538DBB5DEE9C4FB29A8C" unitRef="usd">201000</nlnk:LicenseRevenueManagerLabor>
	<nlnk:LicenseRevenueManagerLabor contextRef="FD2016Q3YTD_dei_LegalEntityAxis_nlnk_GenentechInc.Member_us-gaap_TypeOfArrangementAxis_us-gaap_CollaborativeArrangementMember" decimals="0" id="Fact-49BCF07890BE5E6CAAE44CECAEC08B52" unitRef="usd">502000</nlnk:LicenseRevenueManagerLabor>
	<nlnk:MaximumAvailableUnderATMOffering contextRef="D2016Q4SD_us-gaap_SubsidiarySaleOfStockAxis_nlnk_ATMOfferingMember" decimals="-5" id="Fact-ED5509E2C09E55ACAD7B968B2A4CEA2C" unitRef="usd">40000000</nlnk:MaximumAvailableUnderATMOffering>
	<nlnk:RevenueRecogitionMilestoneMethodMaximumPotentialRevenue contextRef="FI2017Q3_dei_LegalEntityAxis_nlnk_GenentechInc.Member_us-gaap_TypeOfArrangementAxis_us-gaap_CollaborativeArrangementMember" decimals="-5" id="Fact-11AFF4BC59765898963D676195650EE4" unitRef="usd">561000000</nlnk:RevenueRecogitionMilestoneMethodMaximumPotentialRevenue>
	<nlnk:SharebasedCompensationArrangementbySharebasedPaymentAwardPercentageofAuthorizedStockMaximum contextRef="FD2017Q3YTD_us-gaap_PlanNameAxis_nlnk_A2009EquityIncentivePlanMember" decimals="2" id="Fact-026F1A124F985853AF1DB968E5A98F49" unitRef="number">0.04</nlnk:SharebasedCompensationArrangementbySharebasedPaymentAwardPercentageofAuthorizedStockMaximum>
	<us-gaap:AccountsPayableCurrent contextRef="FI2016Q4" decimals="-3" id="Fact-4B015B1FFD225A3AAFD0D9501C9EBA67" unitRef="usd">22883000</us-gaap:AccountsPayableCurrent>
	<us-gaap:AccountsPayableCurrent contextRef="FI2017Q3" decimals="-3" id="Fact-6D81712F5D6F5C6EA4FECFB53E27449B" unitRef="usd">11860000</us-gaap:AccountsPayableCurrent>
	<us-gaap:AccruedLiabilitiesCurrent contextRef="FI2016Q4" decimals="-3" id="Fact-851C27641777516E86C22A0810B61561" unitRef="usd">14309000</us-gaap:AccruedLiabilitiesCurrent>
	<us-gaap:AccruedLiabilitiesCurrent contextRef="FI2017Q3" decimals="-3" id="Fact-29F2AF9778FF5D488F5B13B9BF915748" unitRef="usd">13832000</us-gaap:AccruedLiabilitiesCurrent>
	<us-gaap:AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment contextRef="FI2016Q4" decimals="-5" id="Fact-B0BFABB4BA4D57E392C244D12A9A5E74" unitRef="usd">5700000</us-gaap:AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment>
	<us-gaap:AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment contextRef="FI2017Q3" decimals="-5" id="Fact-3159256BA3E45FD4850478F2C7B4DFE4" unitRef="usd">6700000</us-gaap:AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment>
	<us-gaap:AdditionalPaidInCapital contextRef="FI2016Q4" decimals="-3" id="Fact-AD581D99470652C38F3E1416CCCE6A7C" unitRef="usd">295535000</us-gaap:AdditionalPaidInCapital>
	<us-gaap:AdditionalPaidInCapital contextRef="FI2017Q3" decimals="-3" id="Fact-5C92DF9066545488AB119F2A4D96A67B" unitRef="usd">331036000</us-gaap:AdditionalPaidInCapital>
	<us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue contextRef="FD2017Q3YTD" decimals="-3" id="Fact-8078770828B55AA28969B4D65B5C28FD" unitRef="usd">14938000</us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue>
	<us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue contextRef="FD2017Q3YTD_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember" decimals="-3" id="Fact-E2703212E59951779C1C42C49153DD1E" unitRef="usd">14938000</us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue>
	<us-gaap:AdjustmentsToAdditionalPaidInCapitalStockIssuedIssuanceCosts contextRef="FD2017Q3YTD" decimals="-3" id="Fact-0DF73086001857A60F717D8D01E78E5A" unitRef="usd">561000</us-gaap:AdjustmentsToAdditionalPaidInCapitalStockIssuedIssuanceCosts>
	<us-gaap:AllocatedShareBasedCompensationExpense contextRef="FD2016Q3QTD" decimals="-5" id="Fact-0ACD6FC374EB55F2800F49FD2E94274B" unitRef="usd">3900000</us-gaap:AllocatedShareBasedCompensationExpense>
	<us-gaap:AllocatedShareBasedCompensationExpense contextRef="FD2016Q3YTD" decimals="-5" id="Fact-3E7B16D2866452F1A87DEB4F2AED2D63" unitRef="usd">13100000</us-gaap:AllocatedShareBasedCompensationExpense>
	<us-gaap:AllocatedShareBasedCompensationExpense contextRef="FD2017Q3QTD" decimals="-5" id="Fact-1EE1E6B0C7255449B0946E47A87311AE" unitRef="usd">4400000</us-gaap:AllocatedShareBasedCompensationExpense>
	<us-gaap:AllocatedShareBasedCompensationExpense contextRef="FD2017Q3YTD" decimals="-5" id="Fact-78CE22A988CB572BA810E02DA03D5FB4" unitRef="usd">14900000</us-gaap:AllocatedShareBasedCompensationExpense>
	<us-gaap:AllocatedShareBasedCompensationExpense contextRef="FD2017Q3YTD_us-gaap_AwardTypeAxis_us-gaap_PerformanceSharesMember" decimals="-5" id="Fact-1026F5DF55F4591CB998672CF6587539" unitRef="usd">1200000</us-gaap:AllocatedShareBasedCompensationExpense>
	<us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount contextRef="FD2016Q3QTD_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_us-gaap_EmployeeStockOptionMember" decimals="0" id="Fact-C9C79F1E13F65D2EB8B7BD86E6C27D2E" unitRef="shares">6453331</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
	<us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount contextRef="FD2016Q3QTD_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_us-gaap_RestrictedStockMember" decimals="0" id="Fact-7AC90AF94A24560E8C34EF65AEDE0FFB" unitRef="shares">307079</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
	<us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount contextRef="FD2017Q3QTD_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_us-gaap_EmployeeStockOptionMember" decimals="0" id="Fact-E1B1404B197252F0ABB0473BCAD697EB" unitRef="shares">7314006</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
	<us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount contextRef="FD2017Q3QTD_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_us-gaap_RestrictedStockMember" decimals="0" id="Fact-DEE17B5A51DE5DCCA707C7D0A59E5AF0" unitRef="shares">181336</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
	<us-gaap:AssetImpairmentCharges contextRef="FD2016Q3YTD" decimals="-3" id="Fact-82925477A2CC57A3BCC28D63EC8839B5" unitRef="usd">3976000</us-gaap:AssetImpairmentCharges>
	<us-gaap:AssetImpairmentCharges contextRef="FD2017Q3YTD" decimals="-3" id="Fact-0851CB9945D65404846407AD21F41D4A" unitRef="usd">0</us-gaap:AssetImpairmentCharges>
	<us-gaap:Assets contextRef="FI2016Q4" decimals="-3" id="Fact-C516658BD7A65E4B8A170B65E9F2250E" unitRef="usd">174747000</us-gaap:Assets>
	<us-gaap:Assets contextRef="FI2017Q3" decimals="-3" id="Fact-CB33C1FAB2CE58508BE7EA86D6A2F8A9" unitRef="usd">139714000</us-gaap:Assets>
	<us-gaap:AssetsCurrent contextRef="FI2016Q4" decimals="-3" id="Fact-D26CC2166D0D583795F02FF722A0112F" unitRef="usd">167912000</us-gaap:AssetsCurrent>
	<us-gaap:AssetsCurrent contextRef="FI2017Q3" decimals="-3" id="Fact-909758C1120F55178B653D9266C80A37" unitRef="usd">134187000</us-gaap:AssetsCurrent>
	<us-gaap:CapitalLeaseObligationsIncurred contextRef="FD2016Q3YTD" decimals="-3" id="Fact-60DB3EEA49345BC99F63C21B5741C941" unitRef="usd">231000</us-gaap:CapitalLeaseObligationsIncurred>
	<us-gaap:CapitalLeaseObligationsIncurred contextRef="FD2017Q3YTD" decimals="-3" id="Fact-2F80899665A8537FBCEEE880503531E6" unitRef="usd">0</us-gaap:CapitalLeaseObligationsIncurred>
	<us-gaap:CashAndCashEquivalentsAtCarryingValue contextRef="FI2015Q4" decimals="-3" id="Fact-0E92CA154A9A5B5AAE96BE8ECCDB6741" unitRef="usd">195620000</us-gaap:CashAndCashEquivalentsAtCarryingValue>
	<us-gaap:CashAndCashEquivalentsAtCarryingValue contextRef="FI2016Q3" decimals="-3" id="Fact-7E8313D3386250E6BFA775CAD516A16F" unitRef="usd">148276000</us-gaap:CashAndCashEquivalentsAtCarryingValue>
	<us-gaap:CashAndCashEquivalentsAtCarryingValue contextRef="FI2016Q4" decimals="-3" id="Fact-94691752E8745A4FA1A447399C8BAE4E" unitRef="usd">131490000</us-gaap:CashAndCashEquivalentsAtCarryingValue>
	<us-gaap:CashAndCashEquivalentsAtCarryingValue contextRef="FI2017Q3" decimals="-3" id="Fact-47017251F61B54AE802B89D289A7DC33" unitRef="usd">120702000</us-gaap:CashAndCashEquivalentsAtCarryingValue>
	<us-gaap:CashAndCashEquivalentsPeriodIncreaseDecrease contextRef="FD2016Q3YTD" decimals="-3" id="Fact-CE581C6A277D5DD3A0D1B3FFDDFFAF8F" unitRef="usd">-47344000</us-gaap:CashAndCashEquivalentsPeriodIncreaseDecrease>
	<us-gaap:CashAndCashEquivalentsPeriodIncreaseDecrease contextRef="FD2017Q3YTD" decimals="-3" id="Fact-8AE19668B9D551DDA879E37CE99865AB" unitRef="usd">-10788000</us-gaap:CashAndCashEquivalentsPeriodIncreaseDecrease>
	<us-gaap:CommonStockParOrStatedValuePerShare contextRef="FI2016Q4" decimals="INF" id="Fact-9D765F4C28395E318291D73DB66FCF95" unitRef="usdPerShare">0.01</us-gaap:CommonStockParOrStatedValuePerShare>
	<us-gaap:CommonStockParOrStatedValuePerShare contextRef="FI2017Q3" decimals="INF" id="Fact-C006CE65DD8C5A228B62AA42C37C87A0" unitRef="usdPerShare">0.01</us-gaap:CommonStockParOrStatedValuePerShare>
	<us-gaap:CommonStockSharesAuthorized contextRef="FI2016Q4" decimals="INF" id="Fact-008A40608DD15EE4888A4319812A0584" unitRef="shares">75000000</us-gaap:CommonStockSharesAuthorized>
	<us-gaap:CommonStockSharesAuthorized contextRef="FI2017Q3" decimals="INF" id="Fact-4F207BFA07725F1C8C42FEA4D233CC01" unitRef="shares">75000000</us-gaap:CommonStockSharesAuthorized>
	<us-gaap:CommonStockSharesIssued contextRef="FI2016Q4" decimals="INF" id="Fact-9E2224E9D67E554AAF04188D716CD006" unitRef="shares">29193718</us-gaap:CommonStockSharesIssued>
	<us-gaap:CommonStockSharesIssued contextRef="FI2017Q3" decimals="INF" id="Fact-01D305726B1D57E0A2356A0130CF7E65" unitRef="shares">31375528</us-gaap:CommonStockSharesIssued>
	<us-gaap:CommonStockSharesOutstanding contextRef="FI2016Q4" decimals="INF" id="Fact-EDE304CB0811560B994526E806EE3716" unitRef="shares">29163673</us-gaap:CommonStockSharesOutstanding>
	<us-gaap:CommonStockSharesOutstanding contextRef="FI2016Q4_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember" decimals="INF" id="Fact-64EAD680F98056618D3D6706B0232B89" unitRef="shares">29163673</us-gaap:CommonStockSharesOutstanding>
	<us-gaap:CommonStockSharesOutstanding contextRef="FI2017Q3" decimals="INF" id="Fact-6B2C72BDF673565992447A6ADBECA230" unitRef="shares">31319751</us-gaap:CommonStockSharesOutstanding>
	<us-gaap:CommonStockSharesOutstanding contextRef="FI2017Q3_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember" decimals="INF" id="Fact-3699F9FCD41754CBA607DD32B8D60162" unitRef="shares">31319751</us-gaap:CommonStockSharesOutstanding>
	<us-gaap:CommonStockValueOutstanding contextRef="FI2016Q4" decimals="-3" id="Fact-8FA4CC0C06E250CBB3F7AE277A802CFA" unitRef="usd">292000</us-gaap:CommonStockValueOutstanding>
	<us-gaap:CommonStockValueOutstanding contextRef="FI2017Q3" decimals="-3" id="Fact-5E47650A2DE656ACAEBB208AB41D8868" unitRef="usd">314000</us-gaap:CommonStockValueOutstanding>
	<us-gaap:DebtInstrumentFaceAmount contextRef="I2010Q1_us-gaap_DebtInstrumentAxis_nlnk_CityOfAmesForgivableLoan2010Member_us-gaap_LongtermDebtTypeAxis_us-gaap_LoansPayableMember" decimals="INF" id="Fact-9DB38030D56B5E56A5B64509DECB6549" unitRef="usd">400000</us-gaap:DebtInstrumentFaceAmount>
	<us-gaap:DeferredRentCreditCurrent contextRef="FI2016Q4" decimals="-3" id="Fact-DEC3818109F55EABB52067C82AB47859" unitRef="usd">90000</us-gaap:DeferredRentCreditCurrent>
	<us-gaap:DeferredRentCreditCurrent contextRef="FI2017Q3" decimals="-3" id="Fact-1AF85C65CEDE5DF29FC15305E3B181D0" unitRef="usd">93000</us-gaap:DeferredRentCreditCurrent>
	<us-gaap:DeferredRentCreditNoncurrent contextRef="FI2016Q4" decimals="-3" id="Fact-DC9ADB74FD9A56BDA65E5E09AB1F7145" unitRef="usd">1091000</us-gaap:DeferredRentCreditNoncurrent>
	<us-gaap:DeferredRentCreditNoncurrent contextRef="FI2017Q3" decimals="-3" id="Fact-9DAF26BE2BF955D8ADFDDA4A6BA95FE7" unitRef="usd">1021000</us-gaap:DeferredRentCreditNoncurrent>
	<us-gaap:DeferredRevenue contextRef="FI2017Q3_dei_LegalEntityAxis_nlnk_GenentechInc.Member_us-gaap_TypeOfArrangementAxis_us-gaap_CollaborativeArrangementMember" decimals="0" id="Fact-E758F69A975E5FA6AE95D50FC12DB36C" unitRef="usd">112000</us-gaap:DeferredRevenue>
	<us-gaap:DeferredRevenueCurrent contextRef="FI2016Q4" decimals="-3" id="Fact-673CAFFB1F70570CBD1CA126D92759D9" unitRef="usd">391000</us-gaap:DeferredRevenueCurrent>
	<us-gaap:DeferredRevenueCurrent contextRef="FI2017Q3" decimals="-3" id="Fact-CAC0B30F6DA05B458E8FDAE6B58CFBF9" unitRef="usd">112000</us-gaap:DeferredRevenueCurrent>
	<us-gaap:DepreciationDepletionAndAmortization contextRef="FD2016Q3YTD" decimals="-3" id="Fact-E57A1566329F5FD7A86602F4FACD4197" unitRef="usd">1536000</us-gaap:DepreciationDepletionAndAmortization>
	<us-gaap:DepreciationDepletionAndAmortization contextRef="FD2017Q3YTD" decimals="-3" id="Fact-7CBDFFDF176F51578F7A9EC2418FD87C" unitRef="usd">1064000</us-gaap:DepreciationDepletionAndAmortization>
	<us-gaap:EarningsPerShareBasicAndDiluted contextRef="FD2016Q3QTD" decimals="2" id="Fact-EE0CE08CBC3C5809A2C38EC496A04E2C" unitRef="usdPerShare">-0.54</us-gaap:EarningsPerShareBasicAndDiluted>
	<us-gaap:EarningsPerShareBasicAndDiluted contextRef="FD2016Q3YTD" decimals="2" id="Fact-2F83E93CB0AA5BC684E1E43A6674BEA4" unitRef="usdPerShare">-2.48</us-gaap:EarningsPerShareBasicAndDiluted>
	<us-gaap:EarningsPerShareBasicAndDiluted contextRef="FD2017Q3QTD" decimals="2" id="Fact-89141611E30857BD918B87B7E55CD2E1" unitRef="usdPerShare">-0.69</us-gaap:EarningsPerShareBasicAndDiluted>
	<us-gaap:EarningsPerShareBasicAndDiluted contextRef="FD2017Q3YTD" decimals="2" id="Fact-558940020EF45E128AD018658C0862E9" unitRef="usdPerShare">-1.98</us-gaap:EarningsPerShareBasicAndDiluted>
	<us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1 contextRef="FD2017Q3YTD_us-gaap_AwardTypeAxis_us-gaap_EmployeeStockOptionMember" id="Fact-DC1A93385A9C5AD9A7C9720F0B7D7B52">P2Y1M24D</us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1>
	<us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1 contextRef="FD2017Q3YTD_us-gaap_AwardTypeAxis_us-gaap_RestrictedStockMember" id="Fact-F4DA166AF6B5565599FC2E710224CCCD">P1Y9M7D</us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1>
	<us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedShareBasedAwardsOtherThanOptions contextRef="FI2017Q3_us-gaap_AwardTypeAxis_nlnk_PerformanceRestrictedStockMember" decimals="-5" id="Fact-55EF5F6FFED5576CAABDA859448ADB36" unitRef="usd">6400000</us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedShareBasedAwardsOtherThanOptions>
	<us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedShareBasedAwardsOtherThanOptions contextRef="FI2017Q3_us-gaap_AwardTypeAxis_us-gaap_RestrictedStockMember" decimals="-5" id="Fact-BBA4ADC9FE7F55A6994CDBFFAE373669" unitRef="usd">4400000</us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedShareBasedAwardsOtherThanOptions>
	<us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions contextRef="FI2017Q3_us-gaap_AwardTypeAxis_us-gaap_EmployeeStockOptionMember" decimals="-5" id="Fact-1E1FD1C49F0C5935A98F9BD54677F52A" unitRef="usd">19900000</us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions>
	<us-gaap:ExcessTaxBenefitFromShareBasedCompensationOperatingActivities contextRef="FD2016Q3YTD" decimals="-3" id="Fact-287A56F3E176547CB3246A56B203A81E" unitRef="usd">640000</us-gaap:ExcessTaxBenefitFromShareBasedCompensationOperatingActivities>
	<us-gaap:ExcessTaxBenefitFromShareBasedCompensationOperatingActivities contextRef="FD2017Q3YTD" decimals="-3" id="Fact-366EE52A30ED53DE82227CE55D3D7720" unitRef="usd">0</us-gaap:ExcessTaxBenefitFromShareBasedCompensationOperatingActivities>
	<us-gaap:FeesAndCommissions contextRef="D2017Q4Oct6_us-gaap_SubsequentEventTypeAxis_us-gaap_SubsequentEventMember_us-gaap_SubsidiarySaleOfStockAxis_nlnk_PublicOfferingMember" decimals="-5" id="Fact-1DFD8E0F5056F874B54250BA77DA4991" unitRef="usd">3700000</us-gaap:FeesAndCommissions>
	<us-gaap:GainLossOnSaleOfPropertyPlantEquipment contextRef="FD2016Q3YTD" decimals="-3" id="Fact-A746C37035EF55E0AC469A8DC795818E" unitRef="usd">0</us-gaap:GainLossOnSaleOfPropertyPlantEquipment>
	<us-gaap:GainLossOnSaleOfPropertyPlantEquipment contextRef="FD2017Q3YTD" decimals="-3" id="Fact-03EBC001199A5F6CA0620B060BF0BD43" unitRef="usd">-102000</us-gaap:GainLossOnSaleOfPropertyPlantEquipment>
	<us-gaap:GainsLossesOnExtinguishmentOfDebt contextRef="FD2016Q3YTD" decimals="-3" id="Fact-D82AC81197C25DD585AEB726AE328EAD" unitRef="usd">397000</us-gaap:GainsLossesOnExtinguishmentOfDebt>
	<us-gaap:GainsLossesOnExtinguishmentOfDebt contextRef="FD2017Q3YTD" decimals="-3" id="Fact-226F803C3E8959B28747ACCEC1A49712" unitRef="usd">0</us-gaap:GainsLossesOnExtinguishmentOfDebt>
	<us-gaap:GeneralAndAdministrativeExpense contextRef="FD2016Q3QTD" decimals="-3" id="Fact-8F9FA928CC2D5051B2C4831D37F74B2E" unitRef="usd">7749000</us-gaap:GeneralAndAdministrativeExpense>
	<us-gaap:GeneralAndAdministrativeExpense contextRef="FD2016Q3YTD" decimals="-3" id="Fact-50ECE5CD429E57E3BC6D883D32B9104B" unitRef="usd">26043000</us-gaap:GeneralAndAdministrativeExpense>
	<us-gaap:GeneralAndAdministrativeExpense contextRef="FD2017Q3QTD" decimals="-3" id="Fact-77C2AFC9D1545EE98B07F11754B7A6B0" unitRef="usd">7907000</us-gaap:GeneralAndAdministrativeExpense>
	<us-gaap:GeneralAndAdministrativeExpense contextRef="FD2017Q3YTD" decimals="-3" id="Fact-65F2E31254CD51B7A258EF5D551960B9" unitRef="usd">25038000</us-gaap:GeneralAndAdministrativeExpense>
	<us-gaap:GovernmentContractReceivable contextRef="FI2016Q4" decimals="-5" id="Fact-3D0F01BCFE8B5C79B9C86FC93219A628" unitRef="usd">23900000</us-gaap:GovernmentContractReceivable>
	<us-gaap:GovernmentContractReceivable contextRef="FI2017Q3" decimals="-5" id="Fact-B0B0D6D071765CD9B890BB79268043D5" unitRef="usd">10100000</us-gaap:GovernmentContractReceivable>
	<us-gaap:GovernmentContractReceivableUnbilledAmounts contextRef="FI2016Q4" decimals="-5" id="Fact-472B52855EF85F2FA708494379BFAB5A" unitRef="usd">4300000</us-gaap:GovernmentContractReceivableUnbilledAmounts>
	<us-gaap:GovernmentContractReceivableUnbilledAmounts contextRef="FI2017Q3" decimals="-5" id="Fact-A426DC4977FE514E9942609ED4391390" unitRef="usd">1500000</us-gaap:GovernmentContractReceivableUnbilledAmounts>
	<us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest contextRef="FD2016Q3QTD" decimals="-3" id="Fact-6FBCEEF23ADA59858965A0A6DA26B5B3" unitRef="usd">-16848000</us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest>
	<us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest contextRef="FD2016Q3YTD" decimals="-3" id="Fact-423FA67368CF506F9CD37F6A0ECD906E" unitRef="usd">-76670000</us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest>
	<us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest contextRef="FD2017Q3QTD" decimals="-3" id="Fact-9D7EA596847C5755B98957F873F90DBF" unitRef="usd">-20745000</us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest>
	<us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest contextRef="FD2017Q3YTD" decimals="-3" id="Fact-096ADAEEFB9C5AA28E24A045EC173344" unitRef="usd">-58694000</us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest>
	<us-gaap:IncomeTaxExpenseBenefit contextRef="FD2016Q3QTD" decimals="-5" id="Fact-EC8315464E9E550786B14E44872A4171" unitRef="usd">-1300000</us-gaap:IncomeTaxExpenseBenefit>
	<us-gaap:IncomeTaxExpenseBenefit contextRef="FD2016Q3QTD" decimals="-3" id="Fact-C3949FA0612A558EB5043C6095F33F61" unitRef="usd">-1308000</us-gaap:IncomeTaxExpenseBenefit>
	<us-gaap:IncomeTaxExpenseBenefit contextRef="FD2016Q3YTD" decimals="-3" id="Fact-60F90AC0BAAD5B29AFF4D4558EB78579" unitRef="usd">-5021000</us-gaap:IncomeTaxExpenseBenefit>
	<us-gaap:IncomeTaxExpenseBenefit contextRef="FD2016Q3YTD" decimals="-5" id="Fact-671CE8C6C18E5360A308FA8E4F2C81D2" unitRef="usd">-5000000</us-gaap:IncomeTaxExpenseBenefit>
	<us-gaap:IncomeTaxExpenseBenefit contextRef="FD2017Q3QTD" decimals="-3" id="Fact-504FDCABEA6C578C9F468090F863C473" unitRef="usd">-119000</us-gaap:IncomeTaxExpenseBenefit>
	<us-gaap:IncomeTaxExpenseBenefit contextRef="FD2017Q3QTD" decimals="0" id="Fact-C78629323D3A51A6A9F8D17594427D9D" unitRef="usd">-119000</us-gaap:IncomeTaxExpenseBenefit>
	<us-gaap:IncomeTaxExpenseBenefit contextRef="FD2017Q3YTD" decimals="0" id="Fact-3802801AF39A5EB485F20A339EB8F081" unitRef="usd">-429000</us-gaap:IncomeTaxExpenseBenefit>
	<us-gaap:IncomeTaxExpenseBenefit contextRef="FD2017Q3YTD" decimals="-3" id="Fact-5D66898CEE8A531B9F0B835F9D229E71" unitRef="usd">-429000</us-gaap:IncomeTaxExpenseBenefit>
	<us-gaap:IncomeTaxesPaidNet contextRef="FD2016Q3YTD" decimals="-3" id="Fact-C5201048F98552C58724BBAF2DB6BC0A" unitRef="usd">1022000</us-gaap:IncomeTaxesPaidNet>
	<us-gaap:IncomeTaxesPaidNet contextRef="FD2017Q3YTD" decimals="-3" id="Fact-7380B414623E532F927724E055D20399" unitRef="usd">-6261000</us-gaap:IncomeTaxesPaidNet>
	<us-gaap:IncomeTaxesReceivable contextRef="FI2016Q4" decimals="-3" id="Fact-B5FD61047B2F5C259A260FD523C7382E" unitRef="usd">5975000</us-gaap:IncomeTaxesReceivable>
	<us-gaap:IncomeTaxesReceivable contextRef="FI2017Q3" decimals="-3" id="Fact-2779E7DB43E354C28E1F1AF7AF2B9E9E" unitRef="usd">114000</us-gaap:IncomeTaxesReceivable>
	<us-gaap:IncreaseDecreaseInAccountsPayableAndAccruedLiabilities contextRef="FD2016Q3YTD" decimals="-3" id="Fact-53BFCB24DEB55B108982492FF02CECBD" unitRef="usd">27204000</us-gaap:IncreaseDecreaseInAccountsPayableAndAccruedLiabilities>
	<us-gaap:IncreaseDecreaseInAccountsPayableAndAccruedLiabilities contextRef="FD2017Q3YTD" decimals="-3" id="Fact-6885C3FFC84B515C90B6A6CA85ADB1CE" unitRef="usd">-11500000</us-gaap:IncreaseDecreaseInAccountsPayableAndAccruedLiabilities>
	<us-gaap:IncreaseDecreaseInAccruedIncomeTaxesPayable contextRef="FD2016Q3YTD" decimals="-3" id="Fact-CA373ED7D8BB5789980CB6119B553103" unitRef="usd">-6056000</us-gaap:IncreaseDecreaseInAccruedIncomeTaxesPayable>
	<us-gaap:IncreaseDecreaseInAccruedIncomeTaxesPayable contextRef="FD2017Q3YTD" decimals="-3" id="Fact-E54B6AAA99B85002B2D640D55606CAE1" unitRef="usd">5861000</us-gaap:IncreaseDecreaseInAccruedIncomeTaxesPayable>
	<us-gaap:IncreaseDecreaseInDeferredCharges contextRef="FD2016Q3YTD" decimals="-3" id="Fact-2A61FE78911B516F938CA4CC2ADF13C9" unitRef="usd">79000</us-gaap:IncreaseDecreaseInDeferredCharges>
	<us-gaap:IncreaseDecreaseInDeferredCharges contextRef="FD2017Q3YTD" decimals="-3" id="Fact-76E1E6D2D22256708FE1660FD2CF0887" unitRef="usd">67000</us-gaap:IncreaseDecreaseInDeferredCharges>
	<us-gaap:IncreaseDecreaseInDeferredRevenue contextRef="FD2016Q3YTD" decimals="-3" id="Fact-20D612B548A7536CBD512221EBCD747F" unitRef="usd">-606000</us-gaap:IncreaseDecreaseInDeferredRevenue>
	<us-gaap:IncreaseDecreaseInDeferredRevenue contextRef="FD2017Q3YTD" decimals="-3" id="Fact-DE52CE959CF65341AED1D95E54E275C6" unitRef="usd">-279000</us-gaap:IncreaseDecreaseInDeferredRevenue>
	<us-gaap:IncreaseDecreaseInOtherReceivables contextRef="FD2016Q3YTD" decimals="-3" id="Fact-5251402588585273A3C08534BD2CF5B6" unitRef="usd">9607000</us-gaap:IncreaseDecreaseInOtherReceivables>
	<us-gaap:IncreaseDecreaseInOtherReceivables contextRef="FD2017Q3YTD" decimals="-3" id="Fact-73FCE342F942544DA2B553CA4D2FC683" unitRef="usd">-13856000</us-gaap:IncreaseDecreaseInOtherReceivables>
	<us-gaap:IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets contextRef="FD2016Q3YTD" decimals="-3" id="Fact-EDD49BE1E0755396AB5AEA88E59956CC" unitRef="usd">5734000</us-gaap:IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets>
	<us-gaap:IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets contextRef="FD2017Q3YTD" decimals="-3" id="Fact-8A37B768AFC755FAA7E15B486D6E0617" unitRef="usd">-3220000</us-gaap:IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets>
	<us-gaap:InterestExpense contextRef="FD2016Q3QTD" decimals="-3" id="Fact-3EBDF9D9AD3F5A53901E74B0224057A5" unitRef="usd">5000</us-gaap:InterestExpense>
	<us-gaap:InterestExpense contextRef="FD2016Q3YTD" decimals="-3" id="Fact-1ED2CFC22AB85B34A9E99923D3D234B9" unitRef="usd">18000</us-gaap:InterestExpense>
	<us-gaap:InterestExpense contextRef="FD2017Q3QTD" decimals="-3" id="Fact-9D18E04CD07C5A1F997DADB006C630AD" unitRef="usd">3000</us-gaap:InterestExpense>
	<us-gaap:InterestExpense contextRef="FD2017Q3YTD" decimals="-3" id="Fact-6B3F738003F45EC192E71949CADA5F7C" unitRef="usd">116000</us-gaap:InterestExpense>
	<us-gaap:InterestPaid contextRef="FD2016Q3YTD" decimals="-3" id="Fact-6EE6B7DDBCA85538A80E6CB25FC82D44" unitRef="usd">18000</us-gaap:InterestPaid>
	<us-gaap:InterestPaid contextRef="FD2017Q3YTD" decimals="-3" id="Fact-D19C4DE06B905F31B89ACD165140BEB6" unitRef="usd">11000</us-gaap:InterestPaid>
	<us-gaap:InvestmentIncomeInterest contextRef="FD2016Q3QTD" decimals="-3" id="Fact-F1456612FBDC5C1DABB65CAA4ECB580D" unitRef="usd">68000</us-gaap:InvestmentIncomeInterest>
	<us-gaap:InvestmentIncomeInterest contextRef="FD2016Q3YTD" decimals="-3" id="Fact-B9088AF774A55D2E81403515C066453E" unitRef="usd">180000</us-gaap:InvestmentIncomeInterest>
	<us-gaap:InvestmentIncomeInterest contextRef="FD2017Q3QTD" decimals="-3" id="Fact-9D79D95CF7115AA6B8FDC0214F48ACC0" unitRef="usd">151000</us-gaap:InvestmentIncomeInterest>
	<us-gaap:InvestmentIncomeInterest contextRef="FD2017Q3YTD" decimals="-3" id="Fact-2D8FEE467D8156C6BC63B157EA673D24" unitRef="usd">353000</us-gaap:InvestmentIncomeInterest>
	<us-gaap:LesseeLeasingArrangementsOperatingLeasesRenewalTerm contextRef="D2010Q1Mar1-31_us-gaap_DebtInstrumentAxis_nlnk_CityOfAmesForgivableLoan2010Member_us-gaap_LongtermDebtTypeAxis_us-gaap_LoansPayableMember" id="Fact-DA4947AF74DC5493AF077FAD3A1EF565">P5Y</us-gaap:LesseeLeasingArrangementsOperatingLeasesRenewalTerm>
	<us-gaap:LesseeLeasingArrangementsOperatingLeasesTermOfContract contextRef="D2010Q1Mar1-31_us-gaap_DebtInstrumentAxis_nlnk_CityOfAmesForgivableLoan2010Member_us-gaap_LongtermDebtTypeAxis_us-gaap_LoansPayableMember" id="Fact-4D10B9DF230658B6A10CBB38E593463F">P5Y</us-gaap:LesseeLeasingArrangementsOperatingLeasesTermOfContract>
	<us-gaap:Liabilities contextRef="FI2016Q4" decimals="-3" id="Fact-9C0E42D9AA5C5D86A29ECA73AD3041CF" unitRef="usd">45281000</us-gaap:Liabilities>
	<us-gaap:Liabilities contextRef="FI2017Q3" decimals="-3" id="Fact-10FECCA32BCD53269DEAB122EAAC5EF1" unitRef="usd">33250000</us-gaap:Liabilities>
	<us-gaap:LiabilitiesAndStockholdersEquity contextRef="FI2016Q4" decimals="-3" id="Fact-D04136DCDF1D52C1ACDB5FC2D6428107" unitRef="usd">174747000</us-gaap:LiabilitiesAndStockholdersEquity>
	<us-gaap:LiabilitiesAndStockholdersEquity contextRef="FI2017Q3" decimals="-3" id="Fact-EA85990F058E543DB99E4886C7570257" unitRef="usd">139714000</us-gaap:LiabilitiesAndStockholdersEquity>
	<us-gaap:LiabilitiesCurrent contextRef="FI2016Q4" decimals="-3" id="Fact-3AB4A4B495315BF5A6C968E29AE124D8" unitRef="usd">37905000</us-gaap:LiabilitiesCurrent>
	<us-gaap:LiabilitiesCurrent contextRef="FI2017Q3" decimals="-3" id="Fact-7AEDFEFBB89053508CD2DE24D29EEF41" unitRef="usd">26091000</us-gaap:LiabilitiesCurrent>
	<us-gaap:LiabilitiesNoncurrent contextRef="FI2016Q4" decimals="-3" id="Fact-DEB86D5C533F53F2AC551A3D38098BAC" unitRef="usd">7376000</us-gaap:LiabilitiesNoncurrent>
	<us-gaap:LiabilitiesNoncurrent contextRef="FI2017Q3" decimals="-3" id="Fact-66609E073E975632A683176F0471A5E8" unitRef="usd">7159000</us-gaap:LiabilitiesNoncurrent>
	<us-gaap:LiabilityForUncertainTaxPositionsCurrent contextRef="FI2017Q3" decimals="0" id="Fact-E5A5F13C7A5F513294735712E179DAE0" unitRef="usd">843000</us-gaap:LiabilityForUncertainTaxPositionsCurrent>
	<us-gaap:LicensesRevenue contextRef="FD2016Q3QTD" decimals="-3" id="Fact-44752B74FE7A590A9CED47EBC3EA96B6" unitRef="usd">888000</us-gaap:LicensesRevenue>
	<us-gaap:LicensesRevenue contextRef="FD2016Q3QTD_dei_LegalEntityAxis_nlnk_GenentechInc.Member_us-gaap_TypeOfArrangementAxis_us-gaap_CollaborativeArrangementMember" decimals="0" id="Fact-DA68C21301365B06808AB6E8ABF83B45" unitRef="usd">687000</us-gaap:LicensesRevenue>
	<us-gaap:LicensesRevenue contextRef="FD2016Q3QTD_dei_LegalEntityAxis_nlnk_MerckSharpeandDohmeCorpMember_us-gaap_TypeOfArrangementAxis_us-gaap_CollaborativeArrangementMember" decimals="-5" id="Fact-4DBDDAE5692058EC92F4E0C6AE782F99" unitRef="usd">0</us-gaap:LicensesRevenue>
	<us-gaap:LicensesRevenue contextRef="FD2016Q3YTD" decimals="-3" id="Fact-E8A13BCBF1055F5597CB250591D0FDC6" unitRef="usd">3008000</us-gaap:LicensesRevenue>
	<us-gaap:LicensesRevenue contextRef="FD2016Q3YTD_dei_LegalEntityAxis_nlnk_GenentechInc.Member_us-gaap_TypeOfArrangementAxis_us-gaap_CollaborativeArrangementMember" decimals="-5" id="Fact-F0E7903DFC73542F91903A7709D8984A" unitRef="usd">2200000</us-gaap:LicensesRevenue>
	<us-gaap:LicensesRevenue contextRef="FD2016Q3YTD_dei_LegalEntityAxis_nlnk_MerckSharpeandDohmeCorpMember_us-gaap_TypeOfArrangementAxis_us-gaap_CollaborativeArrangementMember" decimals="0" id="Fact-26D2B8F7CDF75833BE3A4DA2B09E517D" unitRef="usd">764000</us-gaap:LicensesRevenue>
	<us-gaap:LicensesRevenue contextRef="FD2017Q3QTD" decimals="-3" id="Fact-19CF739D33F955F88902702173A19D39" unitRef="usd">103000</us-gaap:LicensesRevenue>
	<us-gaap:LicensesRevenue contextRef="FD2017Q3QTD_dei_LegalEntityAxis_nlnk_GenentechInc.Member_us-gaap_TypeOfArrangementAxis_us-gaap_CollaborativeArrangementMember" decimals="0" id="Fact-5D966E30746351D8A9F6801474C235D8" unitRef="usd">56000</us-gaap:LicensesRevenue>
	<us-gaap:LicensesRevenue contextRef="FD2017Q3YTD" decimals="-3" id="Fact-7C2F60BC20C158FCA4D2D898E0B77597" unitRef="usd">334000</us-gaap:LicensesRevenue>
	<us-gaap:LicensesRevenue contextRef="FD2017Q3YTD_dei_LegalEntityAxis_nlnk_GenentechInc.Member_us-gaap_TypeOfArrangementAxis_us-gaap_CollaborativeArrangementMember" decimals="0" id="Fact-037AA83D99CC5095A7935FA5148AA206" unitRef="usd">279000</us-gaap:LicensesRevenue>
	<us-gaap:LongTermDebtAndCapitalLeaseObligations contextRef="FI2016Q4" decimals="-3" id="Fact-00179942396451429A01BFA88A09751C" unitRef="usd">285000</us-gaap:LongTermDebtAndCapitalLeaseObligations>
	<us-gaap:LongTermDebtAndCapitalLeaseObligations contextRef="FI2017Q3" decimals="-3" id="Fact-D6D04A3DD5715F6B95969BEF44F0E895" unitRef="usd">138000</us-gaap:LongTermDebtAndCapitalLeaseObligations>
	<us-gaap:LongTermDebtAndCapitalLeaseObligationsCurrent contextRef="FI2016Q4" decimals="-3" id="Fact-CF4A35E339A9506EB8E32E320D3167E8" unitRef="usd">232000</us-gaap:LongTermDebtAndCapitalLeaseObligationsCurrent>
	<us-gaap:LongTermDebtAndCapitalLeaseObligationsCurrent contextRef="FI2017Q3" decimals="-3" id="Fact-ADA1601AF6F454BEBDA094F0ABA9AEC1" unitRef="usd">194000</us-gaap:LongTermDebtAndCapitalLeaseObligationsCurrent>
	<us-gaap:LongTermDebtAndCapitalLeaseObligationsIncludingCurrentMaturities contextRef="FI2016Q4" decimals="0" id="Fact-54A89AFC8FA058D384BB0E6622E20DD2" unitRef="usd">517000</us-gaap:LongTermDebtAndCapitalLeaseObligationsIncludingCurrentMaturities>
	<us-gaap:LongTermDebtAndCapitalLeaseObligationsIncludingCurrentMaturities contextRef="FI2017Q3" decimals="0" id="Fact-E12501F925775B399B6FEE01302AD2A2" unitRef="usd">332000</us-gaap:LongTermDebtAndCapitalLeaseObligationsIncludingCurrentMaturities>
	<us-gaap:NetCashProvidedByUsedInFinancingActivities contextRef="FD2016Q3YTD" decimals="-3" id="Fact-4C88F6D74197527FA50E5F1C1CBD248A" unitRef="usd">1478000</us-gaap:NetCashProvidedByUsedInFinancingActivities>
	<us-gaap:NetCashProvidedByUsedInFinancingActivities contextRef="FD2017Q3YTD" decimals="-3" id="Fact-22DC00A73E255C93BA94A6683F74846B" unitRef="usd">20140000</us-gaap:NetCashProvidedByUsedInFinancingActivities>
	<us-gaap:NetCashProvidedByUsedInInvestingActivities contextRef="FD2016Q3YTD" decimals="-3" id="Fact-73D91702792A5645B0F59117827BFC69" unitRef="usd">111000</us-gaap:NetCashProvidedByUsedInInvestingActivities>
	<us-gaap:NetCashProvidedByUsedInInvestingActivities contextRef="FD2017Q3YTD" decimals="-3" id="Fact-65E3EA3AAA1B5D38AC62735735425F23" unitRef="usd">142000</us-gaap:NetCashProvidedByUsedInInvestingActivities>
	<us-gaap:NetCashProvidedByUsedInOperatingActivities contextRef="FD2016Q3YTD" decimals="-3" id="Fact-D7B24DF8901D5F1C96586FDAFB009C93" unitRef="usd">-48933000</us-gaap:NetCashProvidedByUsedInOperatingActivities>
	<us-gaap:NetCashProvidedByUsedInOperatingActivities contextRef="FD2017Q3YTD" decimals="-3" id="Fact-05E5026B7C4B575E8E63D9564BFFCF2C" unitRef="usd">-31070000</us-gaap:NetCashProvidedByUsedInOperatingActivities>
	<us-gaap:NetIncomeLoss contextRef="FD2016Q3QTD" decimals="-3" id="Fact-61A01F77A0FC52EFAC048CF3417C24C9" unitRef="usd">-15540000</us-gaap:NetIncomeLoss>
	<us-gaap:NetIncomeLoss contextRef="FD2016Q3YTD" decimals="-3" id="Fact-81AE173459BA5DC483309EB1069F4CD4" unitRef="usd">-71649000</us-gaap:NetIncomeLoss>
	<us-gaap:NetIncomeLoss contextRef="FD2017Q3QTD" decimals="-3" id="Fact-316CE43A2129549CA7FD6704E0D8DC99" unitRef="usd">-20626000</us-gaap:NetIncomeLoss>
	<us-gaap:NetIncomeLoss contextRef="FD2017Q3YTD" decimals="-3" id="Fact-0280C79FC32958D8B0F2B1A9BB60FFA2" unitRef="usd">-58265000</us-gaap:NetIncomeLoss>
	<us-gaap:NetIncomeLoss contextRef="FD2017Q3YTD_us-gaap_StatementEquityComponentsAxis_us-gaap_RetainedEarningsMember" decimals="-3" id="Fact-E4C9FFCE2630562D87976EF6E8EE38B4" unitRef="usd">-58265000</us-gaap:NetIncomeLoss>
	<us-gaap:NonoperatingIncomeExpense contextRef="FD2016Q3QTD" decimals="-3" id="Fact-BBF636AEDBDC542BA8CE2D197677D895" unitRef="usd">19000</us-gaap:NonoperatingIncomeExpense>
	<us-gaap:NonoperatingIncomeExpense contextRef="FD2016Q3YTD" decimals="-3" id="Fact-FBB2DC1CF602574889CB43919EB9D2E2" unitRef="usd">118000</us-gaap:NonoperatingIncomeExpense>
	<us-gaap:NonoperatingIncomeExpense contextRef="FD2017Q3QTD" decimals="-3" id="Fact-F8D29DFF24625E47B1D33A51D50D5026" unitRef="usd">160000</us-gaap:NonoperatingIncomeExpense>
	<us-gaap:NonoperatingIncomeExpense contextRef="FD2017Q3YTD" decimals="-3" id="Fact-DC382E83928C5335A22DBAEE26A90C30" unitRef="usd">136000</us-gaap:NonoperatingIncomeExpense>
	<us-gaap:NotesReduction contextRef="FD2016Q3YTD" decimals="-3" id="Fact-488456DB298459FE889313BAA3626514" unitRef="usd">397000</us-gaap:NotesReduction>
	<us-gaap:NotesReduction contextRef="FD2017Q3YTD" decimals="-3" id="Fact-4A113E6F497551A2A9DABCE925E791EF" unitRef="usd">0</us-gaap:NotesReduction>
	<us-gaap:OperatingExpenses contextRef="FD2016Q3QTD" decimals="-3" id="Fact-C12F503A979851C6A53597818CDF4479" unitRef="usd">32212000</us-gaap:OperatingExpenses>
	<us-gaap:OperatingExpenses contextRef="FD2016Q3YTD" decimals="-3" id="Fact-BEDBAA95AF4F571BBC251EE6A946A901" unitRef="usd">99853000</us-gaap:OperatingExpenses>
	<us-gaap:OperatingExpenses contextRef="FD2017Q3QTD" decimals="-3" id="Fact-AE9E8F613691588685C45813E5F3BD79" unitRef="usd">26387000</us-gaap:OperatingExpenses>
	<us-gaap:OperatingExpenses contextRef="FD2017Q3YTD" decimals="-3" id="Fact-F3A3589028165AAF885880B1B52DF5B5" unitRef="usd">77443000</us-gaap:OperatingExpenses>
	<us-gaap:OperatingIncomeLoss contextRef="FD2016Q3QTD" decimals="-3" id="Fact-3A17DA1C12F55AC6983F21AE7E168319" unitRef="usd">-16867000</us-gaap:OperatingIncomeLoss>
	<us-gaap:OperatingIncomeLoss contextRef="FD2016Q3YTD" decimals="-3" id="Fact-68A9828C434B5126A25757CA639E92D0" unitRef="usd">-76788000</us-gaap:OperatingIncomeLoss>
	<us-gaap:OperatingIncomeLoss contextRef="FD2017Q3QTD" decimals="-3" id="Fact-208441547EEF52A9BE56152A817666D7" unitRef="usd">-20905000</us-gaap:OperatingIncomeLoss>
	<us-gaap:OperatingIncomeLoss contextRef="FD2017Q3YTD" decimals="-3" id="Fact-110F0EFBC94B5DCC853BC1E9FCE00EDC" unitRef="usd">-58830000</us-gaap:OperatingIncomeLoss>
	<us-gaap:OtherNonoperatingIncomeExpense contextRef="FD2016Q3QTD" decimals="-3" id="Fact-8DB0DEC51CAA5BC19DFF8F1F4F7D0C81" unitRef="usd">-44000</us-gaap:OtherNonoperatingIncomeExpense>
	<us-gaap:OtherNonoperatingIncomeExpense contextRef="FD2016Q3YTD" decimals="-3" id="Fact-CAB0D4804BE953E1B2438A7B11025D08" unitRef="usd">-44000</us-gaap:OtherNonoperatingIncomeExpense>
	<us-gaap:OtherNonoperatingIncomeExpense contextRef="FD2017Q3QTD" decimals="-3" id="Fact-BBBC2850A368545EAE0824495A574675" unitRef="usd">12000</us-gaap:OtherNonoperatingIncomeExpense>
	<us-gaap:OtherNonoperatingIncomeExpense contextRef="FD2017Q3YTD" decimals="-3" id="Fact-57E2302979AD50078E2FD05F0BFD054F" unitRef="usd">-101000</us-gaap:OtherNonoperatingIncomeExpense>
	<us-gaap:OtherReceivablesNetCurrent contextRef="FI2016Q4" decimals="-3" id="Fact-8A9C826453D45F2DB84D612F562EA8B3" unitRef="usd">24526000</us-gaap:OtherReceivablesNetCurrent>
	<us-gaap:OtherReceivablesNetCurrent contextRef="FI2017Q3" decimals="-3" id="Fact-7EEFC67EE37F59CFB3D096BEB7D880D7" unitRef="usd">10670000</us-gaap:OtherReceivablesNetCurrent>
	<us-gaap:PaymentsForCommissions contextRef="D2017Q3SD_us-gaap_SubsidiarySaleOfStockAxis_nlnk_ATMOfferingMember" decimals="0" id="Fact-8E429EF3DAED525FB6C328AF88B9733C" unitRef="usd">398000</us-gaap:PaymentsForCommissions>
	<us-gaap:PaymentsForRepurchaseOfCommonStock contextRef="FD2016Q3YTD" decimals="-3" id="Fact-A65E6ABA485D5F6BB0E827E0EDD471B9" unitRef="usd">13000</us-gaap:PaymentsForRepurchaseOfCommonStock>
	<us-gaap:PaymentsForRepurchaseOfCommonStock contextRef="FD2017Q3YTD" decimals="-3" id="Fact-ADE0E19654265ADF8C9B3C7440C429EB" unitRef="usd">260000</us-gaap:PaymentsForRepurchaseOfCommonStock>
	<us-gaap:PaymentsForRestructuring contextRef="FD2017Q3YTD" decimals="-3" id="Fact-D0725365600F501F879A7B40637320D1" unitRef="usd">1085000</us-gaap:PaymentsForRestructuring>
	<us-gaap:PaymentsForRestructuring contextRef="FD2017Q3YTD_us-gaap_RestructuringCostAndReserveAxis_us-gaap_EmployeeSeveranceMember" decimals="-3" id="Fact-E00589C62C6357D58064284D47D1C511" unitRef="usd">1085000</us-gaap:PaymentsForRestructuring>
	<us-gaap:PaymentsOfStockIssuanceCosts contextRef="D2017Q3SD_us-gaap_SubsidiarySaleOfStockAxis_nlnk_ATMOfferingMember" decimals="0" id="Fact-05C45055C8C97C1E3AB36EAD41EB2336" unitRef="usd">163000</us-gaap:PaymentsOfStockIssuanceCosts>
	<us-gaap:PaymentsToAcquirePropertyPlantAndEquipment contextRef="FD2016Q3YTD" decimals="-3" id="Fact-600C2265D12B5DF5B7D534E10573AF4F" unitRef="usd">2069000</us-gaap:PaymentsToAcquirePropertyPlantAndEquipment>
	<us-gaap:PaymentsToAcquirePropertyPlantAndEquipment contextRef="FD2017Q3YTD" decimals="-3" id="Fact-5E19F8668B9D55708BAD534BBEB9AD71" unitRef="usd">43000</us-gaap:PaymentsToAcquirePropertyPlantAndEquipment>
	<us-gaap:PreferredStockParOrStatedValuePerShare contextRef="FI2016Q4" decimals="INF" id="Fact-2FB055F8C6AA56D9B0166B35C5908082" unitRef="usdPerShare">0.01</us-gaap:PreferredStockParOrStatedValuePerShare>
	<us-gaap:PreferredStockParOrStatedValuePerShare contextRef="FI2017Q3" decimals="INF" id="Fact-F16DA6BBF3615754B9F6F6DA9539288A" unitRef="usdPerShare">0.01</us-gaap:PreferredStockParOrStatedValuePerShare>
	<us-gaap:PreferredStockSharesAuthorized contextRef="FI2016Q4" decimals="INF" id="Fact-91083F67DF1254288F75419D0415F8BE" unitRef="shares">5000000</us-gaap:PreferredStockSharesAuthorized>
	<us-gaap:PreferredStockSharesAuthorized contextRef="FI2017Q3" decimals="INF" id="Fact-3466FF304C6E53EBB707F2ECF2F5B002" unitRef="shares">5000000</us-gaap:PreferredStockSharesAuthorized>
	<us-gaap:PreferredStockSharesIssued contextRef="FI2016Q4" decimals="INF" id="Fact-37A2B16B87DD5D108FC402B2C4DD174E" unitRef="shares">0</us-gaap:PreferredStockSharesIssued>
	<us-gaap:PreferredStockSharesIssued contextRef="FI2017Q3" decimals="INF" id="Fact-1BD48A9D450B582CB307846F4FD9BB2F" unitRef="shares">0</us-gaap:PreferredStockSharesIssued>
	<us-gaap:PreferredStockSharesOutstanding contextRef="FI2016Q4" decimals="INF" id="Fact-050ECCF107E253B7901A21E88FBA3C13" unitRef="shares">0</us-gaap:PreferredStockSharesOutstanding>
	<us-gaap:PreferredStockSharesOutstanding contextRef="FI2017Q3" decimals="INF" id="Fact-A8C5FF63B8D1585DBB175754987BD00D" unitRef="shares">0</us-gaap:PreferredStockSharesOutstanding>
	<us-gaap:PreferredStockValueOutstanding contextRef="FI2016Q4" decimals="-3" id="Fact-491716C6CB195AD1A1C95D4C831B6AC5" unitRef="usd">0</us-gaap:PreferredStockValueOutstanding>
	<us-gaap:PreferredStockValueOutstanding contextRef="FI2017Q3" decimals="-3" id="Fact-908F472A2CF95F16A70D73D7AED82648" unitRef="usd">0</us-gaap:PreferredStockValueOutstanding>
	<us-gaap:PrepaidExpenseAndOtherAssetsCurrent contextRef="FI2016Q4" decimals="-3" id="Fact-D20CD7A2D099592A99E54048FA71E056" unitRef="usd">5921000</us-gaap:PrepaidExpenseAndOtherAssetsCurrent>
	<us-gaap:PrepaidExpenseAndOtherAssetsCurrent contextRef="FI2017Q3" decimals="-3" id="Fact-91F6A59BD93B597B89AD36A1AB7326C8" unitRef="usd">2701000</us-gaap:PrepaidExpenseAndOtherAssetsCurrent>
	<us-gaap:ProceedsFromIssuanceOfCommonStock contextRef="FD2016Q3YTD" decimals="-3" id="Fact-E1E0667341C15AD3BF9F30FF3BAD8753" unitRef="usd">1686000</us-gaap:ProceedsFromIssuanceOfCommonStock>
	<us-gaap:ProceedsFromIssuanceOfCommonStock contextRef="FD2017Q3YTD" decimals="-3" id="Fact-5F4C24654D1B5A7C8843BC3BDF201DF9" unitRef="usd">20585000</us-gaap:ProceedsFromIssuanceOfCommonStock>
	<us-gaap:ProceedsFromSaleAndMaturityOfHeldToMaturitySecurities contextRef="FD2016Q3YTD" decimals="-3" id="Fact-4BC973D523CF58BF94626C8E3C73B7B9" unitRef="usd">2180000</us-gaap:ProceedsFromSaleAndMaturityOfHeldToMaturitySecurities>
	<us-gaap:ProceedsFromSaleAndMaturityOfHeldToMaturitySecurities contextRef="FD2017Q3YTD" decimals="-3" id="Fact-68ADF37253A958479D73672B6E640DDF" unitRef="usd">0</us-gaap:ProceedsFromSaleAndMaturityOfHeldToMaturitySecurities>
	<us-gaap:ProceedsFromSaleOfPropertyPlantAndEquipment contextRef="FD2016Q3YTD" decimals="-3" id="Fact-21CED0E673BF56DBAAAF5CE68448C360" unitRef="usd">0</us-gaap:ProceedsFromSaleOfPropertyPlantAndEquipment>
	<us-gaap:ProceedsFromSaleOfPropertyPlantAndEquipment contextRef="FD2017Q3YTD" decimals="-3" id="Fact-DD00E45CAB4154AB882078F9EF933BB6" unitRef="usd">185000</us-gaap:ProceedsFromSaleOfPropertyPlantAndEquipment>
	<us-gaap:PropertyPlantAndEquipmentNet contextRef="FI2016Q4" decimals="-3" id="Fact-097772B9EE995F8998AF8F0798632B33" unitRef="usd">6835000</us-gaap:PropertyPlantAndEquipmentNet>
	<us-gaap:PropertyPlantAndEquipmentNet contextRef="FI2017Q3" decimals="-3" id="Fact-A228FBA7921A5905AF3868B52C269D4D" unitRef="usd">5527000</us-gaap:PropertyPlantAndEquipmentNet>
	<us-gaap:PropertyPlantAndEquipmentUsefulLife contextRef="FD2017Q3YTD_us-gaap_PropertyPlantAndEquipmentByTypeAxis_nlnk_ContractManufacturingOrganizationEquipmentMember" id="Fact-A17C9EB9EE7C50A1B466F66EEECDDC9A">P5Y</us-gaap:PropertyPlantAndEquipmentUsefulLife>
	<us-gaap:PropertyPlantAndEquipmentUsefulLife contextRef="FD2017Q3YTD_us-gaap_PropertyPlantAndEquipmentByTypeAxis_us-gaap_ComputerEquipmentMember_us-gaap_RangeAxis_us-gaap_MaximumMember" id="Fact-ADE79448E94B51AFA6DD7A7756938F18">P5Y</us-gaap:PropertyPlantAndEquipmentUsefulLife>
	<us-gaap:PropertyPlantAndEquipmentUsefulLife contextRef="FD2017Q3YTD_us-gaap_PropertyPlantAndEquipmentByTypeAxis_us-gaap_ComputerEquipmentMember_us-gaap_RangeAxis_us-gaap_MinimumMember" id="Fact-3C75C3EC9BA35DBFA84C27246EA7D3FB">P3Y</us-gaap:PropertyPlantAndEquipmentUsefulLife>
	<us-gaap:PropertyPlantAndEquipmentUsefulLife contextRef="FD2017Q3YTD_us-gaap_PropertyPlantAndEquipmentByTypeAxis_us-gaap_EquipmentMember" id="Fact-95EE6A19295052858496D09567493C10">P5Y</us-gaap:PropertyPlantAndEquipmentUsefulLife>
	<us-gaap:RepaymentsOfDebtAndCapitalLeaseObligations contextRef="FD2016Q3YTD" decimals="-3" id="Fact-A29D92FAFA40530B9D5059C65A6ABE89" unitRef="usd">195000</us-gaap:RepaymentsOfDebtAndCapitalLeaseObligations>
	<us-gaap:RepaymentsOfDebtAndCapitalLeaseObligations contextRef="FD2017Q3YTD" decimals="-3" id="Fact-7AE8928ACEA65A10BF3ABD6C8210E56D" unitRef="usd">185000</us-gaap:RepaymentsOfDebtAndCapitalLeaseObligations>
	<us-gaap:ResearchAndDevelopmentExpense contextRef="FD2016Q3QTD" decimals="-3" id="Fact-4F1B9DFB58005FC9AC1365CA2337E0B9" unitRef="usd">24463000</us-gaap:ResearchAndDevelopmentExpense>
	<us-gaap:ResearchAndDevelopmentExpense contextRef="FD2016Q3YTD" decimals="-3" id="Fact-A7CD68A2310652F1A26B9D4C4AE83813" unitRef="usd">73810000</us-gaap:ResearchAndDevelopmentExpense>
	<us-gaap:ResearchAndDevelopmentExpense contextRef="FD2017Q3QTD" decimals="-3" id="Fact-53031C49420C55518082B07FC3B39821" unitRef="usd">18480000</us-gaap:ResearchAndDevelopmentExpense>
	<us-gaap:ResearchAndDevelopmentExpense contextRef="FD2017Q3YTD" decimals="-3" id="Fact-C39477C088615469BA758113CB6A8E4B" unitRef="usd">52405000</us-gaap:ResearchAndDevelopmentExpense>
	<us-gaap:RestructuringAndRelatedCostNumberOfPositionsEliminatedPeriodPercent contextRef="D2017Q3July1-31" decimals="2" id="Fact-C551696BF98EB053E34250A743781317" unitRef="number">0.50</us-gaap:RestructuringAndRelatedCostNumberOfPositionsEliminatedPeriodPercent>
	<us-gaap:RestructuringCharges contextRef="FD2016Q4YTD" decimals="-5" id="Fact-EE72A36E9B2B59D0BFDD0980FFBF12C3" unitRef="usd">12300000</us-gaap:RestructuringCharges>
	<us-gaap:RestructuringCharges contextRef="FD2016Q4YTD_us-gaap_IncomeStatementLocationAxis_us-gaap_GeneralAndAdministrativeExpenseMember" decimals="0" id="Fact-3C4F204ACD2BB68658356EA3D301EFAA" unitRef="usd">500000</us-gaap:RestructuringCharges>
	<us-gaap:RestructuringCharges contextRef="FD2016Q4YTD_us-gaap_IncomeStatementLocationAxis_us-gaap_ResearchAndDevelopmentExpenseMember" decimals="-5" id="Fact-280285CF239457461C906EA3DEF3D3FB" unitRef="usd">11800000</us-gaap:RestructuringCharges>
	<us-gaap:RestructuringCharges contextRef="FD2017Q3QTD_us-gaap_RestructuringCostAndReserveAxis_us-gaap_EmployeeSeveranceMember" decimals="-5" id="Fact-53C3F4E6B37FD74A76435A80259C7BA3" unitRef="usd">1700000</us-gaap:RestructuringCharges>
	<us-gaap:RestructuringCharges contextRef="FD2017Q3QTD_us-gaap_RestructuringPlanAxis_nlnk_TwoThousandSixteenRestructuringPlanMember" decimals="INF" id="Fact-D01171666984537183C44ED523DC97D8" unitRef="usd">0</us-gaap:RestructuringCharges>
	<us-gaap:RestructuringCharges contextRef="FD2017Q3YTD" decimals="-3" id="Fact-F111173C12B45EEA8FDB065E7B138933" unitRef="usd">1695000</us-gaap:RestructuringCharges>
	<us-gaap:RestructuringCharges contextRef="FD2017Q3YTD_us-gaap_RestructuringCostAndReserveAxis_us-gaap_EmployeeSeveranceMember" decimals="-5" id="Fact-4C141DD6DB6D9528CF115A7DEE8D2DD0" unitRef="usd">1700000</us-gaap:RestructuringCharges>
	<us-gaap:RestructuringCharges contextRef="FD2017Q3YTD_us-gaap_RestructuringCostAndReserveAxis_us-gaap_EmployeeSeveranceMember" decimals="-3" id="Fact-B7B556322174533CBDFF19F3D6541BCF" unitRef="usd">1695000</us-gaap:RestructuringCharges>
	<us-gaap:RestructuringCharges contextRef="FD2017Q3YTD_us-gaap_RestructuringPlanAxis_nlnk_TwoThousandSixteenRestructuringPlanMember" decimals="INF" id="Fact-1EAEAB04412C5F9FB8C25A82227D9298" unitRef="usd">0</us-gaap:RestructuringCharges>
	<us-gaap:RestructuringReserve contextRef="FI2016Q4" decimals="-3" id="Fact-1E908E37D28B5042A50111D3BF879D3A" unitRef="usd">42000</us-gaap:RestructuringReserve>
	<us-gaap:RestructuringReserve contextRef="FI2016Q4_us-gaap_RestructuringCostAndReserveAxis_us-gaap_EmployeeSeveranceMember" decimals="-3" id="Fact-DC9EC6A569AA5D91B97F942BF782A69B" unitRef="usd">42000</us-gaap:RestructuringReserve>
	<us-gaap:RestructuringReserve contextRef="FI2017Q3" decimals="-3" id="Fact-66B6D23ABFC65399B094643B476AF248" unitRef="usd">652000</us-gaap:RestructuringReserve>
	<us-gaap:RestructuringReserve contextRef="FI2017Q3_us-gaap_RestructuringCostAndReserveAxis_us-gaap_EmployeeSeveranceMember" decimals="-3" id="Fact-05B3339A18CC5EB1994252E635800F7E" unitRef="usd">652000</us-gaap:RestructuringReserve>
	<us-gaap:RetainedEarningsAccumulatedDeficit contextRef="FI2016Q4" decimals="-3" id="Fact-71E0292033A75E85A3F9B4C19BE24306" unitRef="usd">-165508000</us-gaap:RetainedEarningsAccumulatedDeficit>
	<us-gaap:RetainedEarningsAccumulatedDeficit contextRef="FI2017Q3" decimals="-3" id="Fact-D3C2797FA509511E9F455344C92587EA" unitRef="usd">-223773000</us-gaap:RetainedEarningsAccumulatedDeficit>
	<us-gaap:RevenueFromGrants contextRef="FD2016Q1QTD_us-gaap_DebtInstrumentAxis_nlnk_CityOfAmesForgivableLoan2010Member" decimals="0" id="Fact-1C11C0A890DA56CE88E1445013E68E49" unitRef="usd">397000</us-gaap:RevenueFromGrants>
	<us-gaap:RevenueFromGrants contextRef="FD2016Q3QTD" decimals="-3" id="Fact-ED2568E3B1EA5F5CA49D4CD8A1377811" unitRef="usd">14457000</us-gaap:RevenueFromGrants>
	<us-gaap:RevenueFromGrants contextRef="FD2016Q3YTD" decimals="-3" id="Fact-BAEF9D01F6485C4086E0490FB1C5475E" unitRef="usd">20057000</us-gaap:RevenueFromGrants>
	<us-gaap:RevenueFromGrants contextRef="FD2017Q3QTD" decimals="-3" id="Fact-5703EC89A4E55E80BCF32124EB31C8B2" unitRef="usd">5379000</us-gaap:RevenueFromGrants>
	<us-gaap:RevenueFromGrants contextRef="FD2017Q3YTD" decimals="-3" id="Fact-EA558905EBC55E779D18F77514D99E4F" unitRef="usd">18279000</us-gaap:RevenueFromGrants>
	<us-gaap:RevenueRecognitionMilestoneMethodRevenueRecognized contextRef="D2015Q1Feb1-28_dei_LegalEntityAxis_nlnk_MerckSharpeandDohmeCorpMember_us-gaap_TypeOfArrangementAxis_us-gaap_CollaborativeArrangementMember" decimals="-5" id="Fact-DC6E9CB1F4245489ACA0692A2646D442" unitRef="usd">20000000</us-gaap:RevenueRecognitionMilestoneMethodRevenueRecognized>
	<us-gaap:RevenueRecognitionMilestoneMethodRevenueRecognized contextRef="FD2014Q4YTD_dei_LegalEntityAxis_nlnk_GenentechInc.Member_us-gaap_TypeOfArrangementAxis_us-gaap_CollaborativeArrangementMember" decimals="-5" id="Fact-86185E8E9C1C527A96197A6D07B79891" unitRef="usd">150000000</us-gaap:RevenueRecognitionMilestoneMethodRevenueRecognized>
	<us-gaap:RevenueRecognitionMilestoneMethodRevenueRecognized contextRef="FD2014Q4YTD_dei_LegalEntityAxis_nlnk_MerckSharpeandDohmeCorpMember_us-gaap_TypeOfArrangementAxis_us-gaap_CollaborativeArrangementMember" decimals="-5" id="Fact-EBAD62070F555A96A6944AE40E3AB82D" unitRef="usd">30000000</us-gaap:RevenueRecognitionMilestoneMethodRevenueRecognized>
	<us-gaap:SaleOfStockConsiderationReceivedOnTransaction contextRef="D2017Q3SD_us-gaap_SubsidiarySaleOfStockAxis_nlnk_ATMOfferingMember" decimals="-5" id="Fact-470CCDF57EB75E1CA6714C6EB0A38644" unitRef="usd">19300000</us-gaap:SaleOfStockConsiderationReceivedOnTransaction>
	<us-gaap:SaleOfStockConsiderationReceivedOnTransaction contextRef="D2017Q4Oct6_us-gaap_SubsequentEventTypeAxis_us-gaap_SubsequentEventMember_us-gaap_SubsidiarySaleOfStockAxis_nlnk_PublicOfferingMember" decimals="-5" id="Fact-1A9EC82645EC3425DED850B2D77819C8" unitRef="usd">55200000</us-gaap:SaleOfStockConsiderationReceivedOnTransaction>
	<us-gaap:SaleOfStockConsiderationReceivedOnTransaction contextRef="FD2015Q4YTD_us-gaap_SubsidiarySaleOfStockAxis_nlnk_ATMOfferingMember" decimals="-5" id="Fact-33AA5FBD2D4E5E8EBE6963AF807942F1" unitRef="usd">58700000</us-gaap:SaleOfStockConsiderationReceivedOnTransaction>
	<us-gaap:SaleOfStockConsiderationReceivedOnTransaction contextRef="FD2015Q4YTD_us-gaap_SubsidiarySaleOfStockAxis_nlnk_FollowOnOfferingMember" decimals="-5" id="Fact-ABA50F35AE9F563A9AFE0732E0139DBF" unitRef="usd">49000000</us-gaap:SaleOfStockConsiderationReceivedOnTransaction>
	<us-gaap:SaleOfStockConsiderationReceivedOnTransaction contextRef="FD2015Q4YTD_us-gaap_SubsidiarySaleOfStockAxis_us-gaap_IPOMember" decimals="-5" id="Fact-F3A4A5EB3E47519CA5248971421189E7" unitRef="usd">37600000</us-gaap:SaleOfStockConsiderationReceivedOnTransaction>
	<us-gaap:SaleOfStockNumberOfSharesIssuedInTransaction contextRef="D2017Q4Oct6_us-gaap_SubsequentEventTypeAxis_us-gaap_SubsequentEventMember_us-gaap_SubsidiarySaleOfStockAxis_nlnk_PublicOfferingMember" decimals="INF" id="Fact-089BC4F6AA8881C7311950B1A820AD00" unitRef="shares">5750000</us-gaap:SaleOfStockNumberOfSharesIssuedInTransaction>
	<us-gaap:SalesRevenueNet contextRef="FD2016Q3QTD" decimals="-3" id="Fact-A181C319E52354EC8150BA270F431D4D" unitRef="usd">15345000</us-gaap:SalesRevenueNet>
	<us-gaap:SalesRevenueNet contextRef="FD2016Q3YTD" decimals="-3" id="Fact-3141C005C2815B069F40EA73FAC23FC0" unitRef="usd">23065000</us-gaap:SalesRevenueNet>
	<us-gaap:SalesRevenueNet contextRef="FD2017Q3QTD" decimals="-3" id="Fact-10D182A5292558E1A84ACC8A5B861A72" unitRef="usd">5482000</us-gaap:SalesRevenueNet>
	<us-gaap:SalesRevenueNet contextRef="FD2017Q3YTD" decimals="-3" id="Fact-9EF7638D098C5E439334F985A3020C05" unitRef="usd">18613000</us-gaap:SalesRevenueNet>
	<us-gaap:ShareBasedCompensation contextRef="FD2016Q3YTD" decimals="-3" id="Fact-A913110DAF94538F9CCFB0585D895952" unitRef="usd">13119000</us-gaap:ShareBasedCompensation>
	<us-gaap:ShareBasedCompensation contextRef="FD2017Q3YTD" decimals="-3" id="Fact-7E851F4C32535F71B396AA098EB33B88" unitRef="usd">14938000</us-gaap:ShareBasedCompensation>
	<us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod contextRef="FD2017Q3YTD_us-gaap_AwardTypeAxis_us-gaap_RestrictedStockMember" decimals="INF" id="Fact-AC5939D0626F518C8CD0A04199CF1087" unitRef="shares">27248</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod>
	<us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue contextRef="FD2017Q3YTD_us-gaap_AwardTypeAxis_us-gaap_RestrictedStockMember" decimals="2" id="Fact-47C2956E438A5F23949773A9178FD4E3" unitRef="usdPerShare">33.84</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue>
	<us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod contextRef="FD2017Q3YTD_us-gaap_AwardTypeAxis_us-gaap_PerformanceSharesMember" decimals="INF" id="Fact-F1063AB20A4E5052A7E393DB98505C73" unitRef="shares">388144</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod>
	<us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod contextRef="FD2017Q3YTD_us-gaap_AwardTypeAxis_us-gaap_RestrictedStockMember" decimals="INF" id="Fact-F5039766734E57A794C36053538DFB32" unitRef="shares">0</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod>
	<us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue contextRef="FD2017Q3YTD_us-gaap_AwardTypeAxis_us-gaap_PerformanceSharesMember" decimals="2" id="Fact-59380E6FE51D56CE88A08DBFE7FA9AF7" unitRef="usdPerShare">6.73</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue>
	<us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue contextRef="FD2017Q3YTD_us-gaap_AwardTypeAxis_us-gaap_RestrictedStockMember" decimals="2" id="Fact-BAC45551BFCA558EA0738198889D3361" unitRef="usdPerShare">0.00</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue>
	<us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber contextRef="FI2016Q4_us-gaap_AwardTypeAxis_us-gaap_RestrictedStockMember" decimals="INF" id="Fact-C10F4E9C907A58A7A5273B79D8DD00A8" unitRef="shares">288964</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber>
	<us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber contextRef="FI2017Q3_us-gaap_AwardTypeAxis_us-gaap_RestrictedStockMember" decimals="INF" id="Fact-229A80505BEA569A820FE456944F5095" unitRef="shares">181336</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber>
	<us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue contextRef="FI2016Q4_us-gaap_AwardTypeAxis_us-gaap_RestrictedStockMember" decimals="2" id="Fact-9ED5D46785415CCB9C5F9DA6A194BC70" unitRef="usdPerShare">34.94</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue>
	<us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue contextRef="FI2017Q3_us-gaap_AwardTypeAxis_us-gaap_RestrictedStockMember" decimals="2" id="Fact-EB2C61B9B67A5A2D8D252FF3B74F5A67" unitRef="usdPerShare">35.05</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue>
	<us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod contextRef="FD2017Q3YTD_us-gaap_AwardTypeAxis_us-gaap_PerformanceSharesMember" decimals="INF" id="Fact-2089B91941285352B760B37BF7A287BC" unitRef="shares">194070</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod>
	<us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod contextRef="FD2017Q3YTD_us-gaap_AwardTypeAxis_us-gaap_RestrictedStockMember" decimals="INF" id="Fact-405B76F0CD6E5EFFA697BAAF375DAF19" unitRef="shares">80380</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod>
	<us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodTotalFairValue contextRef="FD2017Q3YTD_us-gaap_AwardTypeAxis_nlnk_PerformanceRestrictedStockMember" decimals="0" id="Fact-06192CA5265855ADBE7D14AF636F6D6E" unitRef="usd">814000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodTotalFairValue>
	<us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue contextRef="FD2017Q3YTD_us-gaap_AwardTypeAxis_us-gaap_RestrictedStockMember" decimals="2" id="Fact-5B15202A77595BAE96286768E66B5E40" unitRef="usdPerShare">35.04</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue>
	<us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate contextRef="FD2017Q3YTD_us-gaap_AwardTypeAxis_us-gaap_EmployeeStockOptionMember" decimals="3" id="Fact-C0D8B112E7595A1CAB2D5453536A84EC" unitRef="number">0.000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate>
	<us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum contextRef="FD2017Q3YTD_us-gaap_AwardTypeAxis_us-gaap_EmployeeStockOptionMember" decimals="3" id="Fact-052CDF7B2F7A59D19B8404A84329B2BE" unitRef="number">0.732</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum>
	<us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum contextRef="FD2017Q3YTD_us-gaap_AwardTypeAxis_us-gaap_EmployeeStockOptionMember" decimals="3" id="Fact-35F0D796C0E954248A5943E7E1490500" unitRef="number">0.689</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum>
	<us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum contextRef="FD2017Q3YTD_us-gaap_AwardTypeAxis_us-gaap_EmployeeStockOptionMember" decimals="4" id="Fact-86C85C81BFC05E9BBA00A8CB57753579" unitRef="number">0.0220</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum>
	<us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum contextRef="FD2017Q3YTD_us-gaap_AwardTypeAxis_us-gaap_EmployeeStockOptionMember" decimals="4" id="Fact-B88137DD7D54585E879CE808BCCF3723" unitRef="number">0.0190</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum>
	<us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized contextRef="D2010Q2May15_us-gaap_PlanNameAxis_nlnk_A2009EquityIncentivePlanMember" decimals="INF" id="Fact-EE80F696DD4F5A20B94561084072A30E" unitRef="shares">1238095</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized>
	<us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized contextRef="D2011Q1Jan7_us-gaap_PlanNameAxis_nlnk_A2009EquityIncentivePlanMember" decimals="INF" id="Fact-3B5CF659B7A958F4BF36EF7464CE3BA0" unitRef="shares">714286</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized>
	<us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized contextRef="D2013Q1Jan1_us-gaap_PlanNameAxis_nlnk_A2009EquityIncentivePlanMember" decimals="INF" id="Fact-D329115F16C95499BEE600AC405A7641" unitRef="shares">838375</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized>
	<us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized contextRef="D2013Q2May9_us-gaap_PlanNameAxis_nlnk_A2010EmployeeStockPurchasePlanMember" decimals="INF" id="Fact-2E237963EDF250799DB2FD8DFF217DE2" unitRef="shares">185715</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized>
	<us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized contextRef="D2013Q2May9_us-gaap_PlanNameAxis_nlnk_A2010NonEmployeeDirectorsStockOptionPlanMember" decimals="INF" id="Fact-FD31F851191550AEB3386E10D8EA98D8" unitRef="shares">161905</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized>
	<us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized contextRef="D2014Q1Jan1_us-gaap_PlanNameAxis_nlnk_A2009EquityIncentivePlanMember" decimals="INF" id="Fact-78C5681B1C6254C4BEA0F5B8FB95C1FB" unitRef="shares">1066340</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized>
	<us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized contextRef="D2015Q1Jan1_us-gaap_PlanNameAxis_nlnk_A2009EquityIncentivePlanMember" decimals="INF" id="Fact-C9E0A0832A345FA89366AAA9BA01D95E" unitRef="shares">1119255</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized>
	<us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized contextRef="D2016Q1Jan1_us-gaap_PlanNameAxis_nlnk_A2009EquityIncentivePlanMember" decimals="INF" id="Fact-E6A1300BD841563CA9DFCD6C15205A52" unitRef="shares">1152565</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized>
	<us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized contextRef="D2017Q1Jan1_us-gaap_PlanNameAxis_nlnk_A2009EquityIncentivePlanMember" decimals="INF" id="Fact-9240CB94161B59189D732B83DEB04DF6" unitRef="shares">1166546</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized>
	<us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized contextRef="FI2017Q3_us-gaap_PlanNameAxis_nlnk_A2009EquityIncentivePlanMember" decimals="INF" id="Fact-7C9952FBC4B95AE1964A9104C7BF2A0C" unitRef="shares">10238220</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized>
	<us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized contextRef="I2011Q4SD2_us-gaap_PlanNameAxis_nlnk_A2010EmployeeStockPurchasePlanMember" decimals="INF" id="Fact-D8A9F24D30B55E9CA367DBCA748D1FAF" unitRef="shares">214285</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized>
	<us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized contextRef="I2011Q4SD2_us-gaap_PlanNameAxis_nlnk_A2010NonEmployeeDirectorsStockOptionPlanMember" decimals="INF" id="Fact-E71FB7B51B0750BDA78DF7D1422FF45B" unitRef="shares">238095</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized>
	<us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant contextRef="FI2017Q3_us-gaap_PlanNameAxis_nlnk_A2009EquityIncentivePlanMember" decimals="INF" id="Fact-6072DD87ACFD5369B2A740A323D90EF4" unitRef="shares">1094264</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant>
	<us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant contextRef="FI2017Q3_us-gaap_PlanNameAxis_nlnk_A2010EmployeeStockPurchasePlanMember" decimals="INF" id="Fact-DB5C02764F355217B20400A5F0EAF954" unitRef="shares">120784</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant>
	<us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant contextRef="FI2017Q3_us-gaap_PlanNameAxis_nlnk_A2010NonEmployeeDirectorsStockOptionPlanMember" decimals="INF" id="Fact-D088FC99252555A1851D0326778E13E7" unitRef="shares">0</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant>
	<us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber contextRef="FI2017Q3_us-gaap_AwardTypeAxis_us-gaap_EmployeeStockOptionMember" decimals="INF" id="Fact-90D7BAB902E65092A452459A3BAF9DC3" unitRef="shares">5456602</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber>
	<us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice contextRef="FI2017Q3_us-gaap_AwardTypeAxis_us-gaap_EmployeeStockOptionMember" decimals="2" id="Fact-37959805D703545E80DE72EAC1808C1F" unitRef="usdPerShare">12.65</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice>
	<us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue contextRef="FD2017Q3YTD_us-gaap_AwardTypeAxis_us-gaap_EmployeeStockOptionMember" decimals="INF" id="Fact-EF35B5D93DD85264AE3CD7C65560651A" unitRef="usd">924164</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue>
	<us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod contextRef="FD2017Q3YTD_us-gaap_AwardTypeAxis_us-gaap_EmployeeStockOptionMember" decimals="INF" id="Fact-F48486AFE22F5EB2A7DC4CE04B8CFB79" unitRef="shares">17605</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod>
	<us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod contextRef="FD2017Q3YTD_us-gaap_AwardTypeAxis_us-gaap_EmployeeStockOptionMember" decimals="INF" id="Fact-0B8AA6CDE1475D5696AF3FB4F28D694B" unitRef="shares">277443</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod>
	<us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross contextRef="FD2017Q3YTD_us-gaap_AwardTypeAxis_us-gaap_EmployeeStockOptionMember" decimals="INF" id="Fact-C62F62DCF4C35AEF92B08523110DDF1E" unitRef="shares">1439287</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross>
	<us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue contextRef="FD2017Q3YTD_us-gaap_AwardTypeAxis_us-gaap_EmployeeStockOptionMember" decimals="2" id="Fact-AE54D671823F571BB34F4F82DEE4361F" unitRef="usdPerShare">7.81</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue>
	<us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber contextRef="FI2016Q4_us-gaap_AwardTypeAxis_us-gaap_EmployeeStockOptionMember" decimals="INF" id="Fact-D61FB65EC4C4555981F30245F3A9694D" unitRef="shares">6278542</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber>
	<us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber contextRef="FI2017Q3_us-gaap_AwardTypeAxis_us-gaap_EmployeeStockOptionMember" decimals="INF" id="Fact-5ED8CF9B17BC5CF3897127A7FCAB51A7" unitRef="shares">7314006</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber>
	<us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice contextRef="FI2016Q4_us-gaap_AwardTypeAxis_us-gaap_EmployeeStockOptionMember" decimals="2" id="Fact-8FC88F5B09C75AA8BA5ACDDFB568C64B" unitRef="usdPerShare">14.93</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice>
	<us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice contextRef="FI2017Q3_us-gaap_AwardTypeAxis_us-gaap_EmployeeStockOptionMember" decimals="2" id="Fact-A608C9C7EEA05484AA8ABE73738F7030" unitRef="usdPerShare">14.15</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice>
	<us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice contextRef="FD2017Q3YTD_us-gaap_AwardTypeAxis_us-gaap_EmployeeStockOptionMember" decimals="2" id="Fact-A690BE55A502522585161E852DBA5B8A" unitRef="usdPerShare">8.51</us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice>
	<us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExpirationsInPeriodWeightedAverageExercisePrice contextRef="FD2017Q3YTD_us-gaap_AwardTypeAxis_us-gaap_EmployeeStockOptionMember" decimals="2" id="Fact-70F75431555B5CC88065FDBF4A70E105" unitRef="usdPerShare">42.00</us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExpirationsInPeriodWeightedAverageExercisePrice>
	<us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice contextRef="FD2017Q3YTD_us-gaap_AwardTypeAxis_us-gaap_EmployeeStockOptionMember" decimals="2" id="Fact-D91E7AD015935B188E639E48831CC6FA" unitRef="usdPerShare">20.13</us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice>
	<us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice contextRef="FD2017Q3YTD_us-gaap_AwardTypeAxis_us-gaap_EmployeeStockOptionMember" decimals="2" id="Fact-0659C30606DB54A586B93F00B14506EF" unitRef="usdPerShare">11.78</us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice>
	<us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1 contextRef="FD2017Q3YTD_us-gaap_AwardTypeAxis_us-gaap_EmployeeStockOptionMember_us-gaap_RangeAxis_us-gaap_MaximumMember" id="Fact-F7AD2CD68A4753538168B3346D2C432B">P7Y9M18D</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1>
	<us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1 contextRef="FD2017Q3YTD_us-gaap_AwardTypeAxis_us-gaap_EmployeeStockOptionMember_us-gaap_RangeAxis_us-gaap_MinimumMember" id="Fact-795D0D38B7C45C72A5B99CF306D1B354">P6Y6M</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1>
	<us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1 contextRef="FD2017Q3YTD_us-gaap_AwardTypeAxis_us-gaap_EmployeeStockOptionMember" id="Fact-F1280AF1DC6357E1B17324C441AE6F23">P4Y5M12D</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1>
	<us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2 contextRef="FD2016Q4YTD_us-gaap_AwardTypeAxis_us-gaap_EmployeeStockOptionMember" id="Fact-CF7CA5C281E6ED3ABAEC0D7280FAC4CB">P5Y9M18D</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2>
	<us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2 contextRef="FD2017Q3YTD_us-gaap_AwardTypeAxis_us-gaap_EmployeeStockOptionMember" id="Fact-88F545D1B38151DD858D27DF0694A4FD">P5Y6M15D</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2>
	<us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedInPeriodFairValue1 contextRef="FD2017Q3YTD_us-gaap_AwardTypeAxis_us-gaap_EmployeeStockOptionMember" decimals="-5" id="Fact-1D7432AA17915CB9B3CCAF03C3BD8D10" unitRef="usd">12400000</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedInPeriodFairValue1>
	<us-gaap:StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans contextRef="FD2017Q3YTD_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember" decimals="INF" id="Fact-5D778DDDB1395A68A5D020234ECAC867" unitRef="shares">51999</us-gaap:StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans>
	<us-gaap:StockIssuedDuringPeriodSharesNewIssues contextRef="D2017Q3SD_us-gaap_SubsidiarySaleOfStockAxis_nlnk_ATMOfferingMember" decimals="INF" id="Fact-F6A2D3DE3B025CCF985824675EFF24A4" unitRef="shares">1940656</us-gaap:StockIssuedDuringPeriodSharesNewIssues>
	<us-gaap:StockIssuedDuringPeriodSharesNewIssues contextRef="FD2017Q3YTD_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember" decimals="0" id="Fact-7937C439451BA9E1752A7D88ED67315A" unitRef="shares">1940656</us-gaap:StockIssuedDuringPeriodSharesNewIssues>
	<us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised contextRef="FD2017Q3YTD_us-gaap_AwardTypeAxis_us-gaap_EmployeeStockOptionMember" decimals="INF" id="Fact-465702A5254D5B2CB6A0D802F800C717" unitRef="shares">108775</us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised>
	<us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised contextRef="FD2017Q3YTD_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember" decimals="INF" id="Fact-1F82C93AFF7F5834BE37F353A7F3D015" unitRef="shares">189155</us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised>
	<us-gaap:StockIssuedDuringPeriodValueEmployeeStockPurchasePlan contextRef="FD2017Q3YTD" decimals="-3" id="Fact-1C6E5D58922259BD81DF2B46A5F6CD6D" unitRef="usd">326000</us-gaap:StockIssuedDuringPeriodValueEmployeeStockPurchasePlan>
	<us-gaap:StockIssuedDuringPeriodValueEmployeeStockPurchasePlan contextRef="FD2017Q3YTD_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember" decimals="-3" id="Fact-CFD221D9A3355DE6A9562B3746E9B82F" unitRef="usd">325000</us-gaap:StockIssuedDuringPeriodValueEmployeeStockPurchasePlan>
	<us-gaap:StockIssuedDuringPeriodValueNewIssues contextRef="FD2017Q3YTD" decimals="-3" id="Fact-79CD128A454D825871067D88B6E2B56E" unitRef="usd">19334000</us-gaap:StockIssuedDuringPeriodValueNewIssues>
	<us-gaap:StockIssuedDuringPeriodValueNewIssues contextRef="FD2017Q3YTD_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember" decimals="-3" id="Fact-30AA3F3678D97342AE687D88B6C3DF98" unitRef="usd">19315000</us-gaap:StockIssuedDuringPeriodValueNewIssues>
	<us-gaap:StockIssuedDuringPeriodValueNewIssues contextRef="FD2017Q3YTD_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember" decimals="-3" id="Fact-80C6200B4ED6800D13DA7D88B6D3C97C" unitRef="usd">19000</us-gaap:StockIssuedDuringPeriodValueNewIssues>
	<us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised contextRef="FD2017Q3YTD" decimals="-3" id="Fact-96FE59946C125C96A73DCAC3F3F6C587" unitRef="usd">925000</us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised>
	<us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised contextRef="FD2017Q3YTD_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember" decimals="-3" id="Fact-D368C6892C4E5A92997FE7A28D4C0A5B" unitRef="usd">923000</us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised>
	<us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised contextRef="FD2017Q3YTD_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember" decimals="-3" id="Fact-4088A8E629CF5508A17FD886901237C1" unitRef="usd">2000</us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised>
	<us-gaap:StockRepurchasedDuringPeriodShares contextRef="FD2017Q3YTD_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember" decimals="INF" id="Fact-174FBDB89F5353ADB2F950473D9DB1BD" unitRef="shares">25732</us-gaap:StockRepurchasedDuringPeriodShares>
	<us-gaap:StockRepurchasedDuringPeriodValue contextRef="FD2017Q3YTD" decimals="-3" id="Fact-D012C2C1D4615C37A2BB6122373C37E5" unitRef="usd">260000</us-gaap:StockRepurchasedDuringPeriodValue>
	<us-gaap:StockRepurchasedDuringPeriodValue contextRef="FD2017Q3YTD_us-gaap_StatementEquityComponentsAxis_us-gaap_TreasuryStockMember" decimals="-3" id="Fact-105666E1887E5685BCCE96902917C4E1" unitRef="usd">260000</us-gaap:StockRepurchasedDuringPeriodValue>
	<us-gaap:StockholdersEquity contextRef="FI2016Q4" decimals="-3" id="Fact-E4EA96C80EE5583687123D80CF30AFAC" unitRef="usd">129466000</us-gaap:StockholdersEquity>
	<us-gaap:StockholdersEquity contextRef="FI2016Q4_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember" decimals="-3" id="Fact-7559B9D17E4D555EBB000D6EAC6B3504" unitRef="usd">295535000</us-gaap:StockholdersEquity>
	<us-gaap:StockholdersEquity contextRef="FI2016Q4_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember" decimals="-3" id="Fact-4518354851155CB39BDAAA04A808AED4" unitRef="usd">292000</us-gaap:StockholdersEquity>
	<us-gaap:StockholdersEquity contextRef="FI2016Q4_us-gaap_StatementEquityComponentsAxis_us-gaap_RetainedEarningsMember" decimals="-3" id="Fact-3103D02E37FE5D449AC4FAA278692E05" unitRef="usd">-165508000</us-gaap:StockholdersEquity>
	<us-gaap:StockholdersEquity contextRef="FI2016Q4_us-gaap_StatementEquityComponentsAxis_us-gaap_TreasuryStockMember" decimals="-3" id="Fact-85CA180E14F9557BA7751D3E1424BB0C" unitRef="usd">-853000</us-gaap:StockholdersEquity>
	<us-gaap:StockholdersEquity contextRef="FI2017Q3" decimals="-3" id="Fact-14EC8AB16A3A5625B6197F05C1C62327" unitRef="usd">106464000</us-gaap:StockholdersEquity>
	<us-gaap:StockholdersEquity contextRef="FI2017Q3_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember" decimals="-3" id="Fact-DFD86B11A88F5B33AFEE784F31297579" unitRef="usd">331036000</us-gaap:StockholdersEquity>
	<us-gaap:StockholdersEquity contextRef="FI2017Q3_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember" decimals="-3" id="Fact-FC12279E8FAB5EAAAAE0AFE61E5FCB2D" unitRef="usd">314000</us-gaap:StockholdersEquity>
	<us-gaap:StockholdersEquity contextRef="FI2017Q3_us-gaap_StatementEquityComponentsAxis_us-gaap_RetainedEarningsMember" decimals="-3" id="Fact-2584AE3C4F735CB7B7F46D38D3EACCA3" unitRef="usd">-223773000</us-gaap:StockholdersEquity>
	<us-gaap:StockholdersEquity contextRef="FI2017Q3_us-gaap_StatementEquityComponentsAxis_us-gaap_TreasuryStockMember" decimals="-3" id="Fact-546B2187D50359798DAB6F24515F996E" unitRef="usd">-1113000</us-gaap:StockholdersEquity>
	<us-gaap:TangibleAssetImpairmentCharges contextRef="FD2016Q4YTD" decimals="-5" id="Fact-3F9E816FFB215FA6AC61535815B04764" unitRef="usd">4000000</us-gaap:TangibleAssetImpairmentCharges>
	<us-gaap:TreasuryStockShares contextRef="FI2016Q4" decimals="INF" id="Fact-DD1388FB803157D8AB17137C50B62F08" unitRef="shares">30045</us-gaap:TreasuryStockShares>
	<us-gaap:TreasuryStockShares contextRef="FI2017Q3" decimals="INF" id="Fact-653E115C86CC5EA8B0F4412861299DC9" unitRef="shares">55777</us-gaap:TreasuryStockShares>
	<us-gaap:TreasuryStockValue contextRef="FI2016Q4" decimals="-3" id="Fact-BC50A3896C085595A6884F6AD6BBB3BA" unitRef="usd">853000</us-gaap:TreasuryStockValue>
	<us-gaap:TreasuryStockValue contextRef="FI2017Q3" decimals="-3" id="Fact-CBDA077BC0505D53B0D15731A64189D9" unitRef="usd">1113000</us-gaap:TreasuryStockValue>
	<us-gaap:WeightedAverageNumberOfShareOutstandingBasicAndDiluted contextRef="FD2016Q3QTD" decimals="0" id="Fact-E1440696110D5F96A8A44245CBDC7CD9" unitRef="shares">28983561</us-gaap:WeightedAverageNumberOfShareOutstandingBasicAndDiluted>
	<us-gaap:WeightedAverageNumberOfShareOutstandingBasicAndDiluted contextRef="FD2016Q3YTD" decimals="0" id="Fact-2D26BCE398FD5DC2BC768CF2F9638FE1" unitRef="shares">28911042</us-gaap:WeightedAverageNumberOfShareOutstandingBasicAndDiluted>
	<us-gaap:WeightedAverageNumberOfShareOutstandingBasicAndDiluted contextRef="FD2017Q3QTD" decimals="0" id="Fact-81F086F97E1F51FA9C52E44594C4F68A" unitRef="shares">29939823</us-gaap:WeightedAverageNumberOfShareOutstandingBasicAndDiluted>
	<us-gaap:WeightedAverageNumberOfShareOutstandingBasicAndDiluted contextRef="FD2017Q3YTD" decimals="0" id="Fact-9E37CE283D03573DB15BD52E67D37EC9" unitRef="shares">29462226</us-gaap:WeightedAverageNumberOfShareOutstandingBasicAndDiluted>
	<us-gaap:BasisOfAccounting contextRef="FD2017Q3YTD" id="Fact-754F9789EB4F5EFB8DE301612F0721AC">&lt;div style="font-family:Times New Roman;font-size:10pt;"&gt;&lt;div style="line-height:120%;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;font-weight:bold;"&gt;Basis of Presentation&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-bottom:12px;padding-top:12px;text-align:justify;text-indent:29px;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;The accompanying unaudited condensed consolidated financial statements have been prepared and presented by the Company in accordance with U.S. generally accepted accounting principles (U.S.&amp;#160;GAAP) and the rules&amp;#160;and regulations of the U.S. Securities and Exchange Commission (the SEC), and, in management&amp;#8217;s opinion, reflect all adjustments necessary to present fairly the Company&amp;#8217;s interim condensed financial information.&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-bottom:12px;padding-top:12px;text-align:justify;text-indent:29px;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;Certain information and footnote disclosures normally included in the Company&amp;#8217;s annual financial statements prepared in accordance with U.S. GAAP have been condensed or omitted. The accompanying unaudited condensed consolidated financial statements should be read in conjunction with the audited consolidated financial statements for the year ended &lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;December&amp;#160;31, 2016&lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;, included in the Company&amp;#8217;s Annual Report on Form 10-K. There were no significant changes in the Company&amp;#8217;s accounting policies since the end of fiscal &lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;2016&lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;. The financial results for any interim period are not necessarily indicative of financial results for the full year.&lt;/font&gt;&lt;/div&gt;&lt;/div&gt;</us-gaap:BasisOfAccounting>
	<us-gaap:CollaborativeArrangementDisclosureTextBlock contextRef="FD2017Q3YTD" id="Fact-3C6872D6273D5C56B3A3312472022AF8">&lt;div style="font-family:Times New Roman;font-size:10pt;"&gt;&lt;div style="line-height:120%;padding-bottom:12px;padding-top:12px;text-align:justify;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;font-weight:bold;"&gt;License and Research Collaboration Agreements&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-bottom:12px;padding-top:12px;text-align:left;text-indent:30px;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;"&gt;Genentech, a Member of the Roche Group&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-bottom:12px;padding-top:12px;text-align:justify;text-indent:30px;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;In October 2014, the Company entered into an exclusive worldwide collaboration and license agreement with Genentech, or the Genentech Agreement, for the development and commercialization of navoximod (GDC-0919), one of the Company's clinical stage IDO pathway inhibitors. The parties also entered into a research collaboration for the discovery of next generation IDO and TDO pathway inhibitors to be developed and commercialized under this agreement.  Under the terms of the Genentech Agreement, the Company received a nonrefundable upfront cash payment of &lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;$150.0 million&lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt; from Genentech in 2014 and is eligible to receive additional milestone payments of up to &lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;$561.0 million&lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt; upon achieving certain Next Generation Product Development regulatory development, international patent acceptance, country marketing approval, and sales-based milestones. The Company retains the right to exercise an option to co-promote any products for the U.S. market and is also eligible to receive escalating  royalty payments on potential commercial sales of products by Genentech. &lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-bottom:12px;padding-top:12px;text-align:justify;text-indent:30px;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;On June 6, 2017, the Company received a formal notice of Genentech&amp;#8217;s intent to terminate the Genentech Agreement with respect to navoximod with such termination to be effective no later than December 6, 2017.  Discussions regarding the termination are ongoing.  The Genentech Agreement continues with regards to any Next Generation Products as defined under the Genentech Agreement.&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-bottom:12px;padding-top:12px;text-align:justify;text-indent:30px;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;For the &lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;three and nine months ended&lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt; &lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;September&amp;#160;30, 2017&lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;, the Company recognized license and collaboration revenue under the Genentech Agreement of &lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;$56,000&lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt; and &lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;$279,000&lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;, respectively, for providing an alliance manager.  For the &lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;three months ended&lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt; &lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;September&amp;#160;30, 2016&lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;, the Company recognized license and collaboration revenue under the Genentech Agreement of &lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;$687,000&lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;, including &lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;$486,000&lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt; for amounts received as reimbursement for the Company's employees working on the project, and &lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;$201,000&lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt; for providing an alliance manager. For the &lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;nine months ended&lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt; &lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;September&amp;#160;30, 2016&lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;, the Company recognized license and collaboration revenue under the Genentech Agreement of &lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;$2.2 million&lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;, including &lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;$1.6 million&lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt; for amounts received as reimbursement for the Company's employees working on the project, &lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;$502,000&lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt; for providing an alliance manager, and &lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;$101,000&lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt; for participation in the joint research committee. In accordance with the Company&amp;#8217;s continuing performance obligation, &lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;$112,000&lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt; of the &lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;$150.0 million&lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt; upfront payment remains deferred as of &lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;September&amp;#160;30, 2017&lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt; and will be recognized during the remainder of 2017. The upfront payment provides no general right of return for any non-contingent deliverable and no portion of any revenue recognized is refundable.&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-bottom:12px;padding-top:12px;text-align:left;text-indent:30px;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;"&gt;Merck Sharp &amp;amp; Dohme Corp. &lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-bottom:12px;padding-top:12px;text-align:justify;text-indent:30px;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;In November 2014, the Company entered into a licensing and collaboration agreement with Merck, or the Merck Agreement, to develop, manufacture and commercialize rVSV-ZEBOV GP, an Ebola vaccine the Company licensed from the Public Health Agency of Canada, or PHAC.  Under the terms of the Merck Agreement, the Company granted Merck an exclusive, royalty bearing license to rVSV-ZEBOV GP and related technology. Under the Merck Agreement, the Company received a &lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;$30.0 million&lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt; non-refundable, upfront payment in December 2014, and a one-time &lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;$20.0 million&lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt; non-refundable milestone payment in February 2015 upon the initiation of the pivotal clinical trial using the current rVSV-ZEBOV GP vaccine product as one arm of the trial. In addition, the Company can receive escalating royalties on potential commercial sales by Merck of the current product candidate ranging from single digit to double digits on the rVSV-ZEBOV GP license agreement product sales and escalating royalties on potential commercial sales by Merck of products other than current products within the Company&amp;#8217;s patent rights ranging from low to high single digit, on increasing levels of annual net sales worldwide. Merck will lead the development of rVSV-ZEBOV GP and any other rVSV-based viral hemorrhagic fever vaccine product candidates in order to create a marketable product safe for human use.&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-bottom:12px;padding-top:12px;text-align:justify;text-indent:30px;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;The Company completed all deliverables under the Merck Agreement in their entirety during the year ended &lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;December&amp;#160;31, 2016&lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;. For the &lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;three months ended&lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt; &lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;September&amp;#160;30, 2016&lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;, the Company recognized &lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;no&lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt; revenues under the Merck Agreement. For the &lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;nine months ended&lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt; &lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;September&amp;#160;30, 2016&lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;, the Company recognized license and collaboration revenues under the Merck Agreement of &lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;$764,000&lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;, for the reimbursement of costs not covered under government contracts.&lt;/font&gt;&lt;/div&gt;&lt;/div&gt;</us-gaap:CollaborativeArrangementDisclosureTextBlock>
	<us-gaap:CommitmentsAndContingenciesDisclosureTextBlock contextRef="FD2017Q3YTD" id="Fact-7DA32413F4165A119BEE6BD99DC169EB">&lt;div style="font-family:Times New Roman;font-size:10pt;"&gt;&lt;div style="line-height:120%;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;font-weight:bold;"&gt;Commitments and Contingencies &lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-bottom:12px;padding-top:12px;text-align:justify;text-indent:30px;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;From time to time, claims are asserted against the Company arising in the ordinary course of business. In the opinion of management, liabilities, if any, arising from existing claims are not expected to have a material effect on the Company's earnings, financial position, or liquidity.&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-bottom:12px;text-align:justify;text-indent:30px;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;On or about May 12, 2016, Trevor Abramson filed a putative securities class action lawsuit in the United States District Court for the Southern District of New York, or the Court, captioned Abramson v. NewLink Genetics Corp., et al., Case 1:16-cv-3545, or the Securities Action. &amp;#160;Subsequently, the Court appointed Michael and Kelly Nguyen as lead plaintiffs and approved their selection of Kahn, Swick &amp;amp; Foti, LLC as lead counsel in the Securities Action.&amp;#160;&amp;#160;On October 31, 2016, the lead plaintiffs filed an amended complaint which asserts claims under the federal securities laws against the Company, the Company&amp;#8217;s Chief Executive Officer Charles J. Link, Jr., and the Company&amp;#8217;s Chief Medical Officer and President Nicholas Vahanian, or collectively, the Defendants.&amp;#160; The amended complaint alleges the Defendants made material false and/or misleading statements that caused losses to the Company&amp;#8217;s investors. In particular, the lead plaintiffs allege that the Defendants made material misstatements or omissions related to the Phase II and III trials and efficacy of the product candidate algenpantucel-L. The lead plaintiffs do not quantify any alleged damages in the amended complaint but, in addition to attorneys&amp;#8217; fees and costs, they seek to recover damages on behalf of themselves and other persons who purchased or otherwise acquired the Company&amp;#8217;s stock during the putative class period of September 17, 2013 through May 9, 2016, inclusive, at allegedly inflated prices and purportedly suffered financial harm as a result.  On April 27, 2017, the Court granted the parties&amp;#8217; request for leave to brief a motion to dismiss the amended complaint, and ordered the parties to file a stipulation and proposed order setting forth a schedule for the briefing of that motion. &amp;#160;On May 15, 2017, the Court ordered the following briefing schedule: motion to dismiss due July 14, 2017, opposition due September 12, 2017, and reply due September 26, 2017.&amp;#160; The Defendants filed a motion to dismiss on July 14, 2017. The lead plaintiffs filed an opposition to the motion to dismiss on September 12, 2017. The Defendants filed a reply in support of the motion to dismiss on September 26, 2017. Oral argument was held on October 19, 2017, after which the Court reserved decision. The Company disputes the claims in the Securities Action and intends to defend against them vigorously.&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;text-align:justify;text-indent:30px;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;On or about April 26, 2017, Ronald Morrow filed a shareholder derivative lawsuit on behalf of the Company in the United States District Court for the Southern District of New York, or the Court, against the Company&amp;#8217;s Chief Executive Officer Charles J. Link, Jr., the Company&amp;#8217;s Chief Medical Officer and President Nicholas Vahanian, and Company directors Thomas A. Raffin, Joseph Saluri, Ernest J. Talarico, III, Paul R. Edick, Paolo Pucci, and Lota S. Zoth, or collectively, the Morrow Defendants, captioned Morrow v. Link., et al., Case 1:17-cv-03039, or the Morrow Action.&amp;#160; The complaint alleges that the Morrow Defendants caused the Company to issue false statements in its 2016 proxy statement regarding risk management and compensation matters in violation of federal securities law.&amp;#160; The complaint also asserts state law claims against the Morrow Defendants for breaches of fiduciary duties, unjust enrichment, abuse of control, insider trading, gross mismanagement, and corporate waste, alleging that the Morrow Defendants made material misstatements or omissions related to the Phase II and III trials and efficacy of the product candidate algenpantucel-L, awarded themselves excessive compensation, engaged in illegal insider trading, and grossly mismanaged the Company.&amp;#160; The plaintiff does not quantify any alleged damages in the complaint but seeks restitution for damages to the Company, attorneys&amp;#8217; fees, costs, and expenses, as well as an order directing that proposals for strengthening board oversight be put to a vote of the Company&amp;#8217;s shareholders. &amp;#160;The language for such proposals is not specified in the complaint.&amp;#160; The plaintiff also contemporaneously filed a statement of relatedness, informing the Court that the Morrow Action is related to Abramson v. NewLink Genetics Corp., et al., Case 1:16-cv-3545.&amp;#160; On May 19, 2017, the plaintiff dismissed the Morrow Action without prejudice.&amp;#160; Also on May 19, 2017, plaintiffs&amp;#8217; counsel in the Morrow Action filed a new shareholder derivative complaint that is substantively identical to the Morrow Action, except that the plaintiff is Rickey Ely.&amp;#160; The latter action is captioned Ely v. Link, et al., Case 17-cv-3799, or the Ely Action.&amp;#160; By agreement of the parties and order dated June 26, 2017, the Court temporarily stayed the Ely Action until the Securities Action is dismissed or otherwise resolved.&amp;#160; Under the terms of the stay, the plaintiff in the Ely Action will be provided with any discovery that is provided in the Securities Action, and given an opportunity to participate in any mediation or settlement efforts in the Securities Action.&amp;#160; The Company disputes the claims in the Ely Action and intends to defend against them vigorously.&lt;/font&gt;&lt;/div&gt;&lt;/div&gt;</us-gaap:CommitmentsAndContingenciesDisclosureTextBlock>
	<us-gaap:ConcentrationRiskCreditRisk contextRef="FD2017Q3YTD" id="Fact-AA920CB9FAD85B7B9467C0C085E361BD">&lt;div style="font-family:Times New Roman;font-size:10pt;"&gt;&lt;div style="line-height:120%;padding-bottom:12px;padding-top:12px;text-align:justify;text-indent:30px;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;Financial instruments that potentially subject the Company to concentrations of credit risk consist primarily of cash and cash equivalents. Cash and cash equivalents are held by financial institutions and are federally insured up to certain limits. At times, the Company&amp;#8217;s cash and cash equivalents balance exceeds the federally insured limits. To limit the credit risk, the Company invests its excess cash primarily in high-quality securities such as certificates of deposit and money market funds.&lt;/font&gt;&lt;/div&gt;&lt;/div&gt;</us-gaap:ConcentrationRiskCreditRisk>
	<us-gaap:ConsolidationPolicyTextBlock contextRef="FD2017Q3YTD" id="Fact-E5895B21691C5E0E9E28CFD92680AF59">&lt;div style="font-family:Times New Roman;font-size:10pt;"&gt;&lt;div style="line-height:120%;padding-bottom:12px;padding-top:12px;text-align:justify;text-indent:18px;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;"&gt;Principles of Consolidation&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-bottom:12px;padding-top:12px;text-align:justify;text-indent:32px;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;The condensed consolidated financial statements include the financial statements of NewLink and its wholly owned subsidiaries.  All significant intercompany balances and transactions have been eliminated in consolidation.&lt;/font&gt;&lt;/div&gt;&lt;/div&gt;</us-gaap:ConsolidationPolicyTextBlock>
	<us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock contextRef="FD2017Q3YTD" id="Fact-2E8500E6183757B18E1797E1D9DBC36F">&lt;div style="font-family:Times New Roman;font-size:10pt;"&gt;&lt;div style="line-height:120%;padding-bottom:12px;padding-top:12px;text-align:justify;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;font-weight:bold;"&gt;Common Stock Equity Incentive Plan&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-bottom:12px;padding-top:12px;text-indent:30px;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;"&gt;2009 Equity Incentive Plan&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-bottom:12px;padding-top:12px;text-align:justify;text-indent:32px;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;In April 2000, the stockholders approved the Company's 2000 Equity Incentive Plan, or the 2000 Plan, and in July 2009, the stockholders approved the Company's 2009 Equity Incentive Plan, or the 2009 Plan. Following the approval of the 2009 Plan, all options outstanding under the 2000 Plan are effectively included under the 2009 Plan. Under the provisions of the 2009 Plan, the Company may grant the following types of common stock awards:&lt;/font&gt;&lt;/div&gt;&lt;table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"&gt;&lt;tr&gt;&lt;td style="width:48px;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top" rowspan="1" colspan="1"&gt;&lt;div style="line-height:120%;font-size:10pt;padding-left:24px;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#8226;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:top;" rowspan="1" colspan="1"&gt;&lt;div style="line-height:120%;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;Incentive Stock Options&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"&gt;&lt;tr&gt;&lt;td style="width:48px;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top" rowspan="1" colspan="1"&gt;&lt;div style="line-height:120%;font-size:10pt;padding-left:24px;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#8226;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:top;" rowspan="1" colspan="1"&gt;&lt;div style="line-height:120%;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;Nonstatutory Stock Options&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"&gt;&lt;tr&gt;&lt;td style="width:48px;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top" rowspan="1" colspan="1"&gt;&lt;div style="line-height:120%;font-size:10pt;padding-left:24px;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#8226;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:top;" rowspan="1" colspan="1"&gt;&lt;div style="line-height:120%;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;Restricted Stock Awards&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"&gt;&lt;tr&gt;&lt;td style="width:48px;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top" rowspan="1" colspan="1"&gt;&lt;div style="line-height:120%;font-size:10pt;padding-left:24px;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#8226;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:top;" rowspan="1" colspan="1"&gt;&lt;div style="line-height:120%;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;Stock Appreciation Rights&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;div style="line-height:120%;padding-bottom:12px;padding-top:12px;text-align:justify;text-indent:32px;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;Awards under the 2009 Plan, as amended, may be made to officers, employees, members of the Board of Directors, advisors, and consultants to the Company.  As of &lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;September&amp;#160;30, 2017&lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;, there were &lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;10,238,220&lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt; shares of common stock authorized for the 2009 Plan and &lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;1,094,264&lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt; shares remained available for issuance.&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-bottom:12px;padding-top:12px;text-align:justify;text-indent:32px;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;The following table summarizes the authorized increases of common stock under the 2009 Plan:&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-bottom:12px;padding-top:12px;text-align:center;text-indent:32px;font-size:10pt;"&gt;&lt;div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"&gt;&lt;table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:57.421875%;border-collapse:collapse;text-align:left;"&gt;&lt;tr&gt;&lt;td colspan="4" rowspan="1"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="width:43%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:55%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:center;font-size:9pt;"&gt;&lt;font style="font-family:inherit;font-size:9pt;font-weight:bold;"&gt;Date Authorized&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:9pt;"&gt;&lt;font style="font-family:inherit;font-size:9pt;font-weight:bold;"&gt;Authorized Shares Added&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:9pt;"&gt;&lt;font style="font-family:inherit;font-size:9pt;"&gt;May 15, 2010&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:9pt;"&gt;&lt;font style="font-family:inherit;font-size:9pt;"&gt;1,238,095&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:9pt;"&gt;&lt;font style="font-family:inherit;font-size:9pt;"&gt;January 7, 2011&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:9pt;"&gt;&lt;font style="font-family:inherit;font-size:9pt;"&gt;714,286&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:9pt;"&gt;&lt;font style="font-family:inherit;font-size:9pt;"&gt;January 1, 2013&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:9pt;"&gt;&lt;font style="font-family:inherit;font-size:9pt;"&gt;838,375&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:9pt;"&gt;&lt;font style="font-family:inherit;font-size:9pt;"&gt;January 1, 2014&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:9pt;"&gt;&lt;font style="font-family:inherit;font-size:9pt;"&gt;1,066,340&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:9pt;"&gt;&lt;font style="font-family:inherit;font-size:9pt;"&gt;January 1, 2015&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:9pt;"&gt;&lt;font style="font-family:inherit;font-size:9pt;"&gt;1,119,255&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:9pt;"&gt;&lt;font style="font-family:inherit;font-size:9pt;"&gt;January 1, 2016&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:9pt;"&gt;&lt;font style="font-family:inherit;font-size:9pt;"&gt;1,152,565&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:9pt;"&gt;&lt;font style="font-family:inherit;font-size:9pt;"&gt;January 1, 2017&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:9pt;"&gt;&lt;font style="font-family:inherit;font-size:9pt;"&gt;1,166,546&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-bottom:12px;padding-top:12px;text-align:justify;text-indent:32px;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;The increases in the authorized shares of common stock under the 2009 Plan in 2010 and 2011 were approved by the Company&amp;#8217;s stockholders. The increases in the authorized shares of common stock under the 2009 Plan in 2012 through 2017 were made pursuant to an &amp;#8220;evergreen provision,&amp;#8221; in accordance with which, on January 1 of each year, from 2012 to (and including) 2019, a number of shares of common stock in an amount equal to &lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;4%&lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt; of the total number of shares of common stock outstanding on December 31 of the preceding calendar year, or such lesser amount of shares (or no shares) approved by the Company's Board of Directors, was added or will be added to the shares reserved under the 2009 Plan. &lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-bottom:12px;padding-top:12px;text-align:justify;text-indent:32px;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;"&gt;2010 Non-Employee Directors' Stock Award Plan&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-bottom:12px;padding-top:12px;text-align:justify;text-indent:32px;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;Under the terms of the Company&amp;#8217;s 2010 Non-Employee Directors&amp;#8217; Stock Award Plan, or the Directors&amp;#8217; Plan, which became effective on November 10, 2011, &lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;238,095&lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt; shares of common stock were reserved for future issuance. On &lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;May&amp;#160;9, 2013&lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;, an additional &lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;161,905&lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt; shares of common stock were added to the shares reserved for future issuance under the Directors' Plan.  As of &lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;September&amp;#160;30, 2017&lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;, &lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;no&lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt; shares remained available for issuance under the Directors' Plan.&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-bottom:12px;padding-top:12px;text-align:justify;text-indent:32px;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;"&gt;2010 Employee Stock Purchase Plan&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-bottom:12px;padding-top:12px;text-align:justify;text-indent:32px;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;Under the terms of the Company&amp;#8217;s 2010 Employee Stock Purchase Plan, or the 2010 Purchase Plan, which became effective on November 10, 2011, &lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;214,285&lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt; shares of common stock were reserved for future issuance. On &lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;May&amp;#160;9, 2013&lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;, an additional &lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;185,715&lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt; shares of common stock were added to the shares reserved for future issuance under the 2010 Purchase Plan. As of &lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;September&amp;#160;30, 2017&lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;, &lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;120,784&lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt; shares remained available for issuance under the 2010 Purchase Plan.&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-bottom:12px;padding-top:12px;text-align:justify;text-indent:32px;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;"&gt;Share-based Compensation&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-bottom:12px;padding-top:12px;text-align:justify;text-indent:32px;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;Share-based compensation expense for the &lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;three months ended&lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt; &lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;September&amp;#160;30, 2017&lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt; and &lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;2016&lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt; was &lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;$4.4 million&lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt; and &lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;$3.9 million&lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;, respectively, and was &lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;$14.9 million&lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt; and &lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;$13.1 million&lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;, respectively, for &lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;nine months ended&lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt; &lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;September&amp;#160;30, 2017&lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt; and &lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;2016&lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;.  Share-based compensation expense is allocated between research and development and general and administrative expenses within the condensed consolidated statements of operations. &lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-bottom:12px;padding-top:12px;text-align:justify;text-indent:32px;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;As of &lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;September&amp;#160;30, 2017&lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;, the total compensation cost related to nonvested option awards not yet recognized was &lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;$19.9 million&lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt; and the weighted-average period over which it is expected to be recognized is &lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;2.1 years&lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;.&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-bottom:12px;padding-top:12px;text-align:justify;text-indent:32px;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;"&gt;Stock Options and Performance Stock Options&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-bottom:12px;padding-top:12px;text-align:justify;text-indent:32px;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;The following table summarizes the stock option activity, including options with performance conditions, for the &lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;nine months ended&lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt; &lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;September&amp;#160;30, 2017&lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;:&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-bottom:12px;padding-top:12px;text-align:center;font-size:10pt;"&gt;&lt;div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"&gt;&lt;table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:551px;border-collapse:collapse;text-align:left;"&gt;&lt;tr&gt;&lt;td colspan="10" rowspan="1"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="width:226px;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:5px;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:94px;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:4px;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:5px;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:9px;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:83px;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:4px;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:5px;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:114px;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:inherit;font-size:8pt;font-weight:bold;"&gt;Number&lt;/font&gt;&lt;/div&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:inherit;font-size:8pt;font-weight:bold;"&gt;of options&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:inherit;font-size:8pt;font-weight:bold;"&gt;Weighted&lt;/font&gt;&lt;/div&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:inherit;font-size:8pt;font-weight:bold;"&gt;average&lt;/font&gt;&lt;/div&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:inherit;font-size:8pt;font-weight:bold;"&gt;exercise&lt;/font&gt;&lt;/div&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:inherit;font-size:8pt;font-weight:bold;"&gt;price&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:inherit;font-size:8pt;font-weight:bold;"&gt;Weighted average&lt;/font&gt;&lt;/div&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:inherit;font-size:8pt;font-weight:bold;"&gt;remaining contractual&lt;/font&gt;&lt;/div&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:inherit;font-size:8pt;font-weight:bold;"&gt;term (years)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;Outstanding at beginning of period&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;6,278,542&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;14.93&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;5.8&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;Options granted&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;1,439,287&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;11.78&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;Options exercised&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;(108,775&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;8.51&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;Options forfeited&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;(277,443&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;20.13&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;Options expired&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;(17,605&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;42.00&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;Outstanding at end of period&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;7,314,006&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;14.15&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;5.5&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;Options exercisable at end of period&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:3px double #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;5,456,602&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;border-top:3px double #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;12.65&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;4.4&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-bottom:12px;text-align:justify;text-indent:36px;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;The Company estimates the fair value of each stock option grant on the date of grant using a Black-Scholes option pricing model. For stock option grants issued with a market condition, the Company used a Monte Carlo simulation valuation model to determine the grant date fair value. &lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-bottom:12px;text-align:justify;text-indent:36px;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;The following table summarizes the range of assumptions used to estimate the fair value of stock options granted, including those options granted with a market condition, during the &lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;nine months ended&lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt; &lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;September&amp;#160;30, 2017&lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;:&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-bottom:12px;padding-top:12px;text-align:center;text-indent:32px;font-size:10pt;"&gt;&lt;div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"&gt;&lt;table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:63.0859375%;border-collapse:collapse;text-align:left;"&gt;&lt;tr&gt;&lt;td colspan="3" rowspan="1"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="width:68%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:31%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;Risk-free interest rate&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:center;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;1.9% to 2.2%&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;Expected dividend yield&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:center;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#8212;%&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;Expected volatility&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:center;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;68.9% to 73.2%&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;Expected term (in years)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:center;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;6.5 to 7.8&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;Weighted-average grant-date fair value per share&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:center;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;$7.81&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-bottom:12px;padding-top:12px;text-align:justify;text-indent:32px;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;The intrinsic value of options exercised during the &lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;nine months ended&lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt; &lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;September&amp;#160;30, 2017&lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt; was &lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;$924,164&lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;. The fair value of awards vested during the &lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;nine months ended&lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt; &lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;September&amp;#160;30, 2017&lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt; was &lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;$12.4 million&lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;. &lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-bottom:12px;padding-top:12px;text-align:justify;text-indent:32px;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;During the &lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;nine months ended&lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt; &lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;September&amp;#160;30, 2017&lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;, the Company&amp;#8217;s Board of Directors approved and granted &lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;388,144&lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt; shares of compensation and equity awards to certain executives with either market or performance conditions. The compensation and equity awards had a weighted average grant date fair value per share of $&lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;6.73&lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;.   The compensation and equity awards will vest upon the achievement of certain performance conditions. During the &lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;nine months ended&lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt; &lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;September&amp;#160;30, 2017&lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;, certain conditions were met which resulted in the vesting of &lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;194,070&lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt; shares and the recognition of &lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;$1.2 million&lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt; in stock compensation expense.&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-bottom:12px;padding-top:12px;text-align:justify;text-indent:32px;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;"&gt;Restricted Stock and Performance Restricted Stock&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-bottom:12px;padding-top:12px;text-align:justify;text-indent:32px;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;Restricted stock is common stock that is subject to restrictions, including risks of forfeiture, determined by the plan committee of the Board of Directors in its sole discretion, for as long as such common stock remains subject to any such restrictions.  A holder of restricted stock has all rights of a stockholder with respect to such stock, including the right to vote and to receive dividends thereon, except as otherwise provided in the award agreement relating to such award.  Restricted stock awards are classified as equity within the consolidated balance sheets.  The fair value of each restricted stock grant is estimated on the date of grant using the closing price of the Company's common stock on the NASDAQ Stock Market on the date of grant.&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-bottom:12px;padding-top:12px;text-align:justify;text-indent:30px;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;A summary of the Company's unvested restricted stock, including restricted stock with performance conditions, at &lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;September&amp;#160;30, 2017&lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt; and changes during the &lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;nine months ended&lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt; &lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;September&amp;#160;30, 2017&lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt; are as follows:&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-bottom:12px;padding-top:12px;text-align:center;text-indent:30px;font-size:10pt;"&gt;&lt;div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"&gt;&lt;table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:64.84375%;border-collapse:collapse;text-align:left;"&gt;&lt;tr&gt;&lt;td colspan="11" rowspan="1"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="width:57%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:19%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:16%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:inherit;font-size:8pt;font-weight:bold;"&gt;Number of restricted stock shares&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="5" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:inherit;font-size:8pt;font-weight:bold;"&gt;Weighted average grant date fair value&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;Unvested at beginning of period&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;288,964&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;34.94&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;Granted&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#8212;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#8212;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;Vested&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;(80,380&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;35.04&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;Forfeited/cancelled&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;(27,248&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;33.84&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;Unvested at end of period&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;181,336&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;35.05&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-bottom:12px;padding-top:12px;text-align:justify;text-indent:30px;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;As of &lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;September&amp;#160;30, 2017&lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;, the total remaining unrecognized compensation cost related to restricted stock was approximately &lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;$4.4 million&lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt; and is expected to be recognized over a weighted-average period of &lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;1.8 years&lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;. As of &lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;September&amp;#160;30, 2017&lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;, there remains approximately &lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;$6.4 million&lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt; of unrecognized compensation cost related to the issuance of performance restricted stock. The fair value of awards vested during the &lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;nine months ended&lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt; &lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;September&amp;#160;30, 2017&lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt; was &lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;$814,000&lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;.&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-bottom:12px;padding-top:12px;text-align:justify;text-indent:30px;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;The Company does not have a formal policy regarding the source of shares issued upon exercise of stock options or issuance of restricted stock. The Company expects shares issued to be issued from treasury shares or new shares.&lt;/font&gt;&lt;/div&gt;&lt;/div&gt;</us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock>
	<us-gaap:DisclosureOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTextBlock contextRef="FD2017Q3YTD" id="Fact-110D82E2303C5B688C67C529A582F039">&lt;div style="font-family:Times New Roman;font-size:10pt;"&gt;&lt;div style="line-height:120%;padding-bottom:12px;padding-top:12px;text-align:justify;text-indent:32px;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;The following table summarizes the authorized increases of common stock under the 2009 Plan:&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-bottom:12px;padding-top:12px;text-align:center;text-indent:32px;font-size:10pt;"&gt;&lt;div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"&gt;&lt;table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:57.421875%;border-collapse:collapse;text-align:left;"&gt;&lt;tr&gt;&lt;td colspan="4" rowspan="1"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="width:43%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:55%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:center;font-size:9pt;"&gt;&lt;font style="font-family:inherit;font-size:9pt;font-weight:bold;"&gt;Date Authorized&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:9pt;"&gt;&lt;font style="font-family:inherit;font-size:9pt;font-weight:bold;"&gt;Authorized Shares Added&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:9pt;"&gt;&lt;font style="font-family:inherit;font-size:9pt;"&gt;May 15, 2010&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:9pt;"&gt;&lt;font style="font-family:inherit;font-size:9pt;"&gt;1,238,095&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:9pt;"&gt;&lt;font style="font-family:inherit;font-size:9pt;"&gt;January 7, 2011&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:9pt;"&gt;&lt;font style="font-family:inherit;font-size:9pt;"&gt;714,286&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:9pt;"&gt;&lt;font style="font-family:inherit;font-size:9pt;"&gt;January 1, 2013&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:9pt;"&gt;&lt;font style="font-family:inherit;font-size:9pt;"&gt;838,375&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:9pt;"&gt;&lt;font style="font-family:inherit;font-size:9pt;"&gt;January 1, 2014&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:9pt;"&gt;&lt;font style="font-family:inherit;font-size:9pt;"&gt;1,066,340&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:9pt;"&gt;&lt;font style="font-family:inherit;font-size:9pt;"&gt;January 1, 2015&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:9pt;"&gt;&lt;font style="font-family:inherit;font-size:9pt;"&gt;1,119,255&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:9pt;"&gt;&lt;font style="font-family:inherit;font-size:9pt;"&gt;January 1, 2016&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:9pt;"&gt;&lt;font style="font-family:inherit;font-size:9pt;"&gt;1,152,565&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:9pt;"&gt;&lt;font style="font-family:inherit;font-size:9pt;"&gt;January 1, 2017&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:9pt;"&gt;&lt;font style="font-family:inherit;font-size:9pt;"&gt;1,166,546&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;</us-gaap:DisclosureOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTextBlock>
	<us-gaap:EarningsPerShareTextBlock contextRef="FD2017Q3YTD" id="Fact-5077A54795C352B2A791D6C240769FF5">&lt;div style="font-family:Times New Roman;font-size:10pt;"&gt;&lt;div style="line-height:120%;padding-bottom:12px;padding-top:12px;text-align:justify;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;font-weight:bold;"&gt;Net Loss per Common Share&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-bottom:12px;padding-top:12px;text-align:justify;text-indent:30px;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;Basic loss per share is based upon the weighted-average number of common shares outstanding during the period, without consideration of common stock equivalents. Diluted loss per share is based upon the weighted-average number of common shares outstanding during the period plus additional weighted-average potentially dilutive common stock equivalents during the period when the effect is dilutive.&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;text-align:justify;text-indent:30px;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;The following table presents the computation of basic and diluted loss per common share (in thousands, except share and per share data):&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;text-align:center;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt; &lt;/font&gt;&lt;div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"&gt;&lt;table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:639px;border-collapse:collapse;text-align:left;"&gt;&lt;tr&gt;&lt;td colspan="18" rowspan="1"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="width:292px;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:5px;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:9px;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:66px;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:4px;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:5px;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:9px;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:66px;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:4px;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:8px;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:9px;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:64px;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:4px;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:9px;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:9px;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:66px;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:4px;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:5px;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="7" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:9pt;"&gt;&lt;font style="font-family:inherit;font-size:9pt;font-weight:bold;"&gt;Three Months Ended September 30, &lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="7" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:9pt;"&gt;&lt;font style="font-family:inherit;font-size:9pt;font-weight:bold;"&gt;Nine Months Ended September 30, &lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;background-color:;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:9pt;"&gt;&lt;font style="font-family:inherit;font-size:9pt;font-weight:bold;"&gt;2017&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:9pt;"&gt;&lt;font style="font-family:inherit;font-size:9pt;font-weight:bold;"&gt;2016&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:9pt;"&gt;&lt;font style="font-family:inherit;font-size:9pt;font-weight:bold;"&gt;2017&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:9pt;"&gt;&lt;font style="font-family:inherit;font-size:9pt;font-weight:bold;"&gt;2016&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:middle;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;Loss attributable to common stockholders&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;(20,626&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;(15,540&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;(58,265&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;(71,649&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;height:5px;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;height:5px;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="overflow:hidden;height:5px;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;height:5px;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="overflow:hidden;height:5px;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;height:5px;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="overflow:hidden;height:5px;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;height:5px;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="overflow:hidden;height:5px;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;height:5px;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;background-color:;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;Basic and diluted weighted-average shares outstanding&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:3px double #000000;background-color:;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;29,939,823&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:3px double #000000;background-color:;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;28,983,561&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:3px double #000000;background-color:;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;29,462,226&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:3px double #000000;background-color:;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;28,911,042&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;height:8px;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;height:8px;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="overflow:hidden;height:8px;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;height:8px;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="overflow:hidden;height:8px;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;height:8px;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="overflow:hidden;height:8px;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;height:8px;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="overflow:hidden;height:8px;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;height:8px;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;Basic and diluted loss per share&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;(0.69&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;(0.54&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;(1.98&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;(2.48&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-bottom:10px;text-align:justify;text-indent:24px;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;text-align:justify;text-indent:24px;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;All common stock equivalents are excluded from the computation of diluted loss per share during periods in which losses are reported since the result would be anti-dilutive. As of &lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;September&amp;#160;30, 2017&lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;, anti-dilutive stock options and restricted stock awards excluded from our calculation totaled &lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;7,314,006&lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt; and &lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;181,336&lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;, respectively.  As of &lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;September 30,&lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt; &lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;2016&lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;, anti-dilutive stock options and restricted stock awards excluded from our calculation totaled &lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;6,453,331&lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt; and &lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;307,079&lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;, respectively.&lt;/font&gt;&lt;/div&gt;&lt;/div&gt;</us-gaap:EarningsPerShareTextBlock>
	<us-gaap:FairValueOfFinancialInstrumentsPolicy contextRef="FD2017Q3YTD" id="Fact-3D5596CC927F5A258A320BFA3B408B61">&lt;div style="font-family:Times New Roman;font-size:10pt;"&gt;&lt;div style="line-height:120%;padding-bottom:12px;padding-top:12px;text-align:justify;text-indent:18px;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;"&gt;Financial Instruments and Concentrations of Credit Risk&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-bottom:12px;padding-top:12px;text-align:justify;text-indent:30px;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;Cash and cash equivalents, receivables, and accounts payable are recorded at cost, which approximates fair value based on the short-term nature of these financial instruments. The carrying value of notes payable and capital lease obligations was &lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;$332,000&lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt; and &lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;$517,000&lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt; as of &lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;September&amp;#160;30, 2017&lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt; and &lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;December&amp;#160;31, 2016&lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;, respectively, which approximate fair value using Level 2 inputs (computed in accordance with ASC 820). The Company is unable to estimate the fair value of the royalty obligation based on future product sales, as the timing of payments, if any, is uncertain.  &lt;/font&gt;&lt;/div&gt;&lt;/div&gt;</us-gaap:FairValueOfFinancialInstrumentsPolicy>
	<us-gaap:IncomeTaxDisclosureTextBlock contextRef="FD2017Q3YTD" id="Fact-709228C34FA7579D8728F383E047C05E">&lt;div style="font-family:Times New Roman;font-size:10pt;"&gt;&lt;div style="line-height:120%;padding-bottom:12px;padding-top:12px;text-align:justify;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;font-weight:bold;"&gt;Income Taxes&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-bottom:12px;padding-top:12px;text-align:justify;text-indent:32px;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;For the &lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;three and nine months ended&lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt; &lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;September&amp;#160;30, 2017&lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;, the Company recorded an income tax benefit of &lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;$119,000&lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt; and &lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;$429,000&lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;, respectively.  For the &lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;three and nine months ended&lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt; &lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;September&amp;#160;30, 2016&lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;, the Company recorded an income tax benefit of &lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;$1.3 million&lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt; and &lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;$5.0 million&lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;, respectively. The income tax benefit for the &lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;three and nine months ended&lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt; &lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;September&amp;#160;30, 2017&lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt; differs from the amount that would be expected after applying the statutory U.S. federal income tax rate primarily due to the limited potential to carry back losses to 2015 and the net loss generated by NewLink's foreign subsidiary. Income tax benefit for the &lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;three and nine months ended&lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt; &lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;September&amp;#160;30, 2016&lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt; differs from the amount that would be expected after applying the statutory U.S. federal income tax rate primarily due to the ability to carry back losses to 2014 and the net loss generated by the NewLink's foreign subsidiary. &lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-bottom:12px;padding-top:12px;text-align:justify;text-indent:32px;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;In assessing the realizability of deferred tax assets, management considers whether it is more likely than not that some portion or all of the deferred tax assets will not be realized. The ultimate realization of deferred tax assets is dependent upon the generation of future taxable income during the periods in which those temporary differences become deductible. Management considers the scheduled reversal of deferred tax liabilities, projected taxable income, and tax planning strategies in making this assessment. Valuation allowances have been established for the entire amount of the net deferred tax assets as of &lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;September&amp;#160;30, 2017&lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt; and &lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;December&amp;#160;31, 2016&lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;, respectively, due to the uncertainty of future recoverability.&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-bottom:12px;padding-top:12px;text-align:justify;text-indent:32px;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;The Company has a reserve for uncertain tax positions related to state tax matters of &lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;$843,000&lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt; as of &lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;September&amp;#160;30, 2017&lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt; recorded within Accrued Expenses in the condensed consolidated balance sheet, which includes the accrual of interest and penalties. The Company does not expect the amount to change significantly within the next 12 months.&lt;/font&gt;&lt;/div&gt;&lt;/div&gt;</us-gaap:IncomeTaxDisclosureTextBlock>
	<us-gaap:LongTermDebtTextBlock contextRef="FD2017Q3YTD" id="Fact-45FEBAE1157751E49988EA33B7C2059F">&lt;div style="font-family:Times New Roman;font-size:10pt;"&gt;&lt;div style="line-height:120%;padding-bottom:12px;padding-top:12px;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;font-weight:bold;"&gt;Long-Term Debt &lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-bottom:12px;padding-top:12px;text-indent:30px;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;"&gt;March 2010 City of Ames Forgivable Loan&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-bottom:12px;padding-top:12px;text-align:justify;text-indent:30px;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;In March 2010, the Company entered into a &lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;$400,000&lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt; forgivable loan agreement with the City of Ames, Iowa and the Ames Chamber of Commerce, jointly, as lenders. The project provided the Company with financial assistance to construct new facilities within the Ames city limits. &lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-bottom:12px;padding-top:12px;text-align:justify;text-indent:30px;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;The project required the Company to create or retain at least &lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;150&lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt; full-time positions located in Ames, Iowa by March&amp;#160;10, 2016. The agreement required the Company to enter into a &lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;five&lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;-year building lease with the option for extension for an additional &lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;five&lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt; years of not less than &lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;20,000&lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt; square feet within the corporate limits of the City of Ames by March&amp;#160;10, 2015, which requirement was met prior to the deadline of March 10, 2015. As of March&amp;#160;10, 2016, the Company had satisfactorily fulfilled all of the above terms of the loan agreement and the loan was forgiven. Accordingly, the entire outstanding loan amount of &lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;$397,000&lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt; was derecognized with a corresponding amount recorded in grant revenue for the three months ended March 31, 2016.&lt;/font&gt;&lt;/div&gt;&lt;/div&gt;</us-gaap:LongTermDebtTextBlock>
	<us-gaap:NatureOfOperations contextRef="FD2017Q3YTD" id="Fact-55235110978552D89FFBA5E3E034906A">&lt;div style="font-family:Times New Roman;font-size:10pt;"&gt;&lt;div style="line-height:120%;padding-bottom:12px;padding-top:12px;text-align:justify;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;font-weight:bold;"&gt;D&lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;background-color:#ffffff;font-weight:bold;"&gt;escription of Business&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-bottom:12px;padding-top:12px;text-align:justify;text-indent:32px;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;On June&amp;#160;4, 1999, NewLink Genetics Corporation (NewLink) was incorporated as a Delaware corporation. NewLink was formed for the purpose of developing treatments for patients with cancer and other diseases. NewLink initiated operations in April 2000. &lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-bottom:12px;padding-top:12px;text-align:justify;text-indent:32px;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;NewLink and its subsidiaries (the Company) are devoting substantially all of their efforts toward research and development. The Company has never earned revenue from commercial sales of its drugs. The Company incurred a net loss of &lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;$20.6 million&lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt; and &lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;$58.3 million&lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt; for the &lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;three and nine months ended&lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt; &lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;September&amp;#160;30, 2017&lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;. &lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-bottom:12px;padding-top:12px;text-align:justify;text-indent:32px;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;In July 2017, the Company&amp;#160;undertook an organizational realignment to refocus its clinical development efforts and align the Company's resources to focus on the Company's highest value opportunities. The Company's restructuring activities included a reduction of its workforce by approximately &lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;50%&lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;, which consisted primarily of clinical and research and development staff, as well as stopping additional research on the Zika virus. Refer to Note 9 for more information.&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-bottom:12px;padding-top:12px;text-align:justify;text-indent:32px;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;The accompanying condensed consolidated financial statements as of &lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;September&amp;#160;30, 2017&lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt; and for the &lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;three and nine months ended&lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt; have been prepared assuming the Company will continue as a going concern. The Company successfully raised net proceeds of &lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;$37.6 million&lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt; from its IPO, completed a follow-on offering of its common stock raising net proceeds of &lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;$49.0 million&lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;, and raised an additional &lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;$58.7 million&lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt; in net proceeds from an at the market (ATM) offering completed in 2015.&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-bottom:12px;padding-top:12px;text-align:justify;text-indent:32px;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;On November 29, 2016, the Company entered into a Sales Agreement with Cantor Fitzgerald &amp;amp; Co. (Cantor) under which the Company may sell up to &lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;$40.0 million&lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt; of its common stock in one or more placements at prevailing market prices in an ATM offering. The Company launched this ATM offering in June 2017. During the &lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;three months ended&lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt; &lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;September&amp;#160;30, 2017&lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;, &lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;1,940,656&lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt; shares of the Company's common stock were sold under this ATM, with aggregate net proceeds of &lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;$19.3 million&lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt; after commissions of &lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;$398,000&lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt; paid to Cantor as the placement agent, and other costs of &lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;$163,000&lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt; . &lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-bottom:12px;padding-top:12px;text-align:justify;text-indent:32px;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;Subsequent to &lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;September&amp;#160;30, 2017&lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;, the Company sold &lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;5,750,000&lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt; of its shares of common stock in a public offering for aggregate net proceeds of &lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;$55.2 million&lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt; after underwriters' discounts, commissions and other expenses of &lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;$3.7 million&lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;.&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-bottom:12px;padding-top:12px;text-align:justify;text-indent:32px;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;In connection with &lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;two&lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt; license and collaboration agreements the Company entered into during 2014, the Company received a nonrefundable upfront cash payment of &lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;$150.0 million&lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt; from Genentech Inc., a member of the Roche Group, or Genentech, in 2014, and a nonrefundable upfront cash payment of &lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;$30.0 million&lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt; from Merck, Sharpe and Dohme Corp., or Merck, in 2014, as well as a milestone payment of &lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;$20.0 million&lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt; from Merck in February 2015. &lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-bottom:12px;padding-top:12px;text-align:justify;text-indent:32px;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;The Company's cash and cash equivalents after these agreements and the offerings are expected to be adequate to satisfy the Company's liquidity requirements into the second quarter of 2020. If available liquidity becomes insufficient to meet the Company&amp;#8217;s operating obligations as they come due, the Company's plans include pursuing alternative funding arrangements and/or reducing expenditures as necessary to meet the Company&amp;#8217;s cash requirements. However, there is no assurance that, if required, the Company will be able to raise additional capital or reduce discretionary spending to provide the required liquidity. Failure by the Company to successfully execute its plans or otherwise address its liquidity needs may have a material adverse effect on its business and financial position, and may materially affect the Company&amp;#8217;s ability to continue as a going concern.&lt;/font&gt;&lt;/div&gt;&lt;/div&gt;</us-gaap:NatureOfOperations>
	<us-gaap:NewAccountingPronouncementsPolicyPolicyTextBlock contextRef="FD2017Q3YTD" id="Fact-ADD32A7D76B6E2563338509EF578F605">&lt;div style="font-family:Times New Roman;font-size:10pt;"&gt;&lt;div style="line-height:120%;padding-bottom:12px;padding-top:12px;text-align:justify;text-indent:18px;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;"&gt;Recent Accounting Pronouncements&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;text-align:justify;text-indent:30px;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;On May 28, 2014, the FASB issued ASU No. 2014-09, Revenue from Contracts with Customers, which requires an entity to recognize the amount of revenue to which it expects to be entitled for the transfer of promised goods or services to customers. The ASU will replace most existing revenue recognition guidance in U.S. GAAP when it becomes effective. The new standard is effective for the Company on January 1, 2018. The standard permits the use of either the retrospective or cumulative effect transition method. The Company plans to adopt the standard on a modified retrospective basis at January 1, 2018, with an adjustment for the cumulative effect of all changes recognized in beginning retained earnings.  The Company does not expect to record any adjustment relating to the Company&amp;#8217;s licensing and collaboration agreements. The Company continues to assess the impact adoption will have on the government grant revenue contracts. &lt;/font&gt;&lt;/div&gt;&lt;/div&gt;</us-gaap:NewAccountingPronouncementsPolicyPolicyTextBlock>
	<us-gaap:NonvestedRestrictedStockSharesActivityTableTextBlock contextRef="FD2017Q3YTD" id="Fact-CA34897104125F77A5D29CEA40D55743">&lt;div style="font-family:Times New Roman;font-size:10pt;"&gt;&lt;div style="line-height:120%;padding-bottom:12px;padding-top:12px;text-align:justify;text-indent:30px;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;A summary of the Company's unvested restricted stock, including restricted stock with performance conditions, at &lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;September&amp;#160;30, 2017&lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt; and changes during the &lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;nine months ended&lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt; &lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;September&amp;#160;30, 2017&lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt; are as follows:&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-bottom:12px;padding-top:12px;text-align:center;text-indent:30px;font-size:10pt;"&gt;&lt;div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"&gt;&lt;table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:64.84375%;border-collapse:collapse;text-align:left;"&gt;&lt;tr&gt;&lt;td colspan="11" rowspan="1"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="width:57%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:19%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:16%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:inherit;font-size:8pt;font-weight:bold;"&gt;Number of restricted stock shares&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="5" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:inherit;font-size:8pt;font-weight:bold;"&gt;Weighted average grant date fair value&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;Unvested at beginning of period&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;288,964&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;34.94&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;Granted&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#8212;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#8212;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;Vested&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;(80,380&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;35.04&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;Forfeited/cancelled&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;(27,248&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;33.84&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;Unvested at end of period&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;181,336&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;35.05&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;</us-gaap:NonvestedRestrictedStockSharesActivityTableTextBlock>
	<us-gaap:PropertyPlantAndEquipmentPolicyTextBlock contextRef="FD2017Q3YTD" id="Fact-A0130D6E917D5BD3A25DD85832C42FE7">&lt;div style="font-family:Times New Roman;font-size:10pt;"&gt;&lt;div style="line-height:120%;padding-bottom:12px;padding-top:12px;text-align:justify;text-indent:18px;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;"&gt;Property and equipment&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-bottom:12px;padding-top:12px;text-align:justify;text-indent:30px;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;Property and equipment are capitalized as the Company believes they have alternative future uses and are stated at cost, less accumulated depreciation of &lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;$6.7 million&lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt; and &lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;$5.7 million&lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt; as of &lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;September&amp;#160;30, 2017&lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt; and &lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;December&amp;#160;31, 2016&lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;, respectively. Equipment under capital leases is stated at the present value of minimum lease payments. Depreciation on all property and equipment is calculated on the straight-line method over the shorter of the lease term or estimated useful life of the asset. Computer equipment has useful lives of &lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;three&lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt; to &lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;five&lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt; years, lab equipment has a useful life of &lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;five&lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt; years and contract manufacturing organization equipment has a useful life of &lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;five&lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt; years. &lt;/font&gt;&lt;/div&gt;&lt;/div&gt;</us-gaap:PropertyPlantAndEquipmentPolicyTextBlock>
	<us-gaap:RestructuringAndRelatedActivitiesDisclosureTextBlock contextRef="FD2017Q3YTD" id="Fact-C10362C7510A5A879AF64C2530DCFC28">&lt;div style="font-family:Times New Roman;font-size:10pt;"&gt;&lt;div style="line-height:120%;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;font-weight:bold;"&gt;Restructuring Charges&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-bottom:12px;padding-top:12px;text-align:justify;text-indent:30px;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;The Company records liabilities for costs associated with exit or disposal activities in the period in which the liability is incurred. Employee severance costs are accrued when the&amp;#160;restructuring&amp;#160;actions are probable and estimable. Costs for one-time termination benefits in which the employee is required to render service until termination in order to receive the benefits are recognized ratably over the future service period. The Company also records costs incurred with contract terminations associated with restructuring&amp;#160;activities. &lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-bottom:12px;padding-top:12px;text-align:justify;text-indent:30px;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;In July 2017, the Company&amp;#160;undertook an organizational realignment to refocus its clinical development efforts and align the Company's resources to focus on the Company's highest value opportunities. The Company's restructuring activities included a reduction of its workforce by approximately &lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;50%&lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;, which consisted primarily of clinical and research and development staff, as well as stopping additional research on the Zika virus.  Restructuring charges recorded during the &lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;three and nine months ended&lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt; &lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;September&amp;#160;30, 2017&lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt; included &lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;$1.7 million&lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt; in employee severance cost, which is comprised of one-time employee termination benefits and certain expenses related to contractual termination benefits for employees with pre-existing severance arrangements.  &lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;text-align:justify;text-indent:30px;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;In May 2016, the Company announced that its Phase 3 clinical trial Immunotherapy for Pancreatic RESectable cancer Study, or IMPRESS, of algenpantucel-L for patients with resected pancreatic cancer did not achieve its primary endpoint and in order to reduce costs associated with algenpantucel-L and the HyperAcute&amp;#174; Cellular Immunotherapy platform technology, the Company's management adopted a restructuring plan in May 2016 which included a reduction in the Company's workforce; the exit or reduction of certain leased facilities; and the renegotiation or termination of contracts with certain third parties. As a result of the restructuring, the Company also impaired fixed assets which management determined had no or limited future use. The fair value of impaired fixed assets was determined based on management&amp;#8217;s estimate of market resale value. Restructuring charges recorded during 2016 were &lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;$12.3 million&lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;, of which &lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;$500,000&lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt; is included within general and administrative expenses and &lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;$11.8 million&lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt; is included within the research and development expenses in the condensed consolidated statement of operations. Included in the &lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;$12.3 million&lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt; of charges is non-cash asset impairment charges of &lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;$4.0 million&lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;.  &lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;No&lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt; additional charges related to the 2016 restructuring were recorded during the &lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;three and nine months ended&lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt; &lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;September&amp;#160;30, 2017&lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt; and all amounts accrued as of December 31, 2016 were paid by the end of the first quarter of 2017.&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-bottom:12px;padding-top:12px;text-align:justify;text-indent:32px;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;The following table shows the amount accrued for restructuring activities which is recorded within Accrued Expenses in the condensed consolidated balance sheet:&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-bottom:12px;padding-top:12px;text-align:center;text-indent:32px;font-size:10pt;"&gt;&lt;div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"&gt;&lt;table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:428px;border-collapse:collapse;text-align:left;"&gt;&lt;tr&gt;&lt;td colspan="9" rowspan="1"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="width:200px;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:6px;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:9px;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:92px;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:4px;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:6px;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:9px;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:95px;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:4px;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:9pt;"&gt;&lt;font style="font-family:inherit;font-size:9pt;font-weight:bold;"&gt;Employee Severance Cost&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:9pt;"&gt;&lt;font style="font-family:inherit;font-size:9pt;font-weight:bold;"&gt;Total&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;Balance as of December 31, 2016&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;42&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;42&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;Expensed&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;1,695&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;1,695&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;Cash Payments&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;1,085&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;1,085&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;Balance as of September 30, 2017&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;652&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;652&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-bottom:12px;padding-top:12px;text-align:justify;text-indent:30px;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;The majority of the charges are expected to be paid by the end of the year.&lt;/font&gt;&lt;/div&gt;&lt;/div&gt;</us-gaap:RestructuringAndRelatedActivitiesDisclosureTextBlock>
	<us-gaap:RevenueRecognitionPolicyTextBlock contextRef="FD2017Q3YTD" id="Fact-F956D09D22575B3E9C8AEC124B7BB62B">&lt;div style="font-family:Times New Roman;font-size:10pt;"&gt;&lt;div style="line-height:120%;padding-bottom:12px;padding-top:12px;text-align:justify;text-indent:18px;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;"&gt;Revenue Recognition&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-bottom:12px;padding-top:12px;text-align:justify;text-indent:30px;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;The Company receives payments from government entities under its grants and contracts with the Department of Defense and the United States Department of Health and Human Services. These agreements provide the Company cost reimbursement plus a percentage for certain types of expenditures in return for research and development activities over a contractually defined period. Grant revenues are recognized in the period during which the related costs are incurred, provided that the conditions under which the costs submitted or to be submitted for reimbursement have been met and the Company has only perfunctory obligations outstanding. &lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-bottom:12px;padding-top:12px;text-align:justify;text-indent:30px;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;The Company had&amp;#160;&lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;$10.1 million&lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt; and &lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;$23.9 million&lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt; of receivables from the government contracts recorded in other receivables and &lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;$1.5 million&lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt; and &lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;$4.3 million&lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt; of unbilled expenses relating to the government contracts recorded in prepaid expenses and other current assets on the balance sheet as of &lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;September&amp;#160;30, 2017&lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt; and &lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;December&amp;#160;31, 2016&lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;, respectively. The Company had &lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;$1.4 million&lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt; and &lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;$2.9 million&lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt; of accrued expenses for subcontractor fees incurred under the government contracts as of &lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;September&amp;#160;30, 2017&lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt; and &lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;December&amp;#160;31, 2016&lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;, respectively.&lt;/font&gt;&lt;/div&gt;&lt;/div&gt;</us-gaap:RevenueRecognitionPolicyTextBlock>
	<us-gaap:ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock contextRef="FD2017Q3YTD" id="Fact-5AFBFEACF1BC58919B5E8202044B49F6">&lt;div style="font-family:Times New Roman;font-size:10pt;"&gt;&lt;div style="line-height:120%;text-align:justify;text-indent:30px;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;The following table presents the computation of basic and diluted loss per common share (in thousands, except share and per share data):&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;text-align:center;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt; &lt;/font&gt;&lt;div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"&gt;&lt;table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:639px;border-collapse:collapse;text-align:left;"&gt;&lt;tr&gt;&lt;td colspan="18" rowspan="1"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="width:292px;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:5px;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:9px;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:66px;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:4px;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:5px;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:9px;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:66px;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:4px;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:8px;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:9px;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:64px;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:4px;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:9px;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:9px;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:66px;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:4px;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:5px;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="7" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:9pt;"&gt;&lt;font style="font-family:inherit;font-size:9pt;font-weight:bold;"&gt;Three Months Ended September 30, &lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="7" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:9pt;"&gt;&lt;font style="font-family:inherit;font-size:9pt;font-weight:bold;"&gt;Nine Months Ended September 30, &lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;background-color:;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:9pt;"&gt;&lt;font style="font-family:inherit;font-size:9pt;font-weight:bold;"&gt;2017&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:9pt;"&gt;&lt;font style="font-family:inherit;font-size:9pt;font-weight:bold;"&gt;2016&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:9pt;"&gt;&lt;font style="font-family:inherit;font-size:9pt;font-weight:bold;"&gt;2017&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:9pt;"&gt;&lt;font style="font-family:inherit;font-size:9pt;font-weight:bold;"&gt;2016&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:middle;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;Loss attributable to common stockholders&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;(20,626&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;(15,540&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;(58,265&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;(71,649&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;height:5px;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;height:5px;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="overflow:hidden;height:5px;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;height:5px;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="overflow:hidden;height:5px;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;height:5px;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="overflow:hidden;height:5px;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;height:5px;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="overflow:hidden;height:5px;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;height:5px;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;background-color:;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;Basic and diluted weighted-average shares outstanding&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:3px double #000000;background-color:;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;29,939,823&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:3px double #000000;background-color:;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;28,983,561&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:3px double #000000;background-color:;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;29,462,226&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:3px double #000000;background-color:;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;28,911,042&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;height:8px;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;height:8px;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="overflow:hidden;height:8px;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;height:8px;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="overflow:hidden;height:8px;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;height:8px;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="overflow:hidden;height:8px;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;height:8px;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="overflow:hidden;height:8px;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;height:8px;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;Basic and diluted loss per share&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;(0.69&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;(0.54&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;(1.98&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;(2.48&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;</us-gaap:ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock>
	<us-gaap:ScheduleOfRestructuringReserveByTypeOfCostTextBlock contextRef="FD2017Q3YTD" id="Fact-2068BB2A6B825B6F950F3DB978C2FEF5">&lt;div style="font-family:Times New Roman;font-size:10pt;"&gt;&lt;div style="line-height:120%;padding-bottom:12px;padding-top:12px;text-align:justify;text-indent:32px;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;The following table shows the amount accrued for restructuring activities which is recorded within Accrued Expenses in the condensed consolidated balance sheet:&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-bottom:12px;padding-top:12px;text-align:center;text-indent:32px;font-size:10pt;"&gt;&lt;div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"&gt;&lt;table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:428px;border-collapse:collapse;text-align:left;"&gt;&lt;tr&gt;&lt;td colspan="9" rowspan="1"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="width:200px;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:6px;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:9px;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:92px;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:4px;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:6px;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:9px;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:95px;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:4px;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:9pt;"&gt;&lt;font style="font-family:inherit;font-size:9pt;font-weight:bold;"&gt;Employee Severance Cost&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:9pt;"&gt;&lt;font style="font-family:inherit;font-size:9pt;font-weight:bold;"&gt;Total&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;Balance as of December 31, 2016&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;42&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;42&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;Expensed&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;1,695&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;1,695&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;Cash Payments&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;1,085&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;1,085&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;Balance as of September 30, 2017&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;652&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;652&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;</us-gaap:ScheduleOfRestructuringReserveByTypeOfCostTextBlock>
	<us-gaap:ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock contextRef="FD2017Q3YTD" id="Fact-A6D3D60BA5C35DBAB77D1C70CC0ED86F">&lt;div style="font-family:Times New Roman;font-size:10pt;"&gt;&lt;div style="line-height:120%;padding-bottom:12px;text-align:justify;text-indent:36px;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;The following table summarizes the range of assumptions used to estimate the fair value of stock options granted, including those options granted with a market condition, during the &lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;nine months ended&lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt; &lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;September&amp;#160;30, 2017&lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;:&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-bottom:12px;padding-top:12px;text-align:center;text-indent:32px;font-size:10pt;"&gt;&lt;div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"&gt;&lt;table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:63.0859375%;border-collapse:collapse;text-align:left;"&gt;&lt;tr&gt;&lt;td colspan="3" rowspan="1"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="width:68%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:31%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;Risk-free interest rate&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:center;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;1.9% to 2.2%&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;Expected dividend yield&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:center;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#8212;%&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;Expected volatility&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:center;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;68.9% to 73.2%&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;Expected term (in years)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:center;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;6.5 to 7.8&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;Weighted-average grant-date fair value per share&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:center;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;$7.81&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;</us-gaap:ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock>
	<us-gaap:ScheduleOfStockOptionsRollForwardTableTextBlock contextRef="FD2017Q3YTD" id="Fact-100C14F935A356C1B95A3B5CB6B5CC38">&lt;div style="font-family:Times New Roman;font-size:10pt;"&gt;&lt;div style="line-height:120%;padding-bottom:12px;padding-top:12px;text-align:justify;text-indent:32px;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;The following table summarizes the stock option activity, including options with performance conditions, for the &lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;nine months ended&lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt; &lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;September&amp;#160;30, 2017&lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;:&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-bottom:12px;padding-top:12px;text-align:center;font-size:10pt;"&gt;&lt;div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"&gt;&lt;table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:551px;border-collapse:collapse;text-align:left;"&gt;&lt;tr&gt;&lt;td colspan="10" rowspan="1"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="width:226px;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:5px;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:94px;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:4px;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:5px;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:9px;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:83px;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:4px;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:5px;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:114px;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:inherit;font-size:8pt;font-weight:bold;"&gt;Number&lt;/font&gt;&lt;/div&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:inherit;font-size:8pt;font-weight:bold;"&gt;of options&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:inherit;font-size:8pt;font-weight:bold;"&gt;Weighted&lt;/font&gt;&lt;/div&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:inherit;font-size:8pt;font-weight:bold;"&gt;average&lt;/font&gt;&lt;/div&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:inherit;font-size:8pt;font-weight:bold;"&gt;exercise&lt;/font&gt;&lt;/div&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:inherit;font-size:8pt;font-weight:bold;"&gt;price&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:inherit;font-size:8pt;font-weight:bold;"&gt;Weighted average&lt;/font&gt;&lt;/div&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:inherit;font-size:8pt;font-weight:bold;"&gt;remaining contractual&lt;/font&gt;&lt;/div&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:inherit;font-size:8pt;font-weight:bold;"&gt;term (years)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;Outstanding at beginning of period&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;6,278,542&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;14.93&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;5.8&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;Options granted&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;1,439,287&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;11.78&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;Options exercised&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;(108,775&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;8.51&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;Options forfeited&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;(277,443&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;20.13&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;Options expired&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;(17,605&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;42.00&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;Outstanding at end of period&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;7,314,006&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;14.15&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;5.5&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;Options exercisable at end of period&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:3px double #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;5,456,602&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;border-top:3px double #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;12.65&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;4.4&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;</us-gaap:ScheduleOfStockOptionsRollForwardTableTextBlock>
	<us-gaap:SignificantAccountingPoliciesTextBlock contextRef="FD2017Q3YTD" id="Fact-6A1DDBCF2EE95CF8A57EEF6929596ADC">&lt;div style="font-family:Times New Roman;font-size:10pt;"&gt;&lt;div style="line-height:120%;padding-bottom:12px;padding-top:12px;text-align:justify;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;font-weight:bold;"&gt;Significant Accounting Policies&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-bottom:12px;padding-top:12px;text-align:justify;text-indent:18px;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;"&gt;Use of Estimates&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-bottom:12px;padding-top:12px;text-align:justify;text-indent:32px;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;The preparation of the condensed consolidated financial statements in conformity with U.S.&amp;#160;GAAP requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the condensed consolidated financial statements and the reported amounts of revenues and expenses during the reporting period. Actual results could differ from those estimates.&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-bottom:12px;padding-top:12px;text-align:justify;text-indent:18px;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;"&gt;Principles of Consolidation&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-bottom:12px;padding-top:12px;text-align:justify;text-indent:32px;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;The condensed consolidated financial statements include the financial statements of NewLink and its wholly owned subsidiaries.  All significant intercompany balances and transactions have been eliminated in consolidation.&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-bottom:12px;padding-top:12px;text-align:justify;text-indent:18px;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;"&gt;Financial Instruments and Concentrations of Credit Risk&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-bottom:12px;padding-top:12px;text-align:justify;text-indent:30px;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;Cash and cash equivalents, receivables, and accounts payable are recorded at cost, which approximates fair value based on the short-term nature of these financial instruments. The carrying value of notes payable and capital lease obligations was &lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;$332,000&lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt; and &lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;$517,000&lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt; as of &lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;September&amp;#160;30, 2017&lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt; and &lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;December&amp;#160;31, 2016&lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;, respectively, which approximate fair value using Level 2 inputs (computed in accordance with ASC 820). The Company is unable to estimate the fair value of the royalty obligation based on future product sales, as the timing of payments, if any, is uncertain.  &lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-bottom:12px;padding-top:12px;text-align:justify;text-indent:30px;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;Financial instruments that potentially subject the Company to concentrations of credit risk consist primarily of cash and cash equivalents. Cash and cash equivalents are held by financial institutions and are federally insured up to certain limits. At times, the Company&amp;#8217;s cash and cash equivalents balance exceeds the federally insured limits. To limit the credit risk, the Company invests its excess cash primarily in high-quality securities such as certificates of deposit and money market funds.&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-bottom:12px;padding-top:12px;text-align:justify;text-indent:18px;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;"&gt;Property and equipment&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-bottom:12px;padding-top:12px;text-align:justify;text-indent:30px;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;Property and equipment are capitalized as the Company believes they have alternative future uses and are stated at cost, less accumulated depreciation of &lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;$6.7 million&lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt; and &lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;$5.7 million&lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt; as of &lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;September&amp;#160;30, 2017&lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt; and &lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;December&amp;#160;31, 2016&lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;, respectively. Equipment under capital leases is stated at the present value of minimum lease payments. Depreciation on all property and equipment is calculated on the straight-line method over the shorter of the lease term or estimated useful life of the asset. Computer equipment has useful lives of &lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;three&lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt; to &lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;five&lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt; years, lab equipment has a useful life of &lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;five&lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt; years and contract manufacturing organization equipment has a useful life of &lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;five&lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt; years. &lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-bottom:12px;padding-top:12px;text-align:justify;text-indent:18px;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;"&gt;Revenue Recognition&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-bottom:12px;padding-top:12px;text-align:justify;text-indent:30px;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;The Company receives payments from government entities under its grants and contracts with the Department of Defense and the United States Department of Health and Human Services. These agreements provide the Company cost reimbursement plus a percentage for certain types of expenditures in return for research and development activities over a contractually defined period. Grant revenues are recognized in the period during which the related costs are incurred, provided that the conditions under which the costs submitted or to be submitted for reimbursement have been met and the Company has only perfunctory obligations outstanding. &lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-bottom:12px;padding-top:12px;text-align:justify;text-indent:30px;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;The Company had&amp;#160;&lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;$10.1 million&lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt; and &lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;$23.9 million&lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt; of receivables from the government contracts recorded in other receivables and &lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;$1.5 million&lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt; and &lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;$4.3 million&lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt; of unbilled expenses relating to the government contracts recorded in prepaid expenses and other current assets on the balance sheet as of &lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;September&amp;#160;30, 2017&lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt; and &lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;December&amp;#160;31, 2016&lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;, respectively. The Company had &lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;$1.4 million&lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt; and &lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;$2.9 million&lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt; of accrued expenses for subcontractor fees incurred under the government contracts as of &lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;September&amp;#160;30, 2017&lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt; and &lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;December&amp;#160;31, 2016&lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;, respectively. &lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-bottom:12px;padding-top:12px;text-align:justify;text-indent:18px;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;"&gt;Recent Accounting Pronouncements&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;text-align:justify;text-indent:30px;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;On May 28, 2014, the FASB issued ASU No. 2014-09, Revenue from Contracts with Customers, which requires an entity to recognize the amount of revenue to which it expects to be entitled for the transfer of promised goods or services to customers. The ASU will replace most existing revenue recognition guidance in U.S. GAAP when it becomes effective. The new standard is effective for the Company on January 1, 2018. The standard permits the use of either the retrospective or cumulative effect transition method. The Company plans to adopt the standard on a modified retrospective basis at January 1, 2018, with an adjustment for the cumulative effect of all changes recognized in beginning retained earnings.  The Company does not expect to record any adjustment relating to the Company&amp;#8217;s licensing and collaboration agreements. The Company continues to assess the impact adoption will have on the government grant revenue contracts.&lt;/font&gt;&lt;/div&gt;&lt;/div&gt;</us-gaap:SignificantAccountingPoliciesTextBlock>
	<us-gaap:SubsequentEventsTextBlock contextRef="FD2017Q3YTD" id="Fact-4F758B273CD359398BE5892D6B44D81D">&lt;div style="font-family:Times New Roman;font-size:10pt;"&gt;&lt;div style="line-height:120%;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;font-weight:bold;"&gt;Subsequent Events&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-bottom:12px;padding-top:12px;text-align:justify;text-indent:30px;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;On October 6, 2017, the Company sold &lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;5,750,000&lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt; shares of its common stock for total proceeds of &lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;$55.2 million&lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;, net of offering expenses of &lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;$3.7 million&lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;. Net proceeds from the offering will be used to further advance its pipeline of product candidates, including the continued clinical development of indoximod, and for working capital and other general corporate purposes.&lt;/font&gt;&lt;/div&gt;&lt;/div&gt;</us-gaap:SubsequentEventsTextBlock>
	<us-gaap:UseOfEstimates contextRef="FD2017Q3YTD" id="Fact-AB7618F4ED995A2EB501E6A61A5DFCCD">&lt;div style="font-family:Times New Roman;font-size:10pt;"&gt;&lt;div style="line-height:120%;padding-bottom:12px;padding-top:12px;text-align:justify;text-indent:18px;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;"&gt;Use of Estimates&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-bottom:12px;padding-top:12px;text-align:justify;text-indent:32px;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;The preparation of the condensed consolidated financial statements in conformity with U.S.&amp;#160;GAAP requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the condensed consolidated financial statements and the reported amounts of revenues and expenses during the reporting period. Actual results could differ from those estimates.&lt;/font&gt;&lt;/div&gt;&lt;/div&gt;</us-gaap:UseOfEstimates>
	<link:footnoteLink xlink:role="http://www.xbrl.org/2003/role/link" xlink:type="extended">
	</link:footnoteLink>
</xbrli:xbrl>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.SCH
<SEQUENCE>6
<FILENAME>nlnk-20170930.xsd
<DESCRIPTION>XBRL TAXONOMY EXTENSION SCHEMA DOCUMENT
<TEXT>
<XBRL>
<?xml version="1.0" encoding="US-ASCII"?>
<!--XBRL Document Created with Wdesk from Workiva-->
<!-- -->
<xsd:schema attributeFormDefault="unqualified" elementFormDefault="qualified" targetNamespace="http://www.linkp.com/20170930" xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:nlnk="http://www.linkp.com/20170930" xmlns:nonnum="http://www.xbrl.org/dtr/type/non-numeric" xmlns:num="http://www.xbrl.org/dtr/type/numeric" xmlns:xbrldt="http://xbrl.org/2005/xbrldt" xmlns:xbrli="http://www.xbrl.org/2003/instance" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsd="http://www.w3.org/2001/XMLSchema">
  <xsd:import namespace="http://fasb.org/us-gaap/2017-01-31" schemaLocation="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd" />
  <xsd:import namespace="http://fasb.org/us-roles/2017-01-31" schemaLocation="http://xbrl.fasb.org/us-gaap/2017/elts/us-roles-2017-01-31.xsd" />
  <xsd:import namespace="http://fasb.org/us-types/2017-01-31" schemaLocation="http://xbrl.fasb.org/us-gaap/2017/elts/us-types-2017-01-31.xsd" />
  <xsd:import namespace="http://www.xbrl.org/2003/instance" schemaLocation="http://www.xbrl.org/2003/xbrl-instance-2003-12-31.xsd" />
  <xsd:import namespace="http://www.xbrl.org/2003/linkbase" schemaLocation="http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd" />
  <xsd:import namespace="http://www.xbrl.org/2009/arcrole/fact-explanatoryFact" schemaLocation="http://www.xbrl.org/lrr/arcrole/factExplanatory-2009-12-16.xsd" />
  <xsd:import namespace="http://www.xbrl.org/2009/role/negated" schemaLocation="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd" />
  <xsd:import namespace="http://www.xbrl.org/2009/role/net" schemaLocation="http://www.xbrl.org/lrr/role/net-2009-12-16.xsd" />
  <xsd:import namespace="http://www.xbrl.org/dtr/type/non-numeric" schemaLocation="http://www.xbrl.org/dtr/type/nonNumeric-2009-12-16.xsd" />
  <xsd:import namespace="http://www.xbrl.org/dtr/type/numeric" schemaLocation="http://www.xbrl.org/dtr/type/numeric-2009-12-16.xsd" />
  <xsd:import namespace="http://xbrl.org/2005/xbrldt" schemaLocation="http://www.xbrl.org/2005/xbrldt-2005.xsd" />
  <xsd:import namespace="http://xbrl.sec.gov/country/2017-01-31" schemaLocation="http://xbrl.sec.gov/country/2017/country-2017-01-31.xsd" />
  <xsd:import namespace="http://xbrl.sec.gov/currency/2017-01-31" schemaLocation="http://xbrl.sec.gov/currency/2017/currency-2017-01-31.xsd" />
  <xsd:import namespace="http://xbrl.sec.gov/dei/2014-01-31" schemaLocation="http://xbrl.sec.gov/dei/2014/dei-2014-01-31.xsd" />
  <xsd:import namespace="http://xbrl.sec.gov/exch/2017-01-31" schemaLocation="http://xbrl.sec.gov/exch/2017/exch-2017-01-31.xsd" />
  <xsd:import namespace="http://xbrl.sec.gov/invest/2013-01-31" schemaLocation="http://xbrl.sec.gov/invest/2013/invest-2013-01-31.xsd" />
  <xsd:import namespace="http://xbrl.sec.gov/naics/2017-01-31" schemaLocation="http://xbrl.sec.gov/naics/2017/naics-2017-01-31.xsd" />
  <xsd:import namespace="http://xbrl.sec.gov/sic/2011-01-31" schemaLocation="http://xbrl.sec.gov/sic/2011/sic-2011-01-31.xsd" />
  <xsd:import namespace="http://xbrl.sec.gov/stpr/2011-01-31" schemaLocation="http://xbrl.sec.gov/stpr/2011/stpr-2011-01-31.xsd" />
  <xsd:annotation>
    <xsd:appinfo>
      <link:linkbaseRef xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" xlink:href="nlnk-20170930_cal.xml" xlink:role="http://www.xbrl.org/2003/role/calculationLinkbaseRef" xlink:type="simple" />
      <link:linkbaseRef xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" xlink:href="nlnk-20170930_def.xml" xlink:role="http://www.xbrl.org/2003/role/definitionLinkbaseRef" xlink:type="simple" />
      <link:linkbaseRef xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" xlink:href="nlnk-20170930_lab.xml" xlink:role="http://www.xbrl.org/2003/role/labelLinkbaseRef" xlink:type="simple" />
      <link:linkbaseRef xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" xlink:href="nlnk-20170930_pre.xml" xlink:role="http://www.xbrl.org/2003/role/presentationLinkbaseRef" xlink:type="simple" />
      <link:roleType id="BasisOfPresentation" roleURI="http://www.linkp.com/role/BasisOfPresentation">
        <link:definition>2102100 - Disclosure - Basis of Presentation</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="CommitmentsAndContingencies" roleURI="http://www.linkp.com/role/CommitmentsAndContingencies">
        <link:definition>2110100 - Disclosure - Commitments and Contingencies</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="CommonStockEquityIncentivePlan" roleURI="http://www.linkp.com/role/CommonStockEquityIncentivePlan">
        <link:definition>2106100 - Disclosure - Common Stock Equity Incentive Plan</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="CommonStockEquityIncentivePlanAuthorizedIncreasesOfCommonStockDetails" roleURI="http://www.linkp.com/role/CommonStockEquityIncentivePlanAuthorizedIncreasesOfCommonStockDetails">
        <link:definition>2406403 - Disclosure - Common Stock Equity Incentive Plan (Authorized Increases of Common Stock) (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="CommonStockEquityIncentivePlanNarrativedetails" roleURI="http://www.linkp.com/role/CommonStockEquityIncentivePlanNarrativedetails">
        <link:definition>2406402 - Disclosure - Common Stock Equity Incentive Plan (Narrative)(Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="CommonStockEquityIncentivePlanRangeOfAssumptionsUsedDetails" roleURI="http://www.linkp.com/role/CommonStockEquityIncentivePlanRangeOfAssumptionsUsedDetails">
        <link:definition>2406405 - Disclosure - Common Stock Equity Incentive Plan (Range of Assumptions Used) (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="CommonStockEquityIncentivePlanRestrictedStockActivityDetails" roleURI="http://www.linkp.com/role/CommonStockEquityIncentivePlanRestrictedStockActivityDetails">
        <link:definition>2406406 - Disclosure - Common Stock Equity Incentive Plan (Restricted Stock Activity) (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="CommonStockEquityIncentivePlanStockOptionActivityDetails" roleURI="http://www.linkp.com/role/CommonStockEquityIncentivePlanStockOptionActivityDetails">
        <link:definition>2406404 - Disclosure - Common Stock Equity Incentive Plan (Stock Option Activity) (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="CommonStockEquityIncentivePlanTables" roleURI="http://www.linkp.com/role/CommonStockEquityIncentivePlanTables">
        <link:definition>2306301 - Disclosure - Common Stock Equity Incentive Plan (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="CondensedConsolidatedBalanceSheets" roleURI="http://www.linkp.com/role/CondensedConsolidatedBalanceSheets">
        <link:definition>1001000 - Statement - Condensed Consolidated Balance Sheets</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="CondensedConsolidatedBalanceSheetsParentheticals" roleURI="http://www.linkp.com/role/CondensedConsolidatedBalanceSheetsParentheticals">
        <link:definition>1001501 - Statement - Condensed Consolidated Balance Sheets (Parentheticals)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="CondensedConsolidatedStatementOfStockholdersEquity" roleURI="http://www.linkp.com/role/CondensedConsolidatedStatementOfStockholdersEquity">
        <link:definition>1003000 - Statement - Condensed Consolidated Statement of Stockholders' Equity</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="CondensedConsolidatedStatementOfStockholdersEquityParentheticals" roleURI="http://www.linkp.com/role/CondensedConsolidatedStatementOfStockholdersEquityParentheticals">
        <link:definition>1003501 - Statement - Condensed Consolidated Statement of Stockholders' Equity (Parentheticals)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="CondensedConsolidatedStatementsOfCashFlows" roleURI="http://www.linkp.com/role/CondensedConsolidatedStatementsOfCashFlows">
        <link:definition>1004000 - Statement - Condensed Consolidated Statements of Cash Flows</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="CondensedConsolidatedStatementsOfOperations" roleURI="http://www.linkp.com/role/CondensedConsolidatedStatementsOfOperations">
        <link:definition>1002000 - Statement - Condensed Consolidated Statements of Operations</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="DescriptionOfBusiness" roleURI="http://www.linkp.com/role/DescriptionOfBusiness">
        <link:definition>2101100 - Disclosure - Description of Business</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="DescriptionOfBusinessDetails" roleURI="http://www.linkp.com/role/DescriptionOfBusinessDetails">
        <link:definition>2401401 - Disclosure - Description of Business (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="DocumentAndEntityInformation" roleURI="http://www.linkp.com/role/DocumentAndEntityInformation">
        <link:definition>0000000 - Document - Document and Entity Information</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="IncomeTaxes" roleURI="http://www.linkp.com/role/IncomeTaxes">
        <link:definition>2107100 - Disclosure - Income Taxes</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="IncomeTaxesDetails" roleURI="http://www.linkp.com/role/IncomeTaxesDetails">
        <link:definition>2407401 - Disclosure - Income Taxes (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="LicenseAndResearchCollaborationAgreements" roleURI="http://www.linkp.com/role/LicenseAndResearchCollaborationAgreements">
        <link:definition>2105100 - Disclosure - License and Research Collaboration Agreements</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="LicenseAndResearchCollaborationAgreementsDetails" roleURI="http://www.linkp.com/role/LicenseAndResearchCollaborationAgreementsDetails">
        <link:definition>2405401 - Disclosure - License and Research Collaboration Agreements (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="LongTermDebt" roleURI="http://www.linkp.com/role/LongTermDebt">
        <link:definition>2104100 - Disclosure - Long-Term Debt</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="LongTermDebtDetails" roleURI="http://www.linkp.com/role/LongTermDebtDetails">
        <link:definition>2404401 - Disclosure - Long-Term Debt (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="NetLossPerCommonShare" roleURI="http://www.linkp.com/role/NetLossPerCommonShare">
        <link:definition>2108100 - Disclosure - Net Loss per Common Share</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="NetLossPerCommonShareAntidilutiveSecuritiesDetails" roleURI="http://www.linkp.com/role/NetLossPerCommonShareAntidilutiveSecuritiesDetails">
        <link:definition>2408403 - Disclosure - Net Loss per Common Share (Antidilutive Securities) (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="NetLossPerCommonShareNetLossPerShareComputationDetails" roleURI="http://www.linkp.com/role/NetLossPerCommonShareNetLossPerShareComputationDetails">
        <link:definition>2408402 - Disclosure - Net Loss per Common Share (Net Loss Per Share Computation) (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="NetLossPerCommonShareTables" roleURI="http://www.linkp.com/role/NetLossPerCommonShareTables">
        <link:definition>2308301 - Disclosure - Net Loss per Common Share (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="RestructuringCharges" roleURI="http://www.linkp.com/role/RestructuringCharges">
        <link:definition>2109100 - Disclosure - Restructuring Charges</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="RestructuringChargesDetails" roleURI="http://www.linkp.com/role/RestructuringChargesDetails">
        <link:definition>2409402 - Disclosure - Restructuring Charges (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="RestructuringChargesTables" roleURI="http://www.linkp.com/role/RestructuringChargesTables">
        <link:definition>2309301 - Disclosure - Restructuring Charges (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="SignificantAccountingPolicies" roleURI="http://www.linkp.com/role/SignificantAccountingPolicies">
        <link:definition>2103100 - Disclosure - Significant Accounting Policies</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="SignificantAccountingPoliciesDetails" roleURI="http://www.linkp.com/role/SignificantAccountingPoliciesDetails">
        <link:definition>2403402 - Disclosure - Significant Accounting Policies (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="SignificantAccountingPoliciesPolicies" roleURI="http://www.linkp.com/role/SignificantAccountingPoliciesPolicies">
        <link:definition>2203201 - Disclosure - Significant Accounting Policies (Policies)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="SubsequentEvents" roleURI="http://www.linkp.com/role/SubsequentEvents">
        <link:definition>2111100 - Disclosure - Subsequent Events</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="SubsequentEventsDetails" roleURI="http://www.linkp.com/role/SubsequentEventsDetails">
        <link:definition>2411401 - Disclosure - Subsequent Events (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
    </xsd:appinfo>
  </xsd:annotation>
  <xsd:element abstract="true" id="nlnk_A2009EquityIncentivePlanMember" name="A2009EquityIncentivePlanMember" nillable="true" substitutionGroup="xbrli:item" type="nonnum:domainItemType" xbrli:periodType="duration" />
  <xsd:element abstract="true" id="nlnk_A2010EmployeeStockPurchasePlanMember" name="A2010EmployeeStockPurchasePlanMember" nillable="true" substitutionGroup="xbrli:item" type="nonnum:domainItemType" xbrli:periodType="duration" />
  <xsd:element abstract="true" id="nlnk_A2010NonEmployeeDirectorsStockOptionPlanMember" name="A2010NonEmployeeDirectorsStockOptionPlanMember" nillable="true" substitutionGroup="xbrli:item" type="nonnum:domainItemType" xbrli:periodType="duration" />
  <xsd:element abstract="true" id="nlnk_ATMOfferingMember" name="ATMOfferingMember" nillable="true" substitutionGroup="xbrli:item" type="nonnum:domainItemType" xbrli:periodType="duration" />
  <xsd:element abstract="true" id="nlnk_CityOfAmesForgivableLoan2010Member" name="CityOfAmesForgivableLoan2010Member" nillable="true" substitutionGroup="xbrli:item" type="nonnum:domainItemType" xbrli:periodType="duration" />
  <xsd:element id="nlnk_CollaborativeArrangementNumberofArrangements" name="CollaborativeArrangementNumberofArrangements" nillable="true" substitutionGroup="xbrli:item" type="xbrli:integerItemType" xbrli:periodType="duration" />
  <xsd:element abstract="true" id="nlnk_ContractManufacturingOrganizationEquipmentMember" name="ContractManufacturingOrganizationEquipmentMember" nillable="true" substitutionGroup="xbrli:item" type="nonnum:domainItemType" xbrli:periodType="duration" />
  <xsd:element id="nlnk_DebtInstrumentCovenantRequiredMinimumLeaseArea" name="DebtInstrumentCovenantRequiredMinimumLeaseArea" nillable="true" substitutionGroup="xbrli:item" type="num:areaItemType" xbrli:periodType="instant" />
  <xsd:element id="nlnk_DebtInstrumentCovenantRequiredNumberofPositionsCreationandRetention" name="DebtInstrumentCovenantRequiredNumberofPositionsCreationandRetention" nillable="true" substitutionGroup="xbrli:item" type="xbrli:integerItemType" xbrli:periodType="instant" />
  <xsd:element id="nlnk_DeferredGovernmentGrantsObligationsNoncurrent" name="DeferredGovernmentGrantsObligationsNoncurrent" nillable="true" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType" xbrli:balance="credit" xbrli:periodType="instant" />
  <xsd:element abstract="true" id="nlnk_DocumentAndEntityInformationAbstract" name="DocumentAndEntityInformationAbstract" nillable="true" substitutionGroup="xbrli:item" type="xbrli:stringItemType" xbrli:periodType="duration" />
  <xsd:element abstract="true" id="nlnk_FinancingsLineItems" name="FinancingsLineItems" nillable="true" substitutionGroup="xbrli:item" type="xbrli:stringItemType" xbrli:periodType="duration" />
  <xsd:element abstract="true" id="nlnk_FinancingsTable" name="FinancingsTable" nillable="true" substitutionGroup="xbrldt:hypercubeItem" type="xbrli:stringItemType" xbrli:periodType="duration" />
  <xsd:element abstract="true" id="nlnk_FollowOnOfferingMember" name="FollowOnOfferingMember" nillable="true" substitutionGroup="xbrli:item" type="nonnum:domainItemType" xbrli:periodType="duration" />
  <xsd:element abstract="true" id="nlnk_GenentechInc.Member" name="GenentechInc.Member" nillable="true" substitutionGroup="xbrli:item" type="nonnum:domainItemType" xbrli:periodType="duration" />
  <xsd:element id="nlnk_GovernmentContractAccruedSubcontractorFees" name="GovernmentContractAccruedSubcontractorFees" nillable="true" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType" xbrli:balance="credit" xbrli:periodType="instant" />
  <xsd:element id="nlnk_LicenseRevenueCommitteeLabor" name="LicenseRevenueCommitteeLabor" nillable="true" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType" xbrli:balance="credit" xbrli:periodType="duration" />
  <xsd:element id="nlnk_LicenseRevenueEmployeeLabor" name="LicenseRevenueEmployeeLabor" nillable="true" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType" xbrli:balance="debit" xbrli:periodType="duration" />
  <xsd:element id="nlnk_LicenseRevenueManagerLabor" name="LicenseRevenueManagerLabor" nillable="true" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType" xbrli:balance="debit" xbrli:periodType="duration" />
  <xsd:element id="nlnk_MaximumAvailableUnderATMOffering" name="MaximumAvailableUnderATMOffering" nillable="true" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType" xbrli:balance="debit" xbrli:periodType="duration" />
  <xsd:element abstract="true" id="nlnk_MerckSharpeandDohmeCorpMember" name="MerckSharpeandDohmeCorpMember" nillable="true" substitutionGroup="xbrli:item" type="nonnum:domainItemType" xbrli:periodType="duration" />
  <xsd:element abstract="true" id="nlnk_PerformanceRestrictedStockMember" name="PerformanceRestrictedStockMember" nillable="true" substitutionGroup="xbrli:item" type="nonnum:domainItemType" xbrli:periodType="duration" />
  <xsd:element abstract="true" id="nlnk_PublicOfferingMember" name="PublicOfferingMember" nillable="true" substitutionGroup="xbrli:item" type="nonnum:domainItemType" xbrli:periodType="duration" />
  <xsd:element id="nlnk_RevenueRecogitionMilestoneMethodMaximumPotentialRevenue" name="RevenueRecogitionMilestoneMethodMaximumPotentialRevenue" nillable="true" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType" xbrli:balance="credit" xbrli:periodType="instant" />
  <xsd:element id="nlnk_SharebasedCompensationArrangementbySharebasedPaymentAwardPercentageofAuthorizedStockMaximum" name="SharebasedCompensationArrangementbySharebasedPaymentAwardPercentageofAuthorizedStockMaximum" nillable="true" substitutionGroup="xbrli:item" type="num:percentItemType" xbrli:periodType="duration" />
  <xsd:element abstract="true" id="nlnk_TwoThousandSixteenRestructuringPlanMember" name="TwoThousandSixteenRestructuringPlanMember" nillable="true" substitutionGroup="xbrli:item" type="nonnum:domainItemType" xbrli:periodType="duration" />
</xsd:schema>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.CAL
<SEQUENCE>7
<FILENAME>nlnk-20170930_cal.xml
<DESCRIPTION>XBRL TAXONOMY EXTENSION CALCULATION LINKBASE DOCUMENT
<TEXT>
<XBRL>
<?xml version="1.0" encoding="US-ASCII"?>
<!--XBRL Document Created with Wdesk from Workiva-->
<!-- -->
<link:linkbase xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd" xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance">
  <link:roleRef roleURI="http://www.linkp.com/role/BasisOfPresentation" xlink:href="nlnk-20170930.xsd#BasisOfPresentation" xlink:type="simple" />
  <link:roleRef roleURI="http://www.linkp.com/role/CommitmentsAndContingencies" xlink:href="nlnk-20170930.xsd#CommitmentsAndContingencies" xlink:type="simple" />
  <link:roleRef roleURI="http://www.linkp.com/role/CommonStockEquityIncentivePlan" xlink:href="nlnk-20170930.xsd#CommonStockEquityIncentivePlan" xlink:type="simple" />
  <link:roleRef roleURI="http://www.linkp.com/role/CommonStockEquityIncentivePlanAuthorizedIncreasesOfCommonStockDetails" xlink:href="nlnk-20170930.xsd#CommonStockEquityIncentivePlanAuthorizedIncreasesOfCommonStockDetails" xlink:type="simple" />
  <link:roleRef roleURI="http://www.linkp.com/role/CommonStockEquityIncentivePlanNarrativedetails" xlink:href="nlnk-20170930.xsd#CommonStockEquityIncentivePlanNarrativedetails" xlink:type="simple" />
  <link:roleRef roleURI="http://www.linkp.com/role/CommonStockEquityIncentivePlanRangeOfAssumptionsUsedDetails" xlink:href="nlnk-20170930.xsd#CommonStockEquityIncentivePlanRangeOfAssumptionsUsedDetails" xlink:type="simple" />
  <link:roleRef roleURI="http://www.linkp.com/role/CommonStockEquityIncentivePlanRestrictedStockActivityDetails" xlink:href="nlnk-20170930.xsd#CommonStockEquityIncentivePlanRestrictedStockActivityDetails" xlink:type="simple" />
  <link:roleRef roleURI="http://www.linkp.com/role/CommonStockEquityIncentivePlanStockOptionActivityDetails" xlink:href="nlnk-20170930.xsd#CommonStockEquityIncentivePlanStockOptionActivityDetails" xlink:type="simple" />
  <link:roleRef roleURI="http://www.linkp.com/role/CommonStockEquityIncentivePlanTables" xlink:href="nlnk-20170930.xsd#CommonStockEquityIncentivePlanTables" xlink:type="simple" />
  <link:roleRef roleURI="http://www.linkp.com/role/CondensedConsolidatedBalanceSheets" xlink:href="nlnk-20170930.xsd#CondensedConsolidatedBalanceSheets" xlink:type="simple" />
  <link:roleRef roleURI="http://www.linkp.com/role/CondensedConsolidatedBalanceSheetsParentheticals" xlink:href="nlnk-20170930.xsd#CondensedConsolidatedBalanceSheetsParentheticals" xlink:type="simple" />
  <link:roleRef roleURI="http://www.linkp.com/role/CondensedConsolidatedStatementOfStockholdersEquity" xlink:href="nlnk-20170930.xsd#CondensedConsolidatedStatementOfStockholdersEquity" xlink:type="simple" />
  <link:roleRef roleURI="http://www.linkp.com/role/CondensedConsolidatedStatementOfStockholdersEquityParentheticals" xlink:href="nlnk-20170930.xsd#CondensedConsolidatedStatementOfStockholdersEquityParentheticals" xlink:type="simple" />
  <link:roleRef roleURI="http://www.linkp.com/role/CondensedConsolidatedStatementsOfCashFlows" xlink:href="nlnk-20170930.xsd#CondensedConsolidatedStatementsOfCashFlows" xlink:type="simple" />
  <link:roleRef roleURI="http://www.linkp.com/role/CondensedConsolidatedStatementsOfOperations" xlink:href="nlnk-20170930.xsd#CondensedConsolidatedStatementsOfOperations" xlink:type="simple" />
  <link:roleRef roleURI="http://www.linkp.com/role/DescriptionOfBusiness" xlink:href="nlnk-20170930.xsd#DescriptionOfBusiness" xlink:type="simple" />
  <link:roleRef roleURI="http://www.linkp.com/role/DescriptionOfBusinessDetails" xlink:href="nlnk-20170930.xsd#DescriptionOfBusinessDetails" xlink:type="simple" />
  <link:roleRef roleURI="http://www.linkp.com/role/DocumentAndEntityInformation" xlink:href="nlnk-20170930.xsd#DocumentAndEntityInformation" xlink:type="simple" />
  <link:roleRef roleURI="http://www.linkp.com/role/IncomeTaxes" xlink:href="nlnk-20170930.xsd#IncomeTaxes" xlink:type="simple" />
  <link:roleRef roleURI="http://www.linkp.com/role/IncomeTaxesDetails" xlink:href="nlnk-20170930.xsd#IncomeTaxesDetails" xlink:type="simple" />
  <link:roleRef roleURI="http://www.linkp.com/role/LicenseAndResearchCollaborationAgreements" xlink:href="nlnk-20170930.xsd#LicenseAndResearchCollaborationAgreements" xlink:type="simple" />
  <link:roleRef roleURI="http://www.linkp.com/role/LicenseAndResearchCollaborationAgreementsDetails" xlink:href="nlnk-20170930.xsd#LicenseAndResearchCollaborationAgreementsDetails" xlink:type="simple" />
  <link:roleRef roleURI="http://www.linkp.com/role/LongTermDebt" xlink:href="nlnk-20170930.xsd#LongTermDebt" xlink:type="simple" />
  <link:roleRef roleURI="http://www.linkp.com/role/LongTermDebtDetails" xlink:href="nlnk-20170930.xsd#LongTermDebtDetails" xlink:type="simple" />
  <link:roleRef roleURI="http://www.linkp.com/role/NetLossPerCommonShare" xlink:href="nlnk-20170930.xsd#NetLossPerCommonShare" xlink:type="simple" />
  <link:roleRef roleURI="http://www.linkp.com/role/NetLossPerCommonShareAntidilutiveSecuritiesDetails" xlink:href="nlnk-20170930.xsd#NetLossPerCommonShareAntidilutiveSecuritiesDetails" xlink:type="simple" />
  <link:roleRef roleURI="http://www.linkp.com/role/NetLossPerCommonShareNetLossPerShareComputationDetails" xlink:href="nlnk-20170930.xsd#NetLossPerCommonShareNetLossPerShareComputationDetails" xlink:type="simple" />
  <link:roleRef roleURI="http://www.linkp.com/role/NetLossPerCommonShareTables" xlink:href="nlnk-20170930.xsd#NetLossPerCommonShareTables" xlink:type="simple" />
  <link:roleRef roleURI="http://www.linkp.com/role/RestructuringCharges" xlink:href="nlnk-20170930.xsd#RestructuringCharges" xlink:type="simple" />
  <link:roleRef roleURI="http://www.linkp.com/role/RestructuringChargesDetails" xlink:href="nlnk-20170930.xsd#RestructuringChargesDetails" xlink:type="simple" />
  <link:roleRef roleURI="http://www.linkp.com/role/RestructuringChargesTables" xlink:href="nlnk-20170930.xsd#RestructuringChargesTables" xlink:type="simple" />
  <link:roleRef roleURI="http://www.linkp.com/role/SignificantAccountingPolicies" xlink:href="nlnk-20170930.xsd#SignificantAccountingPolicies" xlink:type="simple" />
  <link:roleRef roleURI="http://www.linkp.com/role/SignificantAccountingPoliciesDetails" xlink:href="nlnk-20170930.xsd#SignificantAccountingPoliciesDetails" xlink:type="simple" />
  <link:roleRef roleURI="http://www.linkp.com/role/SignificantAccountingPoliciesPolicies" xlink:href="nlnk-20170930.xsd#SignificantAccountingPoliciesPolicies" xlink:type="simple" />
  <link:roleRef roleURI="http://www.linkp.com/role/SubsequentEvents" xlink:href="nlnk-20170930.xsd#SubsequentEvents" xlink:type="simple" />
  <link:roleRef roleURI="http://www.linkp.com/role/SubsequentEventsDetails" xlink:href="nlnk-20170930.xsd#SubsequentEventsDetails" xlink:type="simple" />
  <link:calculationLink xlink:role="http://www.linkp.com/role/BasisOfPresentation" xlink:type="extended" />
  <link:calculationLink xlink:role="http://www.linkp.com/role/CommitmentsAndContingencies" xlink:type="extended" />
  <link:calculationLink xlink:role="http://www.linkp.com/role/CommonStockEquityIncentivePlan" xlink:type="extended" />
  <link:calculationLink xlink:role="http://www.linkp.com/role/CommonStockEquityIncentivePlanAuthorizedIncreasesOfCommonStockDetails" xlink:type="extended" />
  <link:calculationLink xlink:role="http://www.linkp.com/role/CommonStockEquityIncentivePlanNarrativedetails" xlink:type="extended" />
  <link:calculationLink xlink:role="http://www.linkp.com/role/CommonStockEquityIncentivePlanRangeOfAssumptionsUsedDetails" xlink:type="extended" />
  <link:calculationLink xlink:role="http://www.linkp.com/role/CommonStockEquityIncentivePlanRestrictedStockActivityDetails" xlink:type="extended" />
  <link:calculationLink xlink:role="http://www.linkp.com/role/CommonStockEquityIncentivePlanStockOptionActivityDetails" xlink:type="extended" />
  <link:calculationLink xlink:role="http://www.linkp.com/role/CommonStockEquityIncentivePlanTables" xlink:type="extended" />
  <link:calculationLink xlink:role="http://www.linkp.com/role/CondensedConsolidatedBalanceSheets" xlink:type="extended">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_LiabilitiesAndStockholdersEquity" xlink:label="loc_us-gaap_LiabilitiesAndStockholdersEquity_159dcb00-b17e-17db-7098-be4159799459" xlink:type="locator" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_Liabilities" xlink:label="loc_us-gaap_Liabilities_d8bb821f-d155-9d4e-1738-736b4bf4cb19" xlink:type="locator" />
    <link:calculationArc order="1" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquity_159dcb00-b17e-17db-7098-be4159799459" xlink:to="loc_us-gaap_Liabilities_d8bb821f-d155-9d4e-1738-736b4bf4cb19" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_LiabilitiesCurrent" xlink:label="loc_us-gaap_LiabilitiesCurrent_f5e246cf-e80f-d00b-c8ed-4796aa2df4b4" xlink:type="locator" />
    <link:calculationArc order="1" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_Liabilities_d8bb821f-d155-9d4e-1738-736b4bf4cb19" xlink:to="loc_us-gaap_LiabilitiesCurrent_f5e246cf-e80f-d00b-c8ed-4796aa2df4b4" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_AccountsPayableCurrent" xlink:label="loc_us-gaap_AccountsPayableCurrent_7a72b51a-735c-1ad4-bd3f-d9bcf2d6a26d" xlink:type="locator" />
    <link:calculationArc order="1" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LiabilitiesCurrent_f5e246cf-e80f-d00b-c8ed-4796aa2df4b4" xlink:to="loc_us-gaap_AccountsPayableCurrent_7a72b51a-735c-1ad4-bd3f-d9bcf2d6a26d" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_AccruedLiabilitiesCurrent" xlink:label="loc_us-gaap_AccruedLiabilitiesCurrent_3fe8f96b-142b-97b1-3b39-b8d22cd10e98" xlink:type="locator" />
    <link:calculationArc order="2" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LiabilitiesCurrent_f5e246cf-e80f-d00b-c8ed-4796aa2df4b4" xlink:to="loc_us-gaap_AccruedLiabilitiesCurrent_3fe8f96b-142b-97b1-3b39-b8d22cd10e98" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_DeferredRevenueCurrent" xlink:label="loc_us-gaap_DeferredRevenueCurrent_98f473f8-2d19-99d7-6142-37f86ccd14ec" xlink:type="locator" />
    <link:calculationArc order="3" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LiabilitiesCurrent_f5e246cf-e80f-d00b-c8ed-4796aa2df4b4" xlink:to="loc_us-gaap_DeferredRevenueCurrent_98f473f8-2d19-99d7-6142-37f86ccd14ec" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_DeferredRentCreditCurrent" xlink:label="loc_us-gaap_DeferredRentCreditCurrent_19647a29-cf9d-afd8-c508-550f1bbe8b53" xlink:type="locator" />
    <link:calculationArc order="4" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LiabilitiesCurrent_f5e246cf-e80f-d00b-c8ed-4796aa2df4b4" xlink:to="loc_us-gaap_DeferredRentCreditCurrent_19647a29-cf9d-afd8-c508-550f1bbe8b53" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_LongTermDebtAndCapitalLeaseObligationsCurrent" xlink:label="loc_us-gaap_LongTermDebtAndCapitalLeaseObligationsCurrent_13aaa34e-8d7d-009a-bd8a-20360af7ca09" xlink:type="locator" />
    <link:calculationArc order="5" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LiabilitiesCurrent_f5e246cf-e80f-d00b-c8ed-4796aa2df4b4" xlink:to="loc_us-gaap_LongTermDebtAndCapitalLeaseObligationsCurrent_13aaa34e-8d7d-009a-bd8a-20360af7ca09" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_LiabilitiesNoncurrent" xlink:label="loc_us-gaap_LiabilitiesNoncurrent_ce6ab6ce-f8d5-dad6-a84c-2c96c7d59f75" xlink:type="locator" />
    <link:calculationArc order="2" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_Liabilities_d8bb821f-d155-9d4e-1738-736b4bf4cb19" xlink:to="loc_us-gaap_LiabilitiesNoncurrent_ce6ab6ce-f8d5-dad6-a84c-2c96c7d59f75" xlink:type="arc" />
    <link:loc xlink:href="nlnk-20170930.xsd#nlnk_DeferredGovernmentGrantsObligationsNoncurrent" xlink:label="loc_nlnk_DeferredGovernmentGrantsObligationsNoncurrent_A0B798C5C29F3B768C1B99BFC0C61CA6" xlink:type="locator" />
    <link:calculationArc order="1" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LiabilitiesNoncurrent_ce6ab6ce-f8d5-dad6-a84c-2c96c7d59f75" xlink:to="loc_nlnk_DeferredGovernmentGrantsObligationsNoncurrent_A0B798C5C29F3B768C1B99BFC0C61CA6" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_DeferredRentCreditNoncurrent" xlink:label="loc_us-gaap_DeferredRentCreditNoncurrent_9f03ff53-e1b7-c80d-4f89-ca1750146781" xlink:type="locator" />
    <link:calculationArc order="2" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LiabilitiesNoncurrent_ce6ab6ce-f8d5-dad6-a84c-2c96c7d59f75" xlink:to="loc_us-gaap_DeferredRentCreditNoncurrent_9f03ff53-e1b7-c80d-4f89-ca1750146781" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_LongTermDebtAndCapitalLeaseObligations" xlink:label="loc_us-gaap_LongTermDebtAndCapitalLeaseObligations_f68a050d-d5b6-1395-99ff-ed06c9a31fb4" xlink:type="locator" />
    <link:calculationArc order="3" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LiabilitiesNoncurrent_ce6ab6ce-f8d5-dad6-a84c-2c96c7d59f75" xlink:to="loc_us-gaap_LongTermDebtAndCapitalLeaseObligations_f68a050d-d5b6-1395-99ff-ed06c9a31fb4" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_StockholdersEquity" xlink:label="loc_us-gaap_StockholdersEquity_4b158f76-5f04-5e4d-ead3-d80e1f9943db" xlink:type="locator" />
    <link:calculationArc order="2" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquity_159dcb00-b17e-17db-7098-be4159799459" xlink:to="loc_us-gaap_StockholdersEquity_4b158f76-5f04-5e4d-ead3-d80e1f9943db" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_PreferredStockValueOutstanding" xlink:label="loc_us-gaap_PreferredStockValueOutstanding_4056d3a7-f51f-6ab0-3659-4b0942ea8ed3" xlink:type="locator" />
    <link:calculationArc order="1" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_StockholdersEquity_4b158f76-5f04-5e4d-ead3-d80e1f9943db" xlink:to="loc_us-gaap_PreferredStockValueOutstanding_4056d3a7-f51f-6ab0-3659-4b0942ea8ed3" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_CommonStockValueOutstanding" xlink:label="loc_us-gaap_CommonStockValueOutstanding_84f35893-355e-0c6f-c67d-2f363beeac9a" xlink:type="locator" />
    <link:calculationArc order="2" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_StockholdersEquity_4b158f76-5f04-5e4d-ead3-d80e1f9943db" xlink:to="loc_us-gaap_CommonStockValueOutstanding_84f35893-355e-0c6f-c67d-2f363beeac9a" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_AdditionalPaidInCapital" xlink:label="loc_us-gaap_AdditionalPaidInCapital_2d1b9d27-8b19-82d9-2843-5b3d292b7fbb" xlink:type="locator" />
    <link:calculationArc order="3" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_StockholdersEquity_4b158f76-5f04-5e4d-ead3-d80e1f9943db" xlink:to="loc_us-gaap_AdditionalPaidInCapital_2d1b9d27-8b19-82d9-2843-5b3d292b7fbb" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_TreasuryStockValue" xlink:label="loc_us-gaap_TreasuryStockValue_40678492-c421-af67-b276-f663f9ff2f98" xlink:type="locator" />
    <link:calculationArc order="4" weight="-1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_StockholdersEquity_4b158f76-5f04-5e4d-ead3-d80e1f9943db" xlink:to="loc_us-gaap_TreasuryStockValue_40678492-c421-af67-b276-f663f9ff2f98" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_RetainedEarningsAccumulatedDeficit" xlink:label="loc_us-gaap_RetainedEarningsAccumulatedDeficit_065cb284-7fca-cc9b-5752-2feaf74d0011" xlink:type="locator" />
    <link:calculationArc order="5" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_StockholdersEquity_4b158f76-5f04-5e4d-ead3-d80e1f9943db" xlink:to="loc_us-gaap_RetainedEarningsAccumulatedDeficit_065cb284-7fca-cc9b-5752-2feaf74d0011" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_Assets" xlink:label="loc_us-gaap_Assets_c6057b1d-6685-8249-2051-6c57f3a16a9e" xlink:type="locator" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_PropertyPlantAndEquipmentNet" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentNet_1944a381-5c4e-ce3c-9111-13ccd1c639db" xlink:type="locator" />
    <link:calculationArc order="1" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_Assets_c6057b1d-6685-8249-2051-6c57f3a16a9e" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentNet_1944a381-5c4e-ce3c-9111-13ccd1c639db" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_AssetsCurrent" xlink:label="loc_us-gaap_AssetsCurrent_8a47066b-3628-88d1-49db-ed09aecc7fc7" xlink:type="locator" />
    <link:calculationArc order="2" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_Assets_c6057b1d-6685-8249-2051-6c57f3a16a9e" xlink:to="loc_us-gaap_AssetsCurrent_8a47066b-3628-88d1-49db-ed09aecc7fc7" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:label="loc_us-gaap_CashAndCashEquivalentsAtCarryingValue_07da1db4-2708-4446-4250-1fdd5956185e" xlink:type="locator" />
    <link:calculationArc order="1" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AssetsCurrent_8a47066b-3628-88d1-49db-ed09aecc7fc7" xlink:to="loc_us-gaap_CashAndCashEquivalentsAtCarryingValue_07da1db4-2708-4446-4250-1fdd5956185e" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_PrepaidExpenseAndOtherAssetsCurrent" xlink:label="loc_us-gaap_PrepaidExpenseAndOtherAssetsCurrent_2294e6a2-7bab-43ed-d02c-bdf73b8fa561" xlink:type="locator" />
    <link:calculationArc order="2" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AssetsCurrent_8a47066b-3628-88d1-49db-ed09aecc7fc7" xlink:to="loc_us-gaap_PrepaidExpenseAndOtherAssetsCurrent_2294e6a2-7bab-43ed-d02c-bdf73b8fa561" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_IncomeTaxesReceivable" xlink:label="loc_us-gaap_IncomeTaxesReceivable_789a7873-b967-40a1-5141-a622987f261b" xlink:type="locator" />
    <link:calculationArc order="3" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AssetsCurrent_8a47066b-3628-88d1-49db-ed09aecc7fc7" xlink:to="loc_us-gaap_IncomeTaxesReceivable_789a7873-b967-40a1-5141-a622987f261b" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_OtherReceivablesNetCurrent" xlink:label="loc_us-gaap_OtherReceivablesNetCurrent_08e1f452-d8bf-5d4c-d6fc-93496697815f" xlink:type="locator" />
    <link:calculationArc order="4" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AssetsCurrent_8a47066b-3628-88d1-49db-ed09aecc7fc7" xlink:to="loc_us-gaap_OtherReceivablesNetCurrent_08e1f452-d8bf-5d4c-d6fc-93496697815f" xlink:type="arc" />
  </link:calculationLink>
  <link:calculationLink xlink:role="http://www.linkp.com/role/CondensedConsolidatedBalanceSheetsParentheticals" xlink:type="extended" />
  <link:calculationLink xlink:role="http://www.linkp.com/role/CondensedConsolidatedStatementOfStockholdersEquity" xlink:type="extended" />
  <link:calculationLink xlink:role="http://www.linkp.com/role/CondensedConsolidatedStatementOfStockholdersEquityParentheticals" xlink:type="extended" />
  <link:calculationLink xlink:role="http://www.linkp.com/role/CondensedConsolidatedStatementsOfCashFlows" xlink:type="extended">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:label="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities_deb49b68-c030-7624-a39d-ea301caa5dbf" xlink:type="locator" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ProceedsFromIssuanceOfCommonStock" xlink:label="loc_us-gaap_ProceedsFromIssuanceOfCommonStock_dbbd5d91-eb58-fa81-2753-d9ddf4ada4c1" xlink:type="locator" />
    <link:calculationArc order="1" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities_deb49b68-c030-7624-a39d-ea301caa5dbf" xlink:to="loc_us-gaap_ProceedsFromIssuanceOfCommonStock_dbbd5d91-eb58-fa81-2753-d9ddf4ada4c1" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_PaymentsForRepurchaseOfCommonStock" xlink:label="loc_us-gaap_PaymentsForRepurchaseOfCommonStock_8a1490c4-32d9-5132-1fe2-2675a45abdae" xlink:type="locator" />
    <link:calculationArc order="2" weight="-1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities_deb49b68-c030-7624-a39d-ea301caa5dbf" xlink:to="loc_us-gaap_PaymentsForRepurchaseOfCommonStock_8a1490c4-32d9-5132-1fe2-2675a45abdae" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_RepaymentsOfDebtAndCapitalLeaseObligations" xlink:label="loc_us-gaap_RepaymentsOfDebtAndCapitalLeaseObligations_60290fac-47b0-5b99-e556-f7aa5502ccc2" xlink:type="locator" />
    <link:calculationArc order="3" weight="-1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities_deb49b68-c030-7624-a39d-ea301caa5dbf" xlink:to="loc_us-gaap_RepaymentsOfDebtAndCapitalLeaseObligations_60290fac-47b0-5b99-e556-f7aa5502ccc2" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:label="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_444b1ac7-f47a-4ce3-0caa-537f7e4ab8c3" xlink:type="locator" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_NetIncomeLoss" xlink:label="loc_us-gaap_NetIncomeLoss_641b1cab-a2b3-2e0e-8389-1455ff3f8581" xlink:type="locator" />
    <link:calculationArc order="1" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_444b1ac7-f47a-4ce3-0caa-537f7e4ab8c3" xlink:to="loc_us-gaap_NetIncomeLoss_641b1cab-a2b3-2e0e-8389-1455ff3f8581" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ShareBasedCompensation" xlink:label="loc_us-gaap_ShareBasedCompensation_e3eecf87-b290-4567-8a59-5b0a8e27c85b" xlink:type="locator" />
    <link:calculationArc order="2" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_444b1ac7-f47a-4ce3-0caa-537f7e4ab8c3" xlink:to="loc_us-gaap_ShareBasedCompensation_e3eecf87-b290-4567-8a59-5b0a8e27c85b" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_DepreciationDepletionAndAmortization" xlink:label="loc_us-gaap_DepreciationDepletionAndAmortization_37b0c31d-5d8b-0577-dfd9-aa56a79334e3" xlink:type="locator" />
    <link:calculationArc order="3" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_444b1ac7-f47a-4ce3-0caa-537f7e4ab8c3" xlink:to="loc_us-gaap_DepreciationDepletionAndAmortization_37b0c31d-5d8b-0577-dfd9-aa56a79334e3" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_GainsLossesOnExtinguishmentOfDebt" xlink:label="loc_us-gaap_GainsLossesOnExtinguishmentOfDebt_3db65903-3171-d63c-a688-532ba00b8108" xlink:type="locator" />
    <link:calculationArc order="4" weight="-1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_444b1ac7-f47a-4ce3-0caa-537f7e4ab8c3" xlink:to="loc_us-gaap_GainsLossesOnExtinguishmentOfDebt_3db65903-3171-d63c-a688-532ba00b8108" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ExcessTaxBenefitFromShareBasedCompensationOperatingActivities" xlink:label="loc_us-gaap_ExcessTaxBenefitFromShareBasedCompensationOperatingActivities_94d761b7-b8f1-3ba3-90b8-1443c3232b73" xlink:type="locator" />
    <link:calculationArc order="5" weight="-1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_444b1ac7-f47a-4ce3-0caa-537f7e4ab8c3" xlink:to="loc_us-gaap_ExcessTaxBenefitFromShareBasedCompensationOperatingActivities_94d761b7-b8f1-3ba3-90b8-1443c3232b73" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_AssetImpairmentCharges" xlink:label="loc_us-gaap_AssetImpairmentCharges_922befcd-b5b1-7112-2dca-80fbde69a2fe" xlink:type="locator" />
    <link:calculationArc order="6" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_444b1ac7-f47a-4ce3-0caa-537f7e4ab8c3" xlink:to="loc_us-gaap_AssetImpairmentCharges_922befcd-b5b1-7112-2dca-80fbde69a2fe" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_GainLossOnSaleOfPropertyPlantEquipment" xlink:label="loc_us-gaap_GainLossOnSaleOfPropertyPlantEquipment_5b3d4a64-864e-a67c-1d85-8163ad700c58" xlink:type="locator" />
    <link:calculationArc order="7" weight="-1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_444b1ac7-f47a-4ce3-0caa-537f7e4ab8c3" xlink:to="loc_us-gaap_GainLossOnSaleOfPropertyPlantEquipment_5b3d4a64-864e-a67c-1d85-8163ad700c58" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" xlink:label="loc_us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets_c998cbd2-a633-c2ec-1932-e3bfedecbc9f" xlink:type="locator" />
    <link:calculationArc order="8" weight="-1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_444b1ac7-f47a-4ce3-0caa-537f7e4ab8c3" xlink:to="loc_us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets_c998cbd2-a633-c2ec-1932-e3bfedecbc9f" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_IncreaseDecreaseInOtherReceivables" xlink:label="loc_us-gaap_IncreaseDecreaseInOtherReceivables_6f28486e-f9ed-43d2-2ab7-156fe91bac0d" xlink:type="locator" />
    <link:calculationArc order="9" weight="-1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_444b1ac7-f47a-4ce3-0caa-537f7e4ab8c3" xlink:to="loc_us-gaap_IncreaseDecreaseInOtherReceivables_6f28486e-f9ed-43d2-2ab7-156fe91bac0d" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities" xlink:label="loc_us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities_73e959a8-32b6-697e-66b5-86ef5a29476e" xlink:type="locator" />
    <link:calculationArc order="10" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_444b1ac7-f47a-4ce3-0caa-537f7e4ab8c3" xlink:to="loc_us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities_73e959a8-32b6-697e-66b5-86ef5a29476e" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_IncreaseDecreaseInAccruedIncomeTaxesPayable" xlink:label="loc_us-gaap_IncreaseDecreaseInAccruedIncomeTaxesPayable_2e0100a2-70c7-ab53-9143-6f416ad2f702" xlink:type="locator" />
    <link:calculationArc order="11" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_444b1ac7-f47a-4ce3-0caa-537f7e4ab8c3" xlink:to="loc_us-gaap_IncreaseDecreaseInAccruedIncomeTaxesPayable_2e0100a2-70c7-ab53-9143-6f416ad2f702" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_IncreaseDecreaseInDeferredRevenue" xlink:label="loc_us-gaap_IncreaseDecreaseInDeferredRevenue_91397648-589d-3b53-47c8-16b8909c78f4" xlink:type="locator" />
    <link:calculationArc order="12" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_444b1ac7-f47a-4ce3-0caa-537f7e4ab8c3" xlink:to="loc_us-gaap_IncreaseDecreaseInDeferredRevenue_91397648-589d-3b53-47c8-16b8909c78f4" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_IncreaseDecreaseInDeferredCharges" xlink:label="loc_us-gaap_IncreaseDecreaseInDeferredCharges_df42b422-74b8-5f19-6fc7-0cf65a21f80f" xlink:type="locator" />
    <link:calculationArc order="13" weight="-1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_444b1ac7-f47a-4ce3-0caa-537f7e4ab8c3" xlink:to="loc_us-gaap_IncreaseDecreaseInDeferredCharges_df42b422-74b8-5f19-6fc7-0cf65a21f80f" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivities" xlink:label="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities_70319186-e7bd-7189-88d2-eba26fb93350" xlink:type="locator" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ProceedsFromSaleAndMaturityOfHeldToMaturitySecurities" xlink:label="loc_us-gaap_ProceedsFromSaleAndMaturityOfHeldToMaturitySecurities_329e3ac8-ee75-2d67-1511-70526c880ec4" xlink:type="locator" />
    <link:calculationArc order="1" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities_70319186-e7bd-7189-88d2-eba26fb93350" xlink:to="loc_us-gaap_ProceedsFromSaleAndMaturityOfHeldToMaturitySecurities_329e3ac8-ee75-2d67-1511-70526c880ec4" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_PaymentsToAcquirePropertyPlantAndEquipment" xlink:label="loc_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment_fee12b15-6b42-6245-2e2f-ff030b98332c" xlink:type="locator" />
    <link:calculationArc order="2" weight="-1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities_70319186-e7bd-7189-88d2-eba26fb93350" xlink:to="loc_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment_fee12b15-6b42-6245-2e2f-ff030b98332c" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ProceedsFromSaleOfPropertyPlantAndEquipment" xlink:label="loc_us-gaap_ProceedsFromSaleOfPropertyPlantAndEquipment_f7ed6106-862d-edb5-3fd1-677e7651af64" xlink:type="locator" />
    <link:calculationArc order="3" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities_70319186-e7bd-7189-88d2-eba26fb93350" xlink:to="loc_us-gaap_ProceedsFromSaleOfPropertyPlantAndEquipment_f7ed6106-862d-edb5-3fd1-677e7651af64" xlink:type="arc" />
  </link:calculationLink>
  <link:calculationLink xlink:role="http://www.linkp.com/role/CondensedConsolidatedStatementsOfOperations" xlink:type="extended">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_NetIncomeLoss" xlink:label="loc_us-gaap_NetIncomeLoss_641b1cab-a2b3-2e0e-8389-1455ff3f8581" xlink:type="locator" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" xlink:label="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest_a53f52a4-7a54-3283-f734-95683c76ebff" xlink:type="locator" />
    <link:calculationArc order="1" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetIncomeLoss_641b1cab-a2b3-2e0e-8389-1455ff3f8581" xlink:to="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest_a53f52a4-7a54-3283-f734-95683c76ebff" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_OperatingIncomeLoss" xlink:label="loc_us-gaap_OperatingIncomeLoss_9894e895-7695-402a-9f03-08d60b7373b8" xlink:type="locator" />
    <link:calculationArc order="1" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest_a53f52a4-7a54-3283-f734-95683c76ebff" xlink:to="loc_us-gaap_OperatingIncomeLoss_9894e895-7695-402a-9f03-08d60b7373b8" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_SalesRevenueNet" xlink:label="loc_us-gaap_SalesRevenueNet_ff017a48-8743-bfac-8af0-ca31401cb6de" xlink:type="locator" />
    <link:calculationArc order="1" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_OperatingIncomeLoss_9894e895-7695-402a-9f03-08d60b7373b8" xlink:to="loc_us-gaap_SalesRevenueNet_ff017a48-8743-bfac-8af0-ca31401cb6de" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_RevenueFromGrants" xlink:label="loc_us-gaap_RevenueFromGrants_e1b1191c-a943-4c57-06c8-4d3d7fea920e" xlink:type="locator" />
    <link:calculationArc order="1" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_SalesRevenueNet_ff017a48-8743-bfac-8af0-ca31401cb6de" xlink:to="loc_us-gaap_RevenueFromGrants_e1b1191c-a943-4c57-06c8-4d3d7fea920e" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_LicensesRevenue" xlink:label="loc_us-gaap_LicensesRevenue_76304021-cc4c-b83e-0c43-ed738e4c3281" xlink:type="locator" />
    <link:calculationArc order="2" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_SalesRevenueNet_ff017a48-8743-bfac-8af0-ca31401cb6de" xlink:to="loc_us-gaap_LicensesRevenue_76304021-cc4c-b83e-0c43-ed738e4c3281" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_OperatingExpenses" xlink:label="loc_us-gaap_OperatingExpenses_23a4428c-a5e3-3b9c-fc88-04ae5be27ab3" xlink:type="locator" />
    <link:calculationArc order="2" weight="-1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_OperatingIncomeLoss_9894e895-7695-402a-9f03-08d60b7373b8" xlink:to="loc_us-gaap_OperatingExpenses_23a4428c-a5e3-3b9c-fc88-04ae5be27ab3" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ResearchAndDevelopmentExpense" xlink:label="loc_us-gaap_ResearchAndDevelopmentExpense_25ae5ce2-b413-b975-9a84-c7503d2496cf" xlink:type="locator" />
    <link:calculationArc order="1" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_OperatingExpenses_23a4428c-a5e3-3b9c-fc88-04ae5be27ab3" xlink:to="loc_us-gaap_ResearchAndDevelopmentExpense_25ae5ce2-b413-b975-9a84-c7503d2496cf" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_GeneralAndAdministrativeExpense" xlink:label="loc_us-gaap_GeneralAndAdministrativeExpense_87411e46-c979-a1ff-e8b3-f4f75d86b855" xlink:type="locator" />
    <link:calculationArc order="2" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_OperatingExpenses_23a4428c-a5e3-3b9c-fc88-04ae5be27ab3" xlink:to="loc_us-gaap_GeneralAndAdministrativeExpense_87411e46-c979-a1ff-e8b3-f4f75d86b855" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_NonoperatingIncomeExpense" xlink:label="loc_us-gaap_NonoperatingIncomeExpense_9b894abb-bf85-2810-9d9d-c92a9b0f56f1" xlink:type="locator" />
    <link:calculationArc order="2" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest_a53f52a4-7a54-3283-f734-95683c76ebff" xlink:to="loc_us-gaap_NonoperatingIncomeExpense_9b894abb-bf85-2810-9d9d-c92a9b0f56f1" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_OtherNonoperatingIncomeExpense" xlink:label="loc_us-gaap_OtherNonoperatingIncomeExpense_250c3b2f-7db5-7088-68cc-1dd831a2c2d7" xlink:type="locator" />
    <link:calculationArc order="1" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NonoperatingIncomeExpense_9b894abb-bf85-2810-9d9d-c92a9b0f56f1" xlink:to="loc_us-gaap_OtherNonoperatingIncomeExpense_250c3b2f-7db5-7088-68cc-1dd831a2c2d7" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_InvestmentIncomeInterest" xlink:label="loc_us-gaap_InvestmentIncomeInterest_27459a92-428a-e415-bdb1-176ed2662e11" xlink:type="locator" />
    <link:calculationArc order="2" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NonoperatingIncomeExpense_9b894abb-bf85-2810-9d9d-c92a9b0f56f1" xlink:to="loc_us-gaap_InvestmentIncomeInterest_27459a92-428a-e415-bdb1-176ed2662e11" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_InterestExpense" xlink:label="loc_us-gaap_InterestExpense_7c9599ab-2a77-022c-c720-63fecff6a62c" xlink:type="locator" />
    <link:calculationArc order="3" weight="-1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NonoperatingIncomeExpense_9b894abb-bf85-2810-9d9d-c92a9b0f56f1" xlink:to="loc_us-gaap_InterestExpense_7c9599ab-2a77-022c-c720-63fecff6a62c" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_IncomeTaxExpenseBenefit" xlink:label="loc_us-gaap_IncomeTaxExpenseBenefit_78b7d85e-8366-fe6d-cb1f-faac5a041b79" xlink:type="locator" />
    <link:calculationArc order="2" weight="-1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetIncomeLoss_641b1cab-a2b3-2e0e-8389-1455ff3f8581" xlink:to="loc_us-gaap_IncomeTaxExpenseBenefit_78b7d85e-8366-fe6d-cb1f-faac5a041b79" xlink:type="arc" />
  </link:calculationLink>
  <link:calculationLink xlink:role="http://www.linkp.com/role/DescriptionOfBusiness" xlink:type="extended" />
  <link:calculationLink xlink:role="http://www.linkp.com/role/DescriptionOfBusinessDetails" xlink:type="extended" />
  <link:calculationLink xlink:role="http://www.linkp.com/role/DocumentAndEntityInformation" xlink:type="extended" />
  <link:calculationLink xlink:role="http://www.linkp.com/role/IncomeTaxes" xlink:type="extended" />
  <link:calculationLink xlink:role="http://www.linkp.com/role/IncomeTaxesDetails" xlink:type="extended" />
  <link:calculationLink xlink:role="http://www.linkp.com/role/LicenseAndResearchCollaborationAgreements" xlink:type="extended" />
  <link:calculationLink xlink:role="http://www.linkp.com/role/LicenseAndResearchCollaborationAgreementsDetails" xlink:type="extended" />
  <link:calculationLink xlink:role="http://www.linkp.com/role/LongTermDebt" xlink:type="extended" />
  <link:calculationLink xlink:role="http://www.linkp.com/role/LongTermDebtDetails" xlink:type="extended" />
  <link:calculationLink xlink:role="http://www.linkp.com/role/NetLossPerCommonShare" xlink:type="extended" />
  <link:calculationLink xlink:role="http://www.linkp.com/role/NetLossPerCommonShareAntidilutiveSecuritiesDetails" xlink:type="extended" />
  <link:calculationLink xlink:role="http://www.linkp.com/role/NetLossPerCommonShareNetLossPerShareComputationDetails" xlink:type="extended" />
  <link:calculationLink xlink:role="http://www.linkp.com/role/NetLossPerCommonShareTables" xlink:type="extended" />
  <link:calculationLink xlink:role="http://www.linkp.com/role/RestructuringCharges" xlink:type="extended" />
  <link:calculationLink xlink:role="http://www.linkp.com/role/RestructuringChargesDetails" xlink:type="extended" />
  <link:calculationLink xlink:role="http://www.linkp.com/role/RestructuringChargesTables" xlink:type="extended" />
  <link:calculationLink xlink:role="http://www.linkp.com/role/SignificantAccountingPolicies" xlink:type="extended" />
  <link:calculationLink xlink:role="http://www.linkp.com/role/SignificantAccountingPoliciesDetails" xlink:type="extended" />
  <link:calculationLink xlink:role="http://www.linkp.com/role/SignificantAccountingPoliciesPolicies" xlink:type="extended" />
  <link:calculationLink xlink:role="http://www.linkp.com/role/SubsequentEvents" xlink:type="extended" />
  <link:calculationLink xlink:role="http://www.linkp.com/role/SubsequentEventsDetails" xlink:type="extended" />
</link:linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.DEF
<SEQUENCE>8
<FILENAME>nlnk-20170930_def.xml
<DESCRIPTION>XBRL TAXONOMY EXTENSION DEFINITION LINKBASE DOCUMENT
<TEXT>
<XBRL>
<?xml version="1.0" encoding="US-ASCII"?>
<!--XBRL Document Created with Wdesk from Workiva-->
<!-- -->
<link:linkbase xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd" xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xbrldt="http://xbrl.org/2005/xbrldt" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance">
  <link:roleRef roleURI="http://www.linkp.com/role/BasisOfPresentation" xlink:href="nlnk-20170930.xsd#BasisOfPresentation" xlink:type="simple" />
  <link:roleRef roleURI="http://www.linkp.com/role/CommitmentsAndContingencies" xlink:href="nlnk-20170930.xsd#CommitmentsAndContingencies" xlink:type="simple" />
  <link:roleRef roleURI="http://www.linkp.com/role/CommonStockEquityIncentivePlan" xlink:href="nlnk-20170930.xsd#CommonStockEquityIncentivePlan" xlink:type="simple" />
  <link:roleRef roleURI="http://www.linkp.com/role/CommonStockEquityIncentivePlanAuthorizedIncreasesOfCommonStockDetails" xlink:href="nlnk-20170930.xsd#CommonStockEquityIncentivePlanAuthorizedIncreasesOfCommonStockDetails" xlink:type="simple" />
  <link:roleRef roleURI="http://www.linkp.com/role/CommonStockEquityIncentivePlanNarrativedetails" xlink:href="nlnk-20170930.xsd#CommonStockEquityIncentivePlanNarrativedetails" xlink:type="simple" />
  <link:roleRef roleURI="http://www.linkp.com/role/CommonStockEquityIncentivePlanRangeOfAssumptionsUsedDetails" xlink:href="nlnk-20170930.xsd#CommonStockEquityIncentivePlanRangeOfAssumptionsUsedDetails" xlink:type="simple" />
  <link:roleRef roleURI="http://www.linkp.com/role/CommonStockEquityIncentivePlanRestrictedStockActivityDetails" xlink:href="nlnk-20170930.xsd#CommonStockEquityIncentivePlanRestrictedStockActivityDetails" xlink:type="simple" />
  <link:roleRef roleURI="http://www.linkp.com/role/CommonStockEquityIncentivePlanStockOptionActivityDetails" xlink:href="nlnk-20170930.xsd#CommonStockEquityIncentivePlanStockOptionActivityDetails" xlink:type="simple" />
  <link:roleRef roleURI="http://www.linkp.com/role/CommonStockEquityIncentivePlanTables" xlink:href="nlnk-20170930.xsd#CommonStockEquityIncentivePlanTables" xlink:type="simple" />
  <link:roleRef roleURI="http://www.linkp.com/role/CondensedConsolidatedBalanceSheets" xlink:href="nlnk-20170930.xsd#CondensedConsolidatedBalanceSheets" xlink:type="simple" />
  <link:roleRef roleURI="http://www.linkp.com/role/CondensedConsolidatedBalanceSheetsParentheticals" xlink:href="nlnk-20170930.xsd#CondensedConsolidatedBalanceSheetsParentheticals" xlink:type="simple" />
  <link:roleRef roleURI="http://www.linkp.com/role/CondensedConsolidatedStatementOfStockholdersEquity" xlink:href="nlnk-20170930.xsd#CondensedConsolidatedStatementOfStockholdersEquity" xlink:type="simple" />
  <link:roleRef roleURI="http://www.linkp.com/role/CondensedConsolidatedStatementOfStockholdersEquityParentheticals" xlink:href="nlnk-20170930.xsd#CondensedConsolidatedStatementOfStockholdersEquityParentheticals" xlink:type="simple" />
  <link:roleRef roleURI="http://www.linkp.com/role/CondensedConsolidatedStatementsOfCashFlows" xlink:href="nlnk-20170930.xsd#CondensedConsolidatedStatementsOfCashFlows" xlink:type="simple" />
  <link:roleRef roleURI="http://www.linkp.com/role/CondensedConsolidatedStatementsOfOperations" xlink:href="nlnk-20170930.xsd#CondensedConsolidatedStatementsOfOperations" xlink:type="simple" />
  <link:roleRef roleURI="http://www.linkp.com/role/DescriptionOfBusiness" xlink:href="nlnk-20170930.xsd#DescriptionOfBusiness" xlink:type="simple" />
  <link:roleRef roleURI="http://www.linkp.com/role/DescriptionOfBusinessDetails" xlink:href="nlnk-20170930.xsd#DescriptionOfBusinessDetails" xlink:type="simple" />
  <link:roleRef roleURI="http://www.linkp.com/role/DocumentAndEntityInformation" xlink:href="nlnk-20170930.xsd#DocumentAndEntityInformation" xlink:type="simple" />
  <link:roleRef roleURI="http://www.linkp.com/role/IncomeTaxes" xlink:href="nlnk-20170930.xsd#IncomeTaxes" xlink:type="simple" />
  <link:roleRef roleURI="http://www.linkp.com/role/IncomeTaxesDetails" xlink:href="nlnk-20170930.xsd#IncomeTaxesDetails" xlink:type="simple" />
  <link:roleRef roleURI="http://www.linkp.com/role/LicenseAndResearchCollaborationAgreements" xlink:href="nlnk-20170930.xsd#LicenseAndResearchCollaborationAgreements" xlink:type="simple" />
  <link:roleRef roleURI="http://www.linkp.com/role/LicenseAndResearchCollaborationAgreementsDetails" xlink:href="nlnk-20170930.xsd#LicenseAndResearchCollaborationAgreementsDetails" xlink:type="simple" />
  <link:roleRef roleURI="http://www.linkp.com/role/LongTermDebt" xlink:href="nlnk-20170930.xsd#LongTermDebt" xlink:type="simple" />
  <link:roleRef roleURI="http://www.linkp.com/role/LongTermDebtDetails" xlink:href="nlnk-20170930.xsd#LongTermDebtDetails" xlink:type="simple" />
  <link:roleRef roleURI="http://www.linkp.com/role/NetLossPerCommonShare" xlink:href="nlnk-20170930.xsd#NetLossPerCommonShare" xlink:type="simple" />
  <link:roleRef roleURI="http://www.linkp.com/role/NetLossPerCommonShareAntidilutiveSecuritiesDetails" xlink:href="nlnk-20170930.xsd#NetLossPerCommonShareAntidilutiveSecuritiesDetails" xlink:type="simple" />
  <link:roleRef roleURI="http://www.linkp.com/role/NetLossPerCommonShareNetLossPerShareComputationDetails" xlink:href="nlnk-20170930.xsd#NetLossPerCommonShareNetLossPerShareComputationDetails" xlink:type="simple" />
  <link:roleRef roleURI="http://www.linkp.com/role/NetLossPerCommonShareTables" xlink:href="nlnk-20170930.xsd#NetLossPerCommonShareTables" xlink:type="simple" />
  <link:roleRef roleURI="http://www.linkp.com/role/RestructuringCharges" xlink:href="nlnk-20170930.xsd#RestructuringCharges" xlink:type="simple" />
  <link:roleRef roleURI="http://www.linkp.com/role/RestructuringChargesDetails" xlink:href="nlnk-20170930.xsd#RestructuringChargesDetails" xlink:type="simple" />
  <link:roleRef roleURI="http://www.linkp.com/role/RestructuringChargesTables" xlink:href="nlnk-20170930.xsd#RestructuringChargesTables" xlink:type="simple" />
  <link:roleRef roleURI="http://www.linkp.com/role/SignificantAccountingPolicies" xlink:href="nlnk-20170930.xsd#SignificantAccountingPolicies" xlink:type="simple" />
  <link:roleRef roleURI="http://www.linkp.com/role/SignificantAccountingPoliciesDetails" xlink:href="nlnk-20170930.xsd#SignificantAccountingPoliciesDetails" xlink:type="simple" />
  <link:roleRef roleURI="http://www.linkp.com/role/SignificantAccountingPoliciesPolicies" xlink:href="nlnk-20170930.xsd#SignificantAccountingPoliciesPolicies" xlink:type="simple" />
  <link:roleRef roleURI="http://www.linkp.com/role/SubsequentEvents" xlink:href="nlnk-20170930.xsd#SubsequentEvents" xlink:type="simple" />
  <link:roleRef roleURI="http://www.linkp.com/role/SubsequentEventsDetails" xlink:href="nlnk-20170930.xsd#SubsequentEventsDetails" xlink:type="simple" />
  <link:arcroleRef arcroleURI="http://xbrl.org/int/dim/arcrole/all" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#all" xlink:type="simple" />
  <link:arcroleRef arcroleURI="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#dimension-default" xlink:type="simple" />
  <link:arcroleRef arcroleURI="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#dimension-domain" xlink:type="simple" />
  <link:arcroleRef arcroleURI="http://xbrl.org/int/dim/arcrole/domain-member" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#domain-member" xlink:type="simple" />
  <link:arcroleRef arcroleURI="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#hypercube-dimension" xlink:type="simple" />
  <link:definitionLink xlink:role="http://www.linkp.com/role/BasisOfPresentation" xlink:type="extended" />
  <link:definitionLink xlink:role="http://www.linkp.com/role/CommitmentsAndContingencies" xlink:type="extended" />
  <link:definitionLink xlink:role="http://www.linkp.com/role/CommonStockEquityIncentivePlan" xlink:type="extended" />
  <link:definitionLink xlink:role="http://www.linkp.com/role/CommonStockEquityIncentivePlanAuthorizedIncreasesOfCommonStockDetails" xlink:type="extended">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_BD57D44A8EB35363A87DD90AEFAB04E4" xlink:type="locator" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:label="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_AE46112C08B05317BEA9FD046EA42A97" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_BD57D44A8EB35363A87DD90AEFAB04E4" xlink:to="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_AE46112C08B05317BEA9FD046EA42A97" xlink:type="arc" xbrldt:closed="true" xbrldt:contextElement="segment" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_PlanNameAxis" xlink:label="loc_us-gaap_PlanNameAxis_EBFE77155E615588A351C925495C8CBF" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_AE46112C08B05317BEA9FD046EA42A97" xlink:to="loc_us-gaap_PlanNameAxis_EBFE77155E615588A351C925495C8CBF" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_PlanNameDomain" xlink:label="loc_us-gaap_PlanNameDomain_CA3B36996D2A35168DA097345C003C3B_93C1E088CC9D565FB6E0D603FE544AFD" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_PlanNameAxis_EBFE77155E615588A351C925495C8CBF" xlink:to="loc_us-gaap_PlanNameDomain_CA3B36996D2A35168DA097345C003C3B_93C1E088CC9D565FB6E0D603FE544AFD" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_PlanNameDomain" xlink:label="loc_us-gaap_PlanNameDomain_789635DA94F950BF8FD4F65780C1E2D4" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_PlanNameAxis_EBFE77155E615588A351C925495C8CBF" xlink:to="loc_us-gaap_PlanNameDomain_789635DA94F950BF8FD4F65780C1E2D4" xlink:type="arc" />
    <link:loc xlink:href="nlnk-20170930.xsd#nlnk_A2009EquityIncentivePlanMember" xlink:label="loc_nlnk_A2009EquityIncentivePlanMember_643F40D7B3E952868474542F7E09552A" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_PlanNameDomain_789635DA94F950BF8FD4F65780C1E2D4" xlink:to="loc_nlnk_A2009EquityIncentivePlanMember_643F40D7B3E952868474542F7E09552A" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized_00DABD0246BA54CABE35611BC698315B" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_BD57D44A8EB35363A87DD90AEFAB04E4" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized_00DABD0246BA54CABE35611BC698315B" xlink:type="arc" />
  </link:definitionLink>
  <link:definitionLink xlink:role="http://www.linkp.com/role/CommonStockEquityIncentivePlanNarrativedetails" xlink:type="extended">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_8BA7AAE124125278B85C70980FA793FE" xlink:type="locator" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:label="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_8EB4A68033235F30BC633E562596800E" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_8BA7AAE124125278B85C70980FA793FE" xlink:to="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_8EB4A68033235F30BC633E562596800E" xlink:type="arc" xbrldt:closed="true" xbrldt:contextElement="segment" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_RangeAxis" xlink:label="loc_us-gaap_RangeAxis_2CF76EFC15365ED986AA3C735A643FE1" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_8EB4A68033235F30BC633E562596800E" xlink:to="loc_us-gaap_RangeAxis_2CF76EFC15365ED986AA3C735A643FE1" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_RangeMember" xlink:label="loc_us-gaap_RangeMember_0C0A5178036382C0C0F397345C071007_93C1E088CC9D565FB6E0D603FE544AFD" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_RangeAxis_2CF76EFC15365ED986AA3C735A643FE1" xlink:to="loc_us-gaap_RangeMember_0C0A5178036382C0C0F397345C071007_93C1E088CC9D565FB6E0D603FE544AFD" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_RangeMember" xlink:label="loc_us-gaap_RangeMember_E727579565955403B1173F25791039AE" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_RangeAxis_2CF76EFC15365ED986AA3C735A643FE1" xlink:to="loc_us-gaap_RangeMember_E727579565955403B1173F25791039AE" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_MinimumMember" xlink:label="loc_us-gaap_MinimumMember_241C544D27D15C93BAA6822A3D1A7FA7" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_RangeMember_E727579565955403B1173F25791039AE" xlink:to="loc_us-gaap_MinimumMember_241C544D27D15C93BAA6822A3D1A7FA7" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_MaximumMember" xlink:label="loc_us-gaap_MaximumMember_09DB073D15F7503197824CE3F0CB0A42" xlink:type="locator" />
    <link:definitionArc order="2" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_RangeMember_E727579565955403B1173F25791039AE" xlink:to="loc_us-gaap_MaximumMember_09DB073D15F7503197824CE3F0CB0A42" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_AwardTypeAxis" xlink:label="loc_us-gaap_AwardTypeAxis_14616088DCF5552E8005345113BD0031" xlink:type="locator" />
    <link:definitionArc order="2" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_8EB4A68033235F30BC633E562596800E" xlink:to="loc_us-gaap_AwardTypeAxis_14616088DCF5552E8005345113BD0031" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_F324E701D86C2B14A9DA97345C083A15_93C1E088CC9D565FB6E0D603FE544AFD" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_AwardTypeAxis_14616088DCF5552E8005345113BD0031" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_F324E701D86C2B14A9DA97345C083A15_93C1E088CC9D565FB6E0D603FE544AFD" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_16CB89BD1AE1571F9EE61D74D8D79315" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_AwardTypeAxis_14616088DCF5552E8005345113BD0031" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_16CB89BD1AE1571F9EE61D74D8D79315" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_EmployeeStockOptionMember" xlink:label="loc_us-gaap_EmployeeStockOptionMember_474A2753178A50979192190A1A5507DF" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_16CB89BD1AE1571F9EE61D74D8D79315" xlink:to="loc_us-gaap_EmployeeStockOptionMember_474A2753178A50979192190A1A5507DF" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_PerformanceSharesMember" xlink:label="loc_us-gaap_PerformanceSharesMember_FBAC6F7E45E95C6BBF5BEA0B33361451" xlink:type="locator" />
    <link:definitionArc order="2" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_16CB89BD1AE1571F9EE61D74D8D79315" xlink:to="loc_us-gaap_PerformanceSharesMember_FBAC6F7E45E95C6BBF5BEA0B33361451" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_RestrictedStockMember" xlink:label="loc_us-gaap_RestrictedStockMember_16466D3E6B5B54FEA0EC12D4D177C3D1" xlink:type="locator" />
    <link:definitionArc order="3" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_16CB89BD1AE1571F9EE61D74D8D79315" xlink:to="loc_us-gaap_RestrictedStockMember_16466D3E6B5B54FEA0EC12D4D177C3D1" xlink:type="arc" />
    <link:loc xlink:href="nlnk-20170930.xsd#nlnk_PerformanceRestrictedStockMember" xlink:label="loc_nlnk_PerformanceRestrictedStockMember_ACEA61DA39015E9F9411B9A62E9FF1EF" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_RestrictedStockMember_16466D3E6B5B54FEA0EC12D4D177C3D1" xlink:to="loc_nlnk_PerformanceRestrictedStockMember_ACEA61DA39015E9F9411B9A62E9FF1EF" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" xlink:label="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_29AC741D549B579FB84E60CAF85BE287" xlink:type="locator" />
    <link:definitionArc order="3" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_8EB4A68033235F30BC633E562596800E" xlink:to="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_29AC741D549B579FB84E60CAF85BE287" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_AntidilutiveSecuritiesNameDomain" xlink:label="loc_us-gaap_AntidilutiveSecuritiesNameDomain_047ABFC45106C8F639EA97345C086353_93C1E088CC9D565FB6E0D603FE544AFD" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_29AC741D549B579FB84E60CAF85BE287" xlink:to="loc_us-gaap_AntidilutiveSecuritiesNameDomain_047ABFC45106C8F639EA97345C086353_93C1E088CC9D565FB6E0D603FE544AFD" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_AntidilutiveSecuritiesNameDomain" xlink:label="loc_us-gaap_AntidilutiveSecuritiesNameDomain_FB3A827D7A41590C9489CE87B3919488" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_29AC741D549B579FB84E60CAF85BE287" xlink:to="loc_us-gaap_AntidilutiveSecuritiesNameDomain_FB3A827D7A41590C9489CE87B3919488" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_RestrictedStockMember" xlink:label="loc_us-gaap_RestrictedStockMember_BFF9C4F1D34E5428BDD1CE3D09C25C50" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AntidilutiveSecuritiesNameDomain_FB3A827D7A41590C9489CE87B3919488" xlink:to="loc_us-gaap_RestrictedStockMember_BFF9C4F1D34E5428BDD1CE3D09C25C50" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_PlanNameAxis" xlink:label="loc_us-gaap_PlanNameAxis_BE64B3B82AA25EFE861205FA479A7375" xlink:type="locator" />
    <link:definitionArc order="4" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_8EB4A68033235F30BC633E562596800E" xlink:to="loc_us-gaap_PlanNameAxis_BE64B3B82AA25EFE861205FA479A7375" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_PlanNameDomain" xlink:label="loc_us-gaap_PlanNameDomain_1C3255F4445C0D900E8197345C09FE0D_93C1E088CC9D565FB6E0D603FE544AFD" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_PlanNameAxis_BE64B3B82AA25EFE861205FA479A7375" xlink:to="loc_us-gaap_PlanNameDomain_1C3255F4445C0D900E8197345C09FE0D_93C1E088CC9D565FB6E0D603FE544AFD" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_PlanNameDomain" xlink:label="loc_us-gaap_PlanNameDomain_1A1643A526F1570AB6166F265E50AFA6" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_PlanNameAxis_BE64B3B82AA25EFE861205FA479A7375" xlink:to="loc_us-gaap_PlanNameDomain_1A1643A526F1570AB6166F265E50AFA6" xlink:type="arc" />
    <link:loc xlink:href="nlnk-20170930.xsd#nlnk_A2009EquityIncentivePlanMember" xlink:label="loc_nlnk_A2009EquityIncentivePlanMember_1C0561DF08265DFA90BA510F5D6E4173" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_PlanNameDomain_1A1643A526F1570AB6166F265E50AFA6" xlink:to="loc_nlnk_A2009EquityIncentivePlanMember_1C0561DF08265DFA90BA510F5D6E4173" xlink:type="arc" />
    <link:loc xlink:href="nlnk-20170930.xsd#nlnk_A2010NonEmployeeDirectorsStockOptionPlanMember" xlink:label="loc_nlnk_A2010NonEmployeeDirectorsStockOptionPlanMember_8316DFB7ECFA544BBDD16CFC4E6CA565" xlink:type="locator" />
    <link:definitionArc order="2" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_PlanNameDomain_1A1643A526F1570AB6166F265E50AFA6" xlink:to="loc_nlnk_A2010NonEmployeeDirectorsStockOptionPlanMember_8316DFB7ECFA544BBDD16CFC4E6CA565" xlink:type="arc" />
    <link:loc xlink:href="nlnk-20170930.xsd#nlnk_A2010EmployeeStockPurchasePlanMember" xlink:label="loc_nlnk_A2010EmployeeStockPurchasePlanMember_9340D14C8C5A5DB491E439FD84F489FB" xlink:type="locator" />
    <link:definitionArc order="3" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_PlanNameDomain_1A1643A526F1570AB6166F265E50AFA6" xlink:to="loc_nlnk_A2010EmployeeStockPurchasePlanMember_9340D14C8C5A5DB491E439FD84F489FB" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized_DF61E7B696EC5DA28C5432E803AF5AA2" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_8BA7AAE124125278B85C70980FA793FE" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized_DF61E7B696EC5DA28C5432E803AF5AA2" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant_3CFE67E4824F5BB6AF4920AF2B8289F0" xlink:type="locator" />
    <link:definitionArc order="2" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_8BA7AAE124125278B85C70980FA793FE" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant_3CFE67E4824F5BB6AF4920AF2B8289F0" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized_BC12B6483FC15C4C916739B11E0623C0" xlink:type="locator" />
    <link:definitionArc order="3" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_8BA7AAE124125278B85C70980FA793FE" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized_BC12B6483FC15C4C916739B11E0623C0" xlink:type="arc" />
    <link:loc xlink:href="nlnk-20170930.xsd#nlnk_SharebasedCompensationArrangementbySharebasedPaymentAwardPercentageofAuthorizedStockMaximum" xlink:label="loc_nlnk_SharebasedCompensationArrangementbySharebasedPaymentAwardPercentageofAuthorizedStockMaximum_5441FBEF66425EA4B5296784C1DF3D6B" xlink:type="locator" />
    <link:definitionArc order="4" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_8BA7AAE124125278B85C70980FA793FE" xlink:to="loc_nlnk_SharebasedCompensationArrangementbySharebasedPaymentAwardPercentageofAuthorizedStockMaximum_5441FBEF66425EA4B5296784C1DF3D6B" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_AllocatedShareBasedCompensationExpense" xlink:label="loc_us-gaap_AllocatedShareBasedCompensationExpense_5943F5B570E75FC7AF703D215682073C" xlink:type="locator" />
    <link:definitionArc order="5" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_8BA7AAE124125278B85C70980FA793FE" xlink:to="loc_us-gaap_AllocatedShareBasedCompensationExpense_5943F5B570E75FC7AF703D215682073C" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions" xlink:label="loc_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions_5C2976759DC2551F9E33D9473F3019FF" xlink:type="locator" />
    <link:definitionArc order="6" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_8BA7AAE124125278B85C70980FA793FE" xlink:to="loc_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions_5C2976759DC2551F9E33D9473F3019FF" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1" xlink:label="loc_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1_3D2A0CB62C265A5597BFF9149316BB38" xlink:type="locator" />
    <link:definitionArc order="7" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_8BA7AAE124125278B85C70980FA793FE" xlink:to="loc_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1_3D2A0CB62C265A5597BFF9149316BB38" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue_2B97B13197C75EF9BF6EE2DCBEEF8563" xlink:type="locator" />
    <link:definitionArc order="8" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_8BA7AAE124125278B85C70980FA793FE" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue_2B97B13197C75EF9BF6EE2DCBEEF8563" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedInPeriodFairValue1" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedInPeriodFairValue1_F8F654A6280F534EB4CAB7702A5BCB62" xlink:type="locator" />
    <link:definitionArc order="9" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_8BA7AAE124125278B85C70980FA793FE" xlink:to="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedInPeriodFairValue1_F8F654A6280F534EB4CAB7702A5BCB62" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod_60D8BAB3559353BF87C58668631C4E9C" xlink:type="locator" />
    <link:definitionArc order="10" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_8BA7AAE124125278B85C70980FA793FE" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod_60D8BAB3559353BF87C58668631C4E9C" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_1B1EA12597975E048309B88020AD8D0C" xlink:type="locator" />
    <link:definitionArc order="11" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_8BA7AAE124125278B85C70980FA793FE" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_1B1EA12597975E048309B88020AD8D0C" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod_9A4F81B9F7105D87AC3EA609BC4E2D23" xlink:type="locator" />
    <link:definitionArc order="12" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_8BA7AAE124125278B85C70980FA793FE" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod_9A4F81B9F7105D87AC3EA609BC4E2D23" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedShareBasedAwardsOtherThanOptions" xlink:label="loc_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedShareBasedAwardsOtherThanOptions_4C60DC9086C454B2A85380BC6E056E39" xlink:type="locator" />
    <link:definitionArc order="13" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_8BA7AAE124125278B85C70980FA793FE" xlink:to="loc_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedShareBasedAwardsOtherThanOptions_4C60DC9086C454B2A85380BC6E056E39" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodTotalFairValue" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodTotalFairValue_502AD5591C475F528B26B6D8CCDFA49E" xlink:type="locator" />
    <link:definitionArc order="14" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_8BA7AAE124125278B85C70980FA793FE" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodTotalFairValue_502AD5591C475F528B26B6D8CCDFA49E" xlink:type="arc" />
  </link:definitionLink>
  <link:definitionLink xlink:role="http://www.linkp.com/role/CommonStockEquityIncentivePlanRangeOfAssumptionsUsedDetails" xlink:type="extended">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_6C85785C522D5C99A60E87BE5131238E" xlink:type="locator" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:label="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_CAB234055CF95FF0B6F4911C41311CB4" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_6C85785C522D5C99A60E87BE5131238E" xlink:to="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_CAB234055CF95FF0B6F4911C41311CB4" xlink:type="arc" xbrldt:closed="true" xbrldt:contextElement="segment" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_AwardTypeAxis" xlink:label="loc_us-gaap_AwardTypeAxis_25E5BC9EF2B65E9DB3D5A4F430FE9FAE" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_CAB234055CF95FF0B6F4911C41311CB4" xlink:to="loc_us-gaap_AwardTypeAxis_25E5BC9EF2B65E9DB3D5A4F430FE9FAE" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_B364928CE2CFE9ADD7B796910A630806_93C1E088CC9D565FB6E0D603FE544AFD" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_AwardTypeAxis_25E5BC9EF2B65E9DB3D5A4F430FE9FAE" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_B364928CE2CFE9ADD7B796910A630806_93C1E088CC9D565FB6E0D603FE544AFD" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_C016D8A23BAA5DC0BDC856CD8D0DB7B8" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_AwardTypeAxis_25E5BC9EF2B65E9DB3D5A4F430FE9FAE" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_C016D8A23BAA5DC0BDC856CD8D0DB7B8" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_EmployeeStockOptionMember" xlink:label="loc_us-gaap_EmployeeStockOptionMember_0F6FA055B4DD5C75803656BD9ACA21A3" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_C016D8A23BAA5DC0BDC856CD8D0DB7B8" xlink:to="loc_us-gaap_EmployeeStockOptionMember_0F6FA055B4DD5C75803656BD9ACA21A3" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_RangeAxis" xlink:label="loc_us-gaap_RangeAxis_9BC9036038C253858C682C694986385F" xlink:type="locator" />
    <link:definitionArc order="2" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_CAB234055CF95FF0B6F4911C41311CB4" xlink:to="loc_us-gaap_RangeAxis_9BC9036038C253858C682C694986385F" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_RangeMember" xlink:label="loc_us-gaap_RangeMember_BC28F423FFD70B64F5CC96910A638E89_93C1E088CC9D565FB6E0D603FE544AFD" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_RangeAxis_9BC9036038C253858C682C694986385F" xlink:to="loc_us-gaap_RangeMember_BC28F423FFD70B64F5CC96910A638E89_93C1E088CC9D565FB6E0D603FE544AFD" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_RangeMember" xlink:label="loc_us-gaap_RangeMember_471CF4B3D03B506F81FB185CC3457E7F" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_RangeAxis_9BC9036038C253858C682C694986385F" xlink:to="loc_us-gaap_RangeMember_471CF4B3D03B506F81FB185CC3457E7F" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_MinimumMember" xlink:label="loc_us-gaap_MinimumMember_122CEFBD85F4591C84DC961FE5D574EE" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_RangeMember_471CF4B3D03B506F81FB185CC3457E7F" xlink:to="loc_us-gaap_MinimumMember_122CEFBD85F4591C84DC961FE5D574EE" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_MaximumMember" xlink:label="loc_us-gaap_MaximumMember_9CBAA569511F5D62923BBDEA436FEAC8" xlink:type="locator" />
    <link:definitionArc order="2" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_RangeMember_471CF4B3D03B506F81FB185CC3457E7F" xlink:to="loc_us-gaap_MaximumMember_9CBAA569511F5D62923BBDEA436FEAC8" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum_EE315B2ACBB35FB6B9284F622A6ADA1B" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_6C85785C522D5C99A60E87BE5131238E" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum_EE315B2ACBB35FB6B9284F622A6ADA1B" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum_98C39F2CBE82565A9786981751F099A7" xlink:type="locator" />
    <link:definitionArc order="2" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_6C85785C522D5C99A60E87BE5131238E" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum_98C39F2CBE82565A9786981751F099A7" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate_EC07A97A868B54B0B2CF401D08CDA527" xlink:type="locator" />
    <link:definitionArc order="3" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_6C85785C522D5C99A60E87BE5131238E" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate_EC07A97A868B54B0B2CF401D08CDA527" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum_2328ED8116185FAB8ACB192B6A85568E" xlink:type="locator" />
    <link:definitionArc order="4" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_6C85785C522D5C99A60E87BE5131238E" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum_2328ED8116185FAB8ACB192B6A85568E" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum_192F5410FE775BEEA017387549AF8EF5" xlink:type="locator" />
    <link:definitionArc order="5" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_6C85785C522D5C99A60E87BE5131238E" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum_192F5410FE775BEEA017387549AF8EF5" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1_9D960C7C28185E358D96D0E77417A543" xlink:type="locator" />
    <link:definitionArc order="6" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_6C85785C522D5C99A60E87BE5131238E" xlink:to="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1_9D960C7C28185E358D96D0E77417A543" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_2A6480D9D164506BB6321FB4BB9AC1BC" xlink:type="locator" />
    <link:definitionArc order="7" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_6C85785C522D5C99A60E87BE5131238E" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_2A6480D9D164506BB6321FB4BB9AC1BC" xlink:type="arc" />
  </link:definitionLink>
  <link:definitionLink xlink:role="http://www.linkp.com/role/CommonStockEquityIncentivePlanRestrictedStockActivityDetails" xlink:type="extended">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_F432975837BB52D0835D69DBE9C40D82" xlink:type="locator" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:label="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_6CECF4DD604D5D51B1D4A1A92165941C" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_F432975837BB52D0835D69DBE9C40D82" xlink:to="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_6CECF4DD604D5D51B1D4A1A92165941C" xlink:type="arc" xbrldt:closed="true" xbrldt:contextElement="segment" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_AwardTypeAxis" xlink:label="loc_us-gaap_AwardTypeAxis_1B9231DC3A5454DBA6791B3D37C71266" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_6CECF4DD604D5D51B1D4A1A92165941C" xlink:to="loc_us-gaap_AwardTypeAxis_1B9231DC3A5454DBA6791B3D37C71266" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_A527E886779484F44D0397345BF08805_93C1E088CC9D565FB6E0D603FE544AFD" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_AwardTypeAxis_1B9231DC3A5454DBA6791B3D37C71266" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_A527E886779484F44D0397345BF08805_93C1E088CC9D565FB6E0D603FE544AFD" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_6A1149278AA651B985A23FF12002C3B8" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_AwardTypeAxis_1B9231DC3A5454DBA6791B3D37C71266" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_6A1149278AA651B985A23FF12002C3B8" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_RestrictedStockMember" xlink:label="loc_us-gaap_RestrictedStockMember_E0FB707EF39550E3AA538F2AE3528446" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_6A1149278AA651B985A23FF12002C3B8" xlink:to="loc_us-gaap_RestrictedStockMember_E0FB707EF39550E3AA538F2AE3528446" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingRollForward" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingRollForward_72AEA9B235095EB0A403C6F59F644DF8" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_F432975837BB52D0835D69DBE9C40D82" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingRollForward_72AEA9B235095EB0A403C6F59F644DF8" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_AFB92A8EBA6254EAA0E7FC24F649D36E" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingRollForward_72AEA9B235095EB0A403C6F59F644DF8" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_AFB92A8EBA6254EAA0E7FC24F649D36E" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod_D7B8138FC9D75FFF9D235BD6B7DA2EFB" xlink:type="locator" />
    <link:definitionArc order="2" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingRollForward_72AEA9B235095EB0A403C6F59F644DF8" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod_D7B8138FC9D75FFF9D235BD6B7DA2EFB" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod_FB0C88639806552980DDCBBE93B9A8D4" xlink:type="locator" />
    <link:definitionArc order="3" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingRollForward_72AEA9B235095EB0A403C6F59F644DF8" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod_FB0C88639806552980DDCBBE93B9A8D4" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod_364EF90C57A1551DA869217A78B291AF" xlink:type="locator" />
    <link:definitionArc order="4" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingRollForward_72AEA9B235095EB0A403C6F59F644DF8" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod_364EF90C57A1551DA869217A78B291AF" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedWeightedAverageGrantDateFairValueAbstract" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedWeightedAverageGrantDateFairValueAbstract_B01EF4E8CCEB5374BCB7A8A102E060DE" xlink:type="locator" />
    <link:definitionArc order="2" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_F432975837BB52D0835D69DBE9C40D82" xlink:to="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedWeightedAverageGrantDateFairValueAbstract_B01EF4E8CCEB5374BCB7A8A102E060DE" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue_091B08B741F759328D394BBC0F68BDA2" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedWeightedAverageGrantDateFairValueAbstract_B01EF4E8CCEB5374BCB7A8A102E060DE" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue_091B08B741F759328D394BBC0F68BDA2" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_009AC2765C7A50398882BF29F8C01091" xlink:type="locator" />
    <link:definitionArc order="2" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedWeightedAverageGrantDateFairValueAbstract_B01EF4E8CCEB5374BCB7A8A102E060DE" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_009AC2765C7A50398882BF29F8C01091" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue_FA8ADC84619656EAB15710FB7C0A953D" xlink:type="locator" />
    <link:definitionArc order="3" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedWeightedAverageGrantDateFairValueAbstract_B01EF4E8CCEB5374BCB7A8A102E060DE" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue_FA8ADC84619656EAB15710FB7C0A953D" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue_392B8C4507B4593EB41F9CD26A70FE44" xlink:type="locator" />
    <link:definitionArc order="4" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedWeightedAverageGrantDateFairValueAbstract_B01EF4E8CCEB5374BCB7A8A102E060DE" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue_392B8C4507B4593EB41F9CD26A70FE44" xlink:type="arc" />
  </link:definitionLink>
  <link:definitionLink xlink:role="http://www.linkp.com/role/CommonStockEquityIncentivePlanStockOptionActivityDetails" xlink:type="extended">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_D224ACC33B23520BBEB54045E0A7ABD4" xlink:type="locator" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:label="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_8D9E49EBB05459349DDF85F4CC108AFD" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_D224ACC33B23520BBEB54045E0A7ABD4" xlink:to="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_8D9E49EBB05459349DDF85F4CC108AFD" xlink:type="arc" xbrldt:closed="true" xbrldt:contextElement="segment" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_AwardTypeAxis" xlink:label="loc_us-gaap_AwardTypeAxis_43B8E6C35CA15A5E9E3F2BF2A5BF574B" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_8D9E49EBB05459349DDF85F4CC108AFD" xlink:to="loc_us-gaap_AwardTypeAxis_43B8E6C35CA15A5E9E3F2BF2A5BF574B" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_068783B105F8CBDF42EF96910A69C454_93C1E088CC9D565FB6E0D603FE544AFD" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_AwardTypeAxis_43B8E6C35CA15A5E9E3F2BF2A5BF574B" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_068783B105F8CBDF42EF96910A69C454_93C1E088CC9D565FB6E0D603FE544AFD" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_C4494F8A63095AF99B0E3C65BC26A74E" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_AwardTypeAxis_43B8E6C35CA15A5E9E3F2BF2A5BF574B" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_C4494F8A63095AF99B0E3C65BC26A74E" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_EmployeeStockOptionMember" xlink:label="loc_us-gaap_EmployeeStockOptionMember_838AF05112995375A31F6E9E88E01A2B" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_C4494F8A63095AF99B0E3C65BC26A74E" xlink:to="loc_us-gaap_EmployeeStockOptionMember_838AF05112995375A31F6E9E88E01A2B" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward_65338224DBBB51D4AFB0D6B08E095160" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_D224ACC33B23520BBEB54045E0A7ABD4" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward_65338224DBBB51D4AFB0D6B08E095160" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_BB11D9EA42DA58A195EBBEF3370874F5" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward_65338224DBBB51D4AFB0D6B08E095160" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_BB11D9EA42DA58A195EBBEF3370874F5" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_C86A957E8B4C5BA080F103F08ABDC331" xlink:type="locator" />
    <link:definitionArc order="2" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward_65338224DBBB51D4AFB0D6B08E095160" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_C86A957E8B4C5BA080F103F08ABDC331" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" xlink:label="loc_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised_96C8A0EE63E75C3ABB6F5240DE52DC18" xlink:type="locator" />
    <link:definitionArc order="3" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward_65338224DBBB51D4AFB0D6B08E095160" xlink:to="loc_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised_96C8A0EE63E75C3ABB6F5240DE52DC18" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod_B479A49C7AFD59B4A65B3ED00D3639A3" xlink:type="locator" />
    <link:definitionArc order="4" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward_65338224DBBB51D4AFB0D6B08E095160" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod_B479A49C7AFD59B4A65B3ED00D3639A3" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod_C67DDB2E9E655890A79ABB80FB2BCA82" xlink:type="locator" />
    <link:definitionArc order="5" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward_65338224DBBB51D4AFB0D6B08E095160" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod_C67DDB2E9E655890A79ABB80FB2BCA82" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward_8EF750B40922514EACDF511A9B240780" xlink:type="locator" />
    <link:definitionArc order="2" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_D224ACC33B23520BBEB54045E0A7ABD4" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward_8EF750B40922514EACDF511A9B240780" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_4CFC98D33F7D50A99840B1C2489CE1B0" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward_8EF750B40922514EACDF511A9B240780" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_4CFC98D33F7D50A99840B1C2489CE1B0" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice_46D736B27A9E578C8B6EE41D6D5AF52B" xlink:type="locator" />
    <link:definitionArc order="2" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward_8EF750B40922514EACDF511A9B240780" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice_46D736B27A9E578C8B6EE41D6D5AF52B" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice_0B5EECDB8FBD5CF5844BC31A234F31AC" xlink:type="locator" />
    <link:definitionArc order="3" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward_8EF750B40922514EACDF511A9B240780" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice_0B5EECDB8FBD5CF5844BC31A234F31AC" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice_E51C7ECB30145C41B474CE2AA8268834" xlink:type="locator" />
    <link:definitionArc order="4" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward_8EF750B40922514EACDF511A9B240780" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice_E51C7ECB30145C41B474CE2AA8268834" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExpirationsInPeriodWeightedAverageExercisePrice" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExpirationsInPeriodWeightedAverageExercisePrice_85C3CE593FE755628A8AFD1E2EC4E05F" xlink:type="locator" />
    <link:definitionArc order="5" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward_8EF750B40922514EACDF511A9B240780" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExpirationsInPeriodWeightedAverageExercisePrice_85C3CE593FE755628A8AFD1E2EC4E05F" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber_813EFE60F729591AA7F24294BDE91C58" xlink:type="locator" />
    <link:definitionArc order="3" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_D224ACC33B23520BBEB54045E0A7ABD4" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber_813EFE60F729591AA7F24294BDE91C58" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice_F5F6C312611456C595460099BDBF027B" xlink:type="locator" />
    <link:definitionArc order="4" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_D224ACC33B23520BBEB54045E0A7ABD4" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice_F5F6C312611456C595460099BDBF027B" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2_99C7E5802F7159419748EEAACBAC6C4A" xlink:type="locator" />
    <link:definitionArc order="5" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_D224ACC33B23520BBEB54045E0A7ABD4" xlink:to="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2_99C7E5802F7159419748EEAACBAC6C4A" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1_F18C5856B0DD5891B7DE3D37BBA69D5B" xlink:type="locator" />
    <link:definitionArc order="6" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_D224ACC33B23520BBEB54045E0A7ABD4" xlink:to="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1_F18C5856B0DD5891B7DE3D37BBA69D5B" xlink:type="arc" />
  </link:definitionLink>
  <link:definitionLink xlink:role="http://www.linkp.com/role/CommonStockEquityIncentivePlanTables" xlink:type="extended" />
  <link:definitionLink xlink:role="http://www.linkp.com/role/CondensedConsolidatedBalanceSheets" xlink:type="extended" />
  <link:definitionLink xlink:role="http://www.linkp.com/role/CondensedConsolidatedBalanceSheetsParentheticals" xlink:type="extended" />
  <link:definitionLink xlink:role="http://www.linkp.com/role/CondensedConsolidatedStatementOfStockholdersEquity" xlink:type="extended">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_StatementLineItems" xlink:label="loc_us-gaap_StatementLineItems_C21B50291753FE636D267D80DFD9ED37" xlink:type="locator" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_StatementTable" xlink:label="loc_us-gaap_StatementTable_DF70F78C9F32839EBB697D80DFD74CBF" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_StatementLineItems_C21B50291753FE636D267D80DFD9ED37" xlink:to="loc_us-gaap_StatementTable_DF70F78C9F32839EBB697D80DFD74CBF" xlink:type="arc" xbrldt:closed="true" xbrldt:contextElement="segment" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_StatementEquityComponentsAxis" xlink:label="loc_us-gaap_StatementEquityComponentsAxis_5A7CF8B2BF4212DE62257D80DFD7E990" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_StatementTable_DF70F78C9F32839EBB697D80DFD74CBF" xlink:to="loc_us-gaap_StatementEquityComponentsAxis_5A7CF8B2BF4212DE62257D80DFD7E990" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_EquityComponentDomain" xlink:label="loc_us-gaap_EquityComponentDomain_914537A5DB82F7229E917D80DFD7AA70_default" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_StatementEquityComponentsAxis_5A7CF8B2BF4212DE62257D80DFD7E990" xlink:to="loc_us-gaap_EquityComponentDomain_914537A5DB82F7229E917D80DFD7AA70_default" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_EquityComponentDomain" xlink:label="loc_us-gaap_EquityComponentDomain_914537A5DB82F7229E917D80DFD7AA70" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_StatementEquityComponentsAxis_5A7CF8B2BF4212DE62257D80DFD7E990" xlink:to="loc_us-gaap_EquityComponentDomain_914537A5DB82F7229E917D80DFD7AA70" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_CommonStockMember" xlink:label="loc_us-gaap_CommonStockMember_920BE3831F05ECD13C217D80DFD82831" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_EquityComponentDomain_914537A5DB82F7229E917D80DFD7AA70" xlink:to="loc_us-gaap_CommonStockMember_920BE3831F05ECD13C217D80DFD82831" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_AdditionalPaidInCapitalMember" xlink:label="loc_us-gaap_AdditionalPaidInCapitalMember_128F5D547E68BE0BDD137D80DFD83F9E" xlink:type="locator" />
    <link:definitionArc order="2" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_EquityComponentDomain_914537A5DB82F7229E917D80DFD7AA70" xlink:to="loc_us-gaap_AdditionalPaidInCapitalMember_128F5D547E68BE0BDD137D80DFD83F9E" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_TreasuryStockMember" xlink:label="loc_us-gaap_TreasuryStockMember_60E7CA8F463F3BBAB2E87D80DFD9FB76" xlink:type="locator" />
    <link:definitionArc order="3" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_EquityComponentDomain_914537A5DB82F7229E917D80DFD7AA70" xlink:to="loc_us-gaap_TreasuryStockMember_60E7CA8F463F3BBAB2E87D80DFD9FB76" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_RetainedEarningsMember" xlink:label="loc_us-gaap_RetainedEarningsMember_B02D6D383A05E52B64A77D80DFD97984" xlink:type="locator" />
    <link:definitionArc order="4" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_EquityComponentDomain_914537A5DB82F7229E917D80DFD7AA70" xlink:to="loc_us-gaap_RetainedEarningsMember_B02D6D383A05E52B64A77D80DFD97984" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_IncreaseDecreaseInStockholdersEquityRollForward" xlink:label="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_C7EB8218872E635D2D8D7D80DFD9986F" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_C21B50291753FE636D267D80DFD9ED37" xlink:to="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_C7EB8218872E635D2D8D7D80DFD9986F" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_StockholdersEquity" xlink:label="loc_us-gaap_StockholdersEquity_25E5FC84ECA92E4D26517D80DFD92A6D" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_C7EB8218872E635D2D8D7D80DFD9986F" xlink:to="loc_us-gaap_StockholdersEquity_25E5FC84ECA92E4D26517D80DFD92A6D" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_CommonStockSharesOutstanding" xlink:label="loc_us-gaap_CommonStockSharesOutstanding_9507634E7873485F0DE47D80DFD902C4" xlink:type="locator" />
    <link:definitionArc order="2" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_C7EB8218872E635D2D8D7D80DFD9986F" xlink:to="loc_us-gaap_CommonStockSharesOutstanding_9507634E7873485F0DE47D80DFD902C4" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" xlink:label="loc_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue_01BA0D31937D404F39247D80DFDACB63" xlink:type="locator" />
    <link:definitionArc order="3" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_C7EB8218872E635D2D8D7D80DFD9986F" xlink:to="loc_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue_01BA0D31937D404F39247D80DFDACB63" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised" xlink:label="loc_us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised_BD8A50F59D9C4A333B857D80DFDAB078" xlink:type="locator" />
    <link:definitionArc order="4" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_C7EB8218872E635D2D8D7D80DFD9986F" xlink:to="loc_us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised_BD8A50F59D9C4A333B857D80DFDAB078" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" xlink:label="loc_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised_916F99481EA3FB8BD7BD7D80DFDA8953" xlink:type="locator" />
    <link:definitionArc order="5" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_C7EB8218872E635D2D8D7D80DFD9986F" xlink:to="loc_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised_916F99481EA3FB8BD7BD7D80DFDA8953" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_StockIssuedDuringPeriodValueEmployeeStockPurchasePlan" xlink:label="loc_us-gaap_StockIssuedDuringPeriodValueEmployeeStockPurchasePlan_3EC5C510DFEA3E34F81B7D80DFDA8EE1" xlink:type="locator" />
    <link:definitionArc order="6" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_C7EB8218872E635D2D8D7D80DFD9986F" xlink:to="loc_us-gaap_StockIssuedDuringPeriodValueEmployeeStockPurchasePlan_3EC5C510DFEA3E34F81B7D80DFDA8EE1" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans" xlink:label="loc_us-gaap_StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans_1A5E04C06C5F84DF96867D80DFDA0A18" xlink:type="locator" />
    <link:definitionArc order="7" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_C7EB8218872E635D2D8D7D80DFD9986F" xlink:to="loc_us-gaap_StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans_1A5E04C06C5F84DF96867D80DFDA0A18" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_StockRepurchasedDuringPeriodValue" xlink:label="loc_us-gaap_StockRepurchasedDuringPeriodValue_694F56B6F76168DBB46C7D80DFDA72BC" xlink:type="locator" />
    <link:definitionArc order="8" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_C7EB8218872E635D2D8D7D80DFD9986F" xlink:to="loc_us-gaap_StockRepurchasedDuringPeriodValue_694F56B6F76168DBB46C7D80DFDA72BC" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_StockIssuedDuringPeriodValueNewIssues" xlink:label="loc_us-gaap_StockIssuedDuringPeriodValueNewIssues_6B5DF0CA35DFAABCBDA07D88B967F069" xlink:type="locator" />
    <link:definitionArc order="9" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_C7EB8218872E635D2D8D7D80DFD9986F" xlink:to="loc_us-gaap_StockIssuedDuringPeriodValueNewIssues_6B5DF0CA35DFAABCBDA07D88B967F069" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesNewIssues" xlink:label="loc_us-gaap_StockIssuedDuringPeriodSharesNewIssues_5FE8CDD2630603785EF67D88ED22E33A" xlink:type="locator" />
    <link:definitionArc order="10" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_C7EB8218872E635D2D8D7D80DFD9986F" xlink:to="loc_us-gaap_StockIssuedDuringPeriodSharesNewIssues_5FE8CDD2630603785EF67D88ED22E33A" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_StockRepurchasedDuringPeriodShares" xlink:label="loc_us-gaap_StockRepurchasedDuringPeriodShares_A2758CE6E3B58D60A8C57D80DFDBA977" xlink:type="locator" />
    <link:definitionArc order="11" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_C7EB8218872E635D2D8D7D80DFD9986F" xlink:to="loc_us-gaap_StockRepurchasedDuringPeriodShares_A2758CE6E3B58D60A8C57D80DFDBA977" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_NetIncomeLoss" xlink:label="loc_us-gaap_NetIncomeLoss_CDCE3FC80B84292562607D80DFDBCF0D" xlink:type="locator" />
    <link:definitionArc order="12" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_C7EB8218872E635D2D8D7D80DFD9986F" xlink:to="loc_us-gaap_NetIncomeLoss_CDCE3FC80B84292562607D80DFDBCF0D" xlink:type="arc" />
  </link:definitionLink>
  <link:definitionLink xlink:role="http://www.linkp.com/role/CondensedConsolidatedStatementOfStockholdersEquityParentheticals" xlink:type="extended" />
  <link:definitionLink xlink:role="http://www.linkp.com/role/CondensedConsolidatedStatementsOfCashFlows" xlink:type="extended" />
  <link:definitionLink xlink:role="http://www.linkp.com/role/CondensedConsolidatedStatementsOfOperations" xlink:type="extended" />
  <link:definitionLink xlink:role="http://www.linkp.com/role/DescriptionOfBusiness" xlink:type="extended" />
  <link:definitionLink xlink:role="http://www.linkp.com/role/DescriptionOfBusinessDetails" xlink:type="extended">
    <link:loc xlink:href="nlnk-20170930.xsd#nlnk_FinancingsLineItems" xlink:label="loc_nlnk_FinancingsLineItems_5D536571D0ABE5AA2C257D80DFBF9E70" xlink:type="locator" />
    <link:loc xlink:href="nlnk-20170930.xsd#nlnk_FinancingsTable" xlink:label="loc_nlnk_FinancingsTable_CC182BBAA355648D5D937D80DFBE6BA5" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_nlnk_FinancingsLineItems_5D536571D0ABE5AA2C257D80DFBF9E70" xlink:to="loc_nlnk_FinancingsTable_CC182BBAA355648D5D937D80DFBE6BA5" xlink:type="arc" xbrldt:closed="true" xbrldt:contextElement="segment" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_SubsequentEventTypeAxis" xlink:label="loc_us-gaap_SubsequentEventTypeAxis_5DE06CB86DC10B71E4827D80DFBE0A34" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_nlnk_FinancingsTable_CC182BBAA355648D5D937D80DFBE6BA5" xlink:to="loc_us-gaap_SubsequentEventTypeAxis_5DE06CB86DC10B71E4827D80DFBE0A34" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_SubsequentEventTypeDomain" xlink:label="loc_us-gaap_SubsequentEventTypeDomain_19E2E36329493B77C9F67D80DFBE9448_default" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_SubsequentEventTypeAxis_5DE06CB86DC10B71E4827D80DFBE0A34" xlink:to="loc_us-gaap_SubsequentEventTypeDomain_19E2E36329493B77C9F67D80DFBE9448_default" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_SubsequentEventTypeDomain" xlink:label="loc_us-gaap_SubsequentEventTypeDomain_19E2E36329493B77C9F67D80DFBE9448" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_SubsequentEventTypeAxis_5DE06CB86DC10B71E4827D80DFBE0A34" xlink:to="loc_us-gaap_SubsequentEventTypeDomain_19E2E36329493B77C9F67D80DFBE9448" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_SubsequentEventMember" xlink:label="loc_us-gaap_SubsequentEventMember_7E042DC78372DD41BA617D80DFBE77BA" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SubsequentEventTypeDomain_19E2E36329493B77C9F67D80DFBE9448" xlink:to="loc_us-gaap_SubsequentEventMember_7E042DC78372DD41BA617D80DFBE77BA" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_SubsidiarySaleOfStockAxis" xlink:label="loc_us-gaap_SubsidiarySaleOfStockAxis_533EFC50C571B0492B997D80DFBEA474" xlink:type="locator" />
    <link:definitionArc order="2" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_nlnk_FinancingsTable_CC182BBAA355648D5D937D80DFBE6BA5" xlink:to="loc_us-gaap_SubsidiarySaleOfStockAxis_533EFC50C571B0492B997D80DFBEA474" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_SaleOfStockNameOfTransactionDomain" xlink:label="loc_us-gaap_SaleOfStockNameOfTransactionDomain_D9419FC15A68353A68037D80DFBE0212_default" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_SubsidiarySaleOfStockAxis_533EFC50C571B0492B997D80DFBEA474" xlink:to="loc_us-gaap_SaleOfStockNameOfTransactionDomain_D9419FC15A68353A68037D80DFBE0212_default" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_SaleOfStockNameOfTransactionDomain" xlink:label="loc_us-gaap_SaleOfStockNameOfTransactionDomain_D9419FC15A68353A68037D80DFBE0212" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_SubsidiarySaleOfStockAxis_533EFC50C571B0492B997D80DFBEA474" xlink:to="loc_us-gaap_SaleOfStockNameOfTransactionDomain_D9419FC15A68353A68037D80DFBE0212" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_IPOMember" xlink:label="loc_us-gaap_IPOMember_4541AA2E115E052C19C47D80DFBE8B83" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SaleOfStockNameOfTransactionDomain_D9419FC15A68353A68037D80DFBE0212" xlink:to="loc_us-gaap_IPOMember_4541AA2E115E052C19C47D80DFBE8B83" xlink:type="arc" />
    <link:loc xlink:href="nlnk-20170930.xsd#nlnk_FollowOnOfferingMember" xlink:label="loc_nlnk_FollowOnOfferingMember_ECBF60CB43EA3FE4A2157D80DFBEAB8B" xlink:type="locator" />
    <link:definitionArc order="2" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SaleOfStockNameOfTransactionDomain_D9419FC15A68353A68037D80DFBE0212" xlink:to="loc_nlnk_FollowOnOfferingMember_ECBF60CB43EA3FE4A2157D80DFBEAB8B" xlink:type="arc" />
    <link:loc xlink:href="nlnk-20170930.xsd#nlnk_ATMOfferingMember" xlink:label="loc_nlnk_ATMOfferingMember_4A0F1CE42404F98840AA7D80DFBE09FE" xlink:type="locator" />
    <link:definitionArc order="3" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SaleOfStockNameOfTransactionDomain_D9419FC15A68353A68037D80DFBE0212" xlink:to="loc_nlnk_ATMOfferingMember_4A0F1CE42404F98840AA7D80DFBE09FE" xlink:type="arc" />
    <link:loc xlink:href="nlnk-20170930.xsd#nlnk_PublicOfferingMember" xlink:label="loc_nlnk_PublicOfferingMember_CDE089F53446C33D089E7D80DFBEB1B1" xlink:type="locator" />
    <link:definitionArc order="4" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SaleOfStockNameOfTransactionDomain_D9419FC15A68353A68037D80DFBE0212" xlink:to="loc_nlnk_PublicOfferingMember_CDE089F53446C33D089E7D80DFBEB1B1" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_TypeOfArrangementAxis" xlink:label="loc_us-gaap_TypeOfArrangementAxis_76981BEDDA50E0BC92797D80DFBF03A5" xlink:type="locator" />
    <link:definitionArc order="3" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_nlnk_FinancingsTable_CC182BBAA355648D5D937D80DFBE6BA5" xlink:to="loc_us-gaap_TypeOfArrangementAxis_76981BEDDA50E0BC92797D80DFBF03A5" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:label="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_55F9BDCDF35C049093D87D80DFBFCDFF_default" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_TypeOfArrangementAxis_76981BEDDA50E0BC92797D80DFBF03A5" xlink:to="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_55F9BDCDF35C049093D87D80DFBFCDFF_default" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:label="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_55F9BDCDF35C049093D87D80DFBFCDFF" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_TypeOfArrangementAxis_76981BEDDA50E0BC92797D80DFBF03A5" xlink:to="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_55F9BDCDF35C049093D87D80DFBFCDFF" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_CollaborativeArrangementMember" xlink:label="loc_us-gaap_CollaborativeArrangementMember_3E134908460BA9F6B11D7D80DFBFEA07" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_55F9BDCDF35C049093D87D80DFBFCDFF" xlink:to="loc_us-gaap_CollaborativeArrangementMember_3E134908460BA9F6B11D7D80DFBFEA07" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.sec.gov/dei/2014/dei-2014-01-31.xsd#dei_LegalEntityAxis" xlink:label="loc_dei_LegalEntityAxis_DA6C083D29F0FFDB96797D80DFBF5841" xlink:type="locator" />
    <link:definitionArc order="4" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_nlnk_FinancingsTable_CC182BBAA355648D5D937D80DFBE6BA5" xlink:to="loc_dei_LegalEntityAxis_DA6C083D29F0FFDB96797D80DFBF5841" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.sec.gov/dei/2014/dei-2014-01-31.xsd#dei_EntityDomain" xlink:label="loc_dei_EntityDomain_D05F199B1B92750702F17D80DFBFD844_default" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_dei_LegalEntityAxis_DA6C083D29F0FFDB96797D80DFBF5841" xlink:to="loc_dei_EntityDomain_D05F199B1B92750702F17D80DFBFD844_default" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.sec.gov/dei/2014/dei-2014-01-31.xsd#dei_EntityDomain" xlink:label="loc_dei_EntityDomain_D05F199B1B92750702F17D80DFBFD844" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_dei_LegalEntityAxis_DA6C083D29F0FFDB96797D80DFBF5841" xlink:to="loc_dei_EntityDomain_D05F199B1B92750702F17D80DFBFD844" xlink:type="arc" />
    <link:loc xlink:href="nlnk-20170930.xsd#nlnk_GenentechInc.Member" xlink:label="loc_nlnk_GenentechInc.Member_2C47B6A25A50EA2A1E237D80DFBF8425" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_dei_EntityDomain_D05F199B1B92750702F17D80DFBFD844" xlink:to="loc_nlnk_GenentechInc.Member_2C47B6A25A50EA2A1E237D80DFBF8425" xlink:type="arc" />
    <link:loc xlink:href="nlnk-20170930.xsd#nlnk_MerckSharpeandDohmeCorpMember" xlink:label="loc_nlnk_MerckSharpeandDohmeCorpMember_BBA99A9007AEB1CEBE0E7D80DFBF9410" xlink:type="locator" />
    <link:definitionArc order="2" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_dei_EntityDomain_D05F199B1B92750702F17D80DFBFD844" xlink:to="loc_nlnk_MerckSharpeandDohmeCorpMember_BBA99A9007AEB1CEBE0E7D80DFBF9410" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_SaleOfStockConsiderationReceivedOnTransaction" xlink:label="loc_us-gaap_SaleOfStockConsiderationReceivedOnTransaction_597EA3BB2D460E790A627D80DFBF9F49" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_nlnk_FinancingsLineItems_5D536571D0ABE5AA2C257D80DFBF9E70" xlink:to="loc_us-gaap_SaleOfStockConsiderationReceivedOnTransaction_597EA3BB2D460E790A627D80DFBF9F49" xlink:type="arc" />
    <link:loc xlink:href="nlnk-20170930.xsd#nlnk_MaximumAvailableUnderATMOffering" xlink:label="loc_nlnk_MaximumAvailableUnderATMOffering_4DB53D4E0E66EF6887417D80DFBFDB12" xlink:type="locator" />
    <link:definitionArc order="2" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_nlnk_FinancingsLineItems_5D536571D0ABE5AA2C257D80DFBF9E70" xlink:to="loc_nlnk_MaximumAvailableUnderATMOffering_4DB53D4E0E66EF6887417D80DFBFDB12" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesNewIssues" xlink:label="loc_us-gaap_StockIssuedDuringPeriodSharesNewIssues_0C0F74537A4BE8C125217D80DFBF1397" xlink:type="locator" />
    <link:definitionArc order="3" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_nlnk_FinancingsLineItems_5D536571D0ABE5AA2C257D80DFBF9E70" xlink:to="loc_us-gaap_StockIssuedDuringPeriodSharesNewIssues_0C0F74537A4BE8C125217D80DFBF1397" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_FeesAndCommissions" xlink:label="loc_us-gaap_FeesAndCommissions_D80FEF3E9594C5F4C1D77D80DFBFA59D" xlink:type="locator" />
    <link:definitionArc order="4" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_nlnk_FinancingsLineItems_5D536571D0ABE5AA2C257D80DFBF9E70" xlink:to="loc_us-gaap_FeesAndCommissions_D80FEF3E9594C5F4C1D77D80DFBFA59D" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_PaymentsForCommissions" xlink:label="loc_us-gaap_PaymentsForCommissions_5F2E9D0E86D9446FD4107D80DFBF2A84" xlink:type="locator" />
    <link:definitionArc order="5" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_nlnk_FinancingsLineItems_5D536571D0ABE5AA2C257D80DFBF9E70" xlink:to="loc_us-gaap_PaymentsForCommissions_5F2E9D0E86D9446FD4107D80DFBF2A84" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_PaymentsOfStockIssuanceCosts" xlink:label="loc_us-gaap_PaymentsOfStockIssuanceCosts_9C94B8803837B98118567D8A35282A67" xlink:type="locator" />
    <link:definitionArc order="6" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_nlnk_FinancingsLineItems_5D536571D0ABE5AA2C257D80DFBF9E70" xlink:to="loc_us-gaap_PaymentsOfStockIssuanceCosts_9C94B8803837B98118567D8A35282A67" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction" xlink:label="loc_us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction_EE5D8693BD75A9CE06E67D80DFBFA7DA" xlink:type="locator" />
    <link:definitionArc order="7" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_nlnk_FinancingsLineItems_5D536571D0ABE5AA2C257D80DFBF9E70" xlink:to="loc_us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction_EE5D8693BD75A9CE06E67D80DFBFA7DA" xlink:type="arc" />
    <link:loc xlink:href="nlnk-20170930.xsd#nlnk_CollaborativeArrangementNumberofArrangements" xlink:label="loc_nlnk_CollaborativeArrangementNumberofArrangements_C6F9D60A4B8F1AECF1547D80DFBF7E55" xlink:type="locator" />
    <link:definitionArc order="8" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_nlnk_FinancingsLineItems_5D536571D0ABE5AA2C257D80DFBF9E70" xlink:to="loc_nlnk_CollaborativeArrangementNumberofArrangements_C6F9D60A4B8F1AECF1547D80DFBF7E55" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_RevenueRecognitionMilestoneMethodRevenueRecognized" xlink:label="loc_us-gaap_RevenueRecognitionMilestoneMethodRevenueRecognized_5823B9300C9D805211F37D80DFC0ADA8" xlink:type="locator" />
    <link:definitionArc order="9" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_nlnk_FinancingsLineItems_5D536571D0ABE5AA2C257D80DFBF9E70" xlink:to="loc_us-gaap_RevenueRecognitionMilestoneMethodRevenueRecognized_5823B9300C9D805211F37D80DFC0ADA8" xlink:type="arc" />
  </link:definitionLink>
  <link:definitionLink xlink:role="http://www.linkp.com/role/DocumentAndEntityInformation" xlink:type="extended" />
  <link:definitionLink xlink:role="http://www.linkp.com/role/IncomeTaxes" xlink:type="extended" />
  <link:definitionLink xlink:role="http://www.linkp.com/role/IncomeTaxesDetails" xlink:type="extended" />
  <link:definitionLink xlink:role="http://www.linkp.com/role/LicenseAndResearchCollaborationAgreements" xlink:type="extended" />
  <link:definitionLink xlink:role="http://www.linkp.com/role/LicenseAndResearchCollaborationAgreementsDetails" xlink:type="extended">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_DeferredRevenueArrangementLineItems" xlink:label="loc_us-gaap_DeferredRevenueArrangementLineItems_244E2E2C633B59AA975F6D9784905F46" xlink:type="locator" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_DeferredRevenueArrangementByTypeTable" xlink:label="loc_us-gaap_DeferredRevenueArrangementByTypeTable_87E2F02AFC7B5B9C9D40A44F105DC71E" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_DeferredRevenueArrangementLineItems_244E2E2C633B59AA975F6D9784905F46" xlink:to="loc_us-gaap_DeferredRevenueArrangementByTypeTable_87E2F02AFC7B5B9C9D40A44F105DC71E" xlink:type="arc" xbrldt:closed="true" xbrldt:contextElement="segment" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_TypeOfArrangementAxis" xlink:label="loc_us-gaap_TypeOfArrangementAxis_5000081179025E0FABCF2EEE3C6761FA" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_DeferredRevenueArrangementByTypeTable_87E2F02AFC7B5B9C9D40A44F105DC71E" xlink:to="loc_us-gaap_TypeOfArrangementAxis_5000081179025E0FABCF2EEE3C6761FA" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:label="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_35577E4EF080B92F3E1997BB456A0980_93C1E088CC9D565FB6E0D603FE544AFD" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_TypeOfArrangementAxis_5000081179025E0FABCF2EEE3C6761FA" xlink:to="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_35577E4EF080B92F3E1997BB456A0980_93C1E088CC9D565FB6E0D603FE544AFD" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:label="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_258EE1E9D1EF52F58B5EA95E8126E246" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_TypeOfArrangementAxis_5000081179025E0FABCF2EEE3C6761FA" xlink:to="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_258EE1E9D1EF52F58B5EA95E8126E246" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_CollaborativeArrangementMember" xlink:label="loc_us-gaap_CollaborativeArrangementMember_EE609EDBB353573280C92AF2A3E4391F" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_258EE1E9D1EF52F58B5EA95E8126E246" xlink:to="loc_us-gaap_CollaborativeArrangementMember_EE609EDBB353573280C92AF2A3E4391F" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.sec.gov/dei/2014/dei-2014-01-31.xsd#dei_LegalEntityAxis" xlink:label="loc_dei_LegalEntityAxis_0860DDEC416750F28A35B356D3A8F07B" xlink:type="locator" />
    <link:definitionArc order="2" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_DeferredRevenueArrangementByTypeTable_87E2F02AFC7B5B9C9D40A44F105DC71E" xlink:to="loc_dei_LegalEntityAxis_0860DDEC416750F28A35B356D3A8F07B" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.sec.gov/dei/2014/dei-2014-01-31.xsd#dei_EntityDomain" xlink:label="loc_dei_EntityDomain_AAAAA738BDE832693D7997BB44A6DD75_93C1E088CC9D565FB6E0D603FE544AFD" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_dei_LegalEntityAxis_0860DDEC416750F28A35B356D3A8F07B" xlink:to="loc_dei_EntityDomain_AAAAA738BDE832693D7997BB44A6DD75_93C1E088CC9D565FB6E0D603FE544AFD" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.sec.gov/dei/2014/dei-2014-01-31.xsd#dei_EntityDomain" xlink:label="loc_dei_EntityDomain_4BC1A985A0F45809B3F7372F5A953279" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_dei_LegalEntityAxis_0860DDEC416750F28A35B356D3A8F07B" xlink:to="loc_dei_EntityDomain_4BC1A985A0F45809B3F7372F5A953279" xlink:type="arc" />
    <link:loc xlink:href="nlnk-20170930.xsd#nlnk_MerckSharpeandDohmeCorpMember" xlink:label="loc_nlnk_MerckSharpeandDohmeCorpMember_BB88552F78EF521BB18A1760895874DE" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_dei_EntityDomain_4BC1A985A0F45809B3F7372F5A953279" xlink:to="loc_nlnk_MerckSharpeandDohmeCorpMember_BB88552F78EF521BB18A1760895874DE" xlink:type="arc" />
    <link:loc xlink:href="nlnk-20170930.xsd#nlnk_GenentechInc.Member" xlink:label="loc_nlnk_GenentechInc.Member_28D46C2DF85E5C8C90FA7965FF33133E" xlink:type="locator" />
    <link:definitionArc order="2" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_dei_EntityDomain_4BC1A985A0F45809B3F7372F5A953279" xlink:to="loc_nlnk_GenentechInc.Member_28D46C2DF85E5C8C90FA7965FF33133E" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_RevenueRecognitionMilestoneMethodRevenueRecognized" xlink:label="loc_us-gaap_RevenueRecognitionMilestoneMethodRevenueRecognized_18F263A407FE5A09AC0686A9ADF83616" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DeferredRevenueArrangementLineItems_244E2E2C633B59AA975F6D9784905F46" xlink:to="loc_us-gaap_RevenueRecognitionMilestoneMethodRevenueRecognized_18F263A407FE5A09AC0686A9ADF83616" xlink:type="arc" />
    <link:loc xlink:href="nlnk-20170930.xsd#nlnk_RevenueRecogitionMilestoneMethodMaximumPotentialRevenue" xlink:label="loc_nlnk_RevenueRecogitionMilestoneMethodMaximumPotentialRevenue_391574CEE8DB504B961CCC96C46FF024" xlink:type="locator" />
    <link:definitionArc order="2" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DeferredRevenueArrangementLineItems_244E2E2C633B59AA975F6D9784905F46" xlink:to="loc_nlnk_RevenueRecogitionMilestoneMethodMaximumPotentialRevenue_391574CEE8DB504B961CCC96C46FF024" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_LicensesRevenue" xlink:label="loc_us-gaap_LicensesRevenue_06B99C0AEF6959CC9D356D1BAC341BD4" xlink:type="locator" />
    <link:definitionArc order="3" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DeferredRevenueArrangementLineItems_244E2E2C633B59AA975F6D9784905F46" xlink:to="loc_us-gaap_LicensesRevenue_06B99C0AEF6959CC9D356D1BAC341BD4" xlink:type="arc" />
    <link:loc xlink:href="nlnk-20170930.xsd#nlnk_LicenseRevenueEmployeeLabor" xlink:label="loc_nlnk_LicenseRevenueEmployeeLabor_31400820E7455549BD802A452102A3AB" xlink:type="locator" />
    <link:definitionArc order="4" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DeferredRevenueArrangementLineItems_244E2E2C633B59AA975F6D9784905F46" xlink:to="loc_nlnk_LicenseRevenueEmployeeLabor_31400820E7455549BD802A452102A3AB" xlink:type="arc" />
    <link:loc xlink:href="nlnk-20170930.xsd#nlnk_LicenseRevenueManagerLabor" xlink:label="loc_nlnk_LicenseRevenueManagerLabor_DF6782D6E2A7552DA4ECFCF43DE30552" xlink:type="locator" />
    <link:definitionArc order="5" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DeferredRevenueArrangementLineItems_244E2E2C633B59AA975F6D9784905F46" xlink:to="loc_nlnk_LicenseRevenueManagerLabor_DF6782D6E2A7552DA4ECFCF43DE30552" xlink:type="arc" />
    <link:loc xlink:href="nlnk-20170930.xsd#nlnk_LicenseRevenueCommitteeLabor" xlink:label="loc_nlnk_LicenseRevenueCommitteeLabor_D653EC20FE615899A97CB3A9BB338001" xlink:type="locator" />
    <link:definitionArc order="6" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DeferredRevenueArrangementLineItems_244E2E2C633B59AA975F6D9784905F46" xlink:to="loc_nlnk_LicenseRevenueCommitteeLabor_D653EC20FE615899A97CB3A9BB338001" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_DeferredRevenue" xlink:label="loc_us-gaap_DeferredRevenue_3656D03DA65E5771A5EBA1985D4C4BBC" xlink:type="locator" />
    <link:definitionArc order="7" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DeferredRevenueArrangementLineItems_244E2E2C633B59AA975F6D9784905F46" xlink:to="loc_us-gaap_DeferredRevenue_3656D03DA65E5771A5EBA1985D4C4BBC" xlink:type="arc" />
  </link:definitionLink>
  <link:definitionLink xlink:role="http://www.linkp.com/role/LongTermDebt" xlink:type="extended" />
  <link:definitionLink xlink:role="http://www.linkp.com/role/LongTermDebtDetails" xlink:type="extended">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_DebtInstrumentLineItems" xlink:label="loc_us-gaap_DebtInstrumentLineItems_924C3770DA1153C986CB26F48E562530" xlink:type="locator" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_DebtInstrumentTable" xlink:label="loc_us-gaap_DebtInstrumentTable_8ABEA65787A15F93A4A2F3346748B599" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_DebtInstrumentLineItems_924C3770DA1153C986CB26F48E562530" xlink:to="loc_us-gaap_DebtInstrumentTable_8ABEA65787A15F93A4A2F3346748B599" xlink:type="arc" xbrldt:closed="true" xbrldt:contextElement="segment" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_LongtermDebtTypeAxis" xlink:label="loc_us-gaap_LongtermDebtTypeAxis_AE1DB761518351EFBA3ED531E0C3B905" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_DebtInstrumentTable_8ABEA65787A15F93A4A2F3346748B599" xlink:to="loc_us-gaap_LongtermDebtTypeAxis_AE1DB761518351EFBA3ED531E0C3B905" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_LongtermDebtTypeDomain" xlink:label="loc_us-gaap_LongtermDebtTypeDomain_3701ECD5EDA8440C44A4A5CB9AED780C_93C1E088CC9D565FB6E0D603FE544AFD" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_LongtermDebtTypeAxis_AE1DB761518351EFBA3ED531E0C3B905" xlink:to="loc_us-gaap_LongtermDebtTypeDomain_3701ECD5EDA8440C44A4A5CB9AED780C_93C1E088CC9D565FB6E0D603FE544AFD" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_LongtermDebtTypeDomain" xlink:label="loc_us-gaap_LongtermDebtTypeDomain_7B9815AD3B27570AADDD9140E537DF9F" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_LongtermDebtTypeAxis_AE1DB761518351EFBA3ED531E0C3B905" xlink:to="loc_us-gaap_LongtermDebtTypeDomain_7B9815AD3B27570AADDD9140E537DF9F" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_LoansPayableMember" xlink:label="loc_us-gaap_LoansPayableMember_029E38CA73B353C79A014BEB6DA82B45" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LongtermDebtTypeDomain_7B9815AD3B27570AADDD9140E537DF9F" xlink:to="loc_us-gaap_LoansPayableMember_029E38CA73B353C79A014BEB6DA82B45" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_DebtInstrumentAxis" xlink:label="loc_us-gaap_DebtInstrumentAxis_F81CBA2C332E51DF94C120A14C46A70C" xlink:type="locator" />
    <link:definitionArc order="2" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_DebtInstrumentTable_8ABEA65787A15F93A4A2F3346748B599" xlink:to="loc_us-gaap_DebtInstrumentAxis_F81CBA2C332E51DF94C120A14C46A70C" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_DebtInstrumentNameDomain" xlink:label="loc_us-gaap_DebtInstrumentNameDomain_83463DB28B4C4F33A00EA5CB9AEEFD39_93C1E088CC9D565FB6E0D603FE544AFD" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_DebtInstrumentAxis_F81CBA2C332E51DF94C120A14C46A70C" xlink:to="loc_us-gaap_DebtInstrumentNameDomain_83463DB28B4C4F33A00EA5CB9AEEFD39_93C1E088CC9D565FB6E0D603FE544AFD" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_DebtInstrumentNameDomain" xlink:label="loc_us-gaap_DebtInstrumentNameDomain_B172B8D4219D5F59AD802E3C93504022" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_DebtInstrumentAxis_F81CBA2C332E51DF94C120A14C46A70C" xlink:to="loc_us-gaap_DebtInstrumentNameDomain_B172B8D4219D5F59AD802E3C93504022" xlink:type="arc" />
    <link:loc xlink:href="nlnk-20170930.xsd#nlnk_CityOfAmesForgivableLoan2010Member" xlink:label="loc_nlnk_CityOfAmesForgivableLoan2010Member_59FEF6421E7A58E9A9BC963571B1B776" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_B172B8D4219D5F59AD802E3C93504022" xlink:to="loc_nlnk_CityOfAmesForgivableLoan2010Member_59FEF6421E7A58E9A9BC963571B1B776" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_DebtInstrumentFaceAmount" xlink:label="loc_us-gaap_DebtInstrumentFaceAmount_CB3B62D8999A5F4495E2A5D266C1E0BE" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_924C3770DA1153C986CB26F48E562530" xlink:to="loc_us-gaap_DebtInstrumentFaceAmount_CB3B62D8999A5F4495E2A5D266C1E0BE" xlink:type="arc" />
    <link:loc xlink:href="nlnk-20170930.xsd#nlnk_DebtInstrumentCovenantRequiredNumberofPositionsCreationandRetention" xlink:label="loc_nlnk_DebtInstrumentCovenantRequiredNumberofPositionsCreationandRetention_1D697EDC4A055D1F8A054D191AEFDDB3" xlink:type="locator" />
    <link:definitionArc order="2" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_924C3770DA1153C986CB26F48E562530" xlink:to="loc_nlnk_DebtInstrumentCovenantRequiredNumberofPositionsCreationandRetention_1D697EDC4A055D1F8A054D191AEFDDB3" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_LesseeLeasingArrangementsOperatingLeasesTermOfContract" xlink:label="loc_us-gaap_LesseeLeasingArrangementsOperatingLeasesTermOfContract_EA528AB23D3257CE9E871B52BA37ACC4" xlink:type="locator" />
    <link:definitionArc order="3" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_924C3770DA1153C986CB26F48E562530" xlink:to="loc_us-gaap_LesseeLeasingArrangementsOperatingLeasesTermOfContract_EA528AB23D3257CE9E871B52BA37ACC4" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_LesseeLeasingArrangementsOperatingLeasesRenewalTerm" xlink:label="loc_us-gaap_LesseeLeasingArrangementsOperatingLeasesRenewalTerm_CF1E2C78AC9B5A4D9E94E83D55A80CDA" xlink:type="locator" />
    <link:definitionArc order="4" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_924C3770DA1153C986CB26F48E562530" xlink:to="loc_us-gaap_LesseeLeasingArrangementsOperatingLeasesRenewalTerm_CF1E2C78AC9B5A4D9E94E83D55A80CDA" xlink:type="arc" />
    <link:loc xlink:href="nlnk-20170930.xsd#nlnk_DebtInstrumentCovenantRequiredMinimumLeaseArea" xlink:label="loc_nlnk_DebtInstrumentCovenantRequiredMinimumLeaseArea_D56BECA863C857C998F32506A673F313" xlink:type="locator" />
    <link:definitionArc order="5" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_924C3770DA1153C986CB26F48E562530" xlink:to="loc_nlnk_DebtInstrumentCovenantRequiredMinimumLeaseArea_D56BECA863C857C998F32506A673F313" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_RevenueFromGrants" xlink:label="loc_us-gaap_RevenueFromGrants_082077E4BCC356E1913C109A6AFECBE1" xlink:type="locator" />
    <link:definitionArc order="6" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_924C3770DA1153C986CB26F48E562530" xlink:to="loc_us-gaap_RevenueFromGrants_082077E4BCC356E1913C109A6AFECBE1" xlink:type="arc" />
  </link:definitionLink>
  <link:definitionLink xlink:role="http://www.linkp.com/role/NetLossPerCommonShare" xlink:type="extended" />
  <link:definitionLink xlink:role="http://www.linkp.com/role/NetLossPerCommonShareAntidilutiveSecuritiesDetails" xlink:type="extended">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems" xlink:label="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems_41225EB82D845782BEA507E0721565F4" xlink:type="locator" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable" xlink:label="loc_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable_EBEE6B587D495A3084D05D04D839781B" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems_41225EB82D845782BEA507E0721565F4" xlink:to="loc_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable_EBEE6B587D495A3084D05D04D839781B" xlink:type="arc" xbrldt:closed="true" xbrldt:contextElement="segment" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" xlink:label="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_33717B3CF51750DD84AA5C75C7A0EFC5" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable_EBEE6B587D495A3084D05D04D839781B" xlink:to="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_33717B3CF51750DD84AA5C75C7A0EFC5" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_AntidilutiveSecuritiesNameDomain" xlink:label="loc_us-gaap_AntidilutiveSecuritiesNameDomain_0113EF5DE39F2B9BE9DB97345B7A71BF_93C1E088CC9D565FB6E0D603FE544AFD" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_33717B3CF51750DD84AA5C75C7A0EFC5" xlink:to="loc_us-gaap_AntidilutiveSecuritiesNameDomain_0113EF5DE39F2B9BE9DB97345B7A71BF_93C1E088CC9D565FB6E0D603FE544AFD" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_AntidilutiveSecuritiesNameDomain" xlink:label="loc_us-gaap_AntidilutiveSecuritiesNameDomain_DFFA213C6BB751A2985553A9AEA8977A" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_33717B3CF51750DD84AA5C75C7A0EFC5" xlink:to="loc_us-gaap_AntidilutiveSecuritiesNameDomain_DFFA213C6BB751A2985553A9AEA8977A" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_EmployeeStockOptionMember" xlink:label="loc_us-gaap_EmployeeStockOptionMember_AE7149E211B75860812F174A763ECBBC" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AntidilutiveSecuritiesNameDomain_DFFA213C6BB751A2985553A9AEA8977A" xlink:to="loc_us-gaap_EmployeeStockOptionMember_AE7149E211B75860812F174A763ECBBC" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_RestrictedStockMember" xlink:label="loc_us-gaap_RestrictedStockMember_4DA16DD324ED5235B84EF3A527C258FC" xlink:type="locator" />
    <link:definitionArc order="2" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AntidilutiveSecuritiesNameDomain_DFFA213C6BB751A2985553A9AEA8977A" xlink:to="loc_us-gaap_RestrictedStockMember_4DA16DD324ED5235B84EF3A527C258FC" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" xlink:label="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_80C65C721A8B5658B692E8C5A0B81452" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems_41225EB82D845782BEA507E0721565F4" xlink:to="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_80C65C721A8B5658B692E8C5A0B81452" xlink:type="arc" />
  </link:definitionLink>
  <link:definitionLink xlink:role="http://www.linkp.com/role/NetLossPerCommonShareNetLossPerShareComputationDetails" xlink:type="extended" />
  <link:definitionLink xlink:role="http://www.linkp.com/role/NetLossPerCommonShareTables" xlink:type="extended" />
  <link:definitionLink xlink:role="http://www.linkp.com/role/RestructuringCharges" xlink:type="extended" />
  <link:definitionLink xlink:role="http://www.linkp.com/role/RestructuringChargesDetails" xlink:type="extended">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_RestructuringCostAndReserveLineItems" xlink:label="loc_us-gaap_RestructuringCostAndReserveLineItems_AC111B3C8ECBDB10DFC86E9EA7915E65" xlink:type="locator" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ScheduleOfRestructuringAndRelatedCostsTable" xlink:label="loc_us-gaap_ScheduleOfRestructuringAndRelatedCostsTable_D55E66560BB4A7FA76BE6E9EA790F045" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_RestructuringCostAndReserveLineItems_AC111B3C8ECBDB10DFC86E9EA7915E65" xlink:to="loc_us-gaap_ScheduleOfRestructuringAndRelatedCostsTable_D55E66560BB4A7FA76BE6E9EA790F045" xlink:type="arc" xbrldt:closed="true" xbrldt:contextElement="segment" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_RestructuringPlanAxis" xlink:label="loc_us-gaap_RestructuringPlanAxis_364AABC63FEE2480F6C56E9EA790C41E" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfRestructuringAndRelatedCostsTable_D55E66560BB4A7FA76BE6E9EA790F045" xlink:to="loc_us-gaap_RestructuringPlanAxis_364AABC63FEE2480F6C56E9EA790C41E" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_RestructuringPlanDomain" xlink:label="loc_us-gaap_RestructuringPlanDomain_493D1823876F90D157DE6E9EA790349B_default" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_RestructuringPlanAxis_364AABC63FEE2480F6C56E9EA790C41E" xlink:to="loc_us-gaap_RestructuringPlanDomain_493D1823876F90D157DE6E9EA790349B_default" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_RestructuringPlanDomain" xlink:label="loc_us-gaap_RestructuringPlanDomain_493D1823876F90D157DE6E9EA790349B" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_RestructuringPlanAxis_364AABC63FEE2480F6C56E9EA790C41E" xlink:to="loc_us-gaap_RestructuringPlanDomain_493D1823876F90D157DE6E9EA790349B" xlink:type="arc" />
    <link:loc xlink:href="nlnk-20170930.xsd#nlnk_TwoThousandSixteenRestructuringPlanMember" xlink:label="loc_nlnk_TwoThousandSixteenRestructuringPlanMember_B5331ACD254DA3C2C8566E9EA7909546" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_RestructuringPlanDomain_493D1823876F90D157DE6E9EA790349B" xlink:to="loc_nlnk_TwoThousandSixteenRestructuringPlanMember_B5331ACD254DA3C2C8566E9EA7909546" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_RestructuringCostAndReserveAxis" xlink:label="loc_us-gaap_RestructuringCostAndReserveAxis_C1C1F7FAA4E15A41F87E6E9EA7905839" xlink:type="locator" />
    <link:definitionArc order="2" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfRestructuringAndRelatedCostsTable_D55E66560BB4A7FA76BE6E9EA790F045" xlink:to="loc_us-gaap_RestructuringCostAndReserveAxis_C1C1F7FAA4E15A41F87E6E9EA7905839" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_TypeOfRestructuringDomain" xlink:label="loc_us-gaap_TypeOfRestructuringDomain_63CFDE90A5421FD1EED96E9EA791BFE1_default" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_RestructuringCostAndReserveAxis_C1C1F7FAA4E15A41F87E6E9EA7905839" xlink:to="loc_us-gaap_TypeOfRestructuringDomain_63CFDE90A5421FD1EED96E9EA791BFE1_default" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_TypeOfRestructuringDomain" xlink:label="loc_us-gaap_TypeOfRestructuringDomain_63CFDE90A5421FD1EED96E9EA791BFE1" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_RestructuringCostAndReserveAxis_C1C1F7FAA4E15A41F87E6E9EA7905839" xlink:to="loc_us-gaap_TypeOfRestructuringDomain_63CFDE90A5421FD1EED96E9EA791BFE1" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_EmployeeSeveranceMember" xlink:label="loc_us-gaap_EmployeeSeveranceMember_D2800628185A0D294F986E9EA79181C1" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_TypeOfRestructuringDomain_63CFDE90A5421FD1EED96E9EA791BFE1" xlink:to="loc_us-gaap_EmployeeSeveranceMember_D2800628185A0D294F986E9EA79181C1" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_IncomeStatementLocationAxis" xlink:label="loc_us-gaap_IncomeStatementLocationAxis_77ED65AEB7AD2A80C8326EA41FF9F974" xlink:type="locator" />
    <link:definitionArc order="3" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfRestructuringAndRelatedCostsTable_D55E66560BB4A7FA76BE6E9EA790F045" xlink:to="loc_us-gaap_IncomeStatementLocationAxis_77ED65AEB7AD2A80C8326EA41FF9F974" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_IncomeStatementLocationDomain" xlink:label="loc_us-gaap_IncomeStatementLocationDomain_70F3A10D6327D0193E8D6EA420009B9A_default" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_IncomeStatementLocationAxis_77ED65AEB7AD2A80C8326EA41FF9F974" xlink:to="loc_us-gaap_IncomeStatementLocationDomain_70F3A10D6327D0193E8D6EA420009B9A_default" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_IncomeStatementLocationDomain" xlink:label="loc_us-gaap_IncomeStatementLocationDomain_70F3A10D6327D0193E8D6EA420009B9A" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_IncomeStatementLocationAxis_77ED65AEB7AD2A80C8326EA41FF9F974" xlink:to="loc_us-gaap_IncomeStatementLocationDomain_70F3A10D6327D0193E8D6EA420009B9A" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_GeneralAndAdministrativeExpenseMember" xlink:label="loc_us-gaap_GeneralAndAdministrativeExpenseMember_0D6B8DAB5379EE26EFDC6EA4FB59FEB4" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncomeStatementLocationDomain_70F3A10D6327D0193E8D6EA420009B9A" xlink:to="loc_us-gaap_GeneralAndAdministrativeExpenseMember_0D6B8DAB5379EE26EFDC6EA4FB59FEB4" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ResearchAndDevelopmentExpenseMember" xlink:label="loc_us-gaap_ResearchAndDevelopmentExpenseMember_B05902B90981ECD5849E6EA7C20BFCF9" xlink:type="locator" />
    <link:definitionArc order="2" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncomeStatementLocationDomain_70F3A10D6327D0193E8D6EA420009B9A" xlink:to="loc_us-gaap_ResearchAndDevelopmentExpenseMember_B05902B90981ECD5849E6EA7C20BFCF9" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_RestructuringAndRelatedCostNumberOfPositionsEliminatedPeriodPercent" xlink:label="loc_us-gaap_RestructuringAndRelatedCostNumberOfPositionsEliminatedPeriodPercent_7D47A0D572FA9076C1686E9EA7915644" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_RestructuringCostAndReserveLineItems_AC111B3C8ECBDB10DFC86E9EA7915E65" xlink:to="loc_us-gaap_RestructuringAndRelatedCostNumberOfPositionsEliminatedPeriodPercent_7D47A0D572FA9076C1686E9EA7915644" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_TangibleAssetImpairmentCharges" xlink:label="loc_us-gaap_TangibleAssetImpairmentCharges_95BECAF172630DD045556E9EA791EDA9" xlink:type="locator" />
    <link:definitionArc order="2" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_RestructuringCostAndReserveLineItems_AC111B3C8ECBDB10DFC86E9EA7915E65" xlink:to="loc_us-gaap_TangibleAssetImpairmentCharges_95BECAF172630DD045556E9EA791EDA9" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_RestructuringReserveRollForward" xlink:label="loc_us-gaap_RestructuringReserveRollForward_CE668F27A768B1102DA46E9EA791AA43" xlink:type="locator" />
    <link:definitionArc order="3" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_RestructuringCostAndReserveLineItems_AC111B3C8ECBDB10DFC86E9EA7915E65" xlink:to="loc_us-gaap_RestructuringReserveRollForward_CE668F27A768B1102DA46E9EA791AA43" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_RestructuringReserve" xlink:label="loc_us-gaap_RestructuringReserve_A8D3BC8F25156B0BD6AD6E9EA79142B0" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_RestructuringReserveRollForward_CE668F27A768B1102DA46E9EA791AA43" xlink:to="loc_us-gaap_RestructuringReserve_A8D3BC8F25156B0BD6AD6E9EA79142B0" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_RestructuringCharges" xlink:label="loc_us-gaap_RestructuringCharges_B016032B15D5FA51E78C6E9EA7916BF5" xlink:type="locator" />
    <link:definitionArc order="2" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_RestructuringReserveRollForward_CE668F27A768B1102DA46E9EA791AA43" xlink:to="loc_us-gaap_RestructuringCharges_B016032B15D5FA51E78C6E9EA7916BF5" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_PaymentsForRestructuring" xlink:label="loc_us-gaap_PaymentsForRestructuring_5F7C2A47BBA90F6B19706E9EA794B7D3" xlink:type="locator" />
    <link:definitionArc order="3" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_RestructuringReserveRollForward_CE668F27A768B1102DA46E9EA791AA43" xlink:to="loc_us-gaap_PaymentsForRestructuring_5F7C2A47BBA90F6B19706E9EA794B7D3" xlink:type="arc" />
  </link:definitionLink>
  <link:definitionLink xlink:role="http://www.linkp.com/role/RestructuringChargesTables" xlink:type="extended" />
  <link:definitionLink xlink:role="http://www.linkp.com/role/SignificantAccountingPolicies" xlink:type="extended" />
  <link:definitionLink xlink:role="http://www.linkp.com/role/SignificantAccountingPoliciesDetails" xlink:type="extended">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_PropertyPlantAndEquipmentLineItems" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentLineItems_754C7397B5F254A4AB9582139E85A981" xlink:type="locator" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ScheduleOfPropertyPlantAndEquipmentTable" xlink:label="loc_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable_ACE48E1C163E515590B650459D6AAAF4" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentLineItems_754C7397B5F254A4AB9582139E85A981" xlink:to="loc_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable_ACE48E1C163E515590B650459D6AAAF4" xlink:type="arc" xbrldt:closed="true" xbrldt:contextElement="segment" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_PropertyPlantAndEquipmentByTypeAxis" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentByTypeAxis_BDB01D77D2AD53C4B33E620C78617522" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable_ACE48E1C163E515590B650459D6AAAF4" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentByTypeAxis_BDB01D77D2AD53C4B33E620C78617522" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_1A8382BB0D6C5185EF0899E0D1C8AD36_93C1E088CC9D565FB6E0D603FE544AFD" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentByTypeAxis_BDB01D77D2AD53C4B33E620C78617522" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_1A8382BB0D6C5185EF0899E0D1C8AD36_93C1E088CC9D565FB6E0D603FE544AFD" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_70B953E5F9DA5A34A287A12496CDC9ED" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentByTypeAxis_BDB01D77D2AD53C4B33E620C78617522" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_70B953E5F9DA5A34A287A12496CDC9ED" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ComputerEquipmentMember" xlink:label="loc_us-gaap_ComputerEquipmentMember_FEE5B3E2884F571ABA7A1CDF82FA1BB3" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_70B953E5F9DA5A34A287A12496CDC9ED" xlink:to="loc_us-gaap_ComputerEquipmentMember_FEE5B3E2884F571ABA7A1CDF82FA1BB3" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_EquipmentMember" xlink:label="loc_us-gaap_EquipmentMember_CE87323608385511BBB1896E33B5C82C" xlink:type="locator" />
    <link:definitionArc order="2" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_70B953E5F9DA5A34A287A12496CDC9ED" xlink:to="loc_us-gaap_EquipmentMember_CE87323608385511BBB1896E33B5C82C" xlink:type="arc" />
    <link:loc xlink:href="nlnk-20170930.xsd#nlnk_ContractManufacturingOrganizationEquipmentMember" xlink:label="loc_nlnk_ContractManufacturingOrganizationEquipmentMember_375F8E9765BA5AAE8717F0F2C57729C5" xlink:type="locator" />
    <link:definitionArc order="3" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_70B953E5F9DA5A34A287A12496CDC9ED" xlink:to="loc_nlnk_ContractManufacturingOrganizationEquipmentMember_375F8E9765BA5AAE8717F0F2C57729C5" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_RangeAxis" xlink:label="loc_us-gaap_RangeAxis_2E066F7F1A1C581AA30328D623109C8E" xlink:type="locator" />
    <link:definitionArc order="2" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable_ACE48E1C163E515590B650459D6AAAF4" xlink:to="loc_us-gaap_RangeAxis_2E066F7F1A1C581AA30328D623109C8E" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_RangeMember" xlink:label="loc_us-gaap_RangeMember_71644BA29A85006E64E199E0D1C8CCB5_93C1E088CC9D565FB6E0D603FE544AFD" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_RangeAxis_2E066F7F1A1C581AA30328D623109C8E" xlink:to="loc_us-gaap_RangeMember_71644BA29A85006E64E199E0D1C8CCB5_93C1E088CC9D565FB6E0D603FE544AFD" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_RangeMember" xlink:label="loc_us-gaap_RangeMember_B9B00260BC355C0784EFA2B6EC530E02" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_RangeAxis_2E066F7F1A1C581AA30328D623109C8E" xlink:to="loc_us-gaap_RangeMember_B9B00260BC355C0784EFA2B6EC530E02" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_MinimumMember" xlink:label="loc_us-gaap_MinimumMember_977C0AFAE253505E9CAC3E6EF428E88E" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_RangeMember_B9B00260BC355C0784EFA2B6EC530E02" xlink:to="loc_us-gaap_MinimumMember_977C0AFAE253505E9CAC3E6EF428E88E" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_MaximumMember" xlink:label="loc_us-gaap_MaximumMember_F9F0B584BE815D4F836273C3D73F3F3F" xlink:type="locator" />
    <link:definitionArc order="2" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_RangeMember_B9B00260BC355C0784EFA2B6EC530E02" xlink:to="loc_us-gaap_MaximumMember_F9F0B584BE815D4F836273C3D73F3F3F" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_PropertyPlantAndEquipmentUsefulLife" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentUsefulLife_ECAF72F879AF559C83117D6F560DDE71" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentLineItems_754C7397B5F254A4AB9582139E85A981" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentUsefulLife_ECAF72F879AF559C83117D6F560DDE71" xlink:type="arc" />
  </link:definitionLink>
  <link:definitionLink xlink:role="http://www.linkp.com/role/SignificantAccountingPoliciesPolicies" xlink:type="extended" />
  <link:definitionLink xlink:role="http://www.linkp.com/role/SubsequentEvents" xlink:type="extended" />
  <link:definitionLink xlink:role="http://www.linkp.com/role/SubsequentEventsDetails" xlink:type="extended">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_SubsequentEventLineItems" xlink:label="loc_us-gaap_SubsequentEventLineItems_8EDAAFE474CB467C69DA7D80DEF0B1E6" xlink:type="locator" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_SubsequentEventTable" xlink:label="loc_us-gaap_SubsequentEventTable_A135507A179004BB776E7D80DEEE2AB9" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_SubsequentEventLineItems_8EDAAFE474CB467C69DA7D80DEF0B1E6" xlink:to="loc_us-gaap_SubsequentEventTable_A135507A179004BB776E7D80DEEE2AB9" xlink:type="arc" xbrldt:closed="true" xbrldt:contextElement="segment" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_SubsequentEventTypeAxis" xlink:label="loc_us-gaap_SubsequentEventTypeAxis_52CC8C4C634355BA71637D80DEEFA30E" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_SubsequentEventTable_A135507A179004BB776E7D80DEEE2AB9" xlink:to="loc_us-gaap_SubsequentEventTypeAxis_52CC8C4C634355BA71637D80DEEFA30E" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_SubsequentEventTypeDomain" xlink:label="loc_us-gaap_SubsequentEventTypeDomain_B45CB0CEE67993169C877D80DEEF5B08_default" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_SubsequentEventTypeAxis_52CC8C4C634355BA71637D80DEEFA30E" xlink:to="loc_us-gaap_SubsequentEventTypeDomain_B45CB0CEE67993169C877D80DEEF5B08_default" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_SubsequentEventTypeDomain" xlink:label="loc_us-gaap_SubsequentEventTypeDomain_B45CB0CEE67993169C877D80DEEF5B08" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_SubsequentEventTypeAxis_52CC8C4C634355BA71637D80DEEFA30E" xlink:to="loc_us-gaap_SubsequentEventTypeDomain_B45CB0CEE67993169C877D80DEEF5B08" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_SubsequentEventMember" xlink:label="loc_us-gaap_SubsequentEventMember_265B83C62438F2BA5D2C7D80DEF037F1" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SubsequentEventTypeDomain_B45CB0CEE67993169C877D80DEEF5B08" xlink:to="loc_us-gaap_SubsequentEventMember_265B83C62438F2BA5D2C7D80DEF037F1" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_SubsidiarySaleOfStockAxis" xlink:label="loc_us-gaap_SubsidiarySaleOfStockAxis_7E8599E6425A9C8411737D83E03B4F3C" xlink:type="locator" />
    <link:definitionArc order="2" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_SubsequentEventTable_A135507A179004BB776E7D80DEEE2AB9" xlink:to="loc_us-gaap_SubsidiarySaleOfStockAxis_7E8599E6425A9C8411737D83E03B4F3C" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_SaleOfStockNameOfTransactionDomain" xlink:label="loc_us-gaap_SaleOfStockNameOfTransactionDomain_DC30A5F3DA72B3A182E77D83E0414260_default" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_SubsidiarySaleOfStockAxis_7E8599E6425A9C8411737D83E03B4F3C" xlink:to="loc_us-gaap_SaleOfStockNameOfTransactionDomain_DC30A5F3DA72B3A182E77D83E0414260_default" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_SaleOfStockNameOfTransactionDomain" xlink:label="loc_us-gaap_SaleOfStockNameOfTransactionDomain_DC30A5F3DA72B3A182E77D83E0414260" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_SubsidiarySaleOfStockAxis_7E8599E6425A9C8411737D83E03B4F3C" xlink:to="loc_us-gaap_SaleOfStockNameOfTransactionDomain_DC30A5F3DA72B3A182E77D83E0414260" xlink:type="arc" />
    <link:loc xlink:href="nlnk-20170930.xsd#nlnk_PublicOfferingMember" xlink:label="loc_nlnk_PublicOfferingMember_7AAC11CAC4D7279EE3367D83E054AE39" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SaleOfStockNameOfTransactionDomain_DC30A5F3DA72B3A182E77D83E0414260" xlink:to="loc_nlnk_PublicOfferingMember_7AAC11CAC4D7279EE3367D83E054AE39" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction" xlink:label="loc_us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction_0006E5AD267EF12079277D83E017C5F6" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SubsequentEventLineItems_8EDAAFE474CB467C69DA7D80DEF0B1E6" xlink:to="loc_us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction_0006E5AD267EF12079277D83E017C5F6" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_SaleOfStockConsiderationReceivedOnTransaction" xlink:label="loc_us-gaap_SaleOfStockConsiderationReceivedOnTransaction_1BB99DAD7F09C931F7307D83E026821C" xlink:type="locator" />
    <link:definitionArc order="2" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SubsequentEventLineItems_8EDAAFE474CB467C69DA7D80DEF0B1E6" xlink:to="loc_us-gaap_SaleOfStockConsiderationReceivedOnTransaction_1BB99DAD7F09C931F7307D83E026821C" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_FeesAndCommissions" xlink:label="loc_us-gaap_FeesAndCommissions_362BD49B3E8DDDE8B0EA7D83E031C1B3" xlink:type="locator" />
    <link:definitionArc order="3" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SubsequentEventLineItems_8EDAAFE474CB467C69DA7D80DEF0B1E6" xlink:to="loc_us-gaap_FeesAndCommissions_362BD49B3E8DDDE8B0EA7D83E031C1B3" xlink:type="arc" />
  </link:definitionLink>
</link:linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.LAB
<SEQUENCE>9
<FILENAME>nlnk-20170930_lab.xml
<DESCRIPTION>XBRL TAXONOMY EXTENSION LABEL LINKBASE DOCUMENT
<TEXT>
<XBRL>
<?xml version="1.0" encoding="US-ASCII"?>
<!--XBRL Document Created with Wdesk from Workiva-->
<!-- -->
<link:linkbase xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd" xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance">
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedPeriodStartLabel" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedPeriodStartLabel" xlink:type="simple" />
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/netLabel" xlink:href="http://www.xbrl.org/lrr/role/net-2009-12-16.xsd#netLabel" xlink:type="simple" />
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedNetLabel" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedNetLabel" xlink:type="simple" />
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedTerseLabel" xlink:type="simple" />
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedPeriodEndLabel" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedPeriodEndLabel" xlink:type="simple" />
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedLabel" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedLabel" xlink:type="simple" />
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedTotalLabel" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedTotalLabel" xlink:type="simple" />
  <link:labelLink xlink:role="http://www.xbrl.org/2003/role/link" xlink:type="extended">
    <link:label id="lab_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_870704320128D1E59DF696910A631AE9_label_en-US" xlink:label="lab_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_53AD0D53993E54D08D9511E8A924998B" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Disclosure of Compensation Related Costs, Share-based Payments [Abstract]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:label="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_53AD0D53993E54D08D9511E8A924998B" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_53AD0D53993E54D08D9511E8A924998B" xlink:to="lab_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_53AD0D53993E54D08D9511E8A924998B" xlink:type="arc" />
    <link:label id="lab_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_7F1D1EBFB7E17D45C39F96910A6372C6_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_CAB234055CF95FF0B6F4911C41311CB4" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Schedule of Share-based Compensation Arrangements by Share-based Payment Award [Table]</link:label>
    <link:label id="lab_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_7F1D1EBFB7E17D45C39F96910A6372C6_label_en-US" xlink:label="lab_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_CAB234055CF95FF0B6F4911C41311CB4" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Schedule of Share-based Compensation Arrangements by Share-based Payment Award [Table]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:label="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_CAB234055CF95FF0B6F4911C41311CB4" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_CAB234055CF95FF0B6F4911C41311CB4" xlink:to="lab_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_CAB234055CF95FF0B6F4911C41311CB4" xlink:type="arc" />
    <link:label id="lab_us-gaap_AwardTypeAxis_62C71A6E7FB7786A5F3A96910A63923F_terseLabel_en-US" xlink:label="lab_us-gaap_AwardTypeAxis_25E5BC9EF2B65E9DB3D5A4F430FE9FAE" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Award Type</link:label>
    <link:label id="lab_us-gaap_AwardTypeAxis_62C71A6E7FB7786A5F3A96910A63923F_label_en-US" xlink:label="lab_us-gaap_AwardTypeAxis_25E5BC9EF2B65E9DB3D5A4F430FE9FAE" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Award Type [Axis]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_AwardTypeAxis" xlink:label="loc_us-gaap_AwardTypeAxis_25E5BC9EF2B65E9DB3D5A4F430FE9FAE" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AwardTypeAxis_25E5BC9EF2B65E9DB3D5A4F430FE9FAE" xlink:to="lab_us-gaap_AwardTypeAxis_25E5BC9EF2B65E9DB3D5A4F430FE9FAE" xlink:type="arc" />
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_B364928CE2CFE9ADD7B796910A630806_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_C016D8A23BAA5DC0BDC856CD8D0DB7B8" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Equity Award</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_B364928CE2CFE9ADD7B796910A630806_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_C016D8A23BAA5DC0BDC856CD8D0DB7B8" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Equity Award [Domain]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_C016D8A23BAA5DC0BDC856CD8D0DB7B8" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_C016D8A23BAA5DC0BDC856CD8D0DB7B8" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_C016D8A23BAA5DC0BDC856CD8D0DB7B8" xlink:type="arc" />
    <link:label id="lab_us-gaap_EmployeeStockOptionMember_D8BD0DB18B7C96A715F296910A639415_terseLabel_en-US" xlink:label="lab_us-gaap_EmployeeStockOptionMember_0F6FA055B4DD5C75803656BD9ACA21A3" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Stock Option</link:label>
    <link:label id="lab_us-gaap_EmployeeStockOptionMember_D8BD0DB18B7C96A715F296910A639415_label_en-US" xlink:label="lab_us-gaap_EmployeeStockOptionMember_0F6FA055B4DD5C75803656BD9ACA21A3" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Employee Stock Option [Member]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_EmployeeStockOptionMember" xlink:label="loc_us-gaap_EmployeeStockOptionMember_0F6FA055B4DD5C75803656BD9ACA21A3" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EmployeeStockOptionMember_0F6FA055B4DD5C75803656BD9ACA21A3" xlink:to="lab_us-gaap_EmployeeStockOptionMember_0F6FA055B4DD5C75803656BD9ACA21A3" xlink:type="arc" />
    <link:label id="lab_us-gaap_RangeAxis_3C85F548DB1B3C6F8DE896910A630195_terseLabel_en-US" xlink:label="lab_us-gaap_RangeAxis_9BC9036038C253858C682C694986385F" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Range [Axis]</link:label>
    <link:label id="lab_us-gaap_RangeAxis_3C85F548DB1B3C6F8DE896910A630195_label_en-US" xlink:label="lab_us-gaap_RangeAxis_9BC9036038C253858C682C694986385F" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Range [Axis]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_RangeAxis" xlink:label="loc_us-gaap_RangeAxis_9BC9036038C253858C682C694986385F" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RangeAxis_9BC9036038C253858C682C694986385F" xlink:to="lab_us-gaap_RangeAxis_9BC9036038C253858C682C694986385F" xlink:type="arc" />
    <link:label id="lab_us-gaap_RangeMember_BC28F423FFD70B64F5CC96910A638E89_terseLabel_en-US" xlink:label="lab_us-gaap_RangeMember_471CF4B3D03B506F81FB185CC3457E7F" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Range [Domain]</link:label>
    <link:label id="lab_us-gaap_RangeMember_BC28F423FFD70B64F5CC96910A638E89_label_en-US" xlink:label="lab_us-gaap_RangeMember_471CF4B3D03B506F81FB185CC3457E7F" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Range [Domain]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_RangeMember" xlink:label="loc_us-gaap_RangeMember_471CF4B3D03B506F81FB185CC3457E7F" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RangeMember_471CF4B3D03B506F81FB185CC3457E7F" xlink:to="lab_us-gaap_RangeMember_471CF4B3D03B506F81FB185CC3457E7F" xlink:type="arc" />
    <link:label id="lab_us-gaap_MinimumMember_A6E60B7008174429591596910A64389B_verboseLabel_en-US" xlink:label="lab_us-gaap_MinimumMember_122CEFBD85F4591C84DC961FE5D574EE" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Minimum</link:label>
    <link:label id="lab_us-gaap_MinimumMember_A6E60B7008174429591596910A64389B_label_en-US" xlink:label="lab_us-gaap_MinimumMember_122CEFBD85F4591C84DC961FE5D574EE" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Minimum [Member]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_MinimumMember" xlink:label="loc_us-gaap_MinimumMember_122CEFBD85F4591C84DC961FE5D574EE" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_MinimumMember_122CEFBD85F4591C84DC961FE5D574EE" xlink:to="lab_us-gaap_MinimumMember_122CEFBD85F4591C84DC961FE5D574EE" xlink:type="arc" />
    <link:label id="lab_us-gaap_MaximumMember_48DE1AA47E1A7C2C6FE296910A6412C5_verboseLabel_en-US" xlink:label="lab_us-gaap_MaximumMember_9CBAA569511F5D62923BBDEA436FEAC8" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Maximum</link:label>
    <link:label id="lab_us-gaap_MaximumMember_48DE1AA47E1A7C2C6FE296910A6412C5_label_en-US" xlink:label="lab_us-gaap_MaximumMember_9CBAA569511F5D62923BBDEA436FEAC8" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Maximum [Member]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_MaximumMember" xlink:label="loc_us-gaap_MaximumMember_9CBAA569511F5D62923BBDEA436FEAC8" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_MaximumMember_9CBAA569511F5D62923BBDEA436FEAC8" xlink:to="lab_us-gaap_MaximumMember_9CBAA569511F5D62923BBDEA436FEAC8" xlink:type="arc" />
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_25CD9529B3850D81690F96910A649908_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_6C85785C522D5C99A60E87BE5131238E" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_25CD9529B3850D81690F96910A649908_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_6C85785C522D5C99A60E87BE5131238E" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award [Line Items]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_6C85785C522D5C99A60E87BE5131238E" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_6C85785C522D5C99A60E87BE5131238E" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_6C85785C522D5C99A60E87BE5131238E" xlink:type="arc" />
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum_4515D97F03D57C85C6D396910A649AD5_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum_EE315B2ACBB35FB6B9284F622A6ADA1B" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Risk-free interest rate, minimum (percent)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum_4515D97F03D57C85C6D396910A649AD5_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum_EE315B2ACBB35FB6B9284F622A6ADA1B" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Risk Free Interest Rate, Minimum</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum_EE315B2ACBB35FB6B9284F622A6ADA1B" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum_EE315B2ACBB35FB6B9284F622A6ADA1B" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum_EE315B2ACBB35FB6B9284F622A6ADA1B" xlink:type="arc" />
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum_4A3BE464EA57FA0C59B096910A64B146_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum_98C39F2CBE82565A9786981751F099A7" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Risk free interest rate, maximum (percent)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum_4A3BE464EA57FA0C59B096910A64B146_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum_98C39F2CBE82565A9786981751F099A7" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Risk Free Interest Rate, Maximum</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum_98C39F2CBE82565A9786981751F099A7" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum_98C39F2CBE82565A9786981751F099A7" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum_98C39F2CBE82565A9786981751F099A7" xlink:type="arc" />
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate_E424C0F127601AFDAAED96910A646FCB_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate_EC07A97A868B54B0B2CF401D08CDA527" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Expected dividend rate (percent)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate_E424C0F127601AFDAAED96910A646FCB_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate_EC07A97A868B54B0B2CF401D08CDA527" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Expected Dividend Rate</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate_EC07A97A868B54B0B2CF401D08CDA527" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate_EC07A97A868B54B0B2CF401D08CDA527" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate_EC07A97A868B54B0B2CF401D08CDA527" xlink:type="arc" />
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum_C9C885FD58C70851256D96910A647747_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum_2328ED8116185FAB8ACB192B6A85568E" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Volatility rate, minimum (percent)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum_C9C885FD58C70851256D96910A647747_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum_2328ED8116185FAB8ACB192B6A85568E" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Expected Volatility Rate, Minimum</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum_2328ED8116185FAB8ACB192B6A85568E" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum_2328ED8116185FAB8ACB192B6A85568E" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum_2328ED8116185FAB8ACB192B6A85568E" xlink:type="arc" />
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum_03DED6AB1762255AC4B196910A6435AF_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum_192F5410FE775BEEA017387549AF8EF5" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Volatility rate, maximum (percent)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum_03DED6AB1762255AC4B196910A6435AF_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum_192F5410FE775BEEA017387549AF8EF5" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Expected Volatility Rate, Maximum</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum_192F5410FE775BEEA017387549AF8EF5" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum_192F5410FE775BEEA017387549AF8EF5" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum_192F5410FE775BEEA017387549AF8EF5" xlink:type="arc" />
    <link:label id="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1_68FBF04FE87AABE189F296910A646FF8_terseLabel_en-US" xlink:label="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1_9D960C7C28185E358D96D0E77417A543" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Expected Term (in years)</link:label>
    <link:label id="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1_68FBF04FE87AABE189F296910A646FF8_label_en-US" xlink:label="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1_9D960C7C28185E358D96D0E77417A543" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Expected Term</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1_9D960C7C28185E358D96D0E77417A543" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1_9D960C7C28185E358D96D0E77417A543" xlink:to="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1_9D960C7C28185E358D96D0E77417A543" xlink:type="arc" />
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_3F64694CFCFA312E159C96910A640333_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_2A6480D9D164506BB6321FB4BB9AC1BC" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Weighted average grant-date fair value per share (in dollars per share)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_3F64694CFCFA312E159C96910A640333_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_2A6480D9D164506BB6321FB4BB9AC1BC" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Weighted Average Grant Date Fair Value</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_2A6480D9D164506BB6321FB4BB9AC1BC" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_2A6480D9D164506BB6321FB4BB9AC1BC" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_2A6480D9D164506BB6321FB4BB9AC1BC" xlink:type="arc" />
    <link:label id="lab_us-gaap_IncomeTaxDisclosureAbstract_CD351C2662DEAA4B4E6299648A6A5319_label_en-US" xlink:label="lab_us-gaap_IncomeTaxDisclosureAbstract_D77BAC171E8E56E5BDEBA5241F9EF985" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Income Tax Disclosure [Abstract]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_IncomeTaxDisclosureAbstract" xlink:label="loc_us-gaap_IncomeTaxDisclosureAbstract_D77BAC171E8E56E5BDEBA5241F9EF985" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeTaxDisclosureAbstract_D77BAC171E8E56E5BDEBA5241F9EF985" xlink:to="lab_us-gaap_IncomeTaxDisclosureAbstract_D77BAC171E8E56E5BDEBA5241F9EF985" xlink:type="arc" />
    <link:label id="lab_us-gaap_IncomeTaxExpenseBenefit_9CA08F5EE7EC19DECE4699648A6AD4EA_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_IncomeTaxExpenseBenefit_2A36108AAFF750E980D50CA67F083E65" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xml:lang="en-US">Income tax benefit</link:label>
    <link:label id="lab_us-gaap_IncomeTaxExpenseBenefit_9CA08F5EE7EC19DECE4699648A6AD4EA_label_en-US" xlink:label="lab_us-gaap_IncomeTaxExpenseBenefit_2A36108AAFF750E980D50CA67F083E65" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Income Tax Expense (Benefit)</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_IncomeTaxExpenseBenefit" xlink:label="loc_us-gaap_IncomeTaxExpenseBenefit_2A36108AAFF750E980D50CA67F083E65" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeTaxExpenseBenefit_2A36108AAFF750E980D50CA67F083E65" xlink:to="lab_us-gaap_IncomeTaxExpenseBenefit_2A36108AAFF750E980D50CA67F083E65" xlink:type="arc" />
    <link:label id="lab_us-gaap_LiabilityForUncertainTaxPositionsCurrent_867F12F54AD6215B8A7599648A6A8068_terseLabel_en-US" xlink:label="lab_us-gaap_LiabilityForUncertainTaxPositionsCurrent_A769EB446EA25007BCC9FC61DD5B610E" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Uncertain tax positions</link:label>
    <link:label id="lab_us-gaap_LiabilityForUncertainTaxPositionsCurrent_867F12F54AD6215B8A7599648A6A8068_label_en-US" xlink:label="lab_us-gaap_LiabilityForUncertainTaxPositionsCurrent_A769EB446EA25007BCC9FC61DD5B610E" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Liability for Uncertainty in Income Taxes, Current</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_LiabilityForUncertainTaxPositionsCurrent" xlink:label="loc_us-gaap_LiabilityForUncertainTaxPositionsCurrent_A769EB446EA25007BCC9FC61DD5B610E" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LiabilityForUncertainTaxPositionsCurrent_A769EB446EA25007BCC9FC61DD5B610E" xlink:to="lab_us-gaap_LiabilityForUncertainTaxPositionsCurrent_A769EB446EA25007BCC9FC61DD5B610E" xlink:type="arc" />
    <link:label id="lab_us-gaap_StatementOfFinancialPositionAbstract_7B03DC2BBED5DDD1CD025088231C776D_label_en-US" xlink:label="lab_us-gaap_StatementOfFinancialPositionAbstract_7B03DC2BBED5DDD1CD025088231C776D" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Statement of Financial Position [Abstract]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_StatementOfFinancialPositionAbstract" xlink:label="loc_us-gaap_StatementOfFinancialPositionAbstract_7B03DC2BBED5DDD1CD025088231C776D" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StatementOfFinancialPositionAbstract_7B03DC2BBED5DDD1CD025088231C776D" xlink:to="lab_us-gaap_StatementOfFinancialPositionAbstract_7B03DC2BBED5DDD1CD025088231C776D" xlink:type="arc" />
    <link:label id="lab_us-gaap_StockholdersEquityNumberOfSharesParValueAndOtherDisclosuresAbstract_77E65BA0BDED9C8C63F15088231C9931_terseLabel_en-US" xlink:label="lab_us-gaap_StockholdersEquityNumberOfSharesParValueAndOtherDisclosuresAbstract_77E65BA0BDED9C8C63F15088231C9931" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Stockholders' Equity:</link:label>
    <link:label id="lab_us-gaap_StockholdersEquityNumberOfSharesParValueAndOtherDisclosuresAbstract_77E65BA0BDED9C8C63F15088231C9931_label_en-US" xlink:label="lab_us-gaap_StockholdersEquityNumberOfSharesParValueAndOtherDisclosuresAbstract_77E65BA0BDED9C8C63F15088231C9931" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Stockholders' Equity, Number of Shares, Par Value and Other Disclosures [Abstract]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_StockholdersEquityNumberOfSharesParValueAndOtherDisclosuresAbstract" xlink:label="loc_us-gaap_StockholdersEquityNumberOfSharesParValueAndOtherDisclosuresAbstract_77E65BA0BDED9C8C63F15088231C9931" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StockholdersEquityNumberOfSharesParValueAndOtherDisclosuresAbstract_77E65BA0BDED9C8C63F15088231C9931" xlink:to="lab_us-gaap_StockholdersEquityNumberOfSharesParValueAndOtherDisclosuresAbstract_77E65BA0BDED9C8C63F15088231C9931" xlink:type="arc" />
    <link:label id="lab_us-gaap_PreferredStockParOrStatedValuePerShare_2876EC28E4D01B6538565088231DB37E_terseLabel_en-US" xlink:label="lab_us-gaap_PreferredStockParOrStatedValuePerShare_2876EC28E4D01B6538565088231DB37E" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Blank check preferred stock, par value (in dollars per share)</link:label>
    <link:label id="lab_us-gaap_PreferredStockParOrStatedValuePerShare_2876EC28E4D01B6538565088231DB37E_label_en-US" xlink:label="lab_us-gaap_PreferredStockParOrStatedValuePerShare_2876EC28E4D01B6538565088231DB37E" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Preferred Stock, Par or Stated Value Per Share</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_PreferredStockParOrStatedValuePerShare" xlink:label="loc_us-gaap_PreferredStockParOrStatedValuePerShare_2876EC28E4D01B6538565088231DB37E" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PreferredStockParOrStatedValuePerShare_2876EC28E4D01B6538565088231DB37E" xlink:to="lab_us-gaap_PreferredStockParOrStatedValuePerShare_2876EC28E4D01B6538565088231DB37E" xlink:type="arc" />
    <link:label id="lab_us-gaap_PreferredStockSharesAuthorized_79B720F570F07964F2905088231DE4A5_terseLabel_en-US" xlink:label="lab_us-gaap_PreferredStockSharesAuthorized_79B720F570F07964F2905088231DE4A5" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Blank check preferred stock, authorized shares</link:label>
    <link:label id="lab_us-gaap_PreferredStockSharesAuthorized_79B720F570F07964F2905088231DE4A5_label_en-US" xlink:label="lab_us-gaap_PreferredStockSharesAuthorized_79B720F570F07964F2905088231DE4A5" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Preferred Stock, Shares Authorized</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_PreferredStockSharesAuthorized" xlink:label="loc_us-gaap_PreferredStockSharesAuthorized_79B720F570F07964F2905088231DE4A5" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PreferredStockSharesAuthorized_79B720F570F07964F2905088231DE4A5" xlink:to="lab_us-gaap_PreferredStockSharesAuthorized_79B720F570F07964F2905088231DE4A5" xlink:type="arc" />
    <link:label id="lab_us-gaap_PreferredStockSharesIssued_01AEFA3E5595975E60715088231D68C4_terseLabel_en-US" xlink:label="lab_us-gaap_PreferredStockSharesIssued_01AEFA3E5595975E60715088231D68C4" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Blank check preferred stock, issued shares</link:label>
    <link:label id="lab_us-gaap_PreferredStockSharesIssued_01AEFA3E5595975E60715088231D68C4_label_en-US" xlink:label="lab_us-gaap_PreferredStockSharesIssued_01AEFA3E5595975E60715088231D68C4" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Preferred Stock, Shares Issued</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_PreferredStockSharesIssued" xlink:label="loc_us-gaap_PreferredStockSharesIssued_01AEFA3E5595975E60715088231D68C4" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PreferredStockSharesIssued_01AEFA3E5595975E60715088231D68C4" xlink:to="lab_us-gaap_PreferredStockSharesIssued_01AEFA3E5595975E60715088231D68C4" xlink:type="arc" />
    <link:label id="lab_us-gaap_PreferredStockSharesOutstanding_CE90A44D0B5A649BF2965088231DD5B1_terseLabel_en-US" xlink:label="lab_us-gaap_PreferredStockSharesOutstanding_CE90A44D0B5A649BF2965088231DD5B1" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Blank check preferred stock, outstanding shares</link:label>
    <link:label id="lab_us-gaap_PreferredStockSharesOutstanding_CE90A44D0B5A649BF2965088231DD5B1_label_en-US" xlink:label="lab_us-gaap_PreferredStockSharesOutstanding_CE90A44D0B5A649BF2965088231DD5B1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Preferred Stock, Shares Outstanding</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_PreferredStockSharesOutstanding" xlink:label="loc_us-gaap_PreferredStockSharesOutstanding_CE90A44D0B5A649BF2965088231DD5B1" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PreferredStockSharesOutstanding_CE90A44D0B5A649BF2965088231DD5B1" xlink:to="lab_us-gaap_PreferredStockSharesOutstanding_CE90A44D0B5A649BF2965088231DD5B1" xlink:type="arc" />
    <link:label id="lab_us-gaap_CommonStockParOrStatedValuePerShare_5CAF9CC29EA4AA953B005088231DE494_terseLabel_en-US" xlink:label="lab_us-gaap_CommonStockParOrStatedValuePerShare_5CAF9CC29EA4AA953B005088231DE494" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Common stock, par value (in dollars per share)</link:label>
    <link:label id="lab_us-gaap_CommonStockParOrStatedValuePerShare_5CAF9CC29EA4AA953B005088231DE494_label_en-US" xlink:label="lab_us-gaap_CommonStockParOrStatedValuePerShare_5CAF9CC29EA4AA953B005088231DE494" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Common Stock, Par or Stated Value Per Share</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_CommonStockParOrStatedValuePerShare" xlink:label="loc_us-gaap_CommonStockParOrStatedValuePerShare_5CAF9CC29EA4AA953B005088231DE494" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CommonStockParOrStatedValuePerShare_5CAF9CC29EA4AA953B005088231DE494" xlink:to="lab_us-gaap_CommonStockParOrStatedValuePerShare_5CAF9CC29EA4AA953B005088231DE494" xlink:type="arc" />
    <link:label id="lab_us-gaap_CommonStockSharesAuthorized_B3E8AF3A50521678CF785088231D0BC3_terseLabel_en-US" xlink:label="lab_us-gaap_CommonStockSharesAuthorized_B3E8AF3A50521678CF785088231D0BC3" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Common stock, authorized shares</link:label>
    <link:label id="lab_us-gaap_CommonStockSharesAuthorized_B3E8AF3A50521678CF785088231D0BC3_label_en-US" xlink:label="lab_us-gaap_CommonStockSharesAuthorized_B3E8AF3A50521678CF785088231D0BC3" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Common Stock, Shares Authorized</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_CommonStockSharesAuthorized" xlink:label="loc_us-gaap_CommonStockSharesAuthorized_B3E8AF3A50521678CF785088231D0BC3" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CommonStockSharesAuthorized_B3E8AF3A50521678CF785088231D0BC3" xlink:to="lab_us-gaap_CommonStockSharesAuthorized_B3E8AF3A50521678CF785088231D0BC3" xlink:type="arc" />
    <link:label id="lab_us-gaap_CommonStockSharesIssued_5CFE5A0D3364C948DAB45088231D9CED_terseLabel_en-US" xlink:label="lab_us-gaap_CommonStockSharesIssued_5CFE5A0D3364C948DAB45088231D9CED" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Common stock, issued shares</link:label>
    <link:label id="lab_us-gaap_CommonStockSharesIssued_5CFE5A0D3364C948DAB45088231D9CED_label_en-US" xlink:label="lab_us-gaap_CommonStockSharesIssued_5CFE5A0D3364C948DAB45088231D9CED" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Common Stock, Shares, Issued</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_CommonStockSharesIssued" xlink:label="loc_us-gaap_CommonStockSharesIssued_5CFE5A0D3364C948DAB45088231D9CED" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CommonStockSharesIssued_5CFE5A0D3364C948DAB45088231D9CED" xlink:to="lab_us-gaap_CommonStockSharesIssued_5CFE5A0D3364C948DAB45088231D9CED" xlink:type="arc" />
    <link:label id="lab_us-gaap_CommonStockSharesOutstanding_8930DD0A3740A285F0EF5088231D3669_verboseLabel_en-US" xlink:label="lab_us-gaap_CommonStockSharesOutstanding_8930DD0A3740A285F0EF5088231D3669" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Common stock, outstanding shares</link:label>
    <link:label id="lab_us-gaap_CommonStockSharesOutstanding_8930DD0A3740A285F0EF5088231D3669_label_en-US" xlink:label="lab_us-gaap_CommonStockSharesOutstanding_8930DD0A3740A285F0EF5088231D3669" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Common Stock, Shares, Outstanding</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_CommonStockSharesOutstanding" xlink:label="loc_us-gaap_CommonStockSharesOutstanding_8930DD0A3740A285F0EF5088231D3669" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CommonStockSharesOutstanding_8930DD0A3740A285F0EF5088231D3669" xlink:to="lab_us-gaap_CommonStockSharesOutstanding_8930DD0A3740A285F0EF5088231D3669" xlink:type="arc" />
    <link:label id="lab_us-gaap_TreasuryStockShares_9D4A614CE4C3595BDB755088231D833D_terseLabel_en-US" xlink:label="lab_us-gaap_TreasuryStockShares_9D4A614CE4C3595BDB755088231D833D" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Treasury stock, shares</link:label>
    <link:label id="lab_us-gaap_TreasuryStockShares_9D4A614CE4C3595BDB755088231D833D_label_en-US" xlink:label="lab_us-gaap_TreasuryStockShares_9D4A614CE4C3595BDB755088231D833D" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Treasury Stock, Shares</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_TreasuryStockShares" xlink:label="loc_us-gaap_TreasuryStockShares_9D4A614CE4C3595BDB755088231D833D" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_TreasuryStockShares_9D4A614CE4C3595BDB755088231D833D" xlink:to="lab_us-gaap_TreasuryStockShares_9D4A614CE4C3595BDB755088231D833D" xlink:type="arc" />
    <link:label id="lab_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_E2DD57A22C2FA52CE18497B9454766AC_label_en-US" xlink:label="lab_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_BAA5C94719BF57EB915F87C1ED39F182" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Organization, Consolidation and Presentation of Financial Statements [Abstract]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:label="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_BAA5C94719BF57EB915F87C1ED39F182" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_BAA5C94719BF57EB915F87C1ED39F182" xlink:to="lab_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_BAA5C94719BF57EB915F87C1ED39F182" xlink:type="arc" />
    <link:label id="lab_us-gaap_DeferredRevenueArrangementByTypeTable_227314B3291357084D2097B9454FC882_terseLabel_en-US" xlink:label="lab_us-gaap_DeferredRevenueArrangementByTypeTable_87E2F02AFC7B5B9C9D40A44F105DC71E" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Deferred Revenue Arrangement, by Type [Table]</link:label>
    <link:label id="lab_us-gaap_DeferredRevenueArrangementByTypeTable_227314B3291357084D2097B9454FC882_label_en-US" xlink:label="lab_us-gaap_DeferredRevenueArrangementByTypeTable_87E2F02AFC7B5B9C9D40A44F105DC71E" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Deferred Revenue Arrangement, by Type [Table]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_DeferredRevenueArrangementByTypeTable" xlink:label="loc_us-gaap_DeferredRevenueArrangementByTypeTable_87E2F02AFC7B5B9C9D40A44F105DC71E" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DeferredRevenueArrangementByTypeTable_87E2F02AFC7B5B9C9D40A44F105DC71E" xlink:to="lab_us-gaap_DeferredRevenueArrangementByTypeTable_87E2F02AFC7B5B9C9D40A44F105DC71E" xlink:type="arc" />
    <link:label id="lab_us-gaap_TypeOfArrangementAxis_379C60621A60ED60996197BB4564DE6A_terseLabel_en-US" xlink:label="lab_us-gaap_TypeOfArrangementAxis_5000081179025E0FABCF2EEE3C6761FA" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Type of Arrangement and Non-arrangement Transactions [Axis]</link:label>
    <link:label id="lab_us-gaap_TypeOfArrangementAxis_379C60621A60ED60996197BB4564DE6A_label_en-US" xlink:label="lab_us-gaap_TypeOfArrangementAxis_5000081179025E0FABCF2EEE3C6761FA" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Type of Arrangement and Non-arrangement Transactions [Axis]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_TypeOfArrangementAxis" xlink:label="loc_us-gaap_TypeOfArrangementAxis_5000081179025E0FABCF2EEE3C6761FA" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_TypeOfArrangementAxis_5000081179025E0FABCF2EEE3C6761FA" xlink:to="lab_us-gaap_TypeOfArrangementAxis_5000081179025E0FABCF2EEE3C6761FA" xlink:type="arc" />
    <link:label id="lab_us-gaap_ArrangementsAndNonarrangementTransactionsMember_35577E4EF080B92F3E1997BB456A0980_terseLabel_en-US" xlink:label="lab_us-gaap_ArrangementsAndNonarrangementTransactionsMember_258EE1E9D1EF52F58B5EA95E8126E246" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Arrangements and Non-arrangement Transactions [Domain]</link:label>
    <link:label id="lab_us-gaap_ArrangementsAndNonarrangementTransactionsMember_35577E4EF080B92F3E1997BB456A0980_label_en-US" xlink:label="lab_us-gaap_ArrangementsAndNonarrangementTransactionsMember_258EE1E9D1EF52F58B5EA95E8126E246" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Arrangements and Non-arrangement Transactions [Domain]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:label="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_258EE1E9D1EF52F58B5EA95E8126E246" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_258EE1E9D1EF52F58B5EA95E8126E246" xlink:to="lab_us-gaap_ArrangementsAndNonarrangementTransactionsMember_258EE1E9D1EF52F58B5EA95E8126E246" xlink:type="arc" />
    <link:label id="lab_us-gaap_CollaborativeArrangementMember_613CC636014AC5BD0CB297BB464CA5AA_terseLabel_en-US" xlink:label="lab_us-gaap_CollaborativeArrangementMember_EE609EDBB353573280C92AF2A3E4391F" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">License and Collaborative Arrangement</link:label>
    <link:label id="lab_us-gaap_CollaborativeArrangementMember_613CC636014AC5BD0CB297BB464CA5AA_label_en-US" xlink:label="lab_us-gaap_CollaborativeArrangementMember_EE609EDBB353573280C92AF2A3E4391F" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Collaborative Arrangement [Member]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_CollaborativeArrangementMember" xlink:label="loc_us-gaap_CollaborativeArrangementMember_EE609EDBB353573280C92AF2A3E4391F" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CollaborativeArrangementMember_EE609EDBB353573280C92AF2A3E4391F" xlink:to="lab_us-gaap_CollaborativeArrangementMember_EE609EDBB353573280C92AF2A3E4391F" xlink:type="arc" />
    <link:label id="lab_dei_LegalEntityAxis_D3E2E5D04EB18C2C59ED97BB449FC18C_terseLabel_en-US" xlink:label="lab_dei_LegalEntityAxis_0860DDEC416750F28A35B356D3A8F07B" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Legal Entity [Axis]</link:label>
    <link:label id="lab_dei_LegalEntityAxis_D3E2E5D04EB18C2C59ED97BB449FC18C_label_en-US" xlink:label="lab_dei_LegalEntityAxis_0860DDEC416750F28A35B356D3A8F07B" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Legal Entity [Axis]</link:label>
    <link:loc xlink:href="http://xbrl.sec.gov/dei/2014/dei-2014-01-31.xsd#dei_LegalEntityAxis" xlink:label="loc_dei_LegalEntityAxis_0860DDEC416750F28A35B356D3A8F07B" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_LegalEntityAxis_0860DDEC416750F28A35B356D3A8F07B" xlink:to="lab_dei_LegalEntityAxis_0860DDEC416750F28A35B356D3A8F07B" xlink:type="arc" />
    <link:label id="lab_dei_EntityDomain_AAAAA738BDE832693D7997BB44A6DD75_terseLabel_en-US" xlink:label="lab_dei_EntityDomain_4BC1A985A0F45809B3F7372F5A953279" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Entity [Domain]</link:label>
    <link:label id="lab_dei_EntityDomain_AAAAA738BDE832693D7997BB44A6DD75_label_en-US" xlink:label="lab_dei_EntityDomain_4BC1A985A0F45809B3F7372F5A953279" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Entity [Domain]</link:label>
    <link:loc xlink:href="http://xbrl.sec.gov/dei/2014/dei-2014-01-31.xsd#dei_EntityDomain" xlink:label="loc_dei_EntityDomain_4BC1A985A0F45809B3F7372F5A953279" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityDomain_4BC1A985A0F45809B3F7372F5A953279" xlink:to="lab_dei_EntityDomain_4BC1A985A0F45809B3F7372F5A953279" xlink:type="arc" />
    <link:label id="lab_nlnk_MerckSharpeandDohmeCorpMember_AE8795ED654BE90E85ED97BCF65B56EB_terseLabel_en-US" xlink:label="lab_nlnk_MerckSharpeandDohmeCorpMember_BB88552F78EF521BB18A1760895874DE" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Merck</link:label>
    <link:label id="lab_nlnk_MerckSharpeandDohmeCorpMember_AE8795ED654BE90E85ED97BCF65B56EB_label_en-US" xlink:label="lab_nlnk_MerckSharpeandDohmeCorpMember_BB88552F78EF521BB18A1760895874DE" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Merck, Sharpe and Dohme Corp [Member]</link:label>
    <link:label id="lab_nlnk_MerckSharpeandDohmeCorpMember_AE8795ED654BE90E85ED97BCF65B56EB_documentation_en-US" xlink:label="lab_nlnk_MerckSharpeandDohmeCorpMember_BB88552F78EF521BB18A1760895874DE" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Merck, Sharpe and Dohme Corp [Member]</link:label>
    <link:loc xlink:href="nlnk-20170930.xsd#nlnk_MerckSharpeandDohmeCorpMember" xlink:label="loc_nlnk_MerckSharpeandDohmeCorpMember_BB88552F78EF521BB18A1760895874DE" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_nlnk_MerckSharpeandDohmeCorpMember_BB88552F78EF521BB18A1760895874DE" xlink:to="lab_nlnk_MerckSharpeandDohmeCorpMember_BB88552F78EF521BB18A1760895874DE" xlink:type="arc" />
    <link:label id="lab_nlnk_GenentechInc.Member_DDDD0E4C2691C994288597BB4520DB18_terseLabel_en-US" xlink:label="lab_nlnk_GenentechInc.Member_28D46C2DF85E5C8C90FA7965FF33133E" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Genentech</link:label>
    <link:label id="lab_nlnk_GenentechInc.Member_DDDD0E4C2691C994288597BB4520DB18_label_en-US" xlink:label="lab_nlnk_GenentechInc.Member_28D46C2DF85E5C8C90FA7965FF33133E" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Genentech Inc. [Member]</link:label>
    <link:label id="lab_nlnk_GenentechInc.Member_DDDD0E4C2691C994288597BB4520DB18_documentation_en-US" xlink:label="lab_nlnk_GenentechInc.Member_28D46C2DF85E5C8C90FA7965FF33133E" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Genentech Inc.</link:label>
    <link:loc xlink:href="nlnk-20170930.xsd#nlnk_GenentechInc.Member" xlink:label="loc_nlnk_GenentechInc.Member_28D46C2DF85E5C8C90FA7965FF33133E" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_nlnk_GenentechInc.Member_28D46C2DF85E5C8C90FA7965FF33133E" xlink:to="lab_nlnk_GenentechInc.Member_28D46C2DF85E5C8C90FA7965FF33133E" xlink:type="arc" />
    <link:label id="lab_us-gaap_DeferredRevenueArrangementLineItems_4E5FA481C2321BE4205097B9454FA7D3_terseLabel_en-US" xlink:label="lab_us-gaap_DeferredRevenueArrangementLineItems_244E2E2C633B59AA975F6D9784905F46" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Deferred Revenue Arrangement [Line Items]</link:label>
    <link:label id="lab_us-gaap_DeferredRevenueArrangementLineItems_4E5FA481C2321BE4205097B9454FA7D3_label_en-US" xlink:label="lab_us-gaap_DeferredRevenueArrangementLineItems_244E2E2C633B59AA975F6D9784905F46" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Deferred Revenue Arrangement [Line Items]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_DeferredRevenueArrangementLineItems" xlink:label="loc_us-gaap_DeferredRevenueArrangementLineItems_244E2E2C633B59AA975F6D9784905F46" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DeferredRevenueArrangementLineItems_244E2E2C633B59AA975F6D9784905F46" xlink:to="lab_us-gaap_DeferredRevenueArrangementLineItems_244E2E2C633B59AA975F6D9784905F46" xlink:type="arc" />
    <link:label id="lab_us-gaap_RevenueRecognitionMilestoneMethodRevenueRecognized_D2617B8711AE38A8995C97BB46A6528C_terseLabel_en-US" xlink:label="lab_us-gaap_RevenueRecognitionMilestoneMethodRevenueRecognized_18F263A407FE5A09AC0686A9ADF83616" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Upfront cash payments</link:label>
    <link:label id="lab_us-gaap_RevenueRecognitionMilestoneMethodRevenueRecognized_D2617B8711AE38A8995C97BB46A6528C_label_en-US" xlink:label="lab_us-gaap_RevenueRecognitionMilestoneMethodRevenueRecognized_18F263A407FE5A09AC0686A9ADF83616" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Revenue Recognition, Milestone Method, Revenue Recognized</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_RevenueRecognitionMilestoneMethodRevenueRecognized" xlink:label="loc_us-gaap_RevenueRecognitionMilestoneMethodRevenueRecognized_18F263A407FE5A09AC0686A9ADF83616" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RevenueRecognitionMilestoneMethodRevenueRecognized_18F263A407FE5A09AC0686A9ADF83616" xlink:to="lab_us-gaap_RevenueRecognitionMilestoneMethodRevenueRecognized_18F263A407FE5A09AC0686A9ADF83616" xlink:type="arc" />
    <link:label id="lab_nlnk_RevenueRecogitionMilestoneMethodMaximumPotentialRevenue_E62171BD172A402849EA97C3F225DED4_terseLabel_en-US" xlink:label="lab_nlnk_RevenueRecogitionMilestoneMethodMaximumPotentialRevenue_391574CEE8DB504B961CCC96C46FF024" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Genentech potential milestones</link:label>
    <link:label id="lab_nlnk_RevenueRecogitionMilestoneMethodMaximumPotentialRevenue_E62171BD172A402849EA97C3F225DED4_label_en-US" xlink:label="lab_nlnk_RevenueRecogitionMilestoneMethodMaximumPotentialRevenue_391574CEE8DB504B961CCC96C46FF024" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Revenue Recogition, Milestone Method, Maximum Potential Revenue</link:label>
    <link:label id="lab_nlnk_RevenueRecogitionMilestoneMethodMaximumPotentialRevenue_E62171BD172A402849EA97C3F225DED4_documentation_en-US" xlink:label="lab_nlnk_RevenueRecogitionMilestoneMethodMaximumPotentialRevenue_391574CEE8DB504B961CCC96C46FF024" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Revenue Recogition, Milestone Method, Maximum Potential Revenue</link:label>
    <link:loc xlink:href="nlnk-20170930.xsd#nlnk_RevenueRecogitionMilestoneMethodMaximumPotentialRevenue" xlink:label="loc_nlnk_RevenueRecogitionMilestoneMethodMaximumPotentialRevenue_391574CEE8DB504B961CCC96C46FF024" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_nlnk_RevenueRecogitionMilestoneMethodMaximumPotentialRevenue_391574CEE8DB504B961CCC96C46FF024" xlink:to="lab_nlnk_RevenueRecogitionMilestoneMethodMaximumPotentialRevenue_391574CEE8DB504B961CCC96C46FF024" xlink:type="arc" />
    <link:label id="lab_us-gaap_LicensesRevenue_ABFF8BDE0ED3BF790B3B97BFB70DC235_terseLabel_en-US" xlink:label="lab_us-gaap_LicensesRevenue_06B99C0AEF6959CC9D356D1BAC341BD4" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Licensing and collaboration revenue</link:label>
    <link:label id="lab_us-gaap_LicensesRevenue_ABFF8BDE0ED3BF790B3B97BFB70DC235_label_en-US" xlink:label="lab_us-gaap_LicensesRevenue_06B99C0AEF6959CC9D356D1BAC341BD4" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Licenses Revenue</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_LicensesRevenue" xlink:label="loc_us-gaap_LicensesRevenue_06B99C0AEF6959CC9D356D1BAC341BD4" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LicensesRevenue_06B99C0AEF6959CC9D356D1BAC341BD4" xlink:to="lab_us-gaap_LicensesRevenue_06B99C0AEF6959CC9D356D1BAC341BD4" xlink:type="arc" />
    <link:label id="lab_nlnk_LicenseRevenueEmployeeLabor_33FF0510A3617E976CD997B9454F1EF7_terseLabel_en-US" xlink:label="lab_nlnk_LicenseRevenueEmployeeLabor_31400820E7455549BD802A452102A3AB" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Reimbursement for direct labor</link:label>
    <link:label id="lab_nlnk_LicenseRevenueEmployeeLabor_33FF0510A3617E976CD997B9454F1EF7_label_en-US" xlink:label="lab_nlnk_LicenseRevenueEmployeeLabor_31400820E7455549BD802A452102A3AB" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">License Revenue, Employee Labor</link:label>
    <link:label id="lab_nlnk_LicenseRevenueEmployeeLabor_33FF0510A3617E976CD997B9454F1EF7_documentation_en-US" xlink:label="lab_nlnk_LicenseRevenueEmployeeLabor_31400820E7455549BD802A452102A3AB" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">License Revenue, Employee Labor</link:label>
    <link:loc xlink:href="nlnk-20170930.xsd#nlnk_LicenseRevenueEmployeeLabor" xlink:label="loc_nlnk_LicenseRevenueEmployeeLabor_31400820E7455549BD802A452102A3AB" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_nlnk_LicenseRevenueEmployeeLabor_31400820E7455549BD802A452102A3AB" xlink:to="lab_nlnk_LicenseRevenueEmployeeLabor_31400820E7455549BD802A452102A3AB" xlink:type="arc" />
    <link:label id="lab_nlnk_LicenseRevenueManagerLabor_DF6FA6775E21798E73ED97CDBE9E17CC_terseLabel_en-US" xlink:label="lab_nlnk_LicenseRevenueManagerLabor_DF6782D6E2A7552DA4ECFCF43DE30552" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Alliance manager</link:label>
    <link:label id="lab_nlnk_LicenseRevenueManagerLabor_DF6FA6775E21798E73ED97CDBE9E17CC_label_en-US" xlink:label="lab_nlnk_LicenseRevenueManagerLabor_DF6782D6E2A7552DA4ECFCF43DE30552" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">License Revenue, Manager Labor</link:label>
    <link:label id="lab_nlnk_LicenseRevenueManagerLabor_DF6FA6775E21798E73ED97CDBE9E17CC_documentation_en-US" xlink:label="lab_nlnk_LicenseRevenueManagerLabor_DF6782D6E2A7552DA4ECFCF43DE30552" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">License Revenue, Manager Labor</link:label>
    <link:loc xlink:href="nlnk-20170930.xsd#nlnk_LicenseRevenueManagerLabor" xlink:label="loc_nlnk_LicenseRevenueManagerLabor_DF6782D6E2A7552DA4ECFCF43DE30552" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_nlnk_LicenseRevenueManagerLabor_DF6782D6E2A7552DA4ECFCF43DE30552" xlink:to="lab_nlnk_LicenseRevenueManagerLabor_DF6782D6E2A7552DA4ECFCF43DE30552" xlink:type="arc" />
    <link:label id="lab_nlnk_LicenseRevenueCommitteeLabor_B39EEFEE9160179785FA97B9454F5553_terseLabel_en-US" xlink:label="lab_nlnk_LicenseRevenueCommitteeLabor_D653EC20FE615899A97CB3A9BB338001" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Participation in JRC</link:label>
    <link:label id="lab_nlnk_LicenseRevenueCommitteeLabor_B39EEFEE9160179785FA97B9454F5553_label_en-US" xlink:label="lab_nlnk_LicenseRevenueCommitteeLabor_D653EC20FE615899A97CB3A9BB338001" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">License Revenue, Committee Labor</link:label>
    <link:label id="lab_nlnk_LicenseRevenueCommitteeLabor_B39EEFEE9160179785FA97B9454F5553_documentation_en-US" xlink:label="lab_nlnk_LicenseRevenueCommitteeLabor_D653EC20FE615899A97CB3A9BB338001" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">License Revenue, Committee Labor</link:label>
    <link:loc xlink:href="nlnk-20170930.xsd#nlnk_LicenseRevenueCommitteeLabor" xlink:label="loc_nlnk_LicenseRevenueCommitteeLabor_D653EC20FE615899A97CB3A9BB338001" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_nlnk_LicenseRevenueCommitteeLabor_D653EC20FE615899A97CB3A9BB338001" xlink:to="lab_nlnk_LicenseRevenueCommitteeLabor_D653EC20FE615899A97CB3A9BB338001" xlink:type="arc" />
    <link:label id="lab_us-gaap_DeferredRevenue_D3489D91F8B9E9F1A25497B9454FF11F_terseLabel_en-US" xlink:label="lab_us-gaap_DeferredRevenue_3656D03DA65E5771A5EBA1985D4C4BBC" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Deferred revenue</link:label>
    <link:label id="lab_us-gaap_DeferredRevenue_D3489D91F8B9E9F1A25497B9454FF11F_label_en-US" xlink:label="lab_us-gaap_DeferredRevenue_3656D03DA65E5771A5EBA1985D4C4BBC" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Deferred Revenue</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_DeferredRevenue" xlink:label="loc_us-gaap_DeferredRevenue_3656D03DA65E5771A5EBA1985D4C4BBC" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DeferredRevenue_3656D03DA65E5771A5EBA1985D4C4BBC" xlink:to="lab_us-gaap_DeferredRevenue_3656D03DA65E5771A5EBA1985D4C4BBC" xlink:type="arc" />
    <link:label id="lab_us-gaap_RestructuringAndRelatedActivitiesAbstract_0D6C9DDB009759EA3E335A7AC2820640_label_en-US" xlink:label="lab_us-gaap_RestructuringAndRelatedActivitiesAbstract_0D6C9DDB009759EA3E335A7AC2820640" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Restructuring and Related Activities [Abstract]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_RestructuringAndRelatedActivitiesAbstract" xlink:label="loc_us-gaap_RestructuringAndRelatedActivitiesAbstract_0D6C9DDB009759EA3E335A7AC2820640" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RestructuringAndRelatedActivitiesAbstract_0D6C9DDB009759EA3E335A7AC2820640" xlink:to="lab_us-gaap_RestructuringAndRelatedActivitiesAbstract_0D6C9DDB009759EA3E335A7AC2820640" xlink:type="arc" />
    <link:label id="lab_us-gaap_ScheduleOfRestructuringReserveByTypeOfCostTextBlock_6FA26B03279BA408721F5A7AC28273BD_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfRestructuringReserveByTypeOfCostTextBlock_6FA26B03279BA408721F5A7AC28273BD" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Restructuring and Related Costs</link:label>
    <link:label id="lab_us-gaap_ScheduleOfRestructuringReserveByTypeOfCostTextBlock_6FA26B03279BA408721F5A7AC28273BD_label_en-US" xlink:label="lab_us-gaap_ScheduleOfRestructuringReserveByTypeOfCostTextBlock_6FA26B03279BA408721F5A7AC28273BD" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Schedule of Restructuring Reserve by Type of Cost [Table Text Block]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ScheduleOfRestructuringReserveByTypeOfCostTextBlock" xlink:label="loc_us-gaap_ScheduleOfRestructuringReserveByTypeOfCostTextBlock_6FA26B03279BA408721F5A7AC28273BD" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfRestructuringReserveByTypeOfCostTextBlock_6FA26B03279BA408721F5A7AC28273BD" xlink:to="lab_us-gaap_ScheduleOfRestructuringReserveByTypeOfCostTextBlock_6FA26B03279BA408721F5A7AC28273BD" xlink:type="arc" />
    <link:label id="lab_us-gaap_DisclosureOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTextBlock_84CED340B1EFE5C0CDAE97345C0D519D_terseLabel_en-US" xlink:label="lab_us-gaap_DisclosureOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTextBlock_C420B59D209655349AE8308CDA77C647" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Authorized Increases of Common Stock under the 2009 Plan</link:label>
    <link:label id="lab_us-gaap_DisclosureOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTextBlock_84CED340B1EFE5C0CDAE97345C0D519D_label_en-US" xlink:label="lab_us-gaap_DisclosureOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTextBlock_C420B59D209655349AE8308CDA77C647" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Disclosure of Share-based Compensation Arrangements by Share-based Payment Award [Table Text Block]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_DisclosureOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTextBlock" xlink:label="loc_us-gaap_DisclosureOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTextBlock_C420B59D209655349AE8308CDA77C647" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DisclosureOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTextBlock_C420B59D209655349AE8308CDA77C647" xlink:to="lab_us-gaap_DisclosureOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTextBlock_C420B59D209655349AE8308CDA77C647" xlink:type="arc" />
    <link:label id="lab_us-gaap_ScheduleOfStockOptionsRollForwardTableTextBlock_DC2495EC28F4480F943997345C0D448A_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfStockOptionsRollForwardTableTextBlock_4299C848FE5F5B60A71E7AE6B8831ED0" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Stock Option Activity</link:label>
    <link:label id="lab_us-gaap_ScheduleOfStockOptionsRollForwardTableTextBlock_DC2495EC28F4480F943997345C0D448A_label_en-US" xlink:label="lab_us-gaap_ScheduleOfStockOptionsRollForwardTableTextBlock_4299C848FE5F5B60A71E7AE6B8831ED0" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Schedule of Stock Options Roll Forward [Table Text Block]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ScheduleOfStockOptionsRollForwardTableTextBlock" xlink:label="loc_us-gaap_ScheduleOfStockOptionsRollForwardTableTextBlock_4299C848FE5F5B60A71E7AE6B8831ED0" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfStockOptionsRollForwardTableTextBlock_4299C848FE5F5B60A71E7AE6B8831ED0" xlink:to="lab_us-gaap_ScheduleOfStockOptionsRollForwardTableTextBlock_4299C848FE5F5B60A71E7AE6B8831ED0" xlink:type="arc" />
    <link:label id="lab_us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock_F125CF007C25F74A5CBF97345C0D42EA_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock_974493EB9ED55BD19042F39CE5D1F433" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Assumptions Used in Black-Scholes Pricing Model for New Grants</link:label>
    <link:label id="lab_us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock_F125CF007C25F74A5CBF97345C0D42EA_label_en-US" xlink:label="lab_us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock_974493EB9ED55BD19042F39CE5D1F433" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Schedule of Share-based Payment Award, Stock Options, Valuation Assumptions [Table Text Block]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock" xlink:label="loc_us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock_974493EB9ED55BD19042F39CE5D1F433" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock_974493EB9ED55BD19042F39CE5D1F433" xlink:to="lab_us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock_974493EB9ED55BD19042F39CE5D1F433" xlink:type="arc" />
    <link:label id="lab_us-gaap_NonvestedRestrictedStockSharesActivityTableTextBlock_A6F9BB13C23D24E5448397E727C0E998_terseLabel_en-US" xlink:label="lab_us-gaap_NonvestedRestrictedStockSharesActivityTableTextBlock_3011577DC7865FF3B00861789E683B4A" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Restricted Stock Activity</link:label>
    <link:label id="lab_us-gaap_NonvestedRestrictedStockSharesActivityTableTextBlock_A6F9BB13C23D24E5448397E727C0E998_label_en-US" xlink:label="lab_us-gaap_NonvestedRestrictedStockSharesActivityTableTextBlock_3011577DC7865FF3B00861789E683B4A" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Nonvested Restricted Stock Shares Activity [Table Text Block]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_NonvestedRestrictedStockSharesActivityTableTextBlock" xlink:label="loc_us-gaap_NonvestedRestrictedStockSharesActivityTableTextBlock_3011577DC7865FF3B00861789E683B4A" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NonvestedRestrictedStockSharesActivityTableTextBlock_3011577DC7865FF3B00861789E683B4A" xlink:to="lab_us-gaap_NonvestedRestrictedStockSharesActivityTableTextBlock_3011577DC7865FF3B00861789E683B4A" xlink:type="arc" />
    <link:label id="lab_us-gaap_EarningsPerShareAbstract_022E55692960EFA7A5F95A7AC28A3E5C_label_en-US" xlink:label="lab_us-gaap_EarningsPerShareAbstract_022E55692960EFA7A5F95A7AC28A3E5C" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Earnings Per Share [Abstract]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_EarningsPerShareAbstract" xlink:label="loc_us-gaap_EarningsPerShareAbstract_022E55692960EFA7A5F95A7AC28A3E5C" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EarningsPerShareAbstract_022E55692960EFA7A5F95A7AC28A3E5C" xlink:to="lab_us-gaap_EarningsPerShareAbstract_022E55692960EFA7A5F95A7AC28A3E5C" xlink:type="arc" />
    <link:label id="lab_us-gaap_NetIncomeLoss_3AA4ECB9C300FEA35BCE5A7AC28AA6D3_verboseLabel_en-US" xlink:label="lab_us-gaap_NetIncomeLoss_3AA4ECB9C300FEA35BCE5A7AC28AA6D3" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Loss attributable to common stockholders</link:label>
    <link:label id="lab_us-gaap_NetIncomeLoss_3AA4ECB9C300FEA35BCE5A7AC28AA6D3_label_en-US" xlink:label="lab_us-gaap_NetIncomeLoss_3AA4ECB9C300FEA35BCE5A7AC28AA6D3" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Net Income (Loss) Attributable to Parent</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_NetIncomeLoss" xlink:label="loc_us-gaap_NetIncomeLoss_3AA4ECB9C300FEA35BCE5A7AC28AA6D3" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NetIncomeLoss_3AA4ECB9C300FEA35BCE5A7AC28AA6D3" xlink:to="lab_us-gaap_NetIncomeLoss_3AA4ECB9C300FEA35BCE5A7AC28AA6D3" xlink:type="arc" />
    <link:label id="lab_us-gaap_WeightedAverageNumberOfShareOutstandingBasicAndDiluted_ECCB456B960265FEABD65A7AC28AF851_verboseLabel_en-US" xlink:label="lab_us-gaap_WeightedAverageNumberOfShareOutstandingBasicAndDiluted_ECCB456B960265FEABD65A7AC28AF851" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Basic and diluted weighted-average shares outstanding (in shares)</link:label>
    <link:label id="lab_us-gaap_WeightedAverageNumberOfShareOutstandingBasicAndDiluted_ECCB456B960265FEABD65A7AC28AF851_label_en-US" xlink:label="lab_us-gaap_WeightedAverageNumberOfShareOutstandingBasicAndDiluted_ECCB456B960265FEABD65A7AC28AF851" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Weighted Average Number of Shares Outstanding, Basic and Diluted</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_WeightedAverageNumberOfShareOutstandingBasicAndDiluted" xlink:label="loc_us-gaap_WeightedAverageNumberOfShareOutstandingBasicAndDiluted_ECCB456B960265FEABD65A7AC28AF851" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_WeightedAverageNumberOfShareOutstandingBasicAndDiluted_ECCB456B960265FEABD65A7AC28AF851" xlink:to="lab_us-gaap_WeightedAverageNumberOfShareOutstandingBasicAndDiluted_ECCB456B960265FEABD65A7AC28AF851" xlink:type="arc" />
    <link:label id="lab_us-gaap_EarningsPerShareBasicAndDiluted_7944FD9A3F7F4A2D347D5A7AC28A5117_terseLabel_en-US" xlink:label="lab_us-gaap_EarningsPerShareBasicAndDiluted_7944FD9A3F7F4A2D347D5A7AC28A5117" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Basic and diluted loss per share (in dollars per share)</link:label>
    <link:label id="lab_us-gaap_EarningsPerShareBasicAndDiluted_7944FD9A3F7F4A2D347D5A7AC28A5117_label_en-US" xlink:label="lab_us-gaap_EarningsPerShareBasicAndDiluted_7944FD9A3F7F4A2D347D5A7AC28A5117" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Earnings Per Share, Basic and Diluted</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_EarningsPerShareBasicAndDiluted" xlink:label="loc_us-gaap_EarningsPerShareBasicAndDiluted_7944FD9A3F7F4A2D347D5A7AC28A5117" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EarningsPerShareBasicAndDiluted_7944FD9A3F7F4A2D347D5A7AC28A5117" xlink:to="lab_us-gaap_EarningsPerShareBasicAndDiluted_7944FD9A3F7F4A2D347D5A7AC28A5117" xlink:type="arc" />
    <link:label id="lab_us-gaap_RestructuringAndRelatedActivitiesDisclosureTextBlock_050E5EF1EC2E34BC915796910A5105AB_terseLabel_en-US" xlink:label="lab_us-gaap_RestructuringAndRelatedActivitiesDisclosureTextBlock_FF7229BE9AA7536594268F6A5817A06B" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Restructuring Charges</link:label>
    <link:label id="lab_us-gaap_RestructuringAndRelatedActivitiesDisclosureTextBlock_050E5EF1EC2E34BC915796910A5105AB_label_en-US" xlink:label="lab_us-gaap_RestructuringAndRelatedActivitiesDisclosureTextBlock_FF7229BE9AA7536594268F6A5817A06B" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Restructuring and Related Activities Disclosure [Text Block]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_RestructuringAndRelatedActivitiesDisclosureTextBlock" xlink:label="loc_us-gaap_RestructuringAndRelatedActivitiesDisclosureTextBlock_FF7229BE9AA7536594268F6A5817A06B" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RestructuringAndRelatedActivitiesDisclosureTextBlock_FF7229BE9AA7536594268F6A5817A06B" xlink:to="lab_us-gaap_RestructuringAndRelatedActivitiesDisclosureTextBlock_FF7229BE9AA7536594268F6A5817A06B" xlink:type="arc" />
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward_65649AFF38480D9582D696910A69C88E_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward_65338224DBBB51D4AFB0D6B08E095160" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Number of options</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward_65649AFF38480D9582D696910A69C88E_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward_65338224DBBB51D4AFB0D6B08E095160" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding [Roll Forward]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward_65338224DBBB51D4AFB0D6B08E095160" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward_65338224DBBB51D4AFB0D6B08E095160" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward_65338224DBBB51D4AFB0D6B08E095160" xlink:type="arc" />
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_633D03C5CC2E608672B996910A69E329_periodStartLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_BB11D9EA42DA58A195EBBEF3370874F5" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:type="resource" xml:lang="en-US">Outstanding at beginning of period (in shares)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_633D03C5CC2E608672B996910A69E329_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_BB11D9EA42DA58A195EBBEF3370874F5" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Number</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_BB11D9EA42DA58A195EBBEF3370874F5" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_BB11D9EA42DA58A195EBBEF3370874F5" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_BB11D9EA42DA58A195EBBEF3370874F5" xlink:type="arc" />
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_4E46A1B299A18700236796910A692C7C_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_C86A957E8B4C5BA080F103F08ABDC331" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Options granted (in shares)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_4E46A1B299A18700236796910A692C7C_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_C86A957E8B4C5BA080F103F08ABDC331" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Gross</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_C86A957E8B4C5BA080F103F08ABDC331" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_C86A957E8B4C5BA080F103F08ABDC331" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_C86A957E8B4C5BA080F103F08ABDC331" xlink:type="arc" />
    <link:label id="lab_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised_8F5BA62673356072F54496910A6932DA_negatedLabel_en-US" xlink:label="lab_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised_96C8A0EE63E75C3ABB6F5240DE52DC18" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xml:lang="en-US">Options exercised (in shares)</link:label>
    <link:label id="lab_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised_8F5BA62673356072F54496910A6932DA_label_en-US" xlink:label="lab_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised_96C8A0EE63E75C3ABB6F5240DE52DC18" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercises in Period</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" xlink:label="loc_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised_96C8A0EE63E75C3ABB6F5240DE52DC18" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised_96C8A0EE63E75C3ABB6F5240DE52DC18" xlink:to="lab_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised_96C8A0EE63E75C3ABB6F5240DE52DC18" xlink:type="arc" />
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod_68124E91A2095003904D96910A6AC373_negatedLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod_B479A49C7AFD59B4A65B3ED00D3639A3" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xml:lang="en-US">Options forfeited (in shares)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod_68124E91A2095003904D96910A6AC373_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod_B479A49C7AFD59B4A65B3ED00D3639A3" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Options, Forfeitures in Period</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod_B479A49C7AFD59B4A65B3ED00D3639A3" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod_B479A49C7AFD59B4A65B3ED00D3639A3" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod_B479A49C7AFD59B4A65B3ED00D3639A3" xlink:type="arc" />
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod_46A80262A3975FEBADAD96910A6A3E38_negatedLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod_C67DDB2E9E655890A79ABB80FB2BCA82" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xml:lang="en-US">Options expired (in shares)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod_46A80262A3975FEBADAD96910A6A3E38_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod_C67DDB2E9E655890A79ABB80FB2BCA82" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Options, Expirations in Period</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod_C67DDB2E9E655890A79ABB80FB2BCA82" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod_C67DDB2E9E655890A79ABB80FB2BCA82" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod_C67DDB2E9E655890A79ABB80FB2BCA82" xlink:type="arc" />
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_308874BBC6203B53E06396910A6A4162_periodEndLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_9B028F9E83DF55D49E4FA86262556E15" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:type="resource" xml:lang="en-US">Outstanding at end of period (in shares)</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_9B028F9E83DF55D49E4FA86262556E15" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_9B028F9E83DF55D49E4FA86262556E15" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_9B028F9E83DF55D49E4FA86262556E15" xlink:type="arc" />
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward_982F78ABB0A75F53B1D096910A6A7AF7_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward_8EF750B40922514EACDF511A9B240780" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Weighted average exercise price</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward_982F78ABB0A75F53B1D096910A6A7AF7_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward_8EF750B40922514EACDF511A9B240780" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Weighted Average Exercise Price [Abstract]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward_8EF750B40922514EACDF511A9B240780" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward_8EF750B40922514EACDF511A9B240780" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward_8EF750B40922514EACDF511A9B240780" xlink:type="arc" />
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_A3ADB4BF81214B1B9FCD96910A6AF9A5_periodStartLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_4CFC98D33F7D50A99840B1C2489CE1B0" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:type="resource" xml:lang="en-US">Outstanding, weighted average exercise price at beginning of period (in dollars per share)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_A3ADB4BF81214B1B9FCD96910A6AF9A5_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_4CFC98D33F7D50A99840B1C2489CE1B0" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Weighted Average Exercise Price</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_4CFC98D33F7D50A99840B1C2489CE1B0" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_4CFC98D33F7D50A99840B1C2489CE1B0" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_4CFC98D33F7D50A99840B1C2489CE1B0" xlink:type="arc" />
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice_ECE2DDD4B3BE04915A9D96910A6A2B59_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice_46D736B27A9E578C8B6EE41D6D5AF52B" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Granted, weighted average exercise price (in dollars per share)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice_ECE2DDD4B3BE04915A9D96910A6A2B59_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice_46D736B27A9E578C8B6EE41D6D5AF52B" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share-based Compensation Arrangements by Share-based Payment Award, Options, Grants in Period, Weighted Average Exercise Price</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice_46D736B27A9E578C8B6EE41D6D5AF52B" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice_46D736B27A9E578C8B6EE41D6D5AF52B" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice_46D736B27A9E578C8B6EE41D6D5AF52B" xlink:type="arc" />
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice_439E2FDFCD1CD166FB7F96910A6A7305_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice_0B5EECDB8FBD5CF5844BC31A234F31AC" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Exercised, weighted average exercise price (in dollars per share)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice_439E2FDFCD1CD166FB7F96910A6A7305_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice_0B5EECDB8FBD5CF5844BC31A234F31AC" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share-based Compensation Arrangements by Share-based Payment Award, Options, Exercises in Period, Weighted Average Exercise Price</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice_0B5EECDB8FBD5CF5844BC31A234F31AC" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice_0B5EECDB8FBD5CF5844BC31A234F31AC" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice_0B5EECDB8FBD5CF5844BC31A234F31AC" xlink:type="arc" />
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice_A2AAA8CD6CA0EBCBD91696910A6AEF41_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice_E51C7ECB30145C41B474CE2AA8268834" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Forfeitured, weighted average exercise price (in dollars per share)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice_A2AAA8CD6CA0EBCBD91696910A6AEF41_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice_E51C7ECB30145C41B474CE2AA8268834" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share-based Compensation Arrangements by Share-based Payment Award, Options, Forfeitures in Period, Weighted Average Exercise Price</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice_E51C7ECB30145C41B474CE2AA8268834" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice_E51C7ECB30145C41B474CE2AA8268834" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice_E51C7ECB30145C41B474CE2AA8268834" xlink:type="arc" />
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExpirationsInPeriodWeightedAverageExercisePrice_804ED36EFCEEAEEB8B4C96910A6ACB5A_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExpirationsInPeriodWeightedAverageExercisePrice_85C3CE593FE755628A8AFD1E2EC4E05F" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Expired, weighted average exercise price (in dollars per share)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExpirationsInPeriodWeightedAverageExercisePrice_804ED36EFCEEAEEB8B4C96910A6ACB5A_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExpirationsInPeriodWeightedAverageExercisePrice_85C3CE593FE755628A8AFD1E2EC4E05F" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share-based Compensation Arrangements by Share-based Payment Award, Options, Expirations in Period, Weighted Average Exercise Price</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExpirationsInPeriodWeightedAverageExercisePrice" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExpirationsInPeriodWeightedAverageExercisePrice_85C3CE593FE755628A8AFD1E2EC4E05F" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExpirationsInPeriodWeightedAverageExercisePrice_85C3CE593FE755628A8AFD1E2EC4E05F" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExpirationsInPeriodWeightedAverageExercisePrice_85C3CE593FE755628A8AFD1E2EC4E05F" xlink:type="arc" />
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_5FF6763B3C07F4906E7196910A6A0CB5_periodEndLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_FAFFCBBCDF8F5C23A23CA4DB001BF336" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:type="resource" xml:lang="en-US">Outstanding, weighted average exercise price at end of period (in dollars per share)</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_FAFFCBBCDF8F5C23A23CA4DB001BF336" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_FAFFCBBCDF8F5C23A23CA4DB001BF336" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_FAFFCBBCDF8F5C23A23CA4DB001BF336" xlink:type="arc" />
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber_CA62D2854223F396D9F296910A6A3D97_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber_813EFE60F729591AA7F24294BDE91C58" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Options exercisable at end of period (in shares)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber_CA62D2854223F396D9F296910A6A3D97_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber_813EFE60F729591AA7F24294BDE91C58" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercisable, Number</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber_813EFE60F729591AA7F24294BDE91C58" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber_813EFE60F729591AA7F24294BDE91C58" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber_813EFE60F729591AA7F24294BDE91C58" xlink:type="arc" />
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice_FDE8DAB739561AA6941696910A6A0E58_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice_F5F6C312611456C595460099BDBF027B" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Exercisable, weighted average exercise price (in dollars per share)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice_FDE8DAB739561AA6941696910A6A0E58_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice_F5F6C312611456C595460099BDBF027B" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercisable, Weighted Average Exercise Price</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice_F5F6C312611456C595460099BDBF027B" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice_F5F6C312611456C595460099BDBF027B" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice_F5F6C312611456C595460099BDBF027B" xlink:type="arc" />
    <link:label id="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2_E2FF203C922438235C6596910A6AA61F_terseLabel_en-US" xlink:label="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2_99C7E5802F7159419748EEAACBAC6C4A" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Outstanding, weighted average remaining contractual term, in years</link:label>
    <link:label id="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2_E2FF203C922438235C6596910A6AA61F_label_en-US" xlink:label="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2_99C7E5802F7159419748EEAACBAC6C4A" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Weighted Average Remaining Contractual Term</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2_99C7E5802F7159419748EEAACBAC6C4A" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2_99C7E5802F7159419748EEAACBAC6C4A" xlink:to="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2_99C7E5802F7159419748EEAACBAC6C4A" xlink:type="arc" />
    <link:label id="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1_BD672A9A1E6442339B3896910A6AAA0E_terseLabel_en-US" xlink:label="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1_F18C5856B0DD5891B7DE3D37BBA69D5B" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Exercisable, weighted average remaining contractual term, in years</link:label>
    <link:label id="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1_BD672A9A1E6442339B3896910A6AAA0E_label_en-US" xlink:label="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1_F18C5856B0DD5891B7DE3D37BBA69D5B" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercisable, Weighted Average Remaining Contractual Term</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1_F18C5856B0DD5891B7DE3D37BBA69D5B" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1_F18C5856B0DD5891B7DE3D37BBA69D5B" xlink:to="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1_F18C5856B0DD5891B7DE3D37BBA69D5B" xlink:type="arc" />
    <link:label id="lab_us-gaap_AccountingPoliciesAbstract_15508048B36DA5E2096A508822A66C3E_label_en-US" xlink:label="lab_us-gaap_AccountingPoliciesAbstract_15508048B36DA5E2096A508822A66C3E" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Accounting Policies [Abstract]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_AccountingPoliciesAbstract" xlink:label="loc_us-gaap_AccountingPoliciesAbstract_15508048B36DA5E2096A508822A66C3E" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_15508048B36DA5E2096A508822A66C3E" xlink:to="lab_us-gaap_AccountingPoliciesAbstract_15508048B36DA5E2096A508822A66C3E" xlink:type="arc" />
    <link:label id="lab_us-gaap_UseOfEstimates_3B52CCEC8ED9023075AD508822A6BE3E_terseLabel_en-US" xlink:label="lab_us-gaap_UseOfEstimates_3B52CCEC8ED9023075AD508822A6BE3E" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Use of Estimates</link:label>
    <link:label id="lab_us-gaap_UseOfEstimates_3B52CCEC8ED9023075AD508822A6BE3E_label_en-US" xlink:label="lab_us-gaap_UseOfEstimates_3B52CCEC8ED9023075AD508822A6BE3E" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Use of Estimates, Policy [Policy Text Block]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_UseOfEstimates" xlink:label="loc_us-gaap_UseOfEstimates_3B52CCEC8ED9023075AD508822A6BE3E" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_UseOfEstimates_3B52CCEC8ED9023075AD508822A6BE3E" xlink:to="lab_us-gaap_UseOfEstimates_3B52CCEC8ED9023075AD508822A6BE3E" xlink:type="arc" />
    <link:label id="lab_us-gaap_ConsolidationPolicyTextBlock_4E4143054DAE563C0D07508822A62DFB_terseLabel_en-US" xlink:label="lab_us-gaap_ConsolidationPolicyTextBlock_4E4143054DAE563C0D07508822A62DFB" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Principles of Consolidation</link:label>
    <link:label id="lab_us-gaap_ConsolidationPolicyTextBlock_4E4143054DAE563C0D07508822A62DFB_label_en-US" xlink:label="lab_us-gaap_ConsolidationPolicyTextBlock_4E4143054DAE563C0D07508822A62DFB" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Consolidation, Policy [Policy Text Block]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ConsolidationPolicyTextBlock" xlink:label="loc_us-gaap_ConsolidationPolicyTextBlock_4E4143054DAE563C0D07508822A62DFB" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ConsolidationPolicyTextBlock_4E4143054DAE563C0D07508822A62DFB" xlink:to="lab_us-gaap_ConsolidationPolicyTextBlock_4E4143054DAE563C0D07508822A62DFB" xlink:type="arc" />
    <link:label id="lab_us-gaap_FairValueOfFinancialInstrumentsPolicy_61EC41EA1B0366636BEA508822A63FA4_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueOfFinancialInstrumentsPolicy_61EC41EA1B0366636BEA508822A63FA4" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Financial Instruments</link:label>
    <link:label id="lab_us-gaap_FairValueOfFinancialInstrumentsPolicy_61EC41EA1B0366636BEA508822A63FA4_label_en-US" xlink:label="lab_us-gaap_FairValueOfFinancialInstrumentsPolicy_61EC41EA1B0366636BEA508822A63FA4" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Fair Value of Financial Instruments, Policy [Policy Text Block]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_FairValueOfFinancialInstrumentsPolicy" xlink:label="loc_us-gaap_FairValueOfFinancialInstrumentsPolicy_61EC41EA1B0366636BEA508822A63FA4" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueOfFinancialInstrumentsPolicy_61EC41EA1B0366636BEA508822A63FA4" xlink:to="lab_us-gaap_FairValueOfFinancialInstrumentsPolicy_61EC41EA1B0366636BEA508822A63FA4" xlink:type="arc" />
    <link:label id="lab_us-gaap_ConcentrationRiskCreditRisk_86C2987D7161823F7554508822A65DC8_terseLabel_en-US" xlink:label="lab_us-gaap_ConcentrationRiskCreditRisk_86C2987D7161823F7554508822A65DC8" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Concentration of Credit Risk</link:label>
    <link:label id="lab_us-gaap_ConcentrationRiskCreditRisk_86C2987D7161823F7554508822A65DC8_label_en-US" xlink:label="lab_us-gaap_ConcentrationRiskCreditRisk_86C2987D7161823F7554508822A65DC8" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Concentration Risk, Credit Risk, Policy [Policy Text Block]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ConcentrationRiskCreditRisk" xlink:label="loc_us-gaap_ConcentrationRiskCreditRisk_86C2987D7161823F7554508822A65DC8" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ConcentrationRiskCreditRisk_86C2987D7161823F7554508822A65DC8" xlink:to="lab_us-gaap_ConcentrationRiskCreditRisk_86C2987D7161823F7554508822A65DC8" xlink:type="arc" />
    <link:label id="lab_us-gaap_PropertyPlantAndEquipmentPolicyTextBlock_001D9A4240C63C831E22508822A62C3B_terseLabel_en-US" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentPolicyTextBlock_001D9A4240C63C831E22508822A62C3B" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Property and equipment</link:label>
    <link:label id="lab_us-gaap_PropertyPlantAndEquipmentPolicyTextBlock_001D9A4240C63C831E22508822A62C3B_label_en-US" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentPolicyTextBlock_001D9A4240C63C831E22508822A62C3B" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Property, Plant and Equipment, Policy [Policy Text Block]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_PropertyPlantAndEquipmentPolicyTextBlock" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentPolicyTextBlock_001D9A4240C63C831E22508822A62C3B" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentPolicyTextBlock_001D9A4240C63C831E22508822A62C3B" xlink:to="lab_us-gaap_PropertyPlantAndEquipmentPolicyTextBlock_001D9A4240C63C831E22508822A62C3B" xlink:type="arc" />
    <link:label id="lab_us-gaap_RevenueRecognitionPolicyTextBlock_264E24E7DA19DB45089B508822A6882F_terseLabel_en-US" xlink:label="lab_us-gaap_RevenueRecognitionPolicyTextBlock_264E24E7DA19DB45089B508822A6882F" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Revenue Recognition</link:label>
    <link:label id="lab_us-gaap_RevenueRecognitionPolicyTextBlock_264E24E7DA19DB45089B508822A6882F_label_en-US" xlink:label="lab_us-gaap_RevenueRecognitionPolicyTextBlock_264E24E7DA19DB45089B508822A6882F" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Revenue Recognition, Policy [Policy Text Block]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_RevenueRecognitionPolicyTextBlock" xlink:label="loc_us-gaap_RevenueRecognitionPolicyTextBlock_264E24E7DA19DB45089B508822A6882F" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RevenueRecognitionPolicyTextBlock_264E24E7DA19DB45089B508822A6882F" xlink:to="lab_us-gaap_RevenueRecognitionPolicyTextBlock_264E24E7DA19DB45089B508822A6882F" xlink:type="arc" />
    <link:label id="lab_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock_97E2D2715BD5F8BE1351509EF5657FDA_terseLabel_en-US" xlink:label="lab_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock_97E2D2715BD5F8BE1351509EF5657FDA" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Recent Accounting Pronouncements</link:label>
    <link:label id="lab_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock_97E2D2715BD5F8BE1351509EF5657FDA_label_en-US" xlink:label="lab_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock_97E2D2715BD5F8BE1351509EF5657FDA" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">New Accounting Pronouncements, Policy [Policy Text Block]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock" xlink:label="loc_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock_97E2D2715BD5F8BE1351509EF5657FDA" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock_97E2D2715BD5F8BE1351509EF5657FDA" xlink:to="lab_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock_97E2D2715BD5F8BE1351509EF5657FDA" xlink:type="arc" />
    <link:label id="lab_us-gaap_NetIncomeLoss_C28D4714AF782E276FE07D80DFBE2AA7_terseLabel_en-US" xlink:label="lab_us-gaap_NetIncomeLoss_C28D4714AF782E276FE07D80DFBE2AA7" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Net loss</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_NetIncomeLoss" xlink:label="loc_us-gaap_NetIncomeLoss_C28D4714AF782E276FE07D80DFBE2AA7" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NetIncomeLoss_C28D4714AF782E276FE07D80DFBE2AA7" xlink:to="lab_us-gaap_NetIncomeLoss_C28D4714AF782E276FE07D80DFBE2AA7" xlink:type="arc" />
    <link:label id="lab_us-gaap_RestructuringAndRelatedCostNumberOfPositionsEliminatedPeriodPercent_A045884DCDF6CB6E6F367D80DFBE8B9A_terseLabel_en-US" xlink:label="lab_us-gaap_RestructuringAndRelatedCostNumberOfPositionsEliminatedPeriodPercent_A045884DCDF6CB6E6F367D80DFBE8B9A" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Percentage reduction in force</link:label>
    <link:label id="lab_us-gaap_RestructuringAndRelatedCostNumberOfPositionsEliminatedPeriodPercent_A045884DCDF6CB6E6F367D80DFBE8B9A_label_en-US" xlink:label="lab_us-gaap_RestructuringAndRelatedCostNumberOfPositionsEliminatedPeriodPercent_A045884DCDF6CB6E6F367D80DFBE8B9A" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Restructuring and Related Cost, Number of Positions Eliminated, Period Percent</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_RestructuringAndRelatedCostNumberOfPositionsEliminatedPeriodPercent" xlink:label="loc_us-gaap_RestructuringAndRelatedCostNumberOfPositionsEliminatedPeriodPercent_A045884DCDF6CB6E6F367D80DFBE8B9A" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RestructuringAndRelatedCostNumberOfPositionsEliminatedPeriodPercent_A045884DCDF6CB6E6F367D80DFBE8B9A" xlink:to="lab_us-gaap_RestructuringAndRelatedCostNumberOfPositionsEliminatedPeriodPercent_A045884DCDF6CB6E6F367D80DFBE8B9A" xlink:type="arc" />
    <link:label id="lab_nlnk_FinancingsTable_CC182BBAA355648D5D937D80DFBE6BA5_terseLabel_en-US" xlink:label="lab_nlnk_FinancingsTable_CC182BBAA355648D5D937D80DFBE6BA5" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Schedule of Financing Rounds</link:label>
    <link:label id="lab_nlnk_FinancingsTable_CC182BBAA355648D5D937D80DFBE6BA5_label_en-US" xlink:label="lab_nlnk_FinancingsTable_CC182BBAA355648D5D937D80DFBE6BA5" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Financings [Table]</link:label>
    <link:label id="lab_nlnk_FinancingsTable_CC182BBAA355648D5D937D80DFBE6BA5_documentation_en-US" xlink:label="lab_nlnk_FinancingsTable_CC182BBAA355648D5D937D80DFBE6BA5" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Financings [Table]</link:label>
    <link:loc xlink:href="nlnk-20170930.xsd#nlnk_FinancingsTable" xlink:label="loc_nlnk_FinancingsTable_CC182BBAA355648D5D937D80DFBE6BA5" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_nlnk_FinancingsTable_CC182BBAA355648D5D937D80DFBE6BA5" xlink:to="lab_nlnk_FinancingsTable_CC182BBAA355648D5D937D80DFBE6BA5" xlink:type="arc" />
    <link:label id="lab_us-gaap_SubsequentEventTypeAxis_5DE06CB86DC10B71E4827D80DFBE0A34_terseLabel_en-US" xlink:label="lab_us-gaap_SubsequentEventTypeAxis_5DE06CB86DC10B71E4827D80DFBE0A34" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Subsequent Event Type [Axis]</link:label>
    <link:label id="lab_us-gaap_SubsequentEventTypeAxis_5DE06CB86DC10B71E4827D80DFBE0A34_label_en-US" xlink:label="lab_us-gaap_SubsequentEventTypeAxis_5DE06CB86DC10B71E4827D80DFBE0A34" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Subsequent Event Type [Axis]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_SubsequentEventTypeAxis" xlink:label="loc_us-gaap_SubsequentEventTypeAxis_5DE06CB86DC10B71E4827D80DFBE0A34" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SubsequentEventTypeAxis_5DE06CB86DC10B71E4827D80DFBE0A34" xlink:to="lab_us-gaap_SubsequentEventTypeAxis_5DE06CB86DC10B71E4827D80DFBE0A34" xlink:type="arc" />
    <link:label id="lab_us-gaap_SubsequentEventTypeDomain_19E2E36329493B77C9F67D80DFBE9448_terseLabel_en-US" xlink:label="lab_us-gaap_SubsequentEventTypeDomain_19E2E36329493B77C9F67D80DFBE9448" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Subsequent Event Type [Domain]</link:label>
    <link:label id="lab_us-gaap_SubsequentEventTypeDomain_19E2E36329493B77C9F67D80DFBE9448_label_en-US" xlink:label="lab_us-gaap_SubsequentEventTypeDomain_19E2E36329493B77C9F67D80DFBE9448" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Subsequent Event Type [Domain]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_SubsequentEventTypeDomain" xlink:label="loc_us-gaap_SubsequentEventTypeDomain_19E2E36329493B77C9F67D80DFBE9448" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SubsequentEventTypeDomain_19E2E36329493B77C9F67D80DFBE9448" xlink:to="lab_us-gaap_SubsequentEventTypeDomain_19E2E36329493B77C9F67D80DFBE9448" xlink:type="arc" />
    <link:label id="lab_us-gaap_SubsequentEventMember_7E042DC78372DD41BA617D80DFBE77BA_terseLabel_en-US" xlink:label="lab_us-gaap_SubsequentEventMember_7E042DC78372DD41BA617D80DFBE77BA" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Subsequent event</link:label>
    <link:label id="lab_us-gaap_SubsequentEventMember_7E042DC78372DD41BA617D80DFBE77BA_label_en-US" xlink:label="lab_us-gaap_SubsequentEventMember_7E042DC78372DD41BA617D80DFBE77BA" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Subsequent Event [Member]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_SubsequentEventMember" xlink:label="loc_us-gaap_SubsequentEventMember_7E042DC78372DD41BA617D80DFBE77BA" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SubsequentEventMember_7E042DC78372DD41BA617D80DFBE77BA" xlink:to="lab_us-gaap_SubsequentEventMember_7E042DC78372DD41BA617D80DFBE77BA" xlink:type="arc" />
    <link:label id="lab_us-gaap_SubsidiarySaleOfStockAxis_533EFC50C571B0492B997D80DFBEA474_terseLabel_en-US" xlink:label="lab_us-gaap_SubsidiarySaleOfStockAxis_533EFC50C571B0492B997D80DFBEA474" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Sale of Stock [Axis]</link:label>
    <link:label id="lab_us-gaap_SubsidiarySaleOfStockAxis_533EFC50C571B0492B997D80DFBEA474_label_en-US" xlink:label="lab_us-gaap_SubsidiarySaleOfStockAxis_533EFC50C571B0492B997D80DFBEA474" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Sale of Stock [Axis]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_SubsidiarySaleOfStockAxis" xlink:label="loc_us-gaap_SubsidiarySaleOfStockAxis_533EFC50C571B0492B997D80DFBEA474" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SubsidiarySaleOfStockAxis_533EFC50C571B0492B997D80DFBEA474" xlink:to="lab_us-gaap_SubsidiarySaleOfStockAxis_533EFC50C571B0492B997D80DFBEA474" xlink:type="arc" />
    <link:label id="lab_us-gaap_SaleOfStockNameOfTransactionDomain_D9419FC15A68353A68037D80DFBE0212_terseLabel_en-US" xlink:label="lab_us-gaap_SaleOfStockNameOfTransactionDomain_D9419FC15A68353A68037D80DFBE0212" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Sale of Stock [Domain]</link:label>
    <link:label id="lab_us-gaap_SaleOfStockNameOfTransactionDomain_D9419FC15A68353A68037D80DFBE0212_label_en-US" xlink:label="lab_us-gaap_SaleOfStockNameOfTransactionDomain_D9419FC15A68353A68037D80DFBE0212" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Sale of Stock [Domain]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_SaleOfStockNameOfTransactionDomain" xlink:label="loc_us-gaap_SaleOfStockNameOfTransactionDomain_D9419FC15A68353A68037D80DFBE0212" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SaleOfStockNameOfTransactionDomain_D9419FC15A68353A68037D80DFBE0212" xlink:to="lab_us-gaap_SaleOfStockNameOfTransactionDomain_D9419FC15A68353A68037D80DFBE0212" xlink:type="arc" />
    <link:label id="lab_us-gaap_IPOMember_4541AA2E115E052C19C47D80DFBE8B83_terseLabel_en-US" xlink:label="lab_us-gaap_IPOMember_4541AA2E115E052C19C47D80DFBE8B83" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">IPO [Member]</link:label>
    <link:label id="lab_us-gaap_IPOMember_4541AA2E115E052C19C47D80DFBE8B83_label_en-US" xlink:label="lab_us-gaap_IPOMember_4541AA2E115E052C19C47D80DFBE8B83" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">IPO [Member]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_IPOMember" xlink:label="loc_us-gaap_IPOMember_4541AA2E115E052C19C47D80DFBE8B83" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IPOMember_4541AA2E115E052C19C47D80DFBE8B83" xlink:to="lab_us-gaap_IPOMember_4541AA2E115E052C19C47D80DFBE8B83" xlink:type="arc" />
    <link:label id="lab_nlnk_FollowOnOfferingMember_ECBF60CB43EA3FE4A2157D80DFBEAB8B_terseLabel_en-US" xlink:label="lab_nlnk_FollowOnOfferingMember_ECBF60CB43EA3FE4A2157D80DFBEAB8B" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Follow-on Offering</link:label>
    <link:label id="lab_nlnk_FollowOnOfferingMember_ECBF60CB43EA3FE4A2157D80DFBEAB8B_label_en-US" xlink:label="lab_nlnk_FollowOnOfferingMember_ECBF60CB43EA3FE4A2157D80DFBEAB8B" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Follow-on Offering [Member]</link:label>
    <link:label id="lab_nlnk_FollowOnOfferingMember_ECBF60CB43EA3FE4A2157D80DFBEAB8B_documentation_en-US" xlink:label="lab_nlnk_FollowOnOfferingMember_ECBF60CB43EA3FE4A2157D80DFBEAB8B" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Follow-on Offering [Member]</link:label>
    <link:loc xlink:href="nlnk-20170930.xsd#nlnk_FollowOnOfferingMember" xlink:label="loc_nlnk_FollowOnOfferingMember_ECBF60CB43EA3FE4A2157D80DFBEAB8B" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_nlnk_FollowOnOfferingMember_ECBF60CB43EA3FE4A2157D80DFBEAB8B" xlink:to="lab_nlnk_FollowOnOfferingMember_ECBF60CB43EA3FE4A2157D80DFBEAB8B" xlink:type="arc" />
    <link:label id="lab_nlnk_ATMOfferingMember_4A0F1CE42404F98840AA7D80DFBE09FE_terseLabel_en-US" xlink:label="lab_nlnk_ATMOfferingMember_4A0F1CE42404F98840AA7D80DFBE09FE" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">ATM Offering</link:label>
    <link:label id="lab_nlnk_ATMOfferingMember_4A0F1CE42404F98840AA7D80DFBE09FE_label_en-US" xlink:label="lab_nlnk_ATMOfferingMember_4A0F1CE42404F98840AA7D80DFBE09FE" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">ATM Offering [Member]</link:label>
    <link:label id="lab_nlnk_ATMOfferingMember_4A0F1CE42404F98840AA7D80DFBE09FE_documentation_en-US" xlink:label="lab_nlnk_ATMOfferingMember_4A0F1CE42404F98840AA7D80DFBE09FE" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">ATM Offering [Member]</link:label>
    <link:loc xlink:href="nlnk-20170930.xsd#nlnk_ATMOfferingMember" xlink:label="loc_nlnk_ATMOfferingMember_4A0F1CE42404F98840AA7D80DFBE09FE" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_nlnk_ATMOfferingMember_4A0F1CE42404F98840AA7D80DFBE09FE" xlink:to="lab_nlnk_ATMOfferingMember_4A0F1CE42404F98840AA7D80DFBE09FE" xlink:type="arc" />
    <link:label id="lab_nlnk_PublicOfferingMember_CDE089F53446C33D089E7D80DFBEB1B1_terseLabel_en-US" xlink:label="lab_nlnk_PublicOfferingMember_CDE089F53446C33D089E7D80DFBEB1B1" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Public Offering [Member]</link:label>
    <link:label id="lab_nlnk_PublicOfferingMember_CDE089F53446C33D089E7D80DFBEB1B1_label_en-US" xlink:label="lab_nlnk_PublicOfferingMember_CDE089F53446C33D089E7D80DFBEB1B1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Public Offering [Member]</link:label>
    <link:label id="lab_nlnk_PublicOfferingMember_CDE089F53446C33D089E7D80DFBEB1B1_documentation_en-US" xlink:label="lab_nlnk_PublicOfferingMember_CDE089F53446C33D089E7D80DFBEB1B1" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Public Offering [Member]</link:label>
    <link:loc xlink:href="nlnk-20170930.xsd#nlnk_PublicOfferingMember" xlink:label="loc_nlnk_PublicOfferingMember_CDE089F53446C33D089E7D80DFBEB1B1" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_nlnk_PublicOfferingMember_CDE089F53446C33D089E7D80DFBEB1B1" xlink:to="lab_nlnk_PublicOfferingMember_CDE089F53446C33D089E7D80DFBEB1B1" xlink:type="arc" />
    <link:label id="lab_nlnk_FinancingsLineItems_5D536571D0ABE5AA2C257D80DFBF9E70_terseLabel_en-US" xlink:label="lab_nlnk_FinancingsLineItems_5D536571D0ABE5AA2C257D80DFBF9E70" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Financings</link:label>
    <link:label id="lab_nlnk_FinancingsLineItems_5D536571D0ABE5AA2C257D80DFBF9E70_label_en-US" xlink:label="lab_nlnk_FinancingsLineItems_5D536571D0ABE5AA2C257D80DFBF9E70" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Financings [Line Items]</link:label>
    <link:label id="lab_nlnk_FinancingsLineItems_5D536571D0ABE5AA2C257D80DFBF9E70_documentation_en-US" xlink:label="lab_nlnk_FinancingsLineItems_5D536571D0ABE5AA2C257D80DFBF9E70" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">[Line Items] for Financings [Table]</link:label>
    <link:loc xlink:href="nlnk-20170930.xsd#nlnk_FinancingsLineItems" xlink:label="loc_nlnk_FinancingsLineItems_5D536571D0ABE5AA2C257D80DFBF9E70" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_nlnk_FinancingsLineItems_5D536571D0ABE5AA2C257D80DFBF9E70" xlink:to="lab_nlnk_FinancingsLineItems_5D536571D0ABE5AA2C257D80DFBF9E70" xlink:type="arc" />
    <link:label id="lab_us-gaap_SaleOfStockConsiderationReceivedOnTransaction_597EA3BB2D460E790A627D80DFBF9F49_terseLabel_en-US" xlink:label="lab_us-gaap_SaleOfStockConsiderationReceivedOnTransaction_597EA3BB2D460E790A627D80DFBF9F49" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">FInancing proceeds</link:label>
    <link:label id="lab_us-gaap_SaleOfStockConsiderationReceivedOnTransaction_597EA3BB2D460E790A627D80DFBF9F49_label_en-US" xlink:label="lab_us-gaap_SaleOfStockConsiderationReceivedOnTransaction_597EA3BB2D460E790A627D80DFBF9F49" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Sale of Stock, Consideration Received on Transaction</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_SaleOfStockConsiderationReceivedOnTransaction" xlink:label="loc_us-gaap_SaleOfStockConsiderationReceivedOnTransaction_597EA3BB2D460E790A627D80DFBF9F49" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SaleOfStockConsiderationReceivedOnTransaction_597EA3BB2D460E790A627D80DFBF9F49" xlink:to="lab_us-gaap_SaleOfStockConsiderationReceivedOnTransaction_597EA3BB2D460E790A627D80DFBF9F49" xlink:type="arc" />
    <link:label id="lab_nlnk_MaximumAvailableUnderATMOffering_4DB53D4E0E66EF6887417D80DFBFDB12_terseLabel_en-US" xlink:label="lab_nlnk_MaximumAvailableUnderATMOffering_4DB53D4E0E66EF6887417D80DFBFDB12" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Maximum available under ATM offering</link:label>
    <link:label id="lab_nlnk_MaximumAvailableUnderATMOffering_4DB53D4E0E66EF6887417D80DFBFDB12_label_en-US" xlink:label="lab_nlnk_MaximumAvailableUnderATMOffering_4DB53D4E0E66EF6887417D80DFBFDB12" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">MaximumAvailableUnderATMOffering</link:label>
    <link:label id="lab_nlnk_MaximumAvailableUnderATMOffering_4DB53D4E0E66EF6887417D80DFBFDB12_documentation_en-US" xlink:label="lab_nlnk_MaximumAvailableUnderATMOffering_4DB53D4E0E66EF6887417D80DFBFDB12" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Maximum value of shares available for sale under a ATM offering.</link:label>
    <link:loc xlink:href="nlnk-20170930.xsd#nlnk_MaximumAvailableUnderATMOffering" xlink:label="loc_nlnk_MaximumAvailableUnderATMOffering_4DB53D4E0E66EF6887417D80DFBFDB12" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_nlnk_MaximumAvailableUnderATMOffering_4DB53D4E0E66EF6887417D80DFBFDB12" xlink:to="lab_nlnk_MaximumAvailableUnderATMOffering_4DB53D4E0E66EF6887417D80DFBFDB12" xlink:type="arc" />
    <link:label id="lab_us-gaap_StockIssuedDuringPeriodSharesNewIssues_0C0F74537A4BE8C125217D80DFBF1397_terseLabel_en-US" xlink:label="lab_us-gaap_StockIssuedDuringPeriodSharesNewIssues_0C0F74537A4BE8C125217D80DFBF1397" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Number of shares of common stock sold</link:label>
    <link:label id="lab_us-gaap_StockIssuedDuringPeriodSharesNewIssues_0C0F74537A4BE8C125217D80DFBF1397_label_en-US" xlink:label="lab_us-gaap_StockIssuedDuringPeriodSharesNewIssues_0C0F74537A4BE8C125217D80DFBF1397" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Stock Issued During Period, Shares, New Issues</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesNewIssues" xlink:label="loc_us-gaap_StockIssuedDuringPeriodSharesNewIssues_0C0F74537A4BE8C125217D80DFBF1397" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StockIssuedDuringPeriodSharesNewIssues_0C0F74537A4BE8C125217D80DFBF1397" xlink:to="lab_us-gaap_StockIssuedDuringPeriodSharesNewIssues_0C0F74537A4BE8C125217D80DFBF1397" xlink:type="arc" />
    <link:label id="lab_us-gaap_FeesAndCommissions_D80FEF3E9594C5F4C1D77D80DFBFA59D_terseLabel_en-US" xlink:label="lab_us-gaap_FeesAndCommissions_D80FEF3E9594C5F4C1D77D80DFBFA59D" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Fees and commissions</link:label>
    <link:label id="lab_us-gaap_FeesAndCommissions_D80FEF3E9594C5F4C1D77D80DFBFA59D_label_en-US" xlink:label="lab_us-gaap_FeesAndCommissions_D80FEF3E9594C5F4C1D77D80DFBFA59D" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Fees and Commissions</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_FeesAndCommissions" xlink:label="loc_us-gaap_FeesAndCommissions_D80FEF3E9594C5F4C1D77D80DFBFA59D" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FeesAndCommissions_D80FEF3E9594C5F4C1D77D80DFBFA59D" xlink:to="lab_us-gaap_FeesAndCommissions_D80FEF3E9594C5F4C1D77D80DFBFA59D" xlink:type="arc" />
    <link:label id="lab_us-gaap_PaymentsForCommissions_5F2E9D0E86D9446FD4107D80DFBF2A84_terseLabel_en-US" xlink:label="lab_us-gaap_PaymentsForCommissions_5F2E9D0E86D9446FD4107D80DFBF2A84" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Commissions paid</link:label>
    <link:label id="lab_us-gaap_PaymentsForCommissions_5F2E9D0E86D9446FD4107D80DFBF2A84_label_en-US" xlink:label="lab_us-gaap_PaymentsForCommissions_5F2E9D0E86D9446FD4107D80DFBF2A84" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Payments for Commissions</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_PaymentsForCommissions" xlink:label="loc_us-gaap_PaymentsForCommissions_5F2E9D0E86D9446FD4107D80DFBF2A84" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PaymentsForCommissions_5F2E9D0E86D9446FD4107D80DFBF2A84" xlink:to="lab_us-gaap_PaymentsForCommissions_5F2E9D0E86D9446FD4107D80DFBF2A84" xlink:type="arc" />
    <link:label id="lab_us-gaap_PaymentsOfStockIssuanceCosts_9C94B8803837B98118567D8A35282A67_terseLabel_en-US" xlink:label="lab_us-gaap_PaymentsOfStockIssuanceCosts_9C94B8803837B98118567D8A35282A67" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Other costs</link:label>
    <link:label id="lab_us-gaap_PaymentsOfStockIssuanceCosts_9C94B8803837B98118567D8A35282A67_label_en-US" xlink:label="lab_us-gaap_PaymentsOfStockIssuanceCosts_9C94B8803837B98118567D8A35282A67" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Payments of Stock Issuance Costs</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_PaymentsOfStockIssuanceCosts" xlink:label="loc_us-gaap_PaymentsOfStockIssuanceCosts_9C94B8803837B98118567D8A35282A67" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PaymentsOfStockIssuanceCosts_9C94B8803837B98118567D8A35282A67" xlink:to="lab_us-gaap_PaymentsOfStockIssuanceCosts_9C94B8803837B98118567D8A35282A67" xlink:type="arc" />
    <link:label id="lab_us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction_EE5D8693BD75A9CE06E67D80DFBFA7DA_terseLabel_en-US" xlink:label="lab_us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction_EE5D8693BD75A9CE06E67D80DFBFA7DA" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Number of shares issued</link:label>
    <link:label id="lab_us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction_EE5D8693BD75A9CE06E67D80DFBFA7DA_label_en-US" xlink:label="lab_us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction_EE5D8693BD75A9CE06E67D80DFBFA7DA" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Sale of Stock, Number of Shares Issued in Transaction</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction" xlink:label="loc_us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction_EE5D8693BD75A9CE06E67D80DFBFA7DA" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction_EE5D8693BD75A9CE06E67D80DFBFA7DA" xlink:to="lab_us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction_EE5D8693BD75A9CE06E67D80DFBFA7DA" xlink:type="arc" />
    <link:label id="lab_nlnk_CollaborativeArrangementNumberofArrangements_C6F9D60A4B8F1AECF1547D80DFBF7E55_terseLabel_en-US" xlink:label="lab_nlnk_CollaborativeArrangementNumberofArrangements_C6F9D60A4B8F1AECF1547D80DFBF7E55" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Number of license and collaboration arrangements</link:label>
    <link:label id="lab_nlnk_CollaborativeArrangementNumberofArrangements_C6F9D60A4B8F1AECF1547D80DFBF7E55_label_en-US" xlink:label="lab_nlnk_CollaborativeArrangementNumberofArrangements_C6F9D60A4B8F1AECF1547D80DFBF7E55" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Collaborative Arrangement, Number of Arrangements</link:label>
    <link:label id="lab_nlnk_CollaborativeArrangementNumberofArrangements_C6F9D60A4B8F1AECF1547D80DFBF7E55_documentation_en-US" xlink:label="lab_nlnk_CollaborativeArrangementNumberofArrangements_C6F9D60A4B8F1AECF1547D80DFBF7E55" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Collaborative Arrangement, Number of Arrangements</link:label>
    <link:loc xlink:href="nlnk-20170930.xsd#nlnk_CollaborativeArrangementNumberofArrangements" xlink:label="loc_nlnk_CollaborativeArrangementNumberofArrangements_C6F9D60A4B8F1AECF1547D80DFBF7E55" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_nlnk_CollaborativeArrangementNumberofArrangements_C6F9D60A4B8F1AECF1547D80DFBF7E55" xlink:to="lab_nlnk_CollaborativeArrangementNumberofArrangements_C6F9D60A4B8F1AECF1547D80DFBF7E55" xlink:type="arc" />
    <link:label id="lab_us-gaap_RangeAxis_4817B33F4A5DB1000C9297345C0759A4_verboseLabel_en-US" xlink:label="lab_us-gaap_RangeAxis_2CF76EFC15365ED986AA3C735A643FE1" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Range</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_RangeAxis" xlink:label="loc_us-gaap_RangeAxis_2CF76EFC15365ED986AA3C735A643FE1" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RangeAxis_2CF76EFC15365ED986AA3C735A643FE1" xlink:to="lab_us-gaap_RangeAxis_2CF76EFC15365ED986AA3C735A643FE1" xlink:type="arc" />
    <link:label id="lab_us-gaap_RangeMember_0C0A5178036382C0C0F397345C071007_verboseLabel_en-US" xlink:label="lab_us-gaap_RangeMember_E727579565955403B1173F25791039AE" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Range</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_RangeMember" xlink:label="loc_us-gaap_RangeMember_E727579565955403B1173F25791039AE" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RangeMember_E727579565955403B1173F25791039AE" xlink:to="lab_us-gaap_RangeMember_E727579565955403B1173F25791039AE" xlink:type="arc" />
    <link:label id="lab_us-gaap_PerformanceSharesMember_19E551A692F99BED02EC97345C08D6DA_verboseLabel_en-US" xlink:label="lab_us-gaap_PerformanceSharesMember_FBAC6F7E45E95C6BBF5BEA0B33361451" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Performance Stock</link:label>
    <link:label id="lab_us-gaap_PerformanceSharesMember_19E551A692F99BED02EC97345C08D6DA_label_en-US" xlink:label="lab_us-gaap_PerformanceSharesMember_FBAC6F7E45E95C6BBF5BEA0B33361451" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Performance Shares [Member]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_PerformanceSharesMember" xlink:label="loc_us-gaap_PerformanceSharesMember_FBAC6F7E45E95C6BBF5BEA0B33361451" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PerformanceSharesMember_FBAC6F7E45E95C6BBF5BEA0B33361451" xlink:to="lab_us-gaap_PerformanceSharesMember_FBAC6F7E45E95C6BBF5BEA0B33361451" xlink:type="arc" />
    <link:label id="lab_us-gaap_RestrictedStockMember_7788A2FBA14B51FA834397345C081419_verboseLabel_en-US" xlink:label="lab_us-gaap_RestrictedStockMember_16466D3E6B5B54FEA0EC12D4D177C3D1" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Restricted Stock</link:label>
    <link:label id="lab_us-gaap_RestrictedStockMember_7788A2FBA14B51FA834397345C081419_label_en-US" xlink:label="lab_us-gaap_RestrictedStockMember_16466D3E6B5B54FEA0EC12D4D177C3D1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Restricted Stock [Member]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_RestrictedStockMember" xlink:label="loc_us-gaap_RestrictedStockMember_16466D3E6B5B54FEA0EC12D4D177C3D1" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RestrictedStockMember_16466D3E6B5B54FEA0EC12D4D177C3D1" xlink:to="lab_us-gaap_RestrictedStockMember_16466D3E6B5B54FEA0EC12D4D177C3D1" xlink:type="arc" />
    <link:label id="lab_nlnk_PerformanceRestrictedStockMember_4E097BF73C67E37AA9D997FED0AA422F_terseLabel_en-US" xlink:label="lab_nlnk_PerformanceRestrictedStockMember_ACEA61DA39015E9F9411B9A62E9FF1EF" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Performance Restricted Stock</link:label>
    <link:label id="lab_nlnk_PerformanceRestrictedStockMember_4E097BF73C67E37AA9D997FED0AA422F_label_en-US" xlink:label="lab_nlnk_PerformanceRestrictedStockMember_ACEA61DA39015E9F9411B9A62E9FF1EF" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Performance Restricted Stock [Member]</link:label>
    <link:label id="lab_nlnk_PerformanceRestrictedStockMember_4E097BF73C67E37AA9D997FED0AA422F_documentation_en-US" xlink:label="lab_nlnk_PerformanceRestrictedStockMember_ACEA61DA39015E9F9411B9A62E9FF1EF" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Performance Restricted Stock [Member]</link:label>
    <link:loc xlink:href="nlnk-20170930.xsd#nlnk_PerformanceRestrictedStockMember" xlink:label="loc_nlnk_PerformanceRestrictedStockMember_ACEA61DA39015E9F9411B9A62E9FF1EF" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_nlnk_PerformanceRestrictedStockMember_ACEA61DA39015E9F9411B9A62E9FF1EF" xlink:to="lab_nlnk_PerformanceRestrictedStockMember_ACEA61DA39015E9F9411B9A62E9FF1EF" xlink:type="arc" />
    <link:label id="lab_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_F8636CE6A1ADA0F4EC6397345C08A93D_terseLabel_en-US" xlink:label="lab_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_29AC741D549B579FB84E60CAF85BE287" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Antidilutive Securities</link:label>
    <link:label id="lab_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_F8636CE6A1ADA0F4EC6397345C08A93D_label_en-US" xlink:label="lab_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_29AC741D549B579FB84E60CAF85BE287" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Antidilutive Securities [Axis]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" xlink:label="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_29AC741D549B579FB84E60CAF85BE287" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_29AC741D549B579FB84E60CAF85BE287" xlink:to="lab_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_29AC741D549B579FB84E60CAF85BE287" xlink:type="arc" />
    <link:label id="lab_us-gaap_AntidilutiveSecuritiesNameDomain_047ABFC45106C8F639EA97345C086353_terseLabel_en-US" xlink:label="lab_us-gaap_AntidilutiveSecuritiesNameDomain_FB3A827D7A41590C9489CE87B3919488" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Antidilutive Securities, Name</link:label>
    <link:label id="lab_us-gaap_AntidilutiveSecuritiesNameDomain_047ABFC45106C8F639EA97345C086353_label_en-US" xlink:label="lab_us-gaap_AntidilutiveSecuritiesNameDomain_FB3A827D7A41590C9489CE87B3919488" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Antidilutive Securities, Name [Domain]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_AntidilutiveSecuritiesNameDomain" xlink:label="loc_us-gaap_AntidilutiveSecuritiesNameDomain_FB3A827D7A41590C9489CE87B3919488" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AntidilutiveSecuritiesNameDomain_FB3A827D7A41590C9489CE87B3919488" xlink:to="lab_us-gaap_AntidilutiveSecuritiesNameDomain_FB3A827D7A41590C9489CE87B3919488" xlink:type="arc" />
    <link:label id="lab_us-gaap_PlanNameAxis_0928782AC6AD10DFCBF697345C082722_terseLabel_en-US" xlink:label="lab_us-gaap_PlanNameAxis_BE64B3B82AA25EFE861205FA479A7375" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Plan Name</link:label>
    <link:label id="lab_us-gaap_PlanNameAxis_0928782AC6AD10DFCBF697345C082722_label_en-US" xlink:label="lab_us-gaap_PlanNameAxis_BE64B3B82AA25EFE861205FA479A7375" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Plan Name [Axis]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_PlanNameAxis" xlink:label="loc_us-gaap_PlanNameAxis_BE64B3B82AA25EFE861205FA479A7375" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PlanNameAxis_BE64B3B82AA25EFE861205FA479A7375" xlink:to="lab_us-gaap_PlanNameAxis_BE64B3B82AA25EFE861205FA479A7375" xlink:type="arc" />
    <link:label id="lab_us-gaap_PlanNameDomain_1C3255F4445C0D900E8197345C09FE0D_terseLabel_en-US" xlink:label="lab_us-gaap_PlanNameDomain_1A1643A526F1570AB6166F265E50AFA6" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Plan Name</link:label>
    <link:label id="lab_us-gaap_PlanNameDomain_1C3255F4445C0D900E8197345C09FE0D_label_en-US" xlink:label="lab_us-gaap_PlanNameDomain_1A1643A526F1570AB6166F265E50AFA6" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Plan Name [Domain]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_PlanNameDomain" xlink:label="loc_us-gaap_PlanNameDomain_1A1643A526F1570AB6166F265E50AFA6" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PlanNameDomain_1A1643A526F1570AB6166F265E50AFA6" xlink:to="lab_us-gaap_PlanNameDomain_1A1643A526F1570AB6166F265E50AFA6" xlink:type="arc" />
    <link:label id="lab_nlnk_A2009EquityIncentivePlanMember_D622997C6065D888577597345C09473B_terseLabel_en-US" xlink:label="lab_nlnk_A2009EquityIncentivePlanMember_1C0561DF08265DFA90BA510F5D6E4173" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">2009 Equity Incentive Plan</link:label>
    <link:label id="lab_nlnk_A2009EquityIncentivePlanMember_D622997C6065D888577597345C09473B_label_en-US" xlink:label="lab_nlnk_A2009EquityIncentivePlanMember_1C0561DF08265DFA90BA510F5D6E4173" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">2009 Equity Incentive Plan [Member]</link:label>
    <link:label id="lab_nlnk_A2009EquityIncentivePlanMember_D622997C6065D888577597345C09473B_documentation_en-US" xlink:label="lab_nlnk_A2009EquityIncentivePlanMember_1C0561DF08265DFA90BA510F5D6E4173" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">2009 Equity Incentive Plan [Member]</link:label>
    <link:loc xlink:href="nlnk-20170930.xsd#nlnk_A2009EquityIncentivePlanMember" xlink:label="loc_nlnk_A2009EquityIncentivePlanMember_1C0561DF08265DFA90BA510F5D6E4173" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_nlnk_A2009EquityIncentivePlanMember_1C0561DF08265DFA90BA510F5D6E4173" xlink:to="lab_nlnk_A2009EquityIncentivePlanMember_1C0561DF08265DFA90BA510F5D6E4173" xlink:type="arc" />
    <link:label id="lab_nlnk_A2010NonEmployeeDirectorsStockOptionPlanMember_B0FF2084EF53DF8A96B397345C09BA1A_terseLabel_en-US" xlink:label="lab_nlnk_A2010NonEmployeeDirectorsStockOptionPlanMember_8316DFB7ECFA544BBDD16CFC4E6CA565" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">2010 Non-Employee Directors' Stock Option Plan</link:label>
    <link:label id="lab_nlnk_A2010NonEmployeeDirectorsStockOptionPlanMember_B0FF2084EF53DF8A96B397345C09BA1A_label_en-US" xlink:label="lab_nlnk_A2010NonEmployeeDirectorsStockOptionPlanMember_8316DFB7ECFA544BBDD16CFC4E6CA565" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">2010 Non-Employee Directors' Stock Option Plan [Member]</link:label>
    <link:label id="lab_nlnk_A2010NonEmployeeDirectorsStockOptionPlanMember_B0FF2084EF53DF8A96B397345C09BA1A_documentation_en-US" xlink:label="lab_nlnk_A2010NonEmployeeDirectorsStockOptionPlanMember_8316DFB7ECFA544BBDD16CFC4E6CA565" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">2010 Non-Employee Directors' Stock Option Plan [Member]</link:label>
    <link:loc xlink:href="nlnk-20170930.xsd#nlnk_A2010NonEmployeeDirectorsStockOptionPlanMember" xlink:label="loc_nlnk_A2010NonEmployeeDirectorsStockOptionPlanMember_8316DFB7ECFA544BBDD16CFC4E6CA565" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_nlnk_A2010NonEmployeeDirectorsStockOptionPlanMember_8316DFB7ECFA544BBDD16CFC4E6CA565" xlink:to="lab_nlnk_A2010NonEmployeeDirectorsStockOptionPlanMember_8316DFB7ECFA544BBDD16CFC4E6CA565" xlink:type="arc" />
    <link:label id="lab_nlnk_A2010EmployeeStockPurchasePlanMember_9443372B62E8EF7455F297345C09381B_terseLabel_en-US" xlink:label="lab_nlnk_A2010EmployeeStockPurchasePlanMember_9340D14C8C5A5DB491E439FD84F489FB" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">2010 Employee Stock Purchase Plan</link:label>
    <link:label id="lab_nlnk_A2010EmployeeStockPurchasePlanMember_9443372B62E8EF7455F297345C09381B_label_en-US" xlink:label="lab_nlnk_A2010EmployeeStockPurchasePlanMember_9340D14C8C5A5DB491E439FD84F489FB" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">2010 Employee Stock Purchase Plan [Member]</link:label>
    <link:label id="lab_nlnk_A2010EmployeeStockPurchasePlanMember_9443372B62E8EF7455F297345C09381B_documentation_en-US" xlink:label="lab_nlnk_A2010EmployeeStockPurchasePlanMember_9340D14C8C5A5DB491E439FD84F489FB" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">2010 Employee Stock Purchase Plan [Member]</link:label>
    <link:loc xlink:href="nlnk-20170930.xsd#nlnk_A2010EmployeeStockPurchasePlanMember" xlink:label="loc_nlnk_A2010EmployeeStockPurchasePlanMember_9340D14C8C5A5DB491E439FD84F489FB" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_nlnk_A2010EmployeeStockPurchasePlanMember_9340D14C8C5A5DB491E439FD84F489FB" xlink:to="lab_nlnk_A2010EmployeeStockPurchasePlanMember_9340D14C8C5A5DB491E439FD84F489FB" xlink:type="arc" />
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized_3EFE5804F3FDB547AA0A97345C093FE1_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized_DF61E7B696EC5DA28C5432E803AF5AA2" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Number of shares authorized</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized_3EFE5804F3FDB547AA0A97345C093FE1_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized_DF61E7B696EC5DA28C5432E803AF5AA2" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Number of Shares Authorized</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized_DF61E7B696EC5DA28C5432E803AF5AA2" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized_DF61E7B696EC5DA28C5432E803AF5AA2" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized_DF61E7B696EC5DA28C5432E803AF5AA2" xlink:type="arc" />
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant_24B0A822C3125EA2399597345C092E11_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant_3CFE67E4824F5BB6AF4920AF2B8289F0" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Number of shares remained available for issuance</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant_24B0A822C3125EA2399597345C092E11_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant_3CFE67E4824F5BB6AF4920AF2B8289F0" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Number of Shares Available for Grant</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant_3CFE67E4824F5BB6AF4920AF2B8289F0" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant_3CFE67E4824F5BB6AF4920AF2B8289F0" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant_3CFE67E4824F5BB6AF4920AF2B8289F0" xlink:type="arc" />
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized_27D7CE780FBDB1CE2D1B97E0C1CF63BC_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized_BC12B6483FC15C4C916739B11E0623C0" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Increase in number of shares authorized</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized_27D7CE780FBDB1CE2D1B97E0C1CF63BC_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized_BC12B6483FC15C4C916739B11E0623C0" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Number of Additional Shares Authorized</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized_BC12B6483FC15C4C916739B11E0623C0" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized_BC12B6483FC15C4C916739B11E0623C0" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized_BC12B6483FC15C4C916739B11E0623C0" xlink:type="arc" />
    <link:label id="lab_nlnk_SharebasedCompensationArrangementbySharebasedPaymentAwardPercentageofAuthorizedStockMaximum_A7CD1530A9AF97D55AE097345C092CA4_terseLabel_en-US" xlink:label="lab_nlnk_SharebasedCompensationArrangementbySharebasedPaymentAwardPercentageofAuthorizedStockMaximum_5441FBEF66425EA4B5296784C1DF3D6B" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Evergreen increase (percent)</link:label>
    <link:label id="lab_nlnk_SharebasedCompensationArrangementbySharebasedPaymentAwardPercentageofAuthorizedStockMaximum_A7CD1530A9AF97D55AE097345C092CA4_label_en-US" xlink:label="lab_nlnk_SharebasedCompensationArrangementbySharebasedPaymentAwardPercentageofAuthorizedStockMaximum_5441FBEF66425EA4B5296784C1DF3D6B" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Percentage of Authorized Stock Maximum</link:label>
    <link:label id="lab_nlnk_SharebasedCompensationArrangementbySharebasedPaymentAwardPercentageofAuthorizedStockMaximum_A7CD1530A9AF97D55AE097345C092CA4_documentation_en-US" xlink:label="lab_nlnk_SharebasedCompensationArrangementbySharebasedPaymentAwardPercentageofAuthorizedStockMaximum_5441FBEF66425EA4B5296784C1DF3D6B" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Percentage of Authorized Stock Maximum</link:label>
    <link:loc xlink:href="nlnk-20170930.xsd#nlnk_SharebasedCompensationArrangementbySharebasedPaymentAwardPercentageofAuthorizedStockMaximum" xlink:label="loc_nlnk_SharebasedCompensationArrangementbySharebasedPaymentAwardPercentageofAuthorizedStockMaximum_5441FBEF66425EA4B5296784C1DF3D6B" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_nlnk_SharebasedCompensationArrangementbySharebasedPaymentAwardPercentageofAuthorizedStockMaximum_5441FBEF66425EA4B5296784C1DF3D6B" xlink:to="lab_nlnk_SharebasedCompensationArrangementbySharebasedPaymentAwardPercentageofAuthorizedStockMaximum_5441FBEF66425EA4B5296784C1DF3D6B" xlink:type="arc" />
    <link:label id="lab_us-gaap_AllocatedShareBasedCompensationExpense_051F14FB195E4591471497345C094EC6_terseLabel_en-US" xlink:label="lab_us-gaap_AllocatedShareBasedCompensationExpense_5943F5B570E75FC7AF703D215682073C" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Share-based compensation expense</link:label>
    <link:label id="lab_us-gaap_AllocatedShareBasedCompensationExpense_051F14FB195E4591471497345C094EC6_label_en-US" xlink:label="lab_us-gaap_AllocatedShareBasedCompensationExpense_5943F5B570E75FC7AF703D215682073C" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Allocated Share-based Compensation Expense</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_AllocatedShareBasedCompensationExpense" xlink:label="loc_us-gaap_AllocatedShareBasedCompensationExpense_5943F5B570E75FC7AF703D215682073C" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AllocatedShareBasedCompensationExpense_5943F5B570E75FC7AF703D215682073C" xlink:to="lab_us-gaap_AllocatedShareBasedCompensationExpense_5943F5B570E75FC7AF703D215682073C" xlink:type="arc" />
    <link:label id="lab_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions_AC48B30094B608A3204997345C098299_terseLabel_en-US" xlink:label="lab_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions_5C2976759DC2551F9E33D9473F3019FF" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Total compensation cost related to non-vested option awards</link:label>
    <link:label id="lab_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions_AC48B30094B608A3204997345C098299_label_en-US" xlink:label="lab_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions_5C2976759DC2551F9E33D9473F3019FF" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Employee Service Share-based Compensation, Nonvested Awards, Compensation Not yet Recognized, Stock Options</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions" xlink:label="loc_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions_5C2976759DC2551F9E33D9473F3019FF" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions_5C2976759DC2551F9E33D9473F3019FF" xlink:to="lab_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions_5C2976759DC2551F9E33D9473F3019FF" xlink:type="arc" />
    <link:label id="lab_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1_BB246A87060215E3189697345C0AF5B5_terseLabel_en-US" xlink:label="lab_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1_3D2A0CB62C265A5597BFF9149316BB38" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Weighted average vesting period for non-vested option awards, in years</link:label>
    <link:label id="lab_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1_BB246A87060215E3189697345C0AF5B5_label_en-US" xlink:label="lab_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1_3D2A0CB62C265A5597BFF9149316BB38" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Employee Service Share-based Compensation, Nonvested Awards, Compensation Cost Not yet Recognized, Period for Recognition</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1" xlink:label="loc_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1_3D2A0CB62C265A5597BFF9149316BB38" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1_3D2A0CB62C265A5597BFF9149316BB38" xlink:to="lab_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1_3D2A0CB62C265A5597BFF9149316BB38" xlink:type="arc" />
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue_D982FA1062FCFF488A3597345C09B873_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue_2B97B13197C75EF9BF6EE2DCBEEF8563" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Intrinsic value of options exercised</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue_D982FA1062FCFF488A3597345C09B873_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue_2B97B13197C75EF9BF6EE2DCBEEF8563" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercises in Period, Intrinsic Value</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue_2B97B13197C75EF9BF6EE2DCBEEF8563" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue_2B97B13197C75EF9BF6EE2DCBEEF8563" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue_2B97B13197C75EF9BF6EE2DCBEEF8563" xlink:type="arc" />
    <link:label id="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedInPeriodFairValue1_15FC2A6634BB0E21A73197345C0A8F55_terseLabel_en-US" xlink:label="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedInPeriodFairValue1_F8F654A6280F534EB4CAB7702A5BCB62" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Fair value of awards vested</link:label>
    <link:label id="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedInPeriodFairValue1_15FC2A6634BB0E21A73197345C0A8F55_label_en-US" xlink:label="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedInPeriodFairValue1_F8F654A6280F534EB4CAB7702A5BCB62" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Options, Vested in Period, Fair Value</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedInPeriodFairValue1" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedInPeriodFairValue1_F8F654A6280F534EB4CAB7702A5BCB62" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedInPeriodFairValue1_F8F654A6280F534EB4CAB7702A5BCB62" xlink:to="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedInPeriodFairValue1_F8F654A6280F534EB4CAB7702A5BCB62" xlink:type="arc" />
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod_EC688D82F42BC26FA8A397E9766BE05B_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod_60D8BAB3559353BF87C58668631C4E9C" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Granted (in shares)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod_EC688D82F42BC26FA8A397E9766BE05B_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod_60D8BAB3559353BF87C58668631C4E9C" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Grants in Period</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod_60D8BAB3559353BF87C58668631C4E9C" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod_60D8BAB3559353BF87C58668631C4E9C" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod_60D8BAB3559353BF87C58668631C4E9C" xlink:type="arc" />
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_7039A83C8FF452F0860997EA132EE61B_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_1B1EA12597975E048309B88020AD8D0C" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Weighted average grant-date fair value per share (in dollars per share)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_7039A83C8FF452F0860997EA132EE61B_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_1B1EA12597975E048309B88020AD8D0C" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Grants in Period, Weighted Average Grant Date Fair Value</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_1B1EA12597975E048309B88020AD8D0C" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_1B1EA12597975E048309B88020AD8D0C" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_1B1EA12597975E048309B88020AD8D0C" xlink:type="arc" />
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod_2838F0E18FA9D060175297EB2495A868_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod_9A4F81B9F7105D87AC3EA609BC4E2D23" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Options exercisable at end of period (in shares)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod_2838F0E18FA9D060175297EB2495A868_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod_9A4F81B9F7105D87AC3EA609BC4E2D23" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Vested in Period</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod_9A4F81B9F7105D87AC3EA609BC4E2D23" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod_9A4F81B9F7105D87AC3EA609BC4E2D23" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod_9A4F81B9F7105D87AC3EA609BC4E2D23" xlink:type="arc" />
    <link:label id="lab_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedShareBasedAwardsOtherThanOptions_BE0121ECBCFFD502C2FB97345C0A1F1E_terseLabel_en-US" xlink:label="lab_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedShareBasedAwardsOtherThanOptions_4C60DC9086C454B2A85380BC6E056E39" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Unrecognized compensation cost</link:label>
    <link:label id="lab_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedShareBasedAwardsOtherThanOptions_BE0121ECBCFFD502C2FB97345C0A1F1E_label_en-US" xlink:label="lab_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedShareBasedAwardsOtherThanOptions_4C60DC9086C454B2A85380BC6E056E39" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Employee Service Share-based Compensation, Nonvested Awards, Compensation Not yet Recognized, Share-based Awards Other than Options</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedShareBasedAwardsOtherThanOptions" xlink:label="loc_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedShareBasedAwardsOtherThanOptions_4C60DC9086C454B2A85380BC6E056E39" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedShareBasedAwardsOtherThanOptions_4C60DC9086C454B2A85380BC6E056E39" xlink:to="lab_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedShareBasedAwardsOtherThanOptions_4C60DC9086C454B2A85380BC6E056E39" xlink:type="arc" />
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodTotalFairValue_12A68407420D09A4F39797345C0A1413_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodTotalFairValue_502AD5591C475F528B26B6D8CCDFA49E" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Fair value of restricted stock awards vested</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodTotalFairValue_12A68407420D09A4F39797345C0A1413_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodTotalFairValue_502AD5591C475F528B26B6D8CCDFA49E" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Vested in Period, Fair Value</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodTotalFairValue" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodTotalFairValue_502AD5591C475F528B26B6D8CCDFA49E" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodTotalFairValue_502AD5591C475F528B26B6D8CCDFA49E" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodTotalFairValue_502AD5591C475F528B26B6D8CCDFA49E" xlink:type="arc" />
    <link:label id="lab_us-gaap_StatementOfStockholdersEquityAbstract_64BE640AB66D81758C347D8B4CABD63C_label_en-US" xlink:label="lab_us-gaap_StatementOfStockholdersEquityAbstract_64BE640AB66D81758C347D8B4CABD63C" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Statement of Stockholders' Equity [Abstract]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_StatementOfStockholdersEquityAbstract" xlink:label="loc_us-gaap_StatementOfStockholdersEquityAbstract_64BE640AB66D81758C347D8B4CABD63C" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StatementOfStockholdersEquityAbstract_64BE640AB66D81758C347D8B4CABD63C" xlink:to="lab_us-gaap_StatementOfStockholdersEquityAbstract_64BE640AB66D81758C347D8B4CABD63C" xlink:type="arc" />
    <link:label id="lab_us-gaap_AdjustmentsToAdditionalPaidInCapitalStockIssuedIssuanceCosts_831844A5C349211BF1247D8D016AA1CC_terseLabel_en-US" xlink:label="lab_us-gaap_AdjustmentsToAdditionalPaidInCapitalStockIssuedIssuanceCosts_831844A5C349211BF1247D8D016AA1CC" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Stock issuance costs</link:label>
    <link:label id="lab_us-gaap_AdjustmentsToAdditionalPaidInCapitalStockIssuedIssuanceCosts_831844A5C349211BF1247D8D016AA1CC_label_en-US" xlink:label="lab_us-gaap_AdjustmentsToAdditionalPaidInCapitalStockIssuedIssuanceCosts_831844A5C349211BF1247D8D016AA1CC" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Adjustments to Additional Paid in Capital, Stock Issued, Issuance Costs</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_AdjustmentsToAdditionalPaidInCapitalStockIssuedIssuanceCosts" xlink:label="loc_us-gaap_AdjustmentsToAdditionalPaidInCapitalStockIssuedIssuanceCosts_831844A5C349211BF1247D8D016AA1CC" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AdjustmentsToAdditionalPaidInCapitalStockIssuedIssuanceCosts_831844A5C349211BF1247D8D016AA1CC" xlink:to="lab_us-gaap_AdjustmentsToAdditionalPaidInCapitalStockIssuedIssuanceCosts_831844A5C349211BF1247D8D016AA1CC" xlink:type="arc" />
    <link:label id="lab_us-gaap_IncomeStatementAbstract_346D7A95C97CAC5C14DA82A937174691_label_en-US" xlink:label="lab_us-gaap_IncomeStatementAbstract_346D7A95C97CAC5C14DA82A937174691" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Income Statement [Abstract]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_IncomeStatementAbstract" xlink:label="loc_us-gaap_IncomeStatementAbstract_346D7A95C97CAC5C14DA82A937174691" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeStatementAbstract_346D7A95C97CAC5C14DA82A937174691" xlink:to="lab_us-gaap_IncomeStatementAbstract_346D7A95C97CAC5C14DA82A937174691" xlink:type="arc" />
    <link:label id="lab_us-gaap_RevenueFromGrants_DE7E22CCFAE2B943642282A9371A2E11_terseLabel_en-US" xlink:label="lab_us-gaap_RevenueFromGrants_DE7E22CCFAE2B943642282A9371A2E11" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Grant revenue</link:label>
    <link:label id="lab_us-gaap_RevenueFromGrants_DE7E22CCFAE2B943642282A9371A2E11_label_en-US" xlink:label="lab_us-gaap_RevenueFromGrants_DE7E22CCFAE2B943642282A9371A2E11" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Revenue from Grants</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_RevenueFromGrants" xlink:label="loc_us-gaap_RevenueFromGrants_DE7E22CCFAE2B943642282A9371A2E11" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RevenueFromGrants_DE7E22CCFAE2B943642282A9371A2E11" xlink:to="lab_us-gaap_RevenueFromGrants_DE7E22CCFAE2B943642282A9371A2E11" xlink:type="arc" />
    <link:label id="lab_us-gaap_SalesRevenueNet_E7740E6C5FC6E82991C682A9371D3446_totalLabel_en-US" xlink:label="lab_us-gaap_SalesRevenueNet_E7740E6C5FC6E82991C682A9371D3446" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xml:lang="en-US">Total operating revenues</link:label>
    <link:label id="lab_us-gaap_SalesRevenueNet_E7740E6C5FC6E82991C682A9371D3446_label_en-US" xlink:label="lab_us-gaap_SalesRevenueNet_E7740E6C5FC6E82991C682A9371D3446" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Revenue, Net</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_SalesRevenueNet" xlink:label="loc_us-gaap_SalesRevenueNet_E7740E6C5FC6E82991C682A9371D3446" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SalesRevenueNet_E7740E6C5FC6E82991C682A9371D3446" xlink:to="lab_us-gaap_SalesRevenueNet_E7740E6C5FC6E82991C682A9371D3446" xlink:type="arc" />
    <link:label id="lab_us-gaap_OperatingExpensesAbstract_7655F1BFC672C81450D282A9371D4FA7_terseLabel_en-US" xlink:label="lab_us-gaap_OperatingExpensesAbstract_7655F1BFC672C81450D282A9371D4FA7" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Operating expenses:</link:label>
    <link:label id="lab_us-gaap_OperatingExpensesAbstract_7655F1BFC672C81450D282A9371D4FA7_label_en-US" xlink:label="lab_us-gaap_OperatingExpensesAbstract_7655F1BFC672C81450D282A9371D4FA7" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Operating Expenses [Abstract]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_OperatingExpensesAbstract" xlink:label="loc_us-gaap_OperatingExpensesAbstract_7655F1BFC672C81450D282A9371D4FA7" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OperatingExpensesAbstract_7655F1BFC672C81450D282A9371D4FA7" xlink:to="lab_us-gaap_OperatingExpensesAbstract_7655F1BFC672C81450D282A9371D4FA7" xlink:type="arc" />
    <link:label id="lab_us-gaap_ResearchAndDevelopmentExpense_4A7DB31354C5B602DCB382A9371DA064_terseLabel_en-US" xlink:label="lab_us-gaap_ResearchAndDevelopmentExpense_4A7DB31354C5B602DCB382A9371DA064" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Research and development</link:label>
    <link:label id="lab_us-gaap_ResearchAndDevelopmentExpense_4A7DB31354C5B602DCB382A9371DA064_label_en-US" xlink:label="lab_us-gaap_ResearchAndDevelopmentExpense_4A7DB31354C5B602DCB382A9371DA064" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Research and Development Expense</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ResearchAndDevelopmentExpense" xlink:label="loc_us-gaap_ResearchAndDevelopmentExpense_4A7DB31354C5B602DCB382A9371DA064" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ResearchAndDevelopmentExpense_4A7DB31354C5B602DCB382A9371DA064" xlink:to="lab_us-gaap_ResearchAndDevelopmentExpense_4A7DB31354C5B602DCB382A9371DA064" xlink:type="arc" />
    <link:label id="lab_us-gaap_GeneralAndAdministrativeExpense_72A86AA32E448CFED05082A9371DA291_terseLabel_en-US" xlink:label="lab_us-gaap_GeneralAndAdministrativeExpense_72A86AA32E448CFED05082A9371DA291" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">General and administrative</link:label>
    <link:label id="lab_us-gaap_GeneralAndAdministrativeExpense_72A86AA32E448CFED05082A9371DA291_label_en-US" xlink:label="lab_us-gaap_GeneralAndAdministrativeExpense_72A86AA32E448CFED05082A9371DA291" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">General and Administrative Expense</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_GeneralAndAdministrativeExpense" xlink:label="loc_us-gaap_GeneralAndAdministrativeExpense_72A86AA32E448CFED05082A9371DA291" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_GeneralAndAdministrativeExpense_72A86AA32E448CFED05082A9371DA291" xlink:to="lab_us-gaap_GeneralAndAdministrativeExpense_72A86AA32E448CFED05082A9371DA291" xlink:type="arc" />
    <link:label id="lab_us-gaap_OperatingExpenses_FDFCF5FDA3B9663512E882A9371E018D_totalLabel_en-US" xlink:label="lab_us-gaap_OperatingExpenses_FDFCF5FDA3B9663512E882A9371E018D" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xml:lang="en-US">Total operating expenses</link:label>
    <link:label id="lab_us-gaap_OperatingExpenses_FDFCF5FDA3B9663512E882A9371E018D_label_en-US" xlink:label="lab_us-gaap_OperatingExpenses_FDFCF5FDA3B9663512E882A9371E018D" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Operating Expenses</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_OperatingExpenses" xlink:label="loc_us-gaap_OperatingExpenses_FDFCF5FDA3B9663512E882A9371E018D" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OperatingExpenses_FDFCF5FDA3B9663512E882A9371E018D" xlink:to="lab_us-gaap_OperatingExpenses_FDFCF5FDA3B9663512E882A9371E018D" xlink:type="arc" />
    <link:label id="lab_us-gaap_OperatingIncomeLoss_D85BC13019DB652023F582A9371EF2C4_totalLabel_en-US" xlink:label="lab_us-gaap_OperatingIncomeLoss_D85BC13019DB652023F582A9371EF2C4" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xml:lang="en-US">Loss from operations</link:label>
    <link:label id="lab_us-gaap_OperatingIncomeLoss_D85BC13019DB652023F582A9371EF2C4_label_en-US" xlink:label="lab_us-gaap_OperatingIncomeLoss_D85BC13019DB652023F582A9371EF2C4" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Operating Income (Loss)</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_OperatingIncomeLoss" xlink:label="loc_us-gaap_OperatingIncomeLoss_D85BC13019DB652023F582A9371EF2C4" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OperatingIncomeLoss_D85BC13019DB652023F582A9371EF2C4" xlink:to="lab_us-gaap_OperatingIncomeLoss_D85BC13019DB652023F582A9371EF2C4" xlink:type="arc" />
    <link:label id="lab_us-gaap_NonoperatingIncomeExpenseAbstract_DB90D9D0FA54D600A1B482A9371EA413_terseLabel_en-US" xlink:label="lab_us-gaap_NonoperatingIncomeExpenseAbstract_DB90D9D0FA54D600A1B482A9371EA413" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Other income and expense:</link:label>
    <link:label id="lab_us-gaap_NonoperatingIncomeExpenseAbstract_DB90D9D0FA54D600A1B482A9371EA413_label_en-US" xlink:label="lab_us-gaap_NonoperatingIncomeExpenseAbstract_DB90D9D0FA54D600A1B482A9371EA413" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Nonoperating Income (Expense) [Abstract]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_NonoperatingIncomeExpenseAbstract" xlink:label="loc_us-gaap_NonoperatingIncomeExpenseAbstract_DB90D9D0FA54D600A1B482A9371EA413" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NonoperatingIncomeExpenseAbstract_DB90D9D0FA54D600A1B482A9371EA413" xlink:to="lab_us-gaap_NonoperatingIncomeExpenseAbstract_DB90D9D0FA54D600A1B482A9371EA413" xlink:type="arc" />
    <link:label id="lab_us-gaap_OtherNonoperatingIncomeExpense_4C8060D5C3886C4CA5C982BA8169FD86_terseLabel_en-US" xlink:label="lab_us-gaap_OtherNonoperatingIncomeExpense_4C8060D5C3886C4CA5C982BA8169FD86" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Miscellaneous income (expense)</link:label>
    <link:label id="lab_us-gaap_OtherNonoperatingIncomeExpense_4C8060D5C3886C4CA5C982BA8169FD86_label_en-US" xlink:label="lab_us-gaap_OtherNonoperatingIncomeExpense_4C8060D5C3886C4CA5C982BA8169FD86" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Other Nonoperating Income (Expense)</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_OtherNonoperatingIncomeExpense" xlink:label="loc_us-gaap_OtherNonoperatingIncomeExpense_4C8060D5C3886C4CA5C982BA8169FD86" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OtherNonoperatingIncomeExpense_4C8060D5C3886C4CA5C982BA8169FD86" xlink:to="lab_us-gaap_OtherNonoperatingIncomeExpense_4C8060D5C3886C4CA5C982BA8169FD86" xlink:type="arc" />
    <link:label id="lab_us-gaap_InvestmentIncomeInterest_05EEE5023FF99CAED33582A9371E2522_terseLabel_en-US" xlink:label="lab_us-gaap_InvestmentIncomeInterest_05EEE5023FF99CAED33582A9371E2522" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Interest income</link:label>
    <link:label id="lab_us-gaap_InvestmentIncomeInterest_05EEE5023FF99CAED33582A9371E2522_label_en-US" xlink:label="lab_us-gaap_InvestmentIncomeInterest_05EEE5023FF99CAED33582A9371E2522" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Investment Income, Interest</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_InvestmentIncomeInterest" xlink:label="loc_us-gaap_InvestmentIncomeInterest_05EEE5023FF99CAED33582A9371E2522" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_InvestmentIncomeInterest_05EEE5023FF99CAED33582A9371E2522" xlink:to="lab_us-gaap_InvestmentIncomeInterest_05EEE5023FF99CAED33582A9371E2522" xlink:type="arc" />
    <link:label id="lab_us-gaap_InterestExpense_48438E2F7757CA37947182A9371EF0D9_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_InterestExpense_48438E2F7757CA37947182A9371EF0D9" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xml:lang="en-US">Interest expense</link:label>
    <link:label id="lab_us-gaap_InterestExpense_48438E2F7757CA37947182A9371EF0D9_label_en-US" xlink:label="lab_us-gaap_InterestExpense_48438E2F7757CA37947182A9371EF0D9" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Interest Expense</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_InterestExpense" xlink:label="loc_us-gaap_InterestExpense_48438E2F7757CA37947182A9371EF0D9" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_InterestExpense_48438E2F7757CA37947182A9371EF0D9" xlink:to="lab_us-gaap_InterestExpense_48438E2F7757CA37947182A9371EF0D9" xlink:type="arc" />
    <link:label id="lab_us-gaap_NonoperatingIncomeExpense_39BA71250EBE99AC96E282A9371E364C_totalLabel_en-US" xlink:label="lab_us-gaap_NonoperatingIncomeExpense_39BA71250EBE99AC96E282A9371E364C" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xml:lang="en-US">Other income, net</link:label>
    <link:label id="lab_us-gaap_NonoperatingIncomeExpense_39BA71250EBE99AC96E282A9371E364C_label_en-US" xlink:label="lab_us-gaap_NonoperatingIncomeExpense_39BA71250EBE99AC96E282A9371E364C" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Nonoperating Income (Expense)</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_NonoperatingIncomeExpense" xlink:label="loc_us-gaap_NonoperatingIncomeExpense_39BA71250EBE99AC96E282A9371E364C" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NonoperatingIncomeExpense_39BA71250EBE99AC96E282A9371E364C" xlink:to="lab_us-gaap_NonoperatingIncomeExpense_39BA71250EBE99AC96E282A9371E364C" xlink:type="arc" />
    <link:label id="lab_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest_89570A7CA5F9467A1ECC82A9371EED17_totalLabel_en-US" xlink:label="lab_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest_89570A7CA5F9467A1ECC82A9371EED17" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xml:lang="en-US">Net loss before taxes</link:label>
    <link:label id="lab_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest_89570A7CA5F9467A1ECC82A9371EED17_label_en-US" xlink:label="lab_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest_89570A7CA5F9467A1ECC82A9371EED17" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Income (Loss) from Continuing Operations before Income Taxes, Noncontrolling Interest</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" xlink:label="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest_89570A7CA5F9467A1ECC82A9371EED17" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest_89570A7CA5F9467A1ECC82A9371EED17" xlink:to="lab_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest_89570A7CA5F9467A1ECC82A9371EED17" xlink:type="arc" />
    <link:label id="lab_us-gaap_NetIncomeLoss_1527AD06EEEAF6BDBAE282A9371E557C_totalLabel_en-US" xlink:label="lab_us-gaap_NetIncomeLoss_1527AD06EEEAF6BDBAE282A9371E557C" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xml:lang="en-US">Net loss</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_NetIncomeLoss" xlink:label="loc_us-gaap_NetIncomeLoss_1527AD06EEEAF6BDBAE282A9371E557C" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NetIncomeLoss_1527AD06EEEAF6BDBAE282A9371E557C" xlink:to="lab_us-gaap_NetIncomeLoss_1527AD06EEEAF6BDBAE282A9371E557C" xlink:type="arc" />
    <link:label id="lab_us-gaap_WeightedAverageNumberOfShareOutstandingBasicAndDiluted_DF91865D8999E336808082A93724D701_terseLabel_en-US" xlink:label="lab_us-gaap_WeightedAverageNumberOfShareOutstandingBasicAndDiluted_DF91865D8999E336808082A93724D701" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Basic and diluted average shares outstanding (in shares)</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_WeightedAverageNumberOfShareOutstandingBasicAndDiluted" xlink:label="loc_us-gaap_WeightedAverageNumberOfShareOutstandingBasicAndDiluted_DF91865D8999E336808082A93724D701" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_WeightedAverageNumberOfShareOutstandingBasicAndDiluted_DF91865D8999E336808082A93724D701" xlink:to="lab_us-gaap_WeightedAverageNumberOfShareOutstandingBasicAndDiluted_DF91865D8999E336808082A93724D701" xlink:type="arc" />
    <link:label id="lab_us-gaap_SubsequentEventsAbstract_0144583804052F6FF2D097343FD595D0_label_en-US" xlink:label="lab_us-gaap_SubsequentEventsAbstract_29E2040200AE5D098E343485F972DD61" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Subsequent Events [Abstract]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_SubsequentEventsAbstract" xlink:label="loc_us-gaap_SubsequentEventsAbstract_29E2040200AE5D098E343485F972DD61" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SubsequentEventsAbstract_29E2040200AE5D098E343485F972DD61" xlink:to="lab_us-gaap_SubsequentEventsAbstract_29E2040200AE5D098E343485F972DD61" xlink:type="arc" />
    <link:label id="lab_us-gaap_SubsequentEventsTextBlock_AA9561D28AE90AC922EA97343FDAF0FF_terseLabel_en-US" xlink:label="lab_us-gaap_SubsequentEventsTextBlock_13728D10D1C75AAFBB637CDCB6117566" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Subsequent Events</link:label>
    <link:label id="lab_us-gaap_SubsequentEventsTextBlock_AA9561D28AE90AC922EA97343FDAF0FF_label_en-US" xlink:label="lab_us-gaap_SubsequentEventsTextBlock_13728D10D1C75AAFBB637CDCB6117566" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Subsequent Events [Text Block]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_SubsequentEventsTextBlock" xlink:label="loc_us-gaap_SubsequentEventsTextBlock_13728D10D1C75AAFBB637CDCB6117566" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SubsequentEventsTextBlock_13728D10D1C75AAFBB637CDCB6117566" xlink:to="lab_us-gaap_SubsequentEventsTextBlock_13728D10D1C75AAFBB637CDCB6117566" xlink:type="arc" />
    <link:label id="lab_us-gaap_StatementOfCashFlowsAbstract_70F8181DAE0A0CC3C3D57D2627663ACA_label_en-US" xlink:label="lab_us-gaap_StatementOfCashFlowsAbstract_70F8181DAE0A0CC3C3D57D2627663ACA" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Statement of Cash Flows [Abstract]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_StatementOfCashFlowsAbstract" xlink:label="loc_us-gaap_StatementOfCashFlowsAbstract_70F8181DAE0A0CC3C3D57D2627663ACA" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StatementOfCashFlowsAbstract_70F8181DAE0A0CC3C3D57D2627663ACA" xlink:to="lab_us-gaap_StatementOfCashFlowsAbstract_70F8181DAE0A0CC3C3D57D2627663ACA" xlink:type="arc" />
    <link:label id="lab_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_BD68979D622F49B1F3837D262766D482_terseLabel_en-US" xlink:label="lab_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_BD68979D622F49B1F3837D262766D482" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Cash Flows From Operating Activities</link:label>
    <link:label id="lab_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_BD68979D622F49B1F3837D262766D482_label_en-US" xlink:label="lab_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_BD68979D622F49B1F3837D262766D482" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Net Cash Provided by (Used in) Operating Activities [Abstract]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract" xlink:label="loc_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_BD68979D622F49B1F3837D262766D482" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_BD68979D622F49B1F3837D262766D482" xlink:to="lab_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_BD68979D622F49B1F3837D262766D482" xlink:type="arc" />
    <link:label id="lab_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_9E7F21CBAAF6FBE676A97D26276747A0_terseLabel_en-US" xlink:label="lab_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_9E7F21CBAAF6FBE676A97D26276747A0" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Adjustments to reconcile net loss to net cash used in operating activities:</link:label>
    <link:label id="lab_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_9E7F21CBAAF6FBE676A97D26276747A0_label_en-US" xlink:label="lab_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_9E7F21CBAAF6FBE676A97D26276747A0" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Adjustments to Reconcile Net Income (Loss) to Cash Provided by (Used in) Operating Activities [Abstract]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:label="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_9E7F21CBAAF6FBE676A97D26276747A0" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_9E7F21CBAAF6FBE676A97D26276747A0" xlink:to="lab_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_9E7F21CBAAF6FBE676A97D26276747A0" xlink:type="arc" />
    <link:label id="lab_us-gaap_ShareBasedCompensation_3384AD4D561FCC583C767D262767011C_verboseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensation_3384AD4D561FCC583C767D262767011C" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Share-based compensation</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensation_3384AD4D561FCC583C767D262767011C_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensation_3384AD4D561FCC583C767D262767011C" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share-based Compensation</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ShareBasedCompensation" xlink:label="loc_us-gaap_ShareBasedCompensation_3384AD4D561FCC583C767D262767011C" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensation_3384AD4D561FCC583C767D262767011C" xlink:to="lab_us-gaap_ShareBasedCompensation_3384AD4D561FCC583C767D262767011C" xlink:type="arc" />
    <link:label id="lab_us-gaap_DepreciationDepletionAndAmortization_CDE1100767209E0AD07B7D262767DD6F_terseLabel_en-US" xlink:label="lab_us-gaap_DepreciationDepletionAndAmortization_CDE1100767209E0AD07B7D262767DD6F" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Depreciation and amortization</link:label>
    <link:label id="lab_us-gaap_DepreciationDepletionAndAmortization_CDE1100767209E0AD07B7D262767DD6F_label_en-US" xlink:label="lab_us-gaap_DepreciationDepletionAndAmortization_CDE1100767209E0AD07B7D262767DD6F" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Depreciation, Depletion and Amortization</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_DepreciationDepletionAndAmortization" xlink:label="loc_us-gaap_DepreciationDepletionAndAmortization_CDE1100767209E0AD07B7D262767DD6F" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DepreciationDepletionAndAmortization_CDE1100767209E0AD07B7D262767DD6F" xlink:to="lab_us-gaap_DepreciationDepletionAndAmortization_CDE1100767209E0AD07B7D262767DD6F" xlink:type="arc" />
    <link:label id="lab_us-gaap_GainsLossesOnExtinguishmentOfDebt_DFFF23E2F371CB8164017D2627674EF1_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_GainsLossesOnExtinguishmentOfDebt_DFFF23E2F371CB8164017D2627674EF1" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xml:lang="en-US">Forgiveness of debt</link:label>
    <link:label id="lab_us-gaap_GainsLossesOnExtinguishmentOfDebt_DFFF23E2F371CB8164017D2627674EF1_label_en-US" xlink:label="lab_us-gaap_GainsLossesOnExtinguishmentOfDebt_DFFF23E2F371CB8164017D2627674EF1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Gain (Loss) on Extinguishment of Debt</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_GainsLossesOnExtinguishmentOfDebt" xlink:label="loc_us-gaap_GainsLossesOnExtinguishmentOfDebt_DFFF23E2F371CB8164017D2627674EF1" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_GainsLossesOnExtinguishmentOfDebt_DFFF23E2F371CB8164017D2627674EF1" xlink:to="lab_us-gaap_GainsLossesOnExtinguishmentOfDebt_DFFF23E2F371CB8164017D2627674EF1" xlink:type="arc" />
    <link:label id="lab_us-gaap_ExcessTaxBenefitFromShareBasedCompensationOperatingActivities_7F4EA9CF9079E8C3B0037D262767D7A5_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_ExcessTaxBenefitFromShareBasedCompensationOperatingActivities_7F4EA9CF9079E8C3B0037D262767D7A5" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xml:lang="en-US">Tax shortfall associated with employee stock plans</link:label>
    <link:label id="lab_us-gaap_ExcessTaxBenefitFromShareBasedCompensationOperatingActivities_7F4EA9CF9079E8C3B0037D262767D7A5_label_en-US" xlink:label="lab_us-gaap_ExcessTaxBenefitFromShareBasedCompensationOperatingActivities_7F4EA9CF9079E8C3B0037D262767D7A5" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Excess Tax Benefit from Share-based Compensation, Operating Activities</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ExcessTaxBenefitFromShareBasedCompensationOperatingActivities" xlink:label="loc_us-gaap_ExcessTaxBenefitFromShareBasedCompensationOperatingActivities_7F4EA9CF9079E8C3B0037D262767D7A5" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ExcessTaxBenefitFromShareBasedCompensationOperatingActivities_7F4EA9CF9079E8C3B0037D262767D7A5" xlink:to="lab_us-gaap_ExcessTaxBenefitFromShareBasedCompensationOperatingActivities_7F4EA9CF9079E8C3B0037D262767D7A5" xlink:type="arc" />
    <link:label id="lab_us-gaap_AssetImpairmentCharges_370E26F6E9E656E3BB7B7D262767FC0C_terseLabel_en-US" xlink:label="lab_us-gaap_AssetImpairmentCharges_370E26F6E9E656E3BB7B7D262767FC0C" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Impairment of fixed assets</link:label>
    <link:label id="lab_us-gaap_AssetImpairmentCharges_370E26F6E9E656E3BB7B7D262767FC0C_label_en-US" xlink:label="lab_us-gaap_AssetImpairmentCharges_370E26F6E9E656E3BB7B7D262767FC0C" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Asset Impairment Charges</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_AssetImpairmentCharges" xlink:label="loc_us-gaap_AssetImpairmentCharges_370E26F6E9E656E3BB7B7D262767FC0C" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AssetImpairmentCharges_370E26F6E9E656E3BB7B7D262767FC0C" xlink:to="lab_us-gaap_AssetImpairmentCharges_370E26F6E9E656E3BB7B7D262767FC0C" xlink:type="arc" />
    <link:label id="lab_us-gaap_GainLossOnSaleOfPropertyPlantEquipment_46AA4BE1A9B414D72BE37D262767FA00_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_GainLossOnSaleOfPropertyPlantEquipment_46AA4BE1A9B414D72BE37D262767FA00" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xml:lang="en-US">Loss on sale of fixed assets</link:label>
    <link:label id="lab_us-gaap_GainLossOnSaleOfPropertyPlantEquipment_46AA4BE1A9B414D72BE37D262767FA00_label_en-US" xlink:label="lab_us-gaap_GainLossOnSaleOfPropertyPlantEquipment_46AA4BE1A9B414D72BE37D262767FA00" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Gain (Loss) on Disposition of Property Plant Equipment</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_GainLossOnSaleOfPropertyPlantEquipment" xlink:label="loc_us-gaap_GainLossOnSaleOfPropertyPlantEquipment_46AA4BE1A9B414D72BE37D262767FA00" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_GainLossOnSaleOfPropertyPlantEquipment_46AA4BE1A9B414D72BE37D262767FA00" xlink:to="lab_us-gaap_GainLossOnSaleOfPropertyPlantEquipment_46AA4BE1A9B414D72BE37D262767FA00" xlink:type="arc" />
    <link:label id="lab_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_24415A942DD30FC2DAB47D262767ED83_terseLabel_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_24415A942DD30FC2DAB47D262767ED83" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Changes in operating assets and liabilities:</link:label>
    <link:label id="lab_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_24415A942DD30FC2DAB47D262767ED83_label_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_24415A942DD30FC2DAB47D262767ED83" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Increase (Decrease) in Operating Capital [Abstract]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:label="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_24415A942DD30FC2DAB47D262767ED83" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_24415A942DD30FC2DAB47D262767ED83" xlink:to="lab_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_24415A942DD30FC2DAB47D262767ED83" xlink:type="arc" />
    <link:label id="lab_us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets_1B803FFE1DC66071AEC37D262767A321_negatedLabel_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets_1B803FFE1DC66071AEC37D262767A321" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xml:lang="en-US">Prepaid expenses and other current assets</link:label>
    <link:label id="lab_us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets_1B803FFE1DC66071AEC37D262767A321_label_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets_1B803FFE1DC66071AEC37D262767A321" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Increase (Decrease) in Prepaid Expense and Other Assets</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" xlink:label="loc_us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets_1B803FFE1DC66071AEC37D262767A321" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets_1B803FFE1DC66071AEC37D262767A321" xlink:to="lab_us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets_1B803FFE1DC66071AEC37D262767A321" xlink:type="arc" />
    <link:label id="lab_us-gaap_IncreaseDecreaseInOtherReceivables_679502145BFD97F9796C7D262767027B_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInOtherReceivables_679502145BFD97F9796C7D262767027B" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xml:lang="en-US">Other receivables</link:label>
    <link:label id="lab_us-gaap_IncreaseDecreaseInOtherReceivables_679502145BFD97F9796C7D262767027B_label_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInOtherReceivables_679502145BFD97F9796C7D262767027B" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Increase (Decrease) in Other Receivables</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_IncreaseDecreaseInOtherReceivables" xlink:label="loc_us-gaap_IncreaseDecreaseInOtherReceivables_679502145BFD97F9796C7D262767027B" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncreaseDecreaseInOtherReceivables_679502145BFD97F9796C7D262767027B" xlink:to="lab_us-gaap_IncreaseDecreaseInOtherReceivables_679502145BFD97F9796C7D262767027B" xlink:type="arc" />
    <link:label id="lab_us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities_337FD01CCEFE676BEE007D2627674421_terseLabel_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities_337FD01CCEFE676BEE007D2627674421" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Accounts payable and accrued expenses</link:label>
    <link:label id="lab_us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities_337FD01CCEFE676BEE007D2627674421_label_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities_337FD01CCEFE676BEE007D2627674421" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Increase (Decrease) in Accounts Payable and Accrued Liabilities</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities" xlink:label="loc_us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities_337FD01CCEFE676BEE007D2627674421" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities_337FD01CCEFE676BEE007D2627674421" xlink:to="lab_us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities_337FD01CCEFE676BEE007D2627674421" xlink:type="arc" />
    <link:label id="lab_us-gaap_IncreaseDecreaseInAccruedIncomeTaxesPayable_3AF3471A2C7D819D095D7D262767A67D_terseLabel_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInAccruedIncomeTaxesPayable_3AF3471A2C7D819D095D7D262767A67D" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Income taxes receivable</link:label>
    <link:label id="lab_us-gaap_IncreaseDecreaseInAccruedIncomeTaxesPayable_3AF3471A2C7D819D095D7D262767A67D_label_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInAccruedIncomeTaxesPayable_3AF3471A2C7D819D095D7D262767A67D" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Increase (Decrease) in Income Taxes Payable</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_IncreaseDecreaseInAccruedIncomeTaxesPayable" xlink:label="loc_us-gaap_IncreaseDecreaseInAccruedIncomeTaxesPayable_3AF3471A2C7D819D095D7D262767A67D" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncreaseDecreaseInAccruedIncomeTaxesPayable_3AF3471A2C7D819D095D7D262767A67D" xlink:to="lab_us-gaap_IncreaseDecreaseInAccruedIncomeTaxesPayable_3AF3471A2C7D819D095D7D262767A67D" xlink:type="arc" />
    <link:label id="lab_us-gaap_IncreaseDecreaseInDeferredRevenue_D45C6483C055ACEBB7837D26276769C2_terseLabel_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInDeferredRevenue_D45C6483C055ACEBB7837D26276769C2" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Unearned revenue</link:label>
    <link:label id="lab_us-gaap_IncreaseDecreaseInDeferredRevenue_D45C6483C055ACEBB7837D26276769C2_label_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInDeferredRevenue_D45C6483C055ACEBB7837D26276769C2" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Increase (Decrease) in Deferred Revenue</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_IncreaseDecreaseInDeferredRevenue" xlink:label="loc_us-gaap_IncreaseDecreaseInDeferredRevenue_D45C6483C055ACEBB7837D26276769C2" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncreaseDecreaseInDeferredRevenue_D45C6483C055ACEBB7837D26276769C2" xlink:to="lab_us-gaap_IncreaseDecreaseInDeferredRevenue_D45C6483C055ACEBB7837D26276769C2" xlink:type="arc" />
    <link:label id="lab_us-gaap_IncreaseDecreaseInDeferredCharges_20A1FB914316EEC2B5E77D2627675F8A_negatedLabel_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInDeferredCharges_20A1FB914316EEC2B5E77D2627675F8A" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xml:lang="en-US">Deferred rent</link:label>
    <link:label id="lab_us-gaap_IncreaseDecreaseInDeferredCharges_20A1FB914316EEC2B5E77D2627675F8A_label_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInDeferredCharges_20A1FB914316EEC2B5E77D2627675F8A" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Increase (Decrease) in Deferred Charges</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_IncreaseDecreaseInDeferredCharges" xlink:label="loc_us-gaap_IncreaseDecreaseInDeferredCharges_20A1FB914316EEC2B5E77D2627675F8A" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncreaseDecreaseInDeferredCharges_20A1FB914316EEC2B5E77D2627675F8A" xlink:to="lab_us-gaap_IncreaseDecreaseInDeferredCharges_20A1FB914316EEC2B5E77D2627675F8A" xlink:type="arc" />
    <link:label id="lab_us-gaap_NetCashProvidedByUsedInOperatingActivities_0AF8C827D5FCCCE1199A7D26276894B3_totalLabel_en-US" xlink:label="lab_us-gaap_NetCashProvidedByUsedInOperatingActivities_0AF8C827D5FCCCE1199A7D26276894B3" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xml:lang="en-US">Net cash used in operating activities</link:label>
    <link:label id="lab_us-gaap_NetCashProvidedByUsedInOperatingActivities_0AF8C827D5FCCCE1199A7D26276894B3_label_en-US" xlink:label="lab_us-gaap_NetCashProvidedByUsedInOperatingActivities_0AF8C827D5FCCCE1199A7D26276894B3" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Net Cash Provided by (Used in) Operating Activities</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:label="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_0AF8C827D5FCCCE1199A7D26276894B3" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_0AF8C827D5FCCCE1199A7D26276894B3" xlink:to="lab_us-gaap_NetCashProvidedByUsedInOperatingActivities_0AF8C827D5FCCCE1199A7D26276894B3" xlink:type="arc" />
    <link:label id="lab_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_51FAE962148B6FB9FA827D26276840F8_terseLabel_en-US" xlink:label="lab_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_51FAE962148B6FB9FA827D26276840F8" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Cash Flows From Investing Activities</link:label>
    <link:label id="lab_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_51FAE962148B6FB9FA827D26276840F8_label_en-US" xlink:label="lab_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_51FAE962148B6FB9FA827D26276840F8" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Net Cash Provided by (Used in) Investing Activities [Abstract]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract" xlink:label="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_51FAE962148B6FB9FA827D26276840F8" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_51FAE962148B6FB9FA827D26276840F8" xlink:to="lab_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_51FAE962148B6FB9FA827D26276840F8" xlink:type="arc" />
    <link:label id="lab_us-gaap_ProceedsFromSaleAndMaturityOfHeldToMaturitySecurities_6B86B6ECE2EAE3636A0D7D262768F3BB_terseLabel_en-US" xlink:label="lab_us-gaap_ProceedsFromSaleAndMaturityOfHeldToMaturitySecurities_6B86B6ECE2EAE3636A0D7D262768F3BB" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Maturity of certificates of deposit</link:label>
    <link:label id="lab_us-gaap_ProceedsFromSaleAndMaturityOfHeldToMaturitySecurities_6B86B6ECE2EAE3636A0D7D262768F3BB_label_en-US" xlink:label="lab_us-gaap_ProceedsFromSaleAndMaturityOfHeldToMaturitySecurities_6B86B6ECE2EAE3636A0D7D262768F3BB" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Proceeds from Sale and Maturity of Held-to-maturity Securities</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ProceedsFromSaleAndMaturityOfHeldToMaturitySecurities" xlink:label="loc_us-gaap_ProceedsFromSaleAndMaturityOfHeldToMaturitySecurities_6B86B6ECE2EAE3636A0D7D262768F3BB" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ProceedsFromSaleAndMaturityOfHeldToMaturitySecurities_6B86B6ECE2EAE3636A0D7D262768F3BB" xlink:to="lab_us-gaap_ProceedsFromSaleAndMaturityOfHeldToMaturitySecurities_6B86B6ECE2EAE3636A0D7D262768F3BB" xlink:type="arc" />
    <link:label id="lab_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment_B73A04290B84C36D34077D2627681CCE_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment_B73A04290B84C36D34077D2627681CCE" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xml:lang="en-US">Purchase of equipment</link:label>
    <link:label id="lab_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment_B73A04290B84C36D34077D2627681CCE_label_en-US" xlink:label="lab_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment_B73A04290B84C36D34077D2627681CCE" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Payments to Acquire Property, Plant, and Equipment</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_PaymentsToAcquirePropertyPlantAndEquipment" xlink:label="loc_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment_B73A04290B84C36D34077D2627681CCE" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment_B73A04290B84C36D34077D2627681CCE" xlink:to="lab_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment_B73A04290B84C36D34077D2627681CCE" xlink:type="arc" />
    <link:label id="lab_us-gaap_ProceedsFromSaleOfPropertyPlantAndEquipment_81C830DC6A2DD70F584B7D2627684193_terseLabel_en-US" xlink:label="lab_us-gaap_ProceedsFromSaleOfPropertyPlantAndEquipment_81C830DC6A2DD70F584B7D2627684193" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Proceeds on sale of equipment</link:label>
    <link:label id="lab_us-gaap_ProceedsFromSaleOfPropertyPlantAndEquipment_81C830DC6A2DD70F584B7D2627684193_label_en-US" xlink:label="lab_us-gaap_ProceedsFromSaleOfPropertyPlantAndEquipment_81C830DC6A2DD70F584B7D2627684193" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Proceeds from Sale of Property, Plant, and Equipment</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ProceedsFromSaleOfPropertyPlantAndEquipment" xlink:label="loc_us-gaap_ProceedsFromSaleOfPropertyPlantAndEquipment_81C830DC6A2DD70F584B7D2627684193" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ProceedsFromSaleOfPropertyPlantAndEquipment_81C830DC6A2DD70F584B7D2627684193" xlink:to="lab_us-gaap_ProceedsFromSaleOfPropertyPlantAndEquipment_81C830DC6A2DD70F584B7D2627684193" xlink:type="arc" />
    <link:label id="lab_us-gaap_NetCashProvidedByUsedInInvestingActivities_8BF116CFDECE9431A80A7D2627686278_totalLabel_en-US" xlink:label="lab_us-gaap_NetCashProvidedByUsedInInvestingActivities_8BF116CFDECE9431A80A7D2627686278" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xml:lang="en-US">Net cash provided by investing activities</link:label>
    <link:label id="lab_us-gaap_NetCashProvidedByUsedInInvestingActivities_8BF116CFDECE9431A80A7D2627686278_label_en-US" xlink:label="lab_us-gaap_NetCashProvidedByUsedInInvestingActivities_8BF116CFDECE9431A80A7D2627686278" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Net Cash Provided by (Used in) Investing Activities</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivities" xlink:label="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities_8BF116CFDECE9431A80A7D2627686278" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities_8BF116CFDECE9431A80A7D2627686278" xlink:to="lab_us-gaap_NetCashProvidedByUsedInInvestingActivities_8BF116CFDECE9431A80A7D2627686278" xlink:type="arc" />
    <link:label id="lab_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_6BD4A556DA73209224ED7D26276805BB_terseLabel_en-US" xlink:label="lab_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_6BD4A556DA73209224ED7D26276805BB" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Cash Flows From Financing Activities</link:label>
    <link:label id="lab_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_6BD4A556DA73209224ED7D26276805BB_label_en-US" xlink:label="lab_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_6BD4A556DA73209224ED7D26276805BB" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Net Cash Provided by (Used in) Financing Activities [Abstract]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:label="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_6BD4A556DA73209224ED7D26276805BB" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_6BD4A556DA73209224ED7D26276805BB" xlink:to="lab_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_6BD4A556DA73209224ED7D26276805BB" xlink:type="arc" />
    <link:label id="lab_us-gaap_ProceedsFromIssuanceOfCommonStock_DD4BF6691E6A1AB655E57D262768A24F_terseLabel_en-US" xlink:label="lab_us-gaap_ProceedsFromIssuanceOfCommonStock_DD4BF6691E6A1AB655E57D262768A24F" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Issuance of common stock, net of offering costs</link:label>
    <link:label id="lab_us-gaap_ProceedsFromIssuanceOfCommonStock_DD4BF6691E6A1AB655E57D262768A24F_label_en-US" xlink:label="lab_us-gaap_ProceedsFromIssuanceOfCommonStock_DD4BF6691E6A1AB655E57D262768A24F" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Proceeds from Issuance of Common Stock</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ProceedsFromIssuanceOfCommonStock" xlink:label="loc_us-gaap_ProceedsFromIssuanceOfCommonStock_DD4BF6691E6A1AB655E57D262768A24F" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ProceedsFromIssuanceOfCommonStock_DD4BF6691E6A1AB655E57D262768A24F" xlink:to="lab_us-gaap_ProceedsFromIssuanceOfCommonStock_DD4BF6691E6A1AB655E57D262768A24F" xlink:type="arc" />
    <link:label id="lab_us-gaap_PaymentsForRepurchaseOfCommonStock_5259C12A9781CB7704DD7D26276830BD_negatedLabel_en-US" xlink:label="lab_us-gaap_PaymentsForRepurchaseOfCommonStock_5259C12A9781CB7704DD7D26276830BD" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xml:lang="en-US">Repurchase of common stock</link:label>
    <link:label id="lab_us-gaap_PaymentsForRepurchaseOfCommonStock_5259C12A9781CB7704DD7D26276830BD_label_en-US" xlink:label="lab_us-gaap_PaymentsForRepurchaseOfCommonStock_5259C12A9781CB7704DD7D26276830BD" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Payments for Repurchase of Common Stock</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_PaymentsForRepurchaseOfCommonStock" xlink:label="loc_us-gaap_PaymentsForRepurchaseOfCommonStock_5259C12A9781CB7704DD7D26276830BD" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PaymentsForRepurchaseOfCommonStock_5259C12A9781CB7704DD7D26276830BD" xlink:to="lab_us-gaap_PaymentsForRepurchaseOfCommonStock_5259C12A9781CB7704DD7D26276830BD" xlink:type="arc" />
    <link:label id="lab_us-gaap_RepaymentsOfDebtAndCapitalLeaseObligations_B43E5191769530E872E47D2627685180_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_RepaymentsOfDebtAndCapitalLeaseObligations_B43E5191769530E872E47D2627685180" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xml:lang="en-US">Payments under capital lease obligations and principal payments on notes payable</link:label>
    <link:label id="lab_us-gaap_RepaymentsOfDebtAndCapitalLeaseObligations_B43E5191769530E872E47D2627685180_label_en-US" xlink:label="lab_us-gaap_RepaymentsOfDebtAndCapitalLeaseObligations_B43E5191769530E872E47D2627685180" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Repayments of Debt and Capital Lease Obligations</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_RepaymentsOfDebtAndCapitalLeaseObligations" xlink:label="loc_us-gaap_RepaymentsOfDebtAndCapitalLeaseObligations_B43E5191769530E872E47D2627685180" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RepaymentsOfDebtAndCapitalLeaseObligations_B43E5191769530E872E47D2627685180" xlink:to="lab_us-gaap_RepaymentsOfDebtAndCapitalLeaseObligations_B43E5191769530E872E47D2627685180" xlink:type="arc" />
    <link:label id="lab_us-gaap_NetCashProvidedByUsedInFinancingActivities_21E6DDEB1F1C7FEDC9D07D2627681CD4_totalLabel_en-US" xlink:label="lab_us-gaap_NetCashProvidedByUsedInFinancingActivities_21E6DDEB1F1C7FEDC9D07D2627681CD4" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xml:lang="en-US">Net cash provided by financing activities</link:label>
    <link:label id="lab_us-gaap_NetCashProvidedByUsedInFinancingActivities_21E6DDEB1F1C7FEDC9D07D2627681CD4_label_en-US" xlink:label="lab_us-gaap_NetCashProvidedByUsedInFinancingActivities_21E6DDEB1F1C7FEDC9D07D2627681CD4" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Net Cash Provided by (Used in) Financing Activities</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:label="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities_21E6DDEB1F1C7FEDC9D07D2627681CD4" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities_21E6DDEB1F1C7FEDC9D07D2627681CD4" xlink:to="lab_us-gaap_NetCashProvidedByUsedInFinancingActivities_21E6DDEB1F1C7FEDC9D07D2627681CD4" xlink:type="arc" />
    <link:label id="lab_us-gaap_CashAndCashEquivalentsPeriodIncreaseDecrease_E647789751AF9E3E90AD7D2627681530_terseLabel_en-US" xlink:label="lab_us-gaap_CashAndCashEquivalentsPeriodIncreaseDecrease_E647789751AF9E3E90AD7D2627681530" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Net decrease in cash and cash equivalents</link:label>
    <link:label id="lab_us-gaap_CashAndCashEquivalentsPeriodIncreaseDecrease_E647789751AF9E3E90AD7D2627681530_label_en-US" xlink:label="lab_us-gaap_CashAndCashEquivalentsPeriodIncreaseDecrease_E647789751AF9E3E90AD7D2627681530" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Cash and Cash Equivalents, Period Increase (Decrease)</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_CashAndCashEquivalentsPeriodIncreaseDecrease" xlink:label="loc_us-gaap_CashAndCashEquivalentsPeriodIncreaseDecrease_E647789751AF9E3E90AD7D2627681530" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CashAndCashEquivalentsPeriodIncreaseDecrease_E647789751AF9E3E90AD7D2627681530" xlink:to="lab_us-gaap_CashAndCashEquivalentsPeriodIncreaseDecrease_E647789751AF9E3E90AD7D2627681530" xlink:type="arc" />
    <link:label id="lab_us-gaap_CashAndCashEquivalentsAtCarryingValue_1860EE72D1AC84E8C5217D2627684350_periodStartLabel_en-US" xlink:label="lab_us-gaap_CashAndCashEquivalentsAtCarryingValue_1860EE72D1AC84E8C5217D2627684350" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:type="resource" xml:lang="en-US">Cash and cash equivalents at beginning of period</link:label>
    <link:label id="lab_us-gaap_CashAndCashEquivalentsAtCarryingValue_1860EE72D1AC84E8C5217D2627684350_label_en-US" xlink:label="lab_us-gaap_CashAndCashEquivalentsAtCarryingValue_1860EE72D1AC84E8C5217D2627684350" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Cash and Cash Equivalents, at Carrying Value</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:label="loc_us-gaap_CashAndCashEquivalentsAtCarryingValue_1860EE72D1AC84E8C5217D2627684350" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CashAndCashEquivalentsAtCarryingValue_1860EE72D1AC84E8C5217D2627684350" xlink:to="lab_us-gaap_CashAndCashEquivalentsAtCarryingValue_1860EE72D1AC84E8C5217D2627684350" xlink:type="arc" />
    <link:label id="lab_us-gaap_CashAndCashEquivalentsAtCarryingValue_D3D47F79F29110471F3A7D262768FD03_periodEndLabel_en-US" xlink:label="lab_us-gaap_CashAndCashEquivalentsAtCarryingValue_D3D47F79F29110471F3A7D262768FD03" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:type="resource" xml:lang="en-US">Cash and cash equivalents at end of period</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:label="loc_us-gaap_CashAndCashEquivalentsAtCarryingValue_D3D47F79F29110471F3A7D262768FD03" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CashAndCashEquivalentsAtCarryingValue_D3D47F79F29110471F3A7D262768FD03" xlink:to="lab_us-gaap_CashAndCashEquivalentsAtCarryingValue_D3D47F79F29110471F3A7D262768FD03" xlink:type="arc" />
    <link:label id="lab_us-gaap_SupplementalCashFlowInformationAbstract_91314A5C4E9199E939C87D26276871B7_terseLabel_en-US" xlink:label="lab_us-gaap_SupplementalCashFlowInformationAbstract_91314A5C4E9199E939C87D26276871B7" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Supplemental disclosure of cash flows information:</link:label>
    <link:label id="lab_us-gaap_SupplementalCashFlowInformationAbstract_91314A5C4E9199E939C87D26276871B7_label_en-US" xlink:label="lab_us-gaap_SupplementalCashFlowInformationAbstract_91314A5C4E9199E939C87D26276871B7" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Supplemental Cash Flow Information [Abstract]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_SupplementalCashFlowInformationAbstract" xlink:label="loc_us-gaap_SupplementalCashFlowInformationAbstract_91314A5C4E9199E939C87D26276871B7" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SupplementalCashFlowInformationAbstract_91314A5C4E9199E939C87D26276871B7" xlink:to="lab_us-gaap_SupplementalCashFlowInformationAbstract_91314A5C4E9199E939C87D26276871B7" xlink:type="arc" />
    <link:label id="lab_us-gaap_InterestPaid_938FD14C8B0FEBA3F8677D2627682069_terseLabel_en-US" xlink:label="lab_us-gaap_InterestPaid_938FD14C8B0FEBA3F8677D2627682069" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Cash paid for interest</link:label>
    <link:label id="lab_us-gaap_InterestPaid_938FD14C8B0FEBA3F8677D2627682069_label_en-US" xlink:label="lab_us-gaap_InterestPaid_938FD14C8B0FEBA3F8677D2627682069" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Interest Paid</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_InterestPaid" xlink:label="loc_us-gaap_InterestPaid_938FD14C8B0FEBA3F8677D2627682069" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_InterestPaid_938FD14C8B0FEBA3F8677D2627682069" xlink:to="lab_us-gaap_InterestPaid_938FD14C8B0FEBA3F8677D2627682069" xlink:type="arc" />
    <link:label id="lab_us-gaap_IncomeTaxesPaidNet_A662F7800B1DC3C3B4DB7D262768B29B_terseLabel_en-US" xlink:label="lab_us-gaap_IncomeTaxesPaidNet_A662F7800B1DC3C3B4DB7D262768B29B" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Cash (refunds received) paid for taxes, net</link:label>
    <link:label id="lab_us-gaap_IncomeTaxesPaidNet_A662F7800B1DC3C3B4DB7D262768B29B_label_en-US" xlink:label="lab_us-gaap_IncomeTaxesPaidNet_A662F7800B1DC3C3B4DB7D262768B29B" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Income Taxes Paid, Net</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_IncomeTaxesPaidNet" xlink:label="loc_us-gaap_IncomeTaxesPaidNet_A662F7800B1DC3C3B4DB7D262768B29B" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeTaxesPaidNet_A662F7800B1DC3C3B4DB7D262768B29B" xlink:to="lab_us-gaap_IncomeTaxesPaidNet_A662F7800B1DC3C3B4DB7D262768B29B" xlink:type="arc" />
    <link:label id="lab_us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract_E885F6793DF44958F31C7D26276801E5_terseLabel_en-US" xlink:label="lab_us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract_E885F6793DF44958F31C7D26276801E5" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Noncash financing and investing activities:</link:label>
    <link:label id="lab_us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract_E885F6793DF44958F31C7D26276801E5_label_en-US" xlink:label="lab_us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract_E885F6793DF44958F31C7D26276801E5" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Cash Flow, Noncash Investing and Financing Activities Disclosure [Abstract]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract" xlink:label="loc_us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract_E885F6793DF44958F31C7D26276801E5" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract_E885F6793DF44958F31C7D26276801E5" xlink:to="lab_us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract_E885F6793DF44958F31C7D26276801E5" xlink:type="arc" />
    <link:label id="lab_us-gaap_CapitalLeaseObligationsIncurred_B4089DFBF184A26F0AB97D262768477D_terseLabel_en-US" xlink:label="lab_us-gaap_CapitalLeaseObligationsIncurred_B4089DFBF184A26F0AB97D262768477D" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Equipment acquired by capital lease</link:label>
    <link:label id="lab_us-gaap_CapitalLeaseObligationsIncurred_B4089DFBF184A26F0AB97D262768477D_label_en-US" xlink:label="lab_us-gaap_CapitalLeaseObligationsIncurred_B4089DFBF184A26F0AB97D262768477D" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Capital Lease Obligations Incurred</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_CapitalLeaseObligationsIncurred" xlink:label="loc_us-gaap_CapitalLeaseObligationsIncurred_B4089DFBF184A26F0AB97D262768477D" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CapitalLeaseObligationsIncurred_B4089DFBF184A26F0AB97D262768477D" xlink:to="lab_us-gaap_CapitalLeaseObligationsIncurred_B4089DFBF184A26F0AB97D262768477D" xlink:type="arc" />
    <link:label id="lab_us-gaap_NotesReduction_502B499A2C7115FBA0557D26276997A4_terseLabel_en-US" xlink:label="lab_us-gaap_NotesReduction_502B499A2C7115FBA0557D26276997A4" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Forgiveness of debt</link:label>
    <link:label id="lab_us-gaap_NotesReduction_502B499A2C7115FBA0557D26276997A4_label_en-US" xlink:label="lab_us-gaap_NotesReduction_502B499A2C7115FBA0557D26276997A4" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Notes Reduction</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_NotesReduction" xlink:label="loc_us-gaap_NotesReduction_502B499A2C7115FBA0557D26276997A4" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NotesReduction_502B499A2C7115FBA0557D26276997A4" xlink:to="lab_us-gaap_NotesReduction_502B499A2C7115FBA0557D26276997A4" xlink:type="arc" />
    <link:label id="lab_us-gaap_BasisOfAccounting_9F74ABAAF42B5243460D99F0AB80A642_terseLabel_en-US" xlink:label="lab_us-gaap_BasisOfAccounting_06F913AEDB8C555994F7A0C4D788D753" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Basis of Presentation</link:label>
    <link:label id="lab_us-gaap_BasisOfAccounting_9F74ABAAF42B5243460D99F0AB80A642_label_en-US" xlink:label="lab_us-gaap_BasisOfAccounting_06F913AEDB8C555994F7A0C4D788D753" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Basis of Accounting [Text Block]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_BasisOfAccounting" xlink:label="loc_us-gaap_BasisOfAccounting_06F913AEDB8C555994F7A0C4D788D753" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_BasisOfAccounting_06F913AEDB8C555994F7A0C4D788D753" xlink:to="lab_us-gaap_BasisOfAccounting_06F913AEDB8C555994F7A0C4D788D753" xlink:type="arc" />
    <link:label id="lab_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable_6300932AB27AD132E36897345B7A61C8_verboseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable_EBEE6B587D495A3084D05D04D839781B" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Schedule of Antidilutive Securities Excluded from Computation of Net Loss per Common Share</link:label>
    <link:label id="lab_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable_6300932AB27AD132E36897345B7A61C8_label_en-US" xlink:label="lab_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable_EBEE6B587D495A3084D05D04D839781B" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Schedule of Antidilutive Securities Excluded from Computation of Earnings Per Share [Table]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable" xlink:label="loc_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable_EBEE6B587D495A3084D05D04D839781B" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable_EBEE6B587D495A3084D05D04D839781B" xlink:to="lab_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable_EBEE6B587D495A3084D05D04D839781B" xlink:type="arc" />
    <link:label id="lab_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems_A478D00181D1CA4AB88097345B7A4173_terseLabel_en-US" xlink:label="lab_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems_41225EB82D845782BEA507E0721565F4" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]</link:label>
    <link:label id="lab_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems_A478D00181D1CA4AB88097345B7A4173_label_en-US" xlink:label="lab_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems_41225EB82D845782BEA507E0721565F4" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems" xlink:label="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems_41225EB82D845782BEA507E0721565F4" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems_41225EB82D845782BEA507E0721565F4" xlink:to="lab_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems_41225EB82D845782BEA507E0721565F4" xlink:type="arc" />
    <link:label id="lab_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_D407BBEF7209F457B9CD97345B7B99B6_terseLabel_en-US" xlink:label="lab_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_80C65C721A8B5658B692E8C5A0B81452" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Antidilutive securities (in shares)</link:label>
    <link:label id="lab_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_D407BBEF7209F457B9CD97345B7B99B6_label_en-US" xlink:label="lab_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_80C65C721A8B5658B692E8C5A0B81452" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Antidilutive Securities Excluded from Computation of Earnings Per Share, Amount</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" xlink:label="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_80C65C721A8B5658B692E8C5A0B81452" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_80C65C721A8B5658B692E8C5A0B81452" xlink:to="lab_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_80C65C721A8B5658B692E8C5A0B81452" xlink:type="arc" />
    <link:label id="lab_us-gaap_SignificantAccountingPoliciesTextBlock_E0DCB09EB86B31ED96F899D79F8EEC47_terseLabel_en-US" xlink:label="lab_us-gaap_SignificantAccountingPoliciesTextBlock_2F642C0D1CE7566C8986660C571E05F7" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Significant Accounting Policies</link:label>
    <link:label id="lab_us-gaap_SignificantAccountingPoliciesTextBlock_E0DCB09EB86B31ED96F899D79F8EEC47_label_en-US" xlink:label="lab_us-gaap_SignificantAccountingPoliciesTextBlock_2F642C0D1CE7566C8986660C571E05F7" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Significant Accounting Policies [Text Block]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_SignificantAccountingPoliciesTextBlock" xlink:label="loc_us-gaap_SignificantAccountingPoliciesTextBlock_2F642C0D1CE7566C8986660C571E05F7" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SignificantAccountingPoliciesTextBlock_2F642C0D1CE7566C8986660C571E05F7" xlink:to="lab_us-gaap_SignificantAccountingPoliciesTextBlock_2F642C0D1CE7566C8986660C571E05F7" xlink:type="arc" />
    <link:label id="lab_us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock_AB7F6A1C2E81493E181F96910A573108_verboseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock_9B18BB3C0FAB507B94E0153A2201E0F7" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Basic and Diluted Net Loss per Common Share</link:label>
    <link:label id="lab_us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock_AB7F6A1C2E81493E181F96910A573108_label_en-US" xlink:label="lab_us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock_9B18BB3C0FAB507B94E0153A2201E0F7" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Schedule of Earnings Per Share, Basic and Diluted [Table Text Block]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock" xlink:label="loc_us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock_9B18BB3C0FAB507B94E0153A2201E0F7" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock_9B18BB3C0FAB507B94E0153A2201E0F7" xlink:to="lab_us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock_9B18BB3C0FAB507B94E0153A2201E0F7" xlink:type="arc" />
    <link:label id="lab_us-gaap_DebtDisclosureAbstract_6DE187CC3C69F4BF4E6196910A9DE70C_label_en-US" xlink:label="lab_us-gaap_DebtDisclosureAbstract_B6EEF94AE60C5EF981561CA432A145BC" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Debt Disclosure [Abstract]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_DebtDisclosureAbstract" xlink:label="loc_us-gaap_DebtDisclosureAbstract_B6EEF94AE60C5EF981561CA432A145BC" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DebtDisclosureAbstract_B6EEF94AE60C5EF981561CA432A145BC" xlink:to="lab_us-gaap_DebtDisclosureAbstract_B6EEF94AE60C5EF981561CA432A145BC" xlink:type="arc" />
    <link:label id="lab_us-gaap_LongTermDebtTextBlock_0DB42F0BE5D7A4A927E696910A9DDF41_terseLabel_en-US" xlink:label="lab_us-gaap_LongTermDebtTextBlock_B4F03ECCF0945A5399D46807BE103085" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Long-Term Debt</link:label>
    <link:label id="lab_us-gaap_LongTermDebtTextBlock_0DB42F0BE5D7A4A927E696910A9DDF41_label_en-US" xlink:label="lab_us-gaap_LongTermDebtTextBlock_B4F03ECCF0945A5399D46807BE103085" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Long-term Debt [Text Block]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_LongTermDebtTextBlock" xlink:label="loc_us-gaap_LongTermDebtTextBlock_B4F03ECCF0945A5399D46807BE103085" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LongTermDebtTextBlock_B4F03ECCF0945A5399D46807BE103085" xlink:to="lab_us-gaap_LongTermDebtTextBlock_B4F03ECCF0945A5399D46807BE103085" xlink:type="arc" />
    <link:label id="lab_us-gaap_IncomeTaxDisclosureTextBlock_108F4447A5A73C8BE5C996910A5C8747_terseLabel_en-US" xlink:label="lab_us-gaap_IncomeTaxDisclosureTextBlock_5DE28B05FFF054EFAD4C31E18BFA0F35" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Income Taxes</link:label>
    <link:label id="lab_us-gaap_IncomeTaxDisclosureTextBlock_108F4447A5A73C8BE5C996910A5C8747_label_en-US" xlink:label="lab_us-gaap_IncomeTaxDisclosureTextBlock_5DE28B05FFF054EFAD4C31E18BFA0F35" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Income Tax Disclosure [Text Block]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_IncomeTaxDisclosureTextBlock" xlink:label="loc_us-gaap_IncomeTaxDisclosureTextBlock_5DE28B05FFF054EFAD4C31E18BFA0F35" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeTaxDisclosureTextBlock_5DE28B05FFF054EFAD4C31E18BFA0F35" xlink:to="lab_us-gaap_IncomeTaxDisclosureTextBlock_5DE28B05FFF054EFAD4C31E18BFA0F35" xlink:type="arc" />
    <link:label id="lab_us-gaap_EarningsPerShareTextBlock_1FACC8C26A626B21CEE9A8B92D803622_terseLabel_en-US" xlink:label="lab_us-gaap_EarningsPerShareTextBlock_EC6BE8A6D4ED536095614EE5FAE100CB" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Net Loss per Common Share</link:label>
    <link:label id="lab_us-gaap_EarningsPerShareTextBlock_1FACC8C26A626B21CEE9A8B92D803622_label_en-US" xlink:label="lab_us-gaap_EarningsPerShareTextBlock_EC6BE8A6D4ED536095614EE5FAE100CB" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Earnings Per Share [Text Block]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_EarningsPerShareTextBlock" xlink:label="loc_us-gaap_EarningsPerShareTextBlock_EC6BE8A6D4ED536095614EE5FAE100CB" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EarningsPerShareTextBlock_EC6BE8A6D4ED536095614EE5FAE100CB" xlink:to="lab_us-gaap_EarningsPerShareTextBlock_EC6BE8A6D4ED536095614EE5FAE100CB" xlink:type="arc" />
    <link:label id="lab_us-gaap_ScheduleOfRestructuringAndRelatedCostsTable_D55E66560BB4A7FA76BE6E9EA790F045_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfRestructuringAndRelatedCostsTable_D55E66560BB4A7FA76BE6E9EA790F045" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Schedule of Restructuring Charges</link:label>
    <link:label id="lab_us-gaap_ScheduleOfRestructuringAndRelatedCostsTable_D55E66560BB4A7FA76BE6E9EA790F045_label_en-US" xlink:label="lab_us-gaap_ScheduleOfRestructuringAndRelatedCostsTable_D55E66560BB4A7FA76BE6E9EA790F045" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Schedule of Restructuring and Related Costs [Table]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ScheduleOfRestructuringAndRelatedCostsTable" xlink:label="loc_us-gaap_ScheduleOfRestructuringAndRelatedCostsTable_D55E66560BB4A7FA76BE6E9EA790F045" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfRestructuringAndRelatedCostsTable_D55E66560BB4A7FA76BE6E9EA790F045" xlink:to="lab_us-gaap_ScheduleOfRestructuringAndRelatedCostsTable_D55E66560BB4A7FA76BE6E9EA790F045" xlink:type="arc" />
    <link:label id="lab_us-gaap_RestructuringPlanAxis_364AABC63FEE2480F6C56E9EA790C41E_terseLabel_en-US" xlink:label="lab_us-gaap_RestructuringPlanAxis_364AABC63FEE2480F6C56E9EA790C41E" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Restructuring Plan [Axis]</link:label>
    <link:label id="lab_us-gaap_RestructuringPlanAxis_364AABC63FEE2480F6C56E9EA790C41E_label_en-US" xlink:label="lab_us-gaap_RestructuringPlanAxis_364AABC63FEE2480F6C56E9EA790C41E" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Restructuring Plan [Axis]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_RestructuringPlanAxis" xlink:label="loc_us-gaap_RestructuringPlanAxis_364AABC63FEE2480F6C56E9EA790C41E" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RestructuringPlanAxis_364AABC63FEE2480F6C56E9EA790C41E" xlink:to="lab_us-gaap_RestructuringPlanAxis_364AABC63FEE2480F6C56E9EA790C41E" xlink:type="arc" />
    <link:label id="lab_us-gaap_RestructuringPlanDomain_493D1823876F90D157DE6E9EA790349B_terseLabel_en-US" xlink:label="lab_us-gaap_RestructuringPlanDomain_493D1823876F90D157DE6E9EA790349B" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Restructuring Plan [Domain]</link:label>
    <link:label id="lab_us-gaap_RestructuringPlanDomain_493D1823876F90D157DE6E9EA790349B_label_en-US" xlink:label="lab_us-gaap_RestructuringPlanDomain_493D1823876F90D157DE6E9EA790349B" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Restructuring Plan [Domain]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_RestructuringPlanDomain" xlink:label="loc_us-gaap_RestructuringPlanDomain_493D1823876F90D157DE6E9EA790349B" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RestructuringPlanDomain_493D1823876F90D157DE6E9EA790349B" xlink:to="lab_us-gaap_RestructuringPlanDomain_493D1823876F90D157DE6E9EA790349B" xlink:type="arc" />
    <link:label id="lab_nlnk_TwoThousandSixteenRestructuringPlanMember_B5331ACD254DA3C2C8566E9EA7909546_terseLabel_en-US" xlink:label="lab_nlnk_TwoThousandSixteenRestructuringPlanMember_B5331ACD254DA3C2C8566E9EA7909546" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">2016 Restructuring Plan</link:label>
    <link:label id="lab_nlnk_TwoThousandSixteenRestructuringPlanMember_B5331ACD254DA3C2C8566E9EA7909546_label_en-US" xlink:label="lab_nlnk_TwoThousandSixteenRestructuringPlanMember_B5331ACD254DA3C2C8566E9EA7909546" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Two Thousand Sixteen Restructuring Plan [Member]</link:label>
    <link:label id="lab_nlnk_TwoThousandSixteenRestructuringPlanMember_B5331ACD254DA3C2C8566E9EA7909546_documentation_en-US" xlink:label="lab_nlnk_TwoThousandSixteenRestructuringPlanMember_B5331ACD254DA3C2C8566E9EA7909546" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Two Thousand Sixteen Restructuring Plan [Member]</link:label>
    <link:loc xlink:href="nlnk-20170930.xsd#nlnk_TwoThousandSixteenRestructuringPlanMember" xlink:label="loc_nlnk_TwoThousandSixteenRestructuringPlanMember_B5331ACD254DA3C2C8566E9EA7909546" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_nlnk_TwoThousandSixteenRestructuringPlanMember_B5331ACD254DA3C2C8566E9EA7909546" xlink:to="lab_nlnk_TwoThousandSixteenRestructuringPlanMember_B5331ACD254DA3C2C8566E9EA7909546" xlink:type="arc" />
    <link:label id="lab_us-gaap_RestructuringCostAndReserveAxis_C1C1F7FAA4E15A41F87E6E9EA7905839_terseLabel_en-US" xlink:label="lab_us-gaap_RestructuringCostAndReserveAxis_C1C1F7FAA4E15A41F87E6E9EA7905839" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Restructuring Type</link:label>
    <link:label id="lab_us-gaap_RestructuringCostAndReserveAxis_C1C1F7FAA4E15A41F87E6E9EA7905839_label_en-US" xlink:label="lab_us-gaap_RestructuringCostAndReserveAxis_C1C1F7FAA4E15A41F87E6E9EA7905839" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Restructuring Type [Axis]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_RestructuringCostAndReserveAxis" xlink:label="loc_us-gaap_RestructuringCostAndReserveAxis_C1C1F7FAA4E15A41F87E6E9EA7905839" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RestructuringCostAndReserveAxis_C1C1F7FAA4E15A41F87E6E9EA7905839" xlink:to="lab_us-gaap_RestructuringCostAndReserveAxis_C1C1F7FAA4E15A41F87E6E9EA7905839" xlink:type="arc" />
    <link:label id="lab_us-gaap_TypeOfRestructuringDomain_63CFDE90A5421FD1EED96E9EA791BFE1_terseLabel_en-US" xlink:label="lab_us-gaap_TypeOfRestructuringDomain_63CFDE90A5421FD1EED96E9EA791BFE1" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Type of Restructuring</link:label>
    <link:label id="lab_us-gaap_TypeOfRestructuringDomain_63CFDE90A5421FD1EED96E9EA791BFE1_label_en-US" xlink:label="lab_us-gaap_TypeOfRestructuringDomain_63CFDE90A5421FD1EED96E9EA791BFE1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Type of Restructuring [Domain]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_TypeOfRestructuringDomain" xlink:label="loc_us-gaap_TypeOfRestructuringDomain_63CFDE90A5421FD1EED96E9EA791BFE1" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_TypeOfRestructuringDomain_63CFDE90A5421FD1EED96E9EA791BFE1" xlink:to="lab_us-gaap_TypeOfRestructuringDomain_63CFDE90A5421FD1EED96E9EA791BFE1" xlink:type="arc" />
    <link:label id="lab_us-gaap_EmployeeSeveranceMember_D2800628185A0D294F986E9EA79181C1_terseLabel_en-US" xlink:label="lab_us-gaap_EmployeeSeveranceMember_D2800628185A0D294F986E9EA79181C1" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Employee Severance Cost</link:label>
    <link:label id="lab_us-gaap_EmployeeSeveranceMember_D2800628185A0D294F986E9EA79181C1_label_en-US" xlink:label="lab_us-gaap_EmployeeSeveranceMember_D2800628185A0D294F986E9EA79181C1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Employee Severance [Member]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_EmployeeSeveranceMember" xlink:label="loc_us-gaap_EmployeeSeveranceMember_D2800628185A0D294F986E9EA79181C1" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EmployeeSeveranceMember_D2800628185A0D294F986E9EA79181C1" xlink:to="lab_us-gaap_EmployeeSeveranceMember_D2800628185A0D294F986E9EA79181C1" xlink:type="arc" />
    <link:label id="lab_us-gaap_IncomeStatementLocationAxis_77ED65AEB7AD2A80C8326EA41FF9F974_terseLabel_en-US" xlink:label="lab_us-gaap_IncomeStatementLocationAxis_77ED65AEB7AD2A80C8326EA41FF9F974" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Income Statement Location [Axis]</link:label>
    <link:label id="lab_us-gaap_IncomeStatementLocationAxis_77ED65AEB7AD2A80C8326EA41FF9F974_label_en-US" xlink:label="lab_us-gaap_IncomeStatementLocationAxis_77ED65AEB7AD2A80C8326EA41FF9F974" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Income Statement Location [Axis]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_IncomeStatementLocationAxis" xlink:label="loc_us-gaap_IncomeStatementLocationAxis_77ED65AEB7AD2A80C8326EA41FF9F974" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeStatementLocationAxis_77ED65AEB7AD2A80C8326EA41FF9F974" xlink:to="lab_us-gaap_IncomeStatementLocationAxis_77ED65AEB7AD2A80C8326EA41FF9F974" xlink:type="arc" />
    <link:label id="lab_us-gaap_IncomeStatementLocationDomain_70F3A10D6327D0193E8D6EA420009B9A_terseLabel_en-US" xlink:label="lab_us-gaap_IncomeStatementLocationDomain_70F3A10D6327D0193E8D6EA420009B9A" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Income Statement Location [Domain]</link:label>
    <link:label id="lab_us-gaap_IncomeStatementLocationDomain_70F3A10D6327D0193E8D6EA420009B9A_label_en-US" xlink:label="lab_us-gaap_IncomeStatementLocationDomain_70F3A10D6327D0193E8D6EA420009B9A" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Income Statement Location [Domain]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_IncomeStatementLocationDomain" xlink:label="loc_us-gaap_IncomeStatementLocationDomain_70F3A10D6327D0193E8D6EA420009B9A" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeStatementLocationDomain_70F3A10D6327D0193E8D6EA420009B9A" xlink:to="lab_us-gaap_IncomeStatementLocationDomain_70F3A10D6327D0193E8D6EA420009B9A" xlink:type="arc" />
    <link:label id="lab_us-gaap_GeneralAndAdministrativeExpenseMember_0D6B8DAB5379EE26EFDC6EA4FB59FEB4_terseLabel_en-US" xlink:label="lab_us-gaap_GeneralAndAdministrativeExpenseMember_0D6B8DAB5379EE26EFDC6EA4FB59FEB4" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">General and Administrative Expense [Member]</link:label>
    <link:label id="lab_us-gaap_GeneralAndAdministrativeExpenseMember_0D6B8DAB5379EE26EFDC6EA4FB59FEB4_label_en-US" xlink:label="lab_us-gaap_GeneralAndAdministrativeExpenseMember_0D6B8DAB5379EE26EFDC6EA4FB59FEB4" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">General and Administrative Expense [Member]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_GeneralAndAdministrativeExpenseMember" xlink:label="loc_us-gaap_GeneralAndAdministrativeExpenseMember_0D6B8DAB5379EE26EFDC6EA4FB59FEB4" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_GeneralAndAdministrativeExpenseMember_0D6B8DAB5379EE26EFDC6EA4FB59FEB4" xlink:to="lab_us-gaap_GeneralAndAdministrativeExpenseMember_0D6B8DAB5379EE26EFDC6EA4FB59FEB4" xlink:type="arc" />
    <link:label id="lab_us-gaap_ResearchAndDevelopmentExpenseMember_B05902B90981ECD5849E6EA7C20BFCF9_terseLabel_en-US" xlink:label="lab_us-gaap_ResearchAndDevelopmentExpenseMember_B05902B90981ECD5849E6EA7C20BFCF9" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Research and Development Expense [Member]</link:label>
    <link:label id="lab_us-gaap_ResearchAndDevelopmentExpenseMember_B05902B90981ECD5849E6EA7C20BFCF9_label_en-US" xlink:label="lab_us-gaap_ResearchAndDevelopmentExpenseMember_B05902B90981ECD5849E6EA7C20BFCF9" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Research and Development Expense [Member]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ResearchAndDevelopmentExpenseMember" xlink:label="loc_us-gaap_ResearchAndDevelopmentExpenseMember_B05902B90981ECD5849E6EA7C20BFCF9" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ResearchAndDevelopmentExpenseMember_B05902B90981ECD5849E6EA7C20BFCF9" xlink:to="lab_us-gaap_ResearchAndDevelopmentExpenseMember_B05902B90981ECD5849E6EA7C20BFCF9" xlink:type="arc" />
    <link:label id="lab_us-gaap_RestructuringCostAndReserveLineItems_AC111B3C8ECBDB10DFC86E9EA7915E65_terseLabel_en-US" xlink:label="lab_us-gaap_RestructuringCostAndReserveLineItems_AC111B3C8ECBDB10DFC86E9EA7915E65" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Restructuring Charges</link:label>
    <link:label id="lab_us-gaap_RestructuringCostAndReserveLineItems_AC111B3C8ECBDB10DFC86E9EA7915E65_label_en-US" xlink:label="lab_us-gaap_RestructuringCostAndReserveLineItems_AC111B3C8ECBDB10DFC86E9EA7915E65" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Restructuring Cost and Reserve [Line Items]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_RestructuringCostAndReserveLineItems" xlink:label="loc_us-gaap_RestructuringCostAndReserveLineItems_AC111B3C8ECBDB10DFC86E9EA7915E65" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RestructuringCostAndReserveLineItems_AC111B3C8ECBDB10DFC86E9EA7915E65" xlink:to="lab_us-gaap_RestructuringCostAndReserveLineItems_AC111B3C8ECBDB10DFC86E9EA7915E65" xlink:type="arc" />
    <link:label id="lab_us-gaap_TangibleAssetImpairmentCharges_95BECAF172630DD045556E9EA791EDA9_terseLabel_en-US" xlink:label="lab_us-gaap_TangibleAssetImpairmentCharges_95BECAF172630DD045556E9EA791EDA9" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Asset impairment charges</link:label>
    <link:label id="lab_us-gaap_TangibleAssetImpairmentCharges_95BECAF172630DD045556E9EA791EDA9_label_en-US" xlink:label="lab_us-gaap_TangibleAssetImpairmentCharges_95BECAF172630DD045556E9EA791EDA9" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Tangible Asset Impairment Charges</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_TangibleAssetImpairmentCharges" xlink:label="loc_us-gaap_TangibleAssetImpairmentCharges_95BECAF172630DD045556E9EA791EDA9" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_TangibleAssetImpairmentCharges_95BECAF172630DD045556E9EA791EDA9" xlink:to="lab_us-gaap_TangibleAssetImpairmentCharges_95BECAF172630DD045556E9EA791EDA9" xlink:type="arc" />
    <link:label id="lab_us-gaap_RestructuringReserveRollForward_CE668F27A768B1102DA46E9EA791AA43_terseLabel_en-US" xlink:label="lab_us-gaap_RestructuringReserveRollForward_CE668F27A768B1102DA46E9EA791AA43" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Restructuring Reserve [Roll Forward]</link:label>
    <link:label id="lab_us-gaap_RestructuringReserveRollForward_CE668F27A768B1102DA46E9EA791AA43_label_en-US" xlink:label="lab_us-gaap_RestructuringReserveRollForward_CE668F27A768B1102DA46E9EA791AA43" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Restructuring Reserve [Roll Forward]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_RestructuringReserveRollForward" xlink:label="loc_us-gaap_RestructuringReserveRollForward_CE668F27A768B1102DA46E9EA791AA43" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RestructuringReserveRollForward_CE668F27A768B1102DA46E9EA791AA43" xlink:to="lab_us-gaap_RestructuringReserveRollForward_CE668F27A768B1102DA46E9EA791AA43" xlink:type="arc" />
    <link:label id="lab_us-gaap_RestructuringReserve_A8D3BC8F25156B0BD6AD6E9EA79142B0_periodStartLabel_en-US" xlink:label="lab_us-gaap_RestructuringReserve_A8D3BC8F25156B0BD6AD6E9EA79142B0" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:type="resource" xml:lang="en-US">Balance at beginning of period</link:label>
    <link:label id="lab_us-gaap_RestructuringReserve_A8D3BC8F25156B0BD6AD6E9EA79142B0_label_en-US" xlink:label="lab_us-gaap_RestructuringReserve_A8D3BC8F25156B0BD6AD6E9EA79142B0" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Restructuring Reserve</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_RestructuringReserve" xlink:label="loc_us-gaap_RestructuringReserve_A8D3BC8F25156B0BD6AD6E9EA79142B0" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RestructuringReserve_A8D3BC8F25156B0BD6AD6E9EA79142B0" xlink:to="lab_us-gaap_RestructuringReserve_A8D3BC8F25156B0BD6AD6E9EA79142B0" xlink:type="arc" />
    <link:label id="lab_us-gaap_RestructuringCharges_B016032B15D5FA51E78C6E9EA7916BF5_terseLabel_en-US" xlink:label="lab_us-gaap_RestructuringCharges_B016032B15D5FA51E78C6E9EA7916BF5" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Expensed</link:label>
    <link:label id="lab_us-gaap_RestructuringCharges_B016032B15D5FA51E78C6E9EA7916BF5_label_en-US" xlink:label="lab_us-gaap_RestructuringCharges_B016032B15D5FA51E78C6E9EA7916BF5" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Restructuring Charges</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_RestructuringCharges" xlink:label="loc_us-gaap_RestructuringCharges_B016032B15D5FA51E78C6E9EA7916BF5" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RestructuringCharges_B016032B15D5FA51E78C6E9EA7916BF5" xlink:to="lab_us-gaap_RestructuringCharges_B016032B15D5FA51E78C6E9EA7916BF5" xlink:type="arc" />
    <link:label id="lab_us-gaap_PaymentsForRestructuring_5F7C2A47BBA90F6B19706E9EA794B7D3_terseLabel_en-US" xlink:label="lab_us-gaap_PaymentsForRestructuring_5F7C2A47BBA90F6B19706E9EA794B7D3" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Cash Payments</link:label>
    <link:label id="lab_us-gaap_PaymentsForRestructuring_5F7C2A47BBA90F6B19706E9EA794B7D3_label_en-US" xlink:label="lab_us-gaap_PaymentsForRestructuring_5F7C2A47BBA90F6B19706E9EA794B7D3" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Payments for Restructuring</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_PaymentsForRestructuring" xlink:label="loc_us-gaap_PaymentsForRestructuring_5F7C2A47BBA90F6B19706E9EA794B7D3" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PaymentsForRestructuring_5F7C2A47BBA90F6B19706E9EA794B7D3" xlink:to="lab_us-gaap_PaymentsForRestructuring_5F7C2A47BBA90F6B19706E9EA794B7D3" xlink:type="arc" />
    <link:label id="lab_us-gaap_RestructuringReserve_0EAE9D43939A11917AB26E9EA79474E6_periodEndLabel_en-US" xlink:label="lab_us-gaap_RestructuringReserve_0EAE9D43939A11917AB26E9EA79474E6" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:type="resource" xml:lang="en-US">Balance at end of period</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_RestructuringReserve" xlink:label="loc_us-gaap_RestructuringReserve_0EAE9D43939A11917AB26E9EA79474E6" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RestructuringReserve_0EAE9D43939A11917AB26E9EA79474E6" xlink:to="lab_us-gaap_RestructuringReserve_0EAE9D43939A11917AB26E9EA79474E6" xlink:type="arc" />
    <link:label id="lab_us-gaap_LongTermDebtAndCapitalLeaseObligationsIncludingCurrentMaturities_3AEC9BC50A1E0598308C99D8C1C69957_terseLabel_en-US" xlink:label="lab_us-gaap_LongTermDebtAndCapitalLeaseObligationsIncludingCurrentMaturities_1FB7207D79CF57E09F7BD0F66C442E20" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Fair Value Disclosure of notes payable and capital lease obligations</link:label>
    <link:label id="lab_us-gaap_LongTermDebtAndCapitalLeaseObligationsIncludingCurrentMaturities_3AEC9BC50A1E0598308C99D8C1C69957_label_en-US" xlink:label="lab_us-gaap_LongTermDebtAndCapitalLeaseObligationsIncludingCurrentMaturities_1FB7207D79CF57E09F7BD0F66C442E20" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Long-term Debt and Capital Lease Obligations, Including Current Maturities</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_LongTermDebtAndCapitalLeaseObligationsIncludingCurrentMaturities" xlink:label="loc_us-gaap_LongTermDebtAndCapitalLeaseObligationsIncludingCurrentMaturities_1FB7207D79CF57E09F7BD0F66C442E20" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LongTermDebtAndCapitalLeaseObligationsIncludingCurrentMaturities_1FB7207D79CF57E09F7BD0F66C442E20" xlink:to="lab_us-gaap_LongTermDebtAndCapitalLeaseObligationsIncludingCurrentMaturities_1FB7207D79CF57E09F7BD0F66C442E20" xlink:type="arc" />
    <link:label id="lab_us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment_05AD586FE319F9062D6A99C167F40192_terseLabel_en-US" xlink:label="lab_us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment_BF262DCBC29155E6B862A5CEB822F793" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Accumulated depreciation</link:label>
    <link:label id="lab_us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment_05AD586FE319F9062D6A99C167F40192_label_en-US" xlink:label="lab_us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment_BF262DCBC29155E6B862A5CEB822F793" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Accumulated Depreciation, Depletion and Amortization, Property, Plant, and Equipment</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" xlink:label="loc_us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment_BF262DCBC29155E6B862A5CEB822F793" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment_BF262DCBC29155E6B862A5CEB822F793" xlink:to="lab_us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment_BF262DCBC29155E6B862A5CEB822F793" xlink:type="arc" />
    <link:label id="lab_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable_10E4252A76F43AE1A6AF99E0D1C87FB0_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable_ACE48E1C163E515590B650459D6AAAF4" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Property, Plant and Equipment [Table]</link:label>
    <link:label id="lab_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable_10E4252A76F43AE1A6AF99E0D1C87FB0_label_en-US" xlink:label="lab_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable_ACE48E1C163E515590B650459D6AAAF4" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Property, Plant and Equipment [Table]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ScheduleOfPropertyPlantAndEquipmentTable" xlink:label="loc_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable_ACE48E1C163E515590B650459D6AAAF4" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable_ACE48E1C163E515590B650459D6AAAF4" xlink:to="lab_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable_ACE48E1C163E515590B650459D6AAAF4" xlink:type="arc" />
    <link:label id="lab_us-gaap_PropertyPlantAndEquipmentByTypeAxis_E560DA990CC18981A12599E0D1C88DDF_terseLabel_en-US" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentByTypeAxis_BDB01D77D2AD53C4B33E620C78617522" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Property, Plant and Equipment, Type [Axis]</link:label>
    <link:label id="lab_us-gaap_PropertyPlantAndEquipmentByTypeAxis_E560DA990CC18981A12599E0D1C88DDF_label_en-US" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentByTypeAxis_BDB01D77D2AD53C4B33E620C78617522" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Property, Plant and Equipment, Type [Axis]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_PropertyPlantAndEquipmentByTypeAxis" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentByTypeAxis_BDB01D77D2AD53C4B33E620C78617522" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentByTypeAxis_BDB01D77D2AD53C4B33E620C78617522" xlink:to="lab_us-gaap_PropertyPlantAndEquipmentByTypeAxis_BDB01D77D2AD53C4B33E620C78617522" xlink:type="arc" />
    <link:label id="lab_us-gaap_PropertyPlantAndEquipmentTypeDomain_1A8382BB0D6C5185EF0899E0D1C8AD36_terseLabel_en-US" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentTypeDomain_70B953E5F9DA5A34A287A12496CDC9ED" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Property, Plant and Equipment, Type [Domain]</link:label>
    <link:label id="lab_us-gaap_PropertyPlantAndEquipmentTypeDomain_1A8382BB0D6C5185EF0899E0D1C8AD36_label_en-US" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentTypeDomain_70B953E5F9DA5A34A287A12496CDC9ED" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Property, Plant and Equipment, Type [Domain]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_70B953E5F9DA5A34A287A12496CDC9ED" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_70B953E5F9DA5A34A287A12496CDC9ED" xlink:to="lab_us-gaap_PropertyPlantAndEquipmentTypeDomain_70B953E5F9DA5A34A287A12496CDC9ED" xlink:type="arc" />
    <link:label id="lab_us-gaap_ComputerEquipmentMember_944BEE30832CC3FBB94C99E257D98941_terseLabel_en-US" xlink:label="lab_us-gaap_ComputerEquipmentMember_FEE5B3E2884F571ABA7A1CDF82FA1BB3" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Computer Equipment</link:label>
    <link:label id="lab_us-gaap_ComputerEquipmentMember_944BEE30832CC3FBB94C99E257D98941_label_en-US" xlink:label="lab_us-gaap_ComputerEquipmentMember_FEE5B3E2884F571ABA7A1CDF82FA1BB3" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Computer Equipment [Member]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ComputerEquipmentMember" xlink:label="loc_us-gaap_ComputerEquipmentMember_FEE5B3E2884F571ABA7A1CDF82FA1BB3" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ComputerEquipmentMember_FEE5B3E2884F571ABA7A1CDF82FA1BB3" xlink:to="lab_us-gaap_ComputerEquipmentMember_FEE5B3E2884F571ABA7A1CDF82FA1BB3" xlink:type="arc" />
    <link:label id="lab_us-gaap_EquipmentMember_E62D3E7B38B03A6DBA5099E444CCF8A1_terseLabel_en-US" xlink:label="lab_us-gaap_EquipmentMember_CE87323608385511BBB1896E33B5C82C" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Lab Equipment</link:label>
    <link:label id="lab_us-gaap_EquipmentMember_E62D3E7B38B03A6DBA5099E444CCF8A1_label_en-US" xlink:label="lab_us-gaap_EquipmentMember_CE87323608385511BBB1896E33B5C82C" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Equipment [Member]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_EquipmentMember" xlink:label="loc_us-gaap_EquipmentMember_CE87323608385511BBB1896E33B5C82C" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EquipmentMember_CE87323608385511BBB1896E33B5C82C" xlink:to="lab_us-gaap_EquipmentMember_CE87323608385511BBB1896E33B5C82C" xlink:type="arc" />
    <link:label id="lab_nlnk_ContractManufacturingOrganizationEquipmentMember_1A946EB5B9AD379F30D499E85424072E_terseLabel_en-US" xlink:label="lab_nlnk_ContractManufacturingOrganizationEquipmentMember_375F8E9765BA5AAE8717F0F2C57729C5" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Contract Manufacturing Organization Equipment</link:label>
    <link:label id="lab_nlnk_ContractManufacturingOrganizationEquipmentMember_1A946EB5B9AD379F30D499E85424072E_label_en-US" xlink:label="lab_nlnk_ContractManufacturingOrganizationEquipmentMember_375F8E9765BA5AAE8717F0F2C57729C5" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Contract Manufacturing Organization Equipment [Member]</link:label>
    <link:label id="lab_nlnk_ContractManufacturingOrganizationEquipmentMember_1A946EB5B9AD379F30D499E85424072E_documentation_en-US" xlink:label="lab_nlnk_ContractManufacturingOrganizationEquipmentMember_375F8E9765BA5AAE8717F0F2C57729C5" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Contract Manufacturing Organization Equipment [Member]</link:label>
    <link:loc xlink:href="nlnk-20170930.xsd#nlnk_ContractManufacturingOrganizationEquipmentMember" xlink:label="loc_nlnk_ContractManufacturingOrganizationEquipmentMember_375F8E9765BA5AAE8717F0F2C57729C5" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_nlnk_ContractManufacturingOrganizationEquipmentMember_375F8E9765BA5AAE8717F0F2C57729C5" xlink:to="lab_nlnk_ContractManufacturingOrganizationEquipmentMember_375F8E9765BA5AAE8717F0F2C57729C5" xlink:type="arc" />
    <link:label id="lab_us-gaap_PropertyPlantAndEquipmentLineItems_82860B43A04667F7184599E0D1C84FAA_terseLabel_en-US" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentLineItems_754C7397B5F254A4AB9582139E85A981" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Property, Plant and Equipment [Line Items]</link:label>
    <link:label id="lab_us-gaap_PropertyPlantAndEquipmentLineItems_82860B43A04667F7184599E0D1C84FAA_label_en-US" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentLineItems_754C7397B5F254A4AB9582139E85A981" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Property, Plant and Equipment [Line Items]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_PropertyPlantAndEquipmentLineItems" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentLineItems_754C7397B5F254A4AB9582139E85A981" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentLineItems_754C7397B5F254A4AB9582139E85A981" xlink:to="lab_us-gaap_PropertyPlantAndEquipmentLineItems_754C7397B5F254A4AB9582139E85A981" xlink:type="arc" />
    <link:label id="lab_us-gaap_PropertyPlantAndEquipmentUsefulLife_430B4855C5A481EF096699E1561E6526_terseLabel_en-US" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentUsefulLife_ECAF72F879AF559C83117D6F560DDE71" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Useful life</link:label>
    <link:label id="lab_us-gaap_PropertyPlantAndEquipmentUsefulLife_430B4855C5A481EF096699E1561E6526_label_en-US" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentUsefulLife_ECAF72F879AF559C83117D6F560DDE71" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Property, Plant and Equipment, Useful Life</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_PropertyPlantAndEquipmentUsefulLife" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentUsefulLife_ECAF72F879AF559C83117D6F560DDE71" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentUsefulLife_ECAF72F879AF559C83117D6F560DDE71" xlink:to="lab_us-gaap_PropertyPlantAndEquipmentUsefulLife_ECAF72F879AF559C83117D6F560DDE71" xlink:type="arc" />
    <link:label id="lab_us-gaap_GovernmentContractReceivable_8AEB38DBB0FFA8212DC099DA2AB2A2A2_verboseLabel_en-US" xlink:label="lab_us-gaap_GovernmentContractReceivable_0082D103661F5C87B3820EDAEE6D6463" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Government contract receivable</link:label>
    <link:label id="lab_us-gaap_GovernmentContractReceivable_8AEB38DBB0FFA8212DC099DA2AB2A2A2_label_en-US" xlink:label="lab_us-gaap_GovernmentContractReceivable_0082D103661F5C87B3820EDAEE6D6463" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Government Contract Receivable</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_GovernmentContractReceivable" xlink:label="loc_us-gaap_GovernmentContractReceivable_0082D103661F5C87B3820EDAEE6D6463" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_GovernmentContractReceivable_0082D103661F5C87B3820EDAEE6D6463" xlink:to="lab_us-gaap_GovernmentContractReceivable_0082D103661F5C87B3820EDAEE6D6463" xlink:type="arc" />
    <link:label id="lab_us-gaap_GovernmentContractReceivableUnbilledAmounts_4150FE4841E3310A5AC199DAD56A261D_terseLabel_en-US" xlink:label="lab_us-gaap_GovernmentContractReceivableUnbilledAmounts_613BA3CF41D35C819A8DC90FBD46895A" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Unbilled contracts receivable</link:label>
    <link:label id="lab_us-gaap_GovernmentContractReceivableUnbilledAmounts_4150FE4841E3310A5AC199DAD56A261D_label_en-US" xlink:label="lab_us-gaap_GovernmentContractReceivableUnbilledAmounts_613BA3CF41D35C819A8DC90FBD46895A" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Government Contract Receivable, Unbilled Amounts</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_GovernmentContractReceivableUnbilledAmounts" xlink:label="loc_us-gaap_GovernmentContractReceivableUnbilledAmounts_613BA3CF41D35C819A8DC90FBD46895A" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_GovernmentContractReceivableUnbilledAmounts_613BA3CF41D35C819A8DC90FBD46895A" xlink:to="lab_us-gaap_GovernmentContractReceivableUnbilledAmounts_613BA3CF41D35C819A8DC90FBD46895A" xlink:type="arc" />
    <link:label id="lab_nlnk_GovernmentContractAccruedSubcontractorFees_677E8B1D284E85F6229699DF99D34117_terseLabel_en-US" xlink:label="lab_nlnk_GovernmentContractAccruedSubcontractorFees_7B9719F408B355F3929C042E067E97ED" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Accrued expenses for subcontractor fees incurred under government contracts</link:label>
    <link:label id="lab_nlnk_GovernmentContractAccruedSubcontractorFees_677E8B1D284E85F6229699DF99D34117_label_en-US" xlink:label="lab_nlnk_GovernmentContractAccruedSubcontractorFees_7B9719F408B355F3929C042E067E97ED" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Government Contract, Accrued Subcontractor Fees</link:label>
    <link:label id="lab_nlnk_GovernmentContractAccruedSubcontractorFees_677E8B1D284E85F6229699DF99D34117_documentation_en-US" xlink:label="lab_nlnk_GovernmentContractAccruedSubcontractorFees_7B9719F408B355F3929C042E067E97ED" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Government Contract, Accrued Subcontractor Fees</link:label>
    <link:loc xlink:href="nlnk-20170930.xsd#nlnk_GovernmentContractAccruedSubcontractorFees" xlink:label="loc_nlnk_GovernmentContractAccruedSubcontractorFees_7B9719F408B355F3929C042E067E97ED" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_nlnk_GovernmentContractAccruedSubcontractorFees_7B9719F408B355F3929C042E067E97ED" xlink:to="lab_nlnk_GovernmentContractAccruedSubcontractorFees_7B9719F408B355F3929C042E067E97ED" xlink:type="arc" />
    <link:label id="lab_us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock_65DDB80BBF33BC894F8196910A793160_terseLabel_en-US" xlink:label="lab_us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock_1D438447556E5B47A10DA15579DDD267" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Common Stock Equity Incentive Plan</link:label>
    <link:label id="lab_us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock_65DDB80BBF33BC894F8196910A793160_label_en-US" xlink:label="lab_us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock_1D438447556E5B47A10DA15579DDD267" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Disclosure of Compensation Related Costs, Share-based Payments [Text Block]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock" xlink:label="loc_us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock_1D438447556E5B47A10DA15579DDD267" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock_1D438447556E5B47A10DA15579DDD267" xlink:to="lab_us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock_1D438447556E5B47A10DA15579DDD267" xlink:type="arc" />
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized_04ECBD9FF763E14B403D97D92BB48787_verboseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized_00DABD0246BA54CABE35611BC698315B" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Authorized Shares Added</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized_00DABD0246BA54CABE35611BC698315B" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized_00DABD0246BA54CABE35611BC698315B" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized_00DABD0246BA54CABE35611BC698315B" xlink:type="arc" />
    <link:label id="lab_us-gaap_StatementTable_DF70F78C9F32839EBB697D80DFD74CBF_terseLabel_en-US" xlink:label="lab_us-gaap_StatementTable_DF70F78C9F32839EBB697D80DFD74CBF" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Statement [Table]</link:label>
    <link:label id="lab_us-gaap_StatementTable_DF70F78C9F32839EBB697D80DFD74CBF_label_en-US" xlink:label="lab_us-gaap_StatementTable_DF70F78C9F32839EBB697D80DFD74CBF" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Statement [Table]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_StatementTable" xlink:label="loc_us-gaap_StatementTable_DF70F78C9F32839EBB697D80DFD74CBF" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StatementTable_DF70F78C9F32839EBB697D80DFD74CBF" xlink:to="lab_us-gaap_StatementTable_DF70F78C9F32839EBB697D80DFD74CBF" xlink:type="arc" />
    <link:label id="lab_us-gaap_StatementEquityComponentsAxis_5A7CF8B2BF4212DE62257D80DFD7E990_terseLabel_en-US" xlink:label="lab_us-gaap_StatementEquityComponentsAxis_5A7CF8B2BF4212DE62257D80DFD7E990" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Statement, Equity Components</link:label>
    <link:label id="lab_us-gaap_StatementEquityComponentsAxis_5A7CF8B2BF4212DE62257D80DFD7E990_label_en-US" xlink:label="lab_us-gaap_StatementEquityComponentsAxis_5A7CF8B2BF4212DE62257D80DFD7E990" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Equity Components [Axis]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_StatementEquityComponentsAxis" xlink:label="loc_us-gaap_StatementEquityComponentsAxis_5A7CF8B2BF4212DE62257D80DFD7E990" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StatementEquityComponentsAxis_5A7CF8B2BF4212DE62257D80DFD7E990" xlink:to="lab_us-gaap_StatementEquityComponentsAxis_5A7CF8B2BF4212DE62257D80DFD7E990" xlink:type="arc" />
    <link:label id="lab_us-gaap_EquityComponentDomain_914537A5DB82F7229E917D80DFD7AA70_terseLabel_en-US" xlink:label="lab_us-gaap_EquityComponentDomain_914537A5DB82F7229E917D80DFD7AA70" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Equity Component</link:label>
    <link:label id="lab_us-gaap_EquityComponentDomain_914537A5DB82F7229E917D80DFD7AA70_label_en-US" xlink:label="lab_us-gaap_EquityComponentDomain_914537A5DB82F7229E917D80DFD7AA70" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Equity Component [Domain]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_EquityComponentDomain" xlink:label="loc_us-gaap_EquityComponentDomain_914537A5DB82F7229E917D80DFD7AA70" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EquityComponentDomain_914537A5DB82F7229E917D80DFD7AA70" xlink:to="lab_us-gaap_EquityComponentDomain_914537A5DB82F7229E917D80DFD7AA70" xlink:type="arc" />
    <link:label id="lab_us-gaap_CommonStockMember_920BE3831F05ECD13C217D80DFD82831_terseLabel_en-US" xlink:label="lab_us-gaap_CommonStockMember_920BE3831F05ECD13C217D80DFD82831" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Common Stock</link:label>
    <link:label id="lab_us-gaap_CommonStockMember_920BE3831F05ECD13C217D80DFD82831_label_en-US" xlink:label="lab_us-gaap_CommonStockMember_920BE3831F05ECD13C217D80DFD82831" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Common Stock [Member]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_CommonStockMember" xlink:label="loc_us-gaap_CommonStockMember_920BE3831F05ECD13C217D80DFD82831" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CommonStockMember_920BE3831F05ECD13C217D80DFD82831" xlink:to="lab_us-gaap_CommonStockMember_920BE3831F05ECD13C217D80DFD82831" xlink:type="arc" />
    <link:label id="lab_us-gaap_AdditionalPaidInCapitalMember_128F5D547E68BE0BDD137D80DFD83F9E_terseLabel_en-US" xlink:label="lab_us-gaap_AdditionalPaidInCapitalMember_128F5D547E68BE0BDD137D80DFD83F9E" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Additional Paid-in Capital</link:label>
    <link:label id="lab_us-gaap_AdditionalPaidInCapitalMember_128F5D547E68BE0BDD137D80DFD83F9E_label_en-US" xlink:label="lab_us-gaap_AdditionalPaidInCapitalMember_128F5D547E68BE0BDD137D80DFD83F9E" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Additional Paid-in Capital [Member]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_AdditionalPaidInCapitalMember" xlink:label="loc_us-gaap_AdditionalPaidInCapitalMember_128F5D547E68BE0BDD137D80DFD83F9E" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AdditionalPaidInCapitalMember_128F5D547E68BE0BDD137D80DFD83F9E" xlink:to="lab_us-gaap_AdditionalPaidInCapitalMember_128F5D547E68BE0BDD137D80DFD83F9E" xlink:type="arc" />
    <link:label id="lab_us-gaap_TreasuryStockMember_60E7CA8F463F3BBAB2E87D80DFD9FB76_terseLabel_en-US" xlink:label="lab_us-gaap_TreasuryStockMember_60E7CA8F463F3BBAB2E87D80DFD9FB76" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Treasury Stock</link:label>
    <link:label id="lab_us-gaap_TreasuryStockMember_60E7CA8F463F3BBAB2E87D80DFD9FB76_label_en-US" xlink:label="lab_us-gaap_TreasuryStockMember_60E7CA8F463F3BBAB2E87D80DFD9FB76" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Treasury Stock [Member]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_TreasuryStockMember" xlink:label="loc_us-gaap_TreasuryStockMember_60E7CA8F463F3BBAB2E87D80DFD9FB76" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_TreasuryStockMember_60E7CA8F463F3BBAB2E87D80DFD9FB76" xlink:to="lab_us-gaap_TreasuryStockMember_60E7CA8F463F3BBAB2E87D80DFD9FB76" xlink:type="arc" />
    <link:label id="lab_us-gaap_RetainedEarningsMember_B02D6D383A05E52B64A77D80DFD97984_terseLabel_en-US" xlink:label="lab_us-gaap_RetainedEarningsMember_B02D6D383A05E52B64A77D80DFD97984" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Accumulated Deficit</link:label>
    <link:label id="lab_us-gaap_RetainedEarningsMember_B02D6D383A05E52B64A77D80DFD97984_label_en-US" xlink:label="lab_us-gaap_RetainedEarningsMember_B02D6D383A05E52B64A77D80DFD97984" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Retained Earnings [Member]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_RetainedEarningsMember" xlink:label="loc_us-gaap_RetainedEarningsMember_B02D6D383A05E52B64A77D80DFD97984" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RetainedEarningsMember_B02D6D383A05E52B64A77D80DFD97984" xlink:to="lab_us-gaap_RetainedEarningsMember_B02D6D383A05E52B64A77D80DFD97984" xlink:type="arc" />
    <link:label id="lab_us-gaap_StatementLineItems_C21B50291753FE636D267D80DFD9ED37_terseLabel_en-US" xlink:label="lab_us-gaap_StatementLineItems_C21B50291753FE636D267D80DFD9ED37" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Statement [Line Items]</link:label>
    <link:label id="lab_us-gaap_StatementLineItems_C21B50291753FE636D267D80DFD9ED37_label_en-US" xlink:label="lab_us-gaap_StatementLineItems_C21B50291753FE636D267D80DFD9ED37" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Statement [Line Items]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_StatementLineItems" xlink:label="loc_us-gaap_StatementLineItems_C21B50291753FE636D267D80DFD9ED37" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StatementLineItems_C21B50291753FE636D267D80DFD9ED37" xlink:to="lab_us-gaap_StatementLineItems_C21B50291753FE636D267D80DFD9ED37" xlink:type="arc" />
    <link:label id="lab_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_C7EB8218872E635D2D8D7D80DFD9986F_terseLabel_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_C7EB8218872E635D2D8D7D80DFD9986F" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Increase (Decrease) in Stockholders' Equity [Roll Forward]</link:label>
    <link:label id="lab_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_C7EB8218872E635D2D8D7D80DFD9986F_label_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_C7EB8218872E635D2D8D7D80DFD9986F" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Increase (Decrease) in Stockholders' Equity [Roll Forward]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_IncreaseDecreaseInStockholdersEquityRollForward" xlink:label="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_C7EB8218872E635D2D8D7D80DFD9986F" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_C7EB8218872E635D2D8D7D80DFD9986F" xlink:to="lab_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_C7EB8218872E635D2D8D7D80DFD9986F" xlink:type="arc" />
    <link:label id="lab_us-gaap_StockholdersEquity_25E5FC84ECA92E4D26517D80DFD92A6D_periodStartLabel_en-US" xlink:label="lab_us-gaap_StockholdersEquity_25E5FC84ECA92E4D26517D80DFD92A6D" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:type="resource" xml:lang="en-US">Balance at beginning of period</link:label>
    <link:label id="lab_us-gaap_StockholdersEquity_25E5FC84ECA92E4D26517D80DFD92A6D_label_en-US" xlink:label="lab_us-gaap_StockholdersEquity_25E5FC84ECA92E4D26517D80DFD92A6D" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Stockholders' Equity Attributable to Parent</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_StockholdersEquity" xlink:label="loc_us-gaap_StockholdersEquity_25E5FC84ECA92E4D26517D80DFD92A6D" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StockholdersEquity_25E5FC84ECA92E4D26517D80DFD92A6D" xlink:to="lab_us-gaap_StockholdersEquity_25E5FC84ECA92E4D26517D80DFD92A6D" xlink:type="arc" />
    <link:label id="lab_us-gaap_CommonStockSharesOutstanding_9507634E7873485F0DE47D80DFD902C4_periodStartLabel_en-US" xlink:label="lab_us-gaap_CommonStockSharesOutstanding_9507634E7873485F0DE47D80DFD902C4" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:type="resource" xml:lang="en-US">Balance at beginning of period (shares)</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_CommonStockSharesOutstanding" xlink:label="loc_us-gaap_CommonStockSharesOutstanding_9507634E7873485F0DE47D80DFD902C4" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CommonStockSharesOutstanding_9507634E7873485F0DE47D80DFD902C4" xlink:to="lab_us-gaap_CommonStockSharesOutstanding_9507634E7873485F0DE47D80DFD902C4" xlink:type="arc" />
    <link:label id="lab_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue_01BA0D31937D404F39247D80DFDACB63_terseLabel_en-US" xlink:label="lab_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue_01BA0D31937D404F39247D80DFDACB63" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Share-based compensation</link:label>
    <link:label id="lab_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue_01BA0D31937D404F39247D80DFDACB63_label_en-US" xlink:label="lab_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue_01BA0D31937D404F39247D80DFDACB63" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Adjustments to Additional Paid in Capital, Share-based Compensation, Requisite Service Period Recognition</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" xlink:label="loc_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue_01BA0D31937D404F39247D80DFDACB63" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue_01BA0D31937D404F39247D80DFDACB63" xlink:to="lab_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue_01BA0D31937D404F39247D80DFDACB63" xlink:type="arc" />
    <link:label id="lab_us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised_BD8A50F59D9C4A333B857D80DFDAB078_verboseLabel_en-US" xlink:label="lab_us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised_BD8A50F59D9C4A333B857D80DFDAB078" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Exercise of stock options and restricted stock vested</link:label>
    <link:label id="lab_us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised_BD8A50F59D9C4A333B857D80DFDAB078_label_en-US" xlink:label="lab_us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised_BD8A50F59D9C4A333B857D80DFDAB078" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Stock Issued During Period, Value, Stock Options Exercised</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised" xlink:label="loc_us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised_BD8A50F59D9C4A333B857D80DFDAB078" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised_BD8A50F59D9C4A333B857D80DFDAB078" xlink:to="lab_us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised_BD8A50F59D9C4A333B857D80DFDAB078" xlink:type="arc" />
    <link:label id="lab_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised_916F99481EA3FB8BD7BD7D80DFDA8953_terseLabel_en-US" xlink:label="lab_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised_916F99481EA3FB8BD7BD7D80DFDA8953" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Exercise of stock options and restricted stock vested (shares)</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" xlink:label="loc_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised_916F99481EA3FB8BD7BD7D80DFDA8953" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised_916F99481EA3FB8BD7BD7D80DFDA8953" xlink:to="lab_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised_916F99481EA3FB8BD7BD7D80DFDA8953" xlink:type="arc" />
    <link:label id="lab_us-gaap_StockIssuedDuringPeriodValueEmployeeStockPurchasePlan_3EC5C510DFEA3E34F81B7D80DFDA8EE1_terseLabel_en-US" xlink:label="lab_us-gaap_StockIssuedDuringPeriodValueEmployeeStockPurchasePlan_3EC5C510DFEA3E34F81B7D80DFDA8EE1" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Sales of shares under stock purchase plan</link:label>
    <link:label id="lab_us-gaap_StockIssuedDuringPeriodValueEmployeeStockPurchasePlan_3EC5C510DFEA3E34F81B7D80DFDA8EE1_label_en-US" xlink:label="lab_us-gaap_StockIssuedDuringPeriodValueEmployeeStockPurchasePlan_3EC5C510DFEA3E34F81B7D80DFDA8EE1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Stock Issued During Period, Value, Employee Stock Purchase Plan</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_StockIssuedDuringPeriodValueEmployeeStockPurchasePlan" xlink:label="loc_us-gaap_StockIssuedDuringPeriodValueEmployeeStockPurchasePlan_3EC5C510DFEA3E34F81B7D80DFDA8EE1" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StockIssuedDuringPeriodValueEmployeeStockPurchasePlan_3EC5C510DFEA3E34F81B7D80DFDA8EE1" xlink:to="lab_us-gaap_StockIssuedDuringPeriodValueEmployeeStockPurchasePlan_3EC5C510DFEA3E34F81B7D80DFDA8EE1" xlink:type="arc" />
    <link:label id="lab_us-gaap_StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans_1A5E04C06C5F84DF96867D80DFDA0A18_terseLabel_en-US" xlink:label="lab_us-gaap_StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans_1A5E04C06C5F84DF96867D80DFDA0A18" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Sales of shares under stock purchase plan (shares)</link:label>
    <link:label id="lab_us-gaap_StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans_1A5E04C06C5F84DF96867D80DFDA0A18_label_en-US" xlink:label="lab_us-gaap_StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans_1A5E04C06C5F84DF96867D80DFDA0A18" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Stock Issued During Period, Shares, Employee Stock Purchase Plans</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans" xlink:label="loc_us-gaap_StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans_1A5E04C06C5F84DF96867D80DFDA0A18" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans_1A5E04C06C5F84DF96867D80DFDA0A18" xlink:to="lab_us-gaap_StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans_1A5E04C06C5F84DF96867D80DFDA0A18" xlink:type="arc" />
    <link:label id="lab_us-gaap_StockRepurchasedDuringPeriodValue_694F56B6F76168DBB46C7D80DFDA72BC_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_StockRepurchasedDuringPeriodValue_694F56B6F76168DBB46C7D80DFDA72BC" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xml:lang="en-US">Repurchase of common stock</link:label>
    <link:label id="lab_us-gaap_StockRepurchasedDuringPeriodValue_694F56B6F76168DBB46C7D80DFDA72BC_label_en-US" xlink:label="lab_us-gaap_StockRepurchasedDuringPeriodValue_694F56B6F76168DBB46C7D80DFDA72BC" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Stock Repurchased During Period, Value</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_StockRepurchasedDuringPeriodValue" xlink:label="loc_us-gaap_StockRepurchasedDuringPeriodValue_694F56B6F76168DBB46C7D80DFDA72BC" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StockRepurchasedDuringPeriodValue_694F56B6F76168DBB46C7D80DFDA72BC" xlink:to="lab_us-gaap_StockRepurchasedDuringPeriodValue_694F56B6F76168DBB46C7D80DFDA72BC" xlink:type="arc" />
    <link:label id="lab_us-gaap_StockIssuedDuringPeriodValueNewIssues_6B5DF0CA35DFAABCBDA07D88B967F069_terseLabel_en-US" xlink:label="lab_us-gaap_StockIssuedDuringPeriodValueNewIssues_6B5DF0CA35DFAABCBDA07D88B967F069" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Issuance of common stock under the ATM Offering (net of offering costs of $561)</link:label>
    <link:label id="lab_us-gaap_StockIssuedDuringPeriodValueNewIssues_6B5DF0CA35DFAABCBDA07D88B967F069_label_en-US" xlink:label="lab_us-gaap_StockIssuedDuringPeriodValueNewIssues_6B5DF0CA35DFAABCBDA07D88B967F069" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Stock Issued During Period, Value, New Issues</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_StockIssuedDuringPeriodValueNewIssues" xlink:label="loc_us-gaap_StockIssuedDuringPeriodValueNewIssues_6B5DF0CA35DFAABCBDA07D88B967F069" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StockIssuedDuringPeriodValueNewIssues_6B5DF0CA35DFAABCBDA07D88B967F069" xlink:to="lab_us-gaap_StockIssuedDuringPeriodValueNewIssues_6B5DF0CA35DFAABCBDA07D88B967F069" xlink:type="arc" />
    <link:label id="lab_us-gaap_StockIssuedDuringPeriodSharesNewIssues_5FE8CDD2630603785EF67D88ED22E33A_verboseLabel_en-US" xlink:label="lab_us-gaap_StockIssuedDuringPeriodSharesNewIssues_5FE8CDD2630603785EF67D88ED22E33A" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Issuance of common stock under the ATM Offering (net of offering costs of $561) (shares)</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesNewIssues" xlink:label="loc_us-gaap_StockIssuedDuringPeriodSharesNewIssues_5FE8CDD2630603785EF67D88ED22E33A" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StockIssuedDuringPeriodSharesNewIssues_5FE8CDD2630603785EF67D88ED22E33A" xlink:to="lab_us-gaap_StockIssuedDuringPeriodSharesNewIssues_5FE8CDD2630603785EF67D88ED22E33A" xlink:type="arc" />
    <link:label id="lab_us-gaap_StockRepurchasedDuringPeriodShares_A2758CE6E3B58D60A8C57D80DFDBA977_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_StockRepurchasedDuringPeriodShares_A2758CE6E3B58D60A8C57D80DFDBA977" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xml:lang="en-US">Repurchase of common stock (shares)</link:label>
    <link:label id="lab_us-gaap_StockRepurchasedDuringPeriodShares_A2758CE6E3B58D60A8C57D80DFDBA977_label_en-US" xlink:label="lab_us-gaap_StockRepurchasedDuringPeriodShares_A2758CE6E3B58D60A8C57D80DFDBA977" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Stock Repurchased During Period, Shares</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_StockRepurchasedDuringPeriodShares" xlink:label="loc_us-gaap_StockRepurchasedDuringPeriodShares_A2758CE6E3B58D60A8C57D80DFDBA977" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StockRepurchasedDuringPeriodShares_A2758CE6E3B58D60A8C57D80DFDBA977" xlink:to="lab_us-gaap_StockRepurchasedDuringPeriodShares_A2758CE6E3B58D60A8C57D80DFDBA977" xlink:type="arc" />
    <link:label id="lab_us-gaap_StockholdersEquity_E313C15FC16C566C8D667D80DFDBCC36_periodEndLabel_en-US" xlink:label="lab_us-gaap_StockholdersEquity_E313C15FC16C566C8D667D80DFDBCC36" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:type="resource" xml:lang="en-US">Balance at end of period</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_StockholdersEquity" xlink:label="loc_us-gaap_StockholdersEquity_E313C15FC16C566C8D667D80DFDBCC36" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StockholdersEquity_E313C15FC16C566C8D667D80DFDBCC36" xlink:to="lab_us-gaap_StockholdersEquity_E313C15FC16C566C8D667D80DFDBCC36" xlink:type="arc" />
    <link:label id="lab_us-gaap_CommonStockSharesOutstanding_E0A37281A9E615C35ADC7D80DFDBA813_periodEndLabel_en-US" xlink:label="lab_us-gaap_CommonStockSharesOutstanding_E0A37281A9E615C35ADC7D80DFDBA813" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:type="resource" xml:lang="en-US">Balance at end of period (shares)</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_CommonStockSharesOutstanding" xlink:label="loc_us-gaap_CommonStockSharesOutstanding_E0A37281A9E615C35ADC7D80DFDBA813" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CommonStockSharesOutstanding_E0A37281A9E615C35ADC7D80DFDBA813" xlink:to="lab_us-gaap_CommonStockSharesOutstanding_E0A37281A9E615C35ADC7D80DFDBA813" xlink:type="arc" />
    <link:label id="lab_nlnk_DocumentAndEntityInformationAbstract_9DA18231ED1559A606C0E34B7931B76F_label_en-US" xlink:label="lab_nlnk_DocumentAndEntityInformationAbstract_9DA18231ED1559A606C0E34B7931B76F" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Document and Entity Information [Abstract]</link:label>
    <link:label id="lab_nlnk_DocumentAndEntityInformationAbstract_9DA18231ED1559A606C0E34B7931B76F_documentation_en-US" xlink:label="lab_nlnk_DocumentAndEntityInformationAbstract_9DA18231ED1559A606C0E34B7931B76F" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Document and Entity Information [Abstract]</link:label>
    <link:loc xlink:href="nlnk-20170930.xsd#nlnk_DocumentAndEntityInformationAbstract" xlink:label="loc_nlnk_DocumentAndEntityInformationAbstract_9DA18231ED1559A606C0E34B7931B76F" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_nlnk_DocumentAndEntityInformationAbstract_9DA18231ED1559A606C0E34B7931B76F" xlink:to="lab_nlnk_DocumentAndEntityInformationAbstract_9DA18231ED1559A606C0E34B7931B76F" xlink:type="arc" />
    <link:label id="lab_dei_EntityRegistrantName_E7A859BFAEEFBAA12174E34B7935ACAD_terseLabel_en-US" xlink:label="lab_dei_EntityRegistrantName_E7A859BFAEEFBAA12174E34B7935ACAD" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Entity Registrant Name</link:label>
    <link:label id="lab_dei_EntityRegistrantName_E7A859BFAEEFBAA12174E34B7935ACAD_label_en-US" xlink:label="lab_dei_EntityRegistrantName_E7A859BFAEEFBAA12174E34B7935ACAD" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Entity Registrant Name</link:label>
    <link:loc xlink:href="http://xbrl.sec.gov/dei/2014/dei-2014-01-31.xsd#dei_EntityRegistrantName" xlink:label="loc_dei_EntityRegistrantName_E7A859BFAEEFBAA12174E34B7935ACAD" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityRegistrantName_E7A859BFAEEFBAA12174E34B7935ACAD" xlink:to="lab_dei_EntityRegistrantName_E7A859BFAEEFBAA12174E34B7935ACAD" xlink:type="arc" />
    <link:label id="lab_dei_EntityCentralIndexKey_E2A95D53B6325A759121E34B7936FDE7_terseLabel_en-US" xlink:label="lab_dei_EntityCentralIndexKey_E2A95D53B6325A759121E34B7936FDE7" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Entity Central Index Key</link:label>
    <link:label id="lab_dei_EntityCentralIndexKey_E2A95D53B6325A759121E34B7936FDE7_label_en-US" xlink:label="lab_dei_EntityCentralIndexKey_E2A95D53B6325A759121E34B7936FDE7" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Entity Central Index Key</link:label>
    <link:loc xlink:href="http://xbrl.sec.gov/dei/2014/dei-2014-01-31.xsd#dei_EntityCentralIndexKey" xlink:label="loc_dei_EntityCentralIndexKey_E2A95D53B6325A759121E34B7936FDE7" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityCentralIndexKey_E2A95D53B6325A759121E34B7936FDE7" xlink:to="lab_dei_EntityCentralIndexKey_E2A95D53B6325A759121E34B7936FDE7" xlink:type="arc" />
    <link:label id="lab_dei_CurrentFiscalYearEndDate_964EC2E2D584871FE1D2E34B79368641_terseLabel_en-US" xlink:label="lab_dei_CurrentFiscalYearEndDate_964EC2E2D584871FE1D2E34B79368641" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Current Fiscal Year End Date</link:label>
    <link:label id="lab_dei_CurrentFiscalYearEndDate_964EC2E2D584871FE1D2E34B79368641_label_en-US" xlink:label="lab_dei_CurrentFiscalYearEndDate_964EC2E2D584871FE1D2E34B79368641" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Current Fiscal Year End Date</link:label>
    <link:loc xlink:href="http://xbrl.sec.gov/dei/2014/dei-2014-01-31.xsd#dei_CurrentFiscalYearEndDate" xlink:label="loc_dei_CurrentFiscalYearEndDate_964EC2E2D584871FE1D2E34B79368641" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_CurrentFiscalYearEndDate_964EC2E2D584871FE1D2E34B79368641" xlink:to="lab_dei_CurrentFiscalYearEndDate_964EC2E2D584871FE1D2E34B79368641" xlink:type="arc" />
    <link:label id="lab_dei_EntityFilerCategory_D9BBC9FAA940311A6337E34B79364B8E_terseLabel_en-US" xlink:label="lab_dei_EntityFilerCategory_D9BBC9FAA940311A6337E34B79364B8E" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Entity Filer Category</link:label>
    <link:label id="lab_dei_EntityFilerCategory_D9BBC9FAA940311A6337E34B79364B8E_label_en-US" xlink:label="lab_dei_EntityFilerCategory_D9BBC9FAA940311A6337E34B79364B8E" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Entity Filer Category</link:label>
    <link:loc xlink:href="http://xbrl.sec.gov/dei/2014/dei-2014-01-31.xsd#dei_EntityFilerCategory" xlink:label="loc_dei_EntityFilerCategory_D9BBC9FAA940311A6337E34B79364B8E" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityFilerCategory_D9BBC9FAA940311A6337E34B79364B8E" xlink:to="lab_dei_EntityFilerCategory_D9BBC9FAA940311A6337E34B79364B8E" xlink:type="arc" />
    <link:label id="lab_dei_DocumentType_450EDAB86FEE5A01E72AE34B7936DEEC_terseLabel_en-US" xlink:label="lab_dei_DocumentType_450EDAB86FEE5A01E72AE34B7936DEEC" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Document Type</link:label>
    <link:label id="lab_dei_DocumentType_450EDAB86FEE5A01E72AE34B7936DEEC_label_en-US" xlink:label="lab_dei_DocumentType_450EDAB86FEE5A01E72AE34B7936DEEC" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Document Type</link:label>
    <link:loc xlink:href="http://xbrl.sec.gov/dei/2014/dei-2014-01-31.xsd#dei_DocumentType" xlink:label="loc_dei_DocumentType_450EDAB86FEE5A01E72AE34B7936DEEC" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_DocumentType_450EDAB86FEE5A01E72AE34B7936DEEC" xlink:to="lab_dei_DocumentType_450EDAB86FEE5A01E72AE34B7936DEEC" xlink:type="arc" />
    <link:label id="lab_dei_DocumentPeriodEndDate_E0FF6B1607489DA16DDAE34B7936027E_terseLabel_en-US" xlink:label="lab_dei_DocumentPeriodEndDate_E0FF6B1607489DA16DDAE34B7936027E" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Document Period End Date</link:label>
    <link:label id="lab_dei_DocumentPeriodEndDate_E0FF6B1607489DA16DDAE34B7936027E_label_en-US" xlink:label="lab_dei_DocumentPeriodEndDate_E0FF6B1607489DA16DDAE34B7936027E" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Document Period End Date</link:label>
    <link:loc xlink:href="http://xbrl.sec.gov/dei/2014/dei-2014-01-31.xsd#dei_DocumentPeriodEndDate" xlink:label="loc_dei_DocumentPeriodEndDate_E0FF6B1607489DA16DDAE34B7936027E" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_DocumentPeriodEndDate_E0FF6B1607489DA16DDAE34B7936027E" xlink:to="lab_dei_DocumentPeriodEndDate_E0FF6B1607489DA16DDAE34B7936027E" xlink:type="arc" />
    <link:label id="lab_dei_DocumentFiscalYearFocus_8A107908171820107DEBE34B7937A718_terseLabel_en-US" xlink:label="lab_dei_DocumentFiscalYearFocus_8A107908171820107DEBE34B7937A718" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Document Fiscal Year Focus</link:label>
    <link:label id="lab_dei_DocumentFiscalYearFocus_8A107908171820107DEBE34B7937A718_label_en-US" xlink:label="lab_dei_DocumentFiscalYearFocus_8A107908171820107DEBE34B7937A718" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Document Fiscal Year Focus</link:label>
    <link:loc xlink:href="http://xbrl.sec.gov/dei/2014/dei-2014-01-31.xsd#dei_DocumentFiscalYearFocus" xlink:label="loc_dei_DocumentFiscalYearFocus_8A107908171820107DEBE34B7937A718" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_DocumentFiscalYearFocus_8A107908171820107DEBE34B7937A718" xlink:to="lab_dei_DocumentFiscalYearFocus_8A107908171820107DEBE34B7937A718" xlink:type="arc" />
    <link:label id="lab_dei_DocumentFiscalPeriodFocus_A3406D313B0C4C2041A0E34B7937A73D_terseLabel_en-US" xlink:label="lab_dei_DocumentFiscalPeriodFocus_A3406D313B0C4C2041A0E34B7937A73D" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Document Fiscal Period Focus</link:label>
    <link:label id="lab_dei_DocumentFiscalPeriodFocus_A3406D313B0C4C2041A0E34B7937A73D_label_en-US" xlink:label="lab_dei_DocumentFiscalPeriodFocus_A3406D313B0C4C2041A0E34B7937A73D" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Document Fiscal Period Focus</link:label>
    <link:loc xlink:href="http://xbrl.sec.gov/dei/2014/dei-2014-01-31.xsd#dei_DocumentFiscalPeriodFocus" xlink:label="loc_dei_DocumentFiscalPeriodFocus_A3406D313B0C4C2041A0E34B7937A73D" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_DocumentFiscalPeriodFocus_A3406D313B0C4C2041A0E34B7937A73D" xlink:to="lab_dei_DocumentFiscalPeriodFocus_A3406D313B0C4C2041A0E34B7937A73D" xlink:type="arc" />
    <link:label id="lab_dei_AmendmentFlag_CCAB9E5AAE969C40E18AE34B793775B8_terseLabel_en-US" xlink:label="lab_dei_AmendmentFlag_CCAB9E5AAE969C40E18AE34B793775B8" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Amendment Flag</link:label>
    <link:label id="lab_dei_AmendmentFlag_CCAB9E5AAE969C40E18AE34B793775B8_label_en-US" xlink:label="lab_dei_AmendmentFlag_CCAB9E5AAE969C40E18AE34B793775B8" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Amendment Flag</link:label>
    <link:loc xlink:href="http://xbrl.sec.gov/dei/2014/dei-2014-01-31.xsd#dei_AmendmentFlag" xlink:label="loc_dei_AmendmentFlag_CCAB9E5AAE969C40E18AE34B793775B8" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_AmendmentFlag_CCAB9E5AAE969C40E18AE34B793775B8" xlink:to="lab_dei_AmendmentFlag_CCAB9E5AAE969C40E18AE34B793775B8" xlink:type="arc" />
    <link:label id="lab_dei_EntityCommonStockSharesOutstanding_7516E395684C222828D3E34B79378E03_terseLabel_en-US" xlink:label="lab_dei_EntityCommonStockSharesOutstanding_7516E395684C222828D3E34B79378E03" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Entity Common Stock, Shares Outstanding</link:label>
    <link:label id="lab_dei_EntityCommonStockSharesOutstanding_7516E395684C222828D3E34B79378E03_label_en-US" xlink:label="lab_dei_EntityCommonStockSharesOutstanding_7516E395684C222828D3E34B79378E03" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Entity Common Stock, Shares Outstanding</link:label>
    <link:loc xlink:href="http://xbrl.sec.gov/dei/2014/dei-2014-01-31.xsd#dei_EntityCommonStockSharesOutstanding" xlink:label="loc_dei_EntityCommonStockSharesOutstanding_7516E395684C222828D3E34B79378E03" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityCommonStockSharesOutstanding_7516E395684C222828D3E34B79378E03" xlink:to="lab_dei_EntityCommonStockSharesOutstanding_7516E395684C222828D3E34B79378E03" xlink:type="arc" />
    <link:label id="lab_us-gaap_DebtInstrumentTable_28531D8B918BA3F41CB0A5CB9AEC2DB9_terseLabel_en-US" xlink:label="lab_us-gaap_DebtInstrumentTable_8ABEA65787A15F93A4A2F3346748B599" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Schedule of Long-term Debt Instruments</link:label>
    <link:label id="lab_us-gaap_DebtInstrumentTable_28531D8B918BA3F41CB0A5CB9AEC2DB9_label_en-US" xlink:label="lab_us-gaap_DebtInstrumentTable_8ABEA65787A15F93A4A2F3346748B599" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Schedule of Long-term Debt Instruments [Table]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_DebtInstrumentTable" xlink:label="loc_us-gaap_DebtInstrumentTable_8ABEA65787A15F93A4A2F3346748B599" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DebtInstrumentTable_8ABEA65787A15F93A4A2F3346748B599" xlink:to="lab_us-gaap_DebtInstrumentTable_8ABEA65787A15F93A4A2F3346748B599" xlink:type="arc" />
    <link:label id="lab_us-gaap_LongtermDebtTypeAxis_1A61EED26212ED7916CBA5CB9AED39A5_terseLabel_en-US" xlink:label="lab_us-gaap_LongtermDebtTypeAxis_AE1DB761518351EFBA3ED531E0C3B905" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Long-term Debt, Type [Axis]</link:label>
    <link:label id="lab_us-gaap_LongtermDebtTypeAxis_1A61EED26212ED7916CBA5CB9AED39A5_label_en-US" xlink:label="lab_us-gaap_LongtermDebtTypeAxis_AE1DB761518351EFBA3ED531E0C3B905" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Long-term Debt, Type [Axis]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_LongtermDebtTypeAxis" xlink:label="loc_us-gaap_LongtermDebtTypeAxis_AE1DB761518351EFBA3ED531E0C3B905" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LongtermDebtTypeAxis_AE1DB761518351EFBA3ED531E0C3B905" xlink:to="lab_us-gaap_LongtermDebtTypeAxis_AE1DB761518351EFBA3ED531E0C3B905" xlink:type="arc" />
    <link:label id="lab_us-gaap_LongtermDebtTypeDomain_3701ECD5EDA8440C44A4A5CB9AED780C_terseLabel_en-US" xlink:label="lab_us-gaap_LongtermDebtTypeDomain_7B9815AD3B27570AADDD9140E537DF9F" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Long-term Debt, Type [Domain]</link:label>
    <link:label id="lab_us-gaap_LongtermDebtTypeDomain_3701ECD5EDA8440C44A4A5CB9AED780C_label_en-US" xlink:label="lab_us-gaap_LongtermDebtTypeDomain_7B9815AD3B27570AADDD9140E537DF9F" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Long-term Debt, Type [Domain]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_LongtermDebtTypeDomain" xlink:label="loc_us-gaap_LongtermDebtTypeDomain_7B9815AD3B27570AADDD9140E537DF9F" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LongtermDebtTypeDomain_7B9815AD3B27570AADDD9140E537DF9F" xlink:to="lab_us-gaap_LongtermDebtTypeDomain_7B9815AD3B27570AADDD9140E537DF9F" xlink:type="arc" />
    <link:label id="lab_us-gaap_LoansPayableMember_C0096733F1BC514A09DAA5CB9AEDDA31_terseLabel_en-US" xlink:label="lab_us-gaap_LoansPayableMember_029E38CA73B353C79A014BEB6DA82B45" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Loans Payable</link:label>
    <link:label id="lab_us-gaap_LoansPayableMember_C0096733F1BC514A09DAA5CB9AEDDA31_label_en-US" xlink:label="lab_us-gaap_LoansPayableMember_029E38CA73B353C79A014BEB6DA82B45" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Loans Payable [Member]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_LoansPayableMember" xlink:label="loc_us-gaap_LoansPayableMember_029E38CA73B353C79A014BEB6DA82B45" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LoansPayableMember_029E38CA73B353C79A014BEB6DA82B45" xlink:to="lab_us-gaap_LoansPayableMember_029E38CA73B353C79A014BEB6DA82B45" xlink:type="arc" />
    <link:label id="lab_us-gaap_DebtInstrumentAxis_A59E107DE2828F8DE5F7A5CB9AEEA368_terseLabel_en-US" xlink:label="lab_us-gaap_DebtInstrumentAxis_F81CBA2C332E51DF94C120A14C46A70C" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Debt Instrument</link:label>
    <link:label id="lab_us-gaap_DebtInstrumentAxis_A59E107DE2828F8DE5F7A5CB9AEEA368_label_en-US" xlink:label="lab_us-gaap_DebtInstrumentAxis_F81CBA2C332E51DF94C120A14C46A70C" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Debt Instrument [Axis]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_DebtInstrumentAxis" xlink:label="loc_us-gaap_DebtInstrumentAxis_F81CBA2C332E51DF94C120A14C46A70C" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DebtInstrumentAxis_F81CBA2C332E51DF94C120A14C46A70C" xlink:to="lab_us-gaap_DebtInstrumentAxis_F81CBA2C332E51DF94C120A14C46A70C" xlink:type="arc" />
    <link:label id="lab_us-gaap_DebtInstrumentNameDomain_83463DB28B4C4F33A00EA5CB9AEEFD39_terseLabel_en-US" xlink:label="lab_us-gaap_DebtInstrumentNameDomain_B172B8D4219D5F59AD802E3C93504022" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Debt Instrument, Name</link:label>
    <link:label id="lab_us-gaap_DebtInstrumentNameDomain_83463DB28B4C4F33A00EA5CB9AEEFD39_label_en-US" xlink:label="lab_us-gaap_DebtInstrumentNameDomain_B172B8D4219D5F59AD802E3C93504022" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Debt Instrument, Name [Domain]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_DebtInstrumentNameDomain" xlink:label="loc_us-gaap_DebtInstrumentNameDomain_B172B8D4219D5F59AD802E3C93504022" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_B172B8D4219D5F59AD802E3C93504022" xlink:to="lab_us-gaap_DebtInstrumentNameDomain_B172B8D4219D5F59AD802E3C93504022" xlink:type="arc" />
    <link:label id="lab_nlnk_CityOfAmesForgivableLoan2010Member_9372D823F97850AE1B57A5CB9AEE3D23_terseLabel_en-US" xlink:label="lab_nlnk_CityOfAmesForgivableLoan2010Member_59FEF6421E7A58E9A9BC963571B1B776" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">City of Ames Forgivable Loan 2010</link:label>
    <link:label id="lab_nlnk_CityOfAmesForgivableLoan2010Member_9372D823F97850AE1B57A5CB9AEE3D23_label_en-US" xlink:label="lab_nlnk_CityOfAmesForgivableLoan2010Member_59FEF6421E7A58E9A9BC963571B1B776" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">City of Ames Forgivable Loan 2010 [Member]</link:label>
    <link:label id="lab_nlnk_CityOfAmesForgivableLoan2010Member_9372D823F97850AE1B57A5CB9AEE3D23_documentation_en-US" xlink:label="lab_nlnk_CityOfAmesForgivableLoan2010Member_59FEF6421E7A58E9A9BC963571B1B776" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">City of Ames Forgivable Loan 2010 [Member]</link:label>
    <link:loc xlink:href="nlnk-20170930.xsd#nlnk_CityOfAmesForgivableLoan2010Member" xlink:label="loc_nlnk_CityOfAmesForgivableLoan2010Member_59FEF6421E7A58E9A9BC963571B1B776" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_nlnk_CityOfAmesForgivableLoan2010Member_59FEF6421E7A58E9A9BC963571B1B776" xlink:to="lab_nlnk_CityOfAmesForgivableLoan2010Member_59FEF6421E7A58E9A9BC963571B1B776" xlink:type="arc" />
    <link:label id="lab_us-gaap_DebtInstrumentLineItems_3CC3BAC1BFEEE063A7DFA5CB9AEE3544_terseLabel_en-US" xlink:label="lab_us-gaap_DebtInstrumentLineItems_924C3770DA1153C986CB26F48E562530" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Debt Instrument</link:label>
    <link:label id="lab_us-gaap_DebtInstrumentLineItems_3CC3BAC1BFEEE063A7DFA5CB9AEE3544_label_en-US" xlink:label="lab_us-gaap_DebtInstrumentLineItems_924C3770DA1153C986CB26F48E562530" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Debt Instrument [Line Items]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_DebtInstrumentLineItems" xlink:label="loc_us-gaap_DebtInstrumentLineItems_924C3770DA1153C986CB26F48E562530" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DebtInstrumentLineItems_924C3770DA1153C986CB26F48E562530" xlink:to="lab_us-gaap_DebtInstrumentLineItems_924C3770DA1153C986CB26F48E562530" xlink:type="arc" />
    <link:label id="lab_us-gaap_DebtInstrumentFaceAmount_B6AB597CF762E567646BA5CB9AEE8561_terseLabel_en-US" xlink:label="lab_us-gaap_DebtInstrumentFaceAmount_CB3B62D8999A5F4495E2A5D266C1E0BE" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Original Available Balance</link:label>
    <link:label id="lab_us-gaap_DebtInstrumentFaceAmount_B6AB597CF762E567646BA5CB9AEE8561_label_en-US" xlink:label="lab_us-gaap_DebtInstrumentFaceAmount_CB3B62D8999A5F4495E2A5D266C1E0BE" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Debt Instrument, Face Amount</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_DebtInstrumentFaceAmount" xlink:label="loc_us-gaap_DebtInstrumentFaceAmount_CB3B62D8999A5F4495E2A5D266C1E0BE" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DebtInstrumentFaceAmount_CB3B62D8999A5F4495E2A5D266C1E0BE" xlink:to="lab_us-gaap_DebtInstrumentFaceAmount_CB3B62D8999A5F4495E2A5D266C1E0BE" xlink:type="arc" />
    <link:label id="lab_nlnk_DebtInstrumentCovenantRequiredNumberofPositionsCreationandRetention_BF30CB986D7AF7624518A5CB9AEE6B82_terseLabel_en-US" xlink:label="lab_nlnk_DebtInstrumentCovenantRequiredNumberofPositionsCreationandRetention_1D697EDC4A055D1F8A054D191AEFDDB3" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Full-time position requirement (in positions)</link:label>
    <link:label id="lab_nlnk_DebtInstrumentCovenantRequiredNumberofPositionsCreationandRetention_BF30CB986D7AF7624518A5CB9AEE6B82_label_en-US" xlink:label="lab_nlnk_DebtInstrumentCovenantRequiredNumberofPositionsCreationandRetention_1D697EDC4A055D1F8A054D191AEFDDB3" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Debt Instrument, Covenant Required, Number of Positions Creation and Retention</link:label>
    <link:label id="lab_nlnk_DebtInstrumentCovenantRequiredNumberofPositionsCreationandRetention_BF30CB986D7AF7624518A5CB9AEE6B82_documentation_en-US" xlink:label="lab_nlnk_DebtInstrumentCovenantRequiredNumberofPositionsCreationandRetention_1D697EDC4A055D1F8A054D191AEFDDB3" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Debt Instrument, Covenant Required, Number of Positions Creation and Retention</link:label>
    <link:loc xlink:href="nlnk-20170930.xsd#nlnk_DebtInstrumentCovenantRequiredNumberofPositionsCreationandRetention" xlink:label="loc_nlnk_DebtInstrumentCovenantRequiredNumberofPositionsCreationandRetention_1D697EDC4A055D1F8A054D191AEFDDB3" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_nlnk_DebtInstrumentCovenantRequiredNumberofPositionsCreationandRetention_1D697EDC4A055D1F8A054D191AEFDDB3" xlink:to="lab_nlnk_DebtInstrumentCovenantRequiredNumberofPositionsCreationandRetention_1D697EDC4A055D1F8A054D191AEFDDB3" xlink:type="arc" />
    <link:label id="lab_us-gaap_LesseeLeasingArrangementsOperatingLeasesTermOfContract_0DE8F302282313CC9FEAA5CB9AEE3AAC_terseLabel_en-US" xlink:label="lab_us-gaap_LesseeLeasingArrangementsOperatingLeasesTermOfContract_EA528AB23D3257CE9E871B52BA37ACC4" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Term of lease</link:label>
    <link:label id="lab_us-gaap_LesseeLeasingArrangementsOperatingLeasesTermOfContract_0DE8F302282313CC9FEAA5CB9AEE3AAC_label_en-US" xlink:label="lab_us-gaap_LesseeLeasingArrangementsOperatingLeasesTermOfContract_EA528AB23D3257CE9E871B52BA37ACC4" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Lessee, Operating Lease, Term of Contract</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_LesseeLeasingArrangementsOperatingLeasesTermOfContract" xlink:label="loc_us-gaap_LesseeLeasingArrangementsOperatingLeasesTermOfContract_EA528AB23D3257CE9E871B52BA37ACC4" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LesseeLeasingArrangementsOperatingLeasesTermOfContract_EA528AB23D3257CE9E871B52BA37ACC4" xlink:to="lab_us-gaap_LesseeLeasingArrangementsOperatingLeasesTermOfContract_EA528AB23D3257CE9E871B52BA37ACC4" xlink:type="arc" />
    <link:label id="lab_us-gaap_LesseeLeasingArrangementsOperatingLeasesRenewalTerm_69E1CF57A60D88DBAE45A5CB9AEF0257_terseLabel_en-US" xlink:label="lab_us-gaap_LesseeLeasingArrangementsOperatingLeasesRenewalTerm_CF1E2C78AC9B5A4D9E94E83D55A80CDA" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Lease extension term</link:label>
    <link:label id="lab_us-gaap_LesseeLeasingArrangementsOperatingLeasesRenewalTerm_69E1CF57A60D88DBAE45A5CB9AEF0257_label_en-US" xlink:label="lab_us-gaap_LesseeLeasingArrangementsOperatingLeasesRenewalTerm_CF1E2C78AC9B5A4D9E94E83D55A80CDA" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Lessee, Operating Lease, Renewal Term</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_LesseeLeasingArrangementsOperatingLeasesRenewalTerm" xlink:label="loc_us-gaap_LesseeLeasingArrangementsOperatingLeasesRenewalTerm_CF1E2C78AC9B5A4D9E94E83D55A80CDA" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LesseeLeasingArrangementsOperatingLeasesRenewalTerm_CF1E2C78AC9B5A4D9E94E83D55A80CDA" xlink:to="lab_us-gaap_LesseeLeasingArrangementsOperatingLeasesRenewalTerm_CF1E2C78AC9B5A4D9E94E83D55A80CDA" xlink:type="arc" />
    <link:label id="lab_nlnk_DebtInstrumentCovenantRequiredMinimumLeaseArea_CCF39BEF5D0E8D33DB4FA5CB9AEF823D_terseLabel_en-US" xlink:label="lab_nlnk_DebtInstrumentCovenantRequiredMinimumLeaseArea_D56BECA863C857C998F32506A673F313" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Lease square feet</link:label>
    <link:label id="lab_nlnk_DebtInstrumentCovenantRequiredMinimumLeaseArea_CCF39BEF5D0E8D33DB4FA5CB9AEF823D_label_en-US" xlink:label="lab_nlnk_DebtInstrumentCovenantRequiredMinimumLeaseArea_D56BECA863C857C998F32506A673F313" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Debt Instrument, Covenant Required, Minimum Lease Area</link:label>
    <link:label id="lab_nlnk_DebtInstrumentCovenantRequiredMinimumLeaseArea_CCF39BEF5D0E8D33DB4FA5CB9AEF823D_documentation_en-US" xlink:label="lab_nlnk_DebtInstrumentCovenantRequiredMinimumLeaseArea_D56BECA863C857C998F32506A673F313" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Debt Instrument, Covenant Required, Minimum Lease Area</link:label>
    <link:loc xlink:href="nlnk-20170930.xsd#nlnk_DebtInstrumentCovenantRequiredMinimumLeaseArea" xlink:label="loc_nlnk_DebtInstrumentCovenantRequiredMinimumLeaseArea_D56BECA863C857C998F32506A673F313" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_nlnk_DebtInstrumentCovenantRequiredMinimumLeaseArea_D56BECA863C857C998F32506A673F313" xlink:to="lab_nlnk_DebtInstrumentCovenantRequiredMinimumLeaseArea_D56BECA863C857C998F32506A673F313" xlink:type="arc" />
    <link:label id="lab_us-gaap_SubsequentEventTable_A135507A179004BB776E7D80DEEE2AB9_terseLabel_en-US" xlink:label="lab_us-gaap_SubsequentEventTable_A135507A179004BB776E7D80DEEE2AB9" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Subsequent Event [Table]</link:label>
    <link:label id="lab_us-gaap_SubsequentEventTable_A135507A179004BB776E7D80DEEE2AB9_label_en-US" xlink:label="lab_us-gaap_SubsequentEventTable_A135507A179004BB776E7D80DEEE2AB9" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Subsequent Event [Table]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_SubsequentEventTable" xlink:label="loc_us-gaap_SubsequentEventTable_A135507A179004BB776E7D80DEEE2AB9" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SubsequentEventTable_A135507A179004BB776E7D80DEEE2AB9" xlink:to="lab_us-gaap_SubsequentEventTable_A135507A179004BB776E7D80DEEE2AB9" xlink:type="arc" />
    <link:label id="lab_us-gaap_SubsequentEventLineItems_8EDAAFE474CB467C69DA7D80DEF0B1E6_terseLabel_en-US" xlink:label="lab_us-gaap_SubsequentEventLineItems_8EDAAFE474CB467C69DA7D80DEF0B1E6" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Subsequent Event [Line Items]</link:label>
    <link:label id="lab_us-gaap_SubsequentEventLineItems_8EDAAFE474CB467C69DA7D80DEF0B1E6_label_en-US" xlink:label="lab_us-gaap_SubsequentEventLineItems_8EDAAFE474CB467C69DA7D80DEF0B1E6" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Subsequent Event [Line Items]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_SubsequentEventLineItems" xlink:label="loc_us-gaap_SubsequentEventLineItems_8EDAAFE474CB467C69DA7D80DEF0B1E6" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SubsequentEventLineItems_8EDAAFE474CB467C69DA7D80DEF0B1E6" xlink:to="lab_us-gaap_SubsequentEventLineItems_8EDAAFE474CB467C69DA7D80DEF0B1E6" xlink:type="arc" />
    <link:label id="lab_us-gaap_NatureOfOperations_4E0B7002BDB92406B3BA96910AD67A78_terseLabel_en-US" xlink:label="lab_us-gaap_NatureOfOperations_A3EA6A76721D56D8A7478D6861478C6C" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Description of Business</link:label>
    <link:label id="lab_us-gaap_NatureOfOperations_4E0B7002BDB92406B3BA96910AD67A78_label_en-US" xlink:label="lab_us-gaap_NatureOfOperations_A3EA6A76721D56D8A7478D6861478C6C" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Nature of Operations [Text Block]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_NatureOfOperations" xlink:label="loc_us-gaap_NatureOfOperations_A3EA6A76721D56D8A7478D6861478C6C" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NatureOfOperations_A3EA6A76721D56D8A7478D6861478C6C" xlink:to="lab_us-gaap_NatureOfOperations_A3EA6A76721D56D8A7478D6861478C6C" xlink:type="arc" />
    <link:label id="lab_us-gaap_AssetsAbstract_460F2AE0317981CA449B50882321417F_terseLabel_en-US" xlink:label="lab_us-gaap_AssetsAbstract_460F2AE0317981CA449B50882321417F" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Assets</link:label>
    <link:label id="lab_us-gaap_AssetsAbstract_460F2AE0317981CA449B50882321417F_label_en-US" xlink:label="lab_us-gaap_AssetsAbstract_460F2AE0317981CA449B50882321417F" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Assets [Abstract]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_AssetsAbstract" xlink:label="loc_us-gaap_AssetsAbstract_460F2AE0317981CA449B50882321417F" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AssetsAbstract_460F2AE0317981CA449B50882321417F" xlink:to="lab_us-gaap_AssetsAbstract_460F2AE0317981CA449B50882321417F" xlink:type="arc" />
    <link:label id="lab_us-gaap_AssetsCurrentAbstract_B69038967F1F477A4803508823214798_terseLabel_en-US" xlink:label="lab_us-gaap_AssetsCurrentAbstract_B69038967F1F477A4803508823214798" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Current assets:</link:label>
    <link:label id="lab_us-gaap_AssetsCurrentAbstract_B69038967F1F477A4803508823214798_label_en-US" xlink:label="lab_us-gaap_AssetsCurrentAbstract_B69038967F1F477A4803508823214798" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Assets, Current [Abstract]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_AssetsCurrentAbstract" xlink:label="loc_us-gaap_AssetsCurrentAbstract_B69038967F1F477A4803508823214798" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AssetsCurrentAbstract_B69038967F1F477A4803508823214798" xlink:to="lab_us-gaap_AssetsCurrentAbstract_B69038967F1F477A4803508823214798" xlink:type="arc" />
    <link:label id="lab_us-gaap_CashAndCashEquivalentsAtCarryingValue_A173258E08EF643B25B4508823211DD4_terseLabel_en-US" xlink:label="lab_us-gaap_CashAndCashEquivalentsAtCarryingValue_A173258E08EF643B25B4508823211DD4" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Cash and cash equivalents</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:label="loc_us-gaap_CashAndCashEquivalentsAtCarryingValue_A173258E08EF643B25B4508823211DD4" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CashAndCashEquivalentsAtCarryingValue_A173258E08EF643B25B4508823211DD4" xlink:to="lab_us-gaap_CashAndCashEquivalentsAtCarryingValue_A173258E08EF643B25B4508823211DD4" xlink:type="arc" />
    <link:label id="lab_us-gaap_PrepaidExpenseAndOtherAssetsCurrent_B247C03B9948CBB28BA7508823212D46_terseLabel_en-US" xlink:label="lab_us-gaap_PrepaidExpenseAndOtherAssetsCurrent_B247C03B9948CBB28BA7508823212D46" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Prepaid expenses and other current assets</link:label>
    <link:label id="lab_us-gaap_PrepaidExpenseAndOtherAssetsCurrent_B247C03B9948CBB28BA7508823212D46_label_en-US" xlink:label="lab_us-gaap_PrepaidExpenseAndOtherAssetsCurrent_B247C03B9948CBB28BA7508823212D46" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Prepaid Expense and Other Assets, Current</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_PrepaidExpenseAndOtherAssetsCurrent" xlink:label="loc_us-gaap_PrepaidExpenseAndOtherAssetsCurrent_B247C03B9948CBB28BA7508823212D46" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PrepaidExpenseAndOtherAssetsCurrent_B247C03B9948CBB28BA7508823212D46" xlink:to="lab_us-gaap_PrepaidExpenseAndOtherAssetsCurrent_B247C03B9948CBB28BA7508823212D46" xlink:type="arc" />
    <link:label id="lab_us-gaap_IncomeTaxesReceivable_A2CF0DAC66F13AE1898F5088232126FB_terseLabel_en-US" xlink:label="lab_us-gaap_IncomeTaxesReceivable_A2CF0DAC66F13AE1898F5088232126FB" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Income tax receivable</link:label>
    <link:label id="lab_us-gaap_IncomeTaxesReceivable_A2CF0DAC66F13AE1898F5088232126FB_label_en-US" xlink:label="lab_us-gaap_IncomeTaxesReceivable_A2CF0DAC66F13AE1898F5088232126FB" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Income Taxes Receivable, Current</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_IncomeTaxesReceivable" xlink:label="loc_us-gaap_IncomeTaxesReceivable_A2CF0DAC66F13AE1898F5088232126FB" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeTaxesReceivable_A2CF0DAC66F13AE1898F5088232126FB" xlink:to="lab_us-gaap_IncomeTaxesReceivable_A2CF0DAC66F13AE1898F5088232126FB" xlink:type="arc" />
    <link:label id="lab_us-gaap_OtherReceivablesNetCurrent_C60D5041673E449A0AC750882321190E_terseLabel_en-US" xlink:label="lab_us-gaap_OtherReceivablesNetCurrent_C60D5041673E449A0AC750882321190E" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Other receivables</link:label>
    <link:label id="lab_us-gaap_OtherReceivablesNetCurrent_C60D5041673E449A0AC750882321190E_label_en-US" xlink:label="lab_us-gaap_OtherReceivablesNetCurrent_C60D5041673E449A0AC750882321190E" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Other Receivables, Net, Current</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_OtherReceivablesNetCurrent" xlink:label="loc_us-gaap_OtherReceivablesNetCurrent_C60D5041673E449A0AC750882321190E" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OtherReceivablesNetCurrent_C60D5041673E449A0AC750882321190E" xlink:to="lab_us-gaap_OtherReceivablesNetCurrent_C60D5041673E449A0AC750882321190E" xlink:type="arc" />
    <link:label id="lab_us-gaap_AssetsCurrent_F5C17A8FB4B6AC93D992508823219BE2_totalLabel_en-US" xlink:label="lab_us-gaap_AssetsCurrent_F5C17A8FB4B6AC93D992508823219BE2" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xml:lang="en-US">Total current assets</link:label>
    <link:label id="lab_us-gaap_AssetsCurrent_F5C17A8FB4B6AC93D992508823219BE2_label_en-US" xlink:label="lab_us-gaap_AssetsCurrent_F5C17A8FB4B6AC93D992508823219BE2" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Assets, Current</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_AssetsCurrent" xlink:label="loc_us-gaap_AssetsCurrent_F5C17A8FB4B6AC93D992508823219BE2" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AssetsCurrent_F5C17A8FB4B6AC93D992508823219BE2" xlink:to="lab_us-gaap_AssetsCurrent_F5C17A8FB4B6AC93D992508823219BE2" xlink:type="arc" />
    <link:label id="lab_us-gaap_PropertyPlantAndEquipmentNet_5917309B9149AC17478350882322A8D9_terseLabel_en-US" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentNet_5917309B9149AC17478350882322A8D9" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Property and equipment, net</link:label>
    <link:label id="lab_us-gaap_PropertyPlantAndEquipmentNet_5917309B9149AC17478350882322A8D9_label_en-US" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentNet_5917309B9149AC17478350882322A8D9" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Property, Plant and Equipment, Net</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_PropertyPlantAndEquipmentNet" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentNet_5917309B9149AC17478350882322A8D9" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentNet_5917309B9149AC17478350882322A8D9" xlink:to="lab_us-gaap_PropertyPlantAndEquipmentNet_5917309B9149AC17478350882322A8D9" xlink:type="arc" />
    <link:label id="lab_us-gaap_Assets_74641FA962A0C86C32E950882322AEBB_totalLabel_en-US" xlink:label="lab_us-gaap_Assets_74641FA962A0C86C32E950882322AEBB" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xml:lang="en-US">Total assets</link:label>
    <link:label id="lab_us-gaap_Assets_74641FA962A0C86C32E950882322AEBB_label_en-US" xlink:label="lab_us-gaap_Assets_74641FA962A0C86C32E950882322AEBB" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Assets</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_Assets" xlink:label="loc_us-gaap_Assets_74641FA962A0C86C32E950882322AEBB" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_Assets_74641FA962A0C86C32E950882322AEBB" xlink:to="lab_us-gaap_Assets_74641FA962A0C86C32E950882322AEBB" xlink:type="arc" />
    <link:label id="lab_us-gaap_LiabilitiesAbstract_9EDF9C519C7F58646E5B508823225ED5_terseLabel_en-US" xlink:label="lab_us-gaap_LiabilitiesAbstract_9EDF9C519C7F58646E5B508823225ED5" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Liabilities and Stockholders' Equity</link:label>
    <link:label id="lab_us-gaap_LiabilitiesAbstract_9EDF9C519C7F58646E5B508823225ED5_label_en-US" xlink:label="lab_us-gaap_LiabilitiesAbstract_9EDF9C519C7F58646E5B508823225ED5" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Liabilities [Abstract]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_LiabilitiesAbstract" xlink:label="loc_us-gaap_LiabilitiesAbstract_9EDF9C519C7F58646E5B508823225ED5" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LiabilitiesAbstract_9EDF9C519C7F58646E5B508823225ED5" xlink:to="lab_us-gaap_LiabilitiesAbstract_9EDF9C519C7F58646E5B508823225ED5" xlink:type="arc" />
    <link:label id="lab_us-gaap_LiabilitiesCurrentAbstract_173745AF1597481B09E6508823227212_terseLabel_en-US" xlink:label="lab_us-gaap_LiabilitiesCurrentAbstract_173745AF1597481B09E6508823227212" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Current liabilities:</link:label>
    <link:label id="lab_us-gaap_LiabilitiesCurrentAbstract_173745AF1597481B09E6508823227212_label_en-US" xlink:label="lab_us-gaap_LiabilitiesCurrentAbstract_173745AF1597481B09E6508823227212" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Liabilities, Current [Abstract]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_LiabilitiesCurrentAbstract" xlink:label="loc_us-gaap_LiabilitiesCurrentAbstract_173745AF1597481B09E6508823227212" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LiabilitiesCurrentAbstract_173745AF1597481B09E6508823227212" xlink:to="lab_us-gaap_LiabilitiesCurrentAbstract_173745AF1597481B09E6508823227212" xlink:type="arc" />
    <link:label id="lab_us-gaap_AccountsPayableCurrent_2A473EDE82D802AFED1E508823221F04_terseLabel_en-US" xlink:label="lab_us-gaap_AccountsPayableCurrent_2A473EDE82D802AFED1E508823221F04" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Accounts payable</link:label>
    <link:label id="lab_us-gaap_AccountsPayableCurrent_2A473EDE82D802AFED1E508823221F04_label_en-US" xlink:label="lab_us-gaap_AccountsPayableCurrent_2A473EDE82D802AFED1E508823221F04" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Accounts Payable, Current</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_AccountsPayableCurrent" xlink:label="loc_us-gaap_AccountsPayableCurrent_2A473EDE82D802AFED1E508823221F04" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AccountsPayableCurrent_2A473EDE82D802AFED1E508823221F04" xlink:to="lab_us-gaap_AccountsPayableCurrent_2A473EDE82D802AFED1E508823221F04" xlink:type="arc" />
    <link:label id="lab_us-gaap_AccruedLiabilitiesCurrent_253A11F0974886850F7E5088232284E2_terseLabel_en-US" xlink:label="lab_us-gaap_AccruedLiabilitiesCurrent_253A11F0974886850F7E5088232284E2" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Accrued expenses</link:label>
    <link:label id="lab_us-gaap_AccruedLiabilitiesCurrent_253A11F0974886850F7E5088232284E2_label_en-US" xlink:label="lab_us-gaap_AccruedLiabilitiesCurrent_253A11F0974886850F7E5088232284E2" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Accrued Liabilities, Current</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_AccruedLiabilitiesCurrent" xlink:label="loc_us-gaap_AccruedLiabilitiesCurrent_253A11F0974886850F7E5088232284E2" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AccruedLiabilitiesCurrent_253A11F0974886850F7E5088232284E2" xlink:to="lab_us-gaap_AccruedLiabilitiesCurrent_253A11F0974886850F7E5088232284E2" xlink:type="arc" />
    <link:label id="lab_us-gaap_DeferredRevenueCurrent_7610914EA17236198565508823229BDE_terseLabel_en-US" xlink:label="lab_us-gaap_DeferredRevenueCurrent_7610914EA17236198565508823229BDE" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Current portion of unearned revenue</link:label>
    <link:label id="lab_us-gaap_DeferredRevenueCurrent_7610914EA17236198565508823229BDE_label_en-US" xlink:label="lab_us-gaap_DeferredRevenueCurrent_7610914EA17236198565508823229BDE" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Deferred Revenue, Current</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_DeferredRevenueCurrent" xlink:label="loc_us-gaap_DeferredRevenueCurrent_7610914EA17236198565508823229BDE" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DeferredRevenueCurrent_7610914EA17236198565508823229BDE" xlink:to="lab_us-gaap_DeferredRevenueCurrent_7610914EA17236198565508823229BDE" xlink:type="arc" />
    <link:label id="lab_us-gaap_DeferredRentCreditCurrent_E44BE7FEFB1FD492D70C50882322F73D_terseLabel_en-US" xlink:label="lab_us-gaap_DeferredRentCreditCurrent_E44BE7FEFB1FD492D70C50882322F73D" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Current portion of deferred rent</link:label>
    <link:label id="lab_us-gaap_DeferredRentCreditCurrent_E44BE7FEFB1FD492D70C50882322F73D_label_en-US" xlink:label="lab_us-gaap_DeferredRentCreditCurrent_E44BE7FEFB1FD492D70C50882322F73D" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Deferred Rent Credit, Current</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_DeferredRentCreditCurrent" xlink:label="loc_us-gaap_DeferredRentCreditCurrent_E44BE7FEFB1FD492D70C50882322F73D" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DeferredRentCreditCurrent_E44BE7FEFB1FD492D70C50882322F73D" xlink:to="lab_us-gaap_DeferredRentCreditCurrent_E44BE7FEFB1FD492D70C50882322F73D" xlink:type="arc" />
    <link:label id="lab_us-gaap_LongTermDebtAndCapitalLeaseObligationsCurrent_907E86C8537258494391508823222AF5_terseLabel_en-US" xlink:label="lab_us-gaap_LongTermDebtAndCapitalLeaseObligationsCurrent_907E86C8537258494391508823222AF5" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Current portion of notes payable and obligations under capital leases</link:label>
    <link:label id="lab_us-gaap_LongTermDebtAndCapitalLeaseObligationsCurrent_907E86C8537258494391508823222AF5_label_en-US" xlink:label="lab_us-gaap_LongTermDebtAndCapitalLeaseObligationsCurrent_907E86C8537258494391508823222AF5" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Long-term Debt and Capital Lease Obligations, Current</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_LongTermDebtAndCapitalLeaseObligationsCurrent" xlink:label="loc_us-gaap_LongTermDebtAndCapitalLeaseObligationsCurrent_907E86C8537258494391508823222AF5" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LongTermDebtAndCapitalLeaseObligationsCurrent_907E86C8537258494391508823222AF5" xlink:to="lab_us-gaap_LongTermDebtAndCapitalLeaseObligationsCurrent_907E86C8537258494391508823222AF5" xlink:type="arc" />
    <link:label id="lab_us-gaap_LiabilitiesCurrent_B9F02418CFE39FB23F2B50882322AA4E_totalLabel_en-US" xlink:label="lab_us-gaap_LiabilitiesCurrent_B9F02418CFE39FB23F2B50882322AA4E" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xml:lang="en-US">Total current liabilities</link:label>
    <link:label id="lab_us-gaap_LiabilitiesCurrent_B9F02418CFE39FB23F2B50882322AA4E_label_en-US" xlink:label="lab_us-gaap_LiabilitiesCurrent_B9F02418CFE39FB23F2B50882322AA4E" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Liabilities, Current</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_LiabilitiesCurrent" xlink:label="loc_us-gaap_LiabilitiesCurrent_B9F02418CFE39FB23F2B50882322AA4E" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LiabilitiesCurrent_B9F02418CFE39FB23F2B50882322AA4E" xlink:to="lab_us-gaap_LiabilitiesCurrent_B9F02418CFE39FB23F2B50882322AA4E" xlink:type="arc" />
    <link:label id="lab_us-gaap_LiabilitiesNoncurrentAbstract_0942FD131675E13190B35088232217C1_terseLabel_en-US" xlink:label="lab_us-gaap_LiabilitiesNoncurrentAbstract_0942FD131675E13190B35088232217C1" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Long-term liabilities:</link:label>
    <link:label id="lab_us-gaap_LiabilitiesNoncurrentAbstract_0942FD131675E13190B35088232217C1_label_en-US" xlink:label="lab_us-gaap_LiabilitiesNoncurrentAbstract_0942FD131675E13190B35088232217C1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Liabilities, Noncurrent [Abstract]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_LiabilitiesNoncurrentAbstract" xlink:label="loc_us-gaap_LiabilitiesNoncurrentAbstract_0942FD131675E13190B35088232217C1" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LiabilitiesNoncurrentAbstract_0942FD131675E13190B35088232217C1" xlink:to="lab_us-gaap_LiabilitiesNoncurrentAbstract_0942FD131675E13190B35088232217C1" xlink:type="arc" />
    <link:label id="lab_nlnk_DeferredGovernmentGrantsObligationsNoncurrent_9604D694F70C50C2CED950882322EDD8_terseLabel_en-US" xlink:label="lab_nlnk_DeferredGovernmentGrantsObligationsNoncurrent_9604D694F70C50C2CED950882322EDD8" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Royalty obligation payable to Iowa Economic Development Authority</link:label>
    <link:label id="lab_nlnk_DeferredGovernmentGrantsObligationsNoncurrent_9604D694F70C50C2CED950882322EDD8_label_en-US" xlink:label="lab_nlnk_DeferredGovernmentGrantsObligationsNoncurrent_9604D694F70C50C2CED950882322EDD8" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Deferred Government Grants Obligations, Noncurrent</link:label>
    <link:label id="lab_nlnk_DeferredGovernmentGrantsObligationsNoncurrent_9604D694F70C50C2CED950882322EDD8_documentation_en-US" xlink:label="lab_nlnk_DeferredGovernmentGrantsObligationsNoncurrent_9604D694F70C50C2CED950882322EDD8" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Deferred Government Grants Obligations, Noncurrent</link:label>
    <link:loc xlink:href="nlnk-20170930.xsd#nlnk_DeferredGovernmentGrantsObligationsNoncurrent" xlink:label="loc_nlnk_DeferredGovernmentGrantsObligationsNoncurrent_9604D694F70C50C2CED950882322EDD8" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_nlnk_DeferredGovernmentGrantsObligationsNoncurrent_9604D694F70C50C2CED950882322EDD8" xlink:to="lab_nlnk_DeferredGovernmentGrantsObligationsNoncurrent_9604D694F70C50C2CED950882322EDD8" xlink:type="arc" />
    <link:label id="lab_us-gaap_LongTermDebtAndCapitalLeaseObligations_0F5C2BB6ADC32ED0E36F508823220792_terseLabel_en-US" xlink:label="lab_us-gaap_LongTermDebtAndCapitalLeaseObligations_0F5C2BB6ADC32ED0E36F508823220792" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Notes payable and obligations under capital leases</link:label>
    <link:label id="lab_us-gaap_LongTermDebtAndCapitalLeaseObligations_0F5C2BB6ADC32ED0E36F508823220792_label_en-US" xlink:label="lab_us-gaap_LongTermDebtAndCapitalLeaseObligations_0F5C2BB6ADC32ED0E36F508823220792" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Long-term Debt and Capital Lease Obligations</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_LongTermDebtAndCapitalLeaseObligations" xlink:label="loc_us-gaap_LongTermDebtAndCapitalLeaseObligations_0F5C2BB6ADC32ED0E36F508823220792" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LongTermDebtAndCapitalLeaseObligations_0F5C2BB6ADC32ED0E36F508823220792" xlink:to="lab_us-gaap_LongTermDebtAndCapitalLeaseObligations_0F5C2BB6ADC32ED0E36F508823220792" xlink:type="arc" />
    <link:label id="lab_us-gaap_DeferredRentCreditNoncurrent_A94A3158A0551C842965508823229064_terseLabel_en-US" xlink:label="lab_us-gaap_DeferredRentCreditNoncurrent_A94A3158A0551C842965508823229064" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Deferred rent</link:label>
    <link:label id="lab_us-gaap_DeferredRentCreditNoncurrent_A94A3158A0551C842965508823229064_label_en-US" xlink:label="lab_us-gaap_DeferredRentCreditNoncurrent_A94A3158A0551C842965508823229064" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Deferred Rent Credit, Noncurrent</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_DeferredRentCreditNoncurrent" xlink:label="loc_us-gaap_DeferredRentCreditNoncurrent_A94A3158A0551C842965508823229064" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DeferredRentCreditNoncurrent_A94A3158A0551C842965508823229064" xlink:to="lab_us-gaap_DeferredRentCreditNoncurrent_A94A3158A0551C842965508823229064" xlink:type="arc" />
    <link:label id="lab_us-gaap_LiabilitiesNoncurrent_F216AD83834B55FFFC9350882322FA78_totalLabel_en-US" xlink:label="lab_us-gaap_LiabilitiesNoncurrent_F216AD83834B55FFFC9350882322FA78" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xml:lang="en-US">Total long-term liabilities</link:label>
    <link:label id="lab_us-gaap_LiabilitiesNoncurrent_F216AD83834B55FFFC9350882322FA78_label_en-US" xlink:label="lab_us-gaap_LiabilitiesNoncurrent_F216AD83834B55FFFC9350882322FA78" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Liabilities, Noncurrent</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_LiabilitiesNoncurrent" xlink:label="loc_us-gaap_LiabilitiesNoncurrent_F216AD83834B55FFFC9350882322FA78" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LiabilitiesNoncurrent_F216AD83834B55FFFC9350882322FA78" xlink:to="lab_us-gaap_LiabilitiesNoncurrent_F216AD83834B55FFFC9350882322FA78" xlink:type="arc" />
    <link:label id="lab_us-gaap_Liabilities_7BC0EB245E2C67755E6B5088232250C5_totalLabel_en-US" xlink:label="lab_us-gaap_Liabilities_7BC0EB245E2C67755E6B5088232250C5" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xml:lang="en-US">Total liabilities</link:label>
    <link:label id="lab_us-gaap_Liabilities_7BC0EB245E2C67755E6B5088232250C5_label_en-US" xlink:label="lab_us-gaap_Liabilities_7BC0EB245E2C67755E6B5088232250C5" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Liabilities</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_Liabilities" xlink:label="loc_us-gaap_Liabilities_7BC0EB245E2C67755E6B5088232250C5" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_Liabilities_7BC0EB245E2C67755E6B5088232250C5" xlink:to="lab_us-gaap_Liabilities_7BC0EB245E2C67755E6B5088232250C5" xlink:type="arc" />
    <link:label id="lab_us-gaap_EquityAbstract_73A3F29DF52C8047898550882322BD9A_terseLabel_en-US" xlink:label="lab_us-gaap_EquityAbstract_73A3F29DF52C8047898550882322BD9A" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Stockholders' equity:</link:label>
    <link:label id="lab_us-gaap_EquityAbstract_73A3F29DF52C8047898550882322BD9A_label_en-US" xlink:label="lab_us-gaap_EquityAbstract_73A3F29DF52C8047898550882322BD9A" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Equity [Abstract]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_EquityAbstract" xlink:label="loc_us-gaap_EquityAbstract_73A3F29DF52C8047898550882322BD9A" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EquityAbstract_73A3F29DF52C8047898550882322BD9A" xlink:to="lab_us-gaap_EquityAbstract_73A3F29DF52C8047898550882322BD9A" xlink:type="arc" />
    <link:label id="lab_us-gaap_PreferredStockValueOutstanding_A6BFEF4F6FDCAE5E7824508823235F03_terseLabel_en-US" xlink:label="lab_us-gaap_PreferredStockValueOutstanding_A6BFEF4F6FDCAE5E7824508823235F03" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Blank check preferred stock, $0.01 par value: Authorized shares &#8212; 5,000,000 at September 30, 2017 and December 31, 2016; issued and outstanding shares &#8212; 0 at September 30, 2017 and December 31, 2016</link:label>
    <link:label id="lab_us-gaap_PreferredStockValueOutstanding_A6BFEF4F6FDCAE5E7824508823235F03_label_en-US" xlink:label="lab_us-gaap_PreferredStockValueOutstanding_A6BFEF4F6FDCAE5E7824508823235F03" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Preferred Stock, Value, Outstanding</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_PreferredStockValueOutstanding" xlink:label="loc_us-gaap_PreferredStockValueOutstanding_A6BFEF4F6FDCAE5E7824508823235F03" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PreferredStockValueOutstanding_A6BFEF4F6FDCAE5E7824508823235F03" xlink:to="lab_us-gaap_PreferredStockValueOutstanding_A6BFEF4F6FDCAE5E7824508823235F03" xlink:type="arc" />
    <link:label id="lab_us-gaap_CommonStockValueOutstanding_9324E3E3F0CFE0FC81FC50882323D8BB_terseLabel_en-US" xlink:label="lab_us-gaap_CommonStockValueOutstanding_9324E3E3F0CFE0FC81FC50882323D8BB" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Common stock, $0.01 par value: Authorized shares &#8212; 75,000,000 at September 30, 2017 and December 31, 2016; issued 31,375,528 and 29,193,718 at September 30, 2017 and December 31, 2016, respectively, and outstanding 31,319,751 and 29,163,673 at September 30, 2017 and December 31, 2016, respectively</link:label>
    <link:label id="lab_us-gaap_CommonStockValueOutstanding_9324E3E3F0CFE0FC81FC50882323D8BB_label_en-US" xlink:label="lab_us-gaap_CommonStockValueOutstanding_9324E3E3F0CFE0FC81FC50882323D8BB" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Common Stock, Value, Outstanding</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_CommonStockValueOutstanding" xlink:label="loc_us-gaap_CommonStockValueOutstanding_9324E3E3F0CFE0FC81FC50882323D8BB" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CommonStockValueOutstanding_9324E3E3F0CFE0FC81FC50882323D8BB" xlink:to="lab_us-gaap_CommonStockValueOutstanding_9324E3E3F0CFE0FC81FC50882323D8BB" xlink:type="arc" />
    <link:label id="lab_us-gaap_AdditionalPaidInCapital_4D50F6E039131E5F427F50882323B2EA_terseLabel_en-US" xlink:label="lab_us-gaap_AdditionalPaidInCapital_4D50F6E039131E5F427F50882323B2EA" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Additional paid-in capital</link:label>
    <link:label id="lab_us-gaap_AdditionalPaidInCapital_4D50F6E039131E5F427F50882323B2EA_label_en-US" xlink:label="lab_us-gaap_AdditionalPaidInCapital_4D50F6E039131E5F427F50882323B2EA" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Additional Paid in Capital</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_AdditionalPaidInCapital" xlink:label="loc_us-gaap_AdditionalPaidInCapital_4D50F6E039131E5F427F50882323B2EA" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AdditionalPaidInCapital_4D50F6E039131E5F427F50882323B2EA" xlink:to="lab_us-gaap_AdditionalPaidInCapital_4D50F6E039131E5F427F50882323B2EA" xlink:type="arc" />
    <link:label id="lab_us-gaap_TreasuryStockValue_6D65A848D74E380E20CF508823236F62_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_TreasuryStockValue_6D65A848D74E380E20CF508823236F62" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xml:lang="en-US">Treasury stock, at cost: 55,777 and 30,045 shares at September 30, 2017 and December 31, 2016, respectively</link:label>
    <link:label id="lab_us-gaap_TreasuryStockValue_6D65A848D74E380E20CF508823236F62_label_en-US" xlink:label="lab_us-gaap_TreasuryStockValue_6D65A848D74E380E20CF508823236F62" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Treasury Stock, Value</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_TreasuryStockValue" xlink:label="loc_us-gaap_TreasuryStockValue_6D65A848D74E380E20CF508823236F62" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_TreasuryStockValue_6D65A848D74E380E20CF508823236F62" xlink:to="lab_us-gaap_TreasuryStockValue_6D65A848D74E380E20CF508823236F62" xlink:type="arc" />
    <link:label id="lab_us-gaap_RetainedEarningsAccumulatedDeficit_4519AC02085CACFE2C46508823231A2A_terseLabel_en-US" xlink:label="lab_us-gaap_RetainedEarningsAccumulatedDeficit_4519AC02085CACFE2C46508823231A2A" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Accumulated deficit</link:label>
    <link:label id="lab_us-gaap_RetainedEarningsAccumulatedDeficit_4519AC02085CACFE2C46508823231A2A_label_en-US" xlink:label="lab_us-gaap_RetainedEarningsAccumulatedDeficit_4519AC02085CACFE2C46508823231A2A" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Retained Earnings (Accumulated Deficit)</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_RetainedEarningsAccumulatedDeficit" xlink:label="loc_us-gaap_RetainedEarningsAccumulatedDeficit_4519AC02085CACFE2C46508823231A2A" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RetainedEarningsAccumulatedDeficit_4519AC02085CACFE2C46508823231A2A" xlink:to="lab_us-gaap_RetainedEarningsAccumulatedDeficit_4519AC02085CACFE2C46508823231A2A" xlink:type="arc" />
    <link:label id="lab_us-gaap_StockholdersEquity_0AC362DD59B547E16DFC508823237DBC_totalLabel_en-US" xlink:label="lab_us-gaap_StockholdersEquity_0AC362DD59B547E16DFC508823237DBC" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xml:lang="en-US">Total stockholders' equity</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_StockholdersEquity" xlink:label="loc_us-gaap_StockholdersEquity_0AC362DD59B547E16DFC508823237DBC" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StockholdersEquity_0AC362DD59B547E16DFC508823237DBC" xlink:to="lab_us-gaap_StockholdersEquity_0AC362DD59B547E16DFC508823237DBC" xlink:type="arc" />
    <link:label id="lab_us-gaap_LiabilitiesAndStockholdersEquity_E6E090665F01350ECE18508823230F27_totalLabel_en-US" xlink:label="lab_us-gaap_LiabilitiesAndStockholdersEquity_E6E090665F01350ECE18508823230F27" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xml:lang="en-US">Total liabilities and stockholders' equity</link:label>
    <link:label id="lab_us-gaap_LiabilitiesAndStockholdersEquity_E6E090665F01350ECE18508823230F27_label_en-US" xlink:label="lab_us-gaap_LiabilitiesAndStockholdersEquity_E6E090665F01350ECE18508823230F27" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Liabilities and Equity</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_LiabilitiesAndStockholdersEquity" xlink:label="loc_us-gaap_LiabilitiesAndStockholdersEquity_E6E090665F01350ECE18508823230F27" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquity_E6E090665F01350ECE18508823230F27" xlink:to="lab_us-gaap_LiabilitiesAndStockholdersEquity_E6E090665F01350ECE18508823230F27" xlink:type="arc" />
    <link:label id="lab_us-gaap_CollaborativeArrangementDisclosureTextBlock_F6A3C69CA915EEEFC6AF97B90C5E94DE_terseLabel_en-US" xlink:label="lab_us-gaap_CollaborativeArrangementDisclosureTextBlock_501B27617E2E5477987FED6DE1E32ACA" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Licensing and Research Collaboration Agreements</link:label>
    <link:label id="lab_us-gaap_CollaborativeArrangementDisclosureTextBlock_F6A3C69CA915EEEFC6AF97B90C5E94DE_label_en-US" xlink:label="lab_us-gaap_CollaborativeArrangementDisclosureTextBlock_501B27617E2E5477987FED6DE1E32ACA" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Collaborative Arrangement Disclosure [Text Block]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_CollaborativeArrangementDisclosureTextBlock" xlink:label="loc_us-gaap_CollaborativeArrangementDisclosureTextBlock_501B27617E2E5477987FED6DE1E32ACA" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CollaborativeArrangementDisclosureTextBlock_501B27617E2E5477987FED6DE1E32ACA" xlink:to="lab_us-gaap_CollaborativeArrangementDisclosureTextBlock_501B27617E2E5477987FED6DE1E32ACA" xlink:type="arc" />
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingRollForward_3FFFD0476EE76415D42F97345BF00C69_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingRollForward_72AEA9B235095EB0A403C6F59F644DF8" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Non-Option Equity Instruments, Outstanding [Roll Forward]</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingRollForward_3FFFD0476EE76415D42F97345BF00C69_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingRollForward_72AEA9B235095EB0A403C6F59F644DF8" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Non-Option Equity Instruments, Outstanding [Roll Forward]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingRollForward" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingRollForward_72AEA9B235095EB0A403C6F59F644DF8" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingRollForward_72AEA9B235095EB0A403C6F59F644DF8" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingRollForward_72AEA9B235095EB0A403C6F59F644DF8" xlink:type="arc" />
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_3E48ADFF69CB46728D0197FC4894E85E_periodStartLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_AFB92A8EBA6254EAA0E7FC24F649D36E" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:type="resource" xml:lang="en-US">Unvested at beginning of period (in shares)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_3E48ADFF69CB46728D0197FC4894E85E_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_AFB92A8EBA6254EAA0E7FC24F649D36E" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Nonvested, Number</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_AFB92A8EBA6254EAA0E7FC24F649D36E" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_AFB92A8EBA6254EAA0E7FC24F649D36E" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_AFB92A8EBA6254EAA0E7FC24F649D36E" xlink:type="arc" />
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod_15F116256E2AFA585DBD97345BF103E6_negatedLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod_FB0C88639806552980DDCBBE93B9A8D4" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xml:lang="en-US">Vested (in shares)</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod_FB0C88639806552980DDCBBE93B9A8D4" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod_FB0C88639806552980DDCBBE93B9A8D4" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod_FB0C88639806552980DDCBBE93B9A8D4" xlink:type="arc" />
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod_A6EC66EC13DBBA5E05FE97F7435BA766_negatedLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod_364EF90C57A1551DA869217A78B291AF" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xml:lang="en-US">Forfeited / cancelled (in shares)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod_A6EC66EC13DBBA5E05FE97F7435BA766_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod_364EF90C57A1551DA869217A78B291AF" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Forfeited in Period</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod_364EF90C57A1551DA869217A78B291AF" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod_364EF90C57A1551DA869217A78B291AF" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod_364EF90C57A1551DA869217A78B291AF" xlink:type="arc" />
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_43F0CBB17F9B754BA4FA98099977C4DE_periodEndLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_F58CB22BDE7F564FA8B364E76453BD85" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:type="resource" xml:lang="en-US">Unvested at end of period (in shares)</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_F58CB22BDE7F564FA8B364E76453BD85" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_F58CB22BDE7F564FA8B364E76453BD85" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_F58CB22BDE7F564FA8B364E76453BD85" xlink:type="arc" />
    <link:label id="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedWeightedAverageGrantDateFairValueAbstract_A1128A7190B5E8CCC0E697345BF1D444_terseLabel_en-US" xlink:label="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedWeightedAverageGrantDateFairValueAbstract_B01EF4E8CCEB5374BCB7A8A102E060DE" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Options, Nonvested, Weighted Average Grant Date Fair Value [Abstract]</link:label>
    <link:label id="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedWeightedAverageGrantDateFairValueAbstract_A1128A7190B5E8CCC0E697345BF1D444_label_en-US" xlink:label="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedWeightedAverageGrantDateFairValueAbstract_B01EF4E8CCEB5374BCB7A8A102E060DE" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Options, Nonvested, Weighted Average Grant Date Fair Value [Abstract]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedWeightedAverageGrantDateFairValueAbstract" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedWeightedAverageGrantDateFairValueAbstract_B01EF4E8CCEB5374BCB7A8A102E060DE" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedWeightedAverageGrantDateFairValueAbstract_B01EF4E8CCEB5374BCB7A8A102E060DE" xlink:to="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedWeightedAverageGrantDateFairValueAbstract_B01EF4E8CCEB5374BCB7A8A102E060DE" xlink:type="arc" />
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue_D254AA0CB0948F946B7197F3AAA67780_periodStartLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue_091B08B741F759328D394BBC0F68BDA2" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:type="resource" xml:lang="en-US">Weighted average grant date fair value at beginning of period (in dollars per share)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue_D254AA0CB0948F946B7197F3AAA67780_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue_091B08B741F759328D394BBC0F68BDA2" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Nonvested, Weighted Average Grant Date Fair Value</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue_091B08B741F759328D394BBC0F68BDA2" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue_091B08B741F759328D394BBC0F68BDA2" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue_091B08B741F759328D394BBC0F68BDA2" xlink:type="arc" />
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue_50EE8DC5EAEF59F1BFA097345BF1A3E3_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue_FA8ADC84619656EAB15710FB7C0A953D" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Vested, weighted average grant date fair value (in dollars per share)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue_50EE8DC5EAEF59F1BFA097345BF1A3E3_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue_FA8ADC84619656EAB15710FB7C0A953D" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Vested in Period, Weighted Average Grant Date Fair Value</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue_FA8ADC84619656EAB15710FB7C0A953D" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue_FA8ADC84619656EAB15710FB7C0A953D" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue_FA8ADC84619656EAB15710FB7C0A953D" xlink:type="arc" />
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue_6B73D3886F60C3AFB7EE97F89921D29A_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue_392B8C4507B4593EB41F9CD26A70FE44" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Forfeited/cancelled, weighted average grant date fair value (in dollars per share)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue_6B73D3886F60C3AFB7EE97F89921D29A_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue_392B8C4507B4593EB41F9CD26A70FE44" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Forfeitures, Weighted Average Grant Date Fair Value</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue_392B8C4507B4593EB41F9CD26A70FE44" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue_392B8C4507B4593EB41F9CD26A70FE44" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue_392B8C4507B4593EB41F9CD26A70FE44" xlink:type="arc" />
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue_3FCB23957B834B0CCCAA97F4BF00B1CD_periodEndLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue_BA90EACB4E6B5591B95F26D64BEEBB4E" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:type="resource" xml:lang="en-US">Weighted average grant date fair value at end of period (in dollars per share)</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue_BA90EACB4E6B5591B95F26D64BEEBB4E" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue_BA90EACB4E6B5591B95F26D64BEEBB4E" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue_BA90EACB4E6B5591B95F26D64BEEBB4E" xlink:type="arc" />
    <link:label id="lab_us-gaap_CommitmentsAndContingenciesDisclosureAbstract_384F1B73C85F346FB0EC96910A49CED9_label_en-US" xlink:label="lab_us-gaap_CommitmentsAndContingenciesDisclosureAbstract_3CAAB979A6C15B18BFEA263FFC063508" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Commitments and Contingencies Disclosure [Abstract]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_CommitmentsAndContingenciesDisclosureAbstract" xlink:label="loc_us-gaap_CommitmentsAndContingenciesDisclosureAbstract_3CAAB979A6C15B18BFEA263FFC063508" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CommitmentsAndContingenciesDisclosureAbstract_3CAAB979A6C15B18BFEA263FFC063508" xlink:to="lab_us-gaap_CommitmentsAndContingenciesDisclosureAbstract_3CAAB979A6C15B18BFEA263FFC063508" xlink:type="arc" />
    <link:label id="lab_us-gaap_CommitmentsAndContingenciesDisclosureTextBlock_E1EEEDAB2164FC1026B196910A49FBB5_terseLabel_en-US" xlink:label="lab_us-gaap_CommitmentsAndContingenciesDisclosureTextBlock_CD5BC32728A151FA9A5737C19F436341" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Commitments and Contingencies Disclosure</link:label>
    <link:label id="lab_us-gaap_CommitmentsAndContingenciesDisclosureTextBlock_E1EEEDAB2164FC1026B196910A49FBB5_label_en-US" xlink:label="lab_us-gaap_CommitmentsAndContingenciesDisclosureTextBlock_CD5BC32728A151FA9A5737C19F436341" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Commitments and Contingencies Disclosure [Text Block]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_CommitmentsAndContingenciesDisclosureTextBlock" xlink:label="loc_us-gaap_CommitmentsAndContingenciesDisclosureTextBlock_CD5BC32728A151FA9A5737C19F436341" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CommitmentsAndContingenciesDisclosureTextBlock_CD5BC32728A151FA9A5737C19F436341" xlink:to="lab_us-gaap_CommitmentsAndContingenciesDisclosureTextBlock_CD5BC32728A151FA9A5737C19F436341" xlink:type="arc" />
  </link:labelLink>
</link:linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.PRE
<SEQUENCE>10
<FILENAME>nlnk-20170930_pre.xml
<DESCRIPTION>XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE DOCUMENT
<TEXT>
<XBRL>
<?xml version="1.0" encoding="US-ASCII"?>
<!--XBRL Document Created with Wdesk from Workiva-->
<!-- -->
<link:linkbase xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd" xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance">
  <link:roleRef roleURI="http://www.linkp.com/role/BasisOfPresentation" xlink:href="nlnk-20170930.xsd#BasisOfPresentation" xlink:type="simple" />
  <link:roleRef roleURI="http://www.linkp.com/role/CommitmentsAndContingencies" xlink:href="nlnk-20170930.xsd#CommitmentsAndContingencies" xlink:type="simple" />
  <link:roleRef roleURI="http://www.linkp.com/role/CommonStockEquityIncentivePlan" xlink:href="nlnk-20170930.xsd#CommonStockEquityIncentivePlan" xlink:type="simple" />
  <link:roleRef roleURI="http://www.linkp.com/role/CommonStockEquityIncentivePlanAuthorizedIncreasesOfCommonStockDetails" xlink:href="nlnk-20170930.xsd#CommonStockEquityIncentivePlanAuthorizedIncreasesOfCommonStockDetails" xlink:type="simple" />
  <link:roleRef roleURI="http://www.linkp.com/role/CommonStockEquityIncentivePlanNarrativedetails" xlink:href="nlnk-20170930.xsd#CommonStockEquityIncentivePlanNarrativedetails" xlink:type="simple" />
  <link:roleRef roleURI="http://www.linkp.com/role/CommonStockEquityIncentivePlanRangeOfAssumptionsUsedDetails" xlink:href="nlnk-20170930.xsd#CommonStockEquityIncentivePlanRangeOfAssumptionsUsedDetails" xlink:type="simple" />
  <link:roleRef roleURI="http://www.linkp.com/role/CommonStockEquityIncentivePlanRestrictedStockActivityDetails" xlink:href="nlnk-20170930.xsd#CommonStockEquityIncentivePlanRestrictedStockActivityDetails" xlink:type="simple" />
  <link:roleRef roleURI="http://www.linkp.com/role/CommonStockEquityIncentivePlanStockOptionActivityDetails" xlink:href="nlnk-20170930.xsd#CommonStockEquityIncentivePlanStockOptionActivityDetails" xlink:type="simple" />
  <link:roleRef roleURI="http://www.linkp.com/role/CommonStockEquityIncentivePlanTables" xlink:href="nlnk-20170930.xsd#CommonStockEquityIncentivePlanTables" xlink:type="simple" />
  <link:roleRef roleURI="http://www.linkp.com/role/CondensedConsolidatedBalanceSheets" xlink:href="nlnk-20170930.xsd#CondensedConsolidatedBalanceSheets" xlink:type="simple" />
  <link:roleRef roleURI="http://www.linkp.com/role/CondensedConsolidatedBalanceSheetsParentheticals" xlink:href="nlnk-20170930.xsd#CondensedConsolidatedBalanceSheetsParentheticals" xlink:type="simple" />
  <link:roleRef roleURI="http://www.linkp.com/role/CondensedConsolidatedStatementOfStockholdersEquity" xlink:href="nlnk-20170930.xsd#CondensedConsolidatedStatementOfStockholdersEquity" xlink:type="simple" />
  <link:roleRef roleURI="http://www.linkp.com/role/CondensedConsolidatedStatementOfStockholdersEquityParentheticals" xlink:href="nlnk-20170930.xsd#CondensedConsolidatedStatementOfStockholdersEquityParentheticals" xlink:type="simple" />
  <link:roleRef roleURI="http://www.linkp.com/role/CondensedConsolidatedStatementsOfCashFlows" xlink:href="nlnk-20170930.xsd#CondensedConsolidatedStatementsOfCashFlows" xlink:type="simple" />
  <link:roleRef roleURI="http://www.linkp.com/role/CondensedConsolidatedStatementsOfOperations" xlink:href="nlnk-20170930.xsd#CondensedConsolidatedStatementsOfOperations" xlink:type="simple" />
  <link:roleRef roleURI="http://www.linkp.com/role/DescriptionOfBusiness" xlink:href="nlnk-20170930.xsd#DescriptionOfBusiness" xlink:type="simple" />
  <link:roleRef roleURI="http://www.linkp.com/role/DescriptionOfBusinessDetails" xlink:href="nlnk-20170930.xsd#DescriptionOfBusinessDetails" xlink:type="simple" />
  <link:roleRef roleURI="http://www.linkp.com/role/DocumentAndEntityInformation" xlink:href="nlnk-20170930.xsd#DocumentAndEntityInformation" xlink:type="simple" />
  <link:roleRef roleURI="http://www.linkp.com/role/IncomeTaxes" xlink:href="nlnk-20170930.xsd#IncomeTaxes" xlink:type="simple" />
  <link:roleRef roleURI="http://www.linkp.com/role/IncomeTaxesDetails" xlink:href="nlnk-20170930.xsd#IncomeTaxesDetails" xlink:type="simple" />
  <link:roleRef roleURI="http://www.linkp.com/role/LicenseAndResearchCollaborationAgreements" xlink:href="nlnk-20170930.xsd#LicenseAndResearchCollaborationAgreements" xlink:type="simple" />
  <link:roleRef roleURI="http://www.linkp.com/role/LicenseAndResearchCollaborationAgreementsDetails" xlink:href="nlnk-20170930.xsd#LicenseAndResearchCollaborationAgreementsDetails" xlink:type="simple" />
  <link:roleRef roleURI="http://www.linkp.com/role/LongTermDebt" xlink:href="nlnk-20170930.xsd#LongTermDebt" xlink:type="simple" />
  <link:roleRef roleURI="http://www.linkp.com/role/LongTermDebtDetails" xlink:href="nlnk-20170930.xsd#LongTermDebtDetails" xlink:type="simple" />
  <link:roleRef roleURI="http://www.linkp.com/role/NetLossPerCommonShare" xlink:href="nlnk-20170930.xsd#NetLossPerCommonShare" xlink:type="simple" />
  <link:roleRef roleURI="http://www.linkp.com/role/NetLossPerCommonShareAntidilutiveSecuritiesDetails" xlink:href="nlnk-20170930.xsd#NetLossPerCommonShareAntidilutiveSecuritiesDetails" xlink:type="simple" />
  <link:roleRef roleURI="http://www.linkp.com/role/NetLossPerCommonShareNetLossPerShareComputationDetails" xlink:href="nlnk-20170930.xsd#NetLossPerCommonShareNetLossPerShareComputationDetails" xlink:type="simple" />
  <link:roleRef roleURI="http://www.linkp.com/role/NetLossPerCommonShareTables" xlink:href="nlnk-20170930.xsd#NetLossPerCommonShareTables" xlink:type="simple" />
  <link:roleRef roleURI="http://www.linkp.com/role/RestructuringCharges" xlink:href="nlnk-20170930.xsd#RestructuringCharges" xlink:type="simple" />
  <link:roleRef roleURI="http://www.linkp.com/role/RestructuringChargesDetails" xlink:href="nlnk-20170930.xsd#RestructuringChargesDetails" xlink:type="simple" />
  <link:roleRef roleURI="http://www.linkp.com/role/RestructuringChargesTables" xlink:href="nlnk-20170930.xsd#RestructuringChargesTables" xlink:type="simple" />
  <link:roleRef roleURI="http://www.linkp.com/role/SignificantAccountingPolicies" xlink:href="nlnk-20170930.xsd#SignificantAccountingPolicies" xlink:type="simple" />
  <link:roleRef roleURI="http://www.linkp.com/role/SignificantAccountingPoliciesDetails" xlink:href="nlnk-20170930.xsd#SignificantAccountingPoliciesDetails" xlink:type="simple" />
  <link:roleRef roleURI="http://www.linkp.com/role/SignificantAccountingPoliciesPolicies" xlink:href="nlnk-20170930.xsd#SignificantAccountingPoliciesPolicies" xlink:type="simple" />
  <link:roleRef roleURI="http://www.linkp.com/role/SubsequentEvents" xlink:href="nlnk-20170930.xsd#SubsequentEvents" xlink:type="simple" />
  <link:roleRef roleURI="http://www.linkp.com/role/SubsequentEventsDetails" xlink:href="nlnk-20170930.xsd#SubsequentEventsDetails" xlink:type="simple" />
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedLabel" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedLabel" xlink:type="simple" />
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedNetLabel" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedNetLabel" xlink:type="simple" />
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedPeriodEndLabel" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedPeriodEndLabel" xlink:type="simple" />
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedPeriodStartLabel" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedPeriodStartLabel" xlink:type="simple" />
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedTerseLabel" xlink:type="simple" />
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedTotalLabel" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedTotalLabel" xlink:type="simple" />
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/netLabel" xlink:href="http://www.xbrl.org/lrr/role/net-2009-12-16.xsd#netLabel" xlink:type="simple" />
  <link:presentationLink xlink:role="http://www.linkp.com/role/BasisOfPresentation" xlink:type="extended">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:label="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_6D64FB8A518259C99D74192E76426188" xlink:type="locator" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_BasisOfAccounting" xlink:label="loc_us-gaap_BasisOfAccounting_06F913AEDB8C555994F7A0C4D788D753" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_6D64FB8A518259C99D74192E76426188" xlink:to="loc_us-gaap_BasisOfAccounting_06F913AEDB8C555994F7A0C4D788D753" xlink:type="arc" />
  </link:presentationLink>
  <link:presentationLink xlink:role="http://www.linkp.com/role/CommitmentsAndContingencies" xlink:type="extended">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_CommitmentsAndContingenciesDisclosureAbstract" xlink:label="loc_us-gaap_CommitmentsAndContingenciesDisclosureAbstract_3CAAB979A6C15B18BFEA263FFC063508" xlink:type="locator" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_CommitmentsAndContingenciesDisclosureTextBlock" xlink:label="loc_us-gaap_CommitmentsAndContingenciesDisclosureTextBlock_CD5BC32728A151FA9A5737C19F436341" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CommitmentsAndContingenciesDisclosureAbstract_3CAAB979A6C15B18BFEA263FFC063508" xlink:to="loc_us-gaap_CommitmentsAndContingenciesDisclosureTextBlock_CD5BC32728A151FA9A5737C19F436341" xlink:type="arc" />
  </link:presentationLink>
  <link:presentationLink xlink:role="http://www.linkp.com/role/CommonStockEquityIncentivePlan" xlink:type="extended">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:label="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_8246DA47BE2256C8BA252552F6FD235A" xlink:type="locator" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock" xlink:label="loc_us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock_1D438447556E5B47A10DA15579DDD267" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_8246DA47BE2256C8BA252552F6FD235A" xlink:to="loc_us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock_1D438447556E5B47A10DA15579DDD267" xlink:type="arc" />
  </link:presentationLink>
  <link:presentationLink xlink:role="http://www.linkp.com/role/CommonStockEquityIncentivePlanAuthorizedIncreasesOfCommonStockDetails" xlink:type="extended">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:label="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_C00A6A4D90E854AAAE6A67CFB34147FA" xlink:type="locator" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:label="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_AE46112C08B05317BEA9FD046EA42A97" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_C00A6A4D90E854AAAE6A67CFB34147FA" xlink:to="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_AE46112C08B05317BEA9FD046EA42A97" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_PlanNameAxis" xlink:label="loc_us-gaap_PlanNameAxis_EBFE77155E615588A351C925495C8CBF" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_AE46112C08B05317BEA9FD046EA42A97" xlink:to="loc_us-gaap_PlanNameAxis_EBFE77155E615588A351C925495C8CBF" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_PlanNameDomain" xlink:label="loc_us-gaap_PlanNameDomain_789635DA94F950BF8FD4F65780C1E2D4" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PlanNameAxis_EBFE77155E615588A351C925495C8CBF" xlink:to="loc_us-gaap_PlanNameDomain_789635DA94F950BF8FD4F65780C1E2D4" xlink:type="arc" />
    <link:loc xlink:href="nlnk-20170930.xsd#nlnk_A2009EquityIncentivePlanMember" xlink:label="loc_nlnk_A2009EquityIncentivePlanMember_643F40D7B3E952868474542F7E09552A" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PlanNameDomain_789635DA94F950BF8FD4F65780C1E2D4" xlink:to="loc_nlnk_A2009EquityIncentivePlanMember_643F40D7B3E952868474542F7E09552A" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_BD57D44A8EB35363A87DD90AEFAB04E4" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_AE46112C08B05317BEA9FD046EA42A97" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_BD57D44A8EB35363A87DD90AEFAB04E4" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized_00DABD0246BA54CABE35611BC698315B" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_BD57D44A8EB35363A87DD90AEFAB04E4" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized_00DABD0246BA54CABE35611BC698315B" xlink:type="arc" />
  </link:presentationLink>
  <link:presentationLink xlink:role="http://www.linkp.com/role/CommonStockEquityIncentivePlanNarrativedetails" xlink:type="extended">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:label="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_A32D76564BD852C4926ED01DD62B7387" xlink:type="locator" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:label="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_8EB4A68033235F30BC633E562596800E" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_A32D76564BD852C4926ED01DD62B7387" xlink:to="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_8EB4A68033235F30BC633E562596800E" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_RangeAxis" xlink:label="loc_us-gaap_RangeAxis_2CF76EFC15365ED986AA3C735A643FE1" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_8EB4A68033235F30BC633E562596800E" xlink:to="loc_us-gaap_RangeAxis_2CF76EFC15365ED986AA3C735A643FE1" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_RangeMember" xlink:label="loc_us-gaap_RangeMember_E727579565955403B1173F25791039AE" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RangeAxis_2CF76EFC15365ED986AA3C735A643FE1" xlink:to="loc_us-gaap_RangeMember_E727579565955403B1173F25791039AE" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_MinimumMember" xlink:label="loc_us-gaap_MinimumMember_241C544D27D15C93BAA6822A3D1A7FA7" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RangeMember_E727579565955403B1173F25791039AE" xlink:to="loc_us-gaap_MinimumMember_241C544D27D15C93BAA6822A3D1A7FA7" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_MaximumMember" xlink:label="loc_us-gaap_MaximumMember_09DB073D15F7503197824CE3F0CB0A42" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RangeMember_E727579565955403B1173F25791039AE" xlink:to="loc_us-gaap_MaximumMember_09DB073D15F7503197824CE3F0CB0A42" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_AwardTypeAxis" xlink:label="loc_us-gaap_AwardTypeAxis_14616088DCF5552E8005345113BD0031" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_8EB4A68033235F30BC633E562596800E" xlink:to="loc_us-gaap_AwardTypeAxis_14616088DCF5552E8005345113BD0031" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_16CB89BD1AE1571F9EE61D74D8D79315" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AwardTypeAxis_14616088DCF5552E8005345113BD0031" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_16CB89BD1AE1571F9EE61D74D8D79315" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_EmployeeStockOptionMember" xlink:label="loc_us-gaap_EmployeeStockOptionMember_474A2753178A50979192190A1A5507DF" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_16CB89BD1AE1571F9EE61D74D8D79315" xlink:to="loc_us-gaap_EmployeeStockOptionMember_474A2753178A50979192190A1A5507DF" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_PerformanceSharesMember" xlink:label="loc_us-gaap_PerformanceSharesMember_FBAC6F7E45E95C6BBF5BEA0B33361451" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_16CB89BD1AE1571F9EE61D74D8D79315" xlink:to="loc_us-gaap_PerformanceSharesMember_FBAC6F7E45E95C6BBF5BEA0B33361451" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_RestrictedStockMember" xlink:label="loc_us-gaap_RestrictedStockMember_16466D3E6B5B54FEA0EC12D4D177C3D1" xlink:type="locator" />
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_16CB89BD1AE1571F9EE61D74D8D79315" xlink:to="loc_us-gaap_RestrictedStockMember_16466D3E6B5B54FEA0EC12D4D177C3D1" xlink:type="arc" />
    <link:loc xlink:href="nlnk-20170930.xsd#nlnk_PerformanceRestrictedStockMember" xlink:label="loc_nlnk_PerformanceRestrictedStockMember_ACEA61DA39015E9F9411B9A62E9FF1EF" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RestrictedStockMember_16466D3E6B5B54FEA0EC12D4D177C3D1" xlink:to="loc_nlnk_PerformanceRestrictedStockMember_ACEA61DA39015E9F9411B9A62E9FF1EF" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" xlink:label="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_29AC741D549B579FB84E60CAF85BE287" xlink:type="locator" />
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_8EB4A68033235F30BC633E562596800E" xlink:to="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_29AC741D549B579FB84E60CAF85BE287" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_AntidilutiveSecuritiesNameDomain" xlink:label="loc_us-gaap_AntidilutiveSecuritiesNameDomain_FB3A827D7A41590C9489CE87B3919488" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_29AC741D549B579FB84E60CAF85BE287" xlink:to="loc_us-gaap_AntidilutiveSecuritiesNameDomain_FB3A827D7A41590C9489CE87B3919488" xlink:type="arc" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AntidilutiveSecuritiesNameDomain_FB3A827D7A41590C9489CE87B3919488" xlink:to="loc_us-gaap_RestrictedStockMember_16466D3E6B5B54FEA0EC12D4D177C3D1" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_PlanNameAxis" xlink:label="loc_us-gaap_PlanNameAxis_BE64B3B82AA25EFE861205FA479A7375" xlink:type="locator" />
    <link:presentationArc order="4" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_8EB4A68033235F30BC633E562596800E" xlink:to="loc_us-gaap_PlanNameAxis_BE64B3B82AA25EFE861205FA479A7375" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_PlanNameDomain" xlink:label="loc_us-gaap_PlanNameDomain_1A1643A526F1570AB6166F265E50AFA6" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PlanNameAxis_BE64B3B82AA25EFE861205FA479A7375" xlink:to="loc_us-gaap_PlanNameDomain_1A1643A526F1570AB6166F265E50AFA6" xlink:type="arc" />
    <link:loc xlink:href="nlnk-20170930.xsd#nlnk_A2009EquityIncentivePlanMember" xlink:label="loc_nlnk_A2009EquityIncentivePlanMember_1C0561DF08265DFA90BA510F5D6E4173" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PlanNameDomain_1A1643A526F1570AB6166F265E50AFA6" xlink:to="loc_nlnk_A2009EquityIncentivePlanMember_1C0561DF08265DFA90BA510F5D6E4173" xlink:type="arc" />
    <link:loc xlink:href="nlnk-20170930.xsd#nlnk_A2010NonEmployeeDirectorsStockOptionPlanMember" xlink:label="loc_nlnk_A2010NonEmployeeDirectorsStockOptionPlanMember_8316DFB7ECFA544BBDD16CFC4E6CA565" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PlanNameDomain_1A1643A526F1570AB6166F265E50AFA6" xlink:to="loc_nlnk_A2010NonEmployeeDirectorsStockOptionPlanMember_8316DFB7ECFA544BBDD16CFC4E6CA565" xlink:type="arc" />
    <link:loc xlink:href="nlnk-20170930.xsd#nlnk_A2010EmployeeStockPurchasePlanMember" xlink:label="loc_nlnk_A2010EmployeeStockPurchasePlanMember_9340D14C8C5A5DB491E439FD84F489FB" xlink:type="locator" />
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PlanNameDomain_1A1643A526F1570AB6166F265E50AFA6" xlink:to="loc_nlnk_A2010EmployeeStockPurchasePlanMember_9340D14C8C5A5DB491E439FD84F489FB" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_8BA7AAE124125278B85C70980FA793FE" xlink:type="locator" />
    <link:presentationArc order="5" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_8EB4A68033235F30BC633E562596800E" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_8BA7AAE124125278B85C70980FA793FE" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized_DF61E7B696EC5DA28C5432E803AF5AA2" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_8BA7AAE124125278B85C70980FA793FE" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized_DF61E7B696EC5DA28C5432E803AF5AA2" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant_3CFE67E4824F5BB6AF4920AF2B8289F0" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_8BA7AAE124125278B85C70980FA793FE" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant_3CFE67E4824F5BB6AF4920AF2B8289F0" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized_BC12B6483FC15C4C916739B11E0623C0" xlink:type="locator" />
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_8BA7AAE124125278B85C70980FA793FE" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized_BC12B6483FC15C4C916739B11E0623C0" xlink:type="arc" />
    <link:loc xlink:href="nlnk-20170930.xsd#nlnk_SharebasedCompensationArrangementbySharebasedPaymentAwardPercentageofAuthorizedStockMaximum" xlink:label="loc_nlnk_SharebasedCompensationArrangementbySharebasedPaymentAwardPercentageofAuthorizedStockMaximum_5441FBEF66425EA4B5296784C1DF3D6B" xlink:type="locator" />
    <link:presentationArc order="4" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_8BA7AAE124125278B85C70980FA793FE" xlink:to="loc_nlnk_SharebasedCompensationArrangementbySharebasedPaymentAwardPercentageofAuthorizedStockMaximum_5441FBEF66425EA4B5296784C1DF3D6B" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_AllocatedShareBasedCompensationExpense" xlink:label="loc_us-gaap_AllocatedShareBasedCompensationExpense_5943F5B570E75FC7AF703D215682073C" xlink:type="locator" />
    <link:presentationArc order="5" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_8BA7AAE124125278B85C70980FA793FE" xlink:to="loc_us-gaap_AllocatedShareBasedCompensationExpense_5943F5B570E75FC7AF703D215682073C" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions" xlink:label="loc_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions_5C2976759DC2551F9E33D9473F3019FF" xlink:type="locator" />
    <link:presentationArc order="6" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_8BA7AAE124125278B85C70980FA793FE" xlink:to="loc_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions_5C2976759DC2551F9E33D9473F3019FF" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1" xlink:label="loc_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1_3D2A0CB62C265A5597BFF9149316BB38" xlink:type="locator" />
    <link:presentationArc order="7" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_8BA7AAE124125278B85C70980FA793FE" xlink:to="loc_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1_3D2A0CB62C265A5597BFF9149316BB38" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue_2B97B13197C75EF9BF6EE2DCBEEF8563" xlink:type="locator" />
    <link:presentationArc order="8" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_8BA7AAE124125278B85C70980FA793FE" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue_2B97B13197C75EF9BF6EE2DCBEEF8563" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedInPeriodFairValue1" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedInPeriodFairValue1_F8F654A6280F534EB4CAB7702A5BCB62" xlink:type="locator" />
    <link:presentationArc order="9" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_8BA7AAE124125278B85C70980FA793FE" xlink:to="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedInPeriodFairValue1_F8F654A6280F534EB4CAB7702A5BCB62" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod_60D8BAB3559353BF87C58668631C4E9C" xlink:type="locator" />
    <link:presentationArc order="10" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_8BA7AAE124125278B85C70980FA793FE" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod_60D8BAB3559353BF87C58668631C4E9C" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_1B1EA12597975E048309B88020AD8D0C" xlink:type="locator" />
    <link:presentationArc order="11" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_8BA7AAE124125278B85C70980FA793FE" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_1B1EA12597975E048309B88020AD8D0C" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod_9A4F81B9F7105D87AC3EA609BC4E2D23" xlink:type="locator" />
    <link:presentationArc order="12" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_8BA7AAE124125278B85C70980FA793FE" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod_9A4F81B9F7105D87AC3EA609BC4E2D23" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedShareBasedAwardsOtherThanOptions" xlink:label="loc_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedShareBasedAwardsOtherThanOptions_4C60DC9086C454B2A85380BC6E056E39" xlink:type="locator" />
    <link:presentationArc order="13" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_8BA7AAE124125278B85C70980FA793FE" xlink:to="loc_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedShareBasedAwardsOtherThanOptions_4C60DC9086C454B2A85380BC6E056E39" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodTotalFairValue" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodTotalFairValue_502AD5591C475F528B26B6D8CCDFA49E" xlink:type="locator" />
    <link:presentationArc order="14" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_8BA7AAE124125278B85C70980FA793FE" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodTotalFairValue_502AD5591C475F528B26B6D8CCDFA49E" xlink:type="arc" />
  </link:presentationLink>
  <link:presentationLink xlink:role="http://www.linkp.com/role/CommonStockEquityIncentivePlanRangeOfAssumptionsUsedDetails" xlink:type="extended">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:label="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_53AD0D53993E54D08D9511E8A924998B" xlink:type="locator" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:label="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_CAB234055CF95FF0B6F4911C41311CB4" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_53AD0D53993E54D08D9511E8A924998B" xlink:to="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_CAB234055CF95FF0B6F4911C41311CB4" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_AwardTypeAxis" xlink:label="loc_us-gaap_AwardTypeAxis_25E5BC9EF2B65E9DB3D5A4F430FE9FAE" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_CAB234055CF95FF0B6F4911C41311CB4" xlink:to="loc_us-gaap_AwardTypeAxis_25E5BC9EF2B65E9DB3D5A4F430FE9FAE" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_C016D8A23BAA5DC0BDC856CD8D0DB7B8" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AwardTypeAxis_25E5BC9EF2B65E9DB3D5A4F430FE9FAE" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_C016D8A23BAA5DC0BDC856CD8D0DB7B8" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_EmployeeStockOptionMember" xlink:label="loc_us-gaap_EmployeeStockOptionMember_0F6FA055B4DD5C75803656BD9ACA21A3" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_C016D8A23BAA5DC0BDC856CD8D0DB7B8" xlink:to="loc_us-gaap_EmployeeStockOptionMember_0F6FA055B4DD5C75803656BD9ACA21A3" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_RangeAxis" xlink:label="loc_us-gaap_RangeAxis_9BC9036038C253858C682C694986385F" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_CAB234055CF95FF0B6F4911C41311CB4" xlink:to="loc_us-gaap_RangeAxis_9BC9036038C253858C682C694986385F" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_RangeMember" xlink:label="loc_us-gaap_RangeMember_471CF4B3D03B506F81FB185CC3457E7F" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RangeAxis_9BC9036038C253858C682C694986385F" xlink:to="loc_us-gaap_RangeMember_471CF4B3D03B506F81FB185CC3457E7F" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_MinimumMember" xlink:label="loc_us-gaap_MinimumMember_122CEFBD85F4591C84DC961FE5D574EE" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RangeMember_471CF4B3D03B506F81FB185CC3457E7F" xlink:to="loc_us-gaap_MinimumMember_122CEFBD85F4591C84DC961FE5D574EE" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_MaximumMember" xlink:label="loc_us-gaap_MaximumMember_9CBAA569511F5D62923BBDEA436FEAC8" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RangeMember_471CF4B3D03B506F81FB185CC3457E7F" xlink:to="loc_us-gaap_MaximumMember_9CBAA569511F5D62923BBDEA436FEAC8" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_6C85785C522D5C99A60E87BE5131238E" xlink:type="locator" />
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_CAB234055CF95FF0B6F4911C41311CB4" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_6C85785C522D5C99A60E87BE5131238E" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum_EE315B2ACBB35FB6B9284F622A6ADA1B" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_6C85785C522D5C99A60E87BE5131238E" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum_EE315B2ACBB35FB6B9284F622A6ADA1B" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum_98C39F2CBE82565A9786981751F099A7" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_6C85785C522D5C99A60E87BE5131238E" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum_98C39F2CBE82565A9786981751F099A7" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate_EC07A97A868B54B0B2CF401D08CDA527" xlink:type="locator" />
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_6C85785C522D5C99A60E87BE5131238E" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate_EC07A97A868B54B0B2CF401D08CDA527" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum_2328ED8116185FAB8ACB192B6A85568E" xlink:type="locator" />
    <link:presentationArc order="4" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_6C85785C522D5C99A60E87BE5131238E" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum_2328ED8116185FAB8ACB192B6A85568E" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum_192F5410FE775BEEA017387549AF8EF5" xlink:type="locator" />
    <link:presentationArc order="5" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_6C85785C522D5C99A60E87BE5131238E" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum_192F5410FE775BEEA017387549AF8EF5" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1_9D960C7C28185E358D96D0E77417A543" xlink:type="locator" />
    <link:presentationArc order="6" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_6C85785C522D5C99A60E87BE5131238E" xlink:to="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1_9D960C7C28185E358D96D0E77417A543" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_2A6480D9D164506BB6321FB4BB9AC1BC" xlink:type="locator" />
    <link:presentationArc order="7" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_6C85785C522D5C99A60E87BE5131238E" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_2A6480D9D164506BB6321FB4BB9AC1BC" xlink:type="arc" />
  </link:presentationLink>
  <link:presentationLink xlink:role="http://www.linkp.com/role/CommonStockEquityIncentivePlanRestrictedStockActivityDetails" xlink:type="extended">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:label="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_373BD46EDD365340BD476BF87162CD5C" xlink:type="locator" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:label="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_6CECF4DD604D5D51B1D4A1A92165941C" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_373BD46EDD365340BD476BF87162CD5C" xlink:to="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_6CECF4DD604D5D51B1D4A1A92165941C" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_AwardTypeAxis" xlink:label="loc_us-gaap_AwardTypeAxis_1B9231DC3A5454DBA6791B3D37C71266" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_6CECF4DD604D5D51B1D4A1A92165941C" xlink:to="loc_us-gaap_AwardTypeAxis_1B9231DC3A5454DBA6791B3D37C71266" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_6A1149278AA651B985A23FF12002C3B8" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AwardTypeAxis_1B9231DC3A5454DBA6791B3D37C71266" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_6A1149278AA651B985A23FF12002C3B8" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_RestrictedStockMember" xlink:label="loc_us-gaap_RestrictedStockMember_E0FB707EF39550E3AA538F2AE3528446" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_6A1149278AA651B985A23FF12002C3B8" xlink:to="loc_us-gaap_RestrictedStockMember_E0FB707EF39550E3AA538F2AE3528446" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_F432975837BB52D0835D69DBE9C40D82" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_6CECF4DD604D5D51B1D4A1A92165941C" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_F432975837BB52D0835D69DBE9C40D82" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingRollForward" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingRollForward_72AEA9B235095EB0A403C6F59F644DF8" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_F432975837BB52D0835D69DBE9C40D82" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingRollForward_72AEA9B235095EB0A403C6F59F644DF8" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_AFB92A8EBA6254EAA0E7FC24F649D36E" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingRollForward_72AEA9B235095EB0A403C6F59F644DF8" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_AFB92A8EBA6254EAA0E7FC24F649D36E" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod_D7B8138FC9D75FFF9D235BD6B7DA2EFB" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingRollForward_72AEA9B235095EB0A403C6F59F644DF8" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod_D7B8138FC9D75FFF9D235BD6B7DA2EFB" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod_FB0C88639806552980DDCBBE93B9A8D4" xlink:type="locator" />
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingRollForward_72AEA9B235095EB0A403C6F59F644DF8" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod_FB0C88639806552980DDCBBE93B9A8D4" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod_364EF90C57A1551DA869217A78B291AF" xlink:type="locator" />
    <link:presentationArc order="4" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingRollForward_72AEA9B235095EB0A403C6F59F644DF8" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod_364EF90C57A1551DA869217A78B291AF" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_F58CB22BDE7F564FA8B364E76453BD85" xlink:type="locator" />
    <link:presentationArc order="5" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingRollForward_72AEA9B235095EB0A403C6F59F644DF8" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_F58CB22BDE7F564FA8B364E76453BD85" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedWeightedAverageGrantDateFairValueAbstract" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedWeightedAverageGrantDateFairValueAbstract_B01EF4E8CCEB5374BCB7A8A102E060DE" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_F432975837BB52D0835D69DBE9C40D82" xlink:to="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedWeightedAverageGrantDateFairValueAbstract_B01EF4E8CCEB5374BCB7A8A102E060DE" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue_091B08B741F759328D394BBC0F68BDA2" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedWeightedAverageGrantDateFairValueAbstract_B01EF4E8CCEB5374BCB7A8A102E060DE" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue_091B08B741F759328D394BBC0F68BDA2" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_009AC2765C7A50398882BF29F8C01091" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedWeightedAverageGrantDateFairValueAbstract_B01EF4E8CCEB5374BCB7A8A102E060DE" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_009AC2765C7A50398882BF29F8C01091" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue_FA8ADC84619656EAB15710FB7C0A953D" xlink:type="locator" />
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedWeightedAverageGrantDateFairValueAbstract_B01EF4E8CCEB5374BCB7A8A102E060DE" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue_FA8ADC84619656EAB15710FB7C0A953D" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue_392B8C4507B4593EB41F9CD26A70FE44" xlink:type="locator" />
    <link:presentationArc order="4" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedWeightedAverageGrantDateFairValueAbstract_B01EF4E8CCEB5374BCB7A8A102E060DE" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue_392B8C4507B4593EB41F9CD26A70FE44" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue_BA90EACB4E6B5591B95F26D64BEEBB4E" xlink:type="locator" />
    <link:presentationArc order="5" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedWeightedAverageGrantDateFairValueAbstract_B01EF4E8CCEB5374BCB7A8A102E060DE" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue_BA90EACB4E6B5591B95F26D64BEEBB4E" xlink:type="arc" />
  </link:presentationLink>
  <link:presentationLink xlink:role="http://www.linkp.com/role/CommonStockEquityIncentivePlanStockOptionActivityDetails" xlink:type="extended">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:label="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_86E3BB4E0CF657E0981B25794403FD7B" xlink:type="locator" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:label="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_8D9E49EBB05459349DDF85F4CC108AFD" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_86E3BB4E0CF657E0981B25794403FD7B" xlink:to="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_8D9E49EBB05459349DDF85F4CC108AFD" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_AwardTypeAxis" xlink:label="loc_us-gaap_AwardTypeAxis_43B8E6C35CA15A5E9E3F2BF2A5BF574B" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_8D9E49EBB05459349DDF85F4CC108AFD" xlink:to="loc_us-gaap_AwardTypeAxis_43B8E6C35CA15A5E9E3F2BF2A5BF574B" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_C4494F8A63095AF99B0E3C65BC26A74E" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AwardTypeAxis_43B8E6C35CA15A5E9E3F2BF2A5BF574B" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_C4494F8A63095AF99B0E3C65BC26A74E" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_EmployeeStockOptionMember" xlink:label="loc_us-gaap_EmployeeStockOptionMember_838AF05112995375A31F6E9E88E01A2B" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_C4494F8A63095AF99B0E3C65BC26A74E" xlink:to="loc_us-gaap_EmployeeStockOptionMember_838AF05112995375A31F6E9E88E01A2B" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_D224ACC33B23520BBEB54045E0A7ABD4" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_8D9E49EBB05459349DDF85F4CC108AFD" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_D224ACC33B23520BBEB54045E0A7ABD4" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward_65338224DBBB51D4AFB0D6B08E095160" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_D224ACC33B23520BBEB54045E0A7ABD4" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward_65338224DBBB51D4AFB0D6B08E095160" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_BB11D9EA42DA58A195EBBEF3370874F5" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward_65338224DBBB51D4AFB0D6B08E095160" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_BB11D9EA42DA58A195EBBEF3370874F5" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_C86A957E8B4C5BA080F103F08ABDC331" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward_65338224DBBB51D4AFB0D6B08E095160" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_C86A957E8B4C5BA080F103F08ABDC331" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" xlink:label="loc_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised_96C8A0EE63E75C3ABB6F5240DE52DC18" xlink:type="locator" />
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward_65338224DBBB51D4AFB0D6B08E095160" xlink:to="loc_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised_96C8A0EE63E75C3ABB6F5240DE52DC18" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod_B479A49C7AFD59B4A65B3ED00D3639A3" xlink:type="locator" />
    <link:presentationArc order="4" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward_65338224DBBB51D4AFB0D6B08E095160" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod_B479A49C7AFD59B4A65B3ED00D3639A3" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod_C67DDB2E9E655890A79ABB80FB2BCA82" xlink:type="locator" />
    <link:presentationArc order="5" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward_65338224DBBB51D4AFB0D6B08E095160" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod_C67DDB2E9E655890A79ABB80FB2BCA82" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_9B028F9E83DF55D49E4FA86262556E15" xlink:type="locator" />
    <link:presentationArc order="6" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward_65338224DBBB51D4AFB0D6B08E095160" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_9B028F9E83DF55D49E4FA86262556E15" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward_8EF750B40922514EACDF511A9B240780" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_D224ACC33B23520BBEB54045E0A7ABD4" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward_8EF750B40922514EACDF511A9B240780" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_4CFC98D33F7D50A99840B1C2489CE1B0" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward_8EF750B40922514EACDF511A9B240780" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_4CFC98D33F7D50A99840B1C2489CE1B0" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice_46D736B27A9E578C8B6EE41D6D5AF52B" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward_8EF750B40922514EACDF511A9B240780" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice_46D736B27A9E578C8B6EE41D6D5AF52B" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice_0B5EECDB8FBD5CF5844BC31A234F31AC" xlink:type="locator" />
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward_8EF750B40922514EACDF511A9B240780" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice_0B5EECDB8FBD5CF5844BC31A234F31AC" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice_E51C7ECB30145C41B474CE2AA8268834" xlink:type="locator" />
    <link:presentationArc order="4" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward_8EF750B40922514EACDF511A9B240780" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice_E51C7ECB30145C41B474CE2AA8268834" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExpirationsInPeriodWeightedAverageExercisePrice" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExpirationsInPeriodWeightedAverageExercisePrice_85C3CE593FE755628A8AFD1E2EC4E05F" xlink:type="locator" />
    <link:presentationArc order="5" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward_8EF750B40922514EACDF511A9B240780" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExpirationsInPeriodWeightedAverageExercisePrice_85C3CE593FE755628A8AFD1E2EC4E05F" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_FAFFCBBCDF8F5C23A23CA4DB001BF336" xlink:type="locator" />
    <link:presentationArc order="6" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward_8EF750B40922514EACDF511A9B240780" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_FAFFCBBCDF8F5C23A23CA4DB001BF336" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber_813EFE60F729591AA7F24294BDE91C58" xlink:type="locator" />
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_D224ACC33B23520BBEB54045E0A7ABD4" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber_813EFE60F729591AA7F24294BDE91C58" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice_F5F6C312611456C595460099BDBF027B" xlink:type="locator" />
    <link:presentationArc order="4" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_D224ACC33B23520BBEB54045E0A7ABD4" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice_F5F6C312611456C595460099BDBF027B" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2_99C7E5802F7159419748EEAACBAC6C4A" xlink:type="locator" />
    <link:presentationArc order="5" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_D224ACC33B23520BBEB54045E0A7ABD4" xlink:to="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2_99C7E5802F7159419748EEAACBAC6C4A" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1_F18C5856B0DD5891B7DE3D37BBA69D5B" xlink:type="locator" />
    <link:presentationArc order="6" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_D224ACC33B23520BBEB54045E0A7ABD4" xlink:to="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1_F18C5856B0DD5891B7DE3D37BBA69D5B" xlink:type="arc" />
  </link:presentationLink>
  <link:presentationLink xlink:role="http://www.linkp.com/role/CommonStockEquityIncentivePlanTables" xlink:type="extended">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:label="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_D063A8E6A25B5DFDAA639CEAF1F0BBF0" xlink:type="locator" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_DisclosureOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTextBlock" xlink:label="loc_us-gaap_DisclosureOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTextBlock_C420B59D209655349AE8308CDA77C647" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_D063A8E6A25B5DFDAA639CEAF1F0BBF0" xlink:to="loc_us-gaap_DisclosureOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTextBlock_C420B59D209655349AE8308CDA77C647" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ScheduleOfStockOptionsRollForwardTableTextBlock" xlink:label="loc_us-gaap_ScheduleOfStockOptionsRollForwardTableTextBlock_4299C848FE5F5B60A71E7AE6B8831ED0" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_D063A8E6A25B5DFDAA639CEAF1F0BBF0" xlink:to="loc_us-gaap_ScheduleOfStockOptionsRollForwardTableTextBlock_4299C848FE5F5B60A71E7AE6B8831ED0" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock" xlink:label="loc_us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock_974493EB9ED55BD19042F39CE5D1F433" xlink:type="locator" />
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_D063A8E6A25B5DFDAA639CEAF1F0BBF0" xlink:to="loc_us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock_974493EB9ED55BD19042F39CE5D1F433" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_NonvestedRestrictedStockSharesActivityTableTextBlock" xlink:label="loc_us-gaap_NonvestedRestrictedStockSharesActivityTableTextBlock_3011577DC7865FF3B00861789E683B4A" xlink:type="locator" />
    <link:presentationArc order="4" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_D063A8E6A25B5DFDAA639CEAF1F0BBF0" xlink:to="loc_us-gaap_NonvestedRestrictedStockSharesActivityTableTextBlock_3011577DC7865FF3B00861789E683B4A" xlink:type="arc" />
  </link:presentationLink>
  <link:presentationLink xlink:role="http://www.linkp.com/role/CondensedConsolidatedBalanceSheets" xlink:type="extended">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_StatementOfFinancialPositionAbstract" xlink:label="loc_us-gaap_StatementOfFinancialPositionAbstract_EDCD9394F712C4091D06508823216A98" xlink:type="locator" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_AssetsAbstract" xlink:label="loc_us-gaap_AssetsAbstract_460F2AE0317981CA449B50882321417F" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfFinancialPositionAbstract_EDCD9394F712C4091D06508823216A98" xlink:to="loc_us-gaap_AssetsAbstract_460F2AE0317981CA449B50882321417F" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_AssetsCurrentAbstract" xlink:label="loc_us-gaap_AssetsCurrentAbstract_B69038967F1F477A4803508823214798" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsAbstract_460F2AE0317981CA449B50882321417F" xlink:to="loc_us-gaap_AssetsCurrentAbstract_B69038967F1F477A4803508823214798" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:label="loc_us-gaap_CashAndCashEquivalentsAtCarryingValue_A173258E08EF643B25B4508823211DD4" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsCurrentAbstract_B69038967F1F477A4803508823214798" xlink:to="loc_us-gaap_CashAndCashEquivalentsAtCarryingValue_A173258E08EF643B25B4508823211DD4" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_PrepaidExpenseAndOtherAssetsCurrent" xlink:label="loc_us-gaap_PrepaidExpenseAndOtherAssetsCurrent_B247C03B9948CBB28BA7508823212D46" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsCurrentAbstract_B69038967F1F477A4803508823214798" xlink:to="loc_us-gaap_PrepaidExpenseAndOtherAssetsCurrent_B247C03B9948CBB28BA7508823212D46" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_IncomeTaxesReceivable" xlink:label="loc_us-gaap_IncomeTaxesReceivable_A2CF0DAC66F13AE1898F5088232126FB" xlink:type="locator" />
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsCurrentAbstract_B69038967F1F477A4803508823214798" xlink:to="loc_us-gaap_IncomeTaxesReceivable_A2CF0DAC66F13AE1898F5088232126FB" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_OtherReceivablesNetCurrent" xlink:label="loc_us-gaap_OtherReceivablesNetCurrent_C60D5041673E449A0AC750882321190E" xlink:type="locator" />
    <link:presentationArc order="4" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsCurrentAbstract_B69038967F1F477A4803508823214798" xlink:to="loc_us-gaap_OtherReceivablesNetCurrent_C60D5041673E449A0AC750882321190E" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_AssetsCurrent" xlink:label="loc_us-gaap_AssetsCurrent_F5C17A8FB4B6AC93D992508823219BE2" xlink:type="locator" />
    <link:presentationArc order="5" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsCurrentAbstract_B69038967F1F477A4803508823214798" xlink:to="loc_us-gaap_AssetsCurrent_F5C17A8FB4B6AC93D992508823219BE2" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_PropertyPlantAndEquipmentNet" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentNet_5917309B9149AC17478350882322A8D9" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsAbstract_460F2AE0317981CA449B50882321417F" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentNet_5917309B9149AC17478350882322A8D9" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_Assets" xlink:label="loc_us-gaap_Assets_74641FA962A0C86C32E950882322AEBB" xlink:type="locator" />
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsAbstract_460F2AE0317981CA449B50882321417F" xlink:to="loc_us-gaap_Assets_74641FA962A0C86C32E950882322AEBB" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_LiabilitiesAbstract" xlink:label="loc_us-gaap_LiabilitiesAbstract_9EDF9C519C7F58646E5B508823225ED5" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfFinancialPositionAbstract_EDCD9394F712C4091D06508823216A98" xlink:to="loc_us-gaap_LiabilitiesAbstract_9EDF9C519C7F58646E5B508823225ED5" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_LiabilitiesCurrentAbstract" xlink:label="loc_us-gaap_LiabilitiesCurrentAbstract_173745AF1597481B09E6508823227212" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesAbstract_9EDF9C519C7F58646E5B508823225ED5" xlink:to="loc_us-gaap_LiabilitiesCurrentAbstract_173745AF1597481B09E6508823227212" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_AccountsPayableCurrent" xlink:label="loc_us-gaap_AccountsPayableCurrent_2A473EDE82D802AFED1E508823221F04" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesCurrentAbstract_173745AF1597481B09E6508823227212" xlink:to="loc_us-gaap_AccountsPayableCurrent_2A473EDE82D802AFED1E508823221F04" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_AccruedLiabilitiesCurrent" xlink:label="loc_us-gaap_AccruedLiabilitiesCurrent_253A11F0974886850F7E5088232284E2" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesCurrentAbstract_173745AF1597481B09E6508823227212" xlink:to="loc_us-gaap_AccruedLiabilitiesCurrent_253A11F0974886850F7E5088232284E2" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_DeferredRevenueCurrent" xlink:label="loc_us-gaap_DeferredRevenueCurrent_7610914EA17236198565508823229BDE" xlink:type="locator" />
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesCurrentAbstract_173745AF1597481B09E6508823227212" xlink:to="loc_us-gaap_DeferredRevenueCurrent_7610914EA17236198565508823229BDE" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_DeferredRentCreditCurrent" xlink:label="loc_us-gaap_DeferredRentCreditCurrent_E44BE7FEFB1FD492D70C50882322F73D" xlink:type="locator" />
    <link:presentationArc order="4" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesCurrentAbstract_173745AF1597481B09E6508823227212" xlink:to="loc_us-gaap_DeferredRentCreditCurrent_E44BE7FEFB1FD492D70C50882322F73D" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_LongTermDebtAndCapitalLeaseObligationsCurrent" xlink:label="loc_us-gaap_LongTermDebtAndCapitalLeaseObligationsCurrent_907E86C8537258494391508823222AF5" xlink:type="locator" />
    <link:presentationArc order="5" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesCurrentAbstract_173745AF1597481B09E6508823227212" xlink:to="loc_us-gaap_LongTermDebtAndCapitalLeaseObligationsCurrent_907E86C8537258494391508823222AF5" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_LiabilitiesCurrent" xlink:label="loc_us-gaap_LiabilitiesCurrent_B9F02418CFE39FB23F2B50882322AA4E" xlink:type="locator" />
    <link:presentationArc order="6" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesCurrentAbstract_173745AF1597481B09E6508823227212" xlink:to="loc_us-gaap_LiabilitiesCurrent_B9F02418CFE39FB23F2B50882322AA4E" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_LiabilitiesNoncurrentAbstract" xlink:label="loc_us-gaap_LiabilitiesNoncurrentAbstract_0942FD131675E13190B35088232217C1" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesAbstract_9EDF9C519C7F58646E5B508823225ED5" xlink:to="loc_us-gaap_LiabilitiesNoncurrentAbstract_0942FD131675E13190B35088232217C1" xlink:type="arc" />
    <link:loc xlink:href="nlnk-20170930.xsd#nlnk_DeferredGovernmentGrantsObligationsNoncurrent" xlink:label="loc_nlnk_DeferredGovernmentGrantsObligationsNoncurrent_9604D694F70C50C2CED950882322EDD8" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesNoncurrentAbstract_0942FD131675E13190B35088232217C1" xlink:to="loc_nlnk_DeferredGovernmentGrantsObligationsNoncurrent_9604D694F70C50C2CED950882322EDD8" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_LongTermDebtAndCapitalLeaseObligations" xlink:label="loc_us-gaap_LongTermDebtAndCapitalLeaseObligations_0F5C2BB6ADC32ED0E36F508823220792" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesNoncurrentAbstract_0942FD131675E13190B35088232217C1" xlink:to="loc_us-gaap_LongTermDebtAndCapitalLeaseObligations_0F5C2BB6ADC32ED0E36F508823220792" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_DeferredRentCreditNoncurrent" xlink:label="loc_us-gaap_DeferredRentCreditNoncurrent_A94A3158A0551C842965508823229064" xlink:type="locator" />
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesNoncurrentAbstract_0942FD131675E13190B35088232217C1" xlink:to="loc_us-gaap_DeferredRentCreditNoncurrent_A94A3158A0551C842965508823229064" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_LiabilitiesNoncurrent" xlink:label="loc_us-gaap_LiabilitiesNoncurrent_F216AD83834B55FFFC9350882322FA78" xlink:type="locator" />
    <link:presentationArc order="4" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesNoncurrentAbstract_0942FD131675E13190B35088232217C1" xlink:to="loc_us-gaap_LiabilitiesNoncurrent_F216AD83834B55FFFC9350882322FA78" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_Liabilities" xlink:label="loc_us-gaap_Liabilities_7BC0EB245E2C67755E6B5088232250C5" xlink:type="locator" />
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesAbstract_9EDF9C519C7F58646E5B508823225ED5" xlink:to="loc_us-gaap_Liabilities_7BC0EB245E2C67755E6B5088232250C5" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_EquityAbstract" xlink:label="loc_us-gaap_EquityAbstract_73A3F29DF52C8047898550882322BD9A" xlink:type="locator" />
    <link:presentationArc order="4" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesAbstract_9EDF9C519C7F58646E5B508823225ED5" xlink:to="loc_us-gaap_EquityAbstract_73A3F29DF52C8047898550882322BD9A" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_PreferredStockValueOutstanding" xlink:label="loc_us-gaap_PreferredStockValueOutstanding_A6BFEF4F6FDCAE5E7824508823235F03" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EquityAbstract_73A3F29DF52C8047898550882322BD9A" xlink:to="loc_us-gaap_PreferredStockValueOutstanding_A6BFEF4F6FDCAE5E7824508823235F03" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_CommonStockValueOutstanding" xlink:label="loc_us-gaap_CommonStockValueOutstanding_9324E3E3F0CFE0FC81FC50882323D8BB" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EquityAbstract_73A3F29DF52C8047898550882322BD9A" xlink:to="loc_us-gaap_CommonStockValueOutstanding_9324E3E3F0CFE0FC81FC50882323D8BB" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_AdditionalPaidInCapital" xlink:label="loc_us-gaap_AdditionalPaidInCapital_4D50F6E039131E5F427F50882323B2EA" xlink:type="locator" />
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EquityAbstract_73A3F29DF52C8047898550882322BD9A" xlink:to="loc_us-gaap_AdditionalPaidInCapital_4D50F6E039131E5F427F50882323B2EA" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_TreasuryStockValue" xlink:label="loc_us-gaap_TreasuryStockValue_6D65A848D74E380E20CF508823236F62" xlink:type="locator" />
    <link:presentationArc order="4" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EquityAbstract_73A3F29DF52C8047898550882322BD9A" xlink:to="loc_us-gaap_TreasuryStockValue_6D65A848D74E380E20CF508823236F62" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_RetainedEarningsAccumulatedDeficit" xlink:label="loc_us-gaap_RetainedEarningsAccumulatedDeficit_4519AC02085CACFE2C46508823231A2A" xlink:type="locator" />
    <link:presentationArc order="5" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EquityAbstract_73A3F29DF52C8047898550882322BD9A" xlink:to="loc_us-gaap_RetainedEarningsAccumulatedDeficit_4519AC02085CACFE2C46508823231A2A" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_StockholdersEquity" xlink:label="loc_us-gaap_StockholdersEquity_0AC362DD59B547E16DFC508823237DBC" xlink:type="locator" />
    <link:presentationArc order="6" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EquityAbstract_73A3F29DF52C8047898550882322BD9A" xlink:to="loc_us-gaap_StockholdersEquity_0AC362DD59B547E16DFC508823237DBC" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_LiabilitiesAndStockholdersEquity" xlink:label="loc_us-gaap_LiabilitiesAndStockholdersEquity_E6E090665F01350ECE18508823230F27" xlink:type="locator" />
    <link:presentationArc order="5" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesAbstract_9EDF9C519C7F58646E5B508823225ED5" xlink:to="loc_us-gaap_LiabilitiesAndStockholdersEquity_E6E090665F01350ECE18508823230F27" xlink:type="arc" />
  </link:presentationLink>
  <link:presentationLink xlink:role="http://www.linkp.com/role/CondensedConsolidatedBalanceSheetsParentheticals" xlink:type="extended">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_StatementOfFinancialPositionAbstract" xlink:label="loc_us-gaap_StatementOfFinancialPositionAbstract_7B03DC2BBED5DDD1CD025088231C776D" xlink:type="locator" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_StockholdersEquityNumberOfSharesParValueAndOtherDisclosuresAbstract" xlink:label="loc_us-gaap_StockholdersEquityNumberOfSharesParValueAndOtherDisclosuresAbstract_77E65BA0BDED9C8C63F15088231C9931" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfFinancialPositionAbstract_7B03DC2BBED5DDD1CD025088231C776D" xlink:to="loc_us-gaap_StockholdersEquityNumberOfSharesParValueAndOtherDisclosuresAbstract_77E65BA0BDED9C8C63F15088231C9931" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_PreferredStockParOrStatedValuePerShare" xlink:label="loc_us-gaap_PreferredStockParOrStatedValuePerShare_2876EC28E4D01B6538565088231DB37E" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StockholdersEquityNumberOfSharesParValueAndOtherDisclosuresAbstract_77E65BA0BDED9C8C63F15088231C9931" xlink:to="loc_us-gaap_PreferredStockParOrStatedValuePerShare_2876EC28E4D01B6538565088231DB37E" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_PreferredStockSharesAuthorized" xlink:label="loc_us-gaap_PreferredStockSharesAuthorized_79B720F570F07964F2905088231DE4A5" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StockholdersEquityNumberOfSharesParValueAndOtherDisclosuresAbstract_77E65BA0BDED9C8C63F15088231C9931" xlink:to="loc_us-gaap_PreferredStockSharesAuthorized_79B720F570F07964F2905088231DE4A5" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_PreferredStockSharesIssued" xlink:label="loc_us-gaap_PreferredStockSharesIssued_01AEFA3E5595975E60715088231D68C4" xlink:type="locator" />
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StockholdersEquityNumberOfSharesParValueAndOtherDisclosuresAbstract_77E65BA0BDED9C8C63F15088231C9931" xlink:to="loc_us-gaap_PreferredStockSharesIssued_01AEFA3E5595975E60715088231D68C4" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_PreferredStockSharesOutstanding" xlink:label="loc_us-gaap_PreferredStockSharesOutstanding_CE90A44D0B5A649BF2965088231DD5B1" xlink:type="locator" />
    <link:presentationArc order="4" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StockholdersEquityNumberOfSharesParValueAndOtherDisclosuresAbstract_77E65BA0BDED9C8C63F15088231C9931" xlink:to="loc_us-gaap_PreferredStockSharesOutstanding_CE90A44D0B5A649BF2965088231DD5B1" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_CommonStockParOrStatedValuePerShare" xlink:label="loc_us-gaap_CommonStockParOrStatedValuePerShare_5CAF9CC29EA4AA953B005088231DE494" xlink:type="locator" />
    <link:presentationArc order="5" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StockholdersEquityNumberOfSharesParValueAndOtherDisclosuresAbstract_77E65BA0BDED9C8C63F15088231C9931" xlink:to="loc_us-gaap_CommonStockParOrStatedValuePerShare_5CAF9CC29EA4AA953B005088231DE494" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_CommonStockSharesAuthorized" xlink:label="loc_us-gaap_CommonStockSharesAuthorized_B3E8AF3A50521678CF785088231D0BC3" xlink:type="locator" />
    <link:presentationArc order="6" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StockholdersEquityNumberOfSharesParValueAndOtherDisclosuresAbstract_77E65BA0BDED9C8C63F15088231C9931" xlink:to="loc_us-gaap_CommonStockSharesAuthorized_B3E8AF3A50521678CF785088231D0BC3" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_CommonStockSharesIssued" xlink:label="loc_us-gaap_CommonStockSharesIssued_5CFE5A0D3364C948DAB45088231D9CED" xlink:type="locator" />
    <link:presentationArc order="7" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StockholdersEquityNumberOfSharesParValueAndOtherDisclosuresAbstract_77E65BA0BDED9C8C63F15088231C9931" xlink:to="loc_us-gaap_CommonStockSharesIssued_5CFE5A0D3364C948DAB45088231D9CED" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_CommonStockSharesOutstanding" xlink:label="loc_us-gaap_CommonStockSharesOutstanding_8930DD0A3740A285F0EF5088231D3669" xlink:type="locator" />
    <link:presentationArc order="8" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StockholdersEquityNumberOfSharesParValueAndOtherDisclosuresAbstract_77E65BA0BDED9C8C63F15088231C9931" xlink:to="loc_us-gaap_CommonStockSharesOutstanding_8930DD0A3740A285F0EF5088231D3669" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_TreasuryStockShares" xlink:label="loc_us-gaap_TreasuryStockShares_9D4A614CE4C3595BDB755088231D833D" xlink:type="locator" />
    <link:presentationArc order="9" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StockholdersEquityNumberOfSharesParValueAndOtherDisclosuresAbstract_77E65BA0BDED9C8C63F15088231C9931" xlink:to="loc_us-gaap_TreasuryStockShares_9D4A614CE4C3595BDB755088231D833D" xlink:type="arc" />
  </link:presentationLink>
  <link:presentationLink xlink:role="http://www.linkp.com/role/CondensedConsolidatedStatementOfStockholdersEquity" xlink:type="extended">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_StatementOfStockholdersEquityAbstract" xlink:label="loc_us-gaap_StatementOfStockholdersEquityAbstract_AF3193727B55289554247D80DFD7F218" xlink:type="locator" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_StatementTable" xlink:label="loc_us-gaap_StatementTable_DF70F78C9F32839EBB697D80DFD74CBF" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfStockholdersEquityAbstract_AF3193727B55289554247D80DFD7F218" xlink:to="loc_us-gaap_StatementTable_DF70F78C9F32839EBB697D80DFD74CBF" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_StatementEquityComponentsAxis" xlink:label="loc_us-gaap_StatementEquityComponentsAxis_5A7CF8B2BF4212DE62257D80DFD7E990" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementTable_DF70F78C9F32839EBB697D80DFD74CBF" xlink:to="loc_us-gaap_StatementEquityComponentsAxis_5A7CF8B2BF4212DE62257D80DFD7E990" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_EquityComponentDomain" xlink:label="loc_us-gaap_EquityComponentDomain_914537A5DB82F7229E917D80DFD7AA70" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementEquityComponentsAxis_5A7CF8B2BF4212DE62257D80DFD7E990" xlink:to="loc_us-gaap_EquityComponentDomain_914537A5DB82F7229E917D80DFD7AA70" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_CommonStockMember" xlink:label="loc_us-gaap_CommonStockMember_920BE3831F05ECD13C217D80DFD82831" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EquityComponentDomain_914537A5DB82F7229E917D80DFD7AA70" xlink:to="loc_us-gaap_CommonStockMember_920BE3831F05ECD13C217D80DFD82831" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_AdditionalPaidInCapitalMember" xlink:label="loc_us-gaap_AdditionalPaidInCapitalMember_128F5D547E68BE0BDD137D80DFD83F9E" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EquityComponentDomain_914537A5DB82F7229E917D80DFD7AA70" xlink:to="loc_us-gaap_AdditionalPaidInCapitalMember_128F5D547E68BE0BDD137D80DFD83F9E" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_TreasuryStockMember" xlink:label="loc_us-gaap_TreasuryStockMember_60E7CA8F463F3BBAB2E87D80DFD9FB76" xlink:type="locator" />
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EquityComponentDomain_914537A5DB82F7229E917D80DFD7AA70" xlink:to="loc_us-gaap_TreasuryStockMember_60E7CA8F463F3BBAB2E87D80DFD9FB76" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_RetainedEarningsMember" xlink:label="loc_us-gaap_RetainedEarningsMember_B02D6D383A05E52B64A77D80DFD97984" xlink:type="locator" />
    <link:presentationArc order="4" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EquityComponentDomain_914537A5DB82F7229E917D80DFD7AA70" xlink:to="loc_us-gaap_RetainedEarningsMember_B02D6D383A05E52B64A77D80DFD97984" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_StatementLineItems" xlink:label="loc_us-gaap_StatementLineItems_C21B50291753FE636D267D80DFD9ED37" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementTable_DF70F78C9F32839EBB697D80DFD74CBF" xlink:to="loc_us-gaap_StatementLineItems_C21B50291753FE636D267D80DFD9ED37" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_IncreaseDecreaseInStockholdersEquityRollForward" xlink:label="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_C7EB8218872E635D2D8D7D80DFD9986F" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_C21B50291753FE636D267D80DFD9ED37" xlink:to="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_C7EB8218872E635D2D8D7D80DFD9986F" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_StockholdersEquity" xlink:label="loc_us-gaap_StockholdersEquity_25E5FC84ECA92E4D26517D80DFD92A6D" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_C7EB8218872E635D2D8D7D80DFD9986F" xlink:to="loc_us-gaap_StockholdersEquity_25E5FC84ECA92E4D26517D80DFD92A6D" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_CommonStockSharesOutstanding" xlink:label="loc_us-gaap_CommonStockSharesOutstanding_9507634E7873485F0DE47D80DFD902C4" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_C7EB8218872E635D2D8D7D80DFD9986F" xlink:to="loc_us-gaap_CommonStockSharesOutstanding_9507634E7873485F0DE47D80DFD902C4" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" xlink:label="loc_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue_01BA0D31937D404F39247D80DFDACB63" xlink:type="locator" />
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_C7EB8218872E635D2D8D7D80DFD9986F" xlink:to="loc_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue_01BA0D31937D404F39247D80DFDACB63" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised" xlink:label="loc_us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised_BD8A50F59D9C4A333B857D80DFDAB078" xlink:type="locator" />
    <link:presentationArc order="4" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_C7EB8218872E635D2D8D7D80DFD9986F" xlink:to="loc_us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised_BD8A50F59D9C4A333B857D80DFDAB078" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" xlink:label="loc_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised_916F99481EA3FB8BD7BD7D80DFDA8953" xlink:type="locator" />
    <link:presentationArc order="5" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_C7EB8218872E635D2D8D7D80DFD9986F" xlink:to="loc_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised_916F99481EA3FB8BD7BD7D80DFDA8953" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_StockIssuedDuringPeriodValueEmployeeStockPurchasePlan" xlink:label="loc_us-gaap_StockIssuedDuringPeriodValueEmployeeStockPurchasePlan_3EC5C510DFEA3E34F81B7D80DFDA8EE1" xlink:type="locator" />
    <link:presentationArc order="6" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_C7EB8218872E635D2D8D7D80DFD9986F" xlink:to="loc_us-gaap_StockIssuedDuringPeriodValueEmployeeStockPurchasePlan_3EC5C510DFEA3E34F81B7D80DFDA8EE1" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans" xlink:label="loc_us-gaap_StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans_1A5E04C06C5F84DF96867D80DFDA0A18" xlink:type="locator" />
    <link:presentationArc order="7" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_C7EB8218872E635D2D8D7D80DFD9986F" xlink:to="loc_us-gaap_StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans_1A5E04C06C5F84DF96867D80DFDA0A18" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_StockRepurchasedDuringPeriodValue" xlink:label="loc_us-gaap_StockRepurchasedDuringPeriodValue_694F56B6F76168DBB46C7D80DFDA72BC" xlink:type="locator" />
    <link:presentationArc order="8" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_C7EB8218872E635D2D8D7D80DFD9986F" xlink:to="loc_us-gaap_StockRepurchasedDuringPeriodValue_694F56B6F76168DBB46C7D80DFDA72BC" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_StockIssuedDuringPeriodValueNewIssues" xlink:label="loc_us-gaap_StockIssuedDuringPeriodValueNewIssues_6B5DF0CA35DFAABCBDA07D88B967F069" xlink:type="locator" />
    <link:presentationArc order="9" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_C7EB8218872E635D2D8D7D80DFD9986F" xlink:to="loc_us-gaap_StockIssuedDuringPeriodValueNewIssues_6B5DF0CA35DFAABCBDA07D88B967F069" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesNewIssues" xlink:label="loc_us-gaap_StockIssuedDuringPeriodSharesNewIssues_5FE8CDD2630603785EF67D88ED22E33A" xlink:type="locator" />
    <link:presentationArc order="10" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_C7EB8218872E635D2D8D7D80DFD9986F" xlink:to="loc_us-gaap_StockIssuedDuringPeriodSharesNewIssues_5FE8CDD2630603785EF67D88ED22E33A" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_StockRepurchasedDuringPeriodShares" xlink:label="loc_us-gaap_StockRepurchasedDuringPeriodShares_A2758CE6E3B58D60A8C57D80DFDBA977" xlink:type="locator" />
    <link:presentationArc order="11" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_C7EB8218872E635D2D8D7D80DFD9986F" xlink:to="loc_us-gaap_StockRepurchasedDuringPeriodShares_A2758CE6E3B58D60A8C57D80DFDBA977" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_NetIncomeLoss" xlink:label="loc_us-gaap_NetIncomeLoss_CDCE3FC80B84292562607D80DFDBCF0D" xlink:type="locator" />
    <link:presentationArc order="12" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_C7EB8218872E635D2D8D7D80DFD9986F" xlink:to="loc_us-gaap_NetIncomeLoss_CDCE3FC80B84292562607D80DFDBCF0D" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_StockholdersEquity" xlink:label="loc_us-gaap_StockholdersEquity_E313C15FC16C566C8D667D80DFDBCC36" xlink:type="locator" />
    <link:presentationArc order="13" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_C7EB8218872E635D2D8D7D80DFD9986F" xlink:to="loc_us-gaap_StockholdersEquity_E313C15FC16C566C8D667D80DFDBCC36" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_CommonStockSharesOutstanding" xlink:label="loc_us-gaap_CommonStockSharesOutstanding_E0A37281A9E615C35ADC7D80DFDBA813" xlink:type="locator" />
    <link:presentationArc order="14" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_C7EB8218872E635D2D8D7D80DFD9986F" xlink:to="loc_us-gaap_CommonStockSharesOutstanding_E0A37281A9E615C35ADC7D80DFDBA813" xlink:type="arc" />
  </link:presentationLink>
  <link:presentationLink xlink:role="http://www.linkp.com/role/CondensedConsolidatedStatementOfStockholdersEquityParentheticals" xlink:type="extended">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_StatementOfStockholdersEquityAbstract" xlink:label="loc_us-gaap_StatementOfStockholdersEquityAbstract_64BE640AB66D81758C347D8B4CABD63C" xlink:type="locator" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_AdjustmentsToAdditionalPaidInCapitalStockIssuedIssuanceCosts" xlink:label="loc_us-gaap_AdjustmentsToAdditionalPaidInCapitalStockIssuedIssuanceCosts_831844A5C349211BF1247D8D016AA1CC" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfStockholdersEquityAbstract_64BE640AB66D81758C347D8B4CABD63C" xlink:to="loc_us-gaap_AdjustmentsToAdditionalPaidInCapitalStockIssuedIssuanceCosts_831844A5C349211BF1247D8D016AA1CC" xlink:type="arc" />
  </link:presentationLink>
  <link:presentationLink xlink:role="http://www.linkp.com/role/CondensedConsolidatedStatementsOfCashFlows" xlink:type="extended">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_StatementOfCashFlowsAbstract" xlink:label="loc_us-gaap_StatementOfCashFlowsAbstract_70F8181DAE0A0CC3C3D57D2627663ACA" xlink:type="locator" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract" xlink:label="loc_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_BD68979D622F49B1F3837D262766D482" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfCashFlowsAbstract_70F8181DAE0A0CC3C3D57D2627663ACA" xlink:to="loc_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_BD68979D622F49B1F3837D262766D482" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_NetIncomeLoss" xlink:label="loc_us-gaap_NetIncomeLoss_A9B9D6BBC13FB3179E7E7D262767ABF5" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_BD68979D622F49B1F3837D262766D482" xlink:to="loc_us-gaap_NetIncomeLoss_A9B9D6BBC13FB3179E7E7D262767ABF5" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:label="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_9E7F21CBAAF6FBE676A97D26276747A0" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_BD68979D622F49B1F3837D262766D482" xlink:to="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_9E7F21CBAAF6FBE676A97D26276747A0" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ShareBasedCompensation" xlink:label="loc_us-gaap_ShareBasedCompensation_3384AD4D561FCC583C767D262767011C" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_9E7F21CBAAF6FBE676A97D26276747A0" xlink:to="loc_us-gaap_ShareBasedCompensation_3384AD4D561FCC583C767D262767011C" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_DepreciationDepletionAndAmortization" xlink:label="loc_us-gaap_DepreciationDepletionAndAmortization_CDE1100767209E0AD07B7D262767DD6F" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_9E7F21CBAAF6FBE676A97D26276747A0" xlink:to="loc_us-gaap_DepreciationDepletionAndAmortization_CDE1100767209E0AD07B7D262767DD6F" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_GainsLossesOnExtinguishmentOfDebt" xlink:label="loc_us-gaap_GainsLossesOnExtinguishmentOfDebt_DFFF23E2F371CB8164017D2627674EF1" xlink:type="locator" />
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_9E7F21CBAAF6FBE676A97D26276747A0" xlink:to="loc_us-gaap_GainsLossesOnExtinguishmentOfDebt_DFFF23E2F371CB8164017D2627674EF1" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ExcessTaxBenefitFromShareBasedCompensationOperatingActivities" xlink:label="loc_us-gaap_ExcessTaxBenefitFromShareBasedCompensationOperatingActivities_7F4EA9CF9079E8C3B0037D262767D7A5" xlink:type="locator" />
    <link:presentationArc order="4" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_9E7F21CBAAF6FBE676A97D26276747A0" xlink:to="loc_us-gaap_ExcessTaxBenefitFromShareBasedCompensationOperatingActivities_7F4EA9CF9079E8C3B0037D262767D7A5" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_AssetImpairmentCharges" xlink:label="loc_us-gaap_AssetImpairmentCharges_370E26F6E9E656E3BB7B7D262767FC0C" xlink:type="locator" />
    <link:presentationArc order="5" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_9E7F21CBAAF6FBE676A97D26276747A0" xlink:to="loc_us-gaap_AssetImpairmentCharges_370E26F6E9E656E3BB7B7D262767FC0C" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_GainLossOnSaleOfPropertyPlantEquipment" xlink:label="loc_us-gaap_GainLossOnSaleOfPropertyPlantEquipment_46AA4BE1A9B414D72BE37D262767FA00" xlink:type="locator" />
    <link:presentationArc order="6" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_9E7F21CBAAF6FBE676A97D26276747A0" xlink:to="loc_us-gaap_GainLossOnSaleOfPropertyPlantEquipment_46AA4BE1A9B414D72BE37D262767FA00" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:label="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_24415A942DD30FC2DAB47D262767ED83" xlink:type="locator" />
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_BD68979D622F49B1F3837D262766D482" xlink:to="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_24415A942DD30FC2DAB47D262767ED83" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" xlink:label="loc_us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets_1B803FFE1DC66071AEC37D262767A321" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_24415A942DD30FC2DAB47D262767ED83" xlink:to="loc_us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets_1B803FFE1DC66071AEC37D262767A321" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_IncreaseDecreaseInOtherReceivables" xlink:label="loc_us-gaap_IncreaseDecreaseInOtherReceivables_679502145BFD97F9796C7D262767027B" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_24415A942DD30FC2DAB47D262767ED83" xlink:to="loc_us-gaap_IncreaseDecreaseInOtherReceivables_679502145BFD97F9796C7D262767027B" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities" xlink:label="loc_us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities_337FD01CCEFE676BEE007D2627674421" xlink:type="locator" />
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_24415A942DD30FC2DAB47D262767ED83" xlink:to="loc_us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities_337FD01CCEFE676BEE007D2627674421" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_IncreaseDecreaseInAccruedIncomeTaxesPayable" xlink:label="loc_us-gaap_IncreaseDecreaseInAccruedIncomeTaxesPayable_3AF3471A2C7D819D095D7D262767A67D" xlink:type="locator" />
    <link:presentationArc order="4" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_24415A942DD30FC2DAB47D262767ED83" xlink:to="loc_us-gaap_IncreaseDecreaseInAccruedIncomeTaxesPayable_3AF3471A2C7D819D095D7D262767A67D" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_IncreaseDecreaseInDeferredRevenue" xlink:label="loc_us-gaap_IncreaseDecreaseInDeferredRevenue_D45C6483C055ACEBB7837D26276769C2" xlink:type="locator" />
    <link:presentationArc order="5" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_24415A942DD30FC2DAB47D262767ED83" xlink:to="loc_us-gaap_IncreaseDecreaseInDeferredRevenue_D45C6483C055ACEBB7837D26276769C2" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_IncreaseDecreaseInDeferredCharges" xlink:label="loc_us-gaap_IncreaseDecreaseInDeferredCharges_20A1FB914316EEC2B5E77D2627675F8A" xlink:type="locator" />
    <link:presentationArc order="6" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_24415A942DD30FC2DAB47D262767ED83" xlink:to="loc_us-gaap_IncreaseDecreaseInDeferredCharges_20A1FB914316EEC2B5E77D2627675F8A" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:label="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_0AF8C827D5FCCCE1199A7D26276894B3" xlink:type="locator" />
    <link:presentationArc order="4" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_BD68979D622F49B1F3837D262766D482" xlink:to="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_0AF8C827D5FCCCE1199A7D26276894B3" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract" xlink:label="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_51FAE962148B6FB9FA827D26276840F8" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfCashFlowsAbstract_70F8181DAE0A0CC3C3D57D2627663ACA" xlink:to="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_51FAE962148B6FB9FA827D26276840F8" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ProceedsFromSaleAndMaturityOfHeldToMaturitySecurities" xlink:label="loc_us-gaap_ProceedsFromSaleAndMaturityOfHeldToMaturitySecurities_6B86B6ECE2EAE3636A0D7D262768F3BB" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_51FAE962148B6FB9FA827D26276840F8" xlink:to="loc_us-gaap_ProceedsFromSaleAndMaturityOfHeldToMaturitySecurities_6B86B6ECE2EAE3636A0D7D262768F3BB" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_PaymentsToAcquirePropertyPlantAndEquipment" xlink:label="loc_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment_B73A04290B84C36D34077D2627681CCE" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_51FAE962148B6FB9FA827D26276840F8" xlink:to="loc_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment_B73A04290B84C36D34077D2627681CCE" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ProceedsFromSaleOfPropertyPlantAndEquipment" xlink:label="loc_us-gaap_ProceedsFromSaleOfPropertyPlantAndEquipment_81C830DC6A2DD70F584B7D2627684193" xlink:type="locator" />
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_51FAE962148B6FB9FA827D26276840F8" xlink:to="loc_us-gaap_ProceedsFromSaleOfPropertyPlantAndEquipment_81C830DC6A2DD70F584B7D2627684193" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivities" xlink:label="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities_8BF116CFDECE9431A80A7D2627686278" xlink:type="locator" />
    <link:presentationArc order="4" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_51FAE962148B6FB9FA827D26276840F8" xlink:to="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities_8BF116CFDECE9431A80A7D2627686278" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:label="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_6BD4A556DA73209224ED7D26276805BB" xlink:type="locator" />
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfCashFlowsAbstract_70F8181DAE0A0CC3C3D57D2627663ACA" xlink:to="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_6BD4A556DA73209224ED7D26276805BB" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ProceedsFromIssuanceOfCommonStock" xlink:label="loc_us-gaap_ProceedsFromIssuanceOfCommonStock_DD4BF6691E6A1AB655E57D262768A24F" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_6BD4A556DA73209224ED7D26276805BB" xlink:to="loc_us-gaap_ProceedsFromIssuanceOfCommonStock_DD4BF6691E6A1AB655E57D262768A24F" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_PaymentsForRepurchaseOfCommonStock" xlink:label="loc_us-gaap_PaymentsForRepurchaseOfCommonStock_5259C12A9781CB7704DD7D26276830BD" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_6BD4A556DA73209224ED7D26276805BB" xlink:to="loc_us-gaap_PaymentsForRepurchaseOfCommonStock_5259C12A9781CB7704DD7D26276830BD" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_RepaymentsOfDebtAndCapitalLeaseObligations" xlink:label="loc_us-gaap_RepaymentsOfDebtAndCapitalLeaseObligations_B43E5191769530E872E47D2627685180" xlink:type="locator" />
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_6BD4A556DA73209224ED7D26276805BB" xlink:to="loc_us-gaap_RepaymentsOfDebtAndCapitalLeaseObligations_B43E5191769530E872E47D2627685180" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:label="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities_21E6DDEB1F1C7FEDC9D07D2627681CD4" xlink:type="locator" />
    <link:presentationArc order="4" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_6BD4A556DA73209224ED7D26276805BB" xlink:to="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities_21E6DDEB1F1C7FEDC9D07D2627681CD4" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_CashAndCashEquivalentsPeriodIncreaseDecrease" xlink:label="loc_us-gaap_CashAndCashEquivalentsPeriodIncreaseDecrease_E647789751AF9E3E90AD7D2627681530" xlink:type="locator" />
    <link:presentationArc order="4" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfCashFlowsAbstract_70F8181DAE0A0CC3C3D57D2627663ACA" xlink:to="loc_us-gaap_CashAndCashEquivalentsPeriodIncreaseDecrease_E647789751AF9E3E90AD7D2627681530" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:label="loc_us-gaap_CashAndCashEquivalentsAtCarryingValue_1860EE72D1AC84E8C5217D2627684350" xlink:type="locator" />
    <link:presentationArc order="5" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfCashFlowsAbstract_70F8181DAE0A0CC3C3D57D2627663ACA" xlink:to="loc_us-gaap_CashAndCashEquivalentsAtCarryingValue_1860EE72D1AC84E8C5217D2627684350" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:label="loc_us-gaap_CashAndCashEquivalentsAtCarryingValue_D3D47F79F29110471F3A7D262768FD03" xlink:type="locator" />
    <link:presentationArc order="6" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfCashFlowsAbstract_70F8181DAE0A0CC3C3D57D2627663ACA" xlink:to="loc_us-gaap_CashAndCashEquivalentsAtCarryingValue_D3D47F79F29110471F3A7D262768FD03" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_SupplementalCashFlowInformationAbstract" xlink:label="loc_us-gaap_SupplementalCashFlowInformationAbstract_91314A5C4E9199E939C87D26276871B7" xlink:type="locator" />
    <link:presentationArc order="7" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfCashFlowsAbstract_70F8181DAE0A0CC3C3D57D2627663ACA" xlink:to="loc_us-gaap_SupplementalCashFlowInformationAbstract_91314A5C4E9199E939C87D26276871B7" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_InterestPaid" xlink:label="loc_us-gaap_InterestPaid_938FD14C8B0FEBA3F8677D2627682069" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SupplementalCashFlowInformationAbstract_91314A5C4E9199E939C87D26276871B7" xlink:to="loc_us-gaap_InterestPaid_938FD14C8B0FEBA3F8677D2627682069" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_IncomeTaxesPaidNet" xlink:label="loc_us-gaap_IncomeTaxesPaidNet_A662F7800B1DC3C3B4DB7D262768B29B" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SupplementalCashFlowInformationAbstract_91314A5C4E9199E939C87D26276871B7" xlink:to="loc_us-gaap_IncomeTaxesPaidNet_A662F7800B1DC3C3B4DB7D262768B29B" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract" xlink:label="loc_us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract_E885F6793DF44958F31C7D26276801E5" xlink:type="locator" />
    <link:presentationArc order="8" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfCashFlowsAbstract_70F8181DAE0A0CC3C3D57D2627663ACA" xlink:to="loc_us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract_E885F6793DF44958F31C7D26276801E5" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_CapitalLeaseObligationsIncurred" xlink:label="loc_us-gaap_CapitalLeaseObligationsIncurred_B4089DFBF184A26F0AB97D262768477D" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract_E885F6793DF44958F31C7D26276801E5" xlink:to="loc_us-gaap_CapitalLeaseObligationsIncurred_B4089DFBF184A26F0AB97D262768477D" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_NotesReduction" xlink:label="loc_us-gaap_NotesReduction_502B499A2C7115FBA0557D26276997A4" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract_E885F6793DF44958F31C7D26276801E5" xlink:to="loc_us-gaap_NotesReduction_502B499A2C7115FBA0557D26276997A4" xlink:type="arc" />
  </link:presentationLink>
  <link:presentationLink xlink:role="http://www.linkp.com/role/CondensedConsolidatedStatementsOfOperations" xlink:type="extended">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_IncomeStatementAbstract" xlink:label="loc_us-gaap_IncomeStatementAbstract_346D7A95C97CAC5C14DA82A937174691" xlink:type="locator" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_RevenueFromGrants" xlink:label="loc_us-gaap_RevenueFromGrants_DE7E22CCFAE2B943642282A9371A2E11" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementAbstract_346D7A95C97CAC5C14DA82A937174691" xlink:to="loc_us-gaap_RevenueFromGrants_DE7E22CCFAE2B943642282A9371A2E11" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_LicensesRevenue" xlink:label="loc_us-gaap_LicensesRevenue_64808D1CC92C7A1BA59C82A9371D900A" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementAbstract_346D7A95C97CAC5C14DA82A937174691" xlink:to="loc_us-gaap_LicensesRevenue_64808D1CC92C7A1BA59C82A9371D900A" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_SalesRevenueNet" xlink:label="loc_us-gaap_SalesRevenueNet_E7740E6C5FC6E82991C682A9371D3446" xlink:type="locator" />
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementAbstract_346D7A95C97CAC5C14DA82A937174691" xlink:to="loc_us-gaap_SalesRevenueNet_E7740E6C5FC6E82991C682A9371D3446" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_OperatingExpensesAbstract" xlink:label="loc_us-gaap_OperatingExpensesAbstract_7655F1BFC672C81450D282A9371D4FA7" xlink:type="locator" />
    <link:presentationArc order="4" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementAbstract_346D7A95C97CAC5C14DA82A937174691" xlink:to="loc_us-gaap_OperatingExpensesAbstract_7655F1BFC672C81450D282A9371D4FA7" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ResearchAndDevelopmentExpense" xlink:label="loc_us-gaap_ResearchAndDevelopmentExpense_4A7DB31354C5B602DCB382A9371DA064" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OperatingExpensesAbstract_7655F1BFC672C81450D282A9371D4FA7" xlink:to="loc_us-gaap_ResearchAndDevelopmentExpense_4A7DB31354C5B602DCB382A9371DA064" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_GeneralAndAdministrativeExpense" xlink:label="loc_us-gaap_GeneralAndAdministrativeExpense_72A86AA32E448CFED05082A9371DA291" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OperatingExpensesAbstract_7655F1BFC672C81450D282A9371D4FA7" xlink:to="loc_us-gaap_GeneralAndAdministrativeExpense_72A86AA32E448CFED05082A9371DA291" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_OperatingExpenses" xlink:label="loc_us-gaap_OperatingExpenses_FDFCF5FDA3B9663512E882A9371E018D" xlink:type="locator" />
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OperatingExpensesAbstract_7655F1BFC672C81450D282A9371D4FA7" xlink:to="loc_us-gaap_OperatingExpenses_FDFCF5FDA3B9663512E882A9371E018D" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_OperatingIncomeLoss" xlink:label="loc_us-gaap_OperatingIncomeLoss_D85BC13019DB652023F582A9371EF2C4" xlink:type="locator" />
    <link:presentationArc order="5" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementAbstract_346D7A95C97CAC5C14DA82A937174691" xlink:to="loc_us-gaap_OperatingIncomeLoss_D85BC13019DB652023F582A9371EF2C4" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_NonoperatingIncomeExpenseAbstract" xlink:label="loc_us-gaap_NonoperatingIncomeExpenseAbstract_DB90D9D0FA54D600A1B482A9371EA413" xlink:type="locator" />
    <link:presentationArc order="6" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementAbstract_346D7A95C97CAC5C14DA82A937174691" xlink:to="loc_us-gaap_NonoperatingIncomeExpenseAbstract_DB90D9D0FA54D600A1B482A9371EA413" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_OtherNonoperatingIncomeExpense" xlink:label="loc_us-gaap_OtherNonoperatingIncomeExpense_4C8060D5C3886C4CA5C982BA8169FD86" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NonoperatingIncomeExpenseAbstract_DB90D9D0FA54D600A1B482A9371EA413" xlink:to="loc_us-gaap_OtherNonoperatingIncomeExpense_4C8060D5C3886C4CA5C982BA8169FD86" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_InvestmentIncomeInterest" xlink:label="loc_us-gaap_InvestmentIncomeInterest_05EEE5023FF99CAED33582A9371E2522" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NonoperatingIncomeExpenseAbstract_DB90D9D0FA54D600A1B482A9371EA413" xlink:to="loc_us-gaap_InvestmentIncomeInterest_05EEE5023FF99CAED33582A9371E2522" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_InterestExpense" xlink:label="loc_us-gaap_InterestExpense_48438E2F7757CA37947182A9371EF0D9" xlink:type="locator" />
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NonoperatingIncomeExpenseAbstract_DB90D9D0FA54D600A1B482A9371EA413" xlink:to="loc_us-gaap_InterestExpense_48438E2F7757CA37947182A9371EF0D9" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_NonoperatingIncomeExpense" xlink:label="loc_us-gaap_NonoperatingIncomeExpense_39BA71250EBE99AC96E282A9371E364C" xlink:type="locator" />
    <link:presentationArc order="7" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementAbstract_346D7A95C97CAC5C14DA82A937174691" xlink:to="loc_us-gaap_NonoperatingIncomeExpense_39BA71250EBE99AC96E282A9371E364C" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" xlink:label="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest_89570A7CA5F9467A1ECC82A9371EED17" xlink:type="locator" />
    <link:presentationArc order="8" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementAbstract_346D7A95C97CAC5C14DA82A937174691" xlink:to="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest_89570A7CA5F9467A1ECC82A9371EED17" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_IncomeTaxExpenseBenefit" xlink:label="loc_us-gaap_IncomeTaxExpenseBenefit_BD59D50CDB45400C0E5282A9371E4B18" xlink:type="locator" />
    <link:presentationArc order="9" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementAbstract_346D7A95C97CAC5C14DA82A937174691" xlink:to="loc_us-gaap_IncomeTaxExpenseBenefit_BD59D50CDB45400C0E5282A9371E4B18" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_NetIncomeLoss" xlink:label="loc_us-gaap_NetIncomeLoss_1527AD06EEEAF6BDBAE282A9371E557C" xlink:type="locator" />
    <link:presentationArc order="10" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementAbstract_346D7A95C97CAC5C14DA82A937174691" xlink:to="loc_us-gaap_NetIncomeLoss_1527AD06EEEAF6BDBAE282A9371E557C" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_EarningsPerShareBasicAndDiluted" xlink:label="loc_us-gaap_EarningsPerShareBasicAndDiluted_F05EC92F3A5D27AE874382A93724791B" xlink:type="locator" />
    <link:presentationArc order="11" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementAbstract_346D7A95C97CAC5C14DA82A937174691" xlink:to="loc_us-gaap_EarningsPerShareBasicAndDiluted_F05EC92F3A5D27AE874382A93724791B" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_WeightedAverageNumberOfShareOutstandingBasicAndDiluted" xlink:label="loc_us-gaap_WeightedAverageNumberOfShareOutstandingBasicAndDiluted_DF91865D8999E336808082A93724D701" xlink:type="locator" />
    <link:presentationArc order="12" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementAbstract_346D7A95C97CAC5C14DA82A937174691" xlink:to="loc_us-gaap_WeightedAverageNumberOfShareOutstandingBasicAndDiluted_DF91865D8999E336808082A93724D701" xlink:type="arc" />
  </link:presentationLink>
  <link:presentationLink xlink:role="http://www.linkp.com/role/DescriptionOfBusiness" xlink:type="extended">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:label="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_023F3F88BC3C58FD87981DEB5D4AFD52" xlink:type="locator" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_NatureOfOperations" xlink:label="loc_us-gaap_NatureOfOperations_A3EA6A76721D56D8A7478D6861478C6C" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_023F3F88BC3C58FD87981DEB5D4AFD52" xlink:to="loc_us-gaap_NatureOfOperations_A3EA6A76721D56D8A7478D6861478C6C" xlink:type="arc" />
  </link:presentationLink>
  <link:presentationLink xlink:role="http://www.linkp.com/role/DescriptionOfBusinessDetails" xlink:type="extended">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:label="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_4B7F831E7ECBF4AAD2B27D80DFBEAB86" xlink:type="locator" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_NetIncomeLoss" xlink:label="loc_us-gaap_NetIncomeLoss_C28D4714AF782E276FE07D80DFBE2AA7" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_4B7F831E7ECBF4AAD2B27D80DFBEAB86" xlink:to="loc_us-gaap_NetIncomeLoss_C28D4714AF782E276FE07D80DFBE2AA7" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_RestructuringAndRelatedCostNumberOfPositionsEliminatedPeriodPercent" xlink:label="loc_us-gaap_RestructuringAndRelatedCostNumberOfPositionsEliminatedPeriodPercent_A045884DCDF6CB6E6F367D80DFBE8B9A" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_4B7F831E7ECBF4AAD2B27D80DFBEAB86" xlink:to="loc_us-gaap_RestructuringAndRelatedCostNumberOfPositionsEliminatedPeriodPercent_A045884DCDF6CB6E6F367D80DFBE8B9A" xlink:type="arc" />
    <link:loc xlink:href="nlnk-20170930.xsd#nlnk_FinancingsTable" xlink:label="loc_nlnk_FinancingsTable_CC182BBAA355648D5D937D80DFBE6BA5" xlink:type="locator" />
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_4B7F831E7ECBF4AAD2B27D80DFBEAB86" xlink:to="loc_nlnk_FinancingsTable_CC182BBAA355648D5D937D80DFBE6BA5" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_SubsequentEventTypeAxis" xlink:label="loc_us-gaap_SubsequentEventTypeAxis_5DE06CB86DC10B71E4827D80DFBE0A34" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_nlnk_FinancingsTable_CC182BBAA355648D5D937D80DFBE6BA5" xlink:to="loc_us-gaap_SubsequentEventTypeAxis_5DE06CB86DC10B71E4827D80DFBE0A34" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_SubsequentEventTypeDomain" xlink:label="loc_us-gaap_SubsequentEventTypeDomain_19E2E36329493B77C9F67D80DFBE9448" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SubsequentEventTypeAxis_5DE06CB86DC10B71E4827D80DFBE0A34" xlink:to="loc_us-gaap_SubsequentEventTypeDomain_19E2E36329493B77C9F67D80DFBE9448" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_SubsequentEventMember" xlink:label="loc_us-gaap_SubsequentEventMember_7E042DC78372DD41BA617D80DFBE77BA" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SubsequentEventTypeDomain_19E2E36329493B77C9F67D80DFBE9448" xlink:to="loc_us-gaap_SubsequentEventMember_7E042DC78372DD41BA617D80DFBE77BA" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_SubsidiarySaleOfStockAxis" xlink:label="loc_us-gaap_SubsidiarySaleOfStockAxis_533EFC50C571B0492B997D80DFBEA474" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_nlnk_FinancingsTable_CC182BBAA355648D5D937D80DFBE6BA5" xlink:to="loc_us-gaap_SubsidiarySaleOfStockAxis_533EFC50C571B0492B997D80DFBEA474" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_SaleOfStockNameOfTransactionDomain" xlink:label="loc_us-gaap_SaleOfStockNameOfTransactionDomain_D9419FC15A68353A68037D80DFBE0212" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SubsidiarySaleOfStockAxis_533EFC50C571B0492B997D80DFBEA474" xlink:to="loc_us-gaap_SaleOfStockNameOfTransactionDomain_D9419FC15A68353A68037D80DFBE0212" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_IPOMember" xlink:label="loc_us-gaap_IPOMember_4541AA2E115E052C19C47D80DFBE8B83" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SaleOfStockNameOfTransactionDomain_D9419FC15A68353A68037D80DFBE0212" xlink:to="loc_us-gaap_IPOMember_4541AA2E115E052C19C47D80DFBE8B83" xlink:type="arc" />
    <link:loc xlink:href="nlnk-20170930.xsd#nlnk_FollowOnOfferingMember" xlink:label="loc_nlnk_FollowOnOfferingMember_ECBF60CB43EA3FE4A2157D80DFBEAB8B" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SaleOfStockNameOfTransactionDomain_D9419FC15A68353A68037D80DFBE0212" xlink:to="loc_nlnk_FollowOnOfferingMember_ECBF60CB43EA3FE4A2157D80DFBEAB8B" xlink:type="arc" />
    <link:loc xlink:href="nlnk-20170930.xsd#nlnk_ATMOfferingMember" xlink:label="loc_nlnk_ATMOfferingMember_4A0F1CE42404F98840AA7D80DFBE09FE" xlink:type="locator" />
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SaleOfStockNameOfTransactionDomain_D9419FC15A68353A68037D80DFBE0212" xlink:to="loc_nlnk_ATMOfferingMember_4A0F1CE42404F98840AA7D80DFBE09FE" xlink:type="arc" />
    <link:loc xlink:href="nlnk-20170930.xsd#nlnk_PublicOfferingMember" xlink:label="loc_nlnk_PublicOfferingMember_CDE089F53446C33D089E7D80DFBEB1B1" xlink:type="locator" />
    <link:presentationArc order="4" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SaleOfStockNameOfTransactionDomain_D9419FC15A68353A68037D80DFBE0212" xlink:to="loc_nlnk_PublicOfferingMember_CDE089F53446C33D089E7D80DFBEB1B1" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_TypeOfArrangementAxis" xlink:label="loc_us-gaap_TypeOfArrangementAxis_76981BEDDA50E0BC92797D80DFBF03A5" xlink:type="locator" />
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_nlnk_FinancingsTable_CC182BBAA355648D5D937D80DFBE6BA5" xlink:to="loc_us-gaap_TypeOfArrangementAxis_76981BEDDA50E0BC92797D80DFBF03A5" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:label="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_55F9BDCDF35C049093D87D80DFBFCDFF" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_TypeOfArrangementAxis_76981BEDDA50E0BC92797D80DFBF03A5" xlink:to="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_55F9BDCDF35C049093D87D80DFBFCDFF" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_CollaborativeArrangementMember" xlink:label="loc_us-gaap_CollaborativeArrangementMember_3E134908460BA9F6B11D7D80DFBFEA07" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_55F9BDCDF35C049093D87D80DFBFCDFF" xlink:to="loc_us-gaap_CollaborativeArrangementMember_3E134908460BA9F6B11D7D80DFBFEA07" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.sec.gov/dei/2014/dei-2014-01-31.xsd#dei_LegalEntityAxis" xlink:label="loc_dei_LegalEntityAxis_DA6C083D29F0FFDB96797D80DFBF5841" xlink:type="locator" />
    <link:presentationArc order="4" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_nlnk_FinancingsTable_CC182BBAA355648D5D937D80DFBE6BA5" xlink:to="loc_dei_LegalEntityAxis_DA6C083D29F0FFDB96797D80DFBF5841" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.sec.gov/dei/2014/dei-2014-01-31.xsd#dei_EntityDomain" xlink:label="loc_dei_EntityDomain_D05F199B1B92750702F17D80DFBFD844" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_LegalEntityAxis_DA6C083D29F0FFDB96797D80DFBF5841" xlink:to="loc_dei_EntityDomain_D05F199B1B92750702F17D80DFBFD844" xlink:type="arc" />
    <link:loc xlink:href="nlnk-20170930.xsd#nlnk_GenentechInc.Member" xlink:label="loc_nlnk_GenentechInc.Member_2C47B6A25A50EA2A1E237D80DFBF8425" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_EntityDomain_D05F199B1B92750702F17D80DFBFD844" xlink:to="loc_nlnk_GenentechInc.Member_2C47B6A25A50EA2A1E237D80DFBF8425" xlink:type="arc" />
    <link:loc xlink:href="nlnk-20170930.xsd#nlnk_MerckSharpeandDohmeCorpMember" xlink:label="loc_nlnk_MerckSharpeandDohmeCorpMember_BBA99A9007AEB1CEBE0E7D80DFBF9410" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_EntityDomain_D05F199B1B92750702F17D80DFBFD844" xlink:to="loc_nlnk_MerckSharpeandDohmeCorpMember_BBA99A9007AEB1CEBE0E7D80DFBF9410" xlink:type="arc" />
    <link:loc xlink:href="nlnk-20170930.xsd#nlnk_FinancingsLineItems" xlink:label="loc_nlnk_FinancingsLineItems_5D536571D0ABE5AA2C257D80DFBF9E70" xlink:type="locator" />
    <link:presentationArc order="5" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_nlnk_FinancingsTable_CC182BBAA355648D5D937D80DFBE6BA5" xlink:to="loc_nlnk_FinancingsLineItems_5D536571D0ABE5AA2C257D80DFBF9E70" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_SaleOfStockConsiderationReceivedOnTransaction" xlink:label="loc_us-gaap_SaleOfStockConsiderationReceivedOnTransaction_597EA3BB2D460E790A627D80DFBF9F49" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_nlnk_FinancingsLineItems_5D536571D0ABE5AA2C257D80DFBF9E70" xlink:to="loc_us-gaap_SaleOfStockConsiderationReceivedOnTransaction_597EA3BB2D460E790A627D80DFBF9F49" xlink:type="arc" />
    <link:loc xlink:href="nlnk-20170930.xsd#nlnk_MaximumAvailableUnderATMOffering" xlink:label="loc_nlnk_MaximumAvailableUnderATMOffering_4DB53D4E0E66EF6887417D80DFBFDB12" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_nlnk_FinancingsLineItems_5D536571D0ABE5AA2C257D80DFBF9E70" xlink:to="loc_nlnk_MaximumAvailableUnderATMOffering_4DB53D4E0E66EF6887417D80DFBFDB12" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesNewIssues" xlink:label="loc_us-gaap_StockIssuedDuringPeriodSharesNewIssues_0C0F74537A4BE8C125217D80DFBF1397" xlink:type="locator" />
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_nlnk_FinancingsLineItems_5D536571D0ABE5AA2C257D80DFBF9E70" xlink:to="loc_us-gaap_StockIssuedDuringPeriodSharesNewIssues_0C0F74537A4BE8C125217D80DFBF1397" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_FeesAndCommissions" xlink:label="loc_us-gaap_FeesAndCommissions_D80FEF3E9594C5F4C1D77D80DFBFA59D" xlink:type="locator" />
    <link:presentationArc order="4" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_nlnk_FinancingsLineItems_5D536571D0ABE5AA2C257D80DFBF9E70" xlink:to="loc_us-gaap_FeesAndCommissions_D80FEF3E9594C5F4C1D77D80DFBFA59D" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_PaymentsForCommissions" xlink:label="loc_us-gaap_PaymentsForCommissions_5F2E9D0E86D9446FD4107D80DFBF2A84" xlink:type="locator" />
    <link:presentationArc order="5" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_nlnk_FinancingsLineItems_5D536571D0ABE5AA2C257D80DFBF9E70" xlink:to="loc_us-gaap_PaymentsForCommissions_5F2E9D0E86D9446FD4107D80DFBF2A84" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_PaymentsOfStockIssuanceCosts" xlink:label="loc_us-gaap_PaymentsOfStockIssuanceCosts_9C94B8803837B98118567D8A35282A67" xlink:type="locator" />
    <link:presentationArc order="6" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_nlnk_FinancingsLineItems_5D536571D0ABE5AA2C257D80DFBF9E70" xlink:to="loc_us-gaap_PaymentsOfStockIssuanceCosts_9C94B8803837B98118567D8A35282A67" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction" xlink:label="loc_us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction_EE5D8693BD75A9CE06E67D80DFBFA7DA" xlink:type="locator" />
    <link:presentationArc order="7" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_nlnk_FinancingsLineItems_5D536571D0ABE5AA2C257D80DFBF9E70" xlink:to="loc_us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction_EE5D8693BD75A9CE06E67D80DFBFA7DA" xlink:type="arc" />
    <link:loc xlink:href="nlnk-20170930.xsd#nlnk_CollaborativeArrangementNumberofArrangements" xlink:label="loc_nlnk_CollaborativeArrangementNumberofArrangements_C6F9D60A4B8F1AECF1547D80DFBF7E55" xlink:type="locator" />
    <link:presentationArc order="8" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_nlnk_FinancingsLineItems_5D536571D0ABE5AA2C257D80DFBF9E70" xlink:to="loc_nlnk_CollaborativeArrangementNumberofArrangements_C6F9D60A4B8F1AECF1547D80DFBF7E55" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_RevenueRecognitionMilestoneMethodRevenueRecognized" xlink:label="loc_us-gaap_RevenueRecognitionMilestoneMethodRevenueRecognized_5823B9300C9D805211F37D80DFC0ADA8" xlink:type="locator" />
    <link:presentationArc order="9" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_nlnk_FinancingsLineItems_5D536571D0ABE5AA2C257D80DFBF9E70" xlink:to="loc_us-gaap_RevenueRecognitionMilestoneMethodRevenueRecognized_5823B9300C9D805211F37D80DFC0ADA8" xlink:type="arc" />
  </link:presentationLink>
  <link:presentationLink xlink:role="http://www.linkp.com/role/DocumentAndEntityInformation" xlink:type="extended">
    <link:loc xlink:href="nlnk-20170930.xsd#nlnk_DocumentAndEntityInformationAbstract" xlink:label="loc_nlnk_DocumentAndEntityInformationAbstract_9DA18231ED1559A606C0E34B7931B76F" xlink:type="locator" />
    <link:loc xlink:href="http://xbrl.sec.gov/dei/2014/dei-2014-01-31.xsd#dei_EntityRegistrantName" xlink:label="loc_dei_EntityRegistrantName_E7A859BFAEEFBAA12174E34B7935ACAD" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_nlnk_DocumentAndEntityInformationAbstract_9DA18231ED1559A606C0E34B7931B76F" xlink:to="loc_dei_EntityRegistrantName_E7A859BFAEEFBAA12174E34B7935ACAD" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.sec.gov/dei/2014/dei-2014-01-31.xsd#dei_EntityCentralIndexKey" xlink:label="loc_dei_EntityCentralIndexKey_E2A95D53B6325A759121E34B7936FDE7" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_nlnk_DocumentAndEntityInformationAbstract_9DA18231ED1559A606C0E34B7931B76F" xlink:to="loc_dei_EntityCentralIndexKey_E2A95D53B6325A759121E34B7936FDE7" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.sec.gov/dei/2014/dei-2014-01-31.xsd#dei_CurrentFiscalYearEndDate" xlink:label="loc_dei_CurrentFiscalYearEndDate_964EC2E2D584871FE1D2E34B79368641" xlink:type="locator" />
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_nlnk_DocumentAndEntityInformationAbstract_9DA18231ED1559A606C0E34B7931B76F" xlink:to="loc_dei_CurrentFiscalYearEndDate_964EC2E2D584871FE1D2E34B79368641" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.sec.gov/dei/2014/dei-2014-01-31.xsd#dei_EntityFilerCategory" xlink:label="loc_dei_EntityFilerCategory_D9BBC9FAA940311A6337E34B79364B8E" xlink:type="locator" />
    <link:presentationArc order="4" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_nlnk_DocumentAndEntityInformationAbstract_9DA18231ED1559A606C0E34B7931B76F" xlink:to="loc_dei_EntityFilerCategory_D9BBC9FAA940311A6337E34B79364B8E" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.sec.gov/dei/2014/dei-2014-01-31.xsd#dei_DocumentType" xlink:label="loc_dei_DocumentType_450EDAB86FEE5A01E72AE34B7936DEEC" xlink:type="locator" />
    <link:presentationArc order="5" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_nlnk_DocumentAndEntityInformationAbstract_9DA18231ED1559A606C0E34B7931B76F" xlink:to="loc_dei_DocumentType_450EDAB86FEE5A01E72AE34B7936DEEC" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.sec.gov/dei/2014/dei-2014-01-31.xsd#dei_DocumentPeriodEndDate" xlink:label="loc_dei_DocumentPeriodEndDate_E0FF6B1607489DA16DDAE34B7936027E" xlink:type="locator" />
    <link:presentationArc order="6" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_nlnk_DocumentAndEntityInformationAbstract_9DA18231ED1559A606C0E34B7931B76F" xlink:to="loc_dei_DocumentPeriodEndDate_E0FF6B1607489DA16DDAE34B7936027E" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.sec.gov/dei/2014/dei-2014-01-31.xsd#dei_DocumentFiscalYearFocus" xlink:label="loc_dei_DocumentFiscalYearFocus_8A107908171820107DEBE34B7937A718" xlink:type="locator" />
    <link:presentationArc order="7" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_nlnk_DocumentAndEntityInformationAbstract_9DA18231ED1559A606C0E34B7931B76F" xlink:to="loc_dei_DocumentFiscalYearFocus_8A107908171820107DEBE34B7937A718" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.sec.gov/dei/2014/dei-2014-01-31.xsd#dei_DocumentFiscalPeriodFocus" xlink:label="loc_dei_DocumentFiscalPeriodFocus_A3406D313B0C4C2041A0E34B7937A73D" xlink:type="locator" />
    <link:presentationArc order="8" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_nlnk_DocumentAndEntityInformationAbstract_9DA18231ED1559A606C0E34B7931B76F" xlink:to="loc_dei_DocumentFiscalPeriodFocus_A3406D313B0C4C2041A0E34B7937A73D" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.sec.gov/dei/2014/dei-2014-01-31.xsd#dei_AmendmentFlag" xlink:label="loc_dei_AmendmentFlag_CCAB9E5AAE969C40E18AE34B793775B8" xlink:type="locator" />
    <link:presentationArc order="9" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_nlnk_DocumentAndEntityInformationAbstract_9DA18231ED1559A606C0E34B7931B76F" xlink:to="loc_dei_AmendmentFlag_CCAB9E5AAE969C40E18AE34B793775B8" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.sec.gov/dei/2014/dei-2014-01-31.xsd#dei_EntityCommonStockSharesOutstanding" xlink:label="loc_dei_EntityCommonStockSharesOutstanding_7516E395684C222828D3E34B79378E03" xlink:type="locator" />
    <link:presentationArc order="10" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_nlnk_DocumentAndEntityInformationAbstract_9DA18231ED1559A606C0E34B7931B76F" xlink:to="loc_dei_EntityCommonStockSharesOutstanding_7516E395684C222828D3E34B79378E03" xlink:type="arc" />
  </link:presentationLink>
  <link:presentationLink xlink:role="http://www.linkp.com/role/IncomeTaxes" xlink:type="extended">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_IncomeTaxDisclosureAbstract" xlink:label="loc_us-gaap_IncomeTaxDisclosureAbstract_6CE4B1D7099754C285D20DF871E20C89" xlink:type="locator" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_IncomeTaxDisclosureTextBlock" xlink:label="loc_us-gaap_IncomeTaxDisclosureTextBlock_5DE28B05FFF054EFAD4C31E18BFA0F35" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxDisclosureAbstract_6CE4B1D7099754C285D20DF871E20C89" xlink:to="loc_us-gaap_IncomeTaxDisclosureTextBlock_5DE28B05FFF054EFAD4C31E18BFA0F35" xlink:type="arc" />
  </link:presentationLink>
  <link:presentationLink xlink:role="http://www.linkp.com/role/IncomeTaxesDetails" xlink:type="extended">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_IncomeTaxDisclosureAbstract" xlink:label="loc_us-gaap_IncomeTaxDisclosureAbstract_D77BAC171E8E56E5BDEBA5241F9EF985" xlink:type="locator" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_IncomeTaxExpenseBenefit" xlink:label="loc_us-gaap_IncomeTaxExpenseBenefit_2A36108AAFF750E980D50CA67F083E65" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxDisclosureAbstract_D77BAC171E8E56E5BDEBA5241F9EF985" xlink:to="loc_us-gaap_IncomeTaxExpenseBenefit_2A36108AAFF750E980D50CA67F083E65" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_LiabilityForUncertainTaxPositionsCurrent" xlink:label="loc_us-gaap_LiabilityForUncertainTaxPositionsCurrent_A769EB446EA25007BCC9FC61DD5B610E" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxDisclosureAbstract_D77BAC171E8E56E5BDEBA5241F9EF985" xlink:to="loc_us-gaap_LiabilityForUncertainTaxPositionsCurrent_A769EB446EA25007BCC9FC61DD5B610E" xlink:type="arc" />
  </link:presentationLink>
  <link:presentationLink xlink:role="http://www.linkp.com/role/LicenseAndResearchCollaborationAgreements" xlink:type="extended">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:label="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_30F68C39CFB45464AD66FCA89CE683F5" xlink:type="locator" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_CollaborativeArrangementDisclosureTextBlock" xlink:label="loc_us-gaap_CollaborativeArrangementDisclosureTextBlock_DB98202914B25662B43944F7CDA63197" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_30F68C39CFB45464AD66FCA89CE683F5" xlink:to="loc_us-gaap_CollaborativeArrangementDisclosureTextBlock_DB98202914B25662B43944F7CDA63197" xlink:type="arc" />
  </link:presentationLink>
  <link:presentationLink xlink:role="http://www.linkp.com/role/LicenseAndResearchCollaborationAgreementsDetails" xlink:type="extended">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:label="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_BAA5C94719BF57EB915F87C1ED39F182" xlink:type="locator" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_DeferredRevenueArrangementByTypeTable" xlink:label="loc_us-gaap_DeferredRevenueArrangementByTypeTable_69B819D468625327ABD8BA35C7DDC601" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_BAA5C94719BF57EB915F87C1ED39F182" xlink:to="loc_us-gaap_DeferredRevenueArrangementByTypeTable_69B819D468625327ABD8BA35C7DDC601" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_TypeOfArrangementAxis" xlink:label="loc_us-gaap_TypeOfArrangementAxis_542F105A28585839A95F1B1873E51B8E" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DeferredRevenueArrangementByTypeTable_69B819D468625327ABD8BA35C7DDC601" xlink:to="loc_us-gaap_TypeOfArrangementAxis_542F105A28585839A95F1B1873E51B8E" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:label="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_4C3E1A3E7F205E618D7C5FD9F5D6F38B" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_TypeOfArrangementAxis_542F105A28585839A95F1B1873E51B8E" xlink:to="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_4C3E1A3E7F205E618D7C5FD9F5D6F38B" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_CollaborativeArrangementMember" xlink:label="loc_us-gaap_CollaborativeArrangementMember_D2ACCEE91BB15A36AD7906B5E8ABA3DD" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_4C3E1A3E7F205E618D7C5FD9F5D6F38B" xlink:to="loc_us-gaap_CollaborativeArrangementMember_D2ACCEE91BB15A36AD7906B5E8ABA3DD" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.sec.gov/dei/2014/dei-2014-01-31.xsd#dei_LegalEntityAxis" xlink:label="loc_dei_LegalEntityAxis_62C5435D9D4A5C1EBA7614C957D05761" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DeferredRevenueArrangementByTypeTable_69B819D468625327ABD8BA35C7DDC601" xlink:to="loc_dei_LegalEntityAxis_62C5435D9D4A5C1EBA7614C957D05761" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.sec.gov/dei/2014/dei-2014-01-31.xsd#dei_EntityDomain" xlink:label="loc_dei_EntityDomain_D3A38B22D4045D9DBF1A5EDEB42A4922" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_LegalEntityAxis_62C5435D9D4A5C1EBA7614C957D05761" xlink:to="loc_dei_EntityDomain_D3A38B22D4045D9DBF1A5EDEB42A4922" xlink:type="arc" />
    <link:loc xlink:href="nlnk-20170930.xsd#nlnk_MerckSharpeandDohmeCorpMember" xlink:label="loc_nlnk_MerckSharpeandDohmeCorpMember_DB7281BA37D75323836D2F6A2E739F0A" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_EntityDomain_D3A38B22D4045D9DBF1A5EDEB42A4922" xlink:to="loc_nlnk_MerckSharpeandDohmeCorpMember_DB7281BA37D75323836D2F6A2E739F0A" xlink:type="arc" />
    <link:loc xlink:href="nlnk-20170930.xsd#nlnk_GenentechInc.Member" xlink:label="loc_nlnk_GenentechInc.Member_4CE9675B0C275833A78866213811D4A4" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_EntityDomain_D3A38B22D4045D9DBF1A5EDEB42A4922" xlink:to="loc_nlnk_GenentechInc.Member_4CE9675B0C275833A78866213811D4A4" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_DeferredRevenueArrangementLineItems" xlink:label="loc_us-gaap_DeferredRevenueArrangementLineItems_CFB58E2DC77E56B68E246E4372AF6A6A" xlink:type="locator" />
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DeferredRevenueArrangementByTypeTable_69B819D468625327ABD8BA35C7DDC601" xlink:to="loc_us-gaap_DeferredRevenueArrangementLineItems_CFB58E2DC77E56B68E246E4372AF6A6A" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_RevenueRecognitionMilestoneMethodRevenueRecognized" xlink:label="loc_us-gaap_RevenueRecognitionMilestoneMethodRevenueRecognized_109BCFB1AAB6549788B84339AA4F18F7" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DeferredRevenueArrangementLineItems_CFB58E2DC77E56B68E246E4372AF6A6A" xlink:to="loc_us-gaap_RevenueRecognitionMilestoneMethodRevenueRecognized_109BCFB1AAB6549788B84339AA4F18F7" xlink:type="arc" />
    <link:loc xlink:href="nlnk-20170930.xsd#nlnk_RevenueRecogitionMilestoneMethodMaximumPotentialRevenue" xlink:label="loc_nlnk_RevenueRecogitionMilestoneMethodMaximumPotentialRevenue_C26D2AB7D80C55968CC4DCBDFA8B8C75" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DeferredRevenueArrangementLineItems_CFB58E2DC77E56B68E246E4372AF6A6A" xlink:to="loc_nlnk_RevenueRecogitionMilestoneMethodMaximumPotentialRevenue_C26D2AB7D80C55968CC4DCBDFA8B8C75" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_LicensesRevenue" xlink:label="loc_us-gaap_LicensesRevenue_0C8D42CD37415B5C90EF3B56A85D54F6" xlink:type="locator" />
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DeferredRevenueArrangementLineItems_CFB58E2DC77E56B68E246E4372AF6A6A" xlink:to="loc_us-gaap_LicensesRevenue_0C8D42CD37415B5C90EF3B56A85D54F6" xlink:type="arc" />
    <link:loc xlink:href="nlnk-20170930.xsd#nlnk_LicenseRevenueEmployeeLabor" xlink:label="loc_nlnk_LicenseRevenueEmployeeLabor_ACA3E990E6AC5F1EA8B9C2B3C8188D36" xlink:type="locator" />
    <link:presentationArc order="4" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DeferredRevenueArrangementLineItems_CFB58E2DC77E56B68E246E4372AF6A6A" xlink:to="loc_nlnk_LicenseRevenueEmployeeLabor_ACA3E990E6AC5F1EA8B9C2B3C8188D36" xlink:type="arc" />
    <link:loc xlink:href="nlnk-20170930.xsd#nlnk_LicenseRevenueManagerLabor" xlink:label="loc_nlnk_LicenseRevenueManagerLabor_43101EDC99F05611AD7A8C149CBDA70B" xlink:type="locator" />
    <link:presentationArc order="5" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DeferredRevenueArrangementLineItems_CFB58E2DC77E56B68E246E4372AF6A6A" xlink:to="loc_nlnk_LicenseRevenueManagerLabor_43101EDC99F05611AD7A8C149CBDA70B" xlink:type="arc" />
    <link:loc xlink:href="nlnk-20170930.xsd#nlnk_LicenseRevenueCommitteeLabor" xlink:label="loc_nlnk_LicenseRevenueCommitteeLabor_52D7487A28535757A764D154B88223F9" xlink:type="locator" />
    <link:presentationArc order="6" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DeferredRevenueArrangementLineItems_CFB58E2DC77E56B68E246E4372AF6A6A" xlink:to="loc_nlnk_LicenseRevenueCommitteeLabor_52D7487A28535757A764D154B88223F9" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_DeferredRevenue" xlink:label="loc_us-gaap_DeferredRevenue_31A5EA6509875B37848D92944C0EA6AA" xlink:type="locator" />
    <link:presentationArc order="7" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DeferredRevenueArrangementLineItems_CFB58E2DC77E56B68E246E4372AF6A6A" xlink:to="loc_us-gaap_DeferredRevenue_31A5EA6509875B37848D92944C0EA6AA" xlink:type="arc" />
  </link:presentationLink>
  <link:presentationLink xlink:role="http://www.linkp.com/role/LongTermDebt" xlink:type="extended">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_DebtDisclosureAbstract" xlink:label="loc_us-gaap_DebtDisclosureAbstract_B6EEF94AE60C5EF981561CA432A145BC" xlink:type="locator" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_LongTermDebtTextBlock" xlink:label="loc_us-gaap_LongTermDebtTextBlock_B4F03ECCF0945A5399D46807BE103085" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtDisclosureAbstract_B6EEF94AE60C5EF981561CA432A145BC" xlink:to="loc_us-gaap_LongTermDebtTextBlock_B4F03ECCF0945A5399D46807BE103085" xlink:type="arc" />
  </link:presentationLink>
  <link:presentationLink xlink:role="http://www.linkp.com/role/LongTermDebtDetails" xlink:type="extended">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_DebtDisclosureAbstract" xlink:label="loc_us-gaap_DebtDisclosureAbstract_047DE2A8F6CA5B878489433422D69F9D" xlink:type="locator" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_DebtInstrumentTable" xlink:label="loc_us-gaap_DebtInstrumentTable_8ABEA65787A15F93A4A2F3346748B599" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtDisclosureAbstract_047DE2A8F6CA5B878489433422D69F9D" xlink:to="loc_us-gaap_DebtInstrumentTable_8ABEA65787A15F93A4A2F3346748B599" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_LongtermDebtTypeAxis" xlink:label="loc_us-gaap_LongtermDebtTypeAxis_AE1DB761518351EFBA3ED531E0C3B905" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentTable_8ABEA65787A15F93A4A2F3346748B599" xlink:to="loc_us-gaap_LongtermDebtTypeAxis_AE1DB761518351EFBA3ED531E0C3B905" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_LongtermDebtTypeDomain" xlink:label="loc_us-gaap_LongtermDebtTypeDomain_7B9815AD3B27570AADDD9140E537DF9F" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LongtermDebtTypeAxis_AE1DB761518351EFBA3ED531E0C3B905" xlink:to="loc_us-gaap_LongtermDebtTypeDomain_7B9815AD3B27570AADDD9140E537DF9F" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_LoansPayableMember" xlink:label="loc_us-gaap_LoansPayableMember_029E38CA73B353C79A014BEB6DA82B45" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LongtermDebtTypeDomain_7B9815AD3B27570AADDD9140E537DF9F" xlink:to="loc_us-gaap_LoansPayableMember_029E38CA73B353C79A014BEB6DA82B45" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_DebtInstrumentAxis" xlink:label="loc_us-gaap_DebtInstrumentAxis_F81CBA2C332E51DF94C120A14C46A70C" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentTable_8ABEA65787A15F93A4A2F3346748B599" xlink:to="loc_us-gaap_DebtInstrumentAxis_F81CBA2C332E51DF94C120A14C46A70C" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_DebtInstrumentNameDomain" xlink:label="loc_us-gaap_DebtInstrumentNameDomain_B172B8D4219D5F59AD802E3C93504022" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentAxis_F81CBA2C332E51DF94C120A14C46A70C" xlink:to="loc_us-gaap_DebtInstrumentNameDomain_B172B8D4219D5F59AD802E3C93504022" xlink:type="arc" />
    <link:loc xlink:href="nlnk-20170930.xsd#nlnk_CityOfAmesForgivableLoan2010Member" xlink:label="loc_nlnk_CityOfAmesForgivableLoan2010Member_59FEF6421E7A58E9A9BC963571B1B776" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_B172B8D4219D5F59AD802E3C93504022" xlink:to="loc_nlnk_CityOfAmesForgivableLoan2010Member_59FEF6421E7A58E9A9BC963571B1B776" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_DebtInstrumentLineItems" xlink:label="loc_us-gaap_DebtInstrumentLineItems_924C3770DA1153C986CB26F48E562530" xlink:type="locator" />
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentTable_8ABEA65787A15F93A4A2F3346748B599" xlink:to="loc_us-gaap_DebtInstrumentLineItems_924C3770DA1153C986CB26F48E562530" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_DebtInstrumentFaceAmount" xlink:label="loc_us-gaap_DebtInstrumentFaceAmount_CB3B62D8999A5F4495E2A5D266C1E0BE" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_924C3770DA1153C986CB26F48E562530" xlink:to="loc_us-gaap_DebtInstrumentFaceAmount_CB3B62D8999A5F4495E2A5D266C1E0BE" xlink:type="arc" />
    <link:loc xlink:href="nlnk-20170930.xsd#nlnk_DebtInstrumentCovenantRequiredNumberofPositionsCreationandRetention" xlink:label="loc_nlnk_DebtInstrumentCovenantRequiredNumberofPositionsCreationandRetention_1D697EDC4A055D1F8A054D191AEFDDB3" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_924C3770DA1153C986CB26F48E562530" xlink:to="loc_nlnk_DebtInstrumentCovenantRequiredNumberofPositionsCreationandRetention_1D697EDC4A055D1F8A054D191AEFDDB3" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_LesseeLeasingArrangementsOperatingLeasesTermOfContract" xlink:label="loc_us-gaap_LesseeLeasingArrangementsOperatingLeasesTermOfContract_EA528AB23D3257CE9E871B52BA37ACC4" xlink:type="locator" />
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_924C3770DA1153C986CB26F48E562530" xlink:to="loc_us-gaap_LesseeLeasingArrangementsOperatingLeasesTermOfContract_EA528AB23D3257CE9E871B52BA37ACC4" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_LesseeLeasingArrangementsOperatingLeasesRenewalTerm" xlink:label="loc_us-gaap_LesseeLeasingArrangementsOperatingLeasesRenewalTerm_CF1E2C78AC9B5A4D9E94E83D55A80CDA" xlink:type="locator" />
    <link:presentationArc order="4" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_924C3770DA1153C986CB26F48E562530" xlink:to="loc_us-gaap_LesseeLeasingArrangementsOperatingLeasesRenewalTerm_CF1E2C78AC9B5A4D9E94E83D55A80CDA" xlink:type="arc" />
    <link:loc xlink:href="nlnk-20170930.xsd#nlnk_DebtInstrumentCovenantRequiredMinimumLeaseArea" xlink:label="loc_nlnk_DebtInstrumentCovenantRequiredMinimumLeaseArea_D56BECA863C857C998F32506A673F313" xlink:type="locator" />
    <link:presentationArc order="5" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_924C3770DA1153C986CB26F48E562530" xlink:to="loc_nlnk_DebtInstrumentCovenantRequiredMinimumLeaseArea_D56BECA863C857C998F32506A673F313" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_RevenueFromGrants" xlink:label="loc_us-gaap_RevenueFromGrants_082077E4BCC356E1913C109A6AFECBE1" xlink:type="locator" />
    <link:presentationArc order="6" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_924C3770DA1153C986CB26F48E562530" xlink:to="loc_us-gaap_RevenueFromGrants_082077E4BCC356E1913C109A6AFECBE1" xlink:type="arc" />
  </link:presentationLink>
  <link:presentationLink xlink:role="http://www.linkp.com/role/NetLossPerCommonShare" xlink:type="extended">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_EarningsPerShareAbstract" xlink:label="loc_us-gaap_EarningsPerShareAbstract_1A3C5285280653F5993A1D857FE3A144" xlink:type="locator" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_EarningsPerShareTextBlock" xlink:label="loc_us-gaap_EarningsPerShareTextBlock_EC6BE8A6D4ED536095614EE5FAE100CB" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EarningsPerShareAbstract_1A3C5285280653F5993A1D857FE3A144" xlink:to="loc_us-gaap_EarningsPerShareTextBlock_EC6BE8A6D4ED536095614EE5FAE100CB" xlink:type="arc" />
  </link:presentationLink>
  <link:presentationLink xlink:role="http://www.linkp.com/role/NetLossPerCommonShareAntidilutiveSecuritiesDetails" xlink:type="extended">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_EarningsPerShareAbstract" xlink:label="loc_us-gaap_EarningsPerShareAbstract_9F89428CAACF50158BB8F62D805876E8" xlink:type="locator" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable" xlink:label="loc_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable_EBEE6B587D495A3084D05D04D839781B" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EarningsPerShareAbstract_9F89428CAACF50158BB8F62D805876E8" xlink:to="loc_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable_EBEE6B587D495A3084D05D04D839781B" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" xlink:label="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_33717B3CF51750DD84AA5C75C7A0EFC5" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable_EBEE6B587D495A3084D05D04D839781B" xlink:to="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_33717B3CF51750DD84AA5C75C7A0EFC5" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_AntidilutiveSecuritiesNameDomain" xlink:label="loc_us-gaap_AntidilutiveSecuritiesNameDomain_DFFA213C6BB751A2985553A9AEA8977A" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_33717B3CF51750DD84AA5C75C7A0EFC5" xlink:to="loc_us-gaap_AntidilutiveSecuritiesNameDomain_DFFA213C6BB751A2985553A9AEA8977A" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_EmployeeStockOptionMember" xlink:label="loc_us-gaap_EmployeeStockOptionMember_AE7149E211B75860812F174A763ECBBC" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AntidilutiveSecuritiesNameDomain_DFFA213C6BB751A2985553A9AEA8977A" xlink:to="loc_us-gaap_EmployeeStockOptionMember_AE7149E211B75860812F174A763ECBBC" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_RestrictedStockMember" xlink:label="loc_us-gaap_RestrictedStockMember_4DA16DD324ED5235B84EF3A527C258FC" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AntidilutiveSecuritiesNameDomain_DFFA213C6BB751A2985553A9AEA8977A" xlink:to="loc_us-gaap_RestrictedStockMember_4DA16DD324ED5235B84EF3A527C258FC" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems" xlink:label="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems_41225EB82D845782BEA507E0721565F4" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable_EBEE6B587D495A3084D05D04D839781B" xlink:to="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems_41225EB82D845782BEA507E0721565F4" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" xlink:label="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_80C65C721A8B5658B692E8C5A0B81452" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems_41225EB82D845782BEA507E0721565F4" xlink:to="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_80C65C721A8B5658B692E8C5A0B81452" xlink:type="arc" />
  </link:presentationLink>
  <link:presentationLink xlink:role="http://www.linkp.com/role/NetLossPerCommonShareNetLossPerShareComputationDetails" xlink:type="extended">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_EarningsPerShareAbstract" xlink:label="loc_us-gaap_EarningsPerShareAbstract_022E55692960EFA7A5F95A7AC28A3E5C" xlink:type="locator" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_NetIncomeLoss" xlink:label="loc_us-gaap_NetIncomeLoss_3AA4ECB9C300FEA35BCE5A7AC28AA6D3" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EarningsPerShareAbstract_022E55692960EFA7A5F95A7AC28A3E5C" xlink:to="loc_us-gaap_NetIncomeLoss_3AA4ECB9C300FEA35BCE5A7AC28AA6D3" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_WeightedAverageNumberOfShareOutstandingBasicAndDiluted" xlink:label="loc_us-gaap_WeightedAverageNumberOfShareOutstandingBasicAndDiluted_ECCB456B960265FEABD65A7AC28AF851" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EarningsPerShareAbstract_022E55692960EFA7A5F95A7AC28A3E5C" xlink:to="loc_us-gaap_WeightedAverageNumberOfShareOutstandingBasicAndDiluted_ECCB456B960265FEABD65A7AC28AF851" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_EarningsPerShareBasicAndDiluted" xlink:label="loc_us-gaap_EarningsPerShareBasicAndDiluted_7944FD9A3F7F4A2D347D5A7AC28A5117" xlink:type="locator" />
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EarningsPerShareAbstract_022E55692960EFA7A5F95A7AC28A3E5C" xlink:to="loc_us-gaap_EarningsPerShareBasicAndDiluted_7944FD9A3F7F4A2D347D5A7AC28A5117" xlink:type="arc" />
  </link:presentationLink>
  <link:presentationLink xlink:role="http://www.linkp.com/role/NetLossPerCommonShareTables" xlink:type="extended">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_EarningsPerShareAbstract" xlink:label="loc_us-gaap_EarningsPerShareAbstract_FFE9FB9D4B8E5526898407320AF93AFF" xlink:type="locator" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock" xlink:label="loc_us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock_9B18BB3C0FAB507B94E0153A2201E0F7" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EarningsPerShareAbstract_FFE9FB9D4B8E5526898407320AF93AFF" xlink:to="loc_us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock_9B18BB3C0FAB507B94E0153A2201E0F7" xlink:type="arc" />
  </link:presentationLink>
  <link:presentationLink xlink:role="http://www.linkp.com/role/RestructuringCharges" xlink:type="extended">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_RestructuringAndRelatedActivitiesAbstract" xlink:label="loc_us-gaap_RestructuringAndRelatedActivitiesAbstract_587127FB9F6854DC9A7497937C080A44" xlink:type="locator" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_RestructuringAndRelatedActivitiesDisclosureTextBlock" xlink:label="loc_us-gaap_RestructuringAndRelatedActivitiesDisclosureTextBlock_FF7229BE9AA7536594268F6A5817A06B" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RestructuringAndRelatedActivitiesAbstract_587127FB9F6854DC9A7497937C080A44" xlink:to="loc_us-gaap_RestructuringAndRelatedActivitiesDisclosureTextBlock_FF7229BE9AA7536594268F6A5817A06B" xlink:type="arc" />
  </link:presentationLink>
  <link:presentationLink xlink:role="http://www.linkp.com/role/RestructuringChargesDetails" xlink:type="extended">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_RestructuringAndRelatedActivitiesAbstract" xlink:label="loc_us-gaap_RestructuringAndRelatedActivitiesAbstract_07536877E24A33EA4AB76E9EA790AF45" xlink:type="locator" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ScheduleOfRestructuringAndRelatedCostsTable" xlink:label="loc_us-gaap_ScheduleOfRestructuringAndRelatedCostsTable_D55E66560BB4A7FA76BE6E9EA790F045" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RestructuringAndRelatedActivitiesAbstract_07536877E24A33EA4AB76E9EA790AF45" xlink:to="loc_us-gaap_ScheduleOfRestructuringAndRelatedCostsTable_D55E66560BB4A7FA76BE6E9EA790F045" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_RestructuringPlanAxis" xlink:label="loc_us-gaap_RestructuringPlanAxis_364AABC63FEE2480F6C56E9EA790C41E" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfRestructuringAndRelatedCostsTable_D55E66560BB4A7FA76BE6E9EA790F045" xlink:to="loc_us-gaap_RestructuringPlanAxis_364AABC63FEE2480F6C56E9EA790C41E" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_RestructuringPlanDomain" xlink:label="loc_us-gaap_RestructuringPlanDomain_493D1823876F90D157DE6E9EA790349B" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RestructuringPlanAxis_364AABC63FEE2480F6C56E9EA790C41E" xlink:to="loc_us-gaap_RestructuringPlanDomain_493D1823876F90D157DE6E9EA790349B" xlink:type="arc" />
    <link:loc xlink:href="nlnk-20170930.xsd#nlnk_TwoThousandSixteenRestructuringPlanMember" xlink:label="loc_nlnk_TwoThousandSixteenRestructuringPlanMember_B5331ACD254DA3C2C8566E9EA7909546" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RestructuringPlanDomain_493D1823876F90D157DE6E9EA790349B" xlink:to="loc_nlnk_TwoThousandSixteenRestructuringPlanMember_B5331ACD254DA3C2C8566E9EA7909546" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_RestructuringCostAndReserveAxis" xlink:label="loc_us-gaap_RestructuringCostAndReserveAxis_C1C1F7FAA4E15A41F87E6E9EA7905839" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfRestructuringAndRelatedCostsTable_D55E66560BB4A7FA76BE6E9EA790F045" xlink:to="loc_us-gaap_RestructuringCostAndReserveAxis_C1C1F7FAA4E15A41F87E6E9EA7905839" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_TypeOfRestructuringDomain" xlink:label="loc_us-gaap_TypeOfRestructuringDomain_63CFDE90A5421FD1EED96E9EA791BFE1" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RestructuringCostAndReserveAxis_C1C1F7FAA4E15A41F87E6E9EA7905839" xlink:to="loc_us-gaap_TypeOfRestructuringDomain_63CFDE90A5421FD1EED96E9EA791BFE1" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_EmployeeSeveranceMember" xlink:label="loc_us-gaap_EmployeeSeveranceMember_D2800628185A0D294F986E9EA79181C1" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_TypeOfRestructuringDomain_63CFDE90A5421FD1EED96E9EA791BFE1" xlink:to="loc_us-gaap_EmployeeSeveranceMember_D2800628185A0D294F986E9EA79181C1" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_IncomeStatementLocationAxis" xlink:label="loc_us-gaap_IncomeStatementLocationAxis_77ED65AEB7AD2A80C8326EA41FF9F974" xlink:type="locator" />
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfRestructuringAndRelatedCostsTable_D55E66560BB4A7FA76BE6E9EA790F045" xlink:to="loc_us-gaap_IncomeStatementLocationAxis_77ED65AEB7AD2A80C8326EA41FF9F974" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_IncomeStatementLocationDomain" xlink:label="loc_us-gaap_IncomeStatementLocationDomain_70F3A10D6327D0193E8D6EA420009B9A" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementLocationAxis_77ED65AEB7AD2A80C8326EA41FF9F974" xlink:to="loc_us-gaap_IncomeStatementLocationDomain_70F3A10D6327D0193E8D6EA420009B9A" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_GeneralAndAdministrativeExpenseMember" xlink:label="loc_us-gaap_GeneralAndAdministrativeExpenseMember_0D6B8DAB5379EE26EFDC6EA4FB59FEB4" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementLocationDomain_70F3A10D6327D0193E8D6EA420009B9A" xlink:to="loc_us-gaap_GeneralAndAdministrativeExpenseMember_0D6B8DAB5379EE26EFDC6EA4FB59FEB4" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ResearchAndDevelopmentExpenseMember" xlink:label="loc_us-gaap_ResearchAndDevelopmentExpenseMember_B05902B90981ECD5849E6EA7C20BFCF9" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementLocationDomain_70F3A10D6327D0193E8D6EA420009B9A" xlink:to="loc_us-gaap_ResearchAndDevelopmentExpenseMember_B05902B90981ECD5849E6EA7C20BFCF9" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_RestructuringCostAndReserveLineItems" xlink:label="loc_us-gaap_RestructuringCostAndReserveLineItems_AC111B3C8ECBDB10DFC86E9EA7915E65" xlink:type="locator" />
    <link:presentationArc order="4" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfRestructuringAndRelatedCostsTable_D55E66560BB4A7FA76BE6E9EA790F045" xlink:to="loc_us-gaap_RestructuringCostAndReserveLineItems_AC111B3C8ECBDB10DFC86E9EA7915E65" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_RestructuringAndRelatedCostNumberOfPositionsEliminatedPeriodPercent" xlink:label="loc_us-gaap_RestructuringAndRelatedCostNumberOfPositionsEliminatedPeriodPercent_7D47A0D572FA9076C1686E9EA7915644" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RestructuringCostAndReserveLineItems_AC111B3C8ECBDB10DFC86E9EA7915E65" xlink:to="loc_us-gaap_RestructuringAndRelatedCostNumberOfPositionsEliminatedPeriodPercent_7D47A0D572FA9076C1686E9EA7915644" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_TangibleAssetImpairmentCharges" xlink:label="loc_us-gaap_TangibleAssetImpairmentCharges_95BECAF172630DD045556E9EA791EDA9" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RestructuringCostAndReserveLineItems_AC111B3C8ECBDB10DFC86E9EA7915E65" xlink:to="loc_us-gaap_TangibleAssetImpairmentCharges_95BECAF172630DD045556E9EA791EDA9" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_RestructuringReserveRollForward" xlink:label="loc_us-gaap_RestructuringReserveRollForward_CE668F27A768B1102DA46E9EA791AA43" xlink:type="locator" />
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RestructuringCostAndReserveLineItems_AC111B3C8ECBDB10DFC86E9EA7915E65" xlink:to="loc_us-gaap_RestructuringReserveRollForward_CE668F27A768B1102DA46E9EA791AA43" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_RestructuringReserve" xlink:label="loc_us-gaap_RestructuringReserve_A8D3BC8F25156B0BD6AD6E9EA79142B0" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RestructuringReserveRollForward_CE668F27A768B1102DA46E9EA791AA43" xlink:to="loc_us-gaap_RestructuringReserve_A8D3BC8F25156B0BD6AD6E9EA79142B0" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_RestructuringCharges" xlink:label="loc_us-gaap_RestructuringCharges_B016032B15D5FA51E78C6E9EA7916BF5" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RestructuringReserveRollForward_CE668F27A768B1102DA46E9EA791AA43" xlink:to="loc_us-gaap_RestructuringCharges_B016032B15D5FA51E78C6E9EA7916BF5" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_PaymentsForRestructuring" xlink:label="loc_us-gaap_PaymentsForRestructuring_5F7C2A47BBA90F6B19706E9EA794B7D3" xlink:type="locator" />
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RestructuringReserveRollForward_CE668F27A768B1102DA46E9EA791AA43" xlink:to="loc_us-gaap_PaymentsForRestructuring_5F7C2A47BBA90F6B19706E9EA794B7D3" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_RestructuringReserve" xlink:label="loc_us-gaap_RestructuringReserve_0EAE9D43939A11917AB26E9EA79474E6" xlink:type="locator" />
    <link:presentationArc order="4" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RestructuringReserveRollForward_CE668F27A768B1102DA46E9EA791AA43" xlink:to="loc_us-gaap_RestructuringReserve_0EAE9D43939A11917AB26E9EA79474E6" xlink:type="arc" />
  </link:presentationLink>
  <link:presentationLink xlink:role="http://www.linkp.com/role/RestructuringChargesTables" xlink:type="extended">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_RestructuringAndRelatedActivitiesAbstract" xlink:label="loc_us-gaap_RestructuringAndRelatedActivitiesAbstract_0D6C9DDB009759EA3E335A7AC2820640" xlink:type="locator" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ScheduleOfRestructuringReserveByTypeOfCostTextBlock" xlink:label="loc_us-gaap_ScheduleOfRestructuringReserveByTypeOfCostTextBlock_6FA26B03279BA408721F5A7AC28273BD" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RestructuringAndRelatedActivitiesAbstract_0D6C9DDB009759EA3E335A7AC2820640" xlink:to="loc_us-gaap_ScheduleOfRestructuringReserveByTypeOfCostTextBlock_6FA26B03279BA408721F5A7AC28273BD" xlink:type="arc" />
  </link:presentationLink>
  <link:presentationLink xlink:role="http://www.linkp.com/role/SignificantAccountingPolicies" xlink:type="extended">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_AccountingPoliciesAbstract" xlink:label="loc_us-gaap_AccountingPoliciesAbstract_E11E2DDB71F45D39BDEE7332DD5004EF" xlink:type="locator" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_SignificantAccountingPoliciesTextBlock" xlink:label="loc_us-gaap_SignificantAccountingPoliciesTextBlock_2F642C0D1CE7566C8986660C571E05F7" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_E11E2DDB71F45D39BDEE7332DD5004EF" xlink:to="loc_us-gaap_SignificantAccountingPoliciesTextBlock_2F642C0D1CE7566C8986660C571E05F7" xlink:type="arc" />
  </link:presentationLink>
  <link:presentationLink xlink:role="http://www.linkp.com/role/SignificantAccountingPoliciesDetails" xlink:type="extended">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_AccountingPoliciesAbstract" xlink:label="loc_us-gaap_AccountingPoliciesAbstract_1DA12CDF6CF757939C033794135762F6" xlink:type="locator" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_LongTermDebtAndCapitalLeaseObligationsIncludingCurrentMaturities" xlink:label="loc_us-gaap_LongTermDebtAndCapitalLeaseObligationsIncludingCurrentMaturities_1FB7207D79CF57E09F7BD0F66C442E20" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_1DA12CDF6CF757939C033794135762F6" xlink:to="loc_us-gaap_LongTermDebtAndCapitalLeaseObligationsIncludingCurrentMaturities_1FB7207D79CF57E09F7BD0F66C442E20" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" xlink:label="loc_us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment_BF262DCBC29155E6B862A5CEB822F793" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_1DA12CDF6CF757939C033794135762F6" xlink:to="loc_us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment_BF262DCBC29155E6B862A5CEB822F793" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ScheduleOfPropertyPlantAndEquipmentTable" xlink:label="loc_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable_ACE48E1C163E515590B650459D6AAAF4" xlink:type="locator" />
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_1DA12CDF6CF757939C033794135762F6" xlink:to="loc_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable_ACE48E1C163E515590B650459D6AAAF4" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_PropertyPlantAndEquipmentByTypeAxis" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentByTypeAxis_BDB01D77D2AD53C4B33E620C78617522" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable_ACE48E1C163E515590B650459D6AAAF4" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentByTypeAxis_BDB01D77D2AD53C4B33E620C78617522" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_70B953E5F9DA5A34A287A12496CDC9ED" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentByTypeAxis_BDB01D77D2AD53C4B33E620C78617522" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_70B953E5F9DA5A34A287A12496CDC9ED" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ComputerEquipmentMember" xlink:label="loc_us-gaap_ComputerEquipmentMember_FEE5B3E2884F571ABA7A1CDF82FA1BB3" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_70B953E5F9DA5A34A287A12496CDC9ED" xlink:to="loc_us-gaap_ComputerEquipmentMember_FEE5B3E2884F571ABA7A1CDF82FA1BB3" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_EquipmentMember" xlink:label="loc_us-gaap_EquipmentMember_CE87323608385511BBB1896E33B5C82C" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_70B953E5F9DA5A34A287A12496CDC9ED" xlink:to="loc_us-gaap_EquipmentMember_CE87323608385511BBB1896E33B5C82C" xlink:type="arc" />
    <link:loc xlink:href="nlnk-20170930.xsd#nlnk_ContractManufacturingOrganizationEquipmentMember" xlink:label="loc_nlnk_ContractManufacturingOrganizationEquipmentMember_375F8E9765BA5AAE8717F0F2C57729C5" xlink:type="locator" />
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_70B953E5F9DA5A34A287A12496CDC9ED" xlink:to="loc_nlnk_ContractManufacturingOrganizationEquipmentMember_375F8E9765BA5AAE8717F0F2C57729C5" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_RangeAxis" xlink:label="loc_us-gaap_RangeAxis_2E066F7F1A1C581AA30328D623109C8E" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable_ACE48E1C163E515590B650459D6AAAF4" xlink:to="loc_us-gaap_RangeAxis_2E066F7F1A1C581AA30328D623109C8E" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_RangeMember" xlink:label="loc_us-gaap_RangeMember_B9B00260BC355C0784EFA2B6EC530E02" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RangeAxis_2E066F7F1A1C581AA30328D623109C8E" xlink:to="loc_us-gaap_RangeMember_B9B00260BC355C0784EFA2B6EC530E02" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_MinimumMember" xlink:label="loc_us-gaap_MinimumMember_977C0AFAE253505E9CAC3E6EF428E88E" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RangeMember_B9B00260BC355C0784EFA2B6EC530E02" xlink:to="loc_us-gaap_MinimumMember_977C0AFAE253505E9CAC3E6EF428E88E" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_MaximumMember" xlink:label="loc_us-gaap_MaximumMember_F9F0B584BE815D4F836273C3D73F3F3F" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RangeMember_B9B00260BC355C0784EFA2B6EC530E02" xlink:to="loc_us-gaap_MaximumMember_F9F0B584BE815D4F836273C3D73F3F3F" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_PropertyPlantAndEquipmentLineItems" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentLineItems_754C7397B5F254A4AB9582139E85A981" xlink:type="locator" />
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable_ACE48E1C163E515590B650459D6AAAF4" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentLineItems_754C7397B5F254A4AB9582139E85A981" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_PropertyPlantAndEquipmentUsefulLife" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentUsefulLife_ECAF72F879AF559C83117D6F560DDE71" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentLineItems_754C7397B5F254A4AB9582139E85A981" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentUsefulLife_ECAF72F879AF559C83117D6F560DDE71" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_GovernmentContractReceivable" xlink:label="loc_us-gaap_GovernmentContractReceivable_0082D103661F5C87B3820EDAEE6D6463" xlink:type="locator" />
    <link:presentationArc order="4" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_1DA12CDF6CF757939C033794135762F6" xlink:to="loc_us-gaap_GovernmentContractReceivable_0082D103661F5C87B3820EDAEE6D6463" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_GovernmentContractReceivableUnbilledAmounts" xlink:label="loc_us-gaap_GovernmentContractReceivableUnbilledAmounts_613BA3CF41D35C819A8DC90FBD46895A" xlink:type="locator" />
    <link:presentationArc order="5" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_1DA12CDF6CF757939C033794135762F6" xlink:to="loc_us-gaap_GovernmentContractReceivableUnbilledAmounts_613BA3CF41D35C819A8DC90FBD46895A" xlink:type="arc" />
    <link:loc xlink:href="nlnk-20170930.xsd#nlnk_GovernmentContractAccruedSubcontractorFees" xlink:label="loc_nlnk_GovernmentContractAccruedSubcontractorFees_7B9719F408B355F3929C042E067E97ED" xlink:type="locator" />
    <link:presentationArc order="6" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_1DA12CDF6CF757939C033794135762F6" xlink:to="loc_nlnk_GovernmentContractAccruedSubcontractorFees_7B9719F408B355F3929C042E067E97ED" xlink:type="arc" />
  </link:presentationLink>
  <link:presentationLink xlink:role="http://www.linkp.com/role/SignificantAccountingPoliciesPolicies" xlink:type="extended">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_AccountingPoliciesAbstract" xlink:label="loc_us-gaap_AccountingPoliciesAbstract_15508048B36DA5E2096A508822A66C3E" xlink:type="locator" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_UseOfEstimates" xlink:label="loc_us-gaap_UseOfEstimates_3B52CCEC8ED9023075AD508822A6BE3E" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_15508048B36DA5E2096A508822A66C3E" xlink:to="loc_us-gaap_UseOfEstimates_3B52CCEC8ED9023075AD508822A6BE3E" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ConsolidationPolicyTextBlock" xlink:label="loc_us-gaap_ConsolidationPolicyTextBlock_4E4143054DAE563C0D07508822A62DFB" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_15508048B36DA5E2096A508822A66C3E" xlink:to="loc_us-gaap_ConsolidationPolicyTextBlock_4E4143054DAE563C0D07508822A62DFB" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_FairValueOfFinancialInstrumentsPolicy" xlink:label="loc_us-gaap_FairValueOfFinancialInstrumentsPolicy_61EC41EA1B0366636BEA508822A63FA4" xlink:type="locator" />
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_15508048B36DA5E2096A508822A66C3E" xlink:to="loc_us-gaap_FairValueOfFinancialInstrumentsPolicy_61EC41EA1B0366636BEA508822A63FA4" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ConcentrationRiskCreditRisk" xlink:label="loc_us-gaap_ConcentrationRiskCreditRisk_86C2987D7161823F7554508822A65DC8" xlink:type="locator" />
    <link:presentationArc order="4" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_15508048B36DA5E2096A508822A66C3E" xlink:to="loc_us-gaap_ConcentrationRiskCreditRisk_86C2987D7161823F7554508822A65DC8" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_PropertyPlantAndEquipmentPolicyTextBlock" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentPolicyTextBlock_001D9A4240C63C831E22508822A62C3B" xlink:type="locator" />
    <link:presentationArc order="5" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_15508048B36DA5E2096A508822A66C3E" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentPolicyTextBlock_001D9A4240C63C831E22508822A62C3B" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_RevenueRecognitionPolicyTextBlock" xlink:label="loc_us-gaap_RevenueRecognitionPolicyTextBlock_264E24E7DA19DB45089B508822A6882F" xlink:type="locator" />
    <link:presentationArc order="6" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_15508048B36DA5E2096A508822A66C3E" xlink:to="loc_us-gaap_RevenueRecognitionPolicyTextBlock_264E24E7DA19DB45089B508822A6882F" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock" xlink:label="loc_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock_97E2D2715BD5F8BE1351509EF5657FDA" xlink:type="locator" />
    <link:presentationArc order="7" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_15508048B36DA5E2096A508822A66C3E" xlink:to="loc_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock_97E2D2715BD5F8BE1351509EF5657FDA" xlink:type="arc" />
  </link:presentationLink>
  <link:presentationLink xlink:role="http://www.linkp.com/role/SubsequentEvents" xlink:type="extended">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_SubsequentEventsAbstract" xlink:label="loc_us-gaap_SubsequentEventsAbstract_29E2040200AE5D098E343485F972DD61" xlink:type="locator" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_SubsequentEventsTextBlock" xlink:label="loc_us-gaap_SubsequentEventsTextBlock_13728D10D1C75AAFBB637CDCB6117566" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SubsequentEventsAbstract_29E2040200AE5D098E343485F972DD61" xlink:to="loc_us-gaap_SubsequentEventsTextBlock_13728D10D1C75AAFBB637CDCB6117566" xlink:type="arc" />
  </link:presentationLink>
  <link:presentationLink xlink:role="http://www.linkp.com/role/SubsequentEventsDetails" xlink:type="extended">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_SubsequentEventsAbstract" xlink:label="loc_us-gaap_SubsequentEventsAbstract_E2D3A21DC4130647A27C7D80DEEB8EA5" xlink:type="locator" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_SubsequentEventTable" xlink:label="loc_us-gaap_SubsequentEventTable_A135507A179004BB776E7D80DEEE2AB9" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SubsequentEventsAbstract_E2D3A21DC4130647A27C7D80DEEB8EA5" xlink:to="loc_us-gaap_SubsequentEventTable_A135507A179004BB776E7D80DEEE2AB9" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_SubsequentEventTypeAxis" xlink:label="loc_us-gaap_SubsequentEventTypeAxis_52CC8C4C634355BA71637D80DEEFA30E" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SubsequentEventTable_A135507A179004BB776E7D80DEEE2AB9" xlink:to="loc_us-gaap_SubsequentEventTypeAxis_52CC8C4C634355BA71637D80DEEFA30E" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_SubsequentEventTypeDomain" xlink:label="loc_us-gaap_SubsequentEventTypeDomain_B45CB0CEE67993169C877D80DEEF5B08" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SubsequentEventTypeAxis_52CC8C4C634355BA71637D80DEEFA30E" xlink:to="loc_us-gaap_SubsequentEventTypeDomain_B45CB0CEE67993169C877D80DEEF5B08" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_SubsequentEventMember" xlink:label="loc_us-gaap_SubsequentEventMember_265B83C62438F2BA5D2C7D80DEF037F1" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SubsequentEventTypeDomain_B45CB0CEE67993169C877D80DEEF5B08" xlink:to="loc_us-gaap_SubsequentEventMember_265B83C62438F2BA5D2C7D80DEF037F1" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_SubsidiarySaleOfStockAxis" xlink:label="loc_us-gaap_SubsidiarySaleOfStockAxis_7E8599E6425A9C8411737D83E03B4F3C" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SubsequentEventTable_A135507A179004BB776E7D80DEEE2AB9" xlink:to="loc_us-gaap_SubsidiarySaleOfStockAxis_7E8599E6425A9C8411737D83E03B4F3C" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_SaleOfStockNameOfTransactionDomain" xlink:label="loc_us-gaap_SaleOfStockNameOfTransactionDomain_DC30A5F3DA72B3A182E77D83E0414260" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SubsidiarySaleOfStockAxis_7E8599E6425A9C8411737D83E03B4F3C" xlink:to="loc_us-gaap_SaleOfStockNameOfTransactionDomain_DC30A5F3DA72B3A182E77D83E0414260" xlink:type="arc" />
    <link:loc xlink:href="nlnk-20170930.xsd#nlnk_PublicOfferingMember" xlink:label="loc_nlnk_PublicOfferingMember_7AAC11CAC4D7279EE3367D83E054AE39" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SaleOfStockNameOfTransactionDomain_DC30A5F3DA72B3A182E77D83E0414260" xlink:to="loc_nlnk_PublicOfferingMember_7AAC11CAC4D7279EE3367D83E054AE39" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_SubsequentEventLineItems" xlink:label="loc_us-gaap_SubsequentEventLineItems_8EDAAFE474CB467C69DA7D80DEF0B1E6" xlink:type="locator" />
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SubsequentEventTable_A135507A179004BB776E7D80DEEE2AB9" xlink:to="loc_us-gaap_SubsequentEventLineItems_8EDAAFE474CB467C69DA7D80DEF0B1E6" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction" xlink:label="loc_us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction_0006E5AD267EF12079277D83E017C5F6" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SubsequentEventLineItems_8EDAAFE474CB467C69DA7D80DEF0B1E6" xlink:to="loc_us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction_0006E5AD267EF12079277D83E017C5F6" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_SaleOfStockConsiderationReceivedOnTransaction" xlink:label="loc_us-gaap_SaleOfStockConsiderationReceivedOnTransaction_1BB99DAD7F09C931F7307D83E026821C" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SubsequentEventLineItems_8EDAAFE474CB467C69DA7D80DEF0B1E6" xlink:to="loc_us-gaap_SaleOfStockConsiderationReceivedOnTransaction_1BB99DAD7F09C931F7307D83E026821C" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_FeesAndCommissions" xlink:label="loc_us-gaap_FeesAndCommissions_362BD49B3E8DDDE8B0EA7D83E031C1B3" xlink:type="locator" />
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SubsequentEventLineItems_8EDAAFE474CB467C69DA7D80DEF0B1E6" xlink:to="loc_us-gaap_FeesAndCommissions_362BD49B3E8DDDE8B0EA7D83E031C1B3" xlink:type="arc" />
  </link:presentationLink>
</link:linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>11
<FILENAME>newlinklogorgbwtaga01a01a09.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 newlinklogorgbwtaga01a01a09.jpg
M_]C_X  02D9)1@ ! @$ E@"6  #_[0 L4&AO=&]S:&]P(#,N,  X0DE- ^T
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M(" @(" @(" @(" @(" @(" @(" @( H\/WAP86-K970@96YD/2)W(C\^_^X
M#D%D;V)E &3      ?_; (0  0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$!
M 0$! 0$! 0$! 0$! 0$! 0(" @(" @(" @(" P,# P,# P,# P$! 0$! 0$"
M 0$" @(! @(# P,# P,# P,# P,# P,# P,# P,# P,# P,# P,# P,# P,#
M P,# P,# P,# P,#_\  $0@"N 5O P$1  (1 0,1 ?_$ /T  0 #  ,  P$!
M           )"@L&!P@"! 4# 0$!  $% 0$! 0            ,! @0%"0@'
M!@H0   & @$" @,'$ <%!@("$P ! @,$!08'"!$)$A,A% HBTQ5V%Q@Y,9*3
M5)6UU196MC=7=Y>W>"-5USA8&1I!,M26UE%A0C,DN(>GLR4F-HB8.E)$J&DJ
M8G*"0U-C-&0U$0 " 0($ P0#"0@,"P0(!@,  0(#!!$2!08A,0=!41,(83(S
M<8$BLA1TM'4WL<%"([,5-1;PD:%28E.4U%9V%QC1<M*3TR0T5+4V.()#<X22
M8X.CI(65"?&B)56E9RA$9/_:  P# 0 "$0,1 #\ O\   *?G>D[O&UF=L9CQ
M$XQ9A;:ZQC74Y_&MN;(Q6P<K<NR[+VF4(N\,H+N(;=EC&.XK*<5"GNQ7&)LZ
MP:>:-:8K?23+"*PQ99)]B*P_P_>_#/XQ?#5M^,'K?K_P[\(S/AGU_P 7C]=^
M$_.]=];\7I\SQ^/K_M$A:>^])]U[N!Z%<B-8?R6SV_I8GEM_BSLZ5'VI1+AM
MJ295[#>>L7MA3Q.B"(O@^1#<0GJ2%I(SZT<8LKBR:?C][3':,N0:KE'QYB38
M_P#0-S<UT;;.0I;:4GX'72UYG$^3&FO.H,EF:<BBH)23(F^BB)%CI]Q<I=Y/
M7QI[EW"GE@<"OU+O/%_QPGDTEO7&:NKP38!RW$K4J# QW)B@.9(^PE!FXNH<
ML6$%T_I/20L<6N95-,]W"TJ
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MG*C4DY24L:5269TY5+$@R#Q\
M
M
M
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MU,^%:5=E%8G5UE72F)L"?"E-I>C2X4R,MV/*BR&5DI#B%*0M)D9&9&+"X^Z
M                                        (Q^\U4Y1==KKFE#Q I1V
MK.H)-M+*(;A._BO09!17N;FLVD+5ZJ6%UM@;Y&7A-GQ^(R3U,HJV/A2P[C[=
MY;KBQMNN>VJFH9? >HJ"QY>+4ISA1Y]OC2IY?3AAQ,MD:P[H@ <YUELO.]-[
M!P[:FL<FL\-V!@.05V3XEDU.]Y,^HN:M],B+(;\1+9?96:3;>8=2MB0PM;3J
M%MK4DZIM/%<S5ZWHNE;CTBYT'6Z$+G2;NC*E5IS6,9PDL&N]/M4DU*,DI1:D
MDS3Q[5?<8PKN.\::C8T15=2;APQ,'%MZ8!%=Z*QS,2C+-F]JHSKBY)X;FK$=
M<VL<4:R;,GHBG%O1'5#9TJBJ1Q[>TX@]>.CFI]&]ZU-&J9ZNW;G-5L:[7M*.
M/&$FN'C46U"HN&/P:B2C4B2:"0^)
M
M
M
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M:U=;>URC.WU>SK2I5:<N<9P>#]#B^<9+&,XM2BW%IG8(J:@
M
M
M
M                                ^I/@0+6')KK.%$L:^:RN/,@3XS,R
M'+8<+HXQ)BR$.,/LK+T&E232?_8 (R.0G9Q[??(E,V9;Z.JM891,-:SS#1[K
M6LK1MYXE&_*<H:J(_@-G-D.GYCC\ZFE/+<(U&KJI?BN4Y(I@B!+DK[-INW$2
ML+WB[MC&]O5+?C?C8-L!IG7^=I;))$W!K\@2],PC():ED9F]*<H&B2?3PF9=
M57JHNTM<>XK_ .Z./N[N.N4*PW>.K<UU?D7](J-"RVCF5K%HPTHD.3*&T4A5
M3D-<2S\/K,%^1'-7H)?4C$B:?(MP:.G0    ?)*E)4E25&E23)25),R4E1'U
M)23+TD9']0P!8/[='?>VWQY?HM5<J)%_NS22/5JROS%Z0=CMG6\0EI0RZW93
M72<V!C<)LS2J#.=*P8:\/JTHVV40W;)03XKF7*7>7-=0[CUAOO7]!M+3^:T>
M?8'DL?UBIR&AE>?'6I))*1!FL+2W,JK: XKRY,.4VS*C.D:'6T*(R$+37,O.
MRP                                     'G'EEQ:U1S,T)G_'K<M.5
MEB&<U3C$>QCML?#F'Y)&2MW'<WQ66^VZF!DN,61ID1UF2FG4DMA]#L9YYERV
M<5..67(_9; WUK_3?=EIN_;E3)J%K4Q<7CDK4WPJ4:J36:G5CC&2YKA.+C.,
M9++1YE<2MI<(>0^P..NVX7AR##;#S*;((T9^/29UAT]3CN,9UC:W_$;U+D,!
M'C)/B6N))0]%>\,B.ZA.LG!PEE?,[J=..H&A=3MGVF\=OR_U2YA\.FVG.A6C
MPJT*F'*=.7#'!*47&I'&$XM^718?N0 +8GLU'<I5K/8;O 3;V0J;P#:EK,NN
M/ME9R#]6Q;:<I*Y=UK]$B2\3,&GV0RRJ1 :2:4_C V;3:%OVAF67;5,'X;Y/
MD>!?.GT66MZ.NK.WJ..K6%-0OXQ7&K:KA"XP2QE.W;4:CY_)WF;4:"+S0S3E
MT
M
M
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MMY=KK(I<=3Q5=S&22$S:V7Y3BJ^SCDJ'/;;7X%)>:D,,P-.+P+T\3V.*%0
M      \K\I.:O&GAKC#&3<@-G4^(+L6W%X]BL=+UWG65&TORE_BYA]4B3=SX
MK;YI;=F&TW C*4GSWVB,C%4F^11O KT;D]IMB-6,N#Q^XQ/S:ILW2A9/N#,D
M5\V2752652,'PR+8LQ"3T)2O#D#QJZ^'W/3Q'(J?>4<NX\\PO:8^4;<II=CQ
M^T'*A),_/CPG=AP)3B?"HDDU+?RRR:9,E]#,S8<ZD1ET+KU)X:*9F2(\;O:/
M.-6QK*OQ[D+K7+N/UA-<1'_&RML/E/U\PX:TMI>M9-93TF85#;QJ(R)NHGMM
M%U\QXDEXSHZ;["JDBP/@N>X3L_$Z3.]<Y9CV<X7DD0IU#E.*V\&]HK:+XUM*
M=A6=<](BO^4^VIMQ)*\3;J%(61*29%'RYEQRT                   $'/?
M,[8T7GSQP?SC6]&E_E#H>JM;_6*H++:;#8F-$13LFU',<Z$J4[<-LJE4?C,_
M(N4):2IIF;+6<%>EXD<5ZR/4'E=ZW5.D^\EI>LU<-C:K4C3N<S^#;U/5IW:[
ME!O+7P]:BW)J4J5-&;8^P]&>>C2678\B.ZXP^P^VMIYAYI9MNLO-.$E;;K:T
MFE25$1D9=#&N.SL91G%3@TX-8IKBFGR:?:F?R N/TJ>XML>MZN_H;*=37E'8
MP;BFN*N4_!LZJVK)+4VNLJZ=&6W)ASH,QA#K+K:DK;<02DF1D1@0W%O;WEO4
MM+N$*EK5A*$X22E&<))QE&47BG&2;33X-/!FH3VB>?M=W">'V(;*MIL$MSX,
MIK7>^*6*AJ*<?/*B&RMK*(L!LFR8I,_IULVD?RT%'9D.R8;:E*AN=-G2J>)#
M'M[3AQYA.DU;I%U$N-%MXR_5NZQN+&;Q>-";>-)R[9T)XTI8O,XJ%1I*HC\3
MF-WD>(7##-K_ %3F_P IN9[:QQBO=M<$PK!9L=4 [BMAV].[*R;-'\3QB5 G
M5T]I[SZZ58$E!F7A-Q)MB=0;X]A\,;2(1-R>TR;DMGGXF@^.VO,'@EXVF[?:
M5]?[#MGT'XNDMFKQIS7U;4R"29=&G'K%M)EU-2R/H5ZIKM+<Q]'0?M*N\JG*
M:^)R4TUKG,\$D2V6K*VU1'O,.S>GB.N=)$^+"R')<DQS(UPVC\3<-7P4;IEX
M52D]?$1TUV!2[RVYIW<.N-^ZUQ+;NI,IKLRU_F]6BUQ^^K5+\MYKS'(\J',C
M/);E5MM5S67(TR'(0W)B2FG&74)<0I)1M8/!EYV6*
M
M
M
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M-I_H_&V\OH2E*-4=1<F7Q+3XB+@
M
M
M
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MYG=HH  /YO/,QV79$AUMAAAM;S[[RTM,LLM)-;CKKBS2AMMM"3-2C,B(BZF
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M>0W(8=04,Y8OAR+XK!$V0L+@
M
M
M
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MY1]/,GUF09C-NI5#-=+T&JN]3(D&:$D2#-)G)OF,$CW2+2H
M
M
M
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MSY/<-R48_P &C452@L>/XKF^;DZ$I\0
M
M
M
M                            J5^T2\#FHCE/SLUM2^!$V13X1R"B5\=7
MA3)6TS58%LF4339MMH?\EJAL75K3U=.L)*34MY8EIR_!99)=I5"$A: !+EV3
M^4SO&?G5KNOMK-<+7N]UMZ6S5IQQ)0D3,IF,)P"Y?2Z:8["ZK.VX+;DI1I]6
MKY<L_%X5+)5LUBBL>9H/B D  SYN\_PJL^)/+W++^BJ'F--[YL;;9FN;!EDR
MK:VTM9GKF=8,2TI2S'D8QD,U;L9A/H14S(?0S5XR3/!XKTD<E@R(<7%
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M_GC<:?/Y7:IOC\GK2RUX)=D:5=QJ=[E<R[%PJ4#$.@( %J[V6/E0>$<B=O\
M$N_L3;I-Y8BC8."17E)-M&QM8L2'+N!";(B64C(=?SI4I]1F9>"@;+H1GU/*
MM9X2<'VG@WSV;$_.FS].Z@6D,;K2[CY/7:_W>Y:4)2]%.XC&,5WUV7L!G'+(
M
M
M
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M6WK3MZ\7"O3DXRB^#4HO!I^E-8,^Z!$
M
M
M
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MX2
M
M
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M"<5J6('KTE#9-?"%U/Z.6=_;.(+HY,G/2)3O_C<4(VV^9?R.V10
M    !2 ]J]T.BEW#Q>Y)UL'HUG^!97J'*9;"#2TU::XNH^4XNY./T(7-MZS8
M$]II9>):F:OPJ,DH;(\*ZCQ4CIWY"-U.YV[KFRZTOA6EW2NZ2?-QN(.E5R_P
M82H4VURQJXKBV5(!B'00 "\+[)[N9=OI/E9Q_ER>IX%LS#=LTS#ID;BXVS\9
MDXI=IBJ-1N>K0)6K(BW$="0AR;XBZJ=6,VUE\%Q])S!\_.VU;[FT'=M./^UV
M5:UFUWVU1588^F2NII/FU##E%%MD99S^
M
M
M
M                             A@[^]?&F]M;9\E\EF[49WJ2PAFE9I),
MEW/*FJ4;A%_YB/5+-TNG_P",9'_L%\/6+9<B@:)BP "Q)[-/826^:^X:I)H]
M4F\6\JL'R-!&X<FLVSIR-%-*_JI035L]XB_VF9?]@LJ<BZ/,NVB$O
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MI+#%K#04&><CP
M
M
M
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MHI3;]PD22]TF5%A4   *@/M96VLIJL$X>Z1KI%E$Q#-,DVOLC*&TDIJMN+C
M(&$8_B3'FH<_]6[4,9[:.O-+3X6SD1U^E1EX,2Z;P4>PZ'>0/;]C7U7<6YZR
MA+4+:C:V])\Y0A7E6J57AV*;H4DFN+RS7+G2?&$=,0 .?:QVILK2V:TFR-1Y
MWE>M\\QR04FERW#+RPQ^]@+/H3K;<^M?8>7$E-EY;["S4Q(:,VW4+0HTG5-Q
M>*X,U.MZ#HNY=,JZ-N"UM[W2JRPG2K0C4A+N>62:Q7.,EA*+P<6FDRU)P7]J
M*V'B7P/@?/' /E-HD>1"^7#5==546P(B/<M^NYAKWS*O#\I]VOQ.OU+E(XRR
M@_#$ENGZ<J%TUPJ<?2>$.J7D:T?4/$U7I5=_(KIXR^174I3H/^#1N/A5J7<H
MU563;XU*<2WKQLY8\=>7N!1]D\<MLXIM'%W":3..DEN,7V.RGB6;=;EV)V;4
M'*,1M5);-28UE#BO+;Z.(2IM25'EQG&:QB\4<]=Z;!WCT\U5Z+O+3[BQOECE
MSK&%1+\*E5BY4JL?X5.<DGP;331Z'%Q^/     / W=-UZWM#MR<U<26QZT[\
MW/9N4U\8D)6J1<:_QV7G](RTE25%YSEQC+!(/T=%F1]2^J4=58TY+T'UCH3J
M[T/K)MG4$\L?SS;4I/NA7J*A-OT*%26/H[S*:&K.\X $L/8WS=> ]U;A];D]
MY35MFV3X1(0ITFVI"-A:VS3"&6724_'0[TF7S2VTF:C\Y"#2E:R2DY:#PJH^
M!>:'3%JW0;<5OAC*G:TJRX8M?)[FC6;7!X<*;3?<WBTL6:?HV9P]
M
M
M
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MGW%B;+3$B]R6YD*>M<DR":VP@GILUYZ0M*$H\1(0A*86VWBR3# [H%
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M9<TYZ!?Y5CA\-6M5PXXKE-)\>'?PQ-90;4X$
M
M
M
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M/P /3/"S^^/Q,_F8T/\ Q3Q47T_7C[J/Q/4O[.=P?4E]]%JFN*-J?S[
M
M
M
M     'X.495B^#X_;9;FF24.(8K0Q%S[S)LHN*_'\?I8#9I2Y-MKFVD1*ZNB
M(4LB-QYQ"",RZF#:7%\C+L;"^U2[IZ?IM&K<7]666%.E"52I.7[V$()RD_0D
MV0WYQ[07VQ,-V+\FL#<.1[$L_A"OJ?Q@UM@5]DN%.VEA)3%;AP<H<175]PAI
M;B#7)@G)A&2R)#RU)6E,+N*2>&.)Z,TORC];]1T?\]5=.HV=#)*?AW->G3K*
M,5BW*E\*4,>.$9Y9\.,4FFYKA,>:
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MC(B^J?H%]/UX^ZC\)U2K4[;IEN.XJO"E3T*_E)\\%&TJM\/<1K;C:G\_8
M   %#7VD;D7R#U9W"J;&=8[VW)KC&W..NMK1>/X'L_-L0HUV<K)]B,RK%=3C
M]Y70%3I+45I+CQM^8M+:2,S))=,&YE)5,$VE@=5O)EL[:.N](:M[KFE:;>7J
MUBYCXE>VHUIY52MVHYZD)2RIMM+'!8OO(!/GI\Q_\6?)C]_&T_\ JH0>)/\
M?/\ ;/6?]FG3G^C^B?R&U_T0^>GS'_Q9\F/W\;3_ .J@\2?[Y_MC^S3IS_1_
M1/Y#:_Z(?/3YC_XL^3'[^-I_]5!XD_WS_;']FG3G^C^B?R&U_P!$/GI\Q_\
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MI!NYH)N,X4U*+:;3P:X-KDS2"&P.-
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MU;6UEU5W-9V=.%*TI;AU&$(0BHPA"-Y6C&$(Q2C&,8I*,4DDDDE@>N1>?/@
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MXHZ7JS5SHMRI2M+N,7&%>,<,T7'&7AUJ>9*I3<GAC&492A*,G)$)#XR
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MJLUBL<)3<4_52.A=<_I"P3XY8O\ ?N"+5S1^KUG]#W?S:K\21L5C;G\Z0
M                                    !XYY_P#(YCBCP^WKNU,Q$3(,
M=PJ=58)U4CS'MAY6:,8P?RFE$HY"(>16K$I]"2,RBQW5>@DF95BL7@4?!&9N
MXXXZXMUU:W'7%J<<<<4:W''%F:EK6M1FI:UJ/J9GZ3,9!&?  =Y<9=,V?(?D
M+I?1]4E[UC:&R,3Q"5)92:E5E-:6\9O(;MPD]5^KT-"4F:Z:2-1-,*,B,^A&
M;P6(7,U$:RL@4M;7T]5%9@U=3!B5E;"CI\#$.! CMQ8<5A/4_"S'CM)0DO\
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M  FV )J'M5^SL/@/FC^P3<?S:C]*MS3Z&R.'P
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M3VRQJX]R/*/G/UI:5T,N[/-A+4;^TMEWO+4^5-+_ +-L\?1CV8HT<AL3C<
M    !GH^U!?234?\L^K_ ,Z]EC NO:>\=>?([]B]7Z[N?R5L5SQC'L8
M #0W]FUYH)Y$<*7-!93;+F;*XF6$#"T)E...2K#4&1E83]7SDNO.J\Y%!\'V
M-"33221$A54/Q>EY/786T\T,KYHY!><_IL]G]2UNRPIJ.B[@A*MPY1NZ>6-S
M'!<O$S4Z^+XSG5J8>JRQ.,@\>@           5G/:JOH]=.?SF:]_@CR'&-=
M>S7N_>9[8\AWVO:C_5NX^FZ>4!!@'6< "63L8_2N\.?CGF?\)M@":A[5?L[#
MX#YH_L$W'\VH_2K<T^ALCA\
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M;C^;4?I5N:?0V1P^
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MW'\VH_2K<T^ALCA\
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MCL,H)"$((DI21$1$1"<\IU*E2K4E5JR<JLFVVVVVV\6VWQ;;XMOBV?8 L
M                           *YWM0?T;5%_,SJ_\ -/9@Q[GV?OGL7R._
M;15^I+G\K;&>D->=>@ .9ZY_2%@GQRQ?[]P15<T:W6?T/=_-JOQ)&Q6-N?SI
M                                     >6^9W*?"^&?'/8F_,T\F6G%
MZQ47$\<5)3&D9GGEJER-B6)Q%GU=3\)V?14IUM#BXD!J1)\"DLJ(52Q>!1O
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M9_PFV )J'M5^SL/@/FC^P3<?S:C]*MS3Z&R.'P
M                                                    !G/>TM?2
M@Y5^QG4/WHGC77/M?>.Q?DJ^PZA]97?QXD 0@/6@   :R7;D^CUX'_R9\7_X
M(X.-K3]G'W%]PX$=9/M>W5_634_IM<]F"\^;@
M                                      5SO:@_HVJ+^9G5_P":>S!C
MW/L_?/8OD=^VBK]27/Y6V,](:\Z]  <SUS^D+!/CEB_W[@BJYHUNL_H>[^;5
M?B2-BL;<_G2                                     H3=[?N$(Y?[_
M /DKUK>KF\?M#V-A34+\.0:JS/MAH-VORK/T^4KU>=61?"JLI7?Z1)PFWI32
MR3/6@IH1P6/:1R>)".+R@ $R/92X+_/ Y3P,LS6G]>T?H!VISO/$RVO%79-D
MWK+KN X"X2VW693-Q;0%S;!E:3:=JJ^0RLT*D->*V<L%Z2L5BS0 $!( !1[]
MI(R!ZSYSZ\I/Z1,7&N-6%L);7Y9H7-M-A;2LY4IHTI)PB=BO1FC)1GT-CJ1%
MU/K-3Y%DN97R%Y: !?\ .PAB<?'.VAJ.X90PES/<QV]EDM3/3S')$/9&0X*E
M<KHPR9OE%PMI)=5.GY24>Z(O<(AGZQ?'D3*BPN*;GM6G)K,*I''+B1C]M*K,
M1R>IO-U[(@1G)#2<G=@7*<7UU!G+0EMI^LIIU=<RUQE+=0Y+.,\I"%QF5*P[
MJ3X0[.9T;\A>R=.KO6>H%W3C/4*%2%G;R>#\)2AXMQ*/-J4XRHP4L$U#/%-J
M<DJ8@PSI( !)=P9[M'-'@%-C5VH=BKR75GK27[+2&RO7<JUG)2IU;LE=)7+G
M1;7!["4IU2G9-'+@*D.$@Y)2$H2@2TZLZ?+EW'Q3JCT Z;=6:<JVX;-4-=RX
M1O;;+2N5PP6>65QKQ6'"-:-116.1P;;+K_ CO]<+^9GP+A><VR.,>\K-Z-7M
M8!LVZBJQ')+21Y3;3&![1.+5X_;KERGD,L0[-JGM)$A7EL17R(EJS*=>$^#X
M2.9_5?RF]2>F_BZEI=-ZWM>"<G7MH/Q:<5CBZ]KC*I#!)RE.FZU*,>,IQY*=
M$3GEL      ",SG)VD.%7/IB=;[;UR6,;6>B)CP=WZT7%Q79+"F&B:AE=RTP
MY5+FT2,A*6T,W4.>;+)&EA;!GXBCG2A4YKCWGVSI?Y@>I?2><;?;]YX^@J6,
MK*YQJVSQ>+R+%3HM\VZ,X8OC-2Y%+/GE[/QS2X>MWN<:]K"Y/Z1K%/RU9AK*
MJF?C[CU4E9^"1FVJO-GWT5+#1*<?E4[MU7QF$&[(?CE[DL*I0G#BN,3I5TJ\
MV_37J(Z6EZO/\Q[GG@O!N9+P*DNZC=81IO%\(QK*C4E)Y81GS<$2DJ0I2%I-
M*TF:5)41I4E23Z*2I)]#(R,O20@/5"::Q7(^(%0   ]$\:^67(OB!GC.R...
MV,IU=E"?)1/52R69-%D,1A9N-UV68K:L3\8RNL2M1J3'L8DEI"S\:22LB45T
M92@\8O!GX_>FP-G=0]*>C;RT^A?6/'+G34Z;?X5*K%QJTI?PJ<XMK@\5P-(W
MM!<N^2'-[A[0;ZY(ZSQ+7UU<Y'<4N&V^)+MX,+9N*T"(M<[GY8K;G/7C+,W(
M&IL-!-V$AJ8[#=?::C1U,I7L:,Y3AFDCC)YANGNS.F/42KM39E[<7=M3HPG6
MA5R2E;5:F,E0\6&7Q&J>2;QIQ<%.,92G-2:IK>T'<^6.8/,:1K# KGX0TEQ=
M^&M>8R_$D$[691L5^6PG:&9QS;,V7XIVE8Q30G"4XVY%J2DM*),M1##N*F>>
M"]5'1WRC=)Y=.^G*US5J>3<VNY+BHFL)4K=)_)J+[4\LI5IK@U*KDDL::9 D
M(#U< !;M]ECX;.Y!L+;G.'+:E7P/@$&1IK4$B5'ZM2<SR2'&L-C9!7NN(2MJ
M1CF(O0ZQ+B#4AU%]*;/HIHR&7:PXN;]PY[>>SJ/&TTC3^F&GU/\ 6;N:O+M)
M\51IMQMZ<EVJI54ZC3XIT(/E(NXC-.9(        9Z/M07TDU'_+/J_\Z]EC
M NO:>\=>?([]B]7Z[N?R5L5SQC'L8 "]K[*#:QWN*/)JC2AXI==R%K[5]Q24
M%'5'N=;XS#BH:63AN*>;<HGC<(T)225(Z&HS42<ZU?P&O2<L//O0G'?VB73:
M\.>CRBN_&%S5;Q[,,)K#CW\N&/9/M/?%,MM<-,0Y)4%7ZSEO&'-F%7TEAE"I
M+FJ-GR*W&,@2X331RY?P3FC-!)1U4;<6*J:Z9$1K45;F&,,W:C3>1_?KV_U'
MN-EW=3+I^N6KR)OA\JME*K3YO!9Z+KQ?;*7AQ[$B@", ZT  ?=K;&?3V$"VJ
MILJMM*N;%L:VQA/N1IL"?!?1)AS8DEE2'8\J+(:2MM:3)2%I(R/J0$5:C2N*
M,[>XC&="I%QE&2Q4HR6#33X--/!I\T:K7;)YA5_.;A7I;?OK$=68V%"6);7@
M,JC$NJVMAG@I,S2[%BD35?'OI;"+F"P9$I%99QC/TF-I2GG@I=IP<ZV].ZO2
M[J7J6T\'^;H5?%M9/'X5K6^'1P;XR=--T9RY.I3F>]Q(?*         K.>U5
M?1ZZ<_G,U[_!'D.,:Z]FO=^\SVQY#OM>U'^K=Q]-T\H"# .LX $LG8Q^E=X<
M_'/,_P"$VP!-0]JOV=A\!\T?V";C^;4?I5N:?0V1P^
M                                                         ,Y[
MVEKZ4'*OV,ZA^]$\:ZY]K[QV+\E7V'4/K*[^/$@"$!ZT   #62[<GT>O _\
MDSXO_P $<'&UI^SC[B^X<".LGVO;J_K)J?TVN>S!>?-P
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MGXSB>S!>?-P
M    SGO:6OI0<J_8SJ'[T3QKKGVOO'8OR5?8=0^LKOX\2 (0'K0   -9+MR?
M1Z\#_P"3/B__  1P<;6G[./N+[AP(ZR?:]NK^LFI_3:Y[,%Y\W
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M+%_OW!%5S1K=9_0]W\VJ_$D;%8VY_.D
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M;$ZE;(ZE:8M4V9J%"\I))S@GEK4F_P &M1EA4IO'@G**C+G!RC@SRV+#]T
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M)G 3?VS]0V!O/4MFZIC\KT^ZE3S-8>)#UJ55+CA&M2E"K%?O9H]""X_(
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MIU&3:RPFUWH\4>>C;;U3I;9[AI1QK:7JD,S_ 'M&YA*E/]NLK=%_T9YR7
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M#!0V0 %Y7V3G^[URS_;-A/YD/#-M?5?NG+OS]?\ -^W_ *MK?ET6R1EG@0
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MQK1VEHNKVU6UMHX9X6MO<TJTWABHNXKJGGJ/-AFRTU)PIQ9-2)CS2
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M2W7DW(?7$@9[@BI\B5+L,'O74DE3:W7951-4<62I:5194O8TJJJ+^%VG&/S
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MVEA4P[T>3O.?MK\^]$KC481QKZ3?6]TN_*Y.VG[RC<9Y+E\!/\%&C2-B<<0
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MZ+9(RSP(   &<][2U]*#E7[&=0_>B>-=<^U]X[%^2K[#J'UE=_'B0!" ]:
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MZ8[4K8[6L*W^MU8/X-U=4W[-->M0MI+A^#4KISP:I4INT4,H\-
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MK:^XJ9D>QJK:#$LZRPANI?B3Z^?';E0ID5Y!FAZ/*C.I6A1&9*2HC(8Y*?>
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MC&/8P %OSV2O](?-OXF:.^_FS!F6G.7O??.>/G__ $/MCYS>_$MB[$,PYG
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MA_J)M2OEWKJ5%^)4@_A6=K+%.::]6O7XQI8?"IPSUL82\%RT&!GG(X
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M\*>=[I='7=I6_4O3*:_.FD-4KG!<9V=6:49/M;H5I)I=D*U63>$47PQG'*L
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M/B__  1P<;6G[./N+[AP(ZR?:]NK^LFI_3:Y[,%Y\W
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MFXM8W;KUWN7<%:5QK-[6E5JU)=LI=B7*,(K",(1PC"$8PBE&*2[-%32
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M5MN(4I"T*(R,R,;0X.5:52A4E1K1E"M"3C*,DTXM/!II\4T^#3XIGV@+
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MH9]K+&#7<SDMYZ-M?FOJG9[AI1PH:II<,S[ZUM.5*?[5%V_I][ LOC)/%(
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M71;)&6>!    SGO:6OI0<J_8SJ'[T3QKKGVOO'8OR5?8=0^LKOX\2 (0'K0
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M<_'/,_X3; $U#VJ_9V'P'S1_8)N/YM1^E6YI]#9'#X "N=[4']&U1?S,ZO\
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MYXT[5\&H-*I57&JHQ;I*S ,D\4                 9Z/M07TDU'_+/J_\
M.O98P+KVGO'7GR._8O5^N[G\E;%<\8Q[&  M^>R5_I#YM_$S1WW\V8,RTYR]
M[[YSQ\__ .A]L?.;WXEL78AF',X   *P?M.W"\MO<7\0Y;8C5)?SCC3:IJ<V
M<BL*7,L]-YS8Q8,EYY31J<DIPK-'(4IM!H-#$.QL'E*2E*NN-<PQCG7-'N#R
M0]2?U>WQ<=/]0J8:7K5//1Q?"-Y0BY)+'EXU'/%O'&4Z=&*3;6%!T8!U?
M#1P]G>YI%RCX)T>K\FM/7-I<47JS4=\A]Q!S)^NO4WGM/WYH29F45O&H+U$2
ME?TCCU XXK_S",]C;SS0P[5^Q'&[S@=-7L;JG5URRIY="U]2NX8<HW&*5W3]
MWQ)*OPX)5XQ7+A/<)SRB   %9SVJKZ/73G\YFO?X(\AQC77LU[OWF>V/(=]K
MVH_U;N/INGE 08!UG  ED[&/TKO#GXYYG_";8 FH>U7[.P^ ^:/[!-Q_-J/T
MJW-/H;(X?   !FA]_P Y$.\@>YKNZ+%L#G8OHIJEX_XPWX_$B&O 67W\YC>!
M*4I2ZUM&[O$*/W2C2E)&?H(BUM>6:J^Y<#M7Y3-GQVCT2TR=2&6^U5SOZOI\
M=I4'[CM84'[[(71">E  +4WLJO']C,>3N_.1=I ]8AZ2U?483CC[Z.C4;+]P
M6LTUV,%PR(W9L'$,%LXCI(,R;9M/=D1N-F,JUCC)R[D>$//CNV>G;(TG9U">
M%34[Z=:HES=&TC'X,NZ,JM>G)8\W2X<F7N!G'*\        /Y/L,R67HTEEJ
M1'D-.,/L/MH=9?9=0;;K+S3A*0XTXA1I4E1&1D?0P+HRE"2G!M33Q37!IKDT
M^QHR-^8FE_FZ\K>1FC$1G8T'5>Y]BX92(>-U2WL9I\HLH^+3B6^1/.-6..%%
MD(4OW2D.D9^DQJ9QRS<>YG]!73K<OZX["T;=+DI5;_3;>M/##A4G2BZL>'!.
M-3-%I<FCS<+3]F !HA>S-[VD;4[<[>M[2<J3;<=]MYMKZ(R^ZEV6G$,F.#LW
M'Y#BS-3QQ$V>96<*,2S/RVH!-HZ-MH26PMI8T\.YG'[SL;5AH76-ZS0CEM]8
MT^C<-I8+Q:>:VJ+NQRT:<Y8<W/,^+;+#@R#R" !6^]IZT'\I? /']Q5\);]U
MQTVYC=]-EMM^:J/@VQ4KU_D#!DE)K;0_E5CCSRE]?"E,8_$1]2-./<QQIX]S
M/9?D?W7^9>K-;;M:25MK&GU*:6.&->W_ -8IOWJ4;A8?PN'<\^(:\ZZ  31>
MS^;G3ISNCZ#:F3$PJ3;<3-=,72U+)!/JS+&ILS%(?0TF3BI>PJ*F;)/4O2KJ
M1]2Z'-;RPJKT\#S7YMMMO<?0S5I4XYKK3Y4;R'H\&I%57[UO.LS2\&R.*@
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MLL)N/>CPSY\-M?G#IWI>YZ<<:^FZFZ;?[VE=TVIO'_Q:%".';CZ"^D,XY3
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M=.A>@;9+!8+DC^>76M5N]=UB[UR_>:^O;FK7J/GC4K3E4F^/?*39S45-8
M&<][2U]*#E7[&=0_>B>-=<^U]X[%^2K[#J'UE=_'B0!" ]:   !K)=N3Z/7@
M?_)GQ?\ X(X.-K3]G'W%]PX$=9/M>W5_634_IM<]F"\^;@
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MV-8EB=-78]C>/U,=$2LIJ6IBM0JZN@QT>Y:CQ(K*4)+TGT+J9F?4Q 2'(@
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MCGEAV#TFC3U2I!:KO&*3=Y7@L*4N'^RT<91HX-<)MSK\6O%47E4+PA/28
M>AN,7%;?',3:M/IKCWK^VS[-+7I(E)AH*-1XS3(>:9F9-F%_)\NKQG'("GDD
MY*E.(2IQ2&6B<?<::7=&,IO"*XGY#>^_-J].M!J;CW?=T[33:?!8\9U)X-JG
M1IKX52I+!X1BG@DY2PC&4EH;]JOLR:1[<V/QLWO7*S;7*2\J4QLHVO+KS^",
M0;EM];#%M2UT]HI5'3>[\F19NI1:6R4FIPHS"RA-;"E1C3X\Y'(+KQYD=S]8
M[R6F6JGI^Q:53&E:J7PZK7JU;J47A.?;&FL:5+DL\EXLIH1,>;
M         ST?:@OI)J/^6?5_YU[+&!=>T]XZ\^1W[%ZOUW<_DK8KGC&/8P %
MOSV2O](?-OXF:.^_FS!F6G.7O??.>/G_ /T/MCYS>_$MB[$,PYG   !P[8F
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M/(<8UU[->[]YGMCR'?:]J/\ 5NX^FZ>4!!@'6< "63L8_2N\.?CGF?\ ";8
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MW77O]1=$ET\VK6PW?J-'\?4@_A6EK--/!KU:]=8J'X4*>:I\%RI2=_L9YR8
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M*$;KB(T5I2W7GY,J0MV7865A+=<D2Y3ZW'Y4EU;KBE+6I1P-XO$D.QP
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MZ_X\.&?_ -]!I'_K@/$I_OE^VA_8WU>_HKN3_P"F7O\ H!_F-]O7_'APS_\
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MPRSG2     9SWM+7TH.5?L9U#]Z)XUUS[7WCL7Y*OL.H?65W\>) $(#UH
M&LEVY/H]>!_\F?%_^".#C:T_9Q]Q?<.!'63[7MU?UDU/Z;7/9@O/FX
M                 8ZFQOTA9W\<LH^_<X:A\V?T6Z-^A[3YM2^)$X8*&R
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M*4FW*4F\7*3>+;;>+;XM\6?; C                      ST?:@OI)J/\
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MG%X/FCOWH6M:?N31;3<&DS533+VWIUZ4N'&G5BIQQP;P>#XK'@\5V' A0VP
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M0W\)Y-DUGY;;UUDET\V3DF2X1=>B6VTMLMM-(@;;>+)#NT4
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MED^O_P"*1E_M&/<^S]\]@>2&A3J]:W4GCFI:/=2C[KG0AQ_[,V9X0UYU_
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MG]%NC?H>T^;4OB1.&"AL@ +ROLG/]WKEG^V;"?S(>&;:^J_=.7?GZ_YOV_\
M5M;\NBV2,L\"   !G/>TM?2@Y5^QG4/WHGC77/M?>.Q?DJ^PZA]97?QXD 0@
M/6@ $Y7LYOTKNCOB;NW^$N6B>W]JO?/+OG&^P35/G-E]*I&DH-B<8@
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M\J;4TZOIKQZ>TZ_^N1IIYU<MX6\Z[QP=O@W&GP457:\3&4J&6]$,XY;@
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M;^$\FR:S\MMZZR2Z>;)R3)<(NO1+;:6V6VFD0-MO%DAW:*
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M? ]O[#Z(]+^FRC4VII%M2U"*_P!IJ)U[EOM:K57*<,W;&FX0[HI<#P8(SZL
M    ?WC1I$R0Q$B,/2I<IYJ-%BQFEOR),A]:6F6&&6DJ<>>><424I21J4HR(
MBZ@63G"G!U*C4:<4VVW@DEQ;;?!)+FR?;@O[.]S3Y5_ ^9;@@_-3T_.\B7\,
M;'IY,C:%[7.>%?CQG5'K%=;0_-;/W+UZ_3MFA9.LIDI]R>1"WG+C+@CR=U2\
MX'378?B:;MV7Y^W%'%9+>:5M"7_K+K"4'AW4(UGBLLG!\2YUP:[3W##@%75\
MS3^MH^0;39B.1[3>>Q4PLHVG8+E-.,SDU=LY#CUV$ULJ.Z;*X=%%KF'V4I]8
M)]SQ.JS(4H4_57'O.;G5'KYU)ZLUIT]Q7KHZ$Y8QL;?&E:QP>,<T,7*M)/BI
MUY5)1>.3)'"*DG$A\7                            #/1]J"^DFH_P"6
M?5_YU[+&!=>T]XZ\^1W[%ZOUW<_DK8KGC&/8P %OSV2O](?-OXF:.^_FS!F6
MG.7O??.>/G__ $/MCYS>_$MB[$,PYG       >!>YSP\@\Y^%6Z-")C1W,UF
MT*\PU).?4RU\&;9PQ#MSA?26_P!6H$2_EM+IIS_0S;K;.2:2\701U89X./:?
M6.B/46KTMZEZ;NMR:TV-7P;N*Q>:UK80K<%QDZ::K0CVU*<,>!E2S84RMF2Z
MZQB2H%A E/PI\":P[%F0ID5U;$J)+BOH;?C2HS[:D.-K2E:%I,C(C(:L[QTJ
MM.O3C6HRC.C.*E&46FI)K%--<&FN*:X-'U0)  +?OLK7+\Z;,MV<(\IM$HKL
MRB'O+4K$EU*$(RFBC5^/[-HHGC6IR1+O,9;JK%EE"4H:9I9KA]368R[6?%P?
MNG/'SW]//E.FZ9U.L(8UK:7R*[:7_=3<JEM-]RA4\6FV^+=:E'L+L(S3F<5G
M/:JOH]=.?SF:]_@CR'&-=>S7N_>9[8\AWVO:C_5NX^FZ>4!!@'6< "63L8_2
MN\.?CGF?\)M@":A[5?L[#X#YH_L$W'\VH_2K<T^ALCA\ !7.]J#^C:HOYF=7
M_FGLP8]S[/WSV+Y'?MHJ_4ES^5MC/2&O.O0   :+7"+LU=L[:'"_B)LS/>*6
M)Y%G.Q.,&@LZS/().7;/C2+W+,MU3B=_D5R_&K\XB0([UG<6#SZD,--,H4LR
M0A*2(BV,*--P3:XX(X[=3O,=ULT/J3N'1-*UZXHZ79ZY?T*--4K9J%*E=5:=
M."<J#DU&$5%.3;>'%M\3T_\ Y&':B_P=8;_SKMK^T 7>!2[C\/\ WH^O?]([
MG_,VO^@'^1AVHO\ !UAO_.NVO[0 \"EW#^]'U[_I'<_YFU_T _R,.U%_@ZPW
M_G7;7]H >!2[A_>CZ]_TCN?\S:_Z ?Y&':B_P=8;_P Z[:_M #P*7</[T?7O
M^D=S_F;7_0#_ ",.U%_@ZPW_ )UVU_: '@4NX?WH^O?]([G_ #-K_H!_D8=J
M+_!UAO\ SKMK^T / I=P_O1]>_Z1W/\ F;7_ $ _R,.U%_@ZPW_G7;7]H >!
M2[A_>CZ]_P!([G_,VO\ H!_D8=J+_!UAO_.NVO[0 \"EW#^]'U[_ *1W/^9M
M?] /\C#M1?X.L-_YUVU_: '@4NX?WH^O?]([G_,VO^@'^1AVHO\ !UAO_.NV
MO[0 \"EW#^]'U[_I'<_YFU_T!VSHWM2=OGC7M+%]UZ/XUXS@&T<+^&_Q8RZO
MR?8EC,J?QCQVWQ.Z\F'>YA:U3WK^/7TN,KS6'/"EXU)\*R2HJQI4XO-%<3\_
MNCKUU<WIH5?;.Y]:KW>AW.3Q:4J5O%3\.I"K#%PHQDLM2$)<)+BL'BL42&"0
M^0@  !UUM_6E#NC4^SM/Y42CQG:NOLRUQD/@;0ZLJ7-L=L<:LUMMN&2%NHA6
M2S21F1>(B])"C6*:?)FXV]K5WMK7['<5A_MMA>4;BGV?#HU(U(XONQBL3(1S
MO"[[6^<9EKS*HQ0LHP+*\BPO)(:36I,2^Q:WF4=Q&2IQMIQ1,6$%Q!&I*3/I
MZ2(_0-2U@\'S/Z&-*U*TUG2[;6+"6:QN[>G6IOOIU8*<'V\XR3YLXH*&>>[.
MV+N%_0W<&X@;.;DKB1*K>V#4%]);6:%LXCG]FG7N:+3T(_,_^Q+*9O\ 1GT)
MPO<&:25XBDI/+43])\LZW[=CNKI%N+1&E*I4TJO4@GVU:$?E%'_WM*''LYX/
M# U<AM#@F !20]K'W$].VIQ)X_QW_+CXMK_.=Q7$5"D_^L>SW(XN%8X_(2:U
M++X-1K>U2R9)01^MN=37T(D85T^*B=-O()MV-+0MP;MFL9U[NA:0?<J%-UJB
M7^-\HI8\_5CR[:B Q#H2?I4]199!;U=#31';"WN[&#454!CP^=-LK*2U#@Q&
M?&I"/-DRGDH3U,BZJ])@0W-Q1M+>I=W,E"WI0E.4GRC&*;DWZ$DV;".K<%K]
M7:RUUK.H\/P5KK!,1P6L\))2GX/Q''Z_'X7A2AMI*4^K5Z>A$E)%_P!A?4&W
M2P6!_.WKNJUM<UN\UNX_VB\NJM>7^-5J2J2[^V3[6<[%35$;O=_U<]N'ME\S
M\-C1ES)472UWG\6(TVEY^1+U%.K=LQ68[*FGC>DK?PE)-(0DW5N=";,EFDRC
MK+&G)>@^S>7C7([=ZV[;U*<E&$M2A0;?!)7<96K;>*P6%;BWP2XOAB988U9W
M9  F_P#9W]NNZK[I>EZM<M,.HW%C&RM17CBWO*0ZU:XC.S''XAD:VT/*F9OA
M%4TE!]>JU$9$:B2)[=X55Z3S#YP-O1UWH5J5=1S7&G5[:[APQP<:L:-1^C"C
M6JMON7'AB:3XV)Q>  R/>:FU5[RY?<GMO>N^OQ=A[YVIE%1((R-M./6.:7#F
M-16#(U=8L#'RC,-=34KRVT]5*/J9ZF;S3;[V?T$=--!6U^GFA[>RY)V>E6M*
M:[?$C1AXC?IE4S2?I;P2/,8M/VY.S[.=HE6Y.YOKG)I<%4R@T%A>=[EM_,:,
MXA3HM6C!<2)QXR\*)<7+LYASF$$9+4<)1D1I0OI/;QS54^Q'ECSC;J6W.B5Y
M94Y9;O5KFA9PX\<KEX]7AW.E0G"3Y+.NUHTA1L3C.      !G/>TM?2@Y5^Q
MG4/WHGC77/M?>.Q?DJ^PZA]97?QXD 0@/6@   :R7;D^CUX'_P F?%_^".#C
M:T_9Q]Q?<.!'63[7MU?UDU/Z;7/9@O/FX                       8ZFQ
MOTA9W\<LH^_<X:A\V?T6Z-^A[3YM2^)$X8*&R  O*^R<_P!WKEG^V;"?S(>&
M;:^J_=.7?GZ_YOV_]6UORZ+9(RSP(   &<][2U]*#E7[&=0_>B>-=<^U]X[%
M^2K[#J'UE=_'B0!" ]:  3E>SF_2NZ.^)N[?X2Y:)[?VJ]\\N^<;[!-4^<V7
MTJD:2@V)QB        "D[[6I^D/A)\3-X_?S68P[OG'W_O'3'R ?H?<_SFR^
M)<E0,89T.  ED[&/TKO#GXYYG_";8 FH>U7[.P^ ^:/[!-Q_-J/TJW-/H;(X
M?  5SO:@_HVJ+^9G5_YI[,&/<^S]\]B^1W[:*OU)<_E;8STAKSKT !S/7/Z0
ML$^.6+_?N"*KFC6ZS^A[OYM5^)(U^MAZ^PS:^"Y=K/8F/5N68+GF/6N*Y9C=
MNP4BNN:&[ANP;&#);/H9)>CO'X5I-+C:^BT*2I)&6V:36#Y'\\>CZOJ6@:K;
MZWH]:=OJMI6A5I5(/"4)P:E&2]QKD^#7!IIF8!W4NW;FG;CY-W6LIB+.YU%F
M/KV6:)S^8R1HRC"CD-I?IK"4TA,4\PP>3*;@6K1$VI1FQ+)MMB9'ZZVK3=.6
M'9V'</H1UATWK)LBEK=/)3W#;9:5]03]E6PX3BGQ\&NDYTGQ7K4\SG3F1HB(
M^U@ <XUILC.-/; P[:>M,DLL0S_ ,AK,JQ+):ETFI]/=U$I$N%*:\:5LOM>8
MWX7674K8D,J4VZA;:U).J;3Q7,U>M:+I>XM(N="UJC"XTF[HRI5:<UC&<)K!
MI]J?:FFI1>$HM-)FGIVK>XSA/<>XUU6R(?P90[@PWU+%]YZ]A.J+\6<P]76I
MB[J(S[STP\,S-B.N95NK4YY?1Z(MQQZ(\H;.E452./;VG$#KOT<U/HUO2IHU
M3/5V[<YJMC<->THX\83:27C46U"JDEC\&HDHU(HDR$A\3        #*=V#G.
M1[.SO,]CY?/>M,KSW*K_ #')+%]QQUV;>9):2KBTDK6ZI;A^;,F+,NIGT+T#
M)Y$1Q   !*EVS.USM'N YN=O)7,P3COA]Q&C[$V8XP:95F\CRI,C"-=-R(ST
M2WS&3$<0;SSA*A5##J7Y'F.+C1)=LI*/NE4L?<+]>EM)ZNX\:VQK4FG,.J<&
MP+%(A1:JDJ6322W5]%3+2TF.FY-N+RT?ZO3)LIQV5*>4:W%J4?40MMO%DAVH
M*                        (Y^:'=8X2<$8\^!NS;E?-V/&A'+AZ8UZAG,
M]JSU*;0[%9E4$&2U!Q)$]M?B8D7TNJB/I2KRW5&701SJPI^L^/<?8^FW0;J;
MU4G"KMG3YQT:4L'>7&-&UCV-JI).57+^%&A"K./#&**CG,[VFOEENKX8Q+BU
MC=3Q>P*5Y\1K)_'#S?<MC"7X&S>_&"Q@HQ?$%RVDJ/P5]<[-B&Y_16"E(2X>
M).YG+A'@CH)TV\DNP-M>'J&^J]37-5C@W2XT+.,N[PXR\6K@\.-2HH3P^%12
M;B5R<XSW.=G91:YOLC,LIS_,[UXI-UEF:9!:Y1DEL^E"6TNV5W=RYME-6AM!
M)2;CBO"DB(NA$1#';;>+YGLC2]*TO1+&GIFC6U"TTVDL(4J-.-*G!<\(P@HQ
MCQX\%S.)"AL     #E>$X)F^R\GJ<)USA^49[F5](*)28IAM#:9-D=O),C/R
M*VDI8LVRFN^$C,TMMJ,B+J?H%4FW@N9@:GJNF:+8U-3UBXH6FG4EC.K6J1IT
MX+OE.;48KW66,N&'LR_+;=Q5&7<H<BJ>+6 2T-3%8V\U%S;<UC$<03S+?XKU
MT]K&\1];;,DJ59V1V$)9_P!+7*4DT#(A;3EQEP1XYZD^=GI_MCQ-/V-1J:[J
MT6UXB;HV<7R;\6474JX/BO#I^'->K62>);EX6=J3A)P.8BV.D]30K#8S45,>
M9N;8CK.:;3EJ5'*-*7 OIT5F#B#,]OT2(U#$JHC_ */,:49$8RX4H4_57'O.
M?/4KKUU-ZJRE1W-J$H:,Y8JSMTZ-JN.*S4XMRK./X,J\ZLX]DD2."0^-@
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MAP?Z_P!M*UZU;GI2P3>L7$^'+"I-U%[^$N/IQY\R0T2'R
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MCQ( A >M  )RO9S?I7='?$W=O\)<M$]O[5>^>7?.-]@FJ?.;+Z52-)0;$XQ
M       !2=]K4_2'PD^)F\?OYK,8=WSC[_WCICY /T/N?YS9?$N2H&,,Z'
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M]U;7UK9>XKO:VXJ+H:S95G3J0?+%<5*+_"ISBU.G-<)PE&2X-';8J?GP
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MA@H;( "\K[)S_=ZY9_MFPG\R'AFVOJOW3EWY^O\ F_;_ -6UORZ+9(RSP(
M &<][2U]*#E7[&=0_>B>-=<^U]X[%^2K[#J'UE=_'B0!" ]:  3E>SF_2NZ.
M^)N[?X2Y:)[?VJ]\\N^<;[!-4^<V7TJD:2@V)QB        "D[[6I^D/A)\3
M-X_?S68P[OG'W_O'3'R ?H?<_P YLOB7)4#&&=#@ )9.QC]*[PY^.>9_PFV
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ML5AF-%C,MQXT:.VAEB.PRA+;+##+:4MM,M-I)*4I(DI21$1=!0J?V
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M^(9%':4HHEY06!*9=+_RWF_ ^RIR.\TXN!IIX,EYGH 4
M              !GH^U!?234?\L^K_SKV6,"Z]I[QUY\COV+U?KNY_)6Q7/&
M,>Q@ +?GLE?Z0^;?Q,T=]_-F#,M.<O>^^<\?/_\ H?;'SF]^);%V(9AS.
M     #XJ2E:5(6E*T+2:5)41*2I*BZ*2I)]2-)D?0R,"J;3Q7,RZ.\3PQ5P>
MYX;:UI35GP=K'-Y1;@TVEIIMF&UKW/)UC(;HH3324H9BX3D\.RHFDG[M3-:A
MP_0X1GK*T,E1KL.Y?ETZDKJ?TJT_6KF>?6[6/R2\Q;;=Q0C%.<F^;K4G3KM\
ML:C781="(^Y@ 3A>SX\J3XU]QG7&.7%DJ%@G)*#*T+DK;CJ2C%?Y/)BSM8SB
M9=<:95./8=; KD.F?C:C6DCP^(U&A4]O++47<^!Y@\W.P_UTZ.7MY;0S:KHL
MU?4WAQ\.DG&YCBDWE^3RG4:Y.5*&.&&*M\^T(8^=[VE>3[S;<MZ3CTO2N01F
MHA)42BC;YUI!GN2D&TXM42)46,A]7A-!I-HE&KPI4E67<>R?O?=.>?E%N_DO
MF T.,G%0K1O*;;]-C<RCAQYN<8Q6....&&+36:(-:=JP )9.QC]*[PY^.>9_
MPFV )J'M5^SL/@/FC^P3<?S:C]*MS3Z&R.'P '56]=91-UZ1W'IJ>\U'@[;U
M5L+64U]\EJ98B9[B-OBLEYY+9*<4TVS:FI1)(S,B]'I%)+-%Q[T;[:VMU-L[
MGTW<E)-U=/O[>YBES;H5854EZ6X&0-;55C16MG27$-ZOMJ:PF55I DI\$B#8
MU\ER)-AR$=3\#T:2RI"R_P!BDF-0?T-V]>C=4(75O)3MZD%*,ERE&23BUZ&F
MFC\\"8 "\Q[*'NAB[X^<G>/\F5UL-=[9QS:=:P\X7F*IMIXJUC4IN$A7NE1:
M^UU:;CI)]RVY/29]#<+KG6LO@N/I.77GWVU*UW=H>[81_$WFGU+637[^UJNH
MG+TRC=8+O4'^]+8PRCP*                       $4G>WT'\X7ME\G\<B
M0ES<AP+#VMU8QY+?G2F;'44YC,[=,-DDK6])L</KK.$E""-:O6C)/51D0BK1
MS4VNT^]>63=GZH=;=#O*DE&SN[AV=7%X)QNXNC#%]BC6E2GB^"R\>!E^#6'<
M4 "^S[*MM)62<,=XZHE2G9$S5_(&1>PFW%FI$'&]D83C;D"&P@_0VTK(L1MY
M!_\ :M]0S[5_ :[F<H_/AH2LNI.EZ_3BE3OM(4)/]]4MZU12;]/AU:4?<BB<
M'N$[95HS@URTVJQ+5!L\1T#LZ1CTI+AM*:RVSQ:QI,/\+J3)39KRFSAI(T^Z
M+KZ/3T$U1Y8-^@\P](MOK=/5';^@SCFH7&K6RJ+GC2C5C.M_[J,S)E&J._0
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M7F9#+4B.ZV^P^VAYA]E:767F74DMMUIQ!J0XVXA1&E1&9&1]2$!(?T
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M!RU/1JD;^FDN+A24H7$>_!6\ZE7#ME2BO2M)P;$XO@
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M]        !G/>TM?2@Y5^QG4/WHGC77/M?>.Q?DJ^PZA]97?QXD 0@/6@
M:R7;D^CUX'_R9\7_ .".#C:T_9Q]Q?<.!'63[7MU?UDU/Z;7/9@O/FX
M                  8ZFQOTA9W\<LH^_<X:A\V?T6Z-^A[3YM2^)$X8*&R
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MK]27/Y6V,](:\Z]  <SUS^D+!/CEB_W[@BJYHUNL_H>[^;5?B2-BL;<_G2
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M<ZY0PO,8L;(S,V9M1I%*R;=KH"4DIIS)G4^L/&I1UK;*4,V#V'5N/P:?[?\
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M-V3+U[+=9IY2B(DIA.UIF:W7'5"&<<'BN1?%XHL#"PN
M           #/1]J"^DFH_Y9]7_G7LL8%U[3WCKSY'?L7J_7=S^2MBN>,8]C
M  6_/9*_TA\V_B9H[[^;,&9:<Y>]]\YX^?\ _0^V/G-[\2V+L0S#F<
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M\0'JH "63L8_2N\.?CGF?\)M@":A[5?L[#X#YH_L$W'\VH_2K<T^ALCA\
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MET6R1EG@0   ,Y[VEKZ4'*OV,ZA^]$\:ZY]K[QV+\E7V'4/K*[^/$@"$!ZT
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MK6=5PES<9QYPJTVTLU.K!J<)8+&,EBD\4N]!<?E@
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M279:S?\ 2[4:G^K7L7=V:;?"O3BE<4XKCQJ45&KV)>!-\7(I$C".G(
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M@G&GF76S4AQIQ"B4E23,C(^I#-.9,HRA)PFFIIX-/@TUS378T?U M
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M\K;&>D->=>@ .9ZY_2%@GQRQ?[]P15<T:W6?T/=_-JOQ)&Q6-N?SI
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MD+0HC(S(QL3C;5I5*%25&M&4*T).,HR33BT\&FGQ33X-/BF?: L
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M8L&'5=5(C19L%DO"GP$(JBXXE\7P+$PC+@
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MPJ8]Z.NOD>W(]6Z0U="J2QK:3J=:G&/=2KJ-S%^A.K4K\.]-]I7$&.>R@
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M]27/Y6V,](:\Z]  <SUS^D+!/CEB_P!^X(JN:-;K/Z'N_FU7XDC8K&W/YT@
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M<BE<=.X!IF?/L#@XCMB:_I#,B5(.-%=A;#<C0L8>F.J/U=N+6;!C4\IUQPO
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MQT&1GG(T          SGO:6OI0<J_8SJ'[T3QKKGVOO'8OR5?8=0^LKOX\2
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MA5*=2MTUU_7+2E1GC+&-.M=4H5[.<UQC4IPFU3GCC4I.,U)S52,+$(R#Q^
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M T77K_O*AGZQ)'D3#BPJ
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MQ9J,DI+J9F?U3%Q^*JUJM>HZM>4IU9<Y2;;?NM\6?; C
M
M
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M=Q99DVDB-"_$I7^^0BJ<R^/(L>B,N
M
M
M
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MS9]->H_AZ;JM1:'N>;4? N9Q\&I)]E"ZPC3GB\$H551J2D\(0ES(*Q >I0
M  #3Y['F[<NWWVP^,>7YU-E6N48_1Y/K&;;S'E295M7:OS3(,(QB;*D.&I^3
M-/$Z:"W(>=4IU^0VXXM2C69GLZ#<J2;YG#[S/[9T_:G7#7-/TJ,:=C6JTKF,
M$L%"5S1IUZJ2Y*/BSFXI8*,6DDL"642GP$J[>TZ18*]6<3IKDKP64?/]FQ8D
M+QH+UB#+QW%G;"5X#+S%>IOPHR.I&22\_P!/4S3TDI\V6R*>XE+  +D7LR7Z
M"^3O[6<0_,]T15.:+HEF\1EX
M
M
M
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MI]4Q%4YE\>19.$9<
M
M
M
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M^L7QY$U0L+@
M
M
M
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MXDBY'I<4*@
M
M
M
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MJMC96VI7EM7I:=>1G*A5G3E&G6C3FZ<W2FTHU%"I&4)96\LDT\&<P%37
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M+47(/@ANJ)1ET\Z>V7U3(4D\%B57%FDP,<D
M
M
M
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MQ1S\W#MO7]IZI4T3<UG<6.JT_6I5H2ISP>.$DI)9H2P>6<<8R7&+:.S14T@
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MCL;J1LCJ1IOYTV9J-O>T$EGC%Y:M)ODJU&:C5I-\<,\4I8-Q;7$\PBP_<
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MLI2Z>,T,N/<["N(RUMJ-V#<9,S70&UH4@TOTTI*B41I,HJC["^*[2TN(RX
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MO8-0RGJF0Y/PO(&*Z^5$BND:%RX[+\%2NAH?6E25'8XM<RJ:9Z[%"H
M          $..^>^1POXZ;AV!I#/ZK=KV9ZVOWL<R%W'L&Q^QI5V###$A:JZ
M=*S:ND28_ER$]%+8;/KU] N4&UB6YD=1_P"HR[?_ /4O(;]W.,?VABOAR&9#
M_49=O_\ J7D-^[G&/[0P\.0S(?ZC+M__ -2\AOW<XQ_:&'AR&9#_ %&7;_\
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M52K'ZC(<6QF4B/+K\JO'G+$['+XAH;-I*3:)Q1K(TDE5'%KBRJ:9)D+2H
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MP[;3F&SD7N136T&:"M,GOY$JQEF7H5*E.&70CZ#';Q>)*N!W.*
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M)Q:6(&)[):;2Q5UV435*)J#;-)8C6"_"S);1+43\N*4.U%ZEV,M"",N
M          ,WGNP?2,\N?VLV/WKJAD1]5$3YGGC4'$[DQR I+/)-(Z*VAM2@
MI;4Z.VN,&Q"WR*OKK@HD:>=;+E5T9YIB:4*8T[Y:C)7@<2?U#(&TN8P9VU_E
MJ=P#_!UR&_=AD_\ P 9H]XP8_P M3N ?X.N0W[L,G_X ,T>\8,?Y:G< _P '
M7(;]V&3_ / !FCWC!C_+4[@'^#KD-^[#)_\ @ S1[Q@Q_EJ=P#_!UR&_=AD_
M_ !FCWC!EG_V>CCGOCCUA_**'O+46?ZGE91DNJY..1\\QJRQQV[CU57G+5D]
M6HL6&52VX+DYE+IHZD@W4]?JD(YM/D7Q18T$9<           !6\]IA_NHZ%
M_F%:_AOG DI\RV7(I@UM59W,KU&HKYMG-]5GS?5($9Z7)]3JX$FTLI),,(6X
M;$"MANOO*Z=&V6E+5T2DS$I8=M\=-]Y[QAW9KO>^LYI0\OUUD#%S":>6\F#<
M0%MNP;S&[=,=QIYVDR:CER($Q"5)4J/(7X32KHHC6*P"X&ESQQWW@G)_2.N=
M[ZVF>M8EL;'H]S$8<=:=FTUBA;L&^QJU\A2FD7.,WL61 EI29I*1'7X3-/0S
MQVL'@2KB=VB@     *R'M-OZ"^,7[6<O_,]H24^;+)$"O9K^DQXI?&W+?X8Y
MP))>JRD>9HLC')              H5^T'?2,Y+^R;5GWKG">'JD<N9%)I[CY
MO#D%97%/H_5.=[6M<>@L6=Y7X+CECD4NIKY4@XL>9/9KF7EQH[TDO E2B(C5
MZ!<VES*'?G^6IW /\'7(;]V&3_\  "F:/>,&/\M3N ?X.N0W[L,G_P" #-'O
M&#'^6IW /\'7(;]V&3_\ &:/>,&/\M3N ?X.N0W[L,G_ . #-'O&#'^6IW /
M\'7(;]V&3_\  !FCWC!DX?8(XB<H-!<Q-DYCNO0FU-68K9<:<QQJOR#.,.N,
M>J9F03-HZ;M(M-'FV$9EEVQD5U-+?0T1^)34=Q1%T28LFTUP+HIXEO 1%X
M       !!YW]]'[@W[P[UMAVE-:YEM/*JWDMAV2V&/X/0S\AMH>/P]7;DJY5
MS(A5[3SS5='L;F(PMTR\*79#:3/JHA?!I/B6RY%0_P#RU.X!_@ZY#?NPR?\
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M2Y<IUN/&BQH[:G7Y$A]U2&F6&6D&I:U&24I(S,R(@!2 [M'>5S3DGD>4\?\
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M.7,]9^S)?IUY._LFQ#\\'1;4Y%8\RY"(B\
M"LA[3;^@OC%^UG+_ ,SVA)3YLLD0*]FOZ3'BE\;<M_ACG DEZK*1YFBR,<D
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M-CU3BV+T<%)IC5E)20F8%?%0:C4XZM$=DO&XLU..K,UK4I2C,\?GQ)#EX
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MAD1]5$3YED/V9[^ZCOK^85W^&^#B.IS+X\BR&(RX
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M1C](#3_R]:Y_.;80FI^J62YGH;V9+].O)W]DV(?G@Z*5.0CS+D(B+P
M       S]>^)RB?Y&<Z\\QRKGJDX%QZ)S3&*LH61QW+RAE..;(M3;2GP>M2,
MX7*@^82ED[$K8RNI?[I3P6$2.3Q9^EV0>%4'EIRWB95G%0S:Z?X\QZS8N90I
MK*'ZW(LJ=F/-:WPZ:PZEUJ3$L;F _8RF76UL28%2_'<Z$^GJF\%Z1%8LO\"
MD       J^^T?\0X&0:WP'F7BM6VUD> 65=K+:ST5AM"K+",CE/%A5_8NEX/
M&YC.6O\ P:E1^-UU%VTDS\$=)%)3?86R7:5.M.;4RO1NU]=[AP>6</+-:9C0
M9G1N>8ZVR],H;%B<4";Y*D+=K;-II4:4UU\+T9U;:B-*C(Y6L5@6&H?K+8&.
M[9UQ@6T<1D^MXML;#<9SG'9)]/$]2Y530[RL4X1?[CWJ<Y!+3]5*R,C])#&Y
M$IS@           4J/:7LCGRN76C,2<\[X+I..-?D</Q.=6/7\IV;L6LLO+9
M\HO+>]7P^+XU>-7C+P%X4^'JJ:GR+)<SPUV2ZVBM>YWQ@CY EAR,Q8;,LH#,
ME"38=O:G3.Q+*A4;BGV?(?B6T5F0P9>,U2&6T>$_'U*L_5*1YFAX("0
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MJ)D6T$VVAM)K-+:$H2;CCCKAD@B21K==4MUQ9D7I4HS49^DS,Q85/F
M       S>>[!](SRY_:S8_>NJ&1'U41/F60_9GO[J.^OYA7?X;X.(ZG,OCR+
M(8C+@                     *WGM,/]U'0O\PK7\-\X$E/F6RY%;SM/_2,
M\1OVLUWWKM1)+U66+F:0PQR4IL^T,<##U_L"MYL:VIB:PW:$^%C6Z(4!A*6:
M+9:8JFZ/,5QV$)1'K\[K(7D3'?"2"MXOF.+4]8I(2PEV,LDNTBJ[7W-ZTX+<
MI<6V'.DRW-4YAY&"[II8Z'))2L'LYK"_QAB0D]?.O,*L$-V,7PEYSK;;\5*D
MHE.&=\EBO243P9HTTUS4Y%3U604-C"N*.]K8-S36];(:EUUI4V<5J;76,"6P
MI;,J%.AOH=:<09I6A1&1F1C')#](  !60]IM_07QB_:SE_YGM"2GS99(@5[-
M?TF/%+XVY;_#'.!)+U64CS-%D8Y(             %"OV@[Z1G)?V3:L^]<X
M3P]4CES/6?LR7Z=>3O[)L0_/!T6U.16/,N0B(O
M     K(>TV_H+XQ?M9R_\SVA)3YLLD0*]FOZ3'BE\;<M_ACG DEZK*1YFBR,
M<D                  "BQ[1C](#3_R]:Y_.;80FI^J62YGH;V9+].O)W]D
MV(?G@Z*5.0CS+D(B+P           .IM][0AZ2T?N'<5@3*XNK=8YUL!QE]1
M)1+5B.,V=ZS!+JI!N/3WX*66T)/QN..$E/51D0JEB\ 9;-S<6>0V]K?W<U^R
MN;RRG7%O8RE>.3/L[.4[-GS9"R(B6_*E/K<6?0NJE&,@B+W7L_6B8FJN!%-L
M.1%)O)>0.;93G]@^XGI+;QZAL7\"Q.L49'X50DL8W)LF/JJ_^M5]3]))3#-X
MRP)(\B<46%0      .F.1&C,.Y+Z0V;H?/\ UMO%-GXK.QJRF5Y13LZEYXVY
M55?57KL>5#*VQZXBQYT4W6G&RD1T&I*BZD=4\'B'Q(K< ]GT[<N&FR>08MM7
M:QM&I2CS_:-M!)\S2@D^<C6,/7"#)M2#41)))&:C)74NA%=GD6Y43 ZUUOA.
MH,#Q;6.N*)K&,%PFI8HL6Q^/+L)S%14134<:"S*M9<^P=:9\9DGS7G%$70NO
M0B(6<RXYP           *E_M-.D;9<SC9R,KXC[](U"R;3.53$I?4Q6S_63S
M3!VEF1*CH5;,NWWI/P*,XJ2]WU+P2TWV%DN\K(:1V[EN@MO:WW3@C[;&6ZQS
M&CS&E*1YAPY<BFG-2G:NQ0TMMQZJN(J7(DMLE$;D9Y:.I=1(UBL"TTH>(G+/
M4W,_2F,;IU-;L2(-K&8C91B[TMA[(=?Y:W':<N,.R>,WX'(]E6/.?T;IH2S-
MC*;DL&IAUM1X[33P9*N)Z>%                     0$>TJ:R>S[M?9?DK
M+'GGIG<&I-FN=#3XV69UO/U,Z^A!D:W?+1M(_&2/2ELU+/W"5""Y6-+'N9ZR
M\ENMQTGKC;V4GA^<M.N[;W7&$;I+T?[+PQYO!<VC.8&N.QH %COV8#;K6"=P
M^^UQ-EJ;B;PT1G.,UL+SO B5E6&V./[&@/\ E&LDONQ,6QBZ))$E2TI=49=$
M^+KD6SPJ8=Z/&OGAV]+5>D%+6:4<:FEZK0J2EARI5HU+>2Q[$ZM2CZ."[<#0
MC&P.10   <5S;!L+V5BMU@VP\3QS.<,R2$Y77^*9;2UV0X]<P7>GCBV=/:QY
M4"8R9D1^%QM1$HB,NAD1BC2:P?(S],U34M%OZ6J:/<5K74J,LU.K2G*G4A)=
ML9Q:DG[C*KG/OV8;66?JNMB\#<KBZBRM];DY_2&P;*VL]6V3GEJ<?9PW+5,W
M.685*DO)-3<6:5K7FZX3;:X$=)$G&J6R?&GP?<>[NDWG?UO252T?JM;RU"P2
MRJ]MXPC=1[G6I8PI5DESE#PJF"Q:JS?&G5R*XN<@N)>>OZTY%ZHRW567H0Z_
M#A9'!3\&WL%EXXZ[;%<B@.S,=RVE)\C;]<K9<J-YA&CQ^(C(L.490>$E@SHM
ML[?.T=_Z4M;V=?V]_IS:3=.7PH2:QR5:<DJE*>'')4C&6''# Z#%I^L   #E
MN!YYF>K\SQG8FN\FN<,SG#+F#D.*Y5CTY^MNJ*ZK7TR(5A7S8ZDNLO,NI_[T
MJ29I41I,R.J;3Q7,U^JZ5INN:;7T?6*%.YTNYIRIU:52*E"<)+"491?!IK]K
MFN)JB]M+EJ_S?X3:*Y%VL:+!R[+<<F4VPH,)GU>$QL+"KBQP_,),"+Z4Q*RY
MN*5RPALDI?DQ);39J4I)F-G2GG@I=IPCZU=/X=,.INJ[.H2E+3[>LIV\I/%N
MWK0C6HJ3[90A-4YO!8SA)X),]V"0^6   !5-[RW>6^"?QJXB\1<J_P#K;_UN
M/;IW3CTW_P#Y/^_%M==Z[M8J_P#_ *W^\S;V[*O_ $GNHL57G^:ZQ+"':RV4
MNQ%2 2%@   71.QMVL7-(T-7S"Y XXY&W!EU0;FH<)NHA-R]8XA<Q5)=RNVB
M/]7(F<Y=6R/ RRM+;U56N*0X12)3K4:*<L>"Y%\5AQ+)HC+@
M                   *2GM*67+M.9>I,/;<-<3$N.M%/<09+235ME&P=@N3
M$I)222LE5E/!5XDF9&9FD_2DQ-3Y%DN9XO[)V$1LY[E_&V-.90] QN=GF;R$
MJZ]42<3UIE]K1/-EX%I-;&2M0E^GP]$D9D?4B(ZS]4I'F:'8@)
M                 ,WGNP?2,\N?VLV/WKJAD1]5$3YDW_L_W++C/Q_XV;GQ
MK=V]=8:KO[K>#EY4T^<Y=4X]86-.>!8A *RB1;"0RZ_#.;#=:\Q)&GQMJ+ZI
M&+)IM\"Z+6!/1_F6=O[_ !B\>OWG8S_QPLRR[B[%#_,L[?W^,7CU^\[&?^.#
M++N&*'^99V_O\8O'K]YV,_\ '!EEW#%'ZM%W$."V3W=-C6/<L]#75_D-K7T=
M'3UVQL=E6%M<6TMF!65L",U-4[(F3ILA#33:2-2UK(B])AEEW#%'LH6E0
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M5>0Z^SYDRX??=5X%K1XEGT49=#&.^+9(N1Z@%"H
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MQNESMEHT>/QS, R-%/FD)!%U+Q.P$)ZI,NO4CZ6--<RN*9ZG%"H
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M.GAE<_X7J>&ZTDK=]")2^L!#:)T<Y8<$7*/:RX>(B\
M               *&'M"+SKO<7OT..N.(CZBU<S'0M:EI8:5 LI"FF4J,R:;
M-]]:S2GH7C6H_JF8FAZI'+F?R]GQ^D9QK]DVT_O7!%9^J(\R^H("0
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M_H+XQ?M9R_\ ,]H24^;+)$"O9K^DQXI?&W+?X8YP))>JRD>9HLC')
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M2&VFFT$E#;;:$D24D1$1%T(0EY_0
M  %#WVARL=@=P^9*<<;6BZTIK&SCI1XO$TTTO(Z93;WB21>8;]2M1>'J7@4G
MT]>I%-#U2.7,X?V";^-3=RK5]<^2#=RO!=MT$,U.FV:9,; [?*5&VCRG//7Z
MIC3I>#JCHDS5XO<^%59^J(\R_D("0   (>N^[8V%5VV-OS:N?,K9C>6:C2W+
M@2GX<EM+FR\:0XE#\=;;J26A1D9$?I(^AB^'K%)<B@_^/N<_EIEG_,5Q_P 8
M)L$1C\?<Y_+3+/\ F*X_XP,$!^/N<_EIEG_,5Q_Q@8(#\?<Y_+3+/^8KC_C
MP0-3G U*7@V&*4HU*5B>.J4I1F:E*.GAF:E&?4S,S/TF,=\R4Y8*
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M\HZ3CBL5S*Q?87B1"7E9#VFW]!?&+]K.7_F>T)*?-EDB!7LU_28\4OC;EO\
M#'.!)+U64CS-%D8Y(             %"OV@[Z1G)?V3:L^]<X3P]4CES/1?L
MW.$X9FV[>2<7,\1QC+HT'5>)R(4?)Z"JOV(;[F6N-N/16;6)+;CO.-EX34@B
M,R]!GT%*G(K'F6\/D#T5^I;4W[N</_ PBQ9=@A\@>BOU+:F_=SA_X&#%C!#Y
M ]%?J6U-^[G#_P #!BQ@A\@>BOU+:F_=SA_X&#%C!':<>.Q$88BQ6&8T6,RW
M'C1H[:&6([#*$MLL,,MI2VTRTVDDI2DB2E)$1%T%"I_8
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MDQGFB)7B4GT=2NC*3>#*-+ I3B4L-63 ?_M$PKXI8Y]YX8QWS)3EHH
M      ,WGNP?2,\N?VLV/WKJAD1]5$3YED/V9[^ZCOK^85W^&^#B.IS+X\BR
M&(RX                     "MY[3#_ '4="_S"M?PWS@24^9;+D5O.T_\
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MJ1RYGK/V9+].O)W]DV(?G@Z+:G(K'F7(1$7@
M  5D/:;?T%\8OVLY?^9[0DI\V62(%>S7])CQ2^-N6_PQS@22]5E(\S19&.2
M                 !18]HQ^D!I_Y>M<_G-L(34_5+)<ST-[,E^G7D[^R;$/
MSP=%*G(1YER$1%X           $=O=GUQ(VIVYN6.,1&3D2:_6:\_:;1U\PR
MU1?TFT7_ "O"I*U.'&P]9$DNIKZ^'HKQ>$[H\)(H^1G "<C-(/M/;-8VOV[.
M)^1-2427:35E9K::1> G8\O4TR=K-3,EM*4*0Z;&*(<(UEXG6W$N=5$LEJ@D
ML),D7(D.%I4                                 /#'.?M_:(YX:TL,2
MV310:C/8-=(;UWN"JJXCF:X':&?G1S9EF<=ZZQB3)213ZA]XHTIHS-"F)*69
M+55)QY%&L3.SWWI'/.-^X]AZ-V;7%69MK;(Y6/W+39N*B3$);:F5-W5NNMM.
M2*3(Z67&L(+JD(-Z'):6:4^+H60GBL2-\"6_M3<F+2DXT]S'BA=V;[F,9SPG
MY';;P:#)>4J+69IBFI<@I<MC5C/F$2)658O8QI$CW"B-% @R-)]279)<4_25
M3X-%\00D@           $*_?XXM+Y-]N#:TNFK_7LWX_2H7(+$R9C$[+<AX/
M#L8V?P6W4&4@F'=<7%K)\E'C)^5$CD:#4E"DPUXYJ;[UQ/2WE-WTMD=9;"G<
MSRZ9J\96%7%X+&NXNA+#EBKB%*.+PRQG/C@VGFDC6G:D #W[VON5ZN%O.?0.
M]9TUV'AE9ES.)[0)"C\IS6&=-KQ;,Y+['5*9BL?K;+X6CM*4E*IE>R9J3T\1
M24IY)J78?)NN.P5U*Z7:MM:E%2U*=NZMMWJYH/Q:*3[/$E'PI/C\"I+@^1JN
M,/LR669,9YJ1'D--OL/L.(=9?9=03C3S+K9J0XTXA1*2I)F1D?4AM#@W*,H2
M<)IJ:>#3X--<TUV-']0+0         "!SN/=\+3_ !33?ZHX_*HMV<A(IR:R
MP>;D.S-8:PL6R)#OXU6M<^PK*<@B.*-!T];(3Y#J%IF28SC?D.WQ@WQ?(M<L
M.7,I6;MWMMSD;L.ZVINO.[W8.<WKAG*N+N3XT1(I...1ZFEKF4LUE!103=44
M:#"98B1TF9-MIZF)DDN"+,<3J0  !]ZLK+*[LJ^FIJ^=;W%O.B5E555D21/L
MK.RGR&XL&OKX,5MV5-G393J&VFFT*<<<424D9F1 "X1VH^QQ UPK&^1W-''X
M-SL!/JMUK[0]HQ&L:/!UFV3\+(=E,K4_"O<O0:R7'IS2J)4K03D@WY9DU!BE
M/L1>H]Y9[$9<                                      $!WM$>B)&S
M.$=1M6IA')N./VRJ3);!UMHWGT8+FS:L(R-IEM!>:DDY#84<IY9=4MQX;BEE
MX2\:+Z;XX%LN11B;<<:<0ZTM;;K:TN-N-J-#C;B#)2%H6DR4A:%%U(R])&)B
MPTR^ G)&'RRXB:/W<B6U(OLBPV#5YXTVHO%"V+BY'CF<L+9-UUZ.S(R&M?DQ
MDN&;BH<AEP^I+(SQY+!X$BXH]ABA4      "$+V@C:T# >WCD^%.2D-VNZ]C
M:ZP.MC)5_P"J=CT5^SLZUDH2DR<3$98P-#+SG^X1R4-J_P#-(CO@OA%LN10K
M$Q8:LF __:)A7Q2QS[SPQCOF2G+10            9O/=@^D9Y<_M9L?O75#
M(CZJ(GS+(?LSW]U'?7\PKO\ #?!Q'4YE\>19#$9<
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MB3-*VUD9>@Q'3YLK(@O[-?TF/%+XVY;_  QS@22]5E(\S19&.2
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M0R4\5B1<BTY[-1R3B6N![LXGW5@7PSB=TWN? XC[OB>DXOD+=7C&<1(39_\
ME0L?R&'62%%_XGKM:O\ M$51=I?'N+20C+@      .A^4.[*GCAQWW-O2Y6R
M4;6.O,ERB)'?4A";.]B5[K>,T:#<-+?K%_D;T2"T2C(C=D)(S(A5+%X!\#.\
MU_W'>=^KY:I6&\K]VQ$'(<E%5W&;6>78ZV\\ZIYU3&+Y>N]QR.AQQ1F:$14H
M,O1TZ$1"?+'N(\67C>TGN'D=R"X681NGDWD\7+,UV#D>76.-V;&,8]B3YX)3
MV*,4J#GU.,5=-5'*L+C'["<AY$9LG8\MHTEY?@$,DD\$7K'#B27"TJ
M  'U9TV'6PI=C826(4"OBR)LZ9*=0S&B0XK2WY,F0\X:6VF&&6U+6I1D24D9
MF (==V=^'MWZ@]<ATFP\GW=>Q%N,KJ=/XC-M(GG)\24*3E>6/8AALR(I9%U=
MA6$OHD^I)4?0CO4),IF1Z[X#\W<(Y\Z/E[JPG'+'#6JS.\EP2YQ.XLXMK;4\
M^C37V$!R;)AQHL;QW&.W4*;X&R6ADWU-$XX;9K.V2RO )XGMD4*@      4C
MO:3,-HZ/F9J[+*QEB-:9QH"C=R-#/4G)UACN:YI3PK>41I]+[M,4:&1DKH;4
M%!>$C(S5-3Y%DN9$UPGER8VW,]98>6VU/XB\]8DQ"3+I(C(X0\@IR67/0?5"
M9<)IS_\ >00N?+WT6HTUACDH           'TK*NK[BNGU%M"BV57:0I5=95
MTUAN3"GU\YAR-,A2XSR5M2(LJ.ZI#B%$:5H49&70P):-:M;5H7%O*4*].2E&
M47@XRB\5)-<4TTFFN3,G7N \6K+ACS$WSQTEM2RJ<#SB<K!YLPG3=M];Y"VS
MDFO;53[AK*3(DXC;1$R5)6XE$Q#S9J-2%=-54CDFXG?3I)OJCU)Z=:5O&FX_
M*+NUCX\5AA"XIXT[B."Y)583RXI8P<7A@T>.!8?1@ -*[L'<RRY;\ <"J,AL
MDS-H\<51=&YV3KJES9]5CE='5K;)GB<3YBTW&#G&BNOJ6XJ18UTM9F1GX2V5
M">>GQYK@<6/-?TX_L_ZLW=Q9PRZ%K.-[0P7",JDG\IIKL^!7S244EEIU*:])
M-@)CS.      !TCO_D?I/B[K^=L[>^PJ+7N(PS4RS*M7G';&ZL":6\BFQJBA
M-R;K)+IYMM2D1(3#[W@2I9I)"5**J3?!#D4T>XIWU-Q\GD7VJ>.2+S1FB92W
MX$^Y:EIB;:V/6J/PK;O;:MD.LX5034$1+K*M];[S9K1)FOLNJC)EC!+B^98Y
M8\B H7EH   =Q:*T%M_DML>EU/I'!KG/LXO%]6*NJ:0F-7P4.-MRKJ_MI2V*
MK'J" ;R?/G37F(S7B22EDI22,VEQ8PQ+S7;-[/FI.#-?6;)STZ?:_)V5 Z3,
MX<B+>Q?7"IK"F["FU7 L6&I$=Q3+JHTB]DM-V<UGQI;1"COO15PRFW[A(E@3
M*BPJ                                        =?[7UGB>Y]99_J3.
MH/PCAVR<0R#"LCBI\"7U5.1UDFKE/0W5H<]5L8B)/FQGTEXV)"$.)Z*21D3P
MX@S&.1>B<WXR[OV5HC8D;U?*]:Y/-H)CZ&S;BW$ B;F4.2UJ5+6OX)RB@E1K
M&)XC\?JTE'C(E=2+)3Q6*(FL";#L'=P6MX\;7M.+FUKPJW4V];V#,PFWL)"&
MJO"]Q/-1::,F4M:4IBU6Q:]B+ ??6LT,3H4(_"AMR0ZFR<<5BN9=%]A=W$)>
M     ?XI24)4I2B2E)&I2E&1)2DBZFI1GT(B(B])@"@AWM>>E5S(Y*1L.UM<
M,V^CM HN<3PZW@O^=79IEMC(B%G6<0G675Q9E-*E54>!5O(-:'X4(I3:O#+-
M)3PC@O21R>+(7A<4-63 ?_M$PKXI8Y]YX8QWS)3EHH            ,WGNP?
M2,\N?VLV/WKJAD1]5$3YED/V9[^ZCOK^85W^&^#B.IS+X\BR&(RX
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M L_,_P#33E,=6VXS*388/$8\#O#LU_28\4OC;EO\,<X"7JLK'F:+(QR0
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M%&W702-Y\R4Y%9DW-I/ MP[3RV*@U9,!_P#M$PKXI8Y]YX8QWS)3EHH
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MEEHGTU]5P+FIG-H=;;FUEI$:G0):&WVVGD(D17T+(EI2HB/H9$?H%I4_4
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MSE_YGM"2GS99(@5[-?TF/%+XVY;_  QS@22]5E(\S19&.2
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ML?KHE118_0UT2HI::J@LICPJVKK(#3$*!!B,()#;32$H0DB(B(A$7G[(
M                                           " 'N;]C_!.5]G?[QX
MZ3*/56_['S[+)Z&<TN)KC;%FHU.OV-IZBP^_B.:SS/JY91V78L]XO%+8)YUV
M:5\9X<'R+7''W2G=R"XK<AN+&4NXAOW4^7:XM$OJ8A3+>O\ /QJ]\/F'Y^,Y
M=6KFXODT51,K_I(,N0DC0I*C)25$4J:?(L::.G,:RK*,,M6;W#\DOL4O(Z%M
ML7.-7%C16K#;GA\Q#-C5R(LMM#GA+J25D1]"ZBH.^9?-+F-/JT4<[EER8F4C
M1$ENGE[WVE(JVTDE:"2BO>RI<1!$AU1="1]11E_M,4P7<,6>?94N]RFY5)FR
MK;(\@N9;3:I$IZ9;W-K.?4W'80IUY4B;.EO*\*$%U4M1]"+_ &$*@G2X#=B/
MD+R.LZ3.N1M=>\>M(&Y'FO0[F(F#MW-H!]'?5,<Q6Q8<=Q*++07A.QN66U-I
M6EQB'+29FFR4TN7,N46RR7SXTKJ_CUVGN2FI=.X=48-@6*::FQ*JDIXY-DMS
MX2J/6[2TEJ\4RYO;5Y)O39TI;LJ6^I3CJU+,S$<6W+%ESY&>8)R,U9,!_P#M
M$PKXI8Y]YX8QWS)3EHH            ,WGNP?2,\N?VLV/WKJAD1]5$3YD>@
MJ          #4XT'^@K2W[)M<_F?3#'?,D7([9%"H         !6\]IA_NHZ
M%_F%:_AOG DI\RV7(K>=I_Z1GB-^UFN^]=J))>JRQ<S2&&.2@      ?!QMM
MUM;3J$.-.(4VXVXDEMN-K(TK0M"B-*T+2?0R/T&0 SU>\)P.>X2<H+)>(TZX
MFA]S+L\WU&^PT::^C5ZRTK+M<),D(0T]A-G/;.*V7B(J>;!,UJ=\TD3PEBO2
M1M8,XGV:_I,>*7QMRW^&.<"LO58CS-%D8Y(             %"OV@[Z1G)?V
M3:L^]<X3P]4CES(0A<4          -%GLU?1G<4_BGEW\3\X$$O69)'D2<"T
MJ               5D/:;?T%\8OVLY?^9[0DI\V62(%>S7])CQ2^-N6_PQS@
M22]5E(\S19&.2                  !18]HQ^D!I_Y>M<_G-L(34_5+)<ST
M-[,E^G7D[^R;$/SP=%*G(1YER$1%X              !YQY1\4-(<Q=6V>I-
MZ8DUD6/S/%)I[>(IJ#EF&71)(H^1X9?G'D/TES&-)=3\+D:4UU8DLOQUN,KJ
MFUQ0YE*/F]V/N6'%FPM\GUG26/(W3#;STB%D^ 5,F9G>/U_B\3;&;:\AE*N&
MWHS?B-R=5%85_E-^:\N*:_)1,II^Z1N+(8?_ %=?+_\ RB%.A2/_ .Y&EQ)<
M9S_^!Z/(CO(_[E(47^PR%Q0[XK.6?*FDKU5--R8Y U%4IA$5596;EV- KU1F
MY");<=4*+DC48V$2VDNDCP^$G$DHBZD1A@ABSJO+\]SK8-@FVSW-,LS>U3YO
MAL\OR.XR6P3YZB6]X9MS,FR2\Y:2-7NO=&74P!Z!XR<(>4/+^]9IM#:CR;+8
M'K7JUGFDB,=)KV@-"D>L'=YQ;^J8]%?CM+\SU1#SDYY)&3+#JNB3HY)<PDV7
M'>VOV4M3<,I5/MW;\^IW/R-BHCRJNS*"Y\GNK)OEMK</ JVR:1,N,B8D^(DW
M\YIB0E"4>J182O-4]%*;?!<B]1P)QA87               $)?<F[+NHN:\F
MWVQK&PK=-<CY#"G)F1%"<5@FRI333;<9&Q:NO8=FP[7P,DTF[@-N2TMJ,Y$>
M=X&DMWQFUP?(M:Q*<?)_@5ROX?7$N!O+3^2T-&R_Y4'851%<R36ERA;AHC.5
MN<4Z)-(V_)3T64.4Y&L&DJ23T=M1^$2J2?(M::/*U'D-_C%BU;XU>7&/6S!*
M2Q:4=E-J;%E*C(U):FP'H\ELE&DNI$HNO05*'=?SM>57E^5\YGD%Y7@\OR_E
MFV/Y?E]/#X/!^,GA\'A]'3ZG0,$,6=+W^29%E=BNWRF_NLEMG&T,N6E_:SKB
MQ6TV:C;:7-L7Y,E3;9K/PI-70NI]/J@#TGQDX0\H>7]ZS3:&U'DV6P/6O5K/
M-)$8Z37M :%(]8.[SBW]4QZ*_':7YGJB'G)SR2,F6'5=$G1R2YA)LN@]LSLY
MZKX--PMH;#FU>V^2LB)X4Y;ZBI.):T1*BO1["LUK"G,IG+G2F93C$J[EI;ER
M6")##$)M;[;T4IM^X2)8>Z31"PJ                !2=]J-X+_  #EVO>>
MV!T_AK,U^#-2[V]28]RQEE57N?)KFL[RTK6?PYCD!VDE/K-#+2JNN;+JY(].
M%=0P?B+WSICY&>J7RO3[SI1JM3\?;9KNQS/G2E)?*:,<?WE22K1BL6U5K2Y0
M*@8Q#H< !+WV4^X ? 7F7C5[EMGZGHG<B(.KMVH?=6B#34UC8(7C.QEI)?EH
M>UW?NIDON&AUSX&?L&6D^8^E29J-3PY\?5?,\\^9?I*NK'3BO:Z?#-NK37*Y
MLL%\*<XQ_&6_N7%-98K%+QHT92>6+3O(]X*_Y6XKPJS/8G$;/9V'V^&J;O\
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M-=;\"9<B6MM+A0N3D7I)$BXM*@
M                 ?BY#C6.9=43,?RR@I<GH;%LV;"DR&J@W51.941DIJ96
MV3$F%);,C,C2M"B]( \!9]VDNW#LF0_*R/B7K2 ](6I;OXBJR75K7B6\R^HV
MX^L;_$([/5Q@O]Q*2))J3_NK62KLTN\I@CKN'V0NUW DM2V.+D5;K)FI")FW
MM^6,8S4E2#\V%8;3E0WRZ*]!+;41'T,O21&&>7>,J/9NF>('%OCR[ZWI30&J
M=<6IH4TO(<<PRF8RMYE230;$G+7XS^2R8Y)4KHVY+4A/B5T(O$KK1MOF,$CT
M<*%0
M
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MP:ZNBL0H,*,TDDM1XD2,AJ/'8:271*$))*2^H0M*GW0
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M,QX4"%&:226VFD(0A)="(B$9<?J@
M
M
M
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MW,Z(TN9DN53HC)LMVF69/.7(N\AGD2E&@Y#RFV"6I#*&V^B"B;;YEZ6!Z'%
M
M
M
M
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MXVVNH6VZ.;=>DT7X\(KX5S91QE))?A5;9N52"7&5-U8?#DJ45H #/.2P
M
M
M
M
M                        ?FW%S3X[53[S(+6MHJ2JBNSK2XN)T6LJJV$P
MDUORY]A-=8B0XK*"ZK<<6E"2])F (6N4_?IX3<?SL:'7-O9<EL]A..1O@K6#
MK4;!HTM"5J(K+:%G'<H9,)?A(O.I&;SHI1$:2Z*\-Z@V6N216FY6][OG!R;1
M98_3YDQH+74\G8YXAIQR=1V\V"XAQE3%_L)Y]S,; WV'5-OMQ'ZZ!(0?1<42
M*"1:Y-D0DB0_+?>E2GG9,F2ZY(D2)#BWGY#[RU.////.*4XZZZXHU*4HS-1F
M9F?47%#^(    /5W"CE=G/"[D;@&^,'2_/.AFJJ\OQ=$A4>/G&!W*V6,HQ*6
MHDN-]9\5"7HCBT.)BV,>-))"E,I(4:Q6 3P9=6[J'!G$^ZMP>JK+7T-47;U%
MCD3<O&V\OZM>.W#D^ZH8UE+USDD>[:A6-!7;#IE-0Y;$E4<H%LQ#DR",H:FE
MX5:GXD</PER/07ETZQU^CV_:=_=RF]IWV6A?4UB\*;?P+B,5CC4MY-S7!N5-
MU:<<'4Q6:#=4MQC=S;8[D-784=_06<^EO*6VAOU]K3W%7*=@V=79P)3;4J#8
M5\UA;3S+B4N-.(-*B(R,AK#MW;7-O>VU.\M*D*MI5A&<)P:E&<))2C*,EBI1
MDFFFG@TTT?F 3GR2I2%)6A1I6DR4E23-*DJ2?5*DJ+H9&1EZ# HTFL'R-$KL
M&=TQ/-;1Y:!W)D29/)[0U# B2["SE$NRVYK"'Y-729\ER0ZJ59911'Y-?D2U
M>-;KZX\Y2U+FN(9V%"KGCEEZR./GFPZ%/IIN?];-N4<NQ]5JR:C%?!M+EXRG
M0X+"-*?&I;K@E%3I))4DY6$AD'D0
M
M
M
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M=2-)D?4C(9YR3::>#YGR H
M
M
M
M                                        'CGF+P1XY<YL+B8EO3$G
MI5A2>LKQ#/L:DM4N?X8_+3X9"J&]5%F-.P9)D2GH$UB97/N(0XMA3C;:T54F
MN11K$@Z_TQ6L/Q@]9^=GGOXJ^=XO@;Y+\>_&#R/-Z^7^,WXV?!WG>3[GQ_!/
MA\7NO!T]R+_$?<4RDJW&?M"<#N+JZVVQ?3L'8><5OJ[C6PMR/,["R),N,2#9
ML*^LGQ(^%8]8M/$;B9%94PGTJ5_O]"22;7.3*I)$FB4I0E*4I)*4D24I21$E
M*2+H24D70B(B+T$+2I_H              ( .^KVFF.=NI$[LTKCT3YV&GZ1
M\J>/%2U&D[BP&&<B?+UO.?/P-O9%7//.RL>>=/PE)<>B+-+<LG6(*]+.LT?7
M1ZT\K77Z?2O<'ZL[EK2_4'4:JSMXM6E=X15Q%=E.22C<)?@J-1)NGEEG5384
MRMF2ZZQB2H%A E/PI\":P[%F0ID5U;$J)+BOH;?C2HS[:D.-K2E:%I,C(C(:
MX[#TJM.O3C6HRC.C.*E&46FI)K%--<&FN*:X-'U0)  +HWL^G>2*U9Q#@%RE
MRA1VK"8^/\9=G7TM2SLXR$,1ZO2&1S%,'X9T1"%%C<V2]T?;\-7U):(+;N9;
MUO\ NY>]_@.:_FX\N/@2N.K.Q:'XAXU-2MH+U7Q<KVFL?5?#Y1"*^"\:_)U7
M&XP,PYT
M
M
M
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M1
M
M
M
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M6C5>+BVJ55N62=6Q.,@\>
M
M
M
M
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MR,CZ"G^L?P_W3)G#RC4YNG473B-2+:::T5--<&FGQ33YH_O_ /K"G_Z9?_\
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M,DO0S6N'+1KO'+/EWGGSS'^4W0'H5UOOI=;*TU.UA*M<6-/V-:E%8U)VT/\
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MIMUM?5=N:/;[GO\ 1[B=I*AI%J\LYQJTJ4_%C23IRC5CBI+C'!23- X9YR1
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MVC:_UW:_E8E)WV:7Z4'%?V,[>^]$ 8-M[7WCICYU?L.K_65I\>1HPC8G'0\
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MQOI3,\_G^RC_ -Q4X:N7M7_C??.\NC?83:_U2I?\/B:L VAP:
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MZ_TI<![&/,'?'-[A9:[EY%9/79;G\7=V=84S:5>-4&*1DX]1X_A$^NB'5XY
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ME/@)0$]JJ^D*TY_)GKW^-W(<8%U[1>Y]]G6?R'?9#J/]9+CZ%IY<O[<GT>O
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MN??1[7\^/V0Z=_62W^A:@7^QGG)@   *@7M:GZ/>$?QRWE]Y-9#$N^43H;Y
M/TQN?YM9?'N3N?V4?^YQR+_F8>_A9K\76OJ/W3\YY]OM&T;ZD7TJX+2PR3PJ
M !F9]]#D)-Y4=SW=<?')$O(*'55K3<;]?0(J5S'ENZ]=>K,H@UK3"G4RDV6V
MK2]=C>47]*V^WT(S/J>MKRS57AV<#MCY6]HTMB=#],G>J-&ZOZ<]1N)/@L+A
M*5*4F\,,MI&@I8\G%]AH>\/M#0>+_%K0''Z"W%2K4^J<-Q"W?AD11[/*(%-&
M7F%XGH9I\=_E;TV<LR]!KD'T] V$(Y8J/<CD#U$W75WQOK5MW57+#4+^M5@G
MSC2E-^##_P!G24(+T1*W/M67' \BTOQVY44]>ZY/UGFEQJ/-),5A*S/%=B03
MO\8GV;OA-QJ#19/BC\5D^I(]8O?"9&:T],:ZCC%3[CV;Y#-Y?(]R:QL2YFE2
MO;:%W13?_>V\O#JQBNV4Z56,GVY:&/8SDGLKG)U.9\=MU\4[RS2Y=Z4SB/L7
M"8<F47GJU]M!#K=S JXAGXC@X[G=')ER5I+HE[(6R/TJ+K6UEC%P[C"\]VR'
MIN\-,W[:PPMM3M7;UFEP^46V&24G^^J4)QC%=UN^XM8C*/!@ &4_L;Z4S//Y
M_LH_]Q4X:N7M7_C??.\NC?83:_U2I?\ #XFK -H<&@
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M[%]K_4EK^2B:?7''^[UH?]C.K_S(HQLH^JO<.'V\O^;]5^LKG\M,[F%Q^;
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M@V\4L6RPQ[*/_<XY%_S,/?PLU^,BU]1^Z>0_/M]HVC?4B^E7!:6&2>%0
M  ,I_8WTIF>?S_91_P"XJ<-7+VK_ ,;[YWET;[";7^J5+_A\35@&T.#0
M! Y[1SHB9N;MFYQD=37JL+G0.P<%W2PTPG_U?P-"=L\"RQQM1*1UB5N,Y[)L
M)*%&:#:@^/H:T(Z07$<:?N<3U5Y-MU4]M];+6RN)Y+;5K.O9MOEGDHUZ2]V5
M2A&G%\\9X8X-D#GLK_(ZKU_REW=QPO;%J"UR#UU3Y)B"),AM*+#.=-2;N?\
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MXMKVMLT)0BRK,&K'7O&\GQ-NVDZ<XRM<=;)EG4:?AQP?K,Y:^9#K+'K)OO\
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MD48V$?57N'&+>7_-^J_65S^6F=S"X_-F4_S5^E,Y:?S_ &^/_<5E0U<_:O\
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M<DNT=RFJ\NP^9EL+7M?G+69\:.0U&VZ;1'6V*[?'J6[MF8J:VLV3C#48F["
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MG-7X\CF8&M  AH]H*^B'Y;__  %_]SFEQ#<>Q?O?=1Z0\H__ %"[?_\ /?\
M#;PK-^RJ_2%;C_DSV%_&[CP,:U]H_<^^CVOY\?LAT[^LEO\ 0M0+_8SSDP
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M5?\ UN^GXEK<UI0KTOQEU/+GBDL\,M2/.$XOB7NQG'*X
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M)I)=R2>"1]?Y.->?D'AG_*]'_P "&"+_ ,\ZQ_O=S_G9_P"4/DXUY^0>&?\
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M2W)BQ6GD)<;4:5$2O21]#] &76U+4;FFZ5Q<5JE)\XRG*2>'+@VT<E P@
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M>@R,".IJFI5</%N*\LLE)8U)O"2Y26+X-=C7%'* ,$
M
M
M
M
M
M
M
M
M
M
M
M
M
M
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"_]D!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>12
<FILENAME>nlnkidoclinicalprioritiesa01.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 nlnkidoclinicalprioritiesa01.jpg
M_]C_X  02D9)1@ ! 0$ 8 !@  #_VP!#  ," @," @,# P,$ P,$!0@%!00$
M!0H'!P8(# H,# L*"PL-#A(0#0X1#@L+$!80$1,4%145# \7&!84&!(4%13_
MVP!# 0,$! 4$!0D%!0D4#0L-%!04%!04%!04%!04%!04%!04%!04%!04%!04
M%!04%!04%!04%!04%!04%!04%!04%!3_P  1" +0!0 # 2(  A$! Q$!_\0
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M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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MVZ1DCT) K6HHYI6Y;Z![.#ES6U&+&%Z=*?114F@4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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MOGC]CG2M?TWXN_%*Z_X0[6?!7@[5GAU"QT[5(/*59V8AP@' XQTJ3]GFXM_
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M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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M)0 ZBD_&DH =12?C10 M%)^-'XT +13:7\: %HIM+^- "T4E'XT +12?C24
M.HI/QI* '44GXT4 +12?C1^- "T4VE_&@!:*;2_C0 M%)1^- "T4GXTE #J*
M3\:2@!U%)^-% "T4GXT?C0 M%-I?QH 6BDH_&@!:*2B@!:*3\:2@!U%)^-)0
M ZBD_&B@!:*2C\: %HIM+^- "T4VE_&@!:*2B@!:*3\:2@!U%)^-)0 ZBD_&
MB@!:*2C\: %HIM+^- "T4VE_&@!:*2B@!:*3\:2@!U%)^-)0 ZBD_&B@!:*2
MC\: %HIM+^- "T4VE_&@!:*2B@!:*3\:2@!U%)^-)0 ZBD_&B@!:*2C\: %H
MIM+^- "T4VE_&@!:*2B@!:*3\:2@!U%)^-)0 ZBD_&B@!:*2C\: %HI*/QH
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M (NC^R,J_P"?_P"*#^WL[_Y\?@S[M_X;P^#_ /T'+S_P73__ !-'_#>'P?\
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M_P#0<O/_  73_P#Q-'_#>'P?_P"@Y>?^"Z?_ .)KX2_X97^+G_0@ZI_Y"_\
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M (NC^R,J_P"?_P"*#^WL[_Y\?@S[M_X;P^#_ /T'+S_P73__ !-'_#>'P?\
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M_P#0<O/_  73_P#Q-'_#>'P?_P"@Y>?^"Z?_ .)KX2_X97^+G_0@ZI_Y"_\
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M3_\ Q-?"7_#*_P 7/^A!U3_R%_\ %T?\,K_%S_H0=4_\A?\ Q=']D95_S_\
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MO#X/_P#0<O/_  73_P#Q-?"7_#*_Q<_Z$'5/_(7_ ,71_P ,K_%S_H0=4_\
M(7_Q=']D95_S_P#Q0?V]G?\ SX_!GW;_ ,-X?!__ *#EY_X+I_\ XFC_ (;P
M^#__ $'+S_P73_\ Q-?"7_#*_P 7/^A!U3_R%_\ %T?\,K_%S_H0=4_\A?\
MQ=']D95_S_\ Q0?V]G?_ #X_!GW;_P -X?!__H.7G_@NG_\ B:/^&\/@_P#]
M!R\_\%T__P 37PE_PRO\7/\ H0=4_P#(7_Q='_#*_P 7/^A!U3_R%_\ %T?V
M1E7_ #__ !0?V]G?_/C\&?=O_#>'P?\ ^@Y>?^"Z?_XFC_AO#X/_ /0<O/\
MP73_ /Q-?"7_  RO\7/^A!U3_P A?_%T?\,K_%S_ *$'5/\ R%_\71_9&5?\
M_P#\4']O9W_SX_!GW;_PWA\'_P#H.7G_ (+I_P#XFC_AO#X/_P#0<O/_  73
M_P#Q-?"7_#*_Q<_Z$'5/_(7_ ,71_P ,K_%S_H0=4_\ (7_Q=/\ LC*O^?\
M^*#^WL[_ .?'X,^[?^&\/@__ -!R\_\ !=/_ /$T?\-X?!__ *#EY_X+I_\
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M_P#!=/\ _$T?\-X?!_\ Z#EY_P""Z?\ ^)KX2_X97^+G_0@ZI_Y"_P#BZ/\
MAE?XN?\ 0@ZI_P"0O_BZ7]D95_S_ /Q0?V]G?_/C\&?=O_#>'P?_ .@Y>?\
M@NG_ /B:/^&\/@__ -!R\_\ !=/_ /$U\)?\,K_%S_H0=4_\A?\ Q='_  RO
M\7/^A!U3_P A?_%T_P"R,J_Y_P#XH/[>SO\ Y\?@S[M_X;P^#_\ T'+S_P %
MT_\ \31_PWA\'_\ H.7G_@NG_P#B:^$O^&5_BY_T(.J?^0O_ (NC_AE?XN?]
M"#JG_D+_ .+I?V1E7_/_ /%!_;V=_P#/C\&?=O\ PWA\'_\ H.7G_@NG_P#B
M:/\ AO#X/_\ 0<O/_!=/_P#$U\)?\,K_ !<_Z$'5/_(7_P 71_PRO\7/^A!U
M3_R%_P#%T_[(RK_G_P#B@_M[._\ GQ^#/NW_ (;P^#__ $'+S_P73_\ Q-'_
M  WA\'_^@Y>?^"Z?_P")KX2_X97^+G_0@ZI_Y"_^+H_X97^+G_0@ZI_Y"_\
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MP9]V_P##>'P?_P"@Y>?^"Z?_ .)H_P"&\/@__P!!R\_\%T__ ,37PE_PRO\
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M0_A]X>:22+3-(U/2?M-Q=1HQ ED=\&,OCICCK0!]6 ^V/PH!R<8_&O!OA_\
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M?6CGUH 3;_G%)@?6G<^M-VGGGO2 \3_;-3_C&GQMP/\ 4P]O^F\=?G7^SO\
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M1=-X=/A,V9U(Q_Z/YWG9\O=_>QVH P/B-\6Y?B!^RUX7?2)2NM>/!:Z+"O\
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ML=C><7,F[?N^[M]J /!Y/B#>?%C]G3X;^ WD_P"*@\0:I'X=U:.,X:..T?\
MTIO^^(QS_M5%X<UZ?X?+^U3J6DEK>?2[@FV,:\Q[8-JX'MUKU7P!^S _@O\
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M0!Y3J>IP7WQF^(5YX ^$,OQ;U+[2EGJNM^(;ZW6WL[A 0+>W21/]6HZXY)_
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M$'A'XPZYI?B5]2;$-SH=D;3[.H VL 2?G5N0:X-OV>_C/K^DCP;XD^*VG3^
M#&+24:?I9BU2:U7A4:8G 9@ &('0G% 'L.AZ[8?%GX(V^JBT^S:?KFBF3[*P
M!\M7B/R^G%</^Q-JUSKG[-?A)KIV>2V6>T#$8RL<SJOY  ?A72?%K5]/^"OP
M)U&'2+7REM;%=+TJQC&6>5QY<4:^I)(_6M+X _#MOA3\(/"_A>7;]JL;0?:=
MO3SG)>3_ ,>8T >@*NTC\NM.HHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** $H'>B@=Z74#Q/\ ;._Y-G\;?]<(?_2B.OSI_9W_ .2^?#[_ +#=M_Z%
M7Z+?MG?\FS^-O^N$/_I1'7YT_L[_ /)?/A]_V&[;_P!"K] R/_D6U_G_ .DH
M_*^)/^1QAO\ MW_TH_8*EI*6O@#]4"BBB@ HHHH **** /RK_;:_Y.=\9_\
M;E_Z105]=_\ !/?_ )-\'_88N_YK7R)^VU_R<[XS_P"W+_TB@KZ[_P"">_\
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M[33'_?+5](_#)B_@?1F/)-I'_P"@BOF__@HE_P DUTC_ +":?^@M7T?\+_\
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MF:,T +129HR* %HI,BC(]: %HI,TM "4#O10.]+J!XG^V=_R;/XV_P"N$/\
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M#*I.<$COU%>4:AK<WC+Q?\36\!?#GP9:6=G>20ZIXW\87 E3[7&H#AX"K/M
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MC(Q.>>X'X4 >4^./ ^N?%S]ISQ'X?C^(?B[PCI>FZ):7<<'AZ_\ )1G=V!+
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M0_\ I1'7YT_L[_\ )?/A]_V&[;_T*OT#(_\ D6U_G_Z2C\KXD_Y'&&_[=_\
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MGT^M<=X>^$_AGPMX[\0>,-.LFM]?UX(+^X\UF$FP #"DX7H,XZXKLZ6@#A_
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MY9I=.C9G8G))..3FO0=%T/3_  YI=OIVEV5OIUA;KLBMK6,1QHH[!1P*O44
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M73_!_B;]J#QMX[U"]^('B+P?H>@:M)H^DZ=X;N?LV3&!NFF."7W'^$^_(Z4
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MWT+7=W*I!:2X=V,C,>YW<?A6!\8+.#3OVH/@UJ6GHL>LWGVZSO7B/SR68C#
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M:ZWC(4DG[G&30!]DKGG-.IJ]*=0 4444 %%%% !1110 4444 %%%% !1110
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M+*PMP"TDTA!/"CG  Y/09%<M\7OVB?!WP.NM.M_%4^H12:@CR6XL=.FNLA2
M<F-3CJ.M>0?'/X5Z;X<^,/PX\6O>:CJVN:EXLC3[1J%P76TM_*;$$*#"HF>>
MF23R37T]KFL6OAW1[_5;Z016=E ]Q,YZ*B*23^0H \J^%_[6GP\^,/BX>&O#
M=YJ4NK-;O="*\TR>W7RUQDEG4#N/K7LB=*\)_9@TN\\66VL?%?7D)UGQ;)NL
MD?K:::A(MXE],CYSZEJ]W'TQ0 M%%% !1110 4444 )0.]% [TNH'B?[9W_)
ML_C;_KA#_P"E$=?G3^SO_P E\^'W_8;MO_0J_1;]L[_DV?QM_P!<(?\ THCK
M\Z?V=_\ DOGP^_[#=M_Z%7Z!D?\ R+:_S_\ 24?E?$G_ ".,-_V[_P"E'[!4
MM)2U\ ?J@4444 %%%% !1110!^5?[;7_ "<[XS_[<O\ TB@KZ[_X)[_\F^#_
M +#%W_-:^1/VVO\ DYWQG_VY?^D4%?7?_!/?_DWP?]AB[_FM?H&:?\B:A_VY
M_P"DGY5DG_)0XGUG_P"E'TQ2TE+7Y^?JH4444 %-DC2:-HY%5T8;65AD$'J"
M*=10!@?\(!X8_P"A<TG_ , 8O_B:TM-T73M%A>/3K"VL(V;>R6L*QACZD*!D
MU=HH \%^,_PE^)&O?%30O&WPZUWP[I%[8:=+I\JZ[;RS!ED8-E53Z>M-\(^'
MOVCK7Q1I<WB3Q;X#O?#Z3!KZWT_3;B.XDBP<K&S' /3DU[WMXQTI-HH ^>-4
M_9EU'Q-I/BK6-8U:T/Q)U+4DU'3-9MU?R=.\@G[+"F1NV!<AP/O;VKBO&.@?
M$'6?VI-WA?Q'INA>,[/P?"\S7,+3:=<DRA75TX;;GYE/4'%?7GECKU-9Z^&]
M*776UL:?;#6&@%LU^(AYQB!SLW]=N><4 >(>%?V89]0\,>.A\1=?'B/Q5XVA
M6'4[VQC\F"WC08BCMU/(5#@Y//:LSPO\(OCU;_V;H&M?%/24\(V+(GVW2K!U
MU>>&,_*CR/\ ("P #$#ITKZ2V"C8,8H \$^)GP6\?P_$:X\;?"OQ7I>@:KJE
MI'9ZO::[;-/;SB,8CE79R) ./2C6?V;=1OOV<=0^'R>)Y+WQ)>2_VA+K>H;G
M62\,HE)VY)6/*X"CH.U>]^6/2C:.O?UH ^=_$_P-^)'B"P\'>*K?Q9HNE_%G
MP]#):O?6]M(=,O;=S\T4D9^8#H>.XKI_A[\-/']Y'K<WQ5\8VGB$ZC:/IW]B
MZ';FWTZ.%@0SX<;VD()&2<  8KV':,8[>E&P?KF@#Y,U7]F/XN7G@/5?AS%\
M1])?X?\ V9X-.$MG(NHA0<QPS2#CRQ]TX!)48KZ9\&Z+-X;\'Z)I,[QRSV-C
M#;.\6=C,B!21GG'%;07%&V@#Q;XP?"7QEXD^)G@KQMX(UG2=,U+1(YK2Y@UB
M%Y(IK>4C?MV=&XX)]:YOQ!\"_B?X0\:>(M8^$WC+1=&T_P 23_;=1TO7[-YT
M@N2,/+ 4Z%NI!XX%?1NWW-&V@#SSX'_"6'X.>"1HQU&;6M3NKF74-2U.<8:Z
MNI#EWQV'0 >U<=XT_9VN_''CSXB:E=:M#::1XJ\.0Z'']G#&X@D1BQD.1MQ^
M->Z%0:-@_P * /C;Q!^RQ\;O&/@ >#M5\?>%+#0[)(VM;71]-D@%Y)&5"BZ.
M.1A<DJ,Y KTGQW\$_B OQ"TGQI\/?$^CZ%K3:3'I&L1:M:O<0S1(0P>(#G<#
MG&<>]?0&T4;1VXH ^81^RCXBA^&^K^&QXBL[V\O/%\/B/[==!\O&KHSA\#[[
M%3P.!GK7J7B[X77_ (C^-O@GQK'<VJ:=H5E?6MQ:RAC-(9U"C;@8P,<YKTW;
M2>6* /E9_P!F/XF:;%?>"="^(=AIOPFOKMIS;_9G&K6\3L'>"&5<*%+9&<YP
M3]*]6L/A'=Z;\=K7QK#>6_\ 8UOX;&AI:N7-QO$JL&R1@C QUSDUZD8PW!Y%
M+Y8Y]30!YI\(?A?J'P]\2?$34;V[MKJ+Q)KCZK;+;[MT,;* $?(^]QVXKTN0
M!E(89!X(/2EQ10!\TZY^SK\0O!=]K%O\)O%^DZ?X6UEY);GPUXFM9)[6U:3)
MD-NT9#*&))(SQVK#^"O[-_Q*^#_Q(T?Q%JFJZ-XUBN('L+M9))4;1H6D:0FS
M+Y+)]T%6.>?05]8[!G-&P9SWH \V^.GPSO\ XJ>&M)TW3KNWLY;/5[347>YW
M;62*0,RC ^\0..U>D+]T<^W%+M'XT;?_ -5 'S)X[^#7QMU+XT:AXU\.^)O!
M:6RQBVTFWURRGN)+"' W;, !79LDL.2,"NLC^$WC[XD?"WQ/X5^+'B#0[R\O
MV4Z??^&[22'['M *N1(>7#C(([5[>%Q1MH ^;_#GP'^*/B;Q%X<?XJ^-](UW
MPYX;G6[LK#1[1XGO9T&V.2Z9^&*_>^7N37JGQP\ WOQ2^%>O^%]/N;>SO=1A
M$<<]T&\M3N!R=H)[5WFT=.WI1M% 'F/Q4^#*_%+X767AB74I-)U73S;W-CJ=
MK\QM[J$#9( >HR#P>QKSS2?@9\5_'7B709OBSXVT/5/#^@W27]OIOAVSD@-W
M<)_JVG9^R_>P.]?2)4&C9[T "\Y-.I*6@ HHHH **** "BBB@ HHHH ****
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MQ9XU\1?M4?"ZS^('A:V\->(;.PU)P=.N3<V<\3H,&.0C.X;3N!Z9% 'U]O\
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M_O)OLYYA1AP 1SR: /JL<TM(M+0 4444 %%%% !1110 4444 %%%% !1110
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MA;)\)+_X:>)M5\9644^FZ=>:=9F33;Q79A%*T^<1C#<@^G.,\?9NW.*-IVT
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ME]X?ZW9;_>^[_@GZ:9HS7YE_\/ /BU_SVT/_ ,%Q_P#BZ3_AX!\6O^>VA_\
M@N/_ ,71_JYC^R^\/];LM_O?=_P3]-:,U^9?_#P'XM?\]M#_ /!<?_BZ/^'@
M'Q:_Y[:'_P""X_\ Q='^KF/[+[P_UNRW^]]W_!/TTS1FOS*_X> ?%K_GMH?_
M (+C_P#%TO\ P\ ^+7_/;0__  7'_P"+H_U<Q_9?>'^MV6_WON_X)^FE&:_,
MO_AX#\6O^>VA_P#@N/\ \71_P\ ^+7_/;0__  7'_P"+H_U<Q_9?>'^MV6_W
MON_X)^FF:*_,K_AX!\6O^>VA_P#@N/\ \72_\/ ?BU_SVT/_ ,%Q_P#BZ/\
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M !='^KF/[+[P_P!;LM_O?=_P3]-*,U^9?_#P'XM?\]M#_P#!<?\ XNC_ (>
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M  \ ^+7_ #VT/_P7'_XNC_5S']E]X?ZW9;_>^[_@GZ:9HS7YE_\ #P#XM?\
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MZ/\ AX!\6O\ GMH?_@N/_P 71_JYC^R^\/\ 6[+?[WW?\$_33-&:_,O_ (>
M?%K_ )[:'_X+C_\ %T?\/ /BU_SVT/\ \%Q_^+H_U<Q_9?>'^MV6_P![[O\
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MEO\ >^[_ ()^FF:,U^9?_#P#XM?\]M#_ /!<?_BZ/^'@'Q:_Y[:'_P""X_\
MQ='^KF/[+[P_UNRW^]]W_!/TTS1FOS+_ .'@'Q:_Y[:'_P""X_\ Q='_  \
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M_P#BZ/\ 5S']E]X?ZW9;_>^[_@GZ:9HS7YE_\/ /BU_SVT/_ ,%Q_P#BZ/\
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M?[WW?\$_33-&:_,O_AX!\6O^>VA_^"X__%T?\/ /BU_SVT/_ ,%Q_P#BZ/\
M5S']E]X?ZW9;_>^[_@GZ:9HS7YE_\/ /BU_SVT/_ ,%Q_P#BZ/\ AX!\6O\
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M_P"?GX(/]6<K_P"??XL^ O\ AVGXA_Z'G3?_  7R?_%T?\.T_$/_ $/.F_\
M@OD_^+K[]HH_MS'_ //S\$'^K.5_\^_Q9\!?\.T_$/\ T/.F_P#@OD_^+H_X
M=I^(?^AYTW_P7R?_ !=??M%']N8__GY^"#_5G*_^??XL^ O^':?B'_H>=-_\
M%\G_ ,71_P .T_$/_0\Z;_X+Y/\ XNOOVBC^W,?_ ,_/P0?ZLY7_ ,^_Q9\!
M?\.T_$/_ $/.F_\ @OD_^+H_X=I^(?\ H>=-_P#!?)_\77W[11_;F/\ ^?GX
M(/\ 5G*_^??XL^ O^':?B'_H>=-_\%\G_P 71_P[3\0_]#SIO_@OD_\ BZ^_
M:*/[<Q__ #\_!!_JSE?_ #[_ !9\!?\ #M/Q#_T/.F_^"^3_ .+H_P"':?B'
M_H>=-_\ !?)_\77W[11_;F/_ .?GX(/]6<K_ .??XL^ O^':?B'_ *'G3?\
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MD_\ BZ/^':?B'_H>=-_\%\G_ ,77W[11_;F/_P"?GX(/]6<K_P"??XL^ O\
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M>=-_\%\G_P 72?\ #M7Q$O(\<Z;G_L'R?_%U]_4AH_MW'_\ /S\$'^K.5_\
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M  [3\0_]#SIO_@OD_P#BZ^_:*/[<Q_\ S\_!!_JSE?\ S[_%GP%_P[3\0_\
M0\Z;_P""^3_XNC_AVGXA_P"AYTW_ ,%\G_Q=??M%']N8_P#Y^?@@_P!6<K_Y
M]_BSX"_X=I^(?^AYTW_P7R?_ !='_#M/Q#_T/.F_^"^3_P"+K[]HH_MS'_\
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M?^AYTW_P7R?_ !='_#M/Q#_T/.F_^"^3_P"+K[]HH_MS'_\ /S\$'^K.5_\
M/O\ %GP%_P .T_$/_0\Z;_X+Y/\ XNC_ (=I^(?^AYTW_P %\G_Q=??M%']N
M8_\ Y^?@@_U9RO\ Y]_BSX"_X=I^(?\ H>=-_P#!?)_\71_P[3\0_P#0\Z;_
M ."^3_XNOOVBC^W,?_S\_!!_JSE?_/O\6? 7_#M/Q#_T/.F_^ $G_P 72?\
M#M7Q#N_Y'G3?_ "3_P"+K[]H'>C^W<?_ ,_/P0_]6<L_Y]_BS\T_BU^P[K/P
ME^'>L>+;OQ99:C;Z:B/):0V3HTFYU0 ,6.,%L_A7E7[._P#R7SX??]ANV_\
M0J_17]L[_DV?QM_UPA_]*(Z_.G]G?_DOGP^_[#=M_P"A5];EN,K8S+Z\J\KM
M7_(^$SC 8?+\TP]/#QLGRO\ \F/V"I:2EK\T/V0**** "BBB@ HHHH _*O\
M;:_Y.=\9_P#;E_Z105]=_P#!/?\ Y-\'_88N_P":U\B?MM?\G.^,_P#MR_\
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MP#&7BGB.<^4^.A.1ZURWP!^+OQC^-]KX;\4'1_#6C>!KA2EXT_G?;KAE!#O
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M'(OJK D$?2N1^,?@.Z^*GPZU?PO9:V=!?45$,M[&GF,L>X;U #+@D9&<\9H
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MBI%=?LA?";5=6L/&FM:QXA\0WD%E_:_B:]:Z@T]WR9)HXL850-S;0#T Z<4
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M9A_L](%$'EGJFS&W'MBE3POH\>@#0TTJS711#]G_ +/$"^1Y1XV;,;=OMC%
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M %%%% !1110 4444 %%%% !1110 4444 %%%% !24M(: /F/]OS_ )(C=?\
M7S#_ .ABO4_V>?\ DCWA/_L&P_\ H(KRW]OE"WP-OFZA+B _^/BO3_V<W\SX
M->$GQUTV _\ CHKV:G_(OA_B?Y'SU+_D;U?\"_,]-HHHKQCZ$**** "BBB@
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MX&7'@C6)98_M^N^*--@%E:Q!AYIB'65NNU3C(.:^L@H'':EQ0!X+K'A36?\
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M>*]<U#XG:/\ %;PUI]BVI6=_#$+74DVJQ>.> #"*2N%)&>M9?@'X9?&+X8_
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M?X?^$WQ*T73_ (R>$9-)TN?PYXB>_O\ 2=62^ GDGG'RQ21D?*/]KUS0!?\
MAG9_%VZ^'LOQ U/Q_I]S?ZIHR3V>AZE D&EZ>Y53YTDRC>X"@L1P,D]J\CU;
MXT>)OA'\0/","?'S3_BE>:E?0V]YX=BT^$0K#(VUI$GAR RGH&(..U>]^-O@
MSXA\7?LKVO@&WN(-.\0PZ9:PLLC[X9)(MI:)B.J/M*D].:\0U3X&?&?Q5H_A
MG2T\ ^!_ N@:!JMK??V/H=RK-=D2Y=Q*5^3:"6VG[V<=J /IOXY?%Z/X2^%X
MWM+9M6\4:I+]BT31XAE[NY8?+QV1>K-P !UKBO#OAL_LV?!_Q=X]\23?\)!X
MVN+=M4UK4)&YFF ^2!#VB3(4*..*X#7O"GQ\T_X]:]XYLO _ASQ5"H^QZ$VI
MZX8%L+7^(I& <._4L>>U=UI]C\7/B_HOB/PG\3O!F@>%_#NJ:;);B_T?5C=3
M"5N!\A X'7/M0!\X1_M>7OA^WA\82?'C3O$.J'9/=^ _[ DBM55B/,BBGV[M
MRC."QQD5[9XO\0_$KXF_'J3PAX-\;?\ "&Z%/X:MM8EN?L4=S- 6;CRE; )8
MD!LYXSBJWA?PG^T'IMCIW@V7P_X%M-/L@EI_PFAVS3/"AP)/LA7!=E 7D]3D
MUZEH?PYUW3?VE-6\83QPMH-QX:@TN.X#J':=)0S#RQ]T8[].U 'BR_M,^+?A
M[\ _$]SXBU2PO?%&B^)6\+1:Y/"1$YS_ ,?,D:==JY.%]JYKX;?M0_\ "/\
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M2+8G _PKQSQ,?">I6_B#PKH]S\4=%O=0EG4?"F.T8V1O&)POV@+M"%@LG#8
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M;3MQP33LTM #-O3TI/+.3S4E)D4 )M]Z-I]>*7-+0 S:<]:-G(YI](&#=.:
M&[/?ITH\L^M/HH 9Y?RT;33Z3(H :$Q[4NT\Y[TZDW"@!OE\8ZT;3CKFGT4
M-VFDVD]:<6 HH ;LXZTFQAT(Q4E% #-I[<4NVG44 ,VGG\Z-I]<4ZEH 8$Q0
MJD$T^B@"/R^O>EVG&*?2;A0 FVDVGVI]% #-IQ1M/M3MP]:* &[3_P#7I=O&
M*7-)N'K0 A0XX-+M/L*7<,9HW"@!NP]N/6C:>QI=PY[X]*7(H ;Y>[J?UH*=
M<&G;AQ[TM #-A_3%&TT^B@!FT^M+M-+N%)N'K0 GEYQFC:=W7CTIVX>M&X>M
M #/+-+L.[.>*=N%&X4 -V>]&TGTS3@<]*6@!NVDV_A3Z* &*A[T;#CD\T^B@
M!NVC::=10 S8?6CRSZT^B@!FTXZT;#Z\T^B@!FT[2.M!4],_6GT4 1^6>O&>
MU.5<'V["G44 %(:6DH ^<OV[U'_#/^O'_II;_P#HY:[;]F D_ OP5GK_ &5!
M_P"@UQ/[=_\ R;[KW_72W_\ 1RUVW[,'_)"_!7_8*@_]!%>Q/_D70_Q/\CY^
MG_R.*G^!?F>L4445XY] %%%% !1110 4444 %%%% !1110 4444 %%%-WCKG
MOB@!U%0M>0+*(VGC63.-A<!ORJ3<* '44FX>M&X?A0 M%-W#BD69&9D#J67D
MKGD?44 /HIDDT<*[G=47^\QP*=N% "T4FX>M&X4 +136<*"2< <DT)(LBAE8
M,IZ,IR#0 ZF;32[AZTN: &[6P!GBG#@8I:3<* %HI-PSBF-/&K*K.JLV<*3R
M<>@H DHIK2+&I9V"J!DEC@"A75E!!R#R".] #J*3</6DW#GGI0 ZBDW#UHS^
M% "T4FX4;A0 M%,:1%95+ ,W0$X)IV: %HI-PILDJ1*6=E11U+' H ?12;AV
M.: P.: %HI-P]:-PYH 6BDW4FX>M #J*8TR*RJ74,W12>3]*(YDF7<CJZ_WE
M.10 ^BDW"C</6@!:*;N%*&!^E "T5&TT<;*&=5+'"@G!;Z>M24 %%%% !111
M0 4444 %%%% "4#O10.]+J!XG^V=_P FS^-O^N$/_I1'7YT_L[_\E\^'W_8;
MMO\ T*OT6_;._P"39_&W_7"'_P!*(Z_.G]G?_DOGP^_[#=M_Z%7Z!D?_ "+:
M_P __24?E?$G_(XPW_;O_I1^P5+24M? 'ZH%%%% !1110 4444 ?E7^VU_R<
M[XS_ .W+_P!(H*^N_P#@GO\ \F^#_L,7?\UKY$_;:_Y.=\9_]N7_ *105]=_
M\$]_^3?!_P!AB[_FM?H&:?\ (FH?]N?^DGY5DG_)0XGUG_Z4?3%+24M?GY^J
MA1110 4444 %)N'K22%EC8H-S8.%SC)KYSF^+?[0T<TJQ? G3I(E8A&_X2J
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MBCGNK$9\R*.3[C'CH?:L/X3?$ZR^,'@V'Q-IEC>66EW,TB6KWRJK7$:L5$R
M$_(V#C/..U>7?'#4X/@]\9O!WQ.NG^S:%=6TV@ZU*3M15(,EN['_ 'PRCZT
M>KZS\7O!GAU?$#:GXCL;)?#XC.J-,^T6OF E QQU(!X&33/AO\9O!'Q>M;JX
M\&^)K#Q#%:MLF^QR9,9]U(!Q[XQ7R_:_#*X^(_P,T[7[_P 1Z7X<\8^)_%'_
M  DUB-?"_9[N0,5M[65#]]?+4?* >M=)\#]9USPI\=T\,^/OAWX>T/QCJ6ES
M"V\2^&9%6*_MH7W8:!3^[7G@MR2.@H ^B?B1XN'@'P%X@\1F W?]EV4MWY _
MC*J2!],XKYYT.W_:.\5>$[/Q_IGCWPU.EY -3@\'P:6DEO(A&X6PN]V[D<;N
MH->^_%3Q5I_@?X=:_KNKZ;<:QI=E:L]U8VT8>26(G:X"L0#P22#V!KYSD_9E
M\'KX7C^(/PK^)VL_#^T,#:A!-;ZD+G2[>$H2T:PNVQ%]>N.: /5?'?QPU?P3
M\)M!UF?PQ+'XXUQH;&Q\,S,/^/U^JLP/"+@DG/2N+7P9^T]:VHUP_$+PS>Z@
MO^D'PJVD*EJQ[P?:A\^.V[&:XO5/B'J_B/X9? SXL>*X ]IHNLO_ &Q<0J1&
ML;[H4N]N.%X#9/ W5]93>,O#]OX;/B*36K!-"\KS_P"TC<)Y!C[-OSC% 'D]
MC^T]I_\ PH?4O'VH:9+:ZMI<C6%[H8.9%U!6\OR >X+D8/H:Y230?VFK[21X
MLC\9>';&\9!>#P0NDAX0 ,_9C<D[\D=6Z@DC->7ZII-_XJ^ /Q"\=Z=83#1=
M1\:1^);2#!WRV4,J[Y0I&<-M+8[]:^Q;/XD^&+[P.OC*+6[,^&VMOM9U$3*8
MECQDY(/4=".N>.M $7PG\;7'Q%^'^C>(;S2KC0[R]A#3Z?=*5>"0'#+SR1D'
M!]*Z^N/^%'Q&MOBQX)LO%%CI][IVGWQ8VR7ZJLDL88A90%)^5L9'?%=A0 44
M44 %%%% !1110 4444 %%%% !1110 4444 %)2TE 'SG^W?_ ,F^Z]_UTM__
M $<M=K^S!_R0OP5_V"H/_017$_MX?\F^Z]_UTM__ $<M=M^S!_R0OP5_V"H/
M_0:]B?\ R+H?XG^1\_3_ .1O/_ OS/6****\<^@"BBB@ HHHH **** "BBB@
M I*6D;H: #-%>9?%[X8^+_B#)IC>%_B7J?P^6U603II]C#<"Y+$;2WF=-N#T
M]:X*S_9Q^*UO>6\TO[1?B*XBCD5WA;1;0"10P)4GL"./QH ^BJ\N_:0^(FH?
M"_X0ZSK6D+&=8=H[.Q,@RJSS.(U8CO@MG\*]0KS']I#X=7WQ0^$6LZ+I9 U9
M#'>62MPK30N)$4GMDKC\: /-8_V%/!NIZ*E[KFHZUJ7C^2$2R^+'U.87"W0'
M$BJ&" (<!1CH!WYKKF^)&J? 'X(Z1=_$RY.N^)XV&GQ1Z6IDFU.<L5A"C R[
M#!8XXY-<?;?MX>!['0_LNMV6LZ;X]AC\N?PI)ILQNFN@ !&I"E3N."IST(^E
M8OQ+D^(4OPW^&/Q$\9:$+S4O#_B!=;U/1]+@/G6EFX*JNS)W21@@L?KTH [_
M .'O[35SKWC>P\)>-O &M?#?6-41GTH:I+'/%>E1ET#IPK@?PGDUR][^VG<-
M:^(+G1?AAKVOQ^'M0GM=8FM+B,16D,9_UQ8CYL@,=B@D!>365JGQ>T+]ISXP
M?"^U^'L=WK-CX<U-M8U;5GM)(8;-!&56/<ZC+L3C'H.]6/@M&%^ OQND5=LK
MZWKNX@'/"<4 ;EU^V39PZEHE[%X(UN7X>:K<0VD7C61D2V\Z0[5 B/SE=WR[
MN!7)WOQ1U+X<_M0?$^+0_!VK^.=;O++3WBTS366,+&JMO=Y'.U0"RCU.:S_'
MR!OV"?A\#'GC1N,$D?ODYK:G^-6@?!?]ICXI7WBF.[M-"N;735?5X;9YHH)
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M/_VEHO%D?B;3M<\)ZEX-\8Z!8MJ4_AW4Y%+RVX4D/'*ORL#C!(Z9%<-HO[<
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M59)_R4.)]9_^E'TQ2TE+7Y^?JH4444 %%%% !1110 4444 <O_PKW11\0O\
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M0_\ I1'7YT_L[_\ )?/A]_V&[;_T*OT#(_\ D6U_G_Z2C\KXD_Y'&&_[=_\
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M^N$L[7[0X7SIGX6-<]6/84:/XJTCQ!>:E;:9J5O?W&FW'V6]BMW#-;R@ ['
MZ-@@XKY9\??%A?C)X!^%6MR:9)HVIV_CZSL-1TV5MQMKJ*0K(F<<CI@^]3>%
MOBM;?!N3X^^(I[3[=/\ \)DMK:6GFK$)IY(T5%9SPHSG)/0"@#ZXIN:^7O"/
M[2?CC0_%VC67Q!3P/=Z1KEVMC;3^$=7^T3V<SYV"9&)W*3A<KP#^%:^N?&?X
MH^,/B)X@TSX7^&]#U#P]X7G%GJ=[K<\D;W=P.9(K;9P"HXRV1DCD4 >ZZ#XI
MTCQ5!<W&CZC;:E#;SO:S/;N'$<R'#(<="#U%:9-?/7[$=\^J?#;Q->26DEA+
M<>*-0E>UFQOA9G!*-CN,X/TKM?VF/&VH^ ?@SX@U/1YOL^JR+'9VMQMSY4DS
MB,/^&[- &EXJ^/GPW\#ZW_9'B#QSH>CZH K&TN[Y$D /3()KN[&\@U"SBN;6
M:.XMY5#QRQ,&1U/0@CJ*\C^'_P"RS\./!O@^#3+CPKI>MWDD8>]U'5K9+JXN
M9F4;W,C@D9.3P0!7)_ G2?\ A4?QT\;_  PTNXE?PFNGP:]I=G,S.-/\QRDD
M*$DG83\V.U 'OFH:_INFZII^G75_!;W^H%Q:VTC@23[!EMB]\ \U>#9[?6OE
M"^\ ZMX7_:W^'.LZ_P")[GQ+K&J1:D"6B$-M:0*H,<4,0)Q@'EB26/-?6)![
M8']* .$\2_'3X=^#/$:Z#KOC71=*UH[1]@O+U$E^;[N5)[UU>L:[IV@Z/<:M
MJ5];V.G6\9EEN[B4)$B8SN+'C&*\+\4? KX2_"OX9^*KWQ5IMMK7VYKBXN=5
MUR..>_N)I<[8XY-H;=DA5"\UYG:^#M3N]!_9U^&7C<37-E=-<W^HV%TY+2+"
MI>W@EP?F"AE!'?;B@#ZI\"_$SPI\3+.>\\*>(M-\16UNWERR:=<+,J-C."0>
M*U=8\0:;H/V0ZE?06*W<ZVMOY\@4RRMG:B^K'!X]J\!U?PGH_P *?VJ? ,WA
M/3+;0K?Q-87EEJ=E81B&"41)OC?RUPH8'N!S7/?'[X?ZO9_&#X<>*M;\3W.K
M"3Q7%;:9I4<0AM;&W,;9RN29)"1RY/3  &* /IWQ%XGTKP?H]QJVNZC:Z3IE
MNNZ:[NY1''&/4DUG^"OB+X8^)&G2W_A77]/\06<;^6\^GW"RJK==IP>.M>&?
MMI2:=IL?P]UK7+9=>T#3==5[SPRI+S:AN4JK11 9F9"=VSH1UKGOV=]8\->-
MOVD-=USP5H,G@+1[?18K:[T&^L_[/N;V4L2LXM0 %51\NX=3S0!]=T444 %%
M%% !1110 4444 %%%% !24M)0!\]?MS?\D!U[ZP_^C5KIOV4?^2$^#O^P?%_
MZ#7-?MS?\D!U[_MC_P"C5KI?V4?^2$^#O^P?%_Z#7M2_Y%L?\7Z'ST/^1O+_
M  +\SV"BBBO%/H0HHHH **** "BBB@ HHHH ***0]* %HKS[XG?'CP%\&9=/
M3QKXGM?#S7X=K9;E7)E"D;B-JGID?G7'6O[;WP,O;J&W@^(^ER33.L4:!)LL
MS$ #[G<D4 >Y5QGQ:^(UO\)?A_J_BN[LI]2@TV,2-:VS*LDN2  N[C/-=B*\
M8_;%_P"3<_%__7&/_P!&+0!QLG[9&L:;:C4M<^"/CW1= C"R7.K36\;Q6\1Z
MR$*Q8@ ]A7T)X7\3:9XR\/Z?KFC7:7^EW\*SV]Q&<JZ$=?K[4:#$EUX8TZ&5
M%EBDLHU=' (92@!!'<$5\B?#_6(=)_9?UA+OX@K\-_#</BJ^LSJJ1[Y4LO.(
M\BW/5&.2 P!*\XH ^SFSWX%<UX5^(6C>,=<\2:3ILDSW?A^Y6SOO,B*!967<
M I/7C'(]:^./A/XZA\*_M'>$M \&>./'7BSPSKL<L=[<>+A)):W $>])+221
M5)QGD@#\1BNS_9O^&A\.?%[XW:I;^+=9,^FZ@]K'_:EWYMJ3)%Y@FF7C>R'@
M'(PHQ0!]=K3J_-OXB>.](\-:!)XN\)?&SQ]XZ\:077F3SZ9'(="AG# LLT14
M)%&02 N6'M7Z&^%=2EUCPOH]_<$&>ZLH9Y"HP-S(K''XF@#7HKX"^*GQB7QY
M\6O&&GZ]K7Q2TW2_#]^=/TVU^'=BYA.T#?)/*H^9B?X3T KTGP1KWC;XO?LX
MZQ>-J6M:1XG\+:C)-INI:I;R:=-?QP 2)]IBR 59"4;L2,^M 'UI17RG\,?'
MFN?&;X>>//BW<ZE<Z=9R:7<:=H^CVEXPCM!%&3+,X4X,K2=&_A XZUQ]M\-_
M'\/P%TGXM'XJ^(G\5Z=I,.IV]@+C.G20H@(BEB/^L<H<,Y/)YQ0!]N45\,_&
M_P"/TWC+Q=X?\/WU_P"-]'\.OX>M=9N5^']DTM[-<3C(5I ,I&N#]<U>^%_Q
M^\1^%?A[\4OLR^+-5T;PYI:7VB:EXUTY[>\W-\ABD8C$NUL-N].U 'VQ7*Z;
M\0M&U?QYK7A"VDF?6](MX;J[C:)EC5)<[,-T)..U>'_#/X*_$'PGJ_@WQE8?
M$36/$S:HBS>)--UZ\+6C12IO+6L87$;*Q&!QQ^5<UX.^'\>@_MB?%#7SXCU^
M?^R=-AU,VKWF89_-C8^3(N.43'R#M0!]?4M?FI!\9[_QS9R>,KOQ%\8+;QC,
M\D]A!X?T=WT&'#-Y47ECB5!P"W4_A7NNL>-/&/Q\/PJ\$_VIJG@1M?T=];U^
MZL0;:^VQ,%\E,C=$68;OI0![]<?%*TA^,$'P^-A<&]ETEM6%Z&7R@@DV;,9S
MNSSZ5VA;&,\5\H?#7P-JOPY_:\M]$O\ Q)?>*+*'PI(UA>:J_F7BQ&?F.63
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MV?3C%?6EU;Q75M)!-$DT,JF-XI%W*ZD8*D=P10!\U2_MP:>KR:K%\/?%MSX
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M3T%3BV[1VU^R?DN45:='/\3*I)15Y[NWVC[5H_SUKR+_ (:V^#W?Q]I7YO\
M_$TO_#6WP>_Z'[2_S?\ ^)KX;ZIB/^?<ON9^F?7L)_S]C_X$O\SUS_/6C_/6
MO(O^&MO@]_T/VE_F_P#\32_\-;?![_H?M+_-_P#XFCZIB/\ GV_N8?7L)_S]
MC_X$O\SUS_/6C_/6O(_^&MO@]_T/VE_F_P#\31_PUM\'O^A^TO\ -_\ XFCZ
MIB/^?;^YA]>PG_/V/_@2_P SUJ11)&RG.&!!P>:^<)OV#_AY<32RMKGC<-(Q
M)V^)K@#).>.:[3_AK;X/?]#]I?YO_P#$T?\ #6OP=[^/=*_-_P#XFCZIB/\
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M^.S\5_!+4?B'X?:TVZ=KGAE1+J-I,3\X*\>6!P5;)Y[5Z3_PUM\'O^A^TO\
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M/^$^TO\ -_\ XFC_ (:U^#O_ $/NE_F__P 31]4Q'_/M_<P^O83_ )^Q_P#
ME_F>!P_%[Q)K/Q&O?$OC7X*_$+7QI]RZZ#IUMIBM8V48.!-M8C?,W7<1QT'K
M7HOQ,NO%/C/0_AW\7?#W@G5HM<\.W<TESX4U)!%?O:2 QRKL!/[S"AE ZY%=
MQ_PUM\'O^A^TO\W_ /B:3_AK;X/?]#]I?YO_ /$T?5,1_P ^W]S#Z]A/^?L?
M_ E_F<9X%F\4_'3XU:)XXU?P7JO@?PSX7LYX;*UUY1'>7=U,-K,8P3A%7H<\
MFNF_:,\/:IK^M?"Z33--NK]+/Q-#<W36\1<01!&!=\?=7D<FKO\ PUM\'O\
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MT?5,1_S[?W,/KV$_Y^Q_\"7^9ZY_GK1_GK7D?_#6WP>_Z'[2_P W_P#B:/\
MAK;X/?\ 0_:7^;__ !-'U3$?\^W]S#Z]A/\ G['_ ,"7^9ZY_GK1_GK7D?\
MPUM\'O\ H?M+_-__ (FC_AK;X/?]#]I?YO\ _$T?5,1_S[?W,/KV$_Y^Q_\
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M[2_S?_XFO(^J8C_GV_N9[WU["?\ /V/_ ($O\SUS_/6C_/6O(_\ AK;X/?\
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M_P SSS0?V>/BQJ'Q6\%>./&OCC0]3?0)Y$_L?3;22"TBMFCVYA!&1(3P<\8
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M$\4:;HWQ0T"W,,U]]F9M/O0Z@2QNGWO+W?,!UZ5K_P##6OP=_P"A^TO\W_\
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M_P#$T?5,1_S[?W,/KV$_Y^Q_\"7^9Z[_ )ZT?YZUY'_PUM\'O^A^TO\ -_\
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M+]HSX;>./@/XKT70?%^GZGJUU%$(+6 MOD(FC8@97T!-?&/[._\ R7SX??\
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M?WX'XDY;^ZW_ 'R:,M_=;_ODU^VW]AZ=_P ^%K_WY7_"C^P]._Y\+7_ORO\
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M_OP/Q)RW]UO^^31EO[K?]\FOVV_L/3O^?"U_[\K_ (4?V'IW_/A:_P#?E?\
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M_P" '^I2_P"?WX'XDY;^ZW_?)HRW]UO^^37[;?V'IW_/A:_]^5_PH_L/3O\
MGPM?^_*_X4?ZTR_Y]?C_ , /]2E_S^_ _$G+?W6_[Y-*"?[K?]\FOVU_L/3O
M^?"U_P"_*_X4?V'IW_/A:_\ ?E?\*/\ 6F7_ #Z_'_@!_J4O^?WX'X@7DOE,
MDI1CM.>AI;.0R*\FUAN.>0:_;YM!TUUP;"VQ_P!<5_PH_L'35X%A;8_ZXK_A
M4?ZSRO?V7XFKX-5K>U_ _$G+?W6_[Y-&6_NM_P!\FOVV_L/3O^?"U_[\K_A1
M_8>G?\^%K_WY7_"K_P!:9?\ /K\?^ 9?ZE+_ )_?@?B3EO[K?]\FC+?W6_[Y
M-?MM_8>G?\^%K_WY7_"C^P]._P"?"U_[\K_A1_K3+_GU^/\ P _U*7_/[\#\
M2<M_=;_ODT9;^ZW_ 'R:_;;^P]._Y\+7_ORO^%']AZ=_SX6O_?E?\*/]:9?\
M^OQ_X ?ZE+_G]^!^).6_NM_WR:,M_=;_ +Y-?MM_8>G?\^%K_P!^5_PH_L/3
MO^?"U_[\K_A1_K3+_GU^/_ #_4I?\_OP/Q)RW]UO^^31EO[K?]\FOVV_L/3O
M^?"U_P"_*_X4?V'IW_/A:_\ ?E?\*/\ 6F7_ #Z_'_@!_J4O^?WX'XDY;^ZW
M_?)HRW]UO^^37[;?V'IW_/A:_P#?E?\ "C^P]._Y\+7_ +\K_A1_K3+_ )]?
MC_P _P!2E_S^_ _$G+?W6_[Y-&6_NM_WR:_;;^P]._Y\+7_ORO\ A1_8>G?\
M^%K_ -^5_P */]:9?\^OQ_X ?ZE+_G]^!^).6_NM_P!\FC+?W6_[Y-?MM_8>
MG?\ /A:_]^5_PH_L/3O^?"U_[\K_ (4?ZTR_Y]?C_P  /]2E_P _OP/Q)RW]
MUO\ ODT9;^ZW_?)K]MO[#T[_ )\+7_ORO^%']AZ=_P ^%K_WY7_"C_6F7_/K
M\?\ @!_J4O\ G]^!^).6_NM_WR:,M_=;_ODU^VW]AZ=_SX6O_?E?\*/[#T[_
M )\+7_ORO^%'^M,O^?7X_P# #_4I?\_OP/Q)RW]UO^^31EO[K?\ ?)K]MO[#
MT[_GPM?^_*_X4?V'IW_/A:_]^5_PH_UIE_SZ_'_@!_J4O^?WX'XDY;^ZW_?)
MHRW]UO\ ODU^VW]AZ=_SX6O_ 'Y7_"C^P]._Y\+7_ORO^%'^M,O^?7X_\ /]
M2E_S^_ _$G+?W6_[Y-&6_NM_WR:_;;^P]._Y\+7_ +\K_A1_8>G?\^%K_P!^
M5_PH_P!:9?\ /K\?^ '^I2_Y_?@?B3EO[K?]\FC+?W6_[Y-?MM_8>G?\^%K_
M -^5_P */[#T[_GPM?\ ORO^%'^M,O\ GU^/_ #_ %*7_/[\#\2<M_=;_ODT
M9;^ZW_?)K]MO[#T[_GPM?^_*_P"%']AZ=_SX6O\ WY7_  H_UIE_SZ_'_@!_
MJ4O^?WX'XDY;^ZW_ 'R:,M_=;_ODU^VW]AZ=_P ^%K_WY7_"C^P]._Y\+7_O
MRO\ A1_K3+_GU^/_   _U*7_ #^_ _$G+?W6_P"^31EO[K?]\FOVV_L/3O\
MGPM?^_*_X4?V'IW_ #X6O_?E?\*/]:9?\^OQ_P" '^I2_P"?WX'XDY;^ZW_?
M)HRW]UO^^37[;?V'IW_/A:_]^5_PH_L/3O\ GPM?^_*_X4?ZTR_Y]?C_ , /
M]2E_S^_ _$G+?W6_[Y-&6_NM_P!\FOVV_L/3O^?"U_[\K_A1_8>G?\^%K_WY
M7_"C_6F7_/K\?^ '^I2_Y_?@?B3EO[K?]\FC+?W6_P"^37[;?V'IW_/A:_\
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M^^37[;?V'IW_ #X6O_?E?\*/[#T[_GPM?^_*_P"%'^M,O^?7X_\  #_4I?\
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M,2,C>7'2N*T_QIXATWX]_$/QA;:+:W'BB+X<Z=J+:5YC"(R;M[1A\;N.F<4
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M[L$51N9F. !ZU6TK6+#7;&*^TR^M]1LI<^7<VDJRQO@X.&4D'D8_"O%?A_\
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MC3\0/&TVJZG!'8:+8ZW%J+S3!@RNT>,!5ZECC KU_P !1*?VS_B7(?OKH=@
M?3.<_CP/RKT/P!^SM\-OA;JTVJ>%/!6DZ'J,R['N;:'Y]N<X!)..?2NJL_!.
MAZ?XHO\ Q);:9##KM_$D%U?*#YDL:?=4\]!0!X/^S3G_ (7]^T-G_H/6_P#Z
M(KPJ3G]F/XT_]CY+_P"CXZ^ZM \!Z!X7UC6M6TK2K>QU+6IA<:C<Q [KF0#
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M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 E [T4#O2Z@>)_MG?\FS^-O^N$/_I1'7YT_L[_ /)?/A]_V&[;
M_P!"K]%OVSO^39_&W_7"'_THCK\Z?V=_^2^?#[_L-VW_ *%7Z!D?_(MK_/\
M])1^5\2?\CC#?]N_^E'[!4M)2U\ ?J@4444 %%%% !1110!^5?[;7_)SOC/_
M +<O_2*"OKO_ ()[_P#)O@_[#%W_ #6OD3]MK_DYWQG_ -N7_I%!7UW_ ,$]
M_P#DWP?]AB[_ )K7Z!FG_(FH?]N?^DGY5DG_ "4.)]9_^E'TQ2TE+7Y^?JH4
M444 %%%% !1110 4444 )N'K25Q'Q4^,W@_X+:7::CXQU;^R+.[F\B*3R))=
MSXSC"*3T%<=X+_;"^$/Q#\26>@:'XRM[C5+LD0PS6\T D8?PAY$5<GL,Y/04
M >SY]>M.%<[IWCK1-8\7:OX8M+T3:WI$4,U[:^6P,2R@F,[B-IS@]#71#I0
MM%)D49H 6BDS10 -TIG1NOT%//-<_J'C;1-+\6:7X;N=0BCUO4XI);6RY,CQ
MQXWMP/E'(Y.,]NE &\/O#GDT[-8GBSQ=I7@?0YM7UNZ^QZ?$R*TNQF.YF"J
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M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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MA_ /Q7X;C^&OB?3=#TWXGZMX9TC^Q=5T751'_I\1P?,C:4$!U;H6[>O2N]^
MNC^)KKQ!?ZYK/PO\,_##3_L_V:WL+.**74I'W99WFB 41],+C)(H ]QDR8V
M;:<8#8SCWKY2@^%\/P]_:Z\"7LVL:EXAUK5M/U*6]U/4Y=SN 5V1HH^5$0'
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MXT:EX]\">$8?'EAXBL(;/4-,%XEK/;2P@B.16?@H1U'7/I0!'XJ^,7Q#\/\
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MPKHOB:VBU3Q'IZ+\Y%D^8G.. '/R$GDU]7[1CCH/2@#Y@_:._:-U'PK\0HO
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M$B*;>.*';(Q)/.T\?+G-=)\+/!FM:#\:/BKK=_8/;:7K%Q:/8W#,I$X2+:Q
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M2G*BEI%^[2T %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 E [T4#O2Z@>)_MG?\FS^-O^N$
M/_I1'7YT_L[_ /)?/A]_V&[;_P!"K]%OVSO^39_&W_7"'_THCK\Z?V=_^2^?
M#[_L-VW_ *%7Z!D?_(MK_/\ ])1^5\2?\CC#?]N_^E'[!4M)2U\ ?J@4444
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MGQ]'KD! RLEE%,HEE4?W"03]!0!ZS-KW[3MUI(\8P6/@ZUTTQB\'@V19GO\
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M,D"OO#/\H+29ZMG\*] HH \XM_@#X0CT;QII-W:3:IIWBZ]EO]2M[V0.ID<
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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M8_:/CM_!'@WQWI^E^=X,U*[6UUJ>=F6YTK<=FYE ((23*N2>.M4]1_:0OF\
M_$3QOI.BVMWX6\.DPZ9=S3LIU.5"!,X 'RQ@G ;G.#0![UOX!HW5\R_\-1>.
M=%O-%\0^)OABVB?#+5988(]8-Z'O8#+@1R36^/D0L>YS@BNE^)7QV\6VWC:^
M\)_#/P=9^+=6TJ..75;C5-22QM;<R#*1JQY9R,-@#&#0![KNH+5X?IO[46G0
M_"GQ%XIUS1KK3-:\.S_8-1T!)%DD^UD@)'&X^5@Y(VMZ&JOPU^.WCJ\\?6/A
M3XC^ 8O"-WK%H]WH]Q97WVN*79R\<IP/+?!4X^M 'O/F>HYI=WM7R+^SGX^\
M9:9\3/C7?^+M$M-+\.6>H2W>I7BZD;@V<D<>5BC0]5,8W$C&"<5LK^U-\0+>
MUC\7WWPQAM_AE(%F%^FKQ-J:6['"S-;=ASN(SG% 'U#N_.JD.L65Q?W%C%=V
M\M_;JK36J2J98@WW2RYR >Q/6O&/BA\?-<T[Q)HOA3X9^%X?''B?4+(:K(EU
M=BUM;:S(^5WD(."Q^Z*XW]G/Q1?^+OVDOBGJ&L:))X>UE=.TZVOM/D8/Y4R*
M0VQQ]]#U5NXH ^I-U8FF^//#>M:D^GZ=X@TJ_P!07=NM+6]BDE&W[V45B>._
M%5?B)X3G\=^!]8\/VVLW6@3:C 8!J5D 9H03R5SW(R/QKY?^.'[.?@#X5>&_
M"@^'VC1:+\36U2TCTB^L"1>73AQYSRX.739N9\\4 ?7<6L6,^H36$=Y;R7T*
MAY;595,L:G[I9<Y /J:276+&#4(+"6\MXK^X5GAM7E42R*OWBJ$Y('?'2OD_
MQ-\</"/P._:T\:WGBVZNK5-0T*PBB:SL9;@LR[BV1&I*]>,]:/#_ ,<O"'QP
M_:Y^'UWX4N;JY33]'U&*<W=C+;%2R@C'F*">AZ4 ?77F>M8MQX[\-VNL?V3/
MX@TJ'5=P3[#)>Q+/N.-J["V[)R.,=Q6G?0O<6<\44S6TCQLBS(,M&2,!A].M
M?*?Q&_93^%/P]^#>OZEXAMAK'BSR)9$\4W)QJ=S?.28@C YW%RJA1VXH ^J]
M2U:ST6QEO=0NX+"SA7=)<74JQQH/5F)P*BT;Q!IGB*Q%[I.H6FJ698J+BRG2
M:,D=1N4D9'UKY0O/#>I_$SQ?\%_AM\1FEO[.'PX^MZS9.Y"WUT@")'.!]Y1U
M*GO74^ _!ND_ []J(^%/"-JND^%O$F@MJ$ND0L1;V]S"X7?$G1=RL<@=^: /
MHR?4K:UF@BN+B&WEN',<,<L@5I6 SA0>IP,X%1ZKKFGZ#927FIWUMIMG'C?<
M7DRQ1KGIEF( KY8\8>%?%NG_ +4?POUKQ7XCCU1KO4+^*PTJPB,=I96XB)0\
M\O(1]YC]!Q5C]LR3PYIWC+X<:E\0X9-6^&R3W$-[I,)9]]RR?NI7A7YID&#\
MH!P<&@#Z>TG7=/\ $%FMWI=]:ZE:,2%N+.998R1U 9215^OE']CV3PWJ?Q%\
M?ZG\-8FTOX9-';PP:4^Z+;>@9DE2!OFB0KQR!DYKZNH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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M<Q'YD5<;>>O6OHW\:3GH30!X?\9K"ZN?CW\&)X;6>:""\O#+-'$S)$# 0"S
M87\:YKX[7=Y\,OCSX8^)FI^&M0\4^$;?29=,<Z5:_:KC3;AG+"41#D[@=N1[
MU]*G..#1V]_:@#YI^"-]=?%3X_:Y\2]*\+ZCX6\*-I"Z6)M5MS:W&IW <,7:
M$\@(!C<>O\OIJF#.[FG9% "T4F11D4 +129%&10 M%)D49% "T4F11D4 +12
M9%&10 M%)D49% "T4F11D4 +129%&10 M%)D49% "T4F11D4 +129%&10 M%
M)D49% "T4F11D4 +129%&10 M%)D49% "T4F11D4 +129%&10 M%)D49% "T
M4F11D4 +129%&10 M%)D49% "T4F11D4 +129%&10 M%)D49% "T4F11D4 +
M129%&10 M%)D49% "T4F11D4 +129%&10 M%)D49% "T4F11D4 +129%&10
MM%)D49% "T4F11D4 +129%&10 M%)D49% "T4F11D4 +129%&10 M%)D49%
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M/XE?]!SPK_X%W/\ \CT_JN0_SK[V'USBC_GV_P#P%'I7_#S#1O\ H0M2_P#
M^+_XFC_AYAHW_0A:E_X'Q?\ Q->:_P##N/XE?]!SPK_X%W/_ ,CT?\.X_B5_
MT'/"O_@7<_\ R/2^JY#_ #K[V'USBC_GV_\ P%'I7_#S#1O^A"U+_P #XO\
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M<A_G7WL/KG%'_/M_^ H]*_X>8:-_T(6I?^!\7_Q-'_#S#1O^A"U+_P #XO\
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M-'_#S#1O^A"U+_P/B_\ B:\U_P"'<?Q*_P"@YX5_\"[G_P"1Z/\ AW'\2O\
MH.>%?_ NY_\ D>CZKD/\Z^]A]<XH_P"?;_\  4>E?\/,-&_Z$+4O_ ^+_P")
MH_X>8:-_T(6I?^!\7_Q->:_\.X_B5_T'/"O_ (%W/_R/1_P[C^)7_0<\*_\
M@7<__(]'U7(?YU][#ZYQ1_S[?_@*/2O^'F&C?]"%J7_@?%_\31_P\PT;_H0M
M2_\  ^+_ .)KS7_AW'\2O^@YX5_\"[G_ .1Z/^'<?Q*_Z#GA7_P+N?\ Y'H^
MJY#_ #K[V'USBC_GV_\ P%'I7_#S#1O^A"U+_P #XO\ XFC_ (>8:-_T(6I?
M^!\7_P 37FO_  [C^)7_ $'/"O\ X%W/_P CT?\ #N/XE?\ 0<\*_P#@7<__
M "/1]5R'^=?>P^N<4?\ /M_^ H]*_P"'F&C?]"%J7_@?%_\ $T?\/,-&_P"A
M"U+_ ,#XO_B:\U_X=Q_$K_H.>%?_  +N?_D>C_AW'\2O^@YX5_\  NY_^1Z/
MJN0_SK[V'USBC_GV_P#P%'I7_#S#1O\ H0M2_P# ^+_XFC_AYAHW_0A:E_X'
MQ?\ Q->:_P##N/XE?]!SPK_X%W/_ ,CT?\.X_B5_T'/"O_@7<_\ R/1]5R'^
M=?>P^N<4?\^W_P" H]*_X>8:-_T(6I?^!\7_ ,31_P /,-&_Z$+4O_ ^+_XF
MO-?^'<?Q*_Z#GA7_ ,"[G_Y'H_X=Q_$K_H.>%?\ P+N?_D>CZKD/\Z^]A]<X
MH_Y]O_P%'I7_  \PT;_H0M2_\#XO_B:/^'F&C?\ 0A:E_P"!\7_Q->:_\.X_
MB5_T'/"O_@7<_P#R/1_P[C^)7_0<\*_^!=S_ /(]'U7(?YU][#ZYQ1_S[?\
MX"CTK_AYAHW_ $(6I?\ @?%_\31_P\PT;_H0M2_\#XO_ (FO-?\ AW'\2O\
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M2_\  ^+_ .)H_P"'F&C?]"%J7_@?%_\ $UYK_P .X_B5_P!!SPK_ .!=S_\
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M<A_G7WL/KG%'_/M_^ H]*_X>8:-_T(6I?^!\7_Q-'_#S#1O^A"U+_P #XO\
MXFO-?^'<?Q*_Z#GA7_P+N?\ Y'H_X=Q_$K_H.>%?_ NY_P#D>CZKD/\ .OO8
M?7.*/^?;_P# 4>E?\/,-&_Z$+4O_  /B_P#B:/\ AYAHW_0A:E_X'Q?_ !->
M:_\ #N/XE?\ 0<\*_P#@7<__ "/1_P .X_B5_P!!SPK_ .!=S_\ (]'U7(?Y
MU][#ZYQ1_P ^W_X"CTK_ (>8:-_T(6I?^!\7_P 31_P\PT;_ *$+4O\ P/B_
M^)KS7_AW'\2O^@YX5_\  NY_^1Z/^'<?Q*_Z#GA7_P "[G_Y'H^JY#_.OO8?
M7.*/^?;_ / 4>E?\/,-&_P"A"U+_ ,#XO_B:/^'F&C?]"%J7_@?%_P#$UYK_
M ,.X_B5_T'/"O_@7<_\ R/1_P[C^)7_0<\*_^!=S_P#(]'U7(?YU][#ZYQ1_
MS[?_ ("CTK_AYAHW_0A:E_X'Q?\ Q-'_  \PT;_H0M2_\#XO_B:\U_X=Q_$K
M_H.>%?\ P+N?_D>C_AW'\2O^@YX5_P# NY_^1Z/JN0_SK[V'USBC_GV__ 4>
ME?\ #S#1O^A"U+_P/B_^)H_X>8:-_P!"%J7_ ('Q?_$UYK_P[C^)7_0<\*_^
M!=S_ /(]'_#N/XE?]!SPK_X%W/\ \CT?5<A_G7WL/KG%'_/M_P#@*/2O^'F&
MC?\ 0A:E_P"!\7_Q-'_#S#1O^A"U+_P/B_\ B:\U_P"'<?Q*_P"@YX5_\"[G
M_P"1Z/\ AW'\2O\ H.>%?_ NY_\ D>CZKD/\Z^]A]<XH_P"?;_\  4>E?\/,
M-&_Z$+4O_ ^+_P")H_X>8:-_T(6I?^!\7_Q->:_\.X_B5_T'/"O_ (%W/_R/
M1_P[C^)7_0<\*_\ @7<__(]'U7(?YU][#ZYQ1_S[?_@*/2O^'F&C?]"%J7_@
M?%_\31_P\PT;_H0M2_\  ^+_ .)KS7_AW'\2O^@YX5_\"[G_ .1Z/^'<?Q*_
MZ#GA7_P+N?\ Y'H^JY#_ #K[V'USBC_GV_\ P%'I7_#S#1O^A"U+_P #XO\
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M$K_H.>%?_ NY_P#D>C_AW'\2O^@YX5_\"[G_ .1Z?U7(?YU][#ZYQ1_S[?\
MX"CTK_AYAHW_ $(6I?\ @?%_\31_P\PT;_H0M2_\#XO_ (FO-?\ AW'\2O\
MH.>%?_ NY_\ D>C_ (=Q_$K_ *#GA7_P+N?_ )'I?5<A_G7WL/KG%'_/M_\
M@*/2O^'F&C?]"%J7_@?%_P#$T?\ #S#1O^A"U+_P/B_^)KS7_AW'\2O^@YX5
M_P# NY_^1Z/^'<?Q*_Z#GA7_ ,"[G_Y'I_5<A_G7WL/KG%'_ #[?_@*/2O\
MAYAHW_0A:E_X'Q?_ !-'_#S#1O\ H0M2_P# ^+_XFO-?^'<?Q*_Z#GA7_P "
M[G_Y'H_X=Q_$K_H.>%?_  +N?_D>E]5R'^=?>P^N<4?\^W_X"CTK_AYAHW_0
MA:E_X'Q?_$T?\/,-&_Z$+4O_  /B_P#B:\U_X=Q_$K_H.>%?_ NY_P#D>C_A
MW'\2O^@YX5_\"[G_ .1Z/JN0_P Z^]A]<XH_Y]O_ ,!1Z5_P\PT;_H0M2_\
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MTK_AYAHW_0A:E_X'Q?\ Q-'_  \PT;_H0M2_\#XO_B:\U_X=Q_$K_H.>%?\
MP+N?_D>C_AW'\2O^@YX5_P# NY_^1Z7U7(?YU][#ZYQ1_P ^W_X"CTK_ (>7
MZ,>/^$"U+_P/B_\ B:3_ (>6:*O'_"!:F?\ M_B_^)KS;_AW'\2O^@YX5_\
M NY_^1Z7_AW'\2O^@YX5_P# NY_^1Z/JN1?SK[V/ZYQ1_(__  %%[XV_MS:9
M\7/A?KWA&#PC?:9-J<:(EU+=QND9617R0!D_=Q^->%?L\?+\>/A\>_\ ;=M_
MZ%7L_P#P[C^)7_0;\*?^!=S_ /(]>@_ O]@WQ%X%^)&D>)?%&M:3-;Z5,+F"
MWTN261GE7[NXO&F #SWKK^L99@\)5I8>:UOU;Z'GO!YSF&-I5L73?NM:V2TO
M?H?:^>:<O2DVTHXK\T/V06BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@#_
!V0$!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>13
<FILENAME>R1.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.8.0.1</span><table class="report" border="0" cellspacing="2" id="idp6761196688">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Document and Entity Information - shares<br></strong></div></th>
<th class="th" colspan="1">9 Months Ended</th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th"><div>Sep. 30, 2017</div></th>
<th class="th"><div>Oct. 31, 2017</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_nlnk_DocumentAndEntityInformationAbstract', window );"><strong>Document and Entity Information [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityRegistrantName', window );">Entity Registrant Name</a></td>
<td class="text">NEWLINK GENETICS CORP<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityCentralIndexKey', window );">Entity Central Index Key</a></td>
<td class="text">0001126234<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_CurrentFiscalYearEndDate', window );">Current Fiscal Year End Date</a></td>
<td class="text">--12-31<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityFilerCategory', window );">Entity Filer Category</a></td>
<td class="text">Accelerated Filer<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_DocumentType', window );">Document Type</a></td>
<td class="text">10-Q<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_DocumentPeriodEndDate', window );">Document Period End Date</a></td>
<td class="text">Sep. 30,  2017<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_DocumentFiscalYearFocus', window );">Document Fiscal Year Focus</a></td>
<td class="text">2017<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_DocumentFiscalPeriodFocus', window );">Document Fiscal Period Focus</a></td>
<td class="text">Q3<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_AmendmentFlag', window );">Amendment Flag</a></td>
<td class="text">false<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityCommonStockSharesOutstanding', window );">Entity Common Stock, Shares Outstanding</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">37,077,159<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_AmendmentFlag">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>If the value is true, then the document is an amendment to previously-filed/accepted document.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_AmendmentFlag</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_CurrentFiscalYearEndDate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>End date of current fiscal year in the format --MM-DD.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_CurrentFiscalYearEndDate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:gMonthDayItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentFiscalPeriodFocus">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>This is focus fiscal period of the document report. For a first quarter 2006 quarterly report, which may also provide financial information from prior periods, the first fiscal quarter should be given as the fiscal period focus. Values: FY, Q1, Q2, Q3, Q4, H1, H2, M9, T1, T2, T3, M8, CY.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentFiscalPeriodFocus</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:fiscalPeriodItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentFiscalYearFocus">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>This is focus fiscal year of the document report in CCYY format. For a 2006 annual report, which may also provide financial information from prior periods, fiscal 2006 should be given as the fiscal year focus. Example: 2006.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentFiscalYearFocus</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:gYearItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentPeriodEndDate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The end date of the period reflected on the cover page if a periodic report. For all other reports and registration statements containing historical data, it is the date up through which that historical data is presented.  If there is no historical data in the report, use the filing date. The format of the date is CCYY-MM-DD.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentPeriodEndDate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:dateItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentType">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word "Other".</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentType</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:submissionTypeItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityCentralIndexKey">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation 12B<br> -Number 240<br> -Section 12b<br> -Subsection 1<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityCentralIndexKey</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:centralIndexKeyItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityCommonStockSharesOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Indicate number of shares or other units outstanding of each of registrant's classes of capital or common stock or other ownership interests, if and as stated on cover of related periodic report. Where multiple classes or units exist define each class/interest by adding class of stock items such as Common Class A [Member], Common Class B [Member] or Partnership Interest [Member] onto the Instrument [Domain] of the Entity Listings, Instrument.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityCommonStockSharesOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityFilerCategory">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Indicate whether the registrant is one of the following: (1) Large Accelerated Filer, (2) Accelerated Filer, (3) Non-accelerated Filer, (4) Smaller Reporting Company (Non-accelerated) or (5) Smaller Reporting Accelerated Filer. Definitions of these categories are stated in Rule 12b-2 of the Exchange Act. This information should be based on the registrant's current or most recent filing containing the related disclosure.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityFilerCategory</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:filerCategoryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityRegistrantName">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation 12B<br> -Number 240<br> -Section 12b<br> -Subsection 1<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityRegistrantName</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_nlnk_DocumentAndEntityInformationAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Document and Entity Information [Abstract]</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">nlnk_DocumentAndEntityInformationAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>nlnk_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>14
<FILENAME>R2.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.8.0.1</span><table class="report" border="0" cellspacing="2" id="idp6761707520">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Condensed Consolidated Balance Sheets - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th"><div>Sep. 30, 2017</div></th>
<th class="th"><div>Dec. 31, 2016</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AssetsCurrentAbstract', window );"><strong>Current assets:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsAtCarryingValue', window );">Cash and cash equivalents</a></td>
<td class="nump">$ 120,702<span></span>
</td>
<td class="nump">$ 131,490<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PrepaidExpenseAndOtherAssetsCurrent', window );">Prepaid expenses and other current assets</a></td>
<td class="nump">2,701<span></span>
</td>
<td class="nump">5,921<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeTaxesReceivable', window );">Income tax receivable</a></td>
<td class="nump">114<span></span>
</td>
<td class="nump">5,975<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherReceivablesNetCurrent', window );">Other receivables</a></td>
<td class="nump">10,670<span></span>
</td>
<td class="nump">24,526<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AssetsCurrent', window );">Total current assets</a></td>
<td class="nump">134,187<span></span>
</td>
<td class="nump">167,912<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentNet', window );">Property and equipment, net</a></td>
<td class="nump">5,527<span></span>
</td>
<td class="nump">6,835<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_Assets', window );">Total assets</a></td>
<td class="nump">139,714<span></span>
</td>
<td class="nump">174,747<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LiabilitiesCurrentAbstract', window );"><strong>Current liabilities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccountsPayableCurrent', window );">Accounts payable</a></td>
<td class="nump">11,860<span></span>
</td>
<td class="nump">22,883<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccruedLiabilitiesCurrent', window );">Accrued expenses</a></td>
<td class="nump">13,832<span></span>
</td>
<td class="nump">14,309<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DeferredRevenueCurrent', window );">Current portion of unearned revenue</a></td>
<td class="nump">112<span></span>
</td>
<td class="nump">391<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DeferredRentCreditCurrent', window );">Current portion of deferred rent</a></td>
<td class="nump">93<span></span>
</td>
<td class="nump">90<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LongTermDebtAndCapitalLeaseObligationsCurrent', window );">Current portion of notes payable and obligations under capital leases</a></td>
<td class="nump">194<span></span>
</td>
<td class="nump">232<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LiabilitiesCurrent', window );">Total current liabilities</a></td>
<td class="nump">26,091<span></span>
</td>
<td class="nump">37,905<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LiabilitiesNoncurrentAbstract', window );"><strong>Long-term liabilities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_nlnk_DeferredGovernmentGrantsObligationsNoncurrent', window );">Royalty obligation payable to Iowa Economic Development Authority</a></td>
<td class="nump">6,000<span></span>
</td>
<td class="nump">6,000<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LongTermDebtAndCapitalLeaseObligations', window );">Notes payable and obligations under capital leases</a></td>
<td class="nump">138<span></span>
</td>
<td class="nump">285<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DeferredRentCreditNoncurrent', window );">Deferred rent</a></td>
<td class="nump">1,021<span></span>
</td>
<td class="nump">1,091<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LiabilitiesNoncurrent', window );">Total long-term liabilities</a></td>
<td class="nump">7,159<span></span>
</td>
<td class="nump">7,376<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_Liabilities', window );">Total liabilities</a></td>
<td class="nump">33,250<span></span>
</td>
<td class="nump">45,281<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EquityAbstract', window );"><strong>Stockholders' equity:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PreferredStockValueOutstanding', window );">Blank check preferred stock, $0.01 par value: Authorized shares &#8212; 5,000,000 at September 30, 2017 and December 31, 2016; issued and outstanding shares &#8212; 0 at September 30, 2017 and December 31, 2016</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommonStockValueOutstanding', window );">Common stock, $0.01 par value: Authorized shares &#8212; 75,000,000 at September 30, 2017 and December 31, 2016; issued 31,375,528 and 29,193,718 at September 30, 2017 and December 31, 2016, respectively, and outstanding 31,319,751 and 29,163,673 at September 30, 2017 and December 31, 2016, respectively</a></td>
<td class="nump">314<span></span>
</td>
<td class="nump">292<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AdditionalPaidInCapital', window );">Additional paid-in capital</a></td>
<td class="nump">331,036<span></span>
</td>
<td class="nump">295,535<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TreasuryStockValue', window );">Treasury stock, at cost: 55,777 and 30,045 shares at September 30, 2017 and December 31, 2016, respectively</a></td>
<td class="num">(1,113)<span></span>
</td>
<td class="num">(853)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RetainedEarningsAccumulatedDeficit', window );">Accumulated deficit</a></td>
<td class="num">(223,773)<span></span>
</td>
<td class="num">(165,508)<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Total stockholders' equity</a></td>
<td class="nump">106,464<span></span>
</td>
<td class="nump">129,466<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LiabilitiesAndStockholdersEquity', window );">Total liabilities and stockholders' equity</a></td>
<td class="nump">$ 139,714<span></span>
</td>
<td class="nump">$ 174,747<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_nlnk_DeferredGovernmentGrantsObligationsNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Deferred Government Grants Obligations, Noncurrent</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">nlnk_DeferredGovernmentGrantsObligationsNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>nlnk_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountsPayableCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Carrying value as of the balance sheet date of liabilities incurred (and for which invoices have typically been received) and payable to vendors for goods and services received that are used in an entity's business. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.19(a))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountsPayableCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccruedLiabilitiesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Carrying value as of the balance sheet date of obligations incurred and payable, pertaining to costs that are statutory in nature, are incurred on contractual obligations, or accumulate over time and for which invoices have not yet been received or will not be rendered. Examples include taxes, interest, rent and utilities. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.20)<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccruedLiabilitiesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AdditionalPaidInCapital">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Excess of issue price over par or stated value of the entity's capital stock and amounts received from other transactions involving the entity's stock or stockholders. Includes adjustments to additional paid in capital. Some examples of such adjustments include recording the issuance of debt with a beneficial conversion feature and certain tax consequences of equity instruments awarded to employees. Use this element for the aggregate amount of additional paid-in capital associated with common and preferred stock. For additional paid-in capital associated with only common stock, use the element additional paid in capital, common stock. For additional paid-in capital associated with only preferred stock, use the element additional paid in capital, preferred stock.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(30)(a)(1))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AdditionalPaidInCapital</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_Assets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Sum of the carrying amounts as of the balance sheet date of all assets that are recognized. Assets are probable future economic benefits obtained or controlled by an entity as a result of past transactions or events.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(12))<br> -URI http://asc.fasb.org/extlink&amp;oid=6879938&amp;loc=d3e572229-122910<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(11))<br> -URI http://asc.fasb.org/extlink&amp;oid=6876686&amp;loc=d3e534808-122878<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_Assets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AssetsCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Sum of the carrying amounts as of the balance sheet date of all assets that are expected to be realized in cash, sold, or consumed within one year (or the normal operating cycle, if longer). Assets are probable future economic benefits obtained or controlled by an entity as a result of past transactions or events.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.9)<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=82887183&amp;loc=d3e6801-107765<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=82887183&amp;loc=d3e6676-107765<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AssetsCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AssetsCurrentAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AssetsCurrentAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashAndCashEquivalentsAtCarryingValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of currency on hand as well as demand deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits. Also includes short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates. Excludes cash and cash equivalents within disposal group and discontinued operation.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=82887183&amp;loc=d3e6676-107765<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=98514028&amp;loc=d3e3044-108585<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.1)<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashAndCashEquivalentsAtCarryingValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockValueOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Value of all classes of common stock held by shareholders. May be all or portion of the number of common shares authorized. These shares exclude common shares repurchased by the entity and held as treasury shares.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockValueOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredRentCreditCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>For a classified balance sheet, the cumulative difference as of the balance sheet date between the payments required by a lease agreement and the rental income or expense recognized on a straight-line basis, or other systematic and rational basis more representative of the time pattern in which use or benefit is granted or derived from the leased property, expected to be recognized in income or expense, by the lessor or lessee, respectively, within one year of the balance sheet date.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 840<br> -SubTopic 20<br> -Section 25<br> -Paragraph 2<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=77902458&amp;loc=d3e39927-112707<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.20)<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredRentCreditCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredRentCreditNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>For a classified balance sheet, the cumulative difference between the rental income or payments required by a lease agreement and the rental income or expense recognized on a straight-line basis, or other systematic and rational basis more representative of the time pattern in which use or benefit is granted or derived from the leased property, expected to be recognized in income or expense, by the lessor or lessee, respectively, more than one year after the balance sheet date.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.26(c))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 840<br> -SubTopic 20<br> -Section 25<br> -Paragraph 2<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=77902458&amp;loc=d3e39927-112707<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredRentCreditNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredRevenueCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The carrying amount of consideration received or receivable as of the balance sheet date on potential earnings that were not recognized as revenue in conformity with GAAP, and which are expected to be recognized as such within one year or the normal operating cycle, if longer, including sales, license fees, and royalties, but excluding interest income.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 605<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 13.A.3(b).Q1(c))<br> -URI http://asc.fasb.org/extlink&amp;oid=65893310&amp;loc=d3e214044-122780<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 8<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=82887183&amp;loc=d3e6935-107765<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 605<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB TOPIC 13.A.4(a).Q1)<br> -URI http://asc.fasb.org/extlink&amp;oid=65893310&amp;loc=d3e214044-122780<br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 605<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 13.A.3)<br> -URI http://asc.fasb.org/extlink&amp;oid=65893310&amp;loc=d3e214044-122780<br><br>Reference 5: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 605<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 13.A.3(b).Q2)<br> -URI http://asc.fasb.org/extlink&amp;oid=65893310&amp;loc=d3e214044-122780<br><br>Reference 6: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 605<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 13.A.3(b))<br> -URI http://asc.fasb.org/extlink&amp;oid=65893310&amp;loc=d3e214044-122780<br><br>Reference 7: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 605<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 13.A.3(c).Q3)<br> -URI http://asc.fasb.org/extlink&amp;oid=65893310&amp;loc=d3e214044-122780<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredRevenueCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EquityAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EquityAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxesReceivable">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Carrying amount due within one year of the balance sheet date (or one operating cycle, if longer) from tax authorities as of the balance sheet date representing refunds of overpayments or recoveries based on agreed-upon resolutions of disputes.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03.5(c))<br> -URI http://asc.fasb.org/extlink&amp;oid=6879938&amp;loc=d3e572229-122910<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.3(a)(4))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03.10)<br> -URI http://asc.fasb.org/extlink&amp;oid=6876686&amp;loc=d3e534808-122878<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxesReceivable</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_Liabilities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Sum of the carrying amounts as of the balance sheet date of all liabilities that are recognized. Liabilities are probable future sacrifices of economic benefits arising from present obligations of an entity to transfer assets or provide services to other entities in the future.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.19-26)<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_Liabilities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LiabilitiesAndStockholdersEquity">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of liabilities and equity items, including the portion of equity attributable to noncontrolling interests, if any.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(23))<br> -URI http://asc.fasb.org/extlink&amp;oid=6876686&amp;loc=d3e534808-122878<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(25))<br> -URI http://asc.fasb.org/extlink&amp;oid=6879938&amp;loc=d3e572229-122910<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(32))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LiabilitiesAndStockholdersEquity</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LiabilitiesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Total obligations incurred as part of normal operations that are expected to be paid during the following twelve months or within one business cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.21)<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LiabilitiesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LiabilitiesCurrentAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LiabilitiesCurrentAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LiabilitiesNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of obligation due after one year or beyond the normal operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(22))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 201.5-02(26))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(23))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 201.5-02(25))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br>Reference 5: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 201.5-02(24))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LiabilitiesNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LiabilitiesNoncurrentAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LiabilitiesNoncurrentAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LongTermDebtAndCapitalLeaseObligations">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of long-term debt and capital lease obligation due after one year or beyond the normal operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(22))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LongTermDebtAndCapitalLeaseObligations</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LongTermDebtAndCapitalLeaseObligationsCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of long-term debt and capital leases due within one year or the normal operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.20)<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LongTermDebtAndCapitalLeaseObligationsCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherReceivablesNetCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount, after allowance, of receivables classified as other, due within one year or the operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherReceivablesNetCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PreferredStockValueOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Value of all nonredeemable preferred stock (or preferred stock redeemable solely at the option of the issuer) held by shareholders, which is net of related treasury stock. May be all or a portion of the number of preferred shares authorized. These shares represent the ownership interest of the preferred shareholders.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PreferredStockValueOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PrepaidExpenseAndOtherAssetsCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of asset related to consideration paid in advance for costs that provide economic benefits in future periods, and amount of other assets that are expected to be realized or consumed within one year or the normal operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(8))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(7))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=82887183&amp;loc=d3e6676-107765<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PrepaidExpenseAndOtherAssetsCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount after accumulated depreciation, depletion and amortization of physical assets used in the normal conduct of business to produce goods and services and not intended for resale. Examples include, but are not limited to, land, buildings, machinery and equipment, office equipment, and furniture and fixtures.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(13))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(14))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(8))<br> -URI http://asc.fasb.org/extlink&amp;oid=6879938&amp;loc=d3e572229-122910<br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6391035&amp;loc=d3e2868-110229<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RetainedEarningsAccumulatedDeficit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The cumulative amount of the reporting entity's undistributed earnings or deficit.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(23)(a)(4))<br> -URI http://asc.fasb.org/extlink&amp;oid=6879938&amp;loc=d3e572229-122910<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI http://asc.fasb.org/extlink&amp;oid=27012166&amp;loc=d3e187085-122770<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(30)(a)(3))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RetainedEarningsAccumulatedDeficit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockholdersEquity">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Total of all stockholders' equity (deficit) items, net of receivables from officers, directors, owners, and affiliates of the entity which are attributable to the parent. The amount of the economic entity's stockholders' equity attributable to the parent excludes the amount of stockholders' equity which is allocable to that ownership interest in subsidiary equity which is not attributable to the parent (noncontrolling interest, minority interest). This excludes temporary equity and is sometimes called permanent equity.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(30))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 310<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SAB Topic 4.E)<br> -URI http://asc.fasb.org/extlink&amp;oid=27010918&amp;loc=d3e74512-122707<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(31))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockholdersEquity</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TreasuryStockValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The amount allocated to treasury stock. Treasury stock is common and preferred shares of an entity that were issued, repurchased by the entity, and are held in its treasury.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 30<br> -Section 45<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6405813&amp;loc=d3e23239-112655<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.29,30)<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 30<br> -Section 50<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=6405834&amp;loc=d3e23315-112656<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TreasuryStockValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>15
<FILENAME>R3.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.8.0.1</span><table class="report" border="0" cellspacing="2" id="idp6752414112">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Condensed Consolidated Balance Sheets (Parentheticals) - $ / shares<br></strong></div></th>
<th class="th"><div>Sep. 30, 2017</div></th>
<th class="th"><div>Dec. 31, 2016</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquityNumberOfSharesParValueAndOtherDisclosuresAbstract', window );"><strong>Stockholders' Equity:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PreferredStockParOrStatedValuePerShare', window );">Blank check preferred stock, par value (in dollars per share)</a></td>
<td class="nump">$ 0.01<span></span>
</td>
<td class="nump">$ 0.01<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PreferredStockSharesAuthorized', window );">Blank check preferred stock, authorized shares</a></td>
<td class="nump">5,000,000<span></span>
</td>
<td class="nump">5,000,000<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PreferredStockSharesIssued', window );">Blank check preferred stock, issued shares</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PreferredStockSharesOutstanding', window );">Blank check preferred stock, outstanding shares</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommonStockParOrStatedValuePerShare', window );">Common stock, par value (in dollars per share)</a></td>
<td class="nump">$ 0.01<span></span>
</td>
<td class="nump">$ 0.01<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommonStockSharesAuthorized', window );">Common stock, authorized shares</a></td>
<td class="nump">75,000,000<span></span>
</td>
<td class="nump">75,000,000<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommonStockSharesIssued', window );">Common stock, issued shares</a></td>
<td class="nump">31,375,528<span></span>
</td>
<td class="nump">29,193,718<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommonStockSharesOutstanding', window );">Common stock, outstanding shares</a></td>
<td class="nump">31,319,751<span></span>
</td>
<td class="nump">29,163,673<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TreasuryStockShares', window );">Treasury stock, shares</a></td>
<td class="nump">55,777<span></span>
</td>
<td class="nump">30,045<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockParOrStatedValuePerShare">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Face amount or stated value per share of common stock.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockParOrStatedValuePerShare</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockSharesAuthorized">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The maximum number of common shares permitted to be issued by an entity's charter and bylaws.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockSharesAuthorized</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockSharesIssued">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Total number of common shares of an entity that have been sold or granted to shareholders (includes common shares that were issued, repurchased and remain in the treasury). These shares represent capital invested by the firm's shareholders and owners, and may be all or only a portion of the number of shares authorized. Shares issued include shares outstanding and shares held in the treasury.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockSharesIssued</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockSharesOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of shares of common stock outstanding. Common stock represent the ownership interest in a corporation.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=84159872&amp;loc=d3e21463-112644<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockSharesOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PreferredStockParOrStatedValuePerShare">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Face amount or stated value per share of preferred stock nonredeemable or redeemable solely at the option of the issuer.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PreferredStockParOrStatedValuePerShare</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PreferredStockSharesAuthorized">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The maximum number of nonredeemable preferred shares (or preferred stock redeemable solely at the option of the issuer) permitted to be issued by an entity's charter and bylaws.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PreferredStockSharesAuthorized</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PreferredStockSharesIssued">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Total number of nonredeemable preferred shares (or preferred stock redeemable solely at the option of the issuer) issued to shareholders (includes related preferred shares that were issued, repurchased, and remain in the treasury). May be all or portion of the number of preferred shares authorized. Excludes preferred shares that are classified as debt.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PreferredStockSharesIssued</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PreferredStockSharesOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Aggregate share number for all nonredeemable preferred stock (or preferred stock redeemable solely at the option of the issuer) held by stockholders. Does not include preferred shares that have been repurchased.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PreferredStockSharesOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockholdersEquityNumberOfSharesParValueAndOtherDisclosuresAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockholdersEquityNumberOfSharesParValueAndOtherDisclosuresAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TreasuryStockShares">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of common and preferred shares that were previously issued and that were repurchased by the issuing entity and held in treasury on the financial statement date. This stock has no voting rights and receives no dividends.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.29,30)<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 30<br> -Section 45<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6405813&amp;loc=d3e23239-112655<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TreasuryStockShares</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>16
<FILENAME>R4.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.8.0.1</span><table class="report" border="0" cellspacing="2" id="idp6761470640">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Condensed Consolidated Statements of Operations - USD ($)<br></strong></div></th>
<th class="th" colspan="2">3 Months Ended</th>
<th class="th" colspan="2">9 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Sep. 30, 2017</div></th>
<th class="th"><div>Sep. 30, 2016</div></th>
<th class="th"><div>Sep. 30, 2017</div></th>
<th class="th"><div>Sep. 30, 2016</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeStatementAbstract', window );"><strong>Income Statement [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueFromGrants', window );">Grant revenue</a></td>
<td class="nump">$ 5,379,000<span></span>
</td>
<td class="nump">$ 14,457,000<span></span>
</td>
<td class="nump">$ 18,279,000<span></span>
</td>
<td class="nump">$ 20,057,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LicensesRevenue', window );">Licensing and collaboration revenue</a></td>
<td class="nump">103,000<span></span>
</td>
<td class="nump">888,000<span></span>
</td>
<td class="nump">334,000<span></span>
</td>
<td class="nump">3,008,000<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SalesRevenueNet', window );">Total operating revenues</a></td>
<td class="nump">5,482,000<span></span>
</td>
<td class="nump">15,345,000<span></span>
</td>
<td class="nump">18,613,000<span></span>
</td>
<td class="nump">23,065,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingExpensesAbstract', window );"><strong>Operating expenses:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ResearchAndDevelopmentExpense', window );">Research and development</a></td>
<td class="nump">18,480,000<span></span>
</td>
<td class="nump">24,463,000<span></span>
</td>
<td class="nump">52,405,000<span></span>
</td>
<td class="nump">73,810,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_GeneralAndAdministrativeExpense', window );">General and administrative</a></td>
<td class="nump">7,907,000<span></span>
</td>
<td class="nump">7,749,000<span></span>
</td>
<td class="nump">25,038,000<span></span>
</td>
<td class="nump">26,043,000<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingExpenses', window );">Total operating expenses</a></td>
<td class="nump">26,387,000<span></span>
</td>
<td class="nump">32,212,000<span></span>
</td>
<td class="nump">77,443,000<span></span>
</td>
<td class="nump">99,853,000<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingIncomeLoss', window );">Loss from operations</a></td>
<td class="num">(20,905,000)<span></span>
</td>
<td class="num">(16,867,000)<span></span>
</td>
<td class="num">(58,830,000)<span></span>
</td>
<td class="num">(76,788,000)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NonoperatingIncomeExpenseAbstract', window );"><strong>Other income and expense:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherNonoperatingIncomeExpense', window );">Miscellaneous income (expense)</a></td>
<td class="nump">12,000<span></span>
</td>
<td class="num">(44,000)<span></span>
</td>
<td class="num">(101,000)<span></span>
</td>
<td class="num">(44,000)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InvestmentIncomeInterest', window );">Interest income</a></td>
<td class="nump">151,000<span></span>
</td>
<td class="nump">68,000<span></span>
</td>
<td class="nump">353,000<span></span>
</td>
<td class="nump">180,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InterestExpense', window );">Interest expense</a></td>
<td class="num">(3,000)<span></span>
</td>
<td class="num">(5,000)<span></span>
</td>
<td class="num">(116,000)<span></span>
</td>
<td class="num">(18,000)<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NonoperatingIncomeExpense', window );">Other income, net</a></td>
<td class="nump">160,000<span></span>
</td>
<td class="nump">19,000<span></span>
</td>
<td class="nump">136,000<span></span>
</td>
<td class="nump">118,000<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest', window );">Net loss before taxes</a></td>
<td class="num">(20,745,000)<span></span>
</td>
<td class="num">(16,848,000)<span></span>
</td>
<td class="num">(58,694,000)<span></span>
</td>
<td class="num">(76,670,000)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeTaxExpenseBenefit', window );">Income tax benefit</a></td>
<td class="nump">119,000<span></span>
</td>
<td class="nump">1,308,000<span></span>
</td>
<td class="nump">429,000<span></span>
</td>
<td class="nump">5,021,000<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Net loss</a></td>
<td class="num">$ (20,626,000)<span></span>
</td>
<td class="num">$ (15,540,000)<span></span>
</td>
<td class="num">$ (58,265,000)<span></span>
</td>
<td class="num">$ (71,649,000)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EarningsPerShareBasicAndDiluted', window );">Basic and diluted loss per share (in dollars per share)</a></td>
<td class="num">$ (0.69)<span></span>
</td>
<td class="num">$ (0.54)<span></span>
</td>
<td class="num">$ (1.98)<span></span>
</td>
<td class="num">$ (2.48)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_WeightedAverageNumberOfShareOutstandingBasicAndDiluted', window );">Basic and diluted average shares outstanding (in shares)</a></td>
<td class="nump">29,939,823<span></span>
</td>
<td class="nump">28,983,561<span></span>
</td>
<td class="nump">29,462,226<span></span>
</td>
<td class="nump">28,911,042<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerShareBasicAndDiluted">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The amount of net income or loss for the period per each share in instances when basic and diluted earnings per share are the same amount and reported as a single line item on the face of the financial statements.  Basic earnings per share is the amount of net income or loss for the period per each share of common stock or unit outstanding during the reporting period.  Diluted earnings per share includes the amount of net income or loss for the period available to each share of common stock or common unit outstanding during the reporting period and to each share or unit that would have been outstanding assuming the issuance of common shares or units for all dilutive potential common shares or units outstanding during the reporting period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerShareBasicAndDiluted</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_GeneralAndAdministrativeExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The aggregate total of expenses of managing and administering the affairs of an entity, including affiliates of the reporting entity, which are not directly or indirectly associated with the manufacture, sale or creation of a product or product line.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 225<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03.4)<br> -URI http://asc.fasb.org/extlink&amp;oid=63488584&amp;loc=d3e20235-122688<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_GeneralAndAdministrativeExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of income (loss) from continuing operations, including income (loss) from equity method investments, before deduction of income tax expense (benefit), and income (loss) attributable to noncontrolling interest.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 940<br> -SubTopic 20<br> -Section 25<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=68072869&amp;loc=d3e41242-110953<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 225<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(10))<br> -URI http://asc.fasb.org/extlink&amp;oid=63488584&amp;loc=d3e20235-122688<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 225<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(15))<br> -URI http://asc.fasb.org/extlink&amp;oid=6879574&amp;loc=d3e536633-122882<br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 225<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(8))<br> -URI http://asc.fasb.org/extlink&amp;oid=6879464&amp;loc=d3e573970-122913<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeStatementAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeStatementAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxExpenseBenefit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of current income tax expense (benefit) and deferred income tax expense (benefit) pertaining to continuing operations.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 9<br> -Subparagraph (a),(b)<br> -URI http://asc.fasb.org/extlink&amp;oid=84230637&amp;loc=d3e32639-109319<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08.(h))<br> -URI http://asc.fasb.org/extlink&amp;oid=26873400&amp;loc=d3e23780-122690<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxExpenseBenefit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InterestExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of the cost of borrowed funds accounted for as interest expense.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 835<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6450988&amp;loc=d3e26243-108391<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 835<br> -SubTopic 30<br> -Section 45<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=64930785&amp;loc=d3e28555-108399<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 225<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04.9)<br> -URI http://asc.fasb.org/extlink&amp;oid=6879574&amp;loc=d3e536633-122882<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InterestExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InvestmentIncomeInterest">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount before accretion (amortization) of purchase discount (premium) of interest income on nonoperating securities.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 225<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03.7(b))<br> -URI http://asc.fasb.org/extlink&amp;oid=63488584&amp;loc=d3e20235-122688<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InvestmentIncomeInterest</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LicensesRevenue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Revenue earned during the period relating to consideration received from another party for the right to use, but not own, certain of the entity's intangible assets. Licensing arrangements include, but are not limited to, rights to use a patent, copyright, technology, manufacturing process, software or trademark. Licensing fees are generally, but not always, fixed as to amount and not dependent upon the revenue generated by the licensing party. An entity may receive licensing fees for licenses that also generate royalty payments to the entity.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 225<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03.1(e))<br> -URI http://asc.fasb.org/extlink&amp;oid=63488584&amp;loc=d3e20235-122688<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LicensesRevenue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetIncomeLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The portion of profit or loss for the period, net of income taxes, which is attributable to the parent.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -URI http://asc.fasb.org/extlink&amp;oid=98514028&amp;loc=d3e3602-108585<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6371337&amp;loc=d3e3550-109257<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 225<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(22))<br> -URI http://asc.fasb.org/extlink&amp;oid=6879574&amp;loc=d3e536633-122882<br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 225<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(18))<br> -URI http://asc.fasb.org/extlink&amp;oid=6879464&amp;loc=d3e573970-122913<br><br>Reference 5: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 225<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(20))<br> -URI http://asc.fasb.org/extlink&amp;oid=63488584&amp;loc=d3e20235-122688<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetIncomeLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NonoperatingIncomeExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The aggregate amount of income or expense from ancillary business-related activities (that is to say, excluding major activities considered part of the normal operations of the business).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 225<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03.7)<br> -URI http://asc.fasb.org/extlink&amp;oid=63488584&amp;loc=d3e20235-122688<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NonoperatingIncomeExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NonoperatingIncomeExpenseAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NonoperatingIncomeExpenseAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingExpenses">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Generally recurring costs associated with normal operations except for the portion of these expenses which can be clearly related to production and included in cost of sales or services. Includes selling, general and administrative expense.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingExpenses</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingExpensesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingExpensesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingIncomeLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The net result for the period of deducting operating expenses from operating revenues.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingIncomeLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherNonoperatingIncomeExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of income (expense) related to nonoperating activities, classified as other.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 225<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03.9)<br> -URI http://asc.fasb.org/extlink&amp;oid=63488584&amp;loc=d3e20235-122688<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherNonoperatingIncomeExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ResearchAndDevelopmentExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The aggregate costs incurred (1) in a planned search or critical investigation aimed at discovery of new knowledge with the hope that such knowledge will be useful in developing a new product or service, a new process or technique, or in bringing about a significant improvement to an existing product or process; or (2) to translate research findings or other knowledge into a plan or design for a new product or process or for a significant improvement to an existing product or process whether intended for sale or the entity's use, during the reporting period charged to research and development projects, including the costs of developing computer software up to the point in time of achieving technological feasibility, and costs allocated in accounting for a business combination to in-process projects deemed to have no alternative future use.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 730<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6420194&amp;loc=d3e21568-108373<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 985<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6501960&amp;loc=d3e128462-111756<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ResearchAndDevelopmentExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RevenueFromGrants">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Revenue earned during the period from non-repayable sum of money awarded to an entity to carry out a specific purpose as provided in grant agreements.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 225<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03.1(e))<br> -URI http://asc.fasb.org/extlink&amp;oid=63488584&amp;loc=d3e20235-122688<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RevenueFromGrants</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SalesRevenueNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Total revenue from sale of goods and services rendered during the reporting period, in the normal course of business, reduced by sales returns and allowances, and sales discounts.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 225<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03.1)<br> -URI http://asc.fasb.org/extlink&amp;oid=63488584&amp;loc=d3e20235-122688<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SalesRevenueNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_WeightedAverageNumberOfShareOutstandingBasicAndDiluted">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Average number of shares or units issued and outstanding that are used in calculating basic and diluted earnings per share (EPS).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_WeightedAverageNumberOfShareOutstandingBasicAndDiluted</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>17
<FILENAME>R5.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.8.0.1</span><table class="report" border="0" cellspacing="2" id="idp6763840832">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Condensed Consolidated Statement of Stockholders' Equity - 9 months ended Sep. 30, 2017 - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th"><div>Total</div></th>
<th class="th"><div>Common Stock</div></th>
<th class="th"><div>Additional Paid-in Capital</div></th>
<th class="th"><div>Treasury Stock</div></th>
<th class="th"><div>Accumulated Deficit</div></th>
</tr>
<tr class="rc">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Balance at beginning of period at Dec. 31, 2016</a></td>
<td class="nump">$ 129,466<span></span>
</td>
<td class="nump">$ 292<span></span>
</td>
<td class="nump">$ 295,535<span></span>
</td>
<td class="num">$ (853)<span></span>
</td>
<td class="num">$ (165,508)<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommonStockSharesOutstanding', window );">Balance at beginning of period (shares) at Dec. 31, 2016</a></td>
<td class="nump">29,163,673<span></span>
</td>
<td class="nump">29,163,673<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward', window );"><strong>Increase (Decrease) in Stockholders' Equity [Roll Forward]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue', window );">Share-based compensation</a></td>
<td class="nump">$ 14,938<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">14,938<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised', window );">Exercise of stock options and restricted stock vested</a></td>
<td class="nump">925<span></span>
</td>
<td class="nump">$ 2<span></span>
</td>
<td class="nump">923<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised', window );">Exercise of stock options and restricted stock vested (shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">189,155<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueEmployeeStockPurchasePlan', window );">Sales of shares under stock purchase plan</a></td>
<td class="nump">326<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">325<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans', window );">Sales of shares under stock purchase plan (shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">51,999<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockRepurchasedDuringPeriodValue', window );">Repurchase of common stock</a></td>
<td class="num">(260)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(260)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueNewIssues', window );">Issuance of common stock under the ATM Offering (net of offering costs of $561)</a></td>
<td class="nump">19,334<span></span>
</td>
<td class="nump">$ 19<span></span>
</td>
<td class="nump">19,315<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesNewIssues', window );">Issuance of common stock under the ATM Offering (net of offering costs of $561) (shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,940,656<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockRepurchasedDuringPeriodShares', window );">Repurchase of common stock (shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(25,732)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Net loss</a></td>
<td class="num">(58,265)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(58,265)<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Balance at end of period at Sep. 30, 2017</a></td>
<td class="nump">$ 106,464<span></span>
</td>
<td class="nump">$ 314<span></span>
</td>
<td class="nump">$ 331,036<span></span>
</td>
<td class="num">$ (1,113)<span></span>
</td>
<td class="num">$ (223,773)<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommonStockSharesOutstanding', window );">Balance at end of period (shares) at Sep. 30, 2017</a></td>
<td class="nump">31,319,751<span></span>
</td>
<td class="nump">31,319,751<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of increase to additional paid-in capital (APIC) from recognition of equity-based compensation.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 35<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=79507207&amp;loc=d3e4534-113899<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=96867065&amp;loc=d3e5047-113901<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 20<br> -Section 55<br> -Paragraph 12<br> -URI http://asc.fasb.org/extlink&amp;oid=96864182&amp;loc=d3e11149-113907<br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 20<br> -Section 55<br> -Paragraph 13<br> -URI http://asc.fasb.org/extlink&amp;oid=96864182&amp;loc=d3e11178-113907<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockSharesOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of shares of common stock outstanding. Common stock represent the ownership interest in a corporation.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=84159872&amp;loc=d3e21463-112644<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockSharesOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>A roll forward is a reconciliation of a concept from the beginning of a period to the end of a period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInStockholdersEquityRollForward</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetIncomeLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The portion of profit or loss for the period, net of income taxes, which is attributable to the parent.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -URI http://asc.fasb.org/extlink&amp;oid=98514028&amp;loc=d3e3602-108585<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6371337&amp;loc=d3e3550-109257<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 225<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(22))<br> -URI http://asc.fasb.org/extlink&amp;oid=6879574&amp;loc=d3e536633-122882<br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 225<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(18))<br> -URI http://asc.fasb.org/extlink&amp;oid=6879464&amp;loc=d3e573970-122913<br><br>Reference 5: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 225<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(20))<br> -URI http://asc.fasb.org/extlink&amp;oid=63488584&amp;loc=d3e20235-122688<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetIncomeLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of shares issued during the period as a result of an employee stock purchase plan.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=84159872&amp;loc=d3e21463-112644<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI http://asc.fasb.org/extlink&amp;oid=27012166&amp;loc=d3e187085-122770<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodSharesNewIssues">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of new stock issued during the period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=84159872&amp;loc=d3e21463-112644<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI http://asc.fasb.org/extlink&amp;oid=27012166&amp;loc=d3e187085-122770<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodSharesNewIssues</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of share options (or share units) exercised during the current period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=84159872&amp;loc=d3e21463-112644<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI http://asc.fasb.org/extlink&amp;oid=27012166&amp;loc=d3e187085-122770<br><br>Reference 5: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=96867065&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodValueEmployeeStockPurchasePlan">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Aggregate change in value for stock issued during the period as a result of employee stock purchase plan.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=84159872&amp;loc=d3e21463-112644<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI http://asc.fasb.org/extlink&amp;oid=27012166&amp;loc=d3e187085-122770<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodValueEmployeeStockPurchasePlan</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodValueNewIssues">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Equity impact of the value of new stock issued during the period. Includes shares issued in an initial public offering or a secondary public offering.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=84159872&amp;loc=d3e21463-112644<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI http://asc.fasb.org/extlink&amp;oid=27012166&amp;loc=d3e187085-122770<br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodValueNewIssues</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Value of stock issued as a result of the exercise of stock options.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=84159872&amp;loc=d3e21463-112644<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.29-31)<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI http://asc.fasb.org/extlink&amp;oid=27012166&amp;loc=d3e187085-122770<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockRepurchasedDuringPeriodShares">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of shares that have been repurchased during the period and have not been retired and are not held in treasury. Some state laws may govern the circumstances under which an entity may acquire its own stock and prescribe the accounting treatment therefore. This element is used when state law does not recognize treasury stock.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI http://asc.fasb.org/extlink&amp;oid=27012166&amp;loc=d3e187085-122770<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=84159872&amp;loc=d3e21463-112644<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockRepurchasedDuringPeriodShares</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockRepurchasedDuringPeriodValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Equity impact of the value of stock that has been repurchased during the period and has not been retired and is not held in treasury. Some state laws may mandate the circumstances under which an entity may acquire its own stock and prescribe the accounting treatment therefore. This element is used when state law does not recognize treasury stock.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI http://asc.fasb.org/extlink&amp;oid=27012166&amp;loc=d3e187085-122770<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=84159872&amp;loc=d3e21463-112644<br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockRepurchasedDuringPeriodValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockholdersEquity">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Total of all stockholders' equity (deficit) items, net of receivables from officers, directors, owners, and affiliates of the entity which are attributable to the parent. The amount of the economic entity's stockholders' equity attributable to the parent excludes the amount of stockholders' equity which is allocable to that ownership interest in subsidiary equity which is not attributable to the parent (noncontrolling interest, minority interest). This excludes temporary equity and is sometimes called permanent equity.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(30))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 310<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SAB Topic 4.E)<br> -URI http://asc.fasb.org/extlink&amp;oid=27010918&amp;loc=d3e74512-122707<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(31))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockholdersEquity</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementEquityComponentsAxis=us-gaap_CommonStockMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementEquityComponentsAxis=us-gaap_CommonStockMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementEquityComponentsAxis=us-gaap_AdditionalPaidInCapitalMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementEquityComponentsAxis=us-gaap_AdditionalPaidInCapitalMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementEquityComponentsAxis=us-gaap_TreasuryStockMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementEquityComponentsAxis=us-gaap_TreasuryStockMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementEquityComponentsAxis=us-gaap_RetainedEarningsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementEquityComponentsAxis=us-gaap_RetainedEarningsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>18
<FILENAME>R6.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.8.0.1</span><table class="report" border="0" cellspacing="2" id="idp6754368096">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Condensed Consolidated Statement of Stockholders' Equity (Parentheticals)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="1">9 Months Ended</th>
</tr>
<tr><th class="th">
<div>Sep. 30, 2017 </div>
<div>USD ($)</div>
</th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StatementOfStockholdersEquityAbstract', window );"><strong>Statement of Stockholders' Equity [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AdjustmentsToAdditionalPaidInCapitalStockIssuedIssuanceCosts', window );">Stock issuance costs</a></td>
<td class="nump">$ 561<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AdjustmentsToAdditionalPaidInCapitalStockIssuedIssuanceCosts">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of decrease in additional paid in capital (APIC) resulting from direct costs associated with issuing stock. Includes, but is not limited to, legal and accounting fees and direct costs associated with stock issues under a shelf registration.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=84159872&amp;loc=d3e21463-112644<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI http://asc.fasb.org/extlink&amp;oid=27012166&amp;loc=d3e187085-122770<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AdjustmentsToAdditionalPaidInCapitalStockIssuedIssuanceCosts</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementOfStockholdersEquityAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementOfStockholdersEquityAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>19
<FILENAME>R7.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.8.0.1</span><table class="report" border="0" cellspacing="2" id="idp6761320704">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Condensed Consolidated Statements of Cash Flows - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="2">9 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Sep. 30, 2017</div></th>
<th class="th"><div>Sep. 30, 2016</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract', window );"><strong>Cash Flows From Operating Activities</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Net loss</a></td>
<td class="num">$ (58,265)<span></span>
</td>
<td class="num">$ (71,649)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract', window );"><strong>Adjustments to reconcile net loss to net cash used in operating activities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensation', window );">Share-based compensation</a></td>
<td class="nump">14,938<span></span>
</td>
<td class="nump">13,119<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DepreciationDepletionAndAmortization', window );">Depreciation and amortization</a></td>
<td class="nump">1,064<span></span>
</td>
<td class="nump">1,536<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_GainsLossesOnExtinguishmentOfDebt', window );">Forgiveness of debt</a></td>
<td class="nump">0<span></span>
</td>
<td class="num">(397)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ExcessTaxBenefitFromShareBasedCompensationOperatingActivities', window );">Tax shortfall associated with employee stock plans</a></td>
<td class="nump">0<span></span>
</td>
<td class="num">(640)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AssetImpairmentCharges', window );">Impairment of fixed assets</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">3,976<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_GainLossOnSaleOfPropertyPlantEquipment', window );">Loss on sale of fixed assets</a></td>
<td class="nump">102<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract', window );"><strong>Changes in operating assets and liabilities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets', window );">Prepaid expenses and other current assets</a></td>
<td class="nump">3,220<span></span>
</td>
<td class="num">(5,734)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInOtherReceivables', window );">Other receivables</a></td>
<td class="nump">13,856<span></span>
</td>
<td class="num">(9,607)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities', window );">Accounts payable and accrued expenses</a></td>
<td class="num">(11,500)<span></span>
</td>
<td class="nump">27,204<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInAccruedIncomeTaxesPayable', window );">Income taxes receivable</a></td>
<td class="nump">5,861<span></span>
</td>
<td class="num">(6,056)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInDeferredRevenue', window );">Unearned revenue</a></td>
<td class="num">(279)<span></span>
</td>
<td class="num">(606)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInDeferredCharges', window );">Deferred rent</a></td>
<td class="num">(67)<span></span>
</td>
<td class="num">(79)<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInOperatingActivities', window );">Net cash used in operating activities</a></td>
<td class="num">(31,070)<span></span>
</td>
<td class="num">(48,933)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract', window );"><strong>Cash Flows From Investing Activities</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ProceedsFromSaleAndMaturityOfHeldToMaturitySecurities', window );">Maturity of certificates of deposit</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">2,180<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment', window );">Purchase of equipment</a></td>
<td class="num">(43)<span></span>
</td>
<td class="num">(2,069)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ProceedsFromSaleOfPropertyPlantAndEquipment', window );">Proceeds on sale of equipment</a></td>
<td class="nump">185<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInInvestingActivities', window );">Net cash provided by investing activities</a></td>
<td class="nump">142<span></span>
</td>
<td class="nump">111<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract', window );"><strong>Cash Flows From Financing Activities</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ProceedsFromIssuanceOfCommonStock', window );">Issuance of common stock, net of offering costs</a></td>
<td class="nump">20,585<span></span>
</td>
<td class="nump">1,686<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PaymentsForRepurchaseOfCommonStock', window );">Repurchase of common stock</a></td>
<td class="num">(260)<span></span>
</td>
<td class="num">(13)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RepaymentsOfDebtAndCapitalLeaseObligations', window );">Payments under capital lease obligations and principal payments on notes payable</a></td>
<td class="num">(185)<span></span>
</td>
<td class="num">(195)<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInFinancingActivities', window );">Net cash provided by financing activities</a></td>
<td class="nump">20,140<span></span>
</td>
<td class="nump">1,478<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsPeriodIncreaseDecrease', window );">Net decrease in cash and cash equivalents</a></td>
<td class="num">(10,788)<span></span>
</td>
<td class="num">(47,344)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsAtCarryingValue', window );">Cash and cash equivalents at beginning of period</a></td>
<td class="nump">131,490<span></span>
</td>
<td class="nump">195,620<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsAtCarryingValue', window );">Cash and cash equivalents at end of period</a></td>
<td class="nump">120,702<span></span>
</td>
<td class="nump">148,276<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SupplementalCashFlowInformationAbstract', window );"><strong>Supplemental disclosure of cash flows information:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InterestPaid', window );">Cash paid for interest</a></td>
<td class="nump">11<span></span>
</td>
<td class="nump">18<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeTaxesPaidNet', window );">Cash (refunds received) paid for taxes, net</a></td>
<td class="num">(6,261)<span></span>
</td>
<td class="nump">1,022<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract', window );"><strong>Noncash financing and investing activities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CapitalLeaseObligationsIncurred', window );">Equipment acquired by capital lease</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">231<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NotesReduction', window );">Forgiveness of debt</a></td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">$ 397<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AssetImpairmentCharges">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of write-down of assets recognized in the income statement. Includes, but is not limited to, losses from tangible assets, intangible assets and goodwill.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section 45<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=68055307&amp;loc=d3e2420-110228<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=98514028&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AssetImpairmentCharges</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CapitalLeaseObligationsIncurred">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The increase during the period in capital lease obligations due to entering into new capital leases.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=98513485&amp;loc=d3e4313-108586<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=98513485&amp;loc=d3e4304-108586<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CapitalLeaseObligationsIncurred</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashAndCashEquivalentsAtCarryingValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of currency on hand as well as demand deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits. Also includes short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates. Excludes cash and cash equivalents within disposal group and discontinued operation.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=82887183&amp;loc=d3e6676-107765<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=98514028&amp;loc=d3e3044-108585<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.1)<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashAndCashEquivalentsAtCarryingValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashAndCashEquivalentsPeriodIncreaseDecrease">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of increase (decrease) in cash and cash equivalents. Cash and cash equivalents are the amount of currency on hand as well as demand deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits. Also includes short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates. Includes effect from exchange rate changes.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 24<br> -URI http://asc.fasb.org/extlink&amp;oid=98514028&amp;loc=d3e3521-108585<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 830<br> -SubTopic 230<br> -Section 45<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=98513438&amp;loc=d3e33268-110906<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashAndCashEquivalentsPeriodIncreaseDecrease</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DepreciationDepletionAndAmortization">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The aggregate expense recognized in the current period that allocates the cost of tangible assets, intangible assets, or depleting assets to periods that benefit from use of the assets.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=98514028&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DepreciationDepletionAndAmortization</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ExcessTaxBenefitFromShareBasedCompensationOperatingActivities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of cash outflow for realized tax benefit related to deductible compensation cost reported on the entity's tax return for equity instruments in excess of the compensation cost for those instruments recognized for financial reporting purposes.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 20<br> -Section 55<br> -Paragraph 24<br> -URI http://asc.fasb.org/extlink&amp;oid=96864182&amp;loc=d3e11374-113907<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ExcessTaxBenefitFromShareBasedCompensationOperatingActivities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_GainLossOnSaleOfPropertyPlantEquipment">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of gain (loss) on sale or disposal of property, plant and equipment assets, including oil and gas property and timber property.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=98514028&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_GainLossOnSaleOfPropertyPlantEquipment</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_GainsLossesOnExtinguishmentOfDebt">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Difference between the fair value of payments made and the carrying amount of debt which is extinguished prior to maturity.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 50<br> -Section 40<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=49170532&amp;loc=d3e12317-112629<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=98514028&amp;loc=d3e3602-108585<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 50<br> -Section 40<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=49170532&amp;loc=d3e12355-112629<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_GainsLossesOnExtinguishmentOfDebt</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxesPaidNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The amount of cash paid during the current period to foreign, federal, state, and local authorities as taxes on income, net of any cash received during the current period as refunds for the overpayment of taxes.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=98513485&amp;loc=d3e4297-108586<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxesPaidNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The increase (decrease) during the reporting period in the amounts payable to vendors for goods and services received and the amount of obligations and expenses incurred but not paid.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=98514028&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInAccruedIncomeTaxesPayable">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The increase (decrease) during the period in the amount due for taxes based on the reporting entity's earnings or attributable to the entity's income earning process (business presence) within a given jurisdiction.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=98514028&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInAccruedIncomeTaxesPayable</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInDeferredCharges">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The increase (decrease) during the reporting period in the value of expenditures made during the current reporting period for benefits that will be received over a period of years. Deferred charges differ from prepaid expenses in that they usually extend over a long period of time and may or may not be regularly recurring costs of operation.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=98514028&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInDeferredCharges</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInDeferredRevenue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The increase (decrease) during the reporting period, excluding the portion taken into income, in the liability reflecting revenue yet to be earned for which cash or other forms of consideration was received or recorded as a receivable.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=98514028&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInDeferredRevenue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInOperatingCapitalAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInOtherReceivables">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of increase (decrease) in receivables classified as other.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=98514028&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInOtherReceivables</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of increase (decrease) in prepaid expenses, and assets classified as other.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=98514028&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InterestPaid">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of cash paid for interest. Includes, but is not limited to, payment to settle zero-coupon bond attributable to accreted interest of debt discount and debt instrument with insignificant coupon interest rate in relation to effective interest rate of borrowing attributable to accreted interest of debt discount.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=98513485&amp;loc=d3e4297-108586<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 25<br> -Subparagraph (e)<br> -URI http://asc.fasb.org/extlink&amp;oid=98514028&amp;loc=d3e3536-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InterestPaid</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInFinancingActivities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of cash inflow (outflow) from financing activities, including discontinued operations. Financing activity cash flows include obtaining resources from owners and providing them with a return on, and a return of, their investment; borrowing money and repaying amounts borrowed, or settling the obligation; and obtaining and paying for other resources obtained from creditors on long-term credit.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 24<br> -URI http://asc.fasb.org/extlink&amp;oid=98514028&amp;loc=d3e3521-108585<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 26<br> -URI http://asc.fasb.org/extlink&amp;oid=98514028&amp;loc=d3e3574-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInFinancingActivities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInInvestingActivities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of cash inflow (outflow) from investing activities, including discontinued operations. Investing activity cash flows include making and collecting loans and acquiring and disposing of debt or equity instruments and property, plant, and equipment and other productive assets.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 24<br> -URI http://asc.fasb.org/extlink&amp;oid=98514028&amp;loc=d3e3521-108585<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 26<br> -URI http://asc.fasb.org/extlink&amp;oid=98514028&amp;loc=d3e3574-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInInvestingActivities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInOperatingActivities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of cash inflow (outflow) from operating activities, including discontinued operations. Operating activity cash flows include transactions, adjustments, and changes in value not defined as investing or financing activities.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 24<br> -URI http://asc.fasb.org/extlink&amp;oid=98514028&amp;loc=d3e3521-108585<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -URI http://asc.fasb.org/extlink&amp;oid=98514028&amp;loc=d3e3602-108585<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 25<br> -URI http://asc.fasb.org/extlink&amp;oid=98514028&amp;loc=d3e3536-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInOperatingActivities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetIncomeLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The portion of profit or loss for the period, net of income taxes, which is attributable to the parent.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -URI http://asc.fasb.org/extlink&amp;oid=98514028&amp;loc=d3e3602-108585<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6371337&amp;loc=d3e3550-109257<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 225<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(22))<br> -URI http://asc.fasb.org/extlink&amp;oid=6879574&amp;loc=d3e536633-122882<br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 225<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(18))<br> -URI http://asc.fasb.org/extlink&amp;oid=6879464&amp;loc=d3e573970-122913<br><br>Reference 5: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 225<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(20))<br> -URI http://asc.fasb.org/extlink&amp;oid=63488584&amp;loc=d3e20235-122688<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetIncomeLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NotesReduction">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The value of notes retired (or transferred to another entity) in noncash investing or financing transactions.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=98513485&amp;loc=d3e4304-108586<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=98513485&amp;loc=d3e4313-108586<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 5<br> -URI http://asc.fasb.org/extlink&amp;oid=98513485&amp;loc=d3e4332-108586<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NotesReduction</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PaymentsForRepurchaseOfCommonStock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The cash outflow to reacquire common stock during the period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 15<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=98514028&amp;loc=d3e3291-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PaymentsForRepurchaseOfCommonStock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The cash outflow associated with the acquisition of long-lived, physical assets that are used in the normal conduct of business to produce goods and services and not intended for resale; includes cash outflows to pay for construction of self-constructed assets.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 13<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=98514028&amp;loc=d3e3213-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PaymentsToAcquirePropertyPlantAndEquipment</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromIssuanceOfCommonStock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The cash inflow from the additional capital contribution to the entity.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 14<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=98514028&amp;loc=d3e3255-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProceedsFromIssuanceOfCommonStock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromSaleAndMaturityOfHeldToMaturitySecurities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of cash inflow from the sale or maturity of long-term held-to-maturity securities.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 320<br> -SubTopic 10<br> -Section 45<br> -Paragraph 11<br> -URI http://asc.fasb.org/extlink&amp;oid=82896770&amp;loc=d3e26853-111562<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 12<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=98514028&amp;loc=d3e3179-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProceedsFromSaleAndMaturityOfHeldToMaturitySecurities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromSaleOfPropertyPlantAndEquipment">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The cash inflow from the sale of long-lived, physical assets that are used in the normal conduct of business to produce goods and services and not intended for resale.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 12<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=98514028&amp;loc=d3e3179-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProceedsFromSaleOfPropertyPlantAndEquipment</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RepaymentsOfDebtAndCapitalLeaseObligations">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The cash outflow during the period from the repayment of aggregate short-term and long-term debt and payment of capital lease obligations.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RepaymentsOfDebtAndCapitalLeaseObligations</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensation">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The aggregate amount of noncash, equity-based employee remuneration. This may include the value of stock or unit options, amortization of restricted stock or units, and adjustment for officers' compensation. As noncash, this element is an add back when calculating net cash generated by operating activities using the indirect method.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=98514028&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensation</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SupplementalCashFlowInformationAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SupplementalCashFlowInformationAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>20
<FILENAME>R8.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.8.0.1</span><table class="report" border="0" cellspacing="2" id="idp6609578352">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Description of Business<br></strong></div></th>
<th class="th" colspan="1">9 Months Ended</th>
</tr>
<tr><th class="th"><div>Sep. 30, 2017</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract', window );"><strong>Organization, Consolidation and Presentation of Financial Statements [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NatureOfOperations', window );">Description of Business</a></td>
<td class="text"><div style="font-family:Times New Roman;font-size:10pt;"><div style="line-height:120%;padding-bottom:12px;padding-top:12px;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">D</font><font style="font-family:inherit;font-size:10pt;background-color:#ffffff;font-weight:bold;">escription of Business</font></div><div style="line-height:120%;padding-bottom:12px;padding-top:12px;text-align:justify;text-indent:32px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">On June&#160;4, 1999, NewLink Genetics Corporation (NewLink) was incorporated as a Delaware corporation. NewLink was formed for the purpose of developing treatments for patients with cancer and other diseases. NewLink initiated operations in April 2000. </font></div><div style="line-height:120%;padding-bottom:12px;padding-top:12px;text-align:justify;text-indent:32px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">NewLink and its subsidiaries (the Company) are devoting substantially all of their efforts toward research and development. The Company has never earned revenue from commercial sales of its drugs. The Company incurred a net loss of </font><font style="font-family:inherit;font-size:10pt;">$20.6 million</font><font style="font-family:inherit;font-size:10pt;"> and </font><font style="font-family:inherit;font-size:10pt;">$58.3 million</font><font style="font-family:inherit;font-size:10pt;"> for the </font><font style="font-family:inherit;font-size:10pt;">three and nine months ended</font><font style="font-family:inherit;font-size:10pt;"> </font><font style="font-family:inherit;font-size:10pt;">September&#160;30, 2017</font><font style="font-family:inherit;font-size:10pt;">. </font></div><div style="line-height:120%;padding-bottom:12px;padding-top:12px;text-align:justify;text-indent:32px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">In July 2017, the Company&#160;undertook an organizational realignment to refocus its clinical development efforts and align the Company's resources to focus on the Company's highest value opportunities. The Company's restructuring activities included a reduction of its workforce by approximately </font><font style="font-family:inherit;font-size:10pt;">50%</font><font style="font-family:inherit;font-size:10pt;">, which consisted primarily of clinical and research and development staff, as well as stopping additional research on the Zika virus. Refer to Note 9 for more information.</font></div><div style="line-height:120%;padding-bottom:12px;padding-top:12px;text-align:justify;text-indent:32px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">The accompanying condensed consolidated financial statements as of </font><font style="font-family:inherit;font-size:10pt;">September&#160;30, 2017</font><font style="font-family:inherit;font-size:10pt;"> and for the </font><font style="font-family:inherit;font-size:10pt;">three and nine months ended</font><font style="font-family:inherit;font-size:10pt;"> have been prepared assuming the Company will continue as a going concern. The Company successfully raised net proceeds of </font><font style="font-family:inherit;font-size:10pt;">$37.6 million</font><font style="font-family:inherit;font-size:10pt;"> from its IPO, completed a follow-on offering of its common stock raising net proceeds of </font><font style="font-family:inherit;font-size:10pt;">$49.0 million</font><font style="font-family:inherit;font-size:10pt;">, and raised an additional </font><font style="font-family:inherit;font-size:10pt;">$58.7 million</font><font style="font-family:inherit;font-size:10pt;"> in net proceeds from an at the market (ATM) offering completed in 2015.</font></div><div style="line-height:120%;padding-bottom:12px;padding-top:12px;text-align:justify;text-indent:32px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">On November 29, 2016, the Company entered into a Sales Agreement with Cantor Fitzgerald &amp; Co. (Cantor) under which the Company may sell up to </font><font style="font-family:inherit;font-size:10pt;">$40.0 million</font><font style="font-family:inherit;font-size:10pt;"> of its common stock in one or more placements at prevailing market prices in an ATM offering. The Company launched this ATM offering in June 2017. During the </font><font style="font-family:inherit;font-size:10pt;">three months ended</font><font style="font-family:inherit;font-size:10pt;"> </font><font style="font-family:inherit;font-size:10pt;">September&#160;30, 2017</font><font style="font-family:inherit;font-size:10pt;">, </font><font style="font-family:inherit;font-size:10pt;">1,940,656</font><font style="font-family:inherit;font-size:10pt;"> shares of the Company's common stock were sold under this ATM, with aggregate net proceeds of </font><font style="font-family:inherit;font-size:10pt;">$19.3 million</font><font style="font-family:inherit;font-size:10pt;"> after commissions of </font><font style="font-family:inherit;font-size:10pt;">$398,000</font><font style="font-family:inherit;font-size:10pt;"> paid to Cantor as the placement agent, and other costs of </font><font style="font-family:inherit;font-size:10pt;">$163,000</font><font style="font-family:inherit;font-size:10pt;"> . </font></div><div style="line-height:120%;padding-bottom:12px;padding-top:12px;text-align:justify;text-indent:32px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Subsequent to </font><font style="font-family:inherit;font-size:10pt;">September&#160;30, 2017</font><font style="font-family:inherit;font-size:10pt;">, the Company sold </font><font style="font-family:inherit;font-size:10pt;">5,750,000</font><font style="font-family:inherit;font-size:10pt;"> of its shares of common stock in a public offering for aggregate net proceeds of </font><font style="font-family:inherit;font-size:10pt;">$55.2 million</font><font style="font-family:inherit;font-size:10pt;"> after underwriters' discounts, commissions and other expenses of </font><font style="font-family:inherit;font-size:10pt;">$3.7 million</font><font style="font-family:inherit;font-size:10pt;">.</font></div><div style="line-height:120%;padding-bottom:12px;padding-top:12px;text-align:justify;text-indent:32px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">In connection with </font><font style="font-family:inherit;font-size:10pt;">two</font><font style="font-family:inherit;font-size:10pt;"> license and collaboration agreements the Company entered into during 2014, the Company received a nonrefundable upfront cash payment of </font><font style="font-family:inherit;font-size:10pt;">$150.0 million</font><font style="font-family:inherit;font-size:10pt;"> from Genentech Inc., a member of the Roche Group, or Genentech, in 2014, and a nonrefundable upfront cash payment of </font><font style="font-family:inherit;font-size:10pt;">$30.0 million</font><font style="font-family:inherit;font-size:10pt;"> from Merck, Sharpe and Dohme Corp., or Merck, in 2014, as well as a milestone payment of </font><font style="font-family:inherit;font-size:10pt;">$20.0 million</font><font style="font-family:inherit;font-size:10pt;"> from Merck in February 2015. </font></div><div style="line-height:120%;padding-bottom:12px;padding-top:12px;text-align:justify;text-indent:32px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">The Company's cash and cash equivalents after these agreements and the offerings are expected to be adequate to satisfy the Company's liquidity requirements into the second quarter of 2020. If available liquidity becomes insufficient to meet the Company&#8217;s operating obligations as they come due, the Company's plans include pursuing alternative funding arrangements and/or reducing expenditures as necessary to meet the Company&#8217;s cash requirements. However, there is no assurance that, if required, the Company will be able to raise additional capital or reduce discretionary spending to provide the required liquidity. Failure by the Company to successfully execute its plans or otherwise address its liquidity needs may have a material adverse effect on its business and financial position, and may materially affect the Company&#8217;s ability to continue as a going concern.</font></div></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NatureOfOperations">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for the nature of an entity's business, major products or services, principal markets including location, and the relative importance of its operations in each business and the basis for the determination, including but not limited to, assets, revenues, or earnings. For an entity that has not commenced principal operations, disclosures about the risks and uncertainties related to the activities in which the entity is currently engaged and an understanding of what those activities are being directed toward.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 275<br> -URI http://asc.fasb.org/topic&amp;trid=2134479<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NatureOfOperations</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>21
<FILENAME>R9.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.8.0.1</span><table class="report" border="0" cellspacing="2" id="idp6754230016">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Basis of Presentation<br></strong></div></th>
<th class="th" colspan="1">9 Months Ended</th>
</tr>
<tr><th class="th"><div>Sep. 30, 2017</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract', window );"><strong>Organization, Consolidation and Presentation of Financial Statements [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BasisOfAccounting', window );">Basis of Presentation</a></td>
<td class="text"><div style="font-family:Times New Roman;font-size:10pt;"><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Basis of Presentation</font></div><div style="line-height:120%;padding-bottom:12px;padding-top:12px;text-align:justify;text-indent:29px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">The accompanying unaudited condensed consolidated financial statements have been prepared and presented by the Company in accordance with U.S. generally accepted accounting principles (U.S.&#160;GAAP) and the rules&#160;and regulations of the U.S. Securities and Exchange Commission (the SEC), and, in management&#8217;s opinion, reflect all adjustments necessary to present fairly the Company&#8217;s interim condensed financial information.</font></div><div style="line-height:120%;padding-bottom:12px;padding-top:12px;text-align:justify;text-indent:29px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Certain information and footnote disclosures normally included in the Company&#8217;s annual financial statements prepared in accordance with U.S. GAAP have been condensed or omitted. The accompanying unaudited condensed consolidated financial statements should be read in conjunction with the audited consolidated financial statements for the year ended </font><font style="font-family:inherit;font-size:10pt;">December&#160;31, 2016</font><font style="font-family:inherit;font-size:10pt;">, included in the Company&#8217;s Annual Report on Form 10-K. There were no significant changes in the Company&#8217;s accounting policies since the end of fiscal </font><font style="font-family:inherit;font-size:10pt;">2016</font><font style="font-family:inherit;font-size:10pt;">. The financial results for any interim period are not necessarily indicative of financial results for the full year.</font></div></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BasisOfAccounting">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for the basis of accounting, or basis of presentation, used to prepare the financial statements (for example, US Generally Accepted Accounting Principles, Other Comprehensive Basis of Accounting, IFRS).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -URI http://asc.fasb.org/topic&amp;trid=2122369<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BasisOfAccounting</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>22
<FILENAME>R10.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.8.0.1</span><table class="report" border="0" cellspacing="2" id="idp6616824288">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Significant Accounting Policies<br></strong></div></th>
<th class="th" colspan="1">9 Months Ended</th>
</tr>
<tr><th class="th"><div>Sep. 30, 2017</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccountingPoliciesAbstract', window );"><strong>Accounting Policies [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SignificantAccountingPoliciesTextBlock', window );">Significant Accounting Policies</a></td>
<td class="text"><div style="font-family:Times New Roman;font-size:10pt;"><div style="line-height:120%;padding-bottom:12px;padding-top:12px;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Significant Accounting Policies</font></div><div style="line-height:120%;padding-bottom:12px;padding-top:12px;text-align:justify;text-indent:18px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;">Use of Estimates</font></div><div style="line-height:120%;padding-bottom:12px;padding-top:12px;text-align:justify;text-indent:32px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">The preparation of the condensed consolidated financial statements in conformity with U.S.&#160;GAAP requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the condensed consolidated financial statements and the reported amounts of revenues and expenses during the reporting period. Actual results could differ from those estimates.</font></div><div style="line-height:120%;padding-bottom:12px;padding-top:12px;text-align:justify;text-indent:18px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;">Principles of Consolidation</font></div><div style="line-height:120%;padding-bottom:12px;padding-top:12px;text-align:justify;text-indent:32px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">The condensed consolidated financial statements include the financial statements of NewLink and its wholly owned subsidiaries.  All significant intercompany balances and transactions have been eliminated in consolidation.</font></div><div style="line-height:120%;padding-bottom:12px;padding-top:12px;text-align:justify;text-indent:18px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;">Financial Instruments and Concentrations of Credit Risk</font></div><div style="line-height:120%;padding-bottom:12px;padding-top:12px;text-align:justify;text-indent:30px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Cash and cash equivalents, receivables, and accounts payable are recorded at cost, which approximates fair value based on the short-term nature of these financial instruments. The carrying value of notes payable and capital lease obligations was </font><font style="font-family:inherit;font-size:10pt;">$332,000</font><font style="font-family:inherit;font-size:10pt;"> and </font><font style="font-family:inherit;font-size:10pt;">$517,000</font><font style="font-family:inherit;font-size:10pt;"> as of </font><font style="font-family:inherit;font-size:10pt;">September&#160;30, 2017</font><font style="font-family:inherit;font-size:10pt;"> and </font><font style="font-family:inherit;font-size:10pt;">December&#160;31, 2016</font><font style="font-family:inherit;font-size:10pt;">, respectively, which approximate fair value using Level 2 inputs (computed in accordance with ASC 820). The Company is unable to estimate the fair value of the royalty obligation based on future product sales, as the timing of payments, if any, is uncertain.  </font></div><div style="line-height:120%;padding-bottom:12px;padding-top:12px;text-align:justify;text-indent:30px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Financial instruments that potentially subject the Company to concentrations of credit risk consist primarily of cash and cash equivalents. Cash and cash equivalents are held by financial institutions and are federally insured up to certain limits. At times, the Company&#8217;s cash and cash equivalents balance exceeds the federally insured limits. To limit the credit risk, the Company invests its excess cash primarily in high-quality securities such as certificates of deposit and money market funds.</font></div><div style="line-height:120%;padding-bottom:12px;padding-top:12px;text-align:justify;text-indent:18px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;">Property and equipment</font></div><div style="line-height:120%;padding-bottom:12px;padding-top:12px;text-align:justify;text-indent:30px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Property and equipment are capitalized as the Company believes they have alternative future uses and are stated at cost, less accumulated depreciation of </font><font style="font-family:inherit;font-size:10pt;">$6.7 million</font><font style="font-family:inherit;font-size:10pt;"> and </font><font style="font-family:inherit;font-size:10pt;">$5.7 million</font><font style="font-family:inherit;font-size:10pt;"> as of </font><font style="font-family:inherit;font-size:10pt;">September&#160;30, 2017</font><font style="font-family:inherit;font-size:10pt;"> and </font><font style="font-family:inherit;font-size:10pt;">December&#160;31, 2016</font><font style="font-family:inherit;font-size:10pt;">, respectively. Equipment under capital leases is stated at the present value of minimum lease payments. Depreciation on all property and equipment is calculated on the straight-line method over the shorter of the lease term or estimated useful life of the asset. Computer equipment has useful lives of </font><font style="font-family:inherit;font-size:10pt;">three</font><font style="font-family:inherit;font-size:10pt;"> to </font><font style="font-family:inherit;font-size:10pt;">five</font><font style="font-family:inherit;font-size:10pt;"> years, lab equipment has a useful life of </font><font style="font-family:inherit;font-size:10pt;">five</font><font style="font-family:inherit;font-size:10pt;"> years and contract manufacturing organization equipment has a useful life of </font><font style="font-family:inherit;font-size:10pt;">five</font><font style="font-family:inherit;font-size:10pt;"> years. </font></div><div style="line-height:120%;padding-bottom:12px;padding-top:12px;text-align:justify;text-indent:18px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;">Revenue Recognition</font></div><div style="line-height:120%;padding-bottom:12px;padding-top:12px;text-align:justify;text-indent:30px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">The Company receives payments from government entities under its grants and contracts with the Department of Defense and the United States Department of Health and Human Services. These agreements provide the Company cost reimbursement plus a percentage for certain types of expenditures in return for research and development activities over a contractually defined period. Grant revenues are recognized in the period during which the related costs are incurred, provided that the conditions under which the costs submitted or to be submitted for reimbursement have been met and the Company has only perfunctory obligations outstanding. </font></div><div style="line-height:120%;padding-bottom:12px;padding-top:12px;text-align:justify;text-indent:30px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">The Company had&#160;</font><font style="font-family:inherit;font-size:10pt;">$10.1 million</font><font style="font-family:inherit;font-size:10pt;"> and </font><font style="font-family:inherit;font-size:10pt;">$23.9 million</font><font style="font-family:inherit;font-size:10pt;"> of receivables from the government contracts recorded in other receivables and </font><font style="font-family:inherit;font-size:10pt;">$1.5 million</font><font style="font-family:inherit;font-size:10pt;"> and </font><font style="font-family:inherit;font-size:10pt;">$4.3 million</font><font style="font-family:inherit;font-size:10pt;"> of unbilled expenses relating to the government contracts recorded in prepaid expenses and other current assets on the balance sheet as of </font><font style="font-family:inherit;font-size:10pt;">September&#160;30, 2017</font><font style="font-family:inherit;font-size:10pt;"> and </font><font style="font-family:inherit;font-size:10pt;">December&#160;31, 2016</font><font style="font-family:inherit;font-size:10pt;">, respectively. The Company had </font><font style="font-family:inherit;font-size:10pt;">$1.4 million</font><font style="font-family:inherit;font-size:10pt;"> and </font><font style="font-family:inherit;font-size:10pt;">$2.9 million</font><font style="font-family:inherit;font-size:10pt;"> of accrued expenses for subcontractor fees incurred under the government contracts as of </font><font style="font-family:inherit;font-size:10pt;">September&#160;30, 2017</font><font style="font-family:inherit;font-size:10pt;"> and </font><font style="font-family:inherit;font-size:10pt;">December&#160;31, 2016</font><font style="font-family:inherit;font-size:10pt;">, respectively. </font></div><div style="line-height:120%;padding-bottom:12px;padding-top:12px;text-align:justify;text-indent:18px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;">Recent Accounting Pronouncements</font></div><div style="line-height:120%;text-align:justify;text-indent:30px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">On May 28, 2014, the FASB issued ASU No. 2014-09, Revenue from Contracts with Customers, which requires an entity to recognize the amount of revenue to which it expects to be entitled for the transfer of promised goods or services to customers. The ASU will replace most existing revenue recognition guidance in U.S. GAAP when it becomes effective. The new standard is effective for the Company on January 1, 2018. The standard permits the use of either the retrospective or cumulative effect transition method. The Company plans to adopt the standard on a modified retrospective basis at January 1, 2018, with an adjustment for the cumulative effect of all changes recognized in beginning retained earnings.  The Company does not expect to record any adjustment relating to the Company&#8217;s licensing and collaboration agreements. The Company continues to assess the impact adoption will have on the government grant revenue contracts.</font></div></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountingPoliciesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountingPoliciesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SignificantAccountingPoliciesTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for all significant accounting policies of the reporting entity.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -URI http://asc.fasb.org/topic&amp;trid=2122369<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SignificantAccountingPoliciesTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>23
<FILENAME>R11.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.8.0.1</span><table class="report" border="0" cellspacing="2" id="idp6751363584">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Long-Term Debt<br></strong></div></th>
<th class="th" colspan="1">9 Months Ended</th>
</tr>
<tr><th class="th"><div>Sep. 30, 2017</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtDisclosureAbstract', window );"><strong>Debt Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LongTermDebtTextBlock', window );">Long-Term Debt</a></td>
<td class="text"><div style="font-family:Times New Roman;font-size:10pt;"><div style="line-height:120%;padding-bottom:12px;padding-top:12px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Long-Term Debt </font></div><div style="line-height:120%;padding-bottom:12px;padding-top:12px;text-indent:30px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;">March 2010 City of Ames Forgivable Loan</font></div><div style="line-height:120%;padding-bottom:12px;padding-top:12px;text-align:justify;text-indent:30px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">In March 2010, the Company entered into a </font><font style="font-family:inherit;font-size:10pt;">$400,000</font><font style="font-family:inherit;font-size:10pt;"> forgivable loan agreement with the City of Ames, Iowa and the Ames Chamber of Commerce, jointly, as lenders. The project provided the Company with financial assistance to construct new facilities within the Ames city limits. </font></div><div style="line-height:120%;padding-bottom:12px;padding-top:12px;text-align:justify;text-indent:30px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">The project required the Company to create or retain at least </font><font style="font-family:inherit;font-size:10pt;">150</font><font style="font-family:inherit;font-size:10pt;"> full-time positions located in Ames, Iowa by March&#160;10, 2016. The agreement required the Company to enter into a </font><font style="font-family:inherit;font-size:10pt;">five</font><font style="font-family:inherit;font-size:10pt;">-year building lease with the option for extension for an additional </font><font style="font-family:inherit;font-size:10pt;">five</font><font style="font-family:inherit;font-size:10pt;"> years of not less than </font><font style="font-family:inherit;font-size:10pt;">20,000</font><font style="font-family:inherit;font-size:10pt;"> square feet within the corporate limits of the City of Ames by March&#160;10, 2015, which requirement was met prior to the deadline of March 10, 2015. As of March&#160;10, 2016, the Company had satisfactorily fulfilled all of the above terms of the loan agreement and the loan was forgiven. Accordingly, the entire outstanding loan amount of </font><font style="font-family:inherit;font-size:10pt;">$397,000</font><font style="font-family:inherit;font-size:10pt;"> was derecognized with a corresponding amount recorded in grant revenue for the three months ended March 31, 2016.</font></div></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LongTermDebtTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for long-term debt.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -URI http://asc.fasb.org/topic&amp;trid=2208564<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LongTermDebtTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>24
<FILENAME>R12.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.8.0.1</span><table class="report" border="0" cellspacing="2" id="idp6754363168">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>License and Research Collaboration Agreements<br></strong></div></th>
<th class="th" colspan="1">9 Months Ended</th>
</tr>
<tr><th class="th"><div>Sep. 30, 2017</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract', window );"><strong>Organization, Consolidation and Presentation of Financial Statements [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CollaborativeArrangementDisclosureTextBlock', window );">Licensing and Research Collaboration Agreements</a></td>
<td class="text"><div style="font-family:Times New Roman;font-size:10pt;"><div style="line-height:120%;padding-bottom:12px;padding-top:12px;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">License and Research Collaboration Agreements</font></div><div style="line-height:120%;padding-bottom:12px;padding-top:12px;text-align:left;text-indent:30px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;">Genentech, a Member of the Roche Group</font></div><div style="line-height:120%;padding-bottom:12px;padding-top:12px;text-align:justify;text-indent:30px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">In October 2014, the Company entered into an exclusive worldwide collaboration and license agreement with Genentech, or the Genentech Agreement, for the development and commercialization of navoximod (GDC-0919), one of the Company's clinical stage IDO pathway inhibitors. The parties also entered into a research collaboration for the discovery of next generation IDO and TDO pathway inhibitors to be developed and commercialized under this agreement.  Under the terms of the Genentech Agreement, the Company received a nonrefundable upfront cash payment of </font><font style="font-family:inherit;font-size:10pt;">$150.0 million</font><font style="font-family:inherit;font-size:10pt;"> from Genentech in 2014 and is eligible to receive additional milestone payments of up to </font><font style="font-family:inherit;font-size:10pt;">$561.0 million</font><font style="font-family:inherit;font-size:10pt;"> upon achieving certain Next Generation Product Development regulatory development, international patent acceptance, country marketing approval, and sales-based milestones. The Company retains the right to exercise an option to co-promote any products for the U.S. market and is also eligible to receive escalating  royalty payments on potential commercial sales of products by Genentech. </font></div><div style="line-height:120%;padding-bottom:12px;padding-top:12px;text-align:justify;text-indent:30px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">On June 6, 2017, the Company received a formal notice of Genentech&#8217;s intent to terminate the Genentech Agreement with respect to navoximod with such termination to be effective no later than December 6, 2017.  Discussions regarding the termination are ongoing.  The Genentech Agreement continues with regards to any Next Generation Products as defined under the Genentech Agreement.</font></div><div style="line-height:120%;padding-bottom:12px;padding-top:12px;text-align:justify;text-indent:30px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">For the </font><font style="font-family:inherit;font-size:10pt;">three and nine months ended</font><font style="font-family:inherit;font-size:10pt;"> </font><font style="font-family:inherit;font-size:10pt;">September&#160;30, 2017</font><font style="font-family:inherit;font-size:10pt;">, the Company recognized license and collaboration revenue under the Genentech Agreement of </font><font style="font-family:inherit;font-size:10pt;">$56,000</font><font style="font-family:inherit;font-size:10pt;"> and </font><font style="font-family:inherit;font-size:10pt;">$279,000</font><font style="font-family:inherit;font-size:10pt;">, respectively, for providing an alliance manager.  For the </font><font style="font-family:inherit;font-size:10pt;">three months ended</font><font style="font-family:inherit;font-size:10pt;"> </font><font style="font-family:inherit;font-size:10pt;">September&#160;30, 2016</font><font style="font-family:inherit;font-size:10pt;">, the Company recognized license and collaboration revenue under the Genentech Agreement of </font><font style="font-family:inherit;font-size:10pt;">$687,000</font><font style="font-family:inherit;font-size:10pt;">, including </font><font style="font-family:inherit;font-size:10pt;">$486,000</font><font style="font-family:inherit;font-size:10pt;"> for amounts received as reimbursement for the Company's employees working on the project, and </font><font style="font-family:inherit;font-size:10pt;">$201,000</font><font style="font-family:inherit;font-size:10pt;"> for providing an alliance manager. For the </font><font style="font-family:inherit;font-size:10pt;">nine months ended</font><font style="font-family:inherit;font-size:10pt;"> </font><font style="font-family:inherit;font-size:10pt;">September&#160;30, 2016</font><font style="font-family:inherit;font-size:10pt;">, the Company recognized license and collaboration revenue under the Genentech Agreement of </font><font style="font-family:inherit;font-size:10pt;">$2.2 million</font><font style="font-family:inherit;font-size:10pt;">, including </font><font style="font-family:inherit;font-size:10pt;">$1.6 million</font><font style="font-family:inherit;font-size:10pt;"> for amounts received as reimbursement for the Company's employees working on the project, </font><font style="font-family:inherit;font-size:10pt;">$502,000</font><font style="font-family:inherit;font-size:10pt;"> for providing an alliance manager, and </font><font style="font-family:inherit;font-size:10pt;">$101,000</font><font style="font-family:inherit;font-size:10pt;"> for participation in the joint research committee. In accordance with the Company&#8217;s continuing performance obligation, </font><font style="font-family:inherit;font-size:10pt;">$112,000</font><font style="font-family:inherit;font-size:10pt;"> of the </font><font style="font-family:inherit;font-size:10pt;">$150.0 million</font><font style="font-family:inherit;font-size:10pt;"> upfront payment remains deferred as of </font><font style="font-family:inherit;font-size:10pt;">September&#160;30, 2017</font><font style="font-family:inherit;font-size:10pt;"> and will be recognized during the remainder of 2017. The upfront payment provides no general right of return for any non-contingent deliverable and no portion of any revenue recognized is refundable.</font></div><div style="line-height:120%;padding-bottom:12px;padding-top:12px;text-align:left;text-indent:30px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;">Merck Sharp &amp; Dohme Corp. </font></div><div style="line-height:120%;padding-bottom:12px;padding-top:12px;text-align:justify;text-indent:30px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">In November 2014, the Company entered into a licensing and collaboration agreement with Merck, or the Merck Agreement, to develop, manufacture and commercialize rVSV-ZEBOV GP, an Ebola vaccine the Company licensed from the Public Health Agency of Canada, or PHAC.  Under the terms of the Merck Agreement, the Company granted Merck an exclusive, royalty bearing license to rVSV-ZEBOV GP and related technology. Under the Merck Agreement, the Company received a </font><font style="font-family:inherit;font-size:10pt;">$30.0 million</font><font style="font-family:inherit;font-size:10pt;"> non-refundable, upfront payment in December 2014, and a one-time </font><font style="font-family:inherit;font-size:10pt;">$20.0 million</font><font style="font-family:inherit;font-size:10pt;"> non-refundable milestone payment in February 2015 upon the initiation of the pivotal clinical trial using the current rVSV-ZEBOV GP vaccine product as one arm of the trial. In addition, the Company can receive escalating royalties on potential commercial sales by Merck of the current product candidate ranging from single digit to double digits on the rVSV-ZEBOV GP license agreement product sales and escalating royalties on potential commercial sales by Merck of products other than current products within the Company&#8217;s patent rights ranging from low to high single digit, on increasing levels of annual net sales worldwide. Merck will lead the development of rVSV-ZEBOV GP and any other rVSV-based viral hemorrhagic fever vaccine product candidates in order to create a marketable product safe for human use.</font></div><div style="line-height:120%;padding-bottom:12px;padding-top:12px;text-align:justify;text-indent:30px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">The Company completed all deliverables under the Merck Agreement in their entirety during the year ended </font><font style="font-family:inherit;font-size:10pt;">December&#160;31, 2016</font><font style="font-family:inherit;font-size:10pt;">. For the </font><font style="font-family:inherit;font-size:10pt;">three months ended</font><font style="font-family:inherit;font-size:10pt;"> </font><font style="font-family:inherit;font-size:10pt;">September&#160;30, 2016</font><font style="font-family:inherit;font-size:10pt;">, the Company recognized </font><font style="font-family:inherit;font-size:10pt;">no</font><font style="font-family:inherit;font-size:10pt;"> revenues under the Merck Agreement. For the </font><font style="font-family:inherit;font-size:10pt;">nine months ended</font><font style="font-family:inherit;font-size:10pt;"> </font><font style="font-family:inherit;font-size:10pt;">September&#160;30, 2016</font><font style="font-family:inherit;font-size:10pt;">, the Company recognized license and collaboration revenues under the Merck Agreement of </font><font style="font-family:inherit;font-size:10pt;">$764,000</font><font style="font-family:inherit;font-size:10pt;">, for the reimbursement of costs not covered under government contracts.</font></div></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CollaborativeArrangementDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for collaborative arrangements in which the entity is a participant, including a) information about the nature and purpose of such arrangements; b) its rights and obligations thereunder; c) the accounting policy for collaborative arrangements; and d) the income statement classification and amounts attributable to transactions arising from the collaborative arrangement between participants.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 808<br> -URI http://asc.fasb.org/topic&amp;trid=5833765<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CollaborativeArrangementDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>25
<FILENAME>R13.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.8.0.1</span><table class="report" border="0" cellspacing="2" id="idp6751398016">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Common Stock Equity Incentive Plan<br></strong></div></th>
<th class="th" colspan="1">9 Months Ended</th>
</tr>
<tr><th class="th"><div>Sep. 30, 2017</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract', window );"><strong>Disclosure of Compensation Related Costs, Share-based Payments [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock', window );">Common Stock Equity Incentive Plan</a></td>
<td class="text"><div style="font-family:Times New Roman;font-size:10pt;"><div style="line-height:120%;padding-bottom:12px;padding-top:12px;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Common Stock Equity Incentive Plan</font></div><div style="line-height:120%;padding-bottom:12px;padding-top:12px;text-indent:30px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;">2009 Equity Incentive Plan</font></div><div style="line-height:120%;padding-bottom:12px;padding-top:12px;text-align:justify;text-indent:32px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">In April 2000, the stockholders approved the Company's 2000 Equity Incentive Plan, or the 2000 Plan, and in July 2009, the stockholders approved the Company's 2009 Equity Incentive Plan, or the 2009 Plan. Following the approval of the 2009 Plan, all options outstanding under the 2000 Plan are effectively included under the 2009 Plan. Under the provisions of the 2009 Plan, the Company may grant the following types of common stock awards:</font></div><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;" rowspan="1" colspan="1"></td><td rowspan="1" colspan="1"></td></tr><tr><td style="vertical-align:top" rowspan="1" colspan="1"><div style="line-height:120%;font-size:10pt;padding-left:24px;"><font style="font-family:inherit;font-size:10pt;">&#8226;</font></div></td><td style="vertical-align:top;" rowspan="1" colspan="1"><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Incentive Stock Options</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;" rowspan="1" colspan="1"></td><td rowspan="1" colspan="1"></td></tr><tr><td style="vertical-align:top" rowspan="1" colspan="1"><div style="line-height:120%;font-size:10pt;padding-left:24px;"><font style="font-family:inherit;font-size:10pt;">&#8226;</font></div></td><td style="vertical-align:top;" rowspan="1" colspan="1"><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Nonstatutory Stock Options</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;" rowspan="1" colspan="1"></td><td rowspan="1" colspan="1"></td></tr><tr><td style="vertical-align:top" rowspan="1" colspan="1"><div style="line-height:120%;font-size:10pt;padding-left:24px;"><font style="font-family:inherit;font-size:10pt;">&#8226;</font></div></td><td style="vertical-align:top;" rowspan="1" colspan="1"><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Restricted Stock Awards</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;" rowspan="1" colspan="1"></td><td rowspan="1" colspan="1"></td></tr><tr><td style="vertical-align:top" rowspan="1" colspan="1"><div style="line-height:120%;font-size:10pt;padding-left:24px;"><font style="font-family:inherit;font-size:10pt;">&#8226;</font></div></td><td style="vertical-align:top;" rowspan="1" colspan="1"><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Stock Appreciation Rights</font></div></td></tr></table><div style="line-height:120%;padding-bottom:12px;padding-top:12px;text-align:justify;text-indent:32px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Awards under the 2009 Plan, as amended, may be made to officers, employees, members of the Board of Directors, advisors, and consultants to the Company.  As of </font><font style="font-family:inherit;font-size:10pt;">September&#160;30, 2017</font><font style="font-family:inherit;font-size:10pt;">, there were </font><font style="font-family:inherit;font-size:10pt;">10,238,220</font><font style="font-family:inherit;font-size:10pt;"> shares of common stock authorized for the 2009 Plan and </font><font style="font-family:inherit;font-size:10pt;">1,094,264</font><font style="font-family:inherit;font-size:10pt;"> shares remained available for issuance.</font></div><div style="line-height:120%;padding-bottom:12px;padding-top:12px;text-align:justify;text-indent:32px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">The following table summarizes the authorized increases of common stock under the 2009 Plan:</font></div><div style="line-height:120%;padding-bottom:12px;padding-top:12px;text-align:center;text-indent:32px;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:57.421875%;border-collapse:collapse;text-align:left;"><tr><td colspan="4" rowspan="1"></td></tr><tr><td style="width:43%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:55%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td></tr><tr><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:center;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;font-weight:bold;">Date Authorized</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;font-weight:bold;">Authorized Shares Added</font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">May 15, 2010</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">1,238,095</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">January 7, 2011</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">714,286</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">January 1, 2013</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">838,375</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">January 1, 2014</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">1,066,340</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">January 1, 2015</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">1,119,255</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">January 1, 2016</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">1,152,565</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">January 1, 2017</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">1,166,546</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr></table></div><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;padding-bottom:12px;padding-top:12px;text-align:justify;text-indent:32px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">The increases in the authorized shares of common stock under the 2009 Plan in 2010 and 2011 were approved by the Company&#8217;s stockholders. The increases in the authorized shares of common stock under the 2009 Plan in 2012 through 2017 were made pursuant to an &#8220;evergreen provision,&#8221; in accordance with which, on January 1 of each year, from 2012 to (and including) 2019, a number of shares of common stock in an amount equal to </font><font style="font-family:inherit;font-size:10pt;">4%</font><font style="font-family:inherit;font-size:10pt;"> of the total number of shares of common stock outstanding on December 31 of the preceding calendar year, or such lesser amount of shares (or no shares) approved by the Company's Board of Directors, was added or will be added to the shares reserved under the 2009 Plan. </font></div><div style="line-height:120%;padding-bottom:12px;padding-top:12px;text-align:justify;text-indent:32px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;">2010 Non-Employee Directors' Stock Award Plan</font></div><div style="line-height:120%;padding-bottom:12px;padding-top:12px;text-align:justify;text-indent:32px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Under the terms of the Company&#8217;s 2010 Non-Employee Directors&#8217; Stock Award Plan, or the Directors&#8217; Plan, which became effective on November 10, 2011, </font><font style="font-family:inherit;font-size:10pt;">238,095</font><font style="font-family:inherit;font-size:10pt;"> shares of common stock were reserved for future issuance. On </font><font style="font-family:inherit;font-size:10pt;">May&#160;9, 2013</font><font style="font-family:inherit;font-size:10pt;">, an additional </font><font style="font-family:inherit;font-size:10pt;">161,905</font><font style="font-family:inherit;font-size:10pt;"> shares of common stock were added to the shares reserved for future issuance under the Directors' Plan.  As of </font><font style="font-family:inherit;font-size:10pt;">September&#160;30, 2017</font><font style="font-family:inherit;font-size:10pt;">, </font><font style="font-family:inherit;font-size:10pt;">no</font><font style="font-family:inherit;font-size:10pt;"> shares remained available for issuance under the Directors' Plan.</font></div><div style="line-height:120%;padding-bottom:12px;padding-top:12px;text-align:justify;text-indent:32px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;">2010 Employee Stock Purchase Plan</font></div><div style="line-height:120%;padding-bottom:12px;padding-top:12px;text-align:justify;text-indent:32px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Under the terms of the Company&#8217;s 2010 Employee Stock Purchase Plan, or the 2010 Purchase Plan, which became effective on November 10, 2011, </font><font style="font-family:inherit;font-size:10pt;">214,285</font><font style="font-family:inherit;font-size:10pt;"> shares of common stock were reserved for future issuance. On </font><font style="font-family:inherit;font-size:10pt;">May&#160;9, 2013</font><font style="font-family:inherit;font-size:10pt;">, an additional </font><font style="font-family:inherit;font-size:10pt;">185,715</font><font style="font-family:inherit;font-size:10pt;"> shares of common stock were added to the shares reserved for future issuance under the 2010 Purchase Plan. As of </font><font style="font-family:inherit;font-size:10pt;">September&#160;30, 2017</font><font style="font-family:inherit;font-size:10pt;">, </font><font style="font-family:inherit;font-size:10pt;">120,784</font><font style="font-family:inherit;font-size:10pt;"> shares remained available for issuance under the 2010 Purchase Plan.</font></div><div style="line-height:120%;padding-bottom:12px;padding-top:12px;text-align:justify;text-indent:32px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;">Share-based Compensation</font></div><div style="line-height:120%;padding-bottom:12px;padding-top:12px;text-align:justify;text-indent:32px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Share-based compensation expense for the </font><font style="font-family:inherit;font-size:10pt;">three months ended</font><font style="font-family:inherit;font-size:10pt;"> </font><font style="font-family:inherit;font-size:10pt;">September&#160;30, 2017</font><font style="font-family:inherit;font-size:10pt;"> and </font><font style="font-family:inherit;font-size:10pt;">2016</font><font style="font-family:inherit;font-size:10pt;"> was </font><font style="font-family:inherit;font-size:10pt;">$4.4 million</font><font style="font-family:inherit;font-size:10pt;"> and </font><font style="font-family:inherit;font-size:10pt;">$3.9 million</font><font style="font-family:inherit;font-size:10pt;">, respectively, and was </font><font style="font-family:inherit;font-size:10pt;">$14.9 million</font><font style="font-family:inherit;font-size:10pt;"> and </font><font style="font-family:inherit;font-size:10pt;">$13.1 million</font><font style="font-family:inherit;font-size:10pt;">, respectively, for </font><font style="font-family:inherit;font-size:10pt;">nine months ended</font><font style="font-family:inherit;font-size:10pt;"> </font><font style="font-family:inherit;font-size:10pt;">September&#160;30, 2017</font><font style="font-family:inherit;font-size:10pt;"> and </font><font style="font-family:inherit;font-size:10pt;">2016</font><font style="font-family:inherit;font-size:10pt;">.  Share-based compensation expense is allocated between research and development and general and administrative expenses within the condensed consolidated statements of operations. </font></div><div style="line-height:120%;padding-bottom:12px;padding-top:12px;text-align:justify;text-indent:32px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">As of </font><font style="font-family:inherit;font-size:10pt;">September&#160;30, 2017</font><font style="font-family:inherit;font-size:10pt;">, the total compensation cost related to nonvested option awards not yet recognized was </font><font style="font-family:inherit;font-size:10pt;">$19.9 million</font><font style="font-family:inherit;font-size:10pt;"> and the weighted-average period over which it is expected to be recognized is </font><font style="font-family:inherit;font-size:10pt;">2.1 years</font><font style="font-family:inherit;font-size:10pt;">.</font></div><div style="line-height:120%;padding-bottom:12px;padding-top:12px;text-align:justify;text-indent:32px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;">Stock Options and Performance Stock Options</font></div><div style="line-height:120%;padding-bottom:12px;padding-top:12px;text-align:justify;text-indent:32px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">The following table summarizes the stock option activity, including options with performance conditions, for the </font><font style="font-family:inherit;font-size:10pt;">nine months ended</font><font style="font-family:inherit;font-size:10pt;"> </font><font style="font-family:inherit;font-size:10pt;">September&#160;30, 2017</font><font style="font-family:inherit;font-size:10pt;">:</font></div><div style="line-height:120%;padding-bottom:12px;padding-top:12px;text-align:center;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:551px;border-collapse:collapse;text-align:left;"><tr><td colspan="10" rowspan="1"></td></tr><tr><td style="width:226px;" rowspan="1" colspan="1"></td><td style="width:5px;" rowspan="1" colspan="1"></td><td style="width:94px;" rowspan="1" colspan="1"></td><td style="width:4px;" rowspan="1" colspan="1"></td><td style="width:5px;" rowspan="1" colspan="1"></td><td style="width:9px;" rowspan="1" colspan="1"></td><td style="width:83px;" rowspan="1" colspan="1"></td><td style="width:4px;" rowspan="1" colspan="1"></td><td style="width:5px;" rowspan="1" colspan="1"></td><td style="width:114px;" rowspan="1" colspan="1"></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">Number</font></div><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">of options</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">Weighted</font></div><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">average</font></div><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">exercise</font></div><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">price</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">Weighted average</font></div><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">remaining contractual</font></div><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">term (years)</font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Outstanding at beginning of period</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">6,278,542</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">14.93</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">5.8</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Options granted</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">1,439,287</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">11.78</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Options exercised</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(108,775</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">8.51</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Options forfeited</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(277,443</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">20.13</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Options expired</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(17,605</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">42.00</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Outstanding at end of period</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">7,314,006</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">14.15</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">5.5</font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Options exercisable at end of period</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:3px double #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">5,456,602</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:3px double #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">12.65</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">4.4</font></div></td></tr></table></div><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;padding-bottom:12px;text-align:justify;text-indent:36px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">The Company estimates the fair value of each stock option grant on the date of grant using a Black-Scholes option pricing model. For stock option grants issued with a market condition, the Company used a Monte Carlo simulation valuation model to determine the grant date fair value. </font></div><div style="line-height:120%;padding-bottom:12px;text-align:justify;text-indent:36px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">The following table summarizes the range of assumptions used to estimate the fair value of stock options granted, including those options granted with a market condition, during the </font><font style="font-family:inherit;font-size:10pt;">nine months ended</font><font style="font-family:inherit;font-size:10pt;"> </font><font style="font-family:inherit;font-size:10pt;">September&#160;30, 2017</font><font style="font-family:inherit;font-size:10pt;">:</font></div><div style="line-height:120%;padding-bottom:12px;padding-top:12px;text-align:center;text-indent:32px;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:63.0859375%;border-collapse:collapse;text-align:left;"><tr><td colspan="3" rowspan="1"></td></tr><tr><td style="width:68%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:31%;" rowspan="1" colspan="1"></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Risk-free interest rate</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">1.9% to 2.2%</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Expected dividend yield</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8212;%</font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Expected volatility</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">68.9% to 73.2%</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Expected term (in years)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">6.5 to 7.8</font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Weighted-average grant-date fair value per share</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$7.81</font></div></td></tr></table></div><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;padding-bottom:12px;padding-top:12px;text-align:justify;text-indent:32px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">The intrinsic value of options exercised during the </font><font style="font-family:inherit;font-size:10pt;">nine months ended</font><font style="font-family:inherit;font-size:10pt;"> </font><font style="font-family:inherit;font-size:10pt;">September&#160;30, 2017</font><font style="font-family:inherit;font-size:10pt;"> was </font><font style="font-family:inherit;font-size:10pt;">$924,164</font><font style="font-family:inherit;font-size:10pt;">. The fair value of awards vested during the </font><font style="font-family:inherit;font-size:10pt;">nine months ended</font><font style="font-family:inherit;font-size:10pt;"> </font><font style="font-family:inherit;font-size:10pt;">September&#160;30, 2017</font><font style="font-family:inherit;font-size:10pt;"> was </font><font style="font-family:inherit;font-size:10pt;">$12.4 million</font><font style="font-family:inherit;font-size:10pt;">. </font></div><div style="line-height:120%;padding-bottom:12px;padding-top:12px;text-align:justify;text-indent:32px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">During the </font><font style="font-family:inherit;font-size:10pt;">nine months ended</font><font style="font-family:inherit;font-size:10pt;"> </font><font style="font-family:inherit;font-size:10pt;">September&#160;30, 2017</font><font style="font-family:inherit;font-size:10pt;">, the Company&#8217;s Board of Directors approved and granted </font><font style="font-family:inherit;font-size:10pt;">388,144</font><font style="font-family:inherit;font-size:10pt;"> shares of compensation and equity awards to certain executives with either market or performance conditions. The compensation and equity awards had a weighted average grant date fair value per share of $</font><font style="font-family:inherit;font-size:10pt;">6.73</font><font style="font-family:inherit;font-size:10pt;">.   The compensation and equity awards will vest upon the achievement of certain performance conditions. During the </font><font style="font-family:inherit;font-size:10pt;">nine months ended</font><font style="font-family:inherit;font-size:10pt;"> </font><font style="font-family:inherit;font-size:10pt;">September&#160;30, 2017</font><font style="font-family:inherit;font-size:10pt;">, certain conditions were met which resulted in the vesting of </font><font style="font-family:inherit;font-size:10pt;">194,070</font><font style="font-family:inherit;font-size:10pt;"> shares and the recognition of </font><font style="font-family:inherit;font-size:10pt;">$1.2 million</font><font style="font-family:inherit;font-size:10pt;"> in stock compensation expense.</font></div><div style="line-height:120%;padding-bottom:12px;padding-top:12px;text-align:justify;text-indent:32px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;">Restricted Stock and Performance Restricted Stock</font></div><div style="line-height:120%;padding-bottom:12px;padding-top:12px;text-align:justify;text-indent:32px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Restricted stock is common stock that is subject to restrictions, including risks of forfeiture, determined by the plan committee of the Board of Directors in its sole discretion, for as long as such common stock remains subject to any such restrictions.  A holder of restricted stock has all rights of a stockholder with respect to such stock, including the right to vote and to receive dividends thereon, except as otherwise provided in the award agreement relating to such award.  Restricted stock awards are classified as equity within the consolidated balance sheets.  The fair value of each restricted stock grant is estimated on the date of grant using the closing price of the Company's common stock on the NASDAQ Stock Market on the date of grant.</font></div><div style="line-height:120%;padding-bottom:12px;padding-top:12px;text-align:justify;text-indent:30px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">A summary of the Company's unvested restricted stock, including restricted stock with performance conditions, at </font><font style="font-family:inherit;font-size:10pt;">September&#160;30, 2017</font><font style="font-family:inherit;font-size:10pt;"> and changes during the </font><font style="font-family:inherit;font-size:10pt;">nine months ended</font><font style="font-family:inherit;font-size:10pt;"> </font><font style="font-family:inherit;font-size:10pt;">September&#160;30, 2017</font><font style="font-family:inherit;font-size:10pt;"> are as follows:</font></div><div style="line-height:120%;padding-bottom:12px;padding-top:12px;text-align:center;text-indent:30px;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:64.84375%;border-collapse:collapse;text-align:left;"><tr><td colspan="11" rowspan="1"></td></tr><tr><td style="width:57%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:19%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:16%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">Number of restricted stock shares</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="5" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">Weighted average grant date fair value</font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Unvested at beginning of period</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">288,964</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">34.94</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Granted</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Vested</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(80,380</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">35.04</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Forfeited/cancelled</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(27,248</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">33.84</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Unvested at end of period</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">181,336</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">35.05</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr></table></div><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;padding-bottom:12px;padding-top:12px;text-align:justify;text-indent:30px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">As of </font><font style="font-family:inherit;font-size:10pt;">September&#160;30, 2017</font><font style="font-family:inherit;font-size:10pt;">, the total remaining unrecognized compensation cost related to restricted stock was approximately </font><font style="font-family:inherit;font-size:10pt;">$4.4 million</font><font style="font-family:inherit;font-size:10pt;"> and is expected to be recognized over a weighted-average period of </font><font style="font-family:inherit;font-size:10pt;">1.8 years</font><font style="font-family:inherit;font-size:10pt;">. As of </font><font style="font-family:inherit;font-size:10pt;">September&#160;30, 2017</font><font style="font-family:inherit;font-size:10pt;">, there remains approximately </font><font style="font-family:inherit;font-size:10pt;">$6.4 million</font><font style="font-family:inherit;font-size:10pt;"> of unrecognized compensation cost related to the issuance of performance restricted stock. The fair value of awards vested during the </font><font style="font-family:inherit;font-size:10pt;">nine months ended</font><font style="font-family:inherit;font-size:10pt;"> </font><font style="font-family:inherit;font-size:10pt;">September&#160;30, 2017</font><font style="font-family:inherit;font-size:10pt;"> was </font><font style="font-family:inherit;font-size:10pt;">$814,000</font><font style="font-family:inherit;font-size:10pt;">.</font></div><div style="line-height:120%;padding-bottom:12px;padding-top:12px;text-align:justify;text-indent:30px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">The Company does not have a formal policy regarding the source of shares issued upon exercise of stock options or issuance of restricted stock. The Company expects shares issued to be issued from treasury shares or new shares.</font></div></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for compensation-related costs for equity-based compensation, which may include disclosure of policies, compensation plan details, allocation of equity compensation, incentive distributions, equity-based arrangements to obtain goods and services, deferred compensation arrangements, employee stock ownership plan details and employee stock purchase plan details.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -URI http://asc.fasb.org/topic&amp;trid=2228938<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 50<br> -URI http://asc.fasb.org/subtopic&amp;trid=2208855<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>26
<FILENAME>R14.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.8.0.1</span><table class="report" border="0" cellspacing="2" id="idp6751395088">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Income Taxes<br></strong></div></th>
<th class="th" colspan="1">9 Months Ended</th>
</tr>
<tr><th class="th"><div>Sep. 30, 2017</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeTaxDisclosureAbstract', window );"><strong>Income Tax Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeTaxDisclosureTextBlock', window );">Income Taxes</a></td>
<td class="text"><div style="font-family:Times New Roman;font-size:10pt;"><div style="line-height:120%;padding-bottom:12px;padding-top:12px;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Income Taxes</font></div><div style="line-height:120%;padding-bottom:12px;padding-top:12px;text-align:justify;text-indent:32px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">For the </font><font style="font-family:inherit;font-size:10pt;">three and nine months ended</font><font style="font-family:inherit;font-size:10pt;"> </font><font style="font-family:inherit;font-size:10pt;">September&#160;30, 2017</font><font style="font-family:inherit;font-size:10pt;">, the Company recorded an income tax benefit of </font><font style="font-family:inherit;font-size:10pt;">$119,000</font><font style="font-family:inherit;font-size:10pt;"> and </font><font style="font-family:inherit;font-size:10pt;">$429,000</font><font style="font-family:inherit;font-size:10pt;">, respectively.  For the </font><font style="font-family:inherit;font-size:10pt;">three and nine months ended</font><font style="font-family:inherit;font-size:10pt;"> </font><font style="font-family:inherit;font-size:10pt;">September&#160;30, 2016</font><font style="font-family:inherit;font-size:10pt;">, the Company recorded an income tax benefit of </font><font style="font-family:inherit;font-size:10pt;">$1.3 million</font><font style="font-family:inherit;font-size:10pt;"> and </font><font style="font-family:inherit;font-size:10pt;">$5.0 million</font><font style="font-family:inherit;font-size:10pt;">, respectively. The income tax benefit for the </font><font style="font-family:inherit;font-size:10pt;">three and nine months ended</font><font style="font-family:inherit;font-size:10pt;"> </font><font style="font-family:inherit;font-size:10pt;">September&#160;30, 2017</font><font style="font-family:inherit;font-size:10pt;"> differs from the amount that would be expected after applying the statutory U.S. federal income tax rate primarily due to the limited potential to carry back losses to 2015 and the net loss generated by NewLink's foreign subsidiary. Income tax benefit for the </font><font style="font-family:inherit;font-size:10pt;">three and nine months ended</font><font style="font-family:inherit;font-size:10pt;"> </font><font style="font-family:inherit;font-size:10pt;">September&#160;30, 2016</font><font style="font-family:inherit;font-size:10pt;"> differs from the amount that would be expected after applying the statutory U.S. federal income tax rate primarily due to the ability to carry back losses to 2014 and the net loss generated by the NewLink's foreign subsidiary. </font></div><div style="line-height:120%;padding-bottom:12px;padding-top:12px;text-align:justify;text-indent:32px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">In assessing the realizability of deferred tax assets, management considers whether it is more likely than not that some portion or all of the deferred tax assets will not be realized. The ultimate realization of deferred tax assets is dependent upon the generation of future taxable income during the periods in which those temporary differences become deductible. Management considers the scheduled reversal of deferred tax liabilities, projected taxable income, and tax planning strategies in making this assessment. Valuation allowances have been established for the entire amount of the net deferred tax assets as of </font><font style="font-family:inherit;font-size:10pt;">September&#160;30, 2017</font><font style="font-family:inherit;font-size:10pt;"> and </font><font style="font-family:inherit;font-size:10pt;">December&#160;31, 2016</font><font style="font-family:inherit;font-size:10pt;">, respectively, due to the uncertainty of future recoverability.</font></div><div style="line-height:120%;padding-bottom:12px;padding-top:12px;text-align:justify;text-indent:32px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">The Company has a reserve for uncertain tax positions related to state tax matters of </font><font style="font-family:inherit;font-size:10pt;">$843,000</font><font style="font-family:inherit;font-size:10pt;"> as of </font><font style="font-family:inherit;font-size:10pt;">September&#160;30, 2017</font><font style="font-family:inherit;font-size:10pt;"> recorded within Accrued Expenses in the condensed consolidated balance sheet, which includes the accrual of interest and penalties. The Company does not expect the amount to change significantly within the next 12 months.</font></div></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for income taxes. Disclosures may include net deferred tax liability or asset recognized in an enterprise's statement of financial position, net change during the year in the total valuation allowance, approximate tax effect of each type of temporary difference and carryforward that gives rise to a significant portion of deferred tax liabilities and deferred tax assets, utilization of a tax carryback, and tax uncertainties information.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -URI http://asc.fasb.org/topic&amp;trid=2144680<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>27
<FILENAME>R15.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.8.0.1</span><table class="report" border="0" cellspacing="2" id="idp6751398016">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Net Loss per Common Share<br></strong></div></th>
<th class="th" colspan="1">9 Months Ended</th>
</tr>
<tr><th class="th"><div>Sep. 30, 2017</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EarningsPerShareAbstract', window );"><strong>Earnings Per Share [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EarningsPerShareTextBlock', window );">Net Loss per Common Share</a></td>
<td class="text"><div style="font-family:Times New Roman;font-size:10pt;"><div style="line-height:120%;padding-bottom:12px;padding-top:12px;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Net Loss per Common Share</font></div><div style="line-height:120%;padding-bottom:12px;padding-top:12px;text-align:justify;text-indent:30px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Basic loss per share is based upon the weighted-average number of common shares outstanding during the period, without consideration of common stock equivalents. Diluted loss per share is based upon the weighted-average number of common shares outstanding during the period plus additional weighted-average potentially dilutive common stock equivalents during the period when the effect is dilutive.</font></div><div style="line-height:120%;text-align:justify;text-indent:30px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">The following table presents the computation of basic and diluted loss per common share (in thousands, except share and per share data):</font></div><div style="line-height:120%;text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:639px;border-collapse:collapse;text-align:left;"><tr><td colspan="18" rowspan="1"></td></tr><tr><td style="width:292px;" rowspan="1" colspan="1"></td><td style="width:5px;" rowspan="1" colspan="1"></td><td style="width:9px;" rowspan="1" colspan="1"></td><td style="width:66px;" rowspan="1" colspan="1"></td><td style="width:4px;" rowspan="1" colspan="1"></td><td style="width:5px;" rowspan="1" colspan="1"></td><td style="width:9px;" rowspan="1" colspan="1"></td><td style="width:66px;" rowspan="1" colspan="1"></td><td style="width:4px;" rowspan="1" colspan="1"></td><td style="width:8px;" rowspan="1" colspan="1"></td><td style="width:9px;" rowspan="1" colspan="1"></td><td style="width:64px;" rowspan="1" colspan="1"></td><td style="width:4px;" rowspan="1" colspan="1"></td><td style="width:9px;" rowspan="1" colspan="1"></td><td style="width:9px;" rowspan="1" colspan="1"></td><td style="width:66px;" rowspan="1" colspan="1"></td><td style="width:4px;" rowspan="1" colspan="1"></td><td style="width:5px;" rowspan="1" colspan="1"></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="7" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:center;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;font-weight:bold;">Three Months Ended September 30, </font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="7" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:center;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;font-weight:bold;">Nine Months Ended September 30, </font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:bottom;background-color:;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;font-weight:bold;">2017</font></div></td><td style="vertical-align:bottom;background-color:;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;font-weight:bold;">2016</font></div></td><td style="vertical-align:bottom;background-color:;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1"><div style="text-align:center;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;font-weight:bold;">2017</font></div></td><td style="vertical-align:bottom;background-color:;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1"><div style="text-align:center;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;font-weight:bold;">2016</font></div></td><td style="vertical-align:bottom;background-color:;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:middle;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Loss attributable to common stockholders</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(20,626</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(15,540</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(58,265</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(71,649</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;height:5px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;height:5px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;height:5px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;height:5px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;height:5px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;height:5px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;height:5px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;height:5px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;height:5px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;height:5px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:bottom;background-color:;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Basic and diluted weighted-average shares outstanding</font></div></td><td style="vertical-align:bottom;background-color:;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:3px double #000000;background-color:;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">29,939,823</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:3px double #000000;background-color:;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">28,983,561</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:3px double #000000;background-color:;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">29,462,226</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:3px double #000000;background-color:;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">28,911,042</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;height:8px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;height:8px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;height:8px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;height:8px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;height:8px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;height:8px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;height:8px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;height:8px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;height:8px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;height:8px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Basic and diluted loss per share</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(0.69</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(0.54</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(1.98</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(2.48</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr></table></div><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;padding-bottom:10px;text-align:justify;text-indent:24px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;text-align:justify;text-indent:24px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">All common stock equivalents are excluded from the computation of diluted loss per share during periods in which losses are reported since the result would be anti-dilutive. As of </font><font style="font-family:inherit;font-size:10pt;">September&#160;30, 2017</font><font style="font-family:inherit;font-size:10pt;">, anti-dilutive stock options and restricted stock awards excluded from our calculation totaled </font><font style="font-family:inherit;font-size:10pt;">7,314,006</font><font style="font-family:inherit;font-size:10pt;"> and </font><font style="font-family:inherit;font-size:10pt;">181,336</font><font style="font-family:inherit;font-size:10pt;">, respectively.  As of </font><font style="font-family:inherit;font-size:10pt;">September 30,</font><font style="font-family:inherit;font-size:10pt;"> </font><font style="font-family:inherit;font-size:10pt;">2016</font><font style="font-family:inherit;font-size:10pt;">, anti-dilutive stock options and restricted stock awards excluded from our calculation totaled </font><font style="font-family:inherit;font-size:10pt;">6,453,331</font><font style="font-family:inherit;font-size:10pt;"> and </font><font style="font-family:inherit;font-size:10pt;">307,079</font><font style="font-family:inherit;font-size:10pt;">, respectively.</font></div></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerShareAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerShareAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerShareTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for earnings per share.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -URI http://asc.fasb.org/topic&amp;trid=2144383<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerShareTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>28
<FILENAME>R16.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.8.0.1</span><table class="report" border="0" cellspacing="2" id="idp6751371088">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Restructuring Charges<br></strong></div></th>
<th class="th" colspan="1">9 Months Ended</th>
</tr>
<tr><th class="th"><div>Sep. 30, 2017</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RestructuringAndRelatedActivitiesAbstract', window );"><strong>Restructuring and Related Activities [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RestructuringAndRelatedActivitiesDisclosureTextBlock', window );">Restructuring Charges</a></td>
<td class="text"><div style="font-family:Times New Roman;font-size:10pt;"><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Restructuring Charges</font></div><div style="line-height:120%;padding-bottom:12px;padding-top:12px;text-align:justify;text-indent:30px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">The Company records liabilities for costs associated with exit or disposal activities in the period in which the liability is incurred. Employee severance costs are accrued when the&#160;restructuring&#160;actions are probable and estimable. Costs for one-time termination benefits in which the employee is required to render service until termination in order to receive the benefits are recognized ratably over the future service period. The Company also records costs incurred with contract terminations associated with restructuring&#160;activities. </font></div><div style="line-height:120%;padding-bottom:12px;padding-top:12px;text-align:justify;text-indent:30px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">In July 2017, the Company&#160;undertook an organizational realignment to refocus its clinical development efforts and align the Company's resources to focus on the Company's highest value opportunities. The Company's restructuring activities included a reduction of its workforce by approximately </font><font style="font-family:inherit;font-size:10pt;">50%</font><font style="font-family:inherit;font-size:10pt;">, which consisted primarily of clinical and research and development staff, as well as stopping additional research on the Zika virus.  Restructuring charges recorded during the </font><font style="font-family:inherit;font-size:10pt;">three and nine months ended</font><font style="font-family:inherit;font-size:10pt;"> </font><font style="font-family:inherit;font-size:10pt;">September&#160;30, 2017</font><font style="font-family:inherit;font-size:10pt;"> included </font><font style="font-family:inherit;font-size:10pt;">$1.7 million</font><font style="font-family:inherit;font-size:10pt;"> in employee severance cost, which is comprised of one-time employee termination benefits and certain expenses related to contractual termination benefits for employees with pre-existing severance arrangements.  </font></div><div style="line-height:120%;text-align:justify;text-indent:30px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">In May 2016, the Company announced that its Phase 3 clinical trial Immunotherapy for Pancreatic RESectable cancer Study, or IMPRESS, of algenpantucel-L for patients with resected pancreatic cancer did not achieve its primary endpoint and in order to reduce costs associated with algenpantucel-L and the HyperAcute&#174; Cellular Immunotherapy platform technology, the Company's management adopted a restructuring plan in May 2016 which included a reduction in the Company's workforce; the exit or reduction of certain leased facilities; and the renegotiation or termination of contracts with certain third parties. As a result of the restructuring, the Company also impaired fixed assets which management determined had no or limited future use. The fair value of impaired fixed assets was determined based on management&#8217;s estimate of market resale value. Restructuring charges recorded during 2016 were </font><font style="font-family:inherit;font-size:10pt;">$12.3 million</font><font style="font-family:inherit;font-size:10pt;">, of which </font><font style="font-family:inherit;font-size:10pt;">$500,000</font><font style="font-family:inherit;font-size:10pt;"> is included within general and administrative expenses and </font><font style="font-family:inherit;font-size:10pt;">$11.8 million</font><font style="font-family:inherit;font-size:10pt;"> is included within the research and development expenses in the condensed consolidated statement of operations. Included in the </font><font style="font-family:inherit;font-size:10pt;">$12.3 million</font><font style="font-family:inherit;font-size:10pt;"> of charges is non-cash asset impairment charges of </font><font style="font-family:inherit;font-size:10pt;">$4.0 million</font><font style="font-family:inherit;font-size:10pt;">.  </font><font style="font-family:inherit;font-size:10pt;">No</font><font style="font-family:inherit;font-size:10pt;"> additional charges related to the 2016 restructuring were recorded during the </font><font style="font-family:inherit;font-size:10pt;">three and nine months ended</font><font style="font-family:inherit;font-size:10pt;"> </font><font style="font-family:inherit;font-size:10pt;">September&#160;30, 2017</font><font style="font-family:inherit;font-size:10pt;"> and all amounts accrued as of December 31, 2016 were paid by the end of the first quarter of 2017.</font></div><div style="line-height:120%;padding-bottom:12px;padding-top:12px;text-align:justify;text-indent:32px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">The following table shows the amount accrued for restructuring activities which is recorded within Accrued Expenses in the condensed consolidated balance sheet:</font></div><div style="line-height:120%;padding-bottom:12px;padding-top:12px;text-align:center;text-indent:32px;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:428px;border-collapse:collapse;text-align:left;"><tr><td colspan="9" rowspan="1"></td></tr><tr><td style="width:200px;" rowspan="1" colspan="1"></td><td style="width:6px;" rowspan="1" colspan="1"></td><td style="width:9px;" rowspan="1" colspan="1"></td><td style="width:92px;" rowspan="1" colspan="1"></td><td style="width:4px;" rowspan="1" colspan="1"></td><td style="width:6px;" rowspan="1" colspan="1"></td><td style="width:9px;" rowspan="1" colspan="1"></td><td style="width:95px;" rowspan="1" colspan="1"></td><td style="width:4px;" rowspan="1" colspan="1"></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;font-weight:bold;">Employee Severance Cost</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;font-weight:bold;">Total</font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Balance as of December 31, 2016</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">42</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">42</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Expensed</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">1,695</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">1,695</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Cash Payments</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">1,085</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">1,085</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Balance as of September 30, 2017</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">652</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">652</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr></table></div><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;padding-bottom:12px;padding-top:12px;text-align:justify;text-indent:30px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">The majority of the charges are expected to be paid by the end of the year.</font></div></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RestructuringAndRelatedActivitiesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RestructuringAndRelatedActivitiesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RestructuringAndRelatedActivitiesDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for restructuring and related activities. Description of restructuring activities such as exit and disposal activities, include facts and circumstances leading to the plan, the expected plan completion date, the major types of costs associated with the plan activities, total expected costs, the accrual balance at the end of the period, and the periods over which the remaining accrual will be settled.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 420<br> -URI http://asc.fasb.org/topic&amp;trid=2175745<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RestructuringAndRelatedActivitiesDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>29
<FILENAME>R17.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.8.0.1</span><table class="report" border="0" cellspacing="2" id="idp6754340016">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Commitments and Contingencies<br></strong></div></th>
<th class="th" colspan="1">9 Months Ended</th>
</tr>
<tr><th class="th"><div>Sep. 30, 2017</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommitmentsAndContingenciesDisclosureAbstract', window );"><strong>Commitments and Contingencies Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommitmentsAndContingenciesDisclosureTextBlock', window );">Commitments and Contingencies Disclosure</a></td>
<td class="text"><div style="font-family:Times New Roman;font-size:10pt;"><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Commitments and Contingencies </font></div><div style="line-height:120%;padding-bottom:12px;padding-top:12px;text-align:justify;text-indent:30px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">From time to time, claims are asserted against the Company arising in the ordinary course of business. In the opinion of management, liabilities, if any, arising from existing claims are not expected to have a material effect on the Company's earnings, financial position, or liquidity.</font></div><div style="line-height:120%;padding-bottom:12px;text-align:justify;text-indent:30px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">On or about May 12, 2016, Trevor Abramson filed a putative securities class action lawsuit in the United States District Court for the Southern District of New York, or the Court, captioned Abramson v. NewLink Genetics Corp., et al., Case 1:16-cv-3545, or the Securities Action. &#160;Subsequently, the Court appointed Michael and Kelly Nguyen as lead plaintiffs and approved their selection of Kahn, Swick &amp; Foti, LLC as lead counsel in the Securities Action.&#160;&#160;On October 31, 2016, the lead plaintiffs filed an amended complaint which asserts claims under the federal securities laws against the Company, the Company&#8217;s Chief Executive Officer Charles J. Link, Jr., and the Company&#8217;s Chief Medical Officer and President Nicholas Vahanian, or collectively, the Defendants.&#160; The amended complaint alleges the Defendants made material false and/or misleading statements that caused losses to the Company&#8217;s investors. In particular, the lead plaintiffs allege that the Defendants made material misstatements or omissions related to the Phase II and III trials and efficacy of the product candidate algenpantucel-L. The lead plaintiffs do not quantify any alleged damages in the amended complaint but, in addition to attorneys&#8217; fees and costs, they seek to recover damages on behalf of themselves and other persons who purchased or otherwise acquired the Company&#8217;s stock during the putative class period of September 17, 2013 through May 9, 2016, inclusive, at allegedly inflated prices and purportedly suffered financial harm as a result.  On April 27, 2017, the Court granted the parties&#8217; request for leave to brief a motion to dismiss the amended complaint, and ordered the parties to file a stipulation and proposed order setting forth a schedule for the briefing of that motion. &#160;On May 15, 2017, the Court ordered the following briefing schedule: motion to dismiss due July 14, 2017, opposition due September 12, 2017, and reply due September 26, 2017.&#160; The Defendants filed a motion to dismiss on July 14, 2017. The lead plaintiffs filed an opposition to the motion to dismiss on September 12, 2017. The Defendants filed a reply in support of the motion to dismiss on September 26, 2017. Oral argument was held on October 19, 2017, after which the Court reserved decision. The Company disputes the claims in the Securities Action and intends to defend against them vigorously.</font></div><div style="line-height:120%;text-align:justify;text-indent:30px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">On or about April 26, 2017, Ronald Morrow filed a shareholder derivative lawsuit on behalf of the Company in the United States District Court for the Southern District of New York, or the Court, against the Company&#8217;s Chief Executive Officer Charles J. Link, Jr., the Company&#8217;s Chief Medical Officer and President Nicholas Vahanian, and Company directors Thomas A. Raffin, Joseph Saluri, Ernest J. Talarico, III, Paul R. Edick, Paolo Pucci, and Lota S. Zoth, or collectively, the Morrow Defendants, captioned Morrow v. Link., et al., Case 1:17-cv-03039, or the Morrow Action.&#160; The complaint alleges that the Morrow Defendants caused the Company to issue false statements in its 2016 proxy statement regarding risk management and compensation matters in violation of federal securities law.&#160; The complaint also asserts state law claims against the Morrow Defendants for breaches of fiduciary duties, unjust enrichment, abuse of control, insider trading, gross mismanagement, and corporate waste, alleging that the Morrow Defendants made material misstatements or omissions related to the Phase II and III trials and efficacy of the product candidate algenpantucel-L, awarded themselves excessive compensation, engaged in illegal insider trading, and grossly mismanaged the Company.&#160; The plaintiff does not quantify any alleged damages in the complaint but seeks restitution for damages to the Company, attorneys&#8217; fees, costs, and expenses, as well as an order directing that proposals for strengthening board oversight be put to a vote of the Company&#8217;s shareholders. &#160;The language for such proposals is not specified in the complaint.&#160; The plaintiff also contemporaneously filed a statement of relatedness, informing the Court that the Morrow Action is related to Abramson v. NewLink Genetics Corp., et al., Case 1:16-cv-3545.&#160; On May 19, 2017, the plaintiff dismissed the Morrow Action without prejudice.&#160; Also on May 19, 2017, plaintiffs&#8217; counsel in the Morrow Action filed a new shareholder derivative complaint that is substantively identical to the Morrow Action, except that the plaintiff is Rickey Ely.&#160; The latter action is captioned Ely v. Link, et al., Case 17-cv-3799, or the Ely Action.&#160; By agreement of the parties and order dated June 26, 2017, the Court temporarily stayed the Ely Action until the Securities Action is dismissed or otherwise resolved.&#160; Under the terms of the stay, the plaintiff in the Ely Action will be provided with any discovery that is provided in the Securities Action, and given an opportunity to participate in any mediation or settlement efforts in the Securities Action.&#160; The Company disputes the claims in the Ely Action and intends to defend against them vigorously.</font></div></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommitmentsAndContingenciesDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommitmentsAndContingenciesDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommitmentsAndContingenciesDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for commitments and contingencies.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 450<br> -URI http://asc.fasb.org/topic&amp;trid=2127136<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 440<br> -URI http://asc.fasb.org/topic&amp;trid=2144648<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommitmentsAndContingenciesDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>30
<FILENAME>R18.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.8.0.1</span><table class="report" border="0" cellspacing="2" id="idp6650067808">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Subsequent Events<br></strong></div></th>
<th class="th" colspan="1">9 Months Ended</th>
</tr>
<tr><th class="th"><div>Sep. 30, 2017</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SubsequentEventsAbstract', window );"><strong>Subsequent Events [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SubsequentEventsTextBlock', window );">Subsequent Events</a></td>
<td class="text"><div style="font-family:Times New Roman;font-size:10pt;"><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Subsequent Events</font></div><div style="line-height:120%;padding-bottom:12px;padding-top:12px;text-align:justify;text-indent:30px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">On October 6, 2017, the Company sold </font><font style="font-family:inherit;font-size:10pt;">5,750,000</font><font style="font-family:inherit;font-size:10pt;"> shares of its common stock for total proceeds of </font><font style="font-family:inherit;font-size:10pt;">$55.2 million</font><font style="font-family:inherit;font-size:10pt;">, net of offering expenses of </font><font style="font-family:inherit;font-size:10pt;">$3.7 million</font><font style="font-family:inherit;font-size:10pt;">. Net proceeds from the offering will be used to further advance its pipeline of product candidates, including the continued clinical development of indoximod, and for working capital and other general corporate purposes.</font></div></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SubsequentEventsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SubsequentEventsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SubsequentEventsTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for significant events or transactions that occurred after the balance sheet date through the date the financial statements were issued or the date the financial statements were available to be issued. Examples include: the sale of a capital stock issue, purchase of a business, settlement of litigation, catastrophic loss, significant foreign exchange rate changes, loans to insiders or affiliates, and transactions not in the ordinary course of business.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 855<br> -URI http://asc.fasb.org/topic&amp;trid=2122774<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SubsequentEventsTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>31
<FILENAME>R19.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.8.0.1</span><table class="report" border="0" cellspacing="2" id="idp6752917248">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Significant Accounting Policies (Policies)<br></strong></div></th>
<th class="th" colspan="1">9 Months Ended</th>
</tr>
<tr><th class="th"><div>Sep. 30, 2017</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccountingPoliciesAbstract', window );"><strong>Accounting Policies [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_UseOfEstimates', window );">Use of Estimates</a></td>
<td class="text"><div style="font-family:Times New Roman;font-size:10pt;"><div style="line-height:120%;padding-bottom:12px;padding-top:12px;text-align:justify;text-indent:18px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;">Use of Estimates</font></div><div style="line-height:120%;padding-bottom:12px;padding-top:12px;text-align:justify;text-indent:32px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">The preparation of the condensed consolidated financial statements in conformity with U.S.&#160;GAAP requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the condensed consolidated financial statements and the reported amounts of revenues and expenses during the reporting period. Actual results could differ from those estimates.</font></div></div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ConsolidationPolicyTextBlock', window );">Principles of Consolidation</a></td>
<td class="text"><div style="font-family:Times New Roman;font-size:10pt;"><div style="line-height:120%;padding-bottom:12px;padding-top:12px;text-align:justify;text-indent:18px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;">Principles of Consolidation</font></div><div style="line-height:120%;padding-bottom:12px;padding-top:12px;text-align:justify;text-indent:32px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">The condensed consolidated financial statements include the financial statements of NewLink and its wholly owned subsidiaries.  All significant intercompany balances and transactions have been eliminated in consolidation.</font></div></div><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueOfFinancialInstrumentsPolicy', window );">Financial Instruments</a></td>
<td class="text"><div style="font-family:Times New Roman;font-size:10pt;"><div style="line-height:120%;padding-bottom:12px;padding-top:12px;text-align:justify;text-indent:18px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;">Financial Instruments and Concentrations of Credit Risk</font></div><div style="line-height:120%;padding-bottom:12px;padding-top:12px;text-align:justify;text-indent:30px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Cash and cash equivalents, receivables, and accounts payable are recorded at cost, which approximates fair value based on the short-term nature of these financial instruments. The carrying value of notes payable and capital lease obligations was </font><font style="font-family:inherit;font-size:10pt;">$332,000</font><font style="font-family:inherit;font-size:10pt;"> and </font><font style="font-family:inherit;font-size:10pt;">$517,000</font><font style="font-family:inherit;font-size:10pt;"> as of </font><font style="font-family:inherit;font-size:10pt;">September&#160;30, 2017</font><font style="font-family:inherit;font-size:10pt;"> and </font><font style="font-family:inherit;font-size:10pt;">December&#160;31, 2016</font><font style="font-family:inherit;font-size:10pt;">, respectively, which approximate fair value using Level 2 inputs (computed in accordance with ASC 820). The Company is unable to estimate the fair value of the royalty obligation based on future product sales, as the timing of payments, if any, is uncertain.  </font></div></div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ConcentrationRiskCreditRisk', window );">Concentration of Credit Risk</a></td>
<td class="text"><div style="font-family:Times New Roman;font-size:10pt;"><div style="line-height:120%;padding-bottom:12px;padding-top:12px;text-align:justify;text-indent:30px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Financial instruments that potentially subject the Company to concentrations of credit risk consist primarily of cash and cash equivalents. Cash and cash equivalents are held by financial institutions and are federally insured up to certain limits. At times, the Company&#8217;s cash and cash equivalents balance exceeds the federally insured limits. To limit the credit risk, the Company invests its excess cash primarily in high-quality securities such as certificates of deposit and money market funds.</font></div></div><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentPolicyTextBlock', window );">Property and equipment</a></td>
<td class="text"><div style="font-family:Times New Roman;font-size:10pt;"><div style="line-height:120%;padding-bottom:12px;padding-top:12px;text-align:justify;text-indent:18px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;">Property and equipment</font></div><div style="line-height:120%;padding-bottom:12px;padding-top:12px;text-align:justify;text-indent:30px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Property and equipment are capitalized as the Company believes they have alternative future uses and are stated at cost, less accumulated depreciation of </font><font style="font-family:inherit;font-size:10pt;">$6.7 million</font><font style="font-family:inherit;font-size:10pt;"> and </font><font style="font-family:inherit;font-size:10pt;">$5.7 million</font><font style="font-family:inherit;font-size:10pt;"> as of </font><font style="font-family:inherit;font-size:10pt;">September&#160;30, 2017</font><font style="font-family:inherit;font-size:10pt;"> and </font><font style="font-family:inherit;font-size:10pt;">December&#160;31, 2016</font><font style="font-family:inherit;font-size:10pt;">, respectively. Equipment under capital leases is stated at the present value of minimum lease payments. Depreciation on all property and equipment is calculated on the straight-line method over the shorter of the lease term or estimated useful life of the asset. Computer equipment has useful lives of </font><font style="font-family:inherit;font-size:10pt;">three</font><font style="font-family:inherit;font-size:10pt;"> to </font><font style="font-family:inherit;font-size:10pt;">five</font><font style="font-family:inherit;font-size:10pt;"> years, lab equipment has a useful life of </font><font style="font-family:inherit;font-size:10pt;">five</font><font style="font-family:inherit;font-size:10pt;"> years and contract manufacturing organization equipment has a useful life of </font><font style="font-family:inherit;font-size:10pt;">five</font><font style="font-family:inherit;font-size:10pt;"> years. </font></div></div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueRecognitionPolicyTextBlock', window );">Revenue Recognition</a></td>
<td class="text"><div style="font-family:Times New Roman;font-size:10pt;"><div style="line-height:120%;padding-bottom:12px;padding-top:12px;text-align:justify;text-indent:18px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;">Revenue Recognition</font></div><div style="line-height:120%;padding-bottom:12px;padding-top:12px;text-align:justify;text-indent:30px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">The Company receives payments from government entities under its grants and contracts with the Department of Defense and the United States Department of Health and Human Services. These agreements provide the Company cost reimbursement plus a percentage for certain types of expenditures in return for research and development activities over a contractually defined period. Grant revenues are recognized in the period during which the related costs are incurred, provided that the conditions under which the costs submitted or to be submitted for reimbursement have been met and the Company has only perfunctory obligations outstanding. </font></div><div style="line-height:120%;padding-bottom:12px;padding-top:12px;text-align:justify;text-indent:30px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">The Company had&#160;</font><font style="font-family:inherit;font-size:10pt;">$10.1 million</font><font style="font-family:inherit;font-size:10pt;"> and </font><font style="font-family:inherit;font-size:10pt;">$23.9 million</font><font style="font-family:inherit;font-size:10pt;"> of receivables from the government contracts recorded in other receivables and </font><font style="font-family:inherit;font-size:10pt;">$1.5 million</font><font style="font-family:inherit;font-size:10pt;"> and </font><font style="font-family:inherit;font-size:10pt;">$4.3 million</font><font style="font-family:inherit;font-size:10pt;"> of unbilled expenses relating to the government contracts recorded in prepaid expenses and other current assets on the balance sheet as of </font><font style="font-family:inherit;font-size:10pt;">September&#160;30, 2017</font><font style="font-family:inherit;font-size:10pt;"> and </font><font style="font-family:inherit;font-size:10pt;">December&#160;31, 2016</font><font style="font-family:inherit;font-size:10pt;">, respectively. The Company had </font><font style="font-family:inherit;font-size:10pt;">$1.4 million</font><font style="font-family:inherit;font-size:10pt;"> and </font><font style="font-family:inherit;font-size:10pt;">$2.9 million</font><font style="font-family:inherit;font-size:10pt;"> of accrued expenses for subcontractor fees incurred under the government contracts as of </font><font style="font-family:inherit;font-size:10pt;">September&#160;30, 2017</font><font style="font-family:inherit;font-size:10pt;"> and </font><font style="font-family:inherit;font-size:10pt;">December&#160;31, 2016</font><font style="font-family:inherit;font-size:10pt;">, respectively.</font></div></div><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock', window );">Recent Accounting Pronouncements</a></td>
<td class="text"><div style="font-family:Times New Roman;font-size:10pt;"><div style="line-height:120%;padding-bottom:12px;padding-top:12px;text-align:justify;text-indent:18px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;">Recent Accounting Pronouncements</font></div><div style="line-height:120%;text-align:justify;text-indent:30px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">On May 28, 2014, the FASB issued ASU No. 2014-09, Revenue from Contracts with Customers, which requires an entity to recognize the amount of revenue to which it expects to be entitled for the transfer of promised goods or services to customers. The ASU will replace most existing revenue recognition guidance in U.S. GAAP when it becomes effective. The new standard is effective for the Company on January 1, 2018. The standard permits the use of either the retrospective or cumulative effect transition method. The Company plans to adopt the standard on a modified retrospective basis at January 1, 2018, with an adjustment for the cumulative effect of all changes recognized in beginning retained earnings.  The Company does not expect to record any adjustment relating to the Company&#8217;s licensing and collaboration agreements. The Company continues to assess the impact adoption will have on the government grant revenue contracts. </font></div></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountingPoliciesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountingPoliciesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ConcentrationRiskCreditRisk">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for credit risk.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 55<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=75027168&amp;loc=d3e14489-108613<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 825<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=75032840&amp;loc=d3e61082-112788<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 825<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=75027451&amp;loc=SL29635902-196195<br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 21<br> -URI http://asc.fasb.org/extlink&amp;oid=77997519&amp;loc=d3e13537-108611<br><br>Reference 5: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 20<br> -URI http://asc.fasb.org/extlink&amp;oid=77997519&amp;loc=d3e13531-108611<br><br>Reference 6: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 825<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=75032840&amp;loc=d3e61044-112788<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ConcentrationRiskCreditRisk</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ConsolidationPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy regarding (1) the principles it follows in consolidating or combining the separate financial statements, including the principles followed in determining the inclusion or exclusion of subsidiaries or other entities in the consolidated or combined financial statements and (2) its treatment of interests (for example, common stock, a partnership interest or other means of exerting influence) in other entities, for example consolidation or use of the equity or cost methods of accounting.  The accounting policy may also address the accounting treatment for intercompany accounts and transactions, noncontrolling interest, and the income statement treatment in consolidation for issuances of stock by a subsidiary.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=84158767&amp;loc=d3e18780-107790<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=84161450&amp;loc=d3e5614-111684<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.3A-03)<br> -URI http://asc.fasb.org/extlink&amp;oid=27015204&amp;loc=d3e355100-122828<br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.3A-02)<br> -URI http://asc.fasb.org/extlink&amp;oid=27015204&amp;loc=d3e355033-122828<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ConsolidationPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueOfFinancialInstrumentsPolicy">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for determining the fair value of financial instruments.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=84158767&amp;loc=d3e18780-107790<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=77997519&amp;loc=d3e13279-108611<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 820<br> -SubTopic 10<br> -Section 60<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=7493716&amp;loc=d3e21868-110260<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueOfFinancialInstrumentsPolicy</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy pertaining to new accounting pronouncements that may impact the entity's financial reporting. Includes, but is not limited to, quantification of the expected or actual impact.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for long-lived, physical assets used in the normal conduct of business and not intended for resale. Includes, but is not limited to, basis of assets, depreciation and depletion methods used, including composite deprecation, estimated useful lives, capitalization policy, accounting treatment for costs incurred for repairs and maintenance, capitalized interest and the method it is calculated, disposals and impairments.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6391035&amp;loc=d3e2868-110229<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=84158767&amp;loc=d3e18780-107790<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.13(a))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RevenueRecognitionPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for revenue recognition. If the entity has different policies for different types of revenue transactions, the policy for each material type of transaction is generally disclosed. If a sales transaction has multiple element arrangements (for example, delivery of multiple products, services or the rights to use assets) the disclosure may indicate the accounting policy for each unit of accounting as well as how units of accounting are determined and valued. The disclosure may encompass important judgment as to appropriateness of principles related to recognition of revenue. The disclosure also may indicate the entity's treatment of any unearned or deferred revenue that arises from the transaction.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=84158767&amp;loc=d3e18823-107790<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 605<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 13.B.Q1)<br> -URI http://asc.fasb.org/extlink&amp;oid=65893310&amp;loc=d3e214044-122780<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=84158767&amp;loc=d3e18780-107790<br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=84158767&amp;loc=d3e18726-107790<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RevenueRecognitionPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_UseOfEstimates">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for the use of estimates in the preparation of financial statements in conformity with generally accepted accounting principles.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 275<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=84177426&amp;loc=d3e6061-108592<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 275<br> -SubTopic 10<br> -Section 50<br> -Paragraph 9<br> -URI http://asc.fasb.org/extlink&amp;oid=84177426&amp;loc=d3e6143-108592<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 275<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=84177426&amp;loc=d3e6132-108592<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_UseOfEstimates</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>32
<FILENAME>R20.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.8.0.1</span><table class="report" border="0" cellspacing="2" id="idp6761390736">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Common Stock Equity Incentive Plan (Tables)<br></strong></div></th>
<th class="th" colspan="1">9 Months Ended</th>
</tr>
<tr><th class="th"><div>Sep. 30, 2017</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract', window );"><strong>Disclosure of Compensation Related Costs, Share-based Payments [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DisclosureOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTextBlock', window );">Authorized Increases of Common Stock under the 2009 Plan</a></td>
<td class="text"><div style="font-family:Times New Roman;font-size:10pt;"><div style="line-height:120%;padding-bottom:12px;padding-top:12px;text-align:justify;text-indent:32px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">The following table summarizes the authorized increases of common stock under the 2009 Plan:</font></div><div style="line-height:120%;padding-bottom:12px;padding-top:12px;text-align:center;text-indent:32px;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:57.421875%;border-collapse:collapse;text-align:left;"><tr><td colspan="4" rowspan="1"></td></tr><tr><td style="width:43%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:55%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td></tr><tr><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:center;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;font-weight:bold;">Date Authorized</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;font-weight:bold;">Authorized Shares Added</font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">May 15, 2010</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">1,238,095</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">January 7, 2011</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">714,286</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">January 1, 2013</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">838,375</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">January 1, 2014</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">1,066,340</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">January 1, 2015</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">1,119,255</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">January 1, 2016</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">1,152,565</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">January 1, 2017</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">1,166,546</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr></table></div></div></div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfStockOptionsRollForwardTableTextBlock', window );">Stock Option Activity</a></td>
<td class="text"><div style="font-family:Times New Roman;font-size:10pt;"><div style="line-height:120%;padding-bottom:12px;padding-top:12px;text-align:justify;text-indent:32px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">The following table summarizes the stock option activity, including options with performance conditions, for the </font><font style="font-family:inherit;font-size:10pt;">nine months ended</font><font style="font-family:inherit;font-size:10pt;"> </font><font style="font-family:inherit;font-size:10pt;">September&#160;30, 2017</font><font style="font-family:inherit;font-size:10pt;">:</font></div><div style="line-height:120%;padding-bottom:12px;padding-top:12px;text-align:center;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:551px;border-collapse:collapse;text-align:left;"><tr><td colspan="10" rowspan="1"></td></tr><tr><td style="width:226px;" rowspan="1" colspan="1"></td><td style="width:5px;" rowspan="1" colspan="1"></td><td style="width:94px;" rowspan="1" colspan="1"></td><td style="width:4px;" rowspan="1" colspan="1"></td><td style="width:5px;" rowspan="1" colspan="1"></td><td style="width:9px;" rowspan="1" colspan="1"></td><td style="width:83px;" rowspan="1" colspan="1"></td><td style="width:4px;" rowspan="1" colspan="1"></td><td style="width:5px;" rowspan="1" colspan="1"></td><td style="width:114px;" rowspan="1" colspan="1"></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">Number</font></div><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">of options</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">Weighted</font></div><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">average</font></div><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">exercise</font></div><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">price</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">Weighted average</font></div><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">remaining contractual</font></div><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">term (years)</font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Outstanding at beginning of period</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">6,278,542</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">14.93</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">5.8</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Options granted</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">1,439,287</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">11.78</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Options exercised</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(108,775</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">8.51</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Options forfeited</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(277,443</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">20.13</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Options expired</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(17,605</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">42.00</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Outstanding at end of period</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">7,314,006</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">14.15</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">5.5</font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Options exercisable at end of period</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:3px double #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">5,456,602</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:3px double #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">12.65</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">4.4</font></div></td></tr></table></div></div></div><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock', window );">Assumptions Used in Black-Scholes Pricing Model for New Grants</a></td>
<td class="text"><div style="font-family:Times New Roman;font-size:10pt;"><div style="line-height:120%;padding-bottom:12px;text-align:justify;text-indent:36px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">The following table summarizes the range of assumptions used to estimate the fair value of stock options granted, including those options granted with a market condition, during the </font><font style="font-family:inherit;font-size:10pt;">nine months ended</font><font style="font-family:inherit;font-size:10pt;"> </font><font style="font-family:inherit;font-size:10pt;">September&#160;30, 2017</font><font style="font-family:inherit;font-size:10pt;">:</font></div><div style="line-height:120%;padding-bottom:12px;padding-top:12px;text-align:center;text-indent:32px;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:63.0859375%;border-collapse:collapse;text-align:left;"><tr><td colspan="3" rowspan="1"></td></tr><tr><td style="width:68%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:31%;" rowspan="1" colspan="1"></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Risk-free interest rate</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">1.9% to 2.2%</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Expected dividend yield</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8212;%</font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Expected volatility</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">68.9% to 73.2%</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Expected term (in years)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">6.5 to 7.8</font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Weighted-average grant-date fair value per share</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$7.81</font></div></td></tr></table></div></div></div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NonvestedRestrictedStockSharesActivityTableTextBlock', window );">Restricted Stock Activity</a></td>
<td class="text"><div style="font-family:Times New Roman;font-size:10pt;"><div style="line-height:120%;padding-bottom:12px;padding-top:12px;text-align:justify;text-indent:30px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">A summary of the Company's unvested restricted stock, including restricted stock with performance conditions, at </font><font style="font-family:inherit;font-size:10pt;">September&#160;30, 2017</font><font style="font-family:inherit;font-size:10pt;"> and changes during the </font><font style="font-family:inherit;font-size:10pt;">nine months ended</font><font style="font-family:inherit;font-size:10pt;"> </font><font style="font-family:inherit;font-size:10pt;">September&#160;30, 2017</font><font style="font-family:inherit;font-size:10pt;"> are as follows:</font></div><div style="line-height:120%;padding-bottom:12px;padding-top:12px;text-align:center;text-indent:30px;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:64.84375%;border-collapse:collapse;text-align:left;"><tr><td colspan="11" rowspan="1"></td></tr><tr><td style="width:57%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:19%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:16%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">Number of restricted stock shares</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="5" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">Weighted average grant date fair value</font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Unvested at beginning of period</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">288,964</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">34.94</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Granted</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Vested</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(80,380</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">35.04</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Forfeited/cancelled</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(27,248</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">33.84</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Unvested at end of period</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">181,336</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">35.05</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr></table></div></div></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DisclosureOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of components of a stock option or other award plan under which equity-based compensation is awarded to employees, typically comprised of the amount of unearned compensation (deferred compensation cost), compensation expense, and changes in the quantity and fair value of the shares (or other type of equity) granted, exercised, forfeited, and issued and outstanding pertaining to that plan.  Disclosure may also include nature and general terms of such arrangements that existed during the period and potential effects of those arrangements on shareholders, effect of compensation cost arising from equity-based payment arrangements on the income statement, method of estimating the fair value of the goods or services received, or the fair value of the equity instruments granted, during the period, cash flow effects resulting from equity-based payment arrangements and, for registrants that accelerate vesting of out of the money share options, reasons for the decision to accelerate.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=96867065&amp;loc=d3e5070-113901<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=96867065&amp;loc=d3e5047-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DisclosureOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NonvestedRestrictedStockSharesActivityTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the changes in outstanding nonvested restricted stock shares.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=96867065&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NonvestedRestrictedStockSharesActivityTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the significant assumptions used during the year to estimate the fair value of stock options, including, but not limited to: (a) expected term of share options and similar instruments, (b) expected volatility of the entity's shares, (c) expected dividends, (d) risk-free rate(s), and (e) discount for post-vesting restrictions.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=96867065&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfStockOptionsRollForwardTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the change in stock options.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfStockOptionsRollForwardTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>33
<FILENAME>R21.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.8.0.1</span><table class="report" border="0" cellspacing="2" id="idp6751386736">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Net Loss per Common Share (Tables)<br></strong></div></th>
<th class="th" colspan="1">9 Months Ended</th>
</tr>
<tr><th class="th"><div>Sep. 30, 2017</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EarningsPerShareAbstract', window );"><strong>Earnings Per Share [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock', window );">Basic and Diluted Net Loss per Common Share</a></td>
<td class="text"><div style="font-family:Times New Roman;font-size:10pt;"><div style="line-height:120%;text-align:justify;text-indent:30px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">The following table presents the computation of basic and diluted loss per common share (in thousands, except share and per share data):</font></div><div style="line-height:120%;text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:639px;border-collapse:collapse;text-align:left;"><tr><td colspan="18" rowspan="1"></td></tr><tr><td style="width:292px;" rowspan="1" colspan="1"></td><td style="width:5px;" rowspan="1" colspan="1"></td><td style="width:9px;" rowspan="1" colspan="1"></td><td style="width:66px;" rowspan="1" colspan="1"></td><td style="width:4px;" rowspan="1" colspan="1"></td><td style="width:5px;" rowspan="1" colspan="1"></td><td style="width:9px;" rowspan="1" colspan="1"></td><td style="width:66px;" rowspan="1" colspan="1"></td><td style="width:4px;" rowspan="1" colspan="1"></td><td style="width:8px;" rowspan="1" colspan="1"></td><td style="width:9px;" rowspan="1" colspan="1"></td><td style="width:64px;" rowspan="1" colspan="1"></td><td style="width:4px;" rowspan="1" colspan="1"></td><td style="width:9px;" rowspan="1" colspan="1"></td><td style="width:9px;" rowspan="1" colspan="1"></td><td style="width:66px;" rowspan="1" colspan="1"></td><td style="width:4px;" rowspan="1" colspan="1"></td><td style="width:5px;" rowspan="1" colspan="1"></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="7" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:center;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;font-weight:bold;">Three Months Ended September 30, </font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="7" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:center;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;font-weight:bold;">Nine Months Ended September 30, </font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:bottom;background-color:;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;font-weight:bold;">2017</font></div></td><td style="vertical-align:bottom;background-color:;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;font-weight:bold;">2016</font></div></td><td style="vertical-align:bottom;background-color:;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1"><div style="text-align:center;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;font-weight:bold;">2017</font></div></td><td style="vertical-align:bottom;background-color:;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1"><div style="text-align:center;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;font-weight:bold;">2016</font></div></td><td style="vertical-align:bottom;background-color:;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:middle;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Loss attributable to common stockholders</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(20,626</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(15,540</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(58,265</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(71,649</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;height:5px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;height:5px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;height:5px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;height:5px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;height:5px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;height:5px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;height:5px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;height:5px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;height:5px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;height:5px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:bottom;background-color:;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Basic and diluted weighted-average shares outstanding</font></div></td><td style="vertical-align:bottom;background-color:;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:3px double #000000;background-color:;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">29,939,823</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:3px double #000000;background-color:;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">28,983,561</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:3px double #000000;background-color:;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">29,462,226</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:3px double #000000;background-color:;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">28,911,042</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;height:8px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;height:8px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;height:8px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;height:8px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;height:8px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;height:8px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;height:8px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;height:8px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;height:8px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;height:8px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Basic and diluted loss per share</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(0.69</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(0.54</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(1.98</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(2.48</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr></table></div></div></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerShareAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerShareAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of an entity's basic and diluted earnings per share calculations, including a reconciliation of numerators and denominators of the basic and diluted per-share computations for income from continuing operations.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6371337&amp;loc=d3e3550-109257<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>34
<FILENAME>R22.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.8.0.1</span><table class="report" border="0" cellspacing="2" id="idp6751362192">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Restructuring Charges (Tables)<br></strong></div></th>
<th class="th" colspan="1">9 Months Ended</th>
</tr>
<tr><th class="th"><div>Sep. 30, 2017</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RestructuringAndRelatedActivitiesAbstract', window );"><strong>Restructuring and Related Activities [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfRestructuringReserveByTypeOfCostTextBlock', window );">Restructuring and Related Costs</a></td>
<td class="text"><div style="font-family:Times New Roman;font-size:10pt;"><div style="line-height:120%;padding-bottom:12px;padding-top:12px;text-align:justify;text-indent:32px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">The following table shows the amount accrued for restructuring activities which is recorded within Accrued Expenses in the condensed consolidated balance sheet:</font></div><div style="line-height:120%;padding-bottom:12px;padding-top:12px;text-align:center;text-indent:32px;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:428px;border-collapse:collapse;text-align:left;"><tr><td colspan="9" rowspan="1"></td></tr><tr><td style="width:200px;" rowspan="1" colspan="1"></td><td style="width:6px;" rowspan="1" colspan="1"></td><td style="width:9px;" rowspan="1" colspan="1"></td><td style="width:92px;" rowspan="1" colspan="1"></td><td style="width:4px;" rowspan="1" colspan="1"></td><td style="width:6px;" rowspan="1" colspan="1"></td><td style="width:9px;" rowspan="1" colspan="1"></td><td style="width:95px;" rowspan="1" colspan="1"></td><td style="width:4px;" rowspan="1" colspan="1"></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;font-weight:bold;">Employee Severance Cost</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;font-weight:bold;">Total</font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Balance as of December 31, 2016</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">42</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">42</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Expensed</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">1,695</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">1,695</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Cash Payments</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">1,085</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">1,085</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Balance as of September 30, 2017</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">652</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">652</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr></table></div></div></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RestructuringAndRelatedActivitiesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RestructuringAndRelatedActivitiesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfRestructuringReserveByTypeOfCostTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of an entity's restructuring reserve that occurred during the period associated with the exit from or disposal of business activities or restructurings for each major type of cost. This element may also include a description of any reversal and other adjustment made during the period to the amount of an accrued liability for restructuring activities. This element may be used to encapsulate the roll forward presentations of an entity's restructuring reserve by type of cost and in total, and explanation of changes that occurred in the period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 420<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=6394359&amp;loc=d3e17939-110869<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 420<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SAB Topic 5.P.4(b)(2))<br> -URI http://asc.fasb.org/extlink&amp;oid=27011515&amp;loc=d3e140904-122747<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfRestructuringReserveByTypeOfCostTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>35
<FILENAME>R23.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.8.0.1</span><table class="report" border="0" cellspacing="2" id="idp6765323232">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Description of Business (Details)<br></strong></div></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="3">1 Months Ended</th>
<th class="th" colspan="2">3 Months Ended</th>
<th class="th" colspan="2">9 Months Ended</th>
<th class="th" colspan="2">12 Months Ended</th>
</tr>
<tr>
<th class="th">
<div>Oct. 06, 2017 </div>
<div>USD ($) </div>
<div>shares</div>
</th>
<th class="th">
<div>Nov. 29, 2016 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Aug. 02, 2017 </div>
<div>USD ($) </div>
<div>shares</div>
</th>
<th class="th"><div>Jul. 31, 2017</div></th>
<th class="th">
<div>Feb. 28, 2015 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Sep. 30, 2017 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Sep. 30, 2016 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Sep. 30, 2017 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Sep. 30, 2016 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Dec. 31, 2015 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Dec. 31, 2014 </div>
<div>USD ($) </div>
<div>arrangement</div>
</th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract', window );"><strong>Organization, Consolidation and Presentation of Financial Statements [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Net loss</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">$ (20,626,000)<span></span>
</td>
<td class="num">$ (15,540,000)<span></span>
</td>
<td class="num">$ (58,265,000)<span></span>
</td>
<td class="num">$ (71,649,000)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RestructuringAndRelatedCostNumberOfPositionsEliminatedPeriodPercent', window );">Percentage reduction in force</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">50.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_nlnk_FinancingsLineItems', window );"><strong>Financings</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_nlnk_CollaborativeArrangementNumberofArrangements', window );">Number of license and collaboration arrangements | arrangement</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TypeOfArrangementAxis=us-gaap_CollaborativeArrangementMember', window );">License and Collaborative Arrangement | Genentech</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_nlnk_FinancingsLineItems', window );"><strong>Financings</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueRecognitionMilestoneMethodRevenueRecognized', window );">Upfront cash payments</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 150,000,000<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TypeOfArrangementAxis=us-gaap_CollaborativeArrangementMember', window );">License and Collaborative Arrangement | Merck</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_nlnk_FinancingsLineItems', window );"><strong>Financings</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueRecognitionMilestoneMethodRevenueRecognized', window );">Upfront cash payments</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 20,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 30,000,000<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SubsidiarySaleOfStockAxis=us-gaap_IPOMember', window );">IPO [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_nlnk_FinancingsLineItems', window );"><strong>Financings</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SaleOfStockConsiderationReceivedOnTransaction', window );">FInancing proceeds</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 37,600,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SubsidiarySaleOfStockAxis=nlnk_FollowOnOfferingMember', window );">Follow-on Offering</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_nlnk_FinancingsLineItems', window );"><strong>Financings</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SaleOfStockConsiderationReceivedOnTransaction', window );">FInancing proceeds</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">49,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SubsidiarySaleOfStockAxis=nlnk_ATMOfferingMember', window );">ATM Offering</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_nlnk_FinancingsLineItems', window );"><strong>Financings</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SaleOfStockConsiderationReceivedOnTransaction', window );">FInancing proceeds</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 19,300,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 58,700,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_nlnk_MaximumAvailableUnderATMOffering', window );">Maximum available under ATM offering</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 40,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesNewIssues', window );">Number of shares of common stock sold | shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,940,656<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PaymentsForCommissions', window );">Commissions paid</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 398,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PaymentsOfStockIssuanceCosts', window );">Other costs</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 163,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SubsequentEventTypeAxis=us-gaap_SubsequentEventMember', window );">Subsequent event | Public Offering [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_nlnk_FinancingsLineItems', window );"><strong>Financings</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SaleOfStockConsiderationReceivedOnTransaction', window );">FInancing proceeds</a></td>
<td class="nump">$ 55,200,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FeesAndCommissions', window );">Fees and commissions</a></td>
<td class="nump">$ 3,700,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction', window );">Number of shares issued | shares</a></td>
<td class="nump">5,750,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_nlnk_CollaborativeArrangementNumberofArrangements">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Collaborative Arrangement, Number of Arrangements</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">nlnk_CollaborativeArrangementNumberofArrangements</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>nlnk_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:integerItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_nlnk_FinancingsLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>[Line Items] for Financings [Table]</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">nlnk_FinancingsLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>nlnk_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_nlnk_MaximumAvailableUnderATMOffering">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Maximum value of shares available for sale under a ATM offering.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">nlnk_MaximumAvailableUnderATMOffering</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>nlnk_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FeesAndCommissions">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of fees and commissions from financial services and banking activities and correspondent clearing. Includes fees from depositor accounts, credit cards, merchant discounts, and fiduciary and trust activities, guarantee fees, investment advisory, management, and administrative fees, transfer agent fees, and insurance commissions.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 225<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04.13)<br> -URI http://asc.fasb.org/extlink&amp;oid=6879574&amp;loc=d3e536633-122882<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FeesAndCommissions</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetIncomeLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The portion of profit or loss for the period, net of income taxes, which is attributable to the parent.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -URI http://asc.fasb.org/extlink&amp;oid=98514028&amp;loc=d3e3602-108585<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6371337&amp;loc=d3e3550-109257<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 225<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(22))<br> -URI http://asc.fasb.org/extlink&amp;oid=6879574&amp;loc=d3e536633-122882<br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 225<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(18))<br> -URI http://asc.fasb.org/extlink&amp;oid=6879464&amp;loc=d3e573970-122913<br><br>Reference 5: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 225<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(20))<br> -URI http://asc.fasb.org/extlink&amp;oid=63488584&amp;loc=d3e20235-122688<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetIncomeLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PaymentsForCommissions">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The amount of cash paid for commissions during the current period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 25<br> -Subparagraph (g)<br> -URI http://asc.fasb.org/extlink&amp;oid=98514028&amp;loc=d3e3536-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PaymentsForCommissions</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PaymentsOfStockIssuanceCosts">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The cash outflow for cost incurred directly with the issuance of an equity security.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 15<br> -URI http://asc.fasb.org/extlink&amp;oid=98514028&amp;loc=d3e3291-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PaymentsOfStockIssuanceCosts</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RestructuringAndRelatedCostNumberOfPositionsEliminatedPeriodPercent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The number of positions eliminated during the period as a percentage of total positions eliminated during the period in connection with the restructuring plan(s).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RestructuringAndRelatedCostNumberOfPositionsEliminatedPeriodPercent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RevenueRecognitionMilestoneMethodRevenueRecognized">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The amount of consideration recognized during the period for the milestone or milestones.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 605<br> -SubTopic 28<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (e)<br> -URI http://asc.fasb.org/extlink&amp;oid=68058744&amp;loc=SL6892177-166501<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RevenueRecognitionMilestoneMethodRevenueRecognized</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SaleOfStockConsiderationReceivedOnTransaction">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Cash received on stock transaction after deduction of issuance costs.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SaleOfStockConsiderationReceivedOnTransaction</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The number of shares issued or sold by the subsidiary or equity method investee per stock transaction.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodSharesNewIssues">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of new stock issued during the period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=84159872&amp;loc=d3e21463-112644<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI http://asc.fasb.org/extlink&amp;oid=27012166&amp;loc=d3e187085-122770<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodSharesNewIssues</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TypeOfArrangementAxis=us-gaap_CollaborativeArrangementMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TypeOfArrangementAxis=us-gaap_CollaborativeArrangementMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_LegalEntityAxis=nlnk_GenentechInc.Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_LegalEntityAxis=nlnk_GenentechInc.Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_LegalEntityAxis=nlnk_MerckSharpeandDohmeCorpMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_LegalEntityAxis=nlnk_MerckSharpeandDohmeCorpMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SubsidiarySaleOfStockAxis=us-gaap_IPOMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SubsidiarySaleOfStockAxis=us-gaap_IPOMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SubsidiarySaleOfStockAxis=nlnk_FollowOnOfferingMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SubsidiarySaleOfStockAxis=nlnk_FollowOnOfferingMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SubsidiarySaleOfStockAxis=nlnk_ATMOfferingMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SubsidiarySaleOfStockAxis=nlnk_ATMOfferingMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SubsequentEventTypeAxis=us-gaap_SubsequentEventMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SubsequentEventTypeAxis=us-gaap_SubsequentEventMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SubsidiarySaleOfStockAxis=nlnk_PublicOfferingMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SubsidiarySaleOfStockAxis=nlnk_PublicOfferingMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>36
<FILENAME>R24.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.8.0.1</span><table class="report" border="0" cellspacing="2" id="idp6752454704">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Significant Accounting Policies (Details) - USD ($)<br></strong></div></th>
<th class="th" colspan="1">9 Months Ended</th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th"><div>Sep. 30, 2017</div></th>
<th class="th"><div>Dec. 31, 2016</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccountingPoliciesAbstract', window );"><strong>Accounting Policies [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LongTermDebtAndCapitalLeaseObligationsIncludingCurrentMaturities', window );">Fair Value Disclosure of notes payable and capital lease obligations</a></td>
<td class="nump">$ 332,000<span></span>
</td>
<td class="nump">$ 517,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment', window );">Accumulated depreciation</a></td>
<td class="nump">6,700,000<span></span>
</td>
<td class="nump">5,700,000<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentLineItems', window );"><strong>Property, Plant and Equipment [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_GovernmentContractReceivable', window );">Government contract receivable</a></td>
<td class="nump">10,100,000<span></span>
</td>
<td class="nump">23,900,000<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_GovernmentContractReceivableUnbilledAmounts', window );">Unbilled contracts receivable</a></td>
<td class="nump">1,500,000<span></span>
</td>
<td class="nump">4,300,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_nlnk_GovernmentContractAccruedSubcontractorFees', window );">Accrued expenses for subcontractor fees incurred under government contracts</a></td>
<td class="nump">$ 1,400,000<span></span>
</td>
<td class="nump">$ 2,900,000<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_ComputerEquipmentMember', window );">Computer Equipment | Minimum</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentLineItems', window );"><strong>Property, Plant and Equipment [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentUsefulLife', window );">Useful life</a></td>
<td class="text">3 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_ComputerEquipmentMember', window );">Computer Equipment | Maximum</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentLineItems', window );"><strong>Property, Plant and Equipment [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentUsefulLife', window );">Useful life</a></td>
<td class="text">5 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_EquipmentMember', window );">Lab Equipment</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentLineItems', window );"><strong>Property, Plant and Equipment [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentUsefulLife', window );">Useful life</a></td>
<td class="text">5 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=nlnk_ContractManufacturingOrganizationEquipmentMember', window );">Contract Manufacturing Organization Equipment</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentLineItems', window );"><strong>Property, Plant and Equipment [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentUsefulLife', window );">Useful life</a></td>
<td class="text">5 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_nlnk_GovernmentContractAccruedSubcontractorFees">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Government Contract, Accrued Subcontractor Fees</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">nlnk_GovernmentContractAccruedSubcontractorFees</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>nlnk_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountingPoliciesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountingPoliciesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of accumulated depreciation, depletion and amortization for physical assets used in the normal conduct of business to produce goods and services.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=6391035&amp;loc=d3e2868-110229<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.14)<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_GovernmentContractReceivable">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The amount of receivables that are derived from government contracts.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 912<br> -SubTopic 310<br> -Section 45<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=68054760&amp;loc=d3e55295-109406<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_GovernmentContractReceivable</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_GovernmentContractReceivableUnbilledAmounts">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Unbilled amounts (net of unliquidated progress payments) of government contract receivables.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 912<br> -SubTopic 310<br> -Section 45<br> -Paragraph 9<br> -URI http://asc.fasb.org/extlink&amp;oid=68054760&amp;loc=d3e55376-109406<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_GovernmentContractReceivableUnbilledAmounts</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LongTermDebtAndCapitalLeaseObligationsIncludingCurrentMaturities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of long-term debt and capital lease obligations including current maturities.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LongTermDebtAndCapitalLeaseObligationsIncludingCurrentMaturities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentUsefulLife">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Useful life of long lived, physical assets used in the normal conduct of business and not intended for resale, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days. Examples include, but not limited to, land, buildings, machinery and equipment, office equipment, furniture and fixtures, and computer equipment.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentUsefulLife</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_ComputerEquipmentMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_ComputerEquipmentMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RangeAxis=us-gaap_MinimumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RangeAxis=us-gaap_MinimumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RangeAxis=us-gaap_MaximumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RangeAxis=us-gaap_MaximumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_EquipmentMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_EquipmentMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=nlnk_ContractManufacturingOrganizationEquipmentMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentByTypeAxis=nlnk_ContractManufacturingOrganizationEquipmentMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>37
<FILENAME>R25.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.8.0.1</span><table class="report" border="0" cellspacing="2" id="idp6765426880">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Long-Term Debt (Details)<br></strong></div></th>
<th class="th" colspan="1">1 Months Ended</th>
<th class="th" colspan="3">3 Months Ended</th>
<th class="th" colspan="2">9 Months Ended</th>
</tr>
<tr>
<th class="th">
<div>Mar. 31, 2010 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Sep. 30, 2017 </div>
<div>USD ($) </div>
<div>ft&#178; </div>
<div>position</div>
</th>
<th class="th">
<div>Sep. 30, 2016 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Mar. 31, 2016 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Sep. 30, 2017 </div>
<div>USD ($) </div>
<div>ft&#178; </div>
<div>position</div>
</th>
<th class="th">
<div>Sep. 30, 2016 </div>
<div>USD ($)</div>
</th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueFromGrants', window );">Grant revenue</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 5,379,000<span></span>
</td>
<td class="nump">$ 14,457,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 18,279,000<span></span>
</td>
<td class="nump">$ 20,057,000<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentAxis=nlnk_CityOfAmesForgivableLoan2010Member', window );">City of Ames Forgivable Loan 2010</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueFromGrants', window );">Grant revenue</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 397,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LongtermDebtTypeAxis=us-gaap_LoansPayableMember', window );">Loans Payable | City of Ames Forgivable Loan 2010</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentFaceAmount', window );">Original Available Balance</a></td>
<td class="nump">$ 400,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_nlnk_DebtInstrumentCovenantRequiredNumberofPositionsCreationandRetention', window );">Full-time position requirement (in positions) | position</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">150<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">150<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LesseeLeasingArrangementsOperatingLeasesTermOfContract', window );">Term of lease</a></td>
<td class="text">5 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LesseeLeasingArrangementsOperatingLeasesRenewalTerm', window );">Lease extension term</a></td>
<td class="text">5 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_nlnk_DebtInstrumentCovenantRequiredMinimumLeaseArea', window );">Lease square feet | ft&#178;</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">20,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">20,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_nlnk_DebtInstrumentCovenantRequiredMinimumLeaseArea">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Debt Instrument, Covenant Required, Minimum Lease Area</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">nlnk_DebtInstrumentCovenantRequiredMinimumLeaseArea</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>nlnk_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:areaItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_nlnk_DebtInstrumentCovenantRequiredNumberofPositionsCreationandRetention">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Debt Instrument, Covenant Required, Number of Positions Creation and Retention</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">nlnk_DebtInstrumentCovenantRequiredNumberofPositionsCreationandRetention</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>nlnk_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:integerItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentFaceAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Face (par) amount of debt instrument at time of issuance.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 835<br> -SubTopic 30<br> -Section 55<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=64930739&amp;loc=d3e28878-108400<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 835<br> -SubTopic 30<br> -Section 45<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=64930785&amp;loc=d3e28551-108399<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentFaceAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeLeasingArrangementsOperatingLeasesRenewalTerm">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Term of lessee's operating lease renewal, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (a)(3)<br> -URI http://asc.fasb.org/extlink&amp;oid=77888426&amp;loc=SL77918673-209980<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeLeasingArrangementsOperatingLeasesRenewalTerm</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeLeasingArrangementsOperatingLeasesTermOfContract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Term of lessee's operating lease, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (a)(3)<br> -URI http://asc.fasb.org/extlink&amp;oid=77888426&amp;loc=SL77918673-209980<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeLeasingArrangementsOperatingLeasesTermOfContract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RevenueFromGrants">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Revenue earned during the period from non-repayable sum of money awarded to an entity to carry out a specific purpose as provided in grant agreements.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 225<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03.1(e))<br> -URI http://asc.fasb.org/extlink&amp;oid=63488584&amp;loc=d3e20235-122688<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RevenueFromGrants</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentAxis=nlnk_CityOfAmesForgivableLoan2010Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentAxis=nlnk_CityOfAmesForgivableLoan2010Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LongtermDebtTypeAxis=us-gaap_LoansPayableMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LongtermDebtTypeAxis=us-gaap_LoansPayableMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>38
<FILENAME>R26.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.8.0.1</span><table class="report" border="0" cellspacing="2" id="idp6763840976">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>License and Research Collaboration Agreements (Details) - USD ($)<br></strong></div></th>
<th class="th" colspan="1">1 Months Ended</th>
<th class="th" colspan="2">3 Months Ended</th>
<th class="th" colspan="2">9 Months Ended</th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Feb. 28, 2015</div></th>
<th class="th"><div>Sep. 30, 2017</div></th>
<th class="th"><div>Sep. 30, 2016</div></th>
<th class="th"><div>Sep. 30, 2017</div></th>
<th class="th"><div>Sep. 30, 2016</div></th>
<th class="th"><div>Dec. 31, 2014</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DeferredRevenueArrangementLineItems', window );"><strong>Deferred Revenue Arrangement [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LicensesRevenue', window );">Licensing and collaboration revenue</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 103,000<span></span>
</td>
<td class="nump">$ 888,000<span></span>
</td>
<td class="nump">$ 334,000<span></span>
</td>
<td class="nump">$ 3,008,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TypeOfArrangementAxis=us-gaap_CollaborativeArrangementMember', window );">License and Collaborative Arrangement | Merck</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DeferredRevenueArrangementLineItems', window );"><strong>Deferred Revenue Arrangement [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueRecognitionMilestoneMethodRevenueRecognized', window );">Upfront cash payments</a></td>
<td class="nump">$ 20,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 30,000,000<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LicensesRevenue', window );">Licensing and collaboration revenue</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">764,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TypeOfArrangementAxis=us-gaap_CollaborativeArrangementMember', window );">License and Collaborative Arrangement | Genentech</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DeferredRevenueArrangementLineItems', window );"><strong>Deferred Revenue Arrangement [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueRecognitionMilestoneMethodRevenueRecognized', window );">Upfront cash payments</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 150,000,000<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_nlnk_RevenueRecogitionMilestoneMethodMaximumPotentialRevenue', window );">Genentech potential milestones</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">561,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">561,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LicensesRevenue', window );">Licensing and collaboration revenue</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">56,000<span></span>
</td>
<td class="nump">687,000<span></span>
</td>
<td class="nump">279,000<span></span>
</td>
<td class="nump">2,200,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_nlnk_LicenseRevenueEmployeeLabor', window );">Reimbursement for direct labor</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">486,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,600,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_nlnk_LicenseRevenueManagerLabor', window );">Alliance manager</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 201,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">502,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_nlnk_LicenseRevenueCommitteeLabor', window );">Participation in JRC</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 101,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DeferredRevenue', window );">Deferred revenue</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 112,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 112,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_nlnk_LicenseRevenueCommitteeLabor">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>License Revenue, Committee Labor</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">nlnk_LicenseRevenueCommitteeLabor</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>nlnk_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_nlnk_LicenseRevenueEmployeeLabor">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>License Revenue, Employee Labor</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">nlnk_LicenseRevenueEmployeeLabor</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>nlnk_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_nlnk_LicenseRevenueManagerLabor">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>License Revenue, Manager Labor</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">nlnk_LicenseRevenueManagerLabor</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>nlnk_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_nlnk_RevenueRecogitionMilestoneMethodMaximumPotentialRevenue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Revenue Recogition, Milestone Method, Maximum Potential Revenue</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">nlnk_RevenueRecogitionMilestoneMethodMaximumPotentialRevenue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>nlnk_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredRevenue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of deferred revenue as of balance sheet date. Deferred revenue represents collections of cash or other assets related to a revenue producing activity for which revenue has not yet been recognized. Generally, an entity records deferred revenue when it receives consideration from a customer before achieving certain criteria that must be met for revenue to be recognized in conformity with GAAP.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 605<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 13.A.3)<br> -URI http://asc.fasb.org/extlink&amp;oid=65893310&amp;loc=d3e214044-122780<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 605<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 13.A.4(a).Q1)<br> -URI http://asc.fasb.org/extlink&amp;oid=65893310&amp;loc=d3e214044-122780<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredRevenue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredRevenueArrangementLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredRevenueArrangementLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LicensesRevenue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Revenue earned during the period relating to consideration received from another party for the right to use, but not own, certain of the entity's intangible assets. Licensing arrangements include, but are not limited to, rights to use a patent, copyright, technology, manufacturing process, software or trademark. Licensing fees are generally, but not always, fixed as to amount and not dependent upon the revenue generated by the licensing party. An entity may receive licensing fees for licenses that also generate royalty payments to the entity.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 225<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03.1(e))<br> -URI http://asc.fasb.org/extlink&amp;oid=63488584&amp;loc=d3e20235-122688<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LicensesRevenue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RevenueRecognitionMilestoneMethodRevenueRecognized">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The amount of consideration recognized during the period for the milestone or milestones.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 605<br> -SubTopic 28<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (e)<br> -URI http://asc.fasb.org/extlink&amp;oid=68058744&amp;loc=SL6892177-166501<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RevenueRecognitionMilestoneMethodRevenueRecognized</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TypeOfArrangementAxis=us-gaap_CollaborativeArrangementMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TypeOfArrangementAxis=us-gaap_CollaborativeArrangementMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_LegalEntityAxis=nlnk_MerckSharpeandDohmeCorpMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_LegalEntityAxis=nlnk_MerckSharpeandDohmeCorpMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_LegalEntityAxis=nlnk_GenentechInc.Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_LegalEntityAxis=nlnk_GenentechInc.Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>39
<FILENAME>R27.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.8.0.1</span><table class="report" border="0" cellspacing="2" id="idp6766524304">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Common Stock Equity Incentive Plan (Narrative)(Details) - USD ($)<br></strong></div></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="2">3 Months Ended</th>
<th class="th" colspan="2">9 Months Ended</th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th"><div>Jan. 01, 2017</div></th>
<th class="th"><div>Jan. 01, 2016</div></th>
<th class="th"><div>Jan. 01, 2015</div></th>
<th class="th"><div>Jan. 01, 2014</div></th>
<th class="th"><div>May 09, 2013</div></th>
<th class="th"><div>Jan. 01, 2013</div></th>
<th class="th"><div>Jan. 07, 2011</div></th>
<th class="th"><div>May 15, 2010</div></th>
<th class="th"><div>Sep. 30, 2017</div></th>
<th class="th"><div>Sep. 30, 2016</div></th>
<th class="th"><div>Sep. 30, 2017</div></th>
<th class="th"><div>Sep. 30, 2016</div></th>
<th class="th"><div>Nov. 10, 2011</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-based Compensation Arrangement by Share-based Payment Award</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AllocatedShareBasedCompensationExpense', window );">Share-based compensation expense</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 4,400,000<span></span>
</td>
<td class="nump">$ 3,900,000<span></span>
</td>
<td class="nump">$ 14,900,000<span></span>
</td>
<td class="nump">$ 13,100,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PlanNameAxis=nlnk_A2009EquityIncentivePlanMember', window );">2009 Equity Incentive Plan</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-based Compensation Arrangement by Share-based Payment Award</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized', window );">Number of shares authorized</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">10,238,220<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">10,238,220<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant', window );">Number of shares remained available for issuance</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,094,264<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,094,264<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized', window );">Increase in number of shares authorized</a></td>
<td class="nump">1,166,546<span></span>
</td>
<td class="nump">1,152,565<span></span>
</td>
<td class="nump">1,119,255<span></span>
</td>
<td class="nump">1,066,340<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">838,375<span></span>
</td>
<td class="nump">714,286<span></span>
</td>
<td class="nump">1,238,095<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_nlnk_SharebasedCompensationArrangementbySharebasedPaymentAwardPercentageofAuthorizedStockMaximum', window );">Evergreen increase (percent)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">4.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PlanNameAxis=nlnk_A2010NonEmployeeDirectorsStockOptionPlanMember', window );">2010 Non-Employee Directors' Stock Option Plan</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-based Compensation Arrangement by Share-based Payment Award</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized', window );">Number of shares authorized</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">238,095<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant', window );">Number of shares remained available for issuance</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized', window );">Increase in number of shares authorized</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">161,905<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PlanNameAxis=nlnk_A2010EmployeeStockPurchasePlanMember', window );">2010 Employee Stock Purchase Plan</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-based Compensation Arrangement by Share-based Payment Award</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized', window );">Number of shares authorized</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">214,285<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant', window );">Number of shares remained available for issuance</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">120,784<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">120,784<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized', window );">Increase in number of shares authorized</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">185,715<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AwardTypeAxis=us-gaap_EmployeeStockOptionMember', window );">Stock Option</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-based Compensation Arrangement by Share-based Payment Award</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions', window );">Total compensation cost related to non-vested option awards</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 19,900,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 19,900,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1', window );">Weighted average vesting period for non-vested option awards, in years</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">2 years 1 month 24 days<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue', window );">Intrinsic value of options exercised</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 924,164<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedInPeriodFairValue1', window );">Fair value of awards vested</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">12,400,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AwardTypeAxis=us-gaap_PerformanceSharesMember', window );">Performance Stock</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-based Compensation Arrangement by Share-based Payment Award</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AllocatedShareBasedCompensationExpense', window );">Share-based compensation expense</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 1,200,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod', window );">Granted (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">388,144<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue', window );">Weighted average grant-date fair value per share (in dollars per share)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 6.73<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod', window );">Options exercisable at end of period (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">194,070<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AwardTypeAxis=us-gaap_RestrictedStockMember', window );">Restricted Stock</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-based Compensation Arrangement by Share-based Payment Award</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1', window );">Weighted average vesting period for non-vested option awards, in years</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">1 year 9 months 7 days<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod', window );">Granted (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue', window );">Weighted average grant-date fair value per share (in dollars per share)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0.00<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod', window );">Options exercisable at end of period (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">80,380<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedShareBasedAwardsOtherThanOptions', window );">Unrecognized compensation cost</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">4,400,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 4,400,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AwardTypeAxis=nlnk_PerformanceRestrictedStockMember', window );">Performance Restricted Stock</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-based Compensation Arrangement by Share-based Payment Award</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedShareBasedAwardsOtherThanOptions', window );">Unrecognized compensation cost</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 6,400,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">6,400,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodTotalFairValue', window );">Fair value of restricted stock awards vested</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 814,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_nlnk_SharebasedCompensationArrangementbySharebasedPaymentAwardPercentageofAuthorizedStockMaximum">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Share-based Compensation Arrangement by Share-based Payment Award, Percentage of Authorized Stock Maximum</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">nlnk_SharebasedCompensationArrangementbySharebasedPaymentAwardPercentageofAuthorizedStockMaximum</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>nlnk_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AllocatedShareBasedCompensationExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Represents the expense recognized during the period arising from equity-based compensation arrangements (for example, shares of stock, unit, stock options or other equity instruments) with employees, directors and certain consultants qualifying for treatment as employees.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 14.F)<br> -URI http://asc.fasb.org/extlink&amp;oid=27013229&amp;loc=d3e301413-122809<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=96867065&amp;loc=d3e5047-113901<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (h)(1)(i)<br> -URI http://asc.fasb.org/extlink&amp;oid=96867065&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AllocatedShareBasedCompensationExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Weighted average period over which unrecognized compensation is expected to be recognized for equity-based compensation plans, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (i)<br> -URI http://asc.fasb.org/extlink&amp;oid=96867065&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedShareBasedAwardsOtherThanOptions">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Unrecognized cost of unvested share-based awards, other than options, awarded to employees as compensation.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (i)<br> -URI http://asc.fasb.org/extlink&amp;oid=96867065&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedShareBasedAwardsOtherThanOptions</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Unrecognized cost of unvested options awarded to employees as compensation.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (i)<br> -URI http://asc.fasb.org/extlink&amp;oid=96867065&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The number of grants made during the period on other than stock (or unit) option plans (for example, phantom stock or unit plan, stock or unit appreciation rights plan, performance target plan).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(iii)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=96867065&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The weighted average fair value at grant date for nonvested equity-based awards issued during the period on other than stock (or unit) option plans (for example, phantom stock or unit plan, stock or unit appreciation rights plan, performance target plan).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(iii)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=96867065&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The number of equity-based payment instruments, excluding stock (or unit) options, that vested during the reporting period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(iii)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=96867065&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodTotalFairValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Fair value of share-based awards for which the grantee gained the right by satisfying service and performance requirements, to receive or retain shares or units, other instruments, or cash.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (d)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=96867065&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodTotalFairValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of additional shares authorized for issuance under an established share-based compensation plan.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The maximum number of shares (or other type of equity) originally approved (usually by shareholders and board of directors), net of any subsequent amendments and adjustments, for awards under the equity-based compensation plan. As stock or unit options and equity instruments other than options are awarded to participants, the shares or units remain authorized and become reserved for issuance under outstanding awards (not necessarily vested).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(3)<br> -URI http://asc.fasb.org/extlink&amp;oid=96867065&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The difference between the maximum number of shares (or other type of equity) authorized for issuance under the plan (including the effects of amendments and adjustments), and the sum of: 1) the number of shares (or other type of equity) already issued upon exercise of options or other equity-based awards under the plan; and 2) shares (or other type of equity) reserved for issuance on granting of outstanding awards, net of cancellations and forfeitures, if applicable.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=96867065&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of accumulated difference between fair value of underlying shares on dates of exercise and exercise price on options exercised (or share units converted) into shares.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (d)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=96867065&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedInPeriodFairValue1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Fair value of options vested. Excludes equity instruments other than options, for example, but not limited to, share units, stock appreciation rights, restricted stock.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=96867065&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedInPeriodFairValue1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PlanNameAxis=nlnk_A2009EquityIncentivePlanMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PlanNameAxis=nlnk_A2009EquityIncentivePlanMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PlanNameAxis=nlnk_A2010NonEmployeeDirectorsStockOptionPlanMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PlanNameAxis=nlnk_A2010NonEmployeeDirectorsStockOptionPlanMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PlanNameAxis=nlnk_A2010EmployeeStockPurchasePlanMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PlanNameAxis=nlnk_A2010EmployeeStockPurchasePlanMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AwardTypeAxis=us-gaap_EmployeeStockOptionMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AwardTypeAxis=us-gaap_EmployeeStockOptionMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AwardTypeAxis=us-gaap_PerformanceSharesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AwardTypeAxis=us-gaap_PerformanceSharesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AwardTypeAxis=us-gaap_RestrictedStockMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AwardTypeAxis=us-gaap_RestrictedStockMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AwardTypeAxis=nlnk_PerformanceRestrictedStockMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AwardTypeAxis=nlnk_PerformanceRestrictedStockMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>40
<FILENAME>R28.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.8.0.1</span><table class="report" border="0" cellspacing="2" id="idp6753218496">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Common Stock Equity Incentive Plan (Authorized Increases of Common Stock) (Details) - shares<br></strong></div></th>
<th class="th"><div>Jan. 01, 2017</div></th>
<th class="th"><div>Jan. 01, 2016</div></th>
<th class="th"><div>Jan. 01, 2015</div></th>
<th class="th"><div>Jan. 01, 2014</div></th>
<th class="th"><div>Jan. 01, 2013</div></th>
<th class="th"><div>Jan. 07, 2011</div></th>
<th class="th"><div>May 15, 2010</div></th>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PlanNameAxis=nlnk_A2009EquityIncentivePlanMember', window );">2009 Equity Incentive Plan</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-based Compensation Arrangement by Share-based Payment Award</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized', window );">Authorized Shares Added</a></td>
<td class="nump">1,166,546<span></span>
</td>
<td class="nump">1,152,565<span></span>
</td>
<td class="nump">1,119,255<span></span>
</td>
<td class="nump">1,066,340<span></span>
</td>
<td class="nump">838,375<span></span>
</td>
<td class="nump">714,286<span></span>
</td>
<td class="nump">1,238,095<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of additional shares authorized for issuance under an established share-based compensation plan.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PlanNameAxis=nlnk_A2009EquityIncentivePlanMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PlanNameAxis=nlnk_A2009EquityIncentivePlanMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>41
<FILENAME>R29.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.8.0.1</span><table class="report" border="0" cellspacing="2" id="idp6752913504">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Common Stock Equity Incentive Plan (Stock Option Activity) (Details) - Stock Option - $ / shares<br></strong></div></th>
<th class="th" colspan="1">9 Months Ended</th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Sep. 30, 2017</div></th>
<th class="th"><div>Dec. 31, 2016</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward', window );"><strong>Number of options</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber', window );">Outstanding at beginning of period (in shares)</a></td>
<td class="nump">6,278,542<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross', window );">Options granted (in shares)</a></td>
<td class="nump">1,439,287<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised', window );">Options exercised (in shares)</a></td>
<td class="num">(108,775)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod', window );">Options forfeited (in shares)</a></td>
<td class="num">(277,443)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod', window );">Options expired (in shares)</a></td>
<td class="num">(17,605)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber', window );">Outstanding at end of period (in shares)</a></td>
<td class="nump">7,314,006<span></span>
</td>
<td class="nump">6,278,542<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward', window );"><strong>Weighted average exercise price</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice', window );">Outstanding, weighted average exercise price at beginning of period (in dollars per share)</a></td>
<td class="nump">$ 14.93<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice', window );">Granted, weighted average exercise price (in dollars per share)</a></td>
<td class="nump">11.78<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice', window );">Exercised, weighted average exercise price (in dollars per share)</a></td>
<td class="nump">8.51<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice', window );">Forfeitured, weighted average exercise price (in dollars per share)</a></td>
<td class="nump">20.13<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExpirationsInPeriodWeightedAverageExercisePrice', window );">Expired, weighted average exercise price (in dollars per share)</a></td>
<td class="nump">42.00<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice', window );">Outstanding, weighted average exercise price at end of period (in dollars per share)</a></td>
<td class="nump">$ 14.15<span></span>
</td>
<td class="nump">$ 14.93<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber', window );">Options exercisable at end of period (in shares)</a></td>
<td class="nump">5,456,602<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice', window );">Exercisable, weighted average exercise price (in dollars per share)</a></td>
<td class="nump">$ 12.65<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2', window );">Outstanding, weighted average remaining contractual term, in years</a></td>
<td class="text">5 years 6 months 15 days<span></span>
</td>
<td class="text">5 years 9 months 18 days<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1', window );">Exercisable, weighted average remaining contractual term, in years</a></td>
<td class="text">4 years 5 months 12 days<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The number of shares into which fully or partially vested stock options outstanding as of the balance sheet date can be currently converted under the option plan.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iii)<br> -URI http://asc.fasb.org/extlink&amp;oid=96867065&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The weighted-average price as of the balance sheet date at which grantees can acquire the shares reserved for issuance on vested portions of options outstanding and currently exercisable under the stock option plan.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iii)<br> -URI http://asc.fasb.org/extlink&amp;oid=96867065&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of options or other stock instruments for which the right to exercise has lapsed under the terms of the plan agreements.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(4)<br> -URI http://asc.fasb.org/extlink&amp;oid=96867065&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The number of shares under options that were cancelled during the reporting period as a result of occurrence of a terminating event specified in contractual agreements pertaining to the stock option plan.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(3)<br> -URI http://asc.fasb.org/extlink&amp;oid=96867065&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Gross number of share options (or share units) granted during the period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of options outstanding, including both vested and non-vested options.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=96867065&amp;loc=d3e5070-113901<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(i)-(ii)<br> -URI http://asc.fasb.org/extlink&amp;oid=96867065&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>A roll forward is a reconciliation of a concept from the beginning of a period to the end of a period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Weighted average price at which grantees can acquire the shares reserved for issuance under the stock option plan.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(i)<br> -URI http://asc.fasb.org/extlink&amp;oid=96867065&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Weighted average price at which option holders acquired shares when converting their stock options into shares.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExpirationsInPeriodWeightedAverageExercisePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Weighted average price at which grantees could have acquired the underlying shares with respect to stock options of the plan that expired.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExpirationsInPeriodWeightedAverageExercisePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Weighted average price at which grantees could have acquired the underlying shares with respect to stock options that were terminated.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Weighted average per share amount at which grantees can acquire shares of common stock by exercise of options.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Weighted average remaining contractual term for vested portions of options outstanding and currently exercisable or convertible, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=96867065&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Weighted average remaining contractual term for option awards outstanding, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (e)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=96867065&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of share options (or share units) exercised during the current period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=84159872&amp;loc=d3e21463-112644<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI http://asc.fasb.org/extlink&amp;oid=27012166&amp;loc=d3e187085-122770<br><br>Reference 5: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=96867065&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AwardTypeAxis=us-gaap_EmployeeStockOptionMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AwardTypeAxis=us-gaap_EmployeeStockOptionMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>42
<FILENAME>R30.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.8.0.1</span><table class="report" border="0" cellspacing="2" id="idp6753313120">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Common Stock Equity Incentive Plan (Range of Assumptions Used) (Details) - Stock Option<br></strong></div></th>
<th class="th" colspan="1">9 Months Ended</th>
</tr>
<tr><th class="th">
<div>Sep. 30, 2017 </div>
<div>$ / shares</div>
</th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-based Compensation Arrangement by Share-based Payment Award</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum', window );">Risk-free interest rate, minimum (percent)</a></td>
<td class="nump">1.90%<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum', window );">Risk free interest rate, maximum (percent)</a></td>
<td class="nump">2.20%<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate', window );">Expected dividend rate (percent)</a></td>
<td class="nump">0.00%<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum', window );">Volatility rate, minimum (percent)</a></td>
<td class="nump">68.90%<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum', window );">Volatility rate, maximum (percent)</a></td>
<td class="nump">73.20%<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue', window );">Weighted average grant-date fair value per share (in dollars per share)</a></td>
<td class="nump">$ 7.81<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AwardTypeAxis=us-gaap_EmployeeStockOptionMember', window );">Minimum</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-based Compensation Arrangement by Share-based Payment Award</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1', window );">Expected Term (in years)</a></td>
<td class="text">6 years 6 months<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AwardTypeAxis=us-gaap_EmployeeStockOptionMember', window );">Maximum</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-based Compensation Arrangement by Share-based Payment Award</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1', window );">Expected Term (in years)</a></td>
<td class="text">7 years 9 months 18 days<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The estimated dividend rate (a percentage of the share price) to be paid (expected dividends) to holders of the underlying shares over the option's term.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(iii)<br> -URI http://asc.fasb.org/extlink&amp;oid=96867065&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The estimated measure of the maximum percentage by which a share price is expected to fluctuate during a period. Volatility also may be defined as a probability-weighted measure of the dispersion of returns about the mean. The volatility of a share price is the standard deviation of the continuously compounded rates of return on the share over a specified period. That is the same as the standard deviation of the differences in the natural logarithms of the stock prices plus dividends, if any, over the period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The estimated measure of the minimum percentage by which a share price is expected to fluctuate during a period. Volatility also may be defined as a probability-weighted measure of the dispersion of returns about the mean. The volatility of a share price is the standard deviation of the continuously compounded rates of return on the share over a specified period. That is the same as the standard deviation of the differences in the natural logarithms of the stock prices plus dividends, if any, over the period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The maximum risk-free interest rate assumption that is used in valuing an option on its own shares.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The minimum risk-free interest rate assumption that is used in valuing an option on its own shares.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The weighted average grant-date fair value of options granted during the reporting period as calculated by applying the disclosed option pricing methodology.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (d)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=96867065&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Expected term of share-based compensation awards, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(i)<br> -URI http://asc.fasb.org/extlink&amp;oid=96867065&amp;loc=d3e5070-113901<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 14.D.2)<br> -URI http://asc.fasb.org/extlink&amp;oid=27013229&amp;loc=d3e301413-122809<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AwardTypeAxis=us-gaap_EmployeeStockOptionMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AwardTypeAxis=us-gaap_EmployeeStockOptionMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RangeAxis=us-gaap_MinimumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RangeAxis=us-gaap_MinimumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RangeAxis=us-gaap_MaximumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RangeAxis=us-gaap_MaximumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>43
<FILENAME>R31.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.8.0.1</span><table class="report" border="0" cellspacing="2" id="idp6752310448">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Common Stock Equity Incentive Plan (Restricted Stock Activity) (Details) - Restricted Stock<br></strong></div></th>
<th class="th" colspan="1">9 Months Ended</th>
</tr>
<tr><th class="th">
<div>Sep. 30, 2017 </div>
<div>$ / shares </div>
<div>shares</div>
</th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingRollForward', window );"><strong>Share-based Compensation Arrangement by Share-based Payment Award, Non-Option Equity Instruments, Outstanding [Roll Forward]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber', window );">Unvested at beginning of period (in shares) | shares</a></td>
<td class="nump">288,964<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod', window );">Granted (in shares) | shares</a></td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod', window );">Vested (in shares) | shares</a></td>
<td class="num">(80,380)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod', window );">Forfeited / cancelled (in shares) | shares</a></td>
<td class="num">(27,248)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber', window );">Unvested at end of period (in shares) | shares</a></td>
<td class="nump">181,336<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedWeightedAverageGrantDateFairValueAbstract', window );"><strong>Share-based Compensation Arrangement by Share-based Payment Award, Options, Nonvested, Weighted Average Grant Date Fair Value [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue', window );">Weighted average grant date fair value at beginning of period (in dollars per share) | $ / shares</a></td>
<td class="nump">$ 34.94<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue', window );">Weighted average grant-date fair value per share (in dollars per share) | $ / shares</a></td>
<td class="nump">0.00<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue', window );">Vested, weighted average grant date fair value (in dollars per share) | $ / shares</a></td>
<td class="nump">35.04<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue', window );">Forfeited/cancelled, weighted average grant date fair value (in dollars per share) | $ / shares</a></td>
<td class="nump">33.84<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue', window );">Weighted average grant date fair value at end of period (in dollars per share) | $ / shares</a></td>
<td class="nump">$ 35.05<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The number of equity-based payment instruments, excluding stock (or unit) options, that were forfeited during the reporting period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(3)<br> -URI http://asc.fasb.org/extlink&amp;oid=96867065&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Weighted average fair value as of the grant date of equity-based award plans other than stock (unit) option plans that were not exercised or put into effect as a result of the occurrence of a terminating event.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(iii)(3)<br> -URI http://asc.fasb.org/extlink&amp;oid=96867065&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The number of grants made during the period on other than stock (or unit) option plans (for example, phantom stock or unit plan, stock or unit appreciation rights plan, performance target plan).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(iii)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=96867065&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The weighted average fair value at grant date for nonvested equity-based awards issued during the period on other than stock (or unit) option plans (for example, phantom stock or unit plan, stock or unit appreciation rights plan, performance target plan).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(iii)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=96867065&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The number of non-vested equity-based payment instruments, excluding stock (or unit) options, that validly exist and are outstanding as of the balance sheet date.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(i)-(ii)<br> -URI http://asc.fasb.org/extlink&amp;oid=96867065&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The weighted average fair value of nonvested awards on equity-based plans excluding option plans (for example, phantom stock or unit plan, stock or unit appreciation rights plan, revenue or profit achievement stock award plan) for which the employer is contingently obligated to issue equity instruments or transfer assets to an employee who has not yet satisfied service or performance criteria necessary to gain title to proceeds from the sale of the award or underlying shares or units.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(i)-(ii)<br> -URI http://asc.fasb.org/extlink&amp;oid=96867065&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The number of equity-based payment instruments, excluding stock (or unit) options, that vested during the reporting period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(iii)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=96867065&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The weighted average fair value as of grant date pertaining to an equity-based award plan other than a stock (or unit) option plan for which the grantee gained the right during the reporting period, by satisfying service and performance requirements, to receive or retain shares or units, other instruments, or cash in accordance with the terms of the arrangement.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(iii)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=96867065&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingRollForward">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>A roll forward is a reconciliation of a concept from the beginning of a period to the end of a period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingRollForward</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedWeightedAverageGrantDateFairValueAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedWeightedAverageGrantDateFairValueAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AwardTypeAxis=us-gaap_RestrictedStockMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AwardTypeAxis=us-gaap_RestrictedStockMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>44
<FILENAME>R32.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.8.0.1</span><table class="report" border="0" cellspacing="2" id="idp6753263808">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Income Taxes (Details) - USD ($)<br></strong></div></th>
<th class="th" colspan="2">3 Months Ended</th>
<th class="th" colspan="2">9 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Sep. 30, 2017</div></th>
<th class="th"><div>Sep. 30, 2016</div></th>
<th class="th"><div>Sep. 30, 2017</div></th>
<th class="th"><div>Sep. 30, 2016</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeTaxDisclosureAbstract', window );"><strong>Income Tax Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeTaxExpenseBenefit', window );">Income tax benefit</a></td>
<td class="nump">$ 119,000<span></span>
</td>
<td class="nump">$ 1,308,000<span></span>
</td>
<td class="nump">$ 429,000<span></span>
</td>
<td class="nump">$ 5,021,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LiabilityForUncertainTaxPositionsCurrent', window );">Uncertain tax positions</a></td>
<td class="nump">$ 843,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 843,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxExpenseBenefit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of current income tax expense (benefit) and deferred income tax expense (benefit) pertaining to continuing operations.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 9<br> -Subparagraph (a),(b)<br> -URI http://asc.fasb.org/extlink&amp;oid=84230637&amp;loc=d3e32639-109319<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08.(h))<br> -URI http://asc.fasb.org/extlink&amp;oid=26873400&amp;loc=d3e23780-122690<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxExpenseBenefit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LiabilityForUncertainTaxPositionsCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount recognized for uncertainty in income taxes classified as current.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.20)<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LiabilityForUncertainTaxPositionsCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>45
<FILENAME>R33.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.8.0.1</span><table class="report" border="0" cellspacing="2" id="idp6653683344">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Net Loss per Common Share (Net Loss Per Share Computation) (Details) - USD ($)<br> $ / shares in Units, $ in Thousands</strong></div></th>
<th class="th" colspan="2">3 Months Ended</th>
<th class="th" colspan="2">9 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Sep. 30, 2017</div></th>
<th class="th"><div>Sep. 30, 2016</div></th>
<th class="th"><div>Sep. 30, 2017</div></th>
<th class="th"><div>Sep. 30, 2016</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EarningsPerShareAbstract', window );"><strong>Earnings Per Share [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Loss attributable to common stockholders</a></td>
<td class="num">$ (20,626)<span></span>
</td>
<td class="num">$ (15,540)<span></span>
</td>
<td class="num">$ (58,265)<span></span>
</td>
<td class="num">$ (71,649)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_WeightedAverageNumberOfShareOutstandingBasicAndDiluted', window );">Basic and diluted weighted-average shares outstanding (in shares)</a></td>
<td class="nump">29,939,823<span></span>
</td>
<td class="nump">28,983,561<span></span>
</td>
<td class="nump">29,462,226<span></span>
</td>
<td class="nump">28,911,042<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EarningsPerShareBasicAndDiluted', window );">Basic and diluted loss per share (in dollars per share)</a></td>
<td class="num">$ (0.69)<span></span>
</td>
<td class="num">$ (0.54)<span></span>
</td>
<td class="num">$ (1.98)<span></span>
</td>
<td class="num">$ (2.48)<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerShareAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerShareAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerShareBasicAndDiluted">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The amount of net income or loss for the period per each share in instances when basic and diluted earnings per share are the same amount and reported as a single line item on the face of the financial statements.  Basic earnings per share is the amount of net income or loss for the period per each share of common stock or unit outstanding during the reporting period.  Diluted earnings per share includes the amount of net income or loss for the period available to each share of common stock or common unit outstanding during the reporting period and to each share or unit that would have been outstanding assuming the issuance of common shares or units for all dilutive potential common shares or units outstanding during the reporting period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerShareBasicAndDiluted</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetIncomeLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The portion of profit or loss for the period, net of income taxes, which is attributable to the parent.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -URI http://asc.fasb.org/extlink&amp;oid=98514028&amp;loc=d3e3602-108585<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6371337&amp;loc=d3e3550-109257<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 225<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(22))<br> -URI http://asc.fasb.org/extlink&amp;oid=6879574&amp;loc=d3e536633-122882<br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 225<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(18))<br> -URI http://asc.fasb.org/extlink&amp;oid=6879464&amp;loc=d3e573970-122913<br><br>Reference 5: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 225<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(20))<br> -URI http://asc.fasb.org/extlink&amp;oid=63488584&amp;loc=d3e20235-122688<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetIncomeLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_WeightedAverageNumberOfShareOutstandingBasicAndDiluted">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Average number of shares or units issued and outstanding that are used in calculating basic and diluted earnings per share (EPS).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_WeightedAverageNumberOfShareOutstandingBasicAndDiluted</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>46
<FILENAME>R34.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.8.0.1</span><table class="report" border="0" cellspacing="2" id="idp6753030672">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Net Loss per Common Share (Antidilutive Securities) (Details) - shares<br></strong></div></th>
<th class="th" colspan="2">3 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Sep. 30, 2017</div></th>
<th class="th"><div>Sep. 30, 2016</div></th>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=us-gaap_EmployeeStockOptionMember', window );">Stock Option</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems', window );"><strong>Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount', window );">Antidilutive securities (in shares)</a></td>
<td class="nump">7,314,006<span></span>
</td>
<td class="nump">6,453,331<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=us-gaap_RestrictedStockMember', window );">Restricted Stock</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems', window );"><strong>Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount', window );">Antidilutive securities (in shares)</a></td>
<td class="nump">181,336<span></span>
</td>
<td class="nump">307,079<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Securities (including those issuable pursuant to contingent stock agreements) that could potentially dilute basic earnings per share (EPS) or earnings per unit (EPU) in the future that were not included in the computation of diluted EPS or EPU because to do so would increase EPS or EPU amounts or decrease loss per share or unit amounts for the period presented.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=6371337&amp;loc=d3e3550-109257<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=us-gaap_EmployeeStockOptionMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=us-gaap_EmployeeStockOptionMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=us-gaap_RestrictedStockMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=us-gaap_RestrictedStockMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>47
<FILENAME>R35.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.8.0.1</span><table class="report" border="0" cellspacing="2" id="idp6752608768">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Restructuring Charges (Details) - USD ($)<br></strong></div></th>
<th class="th" colspan="1">1 Months Ended</th>
<th class="th" colspan="1">3 Months Ended</th>
<th class="th" colspan="1">9 Months Ended</th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Jul. 31, 2017</div></th>
<th class="th"><div>Sep. 30, 2017</div></th>
<th class="th"><div>Sep. 30, 2017</div></th>
<th class="th"><div>Dec. 31, 2016</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RestructuringCostAndReserveLineItems', window );"><strong>Restructuring Charges</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RestructuringAndRelatedCostNumberOfPositionsEliminatedPeriodPercent', window );">Percentage reduction in force</a></td>
<td class="nump">50.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TangibleAssetImpairmentCharges', window );">Asset impairment charges</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 4,000,000<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RestructuringReserveRollForward', window );"><strong>Restructuring Reserve [Roll Forward]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RestructuringReserve', window );">Balance at beginning of period</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 42,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RestructuringCharges', window );">Expensed</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,695,000<span></span>
</td>
<td class="nump">12,300,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PaymentsForRestructuring', window );">Cash Payments</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,085,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RestructuringReserve', window );">Balance at end of period</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 652,000<span></span>
</td>
<td class="nump">652,000<span></span>
</td>
<td class="nump">42,000<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeStatementLocationAxis=us-gaap_GeneralAndAdministrativeExpenseMember', window );">General and Administrative Expense [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RestructuringReserveRollForward', window );"><strong>Restructuring Reserve [Roll Forward]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RestructuringCharges', window );">Expensed</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">500,000<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeStatementLocationAxis=us-gaap_ResearchAndDevelopmentExpenseMember', window );">Research and Development Expense [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RestructuringReserveRollForward', window );"><strong>Restructuring Reserve [Roll Forward]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RestructuringCharges', window );">Expensed</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">11,800,000<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RestructuringCostAndReserveAxis=us-gaap_EmployeeSeveranceMember', window );">Employee Severance Cost</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RestructuringReserveRollForward', window );"><strong>Restructuring Reserve [Roll Forward]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RestructuringReserve', window );">Balance at beginning of period</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">42,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RestructuringCharges', window );">Expensed</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,700,000<span></span>
</td>
<td class="nump">1,695,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PaymentsForRestructuring', window );">Cash Payments</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,085,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RestructuringReserve', window );">Balance at end of period</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">652,000<span></span>
</td>
<td class="nump">652,000<span></span>
</td>
<td class="nump">$ 42,000<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RestructuringPlanAxis=nlnk_TwoThousandSixteenRestructuringPlanMember', window );">2016 Restructuring Plan</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RestructuringReserveRollForward', window );"><strong>Restructuring Reserve [Roll Forward]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RestructuringCharges', window );">Expensed</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PaymentsForRestructuring">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of cash payments made as the result of exit or disposal activities. Excludes payments associated with a discontinued operation or an asset retirement obligation.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 420<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=6394359&amp;loc=d3e17939-110869<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 25<br> -URI http://asc.fasb.org/extlink&amp;oid=98514028&amp;loc=d3e3536-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PaymentsForRestructuring</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RestructuringAndRelatedCostNumberOfPositionsEliminatedPeriodPercent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The number of positions eliminated during the period as a percentage of total positions eliminated during the period in connection with the restructuring plan(s).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RestructuringAndRelatedCostNumberOfPositionsEliminatedPeriodPercent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RestructuringCharges">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of expenses associated with exit or disposal activities pursuant to an authorized plan. Excludes expenses related to a discontinued operation or an asset retirement obligation.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 420<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 5.P.3)<br> -URI http://asc.fasb.org/extlink&amp;oid=27011515&amp;loc=d3e140864-122747<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=98514028&amp;loc=d3e3602-108585<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 420<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=6394359&amp;loc=d3e17939-110869<br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 420<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SAB Topic 5.P.4(b))<br> -URI http://asc.fasb.org/extlink&amp;oid=27011515&amp;loc=d3e140904-122747<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RestructuringCharges</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RestructuringCostAndReserveLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RestructuringCostAndReserveLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RestructuringReserve">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Carrying amount (including both current and noncurrent portions of the accrual) as of the balance sheet date pertaining to a specified type of cost associated with exit from or disposal of business activities or restructuring pursuant to a duly authorized plan.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 420<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SAB TOPIC 5.P.4(b))<br> -URI http://asc.fasb.org/extlink&amp;oid=27011515&amp;loc=d3e140904-122747<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 420<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=6394359&amp;loc=d3e17939-110869<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RestructuringReserve</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RestructuringReserveRollForward">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>A roll forward is a reconciliation of a concept from the beginning of a period to the end of a period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RestructuringReserveRollForward</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TangibleAssetImpairmentCharges">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The charge against earnings resulting from the aggregate write down of tangible assets from their carrying value to their fair value.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=84176398&amp;loc=d3e2921-110230<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=64827811&amp;loc=d3e1361-107760<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TangibleAssetImpairmentCharges</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeStatementLocationAxis=us-gaap_GeneralAndAdministrativeExpenseMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeStatementLocationAxis=us-gaap_GeneralAndAdministrativeExpenseMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeStatementLocationAxis=us-gaap_ResearchAndDevelopmentExpenseMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeStatementLocationAxis=us-gaap_ResearchAndDevelopmentExpenseMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RestructuringCostAndReserveAxis=us-gaap_EmployeeSeveranceMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RestructuringCostAndReserveAxis=us-gaap_EmployeeSeveranceMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RestructuringPlanAxis=nlnk_TwoThousandSixteenRestructuringPlanMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RestructuringPlanAxis=nlnk_TwoThousandSixteenRestructuringPlanMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>48
<FILENAME>R36.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.8.0.1</span><table class="report" border="0" cellspacing="2" id="idp6907573664">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Subsequent Events (Details) - Subsequent event - Public Offering [Member]<br> $ in Millions</strong></div></th>
<th class="th">
<div>Oct. 06, 2017 </div>
<div>USD ($) </div>
<div>shares</div>
</th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SubsequentEventLineItems', window );"><strong>Subsequent Event [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction', window );">Number of shares issued | shares</a></td>
<td class="nump">5,750,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SaleOfStockConsiderationReceivedOnTransaction', window );">FInancing proceeds</a></td>
<td class="nump">$ 55.2<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FeesAndCommissions', window );">Fees and commissions</a></td>
<td class="nump">$ 3.7<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FeesAndCommissions">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of fees and commissions from financial services and banking activities and correspondent clearing. Includes fees from depositor accounts, credit cards, merchant discounts, and fiduciary and trust activities, guarantee fees, investment advisory, management, and administrative fees, transfer agent fees, and insurance commissions.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 225<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04.13)<br> -URI http://asc.fasb.org/extlink&amp;oid=6879574&amp;loc=d3e536633-122882<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FeesAndCommissions</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SaleOfStockConsiderationReceivedOnTransaction">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Cash received on stock transaction after deduction of issuance costs.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SaleOfStockConsiderationReceivedOnTransaction</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The number of shares issued or sold by the subsidiary or equity method investee per stock transaction.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SubsequentEventLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Detail information of subsequent event by type. User is expected to use existing line items from elsewhere in the taxonomy as the primary line items for this disclosure, which is further associated with dimension and member elements pertaining to a subsequent event.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SubsequentEventLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SubsequentEventTypeAxis=us-gaap_SubsequentEventMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SubsequentEventTypeAxis=us-gaap_SubsequentEventMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SubsidiarySaleOfStockAxis=nlnk_PublicOfferingMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SubsidiarySaleOfStockAxis=nlnk_PublicOfferingMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EXCEL
<SEQUENCE>49
<FILENAME>Financial_Report.xlsx
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
begin 644 Financial_Report.xlsx
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MMWF\81AU8\K(XK%T-8943OTJDH\ Q:X831F:3LTXXFBD(3^ G/,6+V2?$9/
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MZ-!3 EYR8'*:&$YCU\(5,,$(HTO?!30+<:[^B9T[P,[),=DE-0Q#.31S+N_
MX>WI\65>M[ ^D?(:\Z]D!9T"KMEE\FOSL-EMF:PKOBHX+ZIFQVMQNQ+5_?OD
M^L/O*NQZ8_?V'QM?!&4+O^Y"?@%02P,$%     @ ^V5C2YE<G",0!@  G"<
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M.AQG0GS/]O:1I24RS^_Y"NM./&<?5I:P7<_/Y)Z,<B.[W?98??9/1VXCUZG
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MBESP/A##W^J(*0KXC/5AEL9HS\[NZ6REMCZ** </XV9$' 8$FB'@A #:]R2
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M.2T8O2HSS?1<#"UD6"C>C>T13#VZ^ -02P,$%     @ ^V5C2_DF%!#= P
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M;F+5YMU]UG4D:_N[.AK^,*S^ 5!+ P04    " #[96-+8<Y[?40$  "8$P
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MN5\I B1U5\L&B7Q%*V&*$B@4R?.=(HP]0MAS04P2:!0E,KF@6M29AS.$L4<
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MU"Z8[[UMIC6;'(?]_(+8\HR+7U!+ P04    " #[96-+"LD5[+ !  #2 P
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MQN/+QOY7QGA *9LK'*$&/]AL2*A\.-[@V8YC-AK>=-,/8O,WSC\ 4$L#!!0
M   ( /ME8TOZF4!<M0$  -(#   9    >&PO=V]R:W-H965T<R]S:&5E=#$T
M+GAM;'U386_;(!#]*X@?4!([7;/(MM1TFE:IE:).VSX3^VRC N<!CMM_/\"N
MY[76O@!WW'OW[CBR <VS;0$<>5%2VYRVSG4'QFS9@N+V"CO0_J9&H[CSIFF8
M[0SP*H*49,EF\XDI+C0MLN@[F2+#WDFAX62([97BYO4($H><;NF;XTDTK0L.
M5F0=;^ [N!_=R7B+S2R54*"M0$T,U#F]W1Z.NQ ? WX*&.SB3$(E9\3G8-Q7
M.=T$02"A=(&!^^T"=R!E(/(R?D^<=$X9@,OS&_O76+NOY<PMW*'\)2K7YG1/
M204U[Z5[PN$;3/5<4S(5_P 7D#X\*/$Y2I0VKJ3LK4,UL7@IBK^,N]!Q'\:;
M-)U@ZX!D B0S8!_SL#%15/Z%.UYD!@=BQMYW/#SQ]I#XWI3!&5L1[[QXZ[V7
M8GM]D[%+()IBCF-,LHR9(YAGGU,D:RF.R0=XL@Y/5Q6F$9[^HW"_3K!;)=A%
M@MU_2UR+^?PN"5OT5(%IXC194F*OXR0OO// WB;Q3?Z&C]/^R$TCM"5G=/YE
M8_]K1 =>RN;*CU#K/]AL2*A=.-[XLQG';#0<=M,/8O,W+OX 4$L#!!0    (
M /ME8TL2JSP/L@$  -(#   9    >&PO=V]R:W-H965T<R]S:&5E=#$U+GAM
M;'U3VV[;, S]%4$?4#E*UA6!;:#I,*S !@0=MCXK-GU!=7$E.>[^?I3LN&[G
M]442*9[#0XI*!V.?7 /@R8N2VF6T\;[;,^:*!I1P5Z8#C3>5L4IX-&W-7&=!
ME!&D).-)<LV4:#7-T^@[VCPUO9>MAJ,EKE=*V#\'D&;(Z(9>' ]MW?C@8'G:
MB1I^@O_5'2U:;&8I6P7:M483"U5&;S?[PR[$QX#?+0QN<2:ADI,Q3\&X+S.:
M!$$@H?"!0>!VACN0,A"AC.>)D\XI W!YOK!_C;5C+2?AX,[(Q[;T349O*"FA
M$KWT#V;X!E,]GRB9BO\.9Y 8'I1@CL)(%U=2],X;-;&@%"5>QKW5<1_&F^T%
MM@[@$X#/@)L(8&.BJ/R+\")/K1F('7O?B?#$FSW'WA3!&5L1[U"\0^\YWUPG
M*3L'HBGF,,;P9<P<P9!]3L'74ASX/W"^#M^N*MQ&^/:-PO_DWZT2["+![L,2
MUV+>JV2+GBJP=9PF1PK3ZSC)"^\\L+<\OLEK^#CM/X2M6^W(R7A\V=C_RA@/
M*"6YPA%J\(/-AH3*A^-G/-MQS$;#FV[Z06S^QOE?4$L#!!0    ( /ME8TL+
M.T_EM $  -(#   9    >&PO=V]R:W-H965T<R]S:&5E=#$V+GAM;'U3VV[<
M(!#]%<0'A%W625<KVU(V4=5(K;1*U>:9M<<7!1@'\#K]^P)V'">U^@+,,.?,
MF6%(!S3/M@%PY%5);3/:.-<=&+-% TK8*^Q ^YL*C1+.FZ9FMC,@R@A2DO'-
MYH8IT6J:I]%W,GF*O9.MAI,AME=*F#]'D#AD=$O?'(]MW;C@8'G:B1I^@OO5
MG8RWV,Q2M@JT;5$3 U5&;[>'8Q+B8\#O%@:[.)-0R1GQ.1@/948W01!(*%Q@
M$'Z[P!U(&8B\C)>)D\XI W!Y?F/_&FOWM9R%A3N43VWIFHSN*2FA$KUTCSA\
M@ZF>:TJFXK_#!:0/#TI\C@*EC2LI>NM032Q>BA*OX][JN _C3;*?8.L /@'X
M#-C'/&Q,%)7?"R?RU.! S-C[3H0GWAZX[TT1G+$5\<Z+M]Y[R;<WNY1= M$4
M<QQC^#)FCF">?4[!UU(<^3]PO@[?K2K<1?CN@\)DG2!9)4@B0?+?$M=BKC\E
M88N>*C!UG"9+"NQUG.2%=Q[86Q[?Y#U\G/8?PM2MMN2,SK]L['^%Z,!+V5SY
M$6K\!YL-"94+QR_^;,8Q&PV'W?2#V/R-\[]02P,$%     @ ^V5C2^E!G@*W
M 0  T@,  !D   !X;"]W;W)K<VAE971S+W-H965T,3<N>&UL;5-A;]L@$/TK
MB!]0$B=-L\BVU+2J5JF5HD[;/A/[;*,"YP&.VW\_P*[G=OX"W''OW;OC2'LT
MK[8!<.1-26TSVCC7'ABS10.*VRML0?N;"HWBSINF9K8UP,L(4I(EJ]6.*2XT
MS=/H.YD\Q<Y)H>%DB.V4XN;]"!+[C*[IA^-%U(T+#I:G+:_A![B?[<EXBTTL
MI5"@K4!-#%09O5T?CML0'P-^">CM[$Q")6?$UV \EAE=!4$@H7"!@?OM G<@
M92#R,OZ,G'1*&8#S\P?[0ZS=UW+F%NY0_A:E:S*ZIZ2$BG?2O6#_'<9ZKBD9
MBW^""T@?'I3X' 5*&U=2=-:A&EF\%,7?AEWHN/?#S74RPI8!R0A()L ^YF%#
MHJC\GCN>IP9[8H;>MSP\\?J0^-X4P1E;$>^\>.N]EWR]VZ7L$HC&F.,0D\QC
MI@CFV:<4R5**8_(?/%F&;Q85;B)\\TGAS3+!=I%@&PFVGPCV7TI<BOGV)0F;
M]52!J>,T65)@I^,DS[S3P-[&1V3_PH=I?^:F%MJ2,SK_LK'_%:(#+V5UY4>H
M\1]L,B14+AQO_-D,8S88#MOQ!['I&^=_ 5!+ P04    " #[96-+2:,1CK,!
M  #2 P  &0   'AL+W=O<FMS:&5E=',O<VAE970Q."YX;6Q]4]N.U# ,_94H
M'[#I9 9V&;65=A8AD$ :+0*>,ZW;1IM+2=+I\O<X:;<4*+PDL>-S?.PX^6C=
MD^\  GG6ROB"=B'T1\9\U8$6_L;V8/"FL4Z+@*9KF>\=B#J!M&(\RUXS+:2A
M99Y\9U?F=@A*&C@[X@>MA?MQ F7'@N[HB^-1MEV(#E;FO6CA,X0O_=FAQ1:6
M6FHP7EI#'#0%O=\=3X<8GP*^2AC]ZDQB)1=KGZ+QH2YH%@6!@BI$!H';%1Y
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MH GQ>(MG-XW99 3;SS^(+=^X_ E02P,$%     @ ^V5C2UC/ ZH) @  - 8
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M,4Z%?/]!M.T@OB2Z04YW7-[&XKYNC]/M@+-*?RIXW??*[#]02P,$%     @
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M"#)^BJB;0NI&ZD41==,OJ)MB#SV0NOUG%@LYSPX*?!H90KIY(9V 0IU ^=$
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MF@UC_JD4"]5[*6 (\N"BC2RS[!EPPX D&S,K%S,;,\\.)@W'S(N+B<;,VL7
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M;9>Q6<MN?'0;+9I^-))A/J>_ 5!+ P04    " #[96-+HU8'0V,"  #"!P
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M"5 &O$9_G2!(O5CYVSU0#MCTQ5-4S!U61L;WZ31"= /]XOF@H^M8[I_C8I;
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M9VW7DMSA)?BS8%1:!..RY7)6)!OI,?^^!L,W=BV<VV(998)9AX:@DLS\#H"
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M1.A23/GF!.L($((D7&^0&(^&70,@/E"BI@QT(JD5+(V9)#>$2/P8@;8/VQ5
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M^YG"3WPD*:$WLMTQ4^!M<#2$+<P6E67A$K'6LB )1R,^;'"=E(PK*P/=2+U
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M"5B\%Y;L-H&S,QM#QO-\4PEU0,R-Y X@ F,ZH?06<ZXI.8"!73:6+V.?F>'
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MH!DN6)E?QIPJP-2T83$M+N9X%>E-<&Y0CZZ"WJA+SL]3-!15I >VE,^D$\<
M"YBF#/^>*/03GG %T[8%$'8D;DB]/247];1.4HJ4L5:O4")(%L]M_+G"(R'^
M9>>Z&*HW.UC8P@(U"F/$A/\28Z5HOL:5"4>5?RC@J#(M3/)K;G?4D#!,1D
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MD$,"<GA*R/,$\IR /.>%'(.OG%['=F$7XJ[SVH#W"=P% 7?!"W>GO/81:^K
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M;G1?5'EP97-=+GAM;,V8WV["(!2'7\7T=K$(;.Y/U)MMMYO)]@*L/;7$MA!
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M+GAM;%!+ 0(4 Q0    ( /ME8TMI T#J[P   "L"   1              "
M 9D!  !D;V-0<F]P<R]C;W)E+GAM;%!+ 0(4 Q0    ( /ME8TN97)PC$ 8
M )PG   3              "  ;<"  !X;"]T:&5M92]T:&5M93$N>&UL4$L!
M A0#%     @ ^V5C2XM@A>M6 @  KP<  !@              ( !^ @  'AL
M+W=O<FMS:&5E=',O<VAE970Q+GAM;%!+ 0(4 Q0    ( /ME8TOY)A00W0,
M .01   8              "  80+  !X;"]W;W)K<VAE971S+W-H965T,BYX
M;6Q02P$"% ,4    " #[96-+C+U;BV$"   \"   &               @ &7
M#P  >&PO=V]R:W-H965T<R]S:&5E=#,N>&UL4$L! A0#%     @ ^V5C2V'.
M>WU$!   F!,  !@              ( !+A(  'AL+W=O<FMS:&5E=',O<VAE
M970T+GAM;%!+ 0(4 Q0    ( /ME8TLU=>9(, ,  *L,   8
M  "  :@6  !X;"]W;W)K<VAE971S+W-H965T-2YX;6Q02P$"% ,4    " #[
M96-+,@2S0[L!  #4 P  &               @ $.&@  >&PO=V]R:W-H965T
M<R]S:&5E=#8N>&UL4$L! A0#%     @ ^V5C2Y4Z@@=N!   ?Q4  !@
M         ( !_QL  'AL+W=O<FMS:&5E=',O<VAE970W+GAM;%!+ 0(4 Q0
M   ( /ME8TN^__C2K@$  -(#   8              "  :,@  !X;"]W;W)K
M<VAE971S+W-H965T."YX;6Q02P$"% ,4    " #[96-+"LD5[+ !  #2 P
M&               @ &'(@  >&PO=V]R:W-H965T<R]S:&5E=#DN>&UL4$L!
M A0#%     @ ^V5C2TZ$LQBT 0  T@,  !D              ( !;20  'AL
M+W=O<FMS:&5E=',O<VAE970Q,"YX;6Q02P$"% ,4    " #[96-+26<KAK4!
M  #2 P  &0              @ %8)@  >&PO=V]R:W-H965T<R]S:&5E=#$Q
M+GAM;%!+ 0(4 Q0    ( /ME8TM&WWW.L@$  -(#   9              "
M 40H  !X;"]W;W)K<VAE971S+W-H965T,3(N>&UL4$L! A0#%     @ ^V5C
M2^HGV]VU 0  T@,  !D              ( !+2H  'AL+W=O<FMS:&5E=',O
M<VAE970Q,RYX;6Q02P$"% ,4    " #[96-+^IE 7+4!  #2 P  &0
M        @ $9+   >&PO=V]R:W-H965T<R]S:&5E=#$T+GAM;%!+ 0(4 Q0
M   ( /ME8TL2JSP/L@$  -(#   9              "  04N  !X;"]W;W)K
M<VAE971S+W-H965T,34N>&UL4$L! A0#%     @ ^V5C2PL[3^6T 0  T@,
M !D              ( ![B\  'AL+W=O<FMS:&5E=',O<VAE970Q-BYX;6Q0
M2P$"% ,4    " #[96-+Z4&> K<!  #2 P  &0              @ '9,0
M>&PO=V]R:W-H965T<R]S:&5E=#$W+GAM;%!+ 0(4 Q0    ( /ME8TM)HQ&.
MLP$  -(#   9              "  <<S  !X;"]W;W)K<VAE971S+W-H965T
M,3@N>&UL4$L! A0#%     @ ^V5C2UC/ ZH) @  - 8  !D
M ( !L34  'AL+W=O<FMS:&5E=',O<VAE970Q.2YX;6Q02P$"% ,4    " #[
M96-+'=)_0^$!   !!0  &0              @ 'Q-P  >&PO=V]R:W-H965T
M<R]S:&5E=#(P+GAM;%!+ 0(4 Q0    ( /ME8TLV&J\WN $  -(#   9
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M970R-2YX;6Q02P$"% ,4    " #[96-+;,SR+AH#  "[#   &0
M    @ &'1P  >&PO=V]R:W-H965T<R]S:&5E=#(V+GAM;%!+ 0(4 Q0    (
M /ME8TOIS%.8E 0   88   9              "  =A*  !X;"]W;W)K<VAE
M971S+W-H965T,C<N>&UL4$L! A0#%     @ ^V5C2]J5"C I @  BP8  !D
M             ( !HT\  'AL+W=O<FMS:&5E=',O<VAE970R."YX;6Q02P$"
M% ,4    " #[96-+W!H%;.@"   P"P  &0              @ $#4@  >&PO
M=V]R:W-H965T<R]S:&5E=#(Y+GAM;%!+ 0(4 Q0    ( /ME8TM./)?C1 (
M *L'   9              "  2)5  !X;"]W;W)K<VAE971S+W-H965T,S N
M>&UL4$L! A0#%     @ ^V5C2Z-6!T-C @  P@<  !D              ( !
MG5<  'AL+W=O<FMS:&5E=',O<VAE970S,2YX;6Q02P$"% ,4    " #[96-+
M"MS4JBH"   H!@  &0              @ $W6@  >&PO=V]R:W-H965T<R]S
M:&5E=#,R+GAM;%!+ 0(4 Q0    ( /ME8TO-;TZN;@(  &,'   9
M      "  9A<  !X;"]W;W)K<VAE971S+W-H965T,S,N>&UL4$L! A0#%
M  @ ^V5C2_G).EP8 @  O04  !D              ( !/5\  'AL+W=O<FMS
M:&5E=',O<VAE970S-"YX;6Q02P$"% ,4    " #[96-+#JV.:2,#  ">#0
M&0              @ &,80  >&PO=V]R:W-H965T<R]S:&5E=#,U+GAM;%!+
M 0(4 Q0    ( /ME8TO5WA -PP$  "L$   9              "  >9D  !X
M;"]W;W)K<VAE971S+W-H965T,S8N>&UL4$L! A0#%     @ ^V5C2Z6@0-D#
M.   G/   !0              ( !X&8  'AL+W-H87)E9%-T<FEN9W,N>&UL
M4$L! A0#%     @ ^V5C2](*6"T_ @  'PL   T              ( !%9\
M 'AL+W-T>6QE<RYX;6Q02P$"% ,4    " #[96-+3F)-3 \#  #C%P  #P
M            @ %_H0  >&PO=V]R:V)O;VLN>&UL4$L! A0#%     @ ^V5C
M2^R615"- 0  D18  !H              ( !NZ0  'AL+U]R96QS+W=O<FMB
M;V]K+GAM;"YR96QS4$L! A0#%     @ ^V5C2UP- YJ< 0  "A<  !,
M         ( !@*8  %M#;VYT96YT7U1Y<&5S72YX;6Q02P4&     "T +0 M
)#   3:@

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>50
<FILENAME>Show.js
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
/**
 * Rivet Software Inc.
 *
 * @copyright Copyright (c) 2006-2011 Rivet Software, Inc. All rights reserved.
 * Version 2.4.0.3
 *
 */

var Show = {};
Show.LastAR = null,

Show.hideAR = function(){
	Show.LastAR.style.display = 'none';
};

Show.showAR = function ( link, id, win ){
	if( Show.LastAR ){
		Show.hideAR();
	}

	var ref = link;
	do {
		ref = ref.nextSibling;
	} while (ref && ref.nodeName != 'TABLE');

	if (!ref || ref.nodeName != 'TABLE') {
		var tmp = win ?
			win.document.getElementById(id) :
			document.getElementById(id);

		if( tmp ){
			ref = tmp.cloneNode(true);
			ref.id = '';
			link.parentNode.appendChild(ref);
		}
	}

	if( ref ){
		ref.style.display = 'block';
		Show.LastAR = ref;
	}
};

Show.toggleNext = function( link ){
	var ref = link;

	do{
		ref = ref.nextSibling;
	}while( ref.nodeName != 'DIV' );

	if( ref.style &&
		ref.style.display &&
		ref.style.display == 'none' ){
		ref.style.display = 'block';

		if( link.textContent ){
			link.textContent = link.textContent.replace( '+', '-' );
		}else{
			link.innerText = link.innerText.replace( '+', '-' );
		}
	}else{
		ref.style.display = 'none';

		if( link.textContent ){
			link.textContent = link.textContent.replace( '-', '+' );
		}else{
			link.innerText = link.innerText.replace( '-', '+' );
		}
	}
};
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>51
<FILENAME>report.css
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
/* Updated 2009-11-04 */
/* v2.2.0.24 */

/* DefRef Styles */
..report table.authRefData{
	background-color: #def;
	border: 2px solid #2F4497;
	font-size: 1em;
	position: absolute;
}

..report table.authRefData a {
	display: block;
	font-weight: bold;
}

..report table.authRefData p {
	margin-top: 0px;
}

..report table.authRefData .hide {
	background-color: #2F4497;
	padding: 1px 3px 0px 0px;
	text-align: right;
}

..report table.authRefData .hide a:hover {
	background-color: #2F4497;
}

..report table.authRefData .body {
	height: 150px;
	overflow: auto;
	width: 400px;
}

..report table.authRefData table{
	font-size: 1em;
}

/* Report Styles */
..pl a, .pl a:visited {
	color: black;
	text-decoration: none;
}

/* table */
..report {
	background-color: white;
	border: 2px solid #acf;
	clear: both;
	color: black;
	font: normal 8pt Helvetica, Arial, san-serif;
	margin-bottom: 2em;
}

..report hr {
	border: 1px solid #acf;
}

/* Top labels */
..report th {
	background-color: #acf;
	color: black;
	font-weight: bold;
	text-align: center;
}

..report th.void	{
	background-color: transparent;
	color: #000000;
	font: bold 10pt Helvetica, Arial, san-serif;
	text-align: left;
}

..report .pl {
	text-align: left;
	vertical-align: top;
	white-space: normal;
	width: 200px;
	white-space: normal; /* word-wrap: break-word; */
}

..report td.pl a.a {
	cursor: pointer;
	display: block;
	width: 200px;
	overflow: hidden;
}

..report td.pl div.a {
	width: 200px;
}

..report td.pl a:hover {
	background-color: #ffc;
}

/* Header rows... */
..report tr.rh {
	background-color: #acf;
	color: black;
	font-weight: bold;
}

/* Calendars... */
..report .rc {
	background-color: #f0f0f0;
}

/* Even rows... */
..report .re, .report .reu {
	background-color: #def;
}

..report .reu td {
	border-bottom: 1px solid black;
}

/* Odd rows... */
..report .ro, .report .rou {
	background-color: white;
}

..report .rou td {
	border-bottom: 1px solid black;
}

..report .rou table td, .report .reu table td {
	border-bottom: 0px solid black;
}

/* styles for footnote marker */
..report .fn {
	white-space: nowrap;
}

/* styles for numeric types */
..report .num, .report .nump {
	text-align: right;
	white-space: nowrap;
}

..report .nump {
	padding-left: 2em;
}

..report .nump {
	padding: 0px 0.4em 0px 2em;
}

/* styles for text types */
..report .text {
	text-align: left;
	white-space: normal;
}

..report .text .big {
	margin-bottom: 1em;
	width: 17em;
}

..report .text .more {
	display: none;
}

..report .text .note {
	font-style: italic;
	font-weight: bold;
}

..report .text .small {
	width: 10em;
}

..report sup {
	font-style: italic;
}

..report .outerFootnotes {
	font-size: 1em;
}
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>53
<FILENAME>FilingSummary.xml
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<XML>
<?xml version='1.0' encoding='UTF-8'?>
<FilingSummary>
  <Version>3.8.0.1</Version>
  <ProcessingTime/>
  <ReportFormat>html</ReportFormat>
  <ContextCount>87</ContextCount>
  <ElementCount>190</ElementCount>
  <EntityCount>1</EntityCount>
  <FootnotesReported>false</FootnotesReported>
  <SegmentCount>32</SegmentCount>
  <ScenarioCount>0</ScenarioCount>
  <TuplesReported>false</TuplesReported>
  <UnitCount>7</UnitCount>
  <MyReports>
    <Report instance="nlnk-20170930.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R1.htm</HtmlFileName>
      <LongName>0000000 - Document - Document and Entity Information</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.linkp.com/role/DocumentAndEntityInformation</Role>
      <ShortName>Document and Entity Information</ShortName>
      <MenuCategory>Cover</MenuCategory>
      <Position>1</Position>
    </Report>
    <Report instance="nlnk-20170930.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R2.htm</HtmlFileName>
      <LongName>1001000 - Statement - Condensed Consolidated Balance Sheets</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.linkp.com/role/CondensedConsolidatedBalanceSheets</Role>
      <ShortName>Condensed Consolidated Balance Sheets</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>2</Position>
    </Report>
    <Report instance="nlnk-20170930.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R3.htm</HtmlFileName>
      <LongName>1001501 - Statement - Condensed Consolidated Balance Sheets (Parentheticals)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.linkp.com/role/CondensedConsolidatedBalanceSheetsParentheticals</Role>
      <ShortName>Condensed Consolidated Balance Sheets (Parentheticals)</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>3</Position>
    </Report>
    <Report instance="nlnk-20170930.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R4.htm</HtmlFileName>
      <LongName>1002000 - Statement - Condensed Consolidated Statements of Operations</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.linkp.com/role/CondensedConsolidatedStatementsOfOperations</Role>
      <ShortName>Condensed Consolidated Statements of Operations</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>4</Position>
    </Report>
    <Report instance="nlnk-20170930.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R5.htm</HtmlFileName>
      <LongName>1003000 - Statement - Condensed Consolidated Statement of Stockholders' Equity</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.linkp.com/role/CondensedConsolidatedStatementOfStockholdersEquity</Role>
      <ShortName>Condensed Consolidated Statement of Stockholders' Equity</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>5</Position>
    </Report>
    <Report instance="nlnk-20170930.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R6.htm</HtmlFileName>
      <LongName>1003501 - Statement - Condensed Consolidated Statement of Stockholders' Equity (Parentheticals)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.linkp.com/role/CondensedConsolidatedStatementOfStockholdersEquityParentheticals</Role>
      <ShortName>Condensed Consolidated Statement of Stockholders' Equity (Parentheticals)</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>6</Position>
    </Report>
    <Report instance="nlnk-20170930.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R7.htm</HtmlFileName>
      <LongName>1004000 - Statement - Condensed Consolidated Statements of Cash Flows</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.linkp.com/role/CondensedConsolidatedStatementsOfCashFlows</Role>
      <ShortName>Condensed Consolidated Statements of Cash Flows</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>7</Position>
    </Report>
    <Report instance="nlnk-20170930.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R8.htm</HtmlFileName>
      <LongName>2101100 - Disclosure - Description of Business</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.linkp.com/role/DescriptionOfBusiness</Role>
      <ShortName>Description of Business</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>8</Position>
    </Report>
    <Report instance="nlnk-20170930.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R9.htm</HtmlFileName>
      <LongName>2102100 - Disclosure - Basis of Presentation</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.linkp.com/role/BasisOfPresentation</Role>
      <ShortName>Basis of Presentation</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>9</Position>
    </Report>
    <Report instance="nlnk-20170930.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R10.htm</HtmlFileName>
      <LongName>2103100 - Disclosure - Significant Accounting Policies</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.linkp.com/role/SignificantAccountingPolicies</Role>
      <ShortName>Significant Accounting Policies</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>10</Position>
    </Report>
    <Report instance="nlnk-20170930.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R11.htm</HtmlFileName>
      <LongName>2104100 - Disclosure - Long-Term Debt</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.linkp.com/role/LongTermDebt</Role>
      <ShortName>Long-Term Debt</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>11</Position>
    </Report>
    <Report instance="nlnk-20170930.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R12.htm</HtmlFileName>
      <LongName>2105100 - Disclosure - License and Research Collaboration Agreements</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.linkp.com/role/LicenseAndResearchCollaborationAgreements</Role>
      <ShortName>License and Research Collaboration Agreements</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>12</Position>
    </Report>
    <Report instance="nlnk-20170930.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R13.htm</HtmlFileName>
      <LongName>2106100 - Disclosure - Common Stock Equity Incentive Plan</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.linkp.com/role/CommonStockEquityIncentivePlan</Role>
      <ShortName>Common Stock Equity Incentive Plan</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>13</Position>
    </Report>
    <Report instance="nlnk-20170930.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R14.htm</HtmlFileName>
      <LongName>2107100 - Disclosure - Income Taxes</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.linkp.com/role/IncomeTaxes</Role>
      <ShortName>Income Taxes</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>14</Position>
    </Report>
    <Report instance="nlnk-20170930.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R15.htm</HtmlFileName>
      <LongName>2108100 - Disclosure - Net Loss per Common Share</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.linkp.com/role/NetLossPerCommonShare</Role>
      <ShortName>Net Loss per Common Share</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>15</Position>
    </Report>
    <Report instance="nlnk-20170930.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R16.htm</HtmlFileName>
      <LongName>2109100 - Disclosure - Restructuring Charges</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.linkp.com/role/RestructuringCharges</Role>
      <ShortName>Restructuring Charges</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>16</Position>
    </Report>
    <Report instance="nlnk-20170930.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R17.htm</HtmlFileName>
      <LongName>2110100 - Disclosure - Commitments and Contingencies</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.linkp.com/role/CommitmentsAndContingencies</Role>
      <ShortName>Commitments and Contingencies</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>17</Position>
    </Report>
    <Report instance="nlnk-20170930.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R18.htm</HtmlFileName>
      <LongName>2111100 - Disclosure - Subsequent Events</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.linkp.com/role/SubsequentEvents</Role>
      <ShortName>Subsequent Events</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>18</Position>
    </Report>
    <Report instance="nlnk-20170930.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R19.htm</HtmlFileName>
      <LongName>2203201 - Disclosure - Significant Accounting Policies (Policies)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.linkp.com/role/SignificantAccountingPoliciesPolicies</Role>
      <ShortName>Significant Accounting Policies (Policies)</ShortName>
      <MenuCategory>Policies</MenuCategory>
      <ParentRole>http://www.linkp.com/role/SignificantAccountingPolicies</ParentRole>
      <Position>19</Position>
    </Report>
    <Report instance="nlnk-20170930.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R20.htm</HtmlFileName>
      <LongName>2306301 - Disclosure - Common Stock Equity Incentive Plan (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.linkp.com/role/CommonStockEquityIncentivePlanTables</Role>
      <ShortName>Common Stock Equity Incentive Plan (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.linkp.com/role/CommonStockEquityIncentivePlan</ParentRole>
      <Position>20</Position>
    </Report>
    <Report instance="nlnk-20170930.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R21.htm</HtmlFileName>
      <LongName>2308301 - Disclosure - Net Loss per Common Share (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.linkp.com/role/NetLossPerCommonShareTables</Role>
      <ShortName>Net Loss per Common Share (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.linkp.com/role/NetLossPerCommonShare</ParentRole>
      <Position>21</Position>
    </Report>
    <Report instance="nlnk-20170930.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R22.htm</HtmlFileName>
      <LongName>2309301 - Disclosure - Restructuring Charges (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.linkp.com/role/RestructuringChargesTables</Role>
      <ShortName>Restructuring Charges (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.linkp.com/role/RestructuringCharges</ParentRole>
      <Position>22</Position>
    </Report>
    <Report instance="nlnk-20170930.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R23.htm</HtmlFileName>
      <LongName>2401401 - Disclosure - Description of Business (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.linkp.com/role/DescriptionOfBusinessDetails</Role>
      <ShortName>Description of Business (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.linkp.com/role/DescriptionOfBusiness</ParentRole>
      <Position>23</Position>
    </Report>
    <Report instance="nlnk-20170930.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R24.htm</HtmlFileName>
      <LongName>2403402 - Disclosure - Significant Accounting Policies (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.linkp.com/role/SignificantAccountingPoliciesDetails</Role>
      <ShortName>Significant Accounting Policies (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.linkp.com/role/SignificantAccountingPoliciesPolicies</ParentRole>
      <Position>24</Position>
    </Report>
    <Report instance="nlnk-20170930.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R25.htm</HtmlFileName>
      <LongName>2404401 - Disclosure - Long-Term Debt (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.linkp.com/role/LongTermDebtDetails</Role>
      <ShortName>Long-Term Debt (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.linkp.com/role/LongTermDebt</ParentRole>
      <Position>25</Position>
    </Report>
    <Report instance="nlnk-20170930.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R26.htm</HtmlFileName>
      <LongName>2405401 - Disclosure - License and Research Collaboration Agreements (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.linkp.com/role/LicenseAndResearchCollaborationAgreementsDetails</Role>
      <ShortName>License and Research Collaboration Agreements (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.linkp.com/role/LicenseAndResearchCollaborationAgreements</ParentRole>
      <Position>26</Position>
    </Report>
    <Report instance="nlnk-20170930.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R27.htm</HtmlFileName>
      <LongName>2406402 - Disclosure - Common Stock Equity Incentive Plan (Narrative)(Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.linkp.com/role/CommonStockEquityIncentivePlanNarrativedetails</Role>
      <ShortName>Common Stock Equity Incentive Plan (Narrative)(Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.linkp.com/role/CommonStockEquityIncentivePlanTables</ParentRole>
      <Position>27</Position>
    </Report>
    <Report instance="nlnk-20170930.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R28.htm</HtmlFileName>
      <LongName>2406403 - Disclosure - Common Stock Equity Incentive Plan (Authorized Increases of Common Stock) (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.linkp.com/role/CommonStockEquityIncentivePlanAuthorizedIncreasesOfCommonStockDetails</Role>
      <ShortName>Common Stock Equity Incentive Plan (Authorized Increases of Common Stock) (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.linkp.com/role/CommonStockEquityIncentivePlanTables</ParentRole>
      <Position>28</Position>
    </Report>
    <Report instance="nlnk-20170930.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R29.htm</HtmlFileName>
      <LongName>2406404 - Disclosure - Common Stock Equity Incentive Plan (Stock Option Activity) (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.linkp.com/role/CommonStockEquityIncentivePlanStockOptionActivityDetails</Role>
      <ShortName>Common Stock Equity Incentive Plan (Stock Option Activity) (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.linkp.com/role/CommonStockEquityIncentivePlanTables</ParentRole>
      <Position>29</Position>
    </Report>
    <Report instance="nlnk-20170930.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R30.htm</HtmlFileName>
      <LongName>2406405 - Disclosure - Common Stock Equity Incentive Plan (Range of Assumptions Used) (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.linkp.com/role/CommonStockEquityIncentivePlanRangeOfAssumptionsUsedDetails</Role>
      <ShortName>Common Stock Equity Incentive Plan (Range of Assumptions Used) (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.linkp.com/role/CommonStockEquityIncentivePlanTables</ParentRole>
      <Position>30</Position>
    </Report>
    <Report instance="nlnk-20170930.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R31.htm</HtmlFileName>
      <LongName>2406406 - Disclosure - Common Stock Equity Incentive Plan (Restricted Stock Activity) (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.linkp.com/role/CommonStockEquityIncentivePlanRestrictedStockActivityDetails</Role>
      <ShortName>Common Stock Equity Incentive Plan (Restricted Stock Activity) (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.linkp.com/role/CommonStockEquityIncentivePlanTables</ParentRole>
      <Position>31</Position>
    </Report>
    <Report instance="nlnk-20170930.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R32.htm</HtmlFileName>
      <LongName>2407401 - Disclosure - Income Taxes (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.linkp.com/role/IncomeTaxesDetails</Role>
      <ShortName>Income Taxes (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.linkp.com/role/IncomeTaxes</ParentRole>
      <Position>32</Position>
    </Report>
    <Report instance="nlnk-20170930.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R33.htm</HtmlFileName>
      <LongName>2408402 - Disclosure - Net Loss per Common Share (Net Loss Per Share Computation) (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.linkp.com/role/NetLossPerCommonShareNetLossPerShareComputationDetails</Role>
      <ShortName>Net Loss per Common Share (Net Loss Per Share Computation) (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.linkp.com/role/NetLossPerCommonShareTables</ParentRole>
      <Position>33</Position>
    </Report>
    <Report instance="nlnk-20170930.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R34.htm</HtmlFileName>
      <LongName>2408403 - Disclosure - Net Loss per Common Share (Antidilutive Securities) (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.linkp.com/role/NetLossPerCommonShareAntidilutiveSecuritiesDetails</Role>
      <ShortName>Net Loss per Common Share (Antidilutive Securities) (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.linkp.com/role/NetLossPerCommonShareTables</ParentRole>
      <Position>34</Position>
    </Report>
    <Report instance="nlnk-20170930.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R35.htm</HtmlFileName>
      <LongName>2409402 - Disclosure - Restructuring Charges (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.linkp.com/role/RestructuringChargesDetails</Role>
      <ShortName>Restructuring Charges (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.linkp.com/role/RestructuringChargesTables</ParentRole>
      <Position>35</Position>
    </Report>
    <Report instance="nlnk-20170930.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R36.htm</HtmlFileName>
      <LongName>2411401 - Disclosure - Subsequent Events (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.linkp.com/role/SubsequentEventsDetails</Role>
      <ShortName>Subsequent Events (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.linkp.com/role/SubsequentEvents</ParentRole>
      <Position>36</Position>
    </Report>
    <Report>
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <LongName>All Reports</LongName>
      <ReportType>Book</ReportType>
      <ShortName>All Reports</ShortName>
    </Report>
  </MyReports>
  <InputFiles>
    <File>nlnk-20170930.xml</File>
    <File>nlnk-20170930.xsd</File>
    <File>nlnk-20170930_cal.xml</File>
    <File>nlnk-20170930_def.xml</File>
    <File>nlnk-20170930_lab.xml</File>
    <File>nlnk-20170930_pre.xml</File>
  </InputFiles>
  <SupplementalFiles/>
  <BaseTaxonomies>
    <BaseTaxonomy>http://xbrl.sec.gov/dei/2014-01-31</BaseTaxonomy>
    <BaseTaxonomy>http://fasb.org/us-gaap/2017-01-31</BaseTaxonomy>
  </BaseTaxonomies>
  <HasPresentationLinkbase>true</HasPresentationLinkbase>
  <HasCalculationLinkbase>true</HasCalculationLinkbase>
</FilingSummary>
</XML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>ZIP
<SEQUENCE>55
<FILENAME>0001126234-17-000107-xbrl.zip
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
begin 644 0001126234-17-000107-xbrl.zip
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M2=<06'&E^0:05SJ&#H9[SQVWA?=OZTU0(F%1.\D6W%>EJ(E8@T64)XRC&7]
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M<:GQZ-5@980BI@5JL__V3P]QGX-G(N)8(D\)"!D3EN5,6$C!U_05TXS4,#D
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M$"6 LZT"'D'$K$N4B5@?EP 1MUP';4/'ZUV/CM$NQ9RRQV(G/%'#A,AB LA
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M'(B!!T@L$+=J':I1"4*G KM4EI\#K=,M;E7/>;M?N3O?P_<N>V-<!=1>"PU
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M,4KJ-RD,H-'@)JGO4,*UY2DCWP7M8@'\/ZNCUS!][H@P[5[ZVR!3T24*+ON
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M1*.;)AYP1AXS9_ /Z,HB<!Y&J#G/,"H:N*R(H\><R3[SFKF#B1*/&^,*=V=
M%!HZKG\[_>\X2ZN_W<7H.$:B';+?1^!=)&.T="E251QW[K$'MF"8O3++H;X/
MJ(K"95)X!NT"PH",@& +P.S'N>?.-2"7U$?<]/AQX>%Y?%2AE#48@Z[>[F]W
M+3B%O!'O**.&N>%]0/N2MMYOC98I500C8'D*SQKML*_X-VM=C7SF'_'R]UX"
MKW3Y-UO#1C\"@D4>N1,_$5CP-#^4N,'F!5<#H<WM<ZSP8D0,X%#B<S)W$OPR
M3B?_ >&+DBH2]R#]EA._(B_^0L).M --(Z87N793;;(B,EGZ3D#O\)*$D7#!
M;W<(><!4+XFQA)EI4R]V(\8SQN#Q&NBX?HA9AK@RX!MK:^:C;M?6C'F"=&%Y
M\2!%AMH<4 $D';PYVH3%')[N@ 0A9P;MS.&_B'M(/L-=2_$2>@%=L)X/Q_@3
M\)*'$(0L,0R$H\M SN>Q8<K+BQAND7UU@1GC[D+\[A%,90TU'K@N9XTDXS3G
M/F)<FD4,8UCX0K$2N@#VN'7&0CJB:'=])XZ]F8?:0)Q)3]R7> EP:BHA=_#N
MB>,32<1SQA*$WK9=1XFB6X#D"@9@4997.'TJ<Y3>ZX?T-XWQSG!$*(=_V4!1
M\:A?AY_&P_\15/R+4)=VO.7"/*XMF8*'(K%SM0VE-!#V]>:!K%'MYF$15N_6
MAW2L!&R$KD$TYLXQQS56[@6I@ 6NX<0BNSB^;,;I4[1TQ1FGW9;=E9IO:AA2
M$DZM_D433HW!95__FF_O-6GU#<FA:%884<%G+7__Z9#K,WU(CX'E"UI!;L56
M[>/ 96=V]I95_6N**LA.HXH[3136R<<ZZP)8]PPL+XV'_S[(U7THL%7:SW[4
M_3VS-<%"G##06P/AME4=8VHAGJ^S/[AIV_I@1YJ"ZL10 RQ1Y*4 IP!7)WNK
M]OQ-=1E:RT7IM@9*MBE.4S&G:8@[K$K<^Y&GD"FO1'UE5VVX<JD(5Q8\ZD(&
M5;-@11<*/@H^<KR]5S?C5/%511?GU&!K9 ]4B7O_(K>\,J*NR<]5&UWXC=W6
M.W;U0P"W,:4Z**GYFY>6EO4F/L6U%.!>Z<37CM5J*X>T(JXZJO/7)0/O> D5
MF[YSL0;#]Y5SNLY.IOHHY&9?-[L'-[(Z%!:O6^^^+M92#XI1'.55P>=ZW=:=
M3LN6IA/7AD<HAW7]--P:V0OGRB174T?K),>>'SY?T5A2:9/L*Y@$:!MZI].[
M/(BK %?CY(HB;04X!;A& $[EKU]__KK5:JLIN8K3G,^8>@VMNJ4WD(JE=2L\
M3X_8)$P<7S1Y \AI:2 Z+_[)INM=#=TP%GW1V+3<N:[H=>6(7K)?J2V9OY+4
MM;$KN7$RM;/"_FGYZ)-0F^0=)W'?2)*EWJ[Y] 5N.LOKG]FR^;05*4]K:4U#
MOHCEW06KP)N>;+P!X!Y.'DA<.'B9NKYQMTO>!&Z3=%13]W/BGL2F[K;1U=MM
M.1UPKZR58GD:^C1DL1:$B38'3@J,E0C!UY:A[[DKH(9[0/4,O>,PC3C%B([
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MZ%A=*$NA8P/0\? 6M37 U=JS3FD-?Q4B7S4B*Z9;$UMH 4OV69V2?*I,YJ#
MO),DD3=)>?PK"=="L'- 4K:CD6 =4H"N"4E/;CE_# !KGVLDKU/SR4,1FM#*
M^8W9UGMF#<8<;%-F=6"L[T0RQ>P:P>P:,9.C&9RP&=-@WAB6;LDKHCPSFVP$
MNBH>JGAH[9!2\5")/-2R=5->,9;BH8J'UIV'RDG'>*TV]P%^WT::W'U#[W4'
MM8'9Z[:X7SM#:VC:K*C0P"3A>@L$!:JC(H#GR9.H,Z@45BFL4EBEL*H)H%)8
MI;!*856C5/@Z)/U4:2#>;!6];S43V&Y)4)G[K ;H>G%RSI?[LNDUAWAVCP+O
M"_+YY#N!S($^Z QTVY376?SE4*L+K>)]9YVPK<A1D>,Z.=KZP.[H5D_:+!%%
MCHH<%3D>+QV[/5,W+YF8J,A1D:,BQUPZ&H;>[IJ*'!4Y-L._<7F@"?^0?7'_
MD +5]3EH:P$JA54*JQ16*:QJ J@45BFL4EC5*!6^1DGHYXU4KK=;K\RP5#G]
MDIP5QP#PM2;U7VTA?;O5JRBG7Y71*U:G6)UB=35B=9:TV=.*U2E6IUB=8G4U
M975&:V#7!V2*U2E6IUB=8G75=()K=16KJPFK>^T<[:")KT<MQ3\B>Z<$IF<G
MB^8S!?EY[AH(:79E^^-E;^K<&QCZ_OXIGCAPDGUU_11GO\RB<+%KQN5NUWDV
M 91/_XPU+] >YYX[I\L8?W3$EF&$M\9>X#)Z=L3BU$^TQS#UI]H$AU\FWMM\
M3J@VC/&-6\ ]9N/Y*)N"1'"FS<XVY<<\7U]?NX!NN$2PQ11S@+TFD><2 .A'
M!P<=QQL0#U- +\=W4Y]#/ D3.)VI'"#T]8[1U=OM[63?8YY&NY+R),,V]$Y'
MSJIT!/22N7@*_JJE58)$. ])#@RE/&5GC_*KQ>*>WK4Z@"_;%227Q>).NZ^W
M^]NA"0E8_+0TGV[.8-\[*+T\3?W.\:)_.7[*?IO=>8$3N)[C_Q3 Z:8TF?U#
MZ'ONZH#)ZIVQ90UZH]' [-]90].RAQVS?7,W[-QTV_9-SZCM9/6RH#4D1N[Y
M1[S\O0=H[[G\FZW) CG4M1+8"1U'88"##?C@<&)?HXA-O43[Z,5?I"E0Q\!)
M^HCMD1//:<\N_E'21I "7 :?0">-=;K$<5VP8P!&2V=%_?"Y5N&B"02_XL#U
M.-&%XN$LEU'XU5LX"2#8#'!=>T!D%_/4Q33U> X:R=N$10LM<)(4'@>PAA]B
MILWRT_&*TVEI.!+<=:)HA=H.?R+<$H3XEGQ9M)TE'KX&FB(\+)P 1,5I/CJQ
M''[S;:=C@C#?[I5[63;XK67T)2ZK.2J@/!". ?,W%FK00JM0D7803)E>TA@Q
M_6<&EVHFT +8 K'VAAL%0$B@Z"-91E,'=?I'+YEKPT\CS3;;WW-B&<&53K#2
MO%A+@VR*!2@1_$5(A*67<>H#8WKE^,FJ1#8%V<Y2HE-8ZS1U8>L.9P\QW0A/
MQ=7"8X 6%YR->#,X&-@E+<!E4>)X :B%+Q2I!TG+LGC]*0 8L<_.U[$7NV %
MI24Q?(!4[;<'IFF/.MV[8=_J#\9VW[3O.G;GMMWMC]K6;6VEJDPANB4R.5 U
M@"I[>NQ)Y7+0E"P'[\*(,%@*@2<T/QC948 S7<':QYFN#&>ZULAJJ=XD3TK\
MI] 3 F!:A$:)\U6;L(#-0+.2)62^-8Q!'85RUY2WK"T36R%O"7EER>B+(&^K
MH\%5/DC<NB&PU6I+7=HF$J.NL@.T,X7:TO7DJ3>;L2@N7,S. NTZ^-,I^8+9
M5SP=Q/D9&&BHGOID=)'=EH"UEH312ON]]:FES=B4162IY><7H7:YC$#+C& ]
MVC0EO1/O]4%'Q,<NP68+$C3P<*P:FG0:QLHRCS5\"3NVZ+3PMH EW.=]#YB!
M3X=%KE#'^MD+OOPE1D0!'2/0XG02>U//B0"G?E+X= 96>6%\<B:>[X&Q\@06
M=9_!(OSE:4RZ+F7W)S :$3QQ!O^(P=O_S"")428&)QH!=!#V>"U:<F#*./<,
M[2TTH  V>.B/<P9/B#2@+;#P%@ [H/ OP-+Q^ /TS' \B/$D,0!%<2PX?]_/
MS,T=+P-+%G['FR?9ZMB4"XG4%[:K6'0>&-OQ%%C1E"T9@5%+E\+K),Y>W"<,
M6KB+K&.!<R*>AI=OQ=22>1C##6P!VP'L$/C/P+B-8;G\=H;6L0</;&F_[ (;
M8;T[A\O0+Q^!>1^!*;VU#]_CA^*AD0TV]W\X":TOEGOG\/*E[P3H>0:$0.2^
MA]MPV0OG"]\,P(,?/*ZFI:%!S>$ IQ$^.K2#N?/ 8!LL0"\!O,6+YQA6$'P3
M67:44[@X0*2J7>!7SJ/JG4<E3IB[5S@-"\1&W17[0'+B?CJ4T3A.5O9PS0'=
M'(0.BP"#$6%S@'#B"&./NX CYA/K![BAY.$2!GA*@I0I39FWNYW7Z8?-K25T
M1P+PAZX;I?#Q%C2 (.8LB6<V(%:@7Q'Y(L[RX +9\<F9"7R'Y>$$X'08W^2,
MT\$'<F[IX?QI8%1$O_!XQT=>N>[ZG(9P'\H2KH*LJ2B@-("8PAZI@+/>S'.=
M( '9)5;.F=O71#-,H=V]-!3XE!NR[*[\.0SN/[-H,6:3Y"5^RJYU=WLSO#4,
MJ]^WC-ON8&#;M\-.YZ8_,MO6X*X>?DI))$\?MYR2"+JW"#L-@7<.5:V"8!S_
M^'S0\A<G FH 3&AK(Z&K#?$0[\+HG@?KM)]#9]M$;W20$O358M_KGAF:/T]Q
M$"!E1Y:SKMV6Q[EGQ<GX<#*:<P]&(VF#%*VAS91.4M=^ DTL-UCH<$=SA[)>
M,! =+A8L<D'G^T_H(:NBV(N/*FXDV)Y0$_&_#QZRX3*\Z)U%;!44-0][0KMB
MN#E%5.#> 'C"S'&%ZEEFA[0@%Q=,AGQ\:=M(-JZ5(1AA/#S:@"#""4P/T!I
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MXOV#4^\_*)GHB0=TFPX Z\P :$BY=+V2QA1\GH7/1<?9/ /+'?![:K#(X#@
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MR]!O AHVL&KZ<L45;^"D+ +M!IA]QCS3F!641N9 27WR$6>!IZ>+U*=? /M
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M-S"UY#DF5?5%JV"GC6P?.L*T5UW$3_9J^Y2YIFC/&K0<OX<E^M#G7>GS4P;
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M3^>S?*PQ'Q?=P(S-@@7'0@9F%4H"O#EXW#!B4AC$'3:<1@ON?H>P=QSGI.M
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M$>=G,MR7?'.U#'!GPH?F&6(<8\H 1YX24LL7#H%SMLX_ELN7#8-// #)C%#
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MV<&0H:=RG9F_.-D;SJ_3$.=!+7XP81R:[><"P7JU_F-VV%I=?]R^*TO39\9
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M*18U->O44&*E>;W[%.9C5R64=B+3CKTXJ4E.7$O!.1XVJY%5]UB.)#R/D=1
M?CIQ.RT1ZF;*$U+4 S]M#L<>KJ'<S]+VL[=7=W8NG*-6,(FUY51)XP!S[)AQ
M\;BW!'IM>.@5I&6%L?V)V>Y,1V^V#DMRI[W6$]U[L/7*TG(:FZW/,MELK[4_
MATQ#$=.8=N$(;L_\-=IH-<4J_%R4V[N?<[4)C7VL'BG8@RD^G/UJ.S/,2\N
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M.;0&90@#4#&)O)3:68"<.?1U85F8[4?U]:=:\5J%4,0=H4Y2P[3V5#L%0NC
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MZGF'I[G-IF^_7-A%&*\/3&,C8D3[[U^>,[(GA@Y#]07\OMC\/?S=W0P1#91
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M5[ZZ3N%&GK?%S-<:\S8-3>F _[GY6203T;JQW]SZJ=AN9U90;6#YE(C5C"*
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MVI;OJ8I@>X.>3S^[<=5>W-3557&[WFW?S+^6#9>%1U=7F]N0DIUFI3.,N;<
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M2Z>]+)DV=L4T-#.%8:V72".YZZB8?KF>KZ\>7Z-EVA)%*;.*8P0D0L0=%P4
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MD?UR@:I4EZC>(^2BB+1F;RI2TMZ A_>B=N,B9H6DS&A^"2:&'T\'N-:+1S8
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M"TF3]&Q<,!K4J4FB4%].N!!_!O?S-"+/\&87(X^O0:.-NB[G;C-+ -?:>8Z
M] &=EL8>M$A+J=F H>: 2 ##J G<**$#/4(SB<K#* IH 0F->LJ]:YS9GB3I
MA^4ZVY8PMT\?,!W33X/$C 0N&B5@O,CVEGQ3L6(/.5V@B'3N=Q$E8FWN-T2T
M8KSQXMGRX[IZ=F^].RW4O2E6RZL L5QPK=9;9PY8HX%TY7-=&#HKF1=26BZ]
M<,Z0N",]S9I$GA%D0$A^':>,&2$%8PP8RJ$#U"<_T7-">;X(7>.,7*WJB>6&
MJU##$QRYNG29VQ%7^IM1=VD9J%_NIR&??1MU?]DF!6?QNP?W=;?<O[A2ZX4M
MI3M?5&M")S1*<\\4-$&#(9'8A7FZETQ"H"C'$+3>)HA#(3446F,#O-)AMJ E
M<0!2K%#HWP[$C>%6^P$5O*HL\P"P_P7^GOT2NY(_GD/:+]D_ELL^]-1^03X;
M3VS;<=QH$3Z-UR8BQZFM?')9/26K306[O"ORD<I;9L-0Y\9@P\+45WOB&-R/
M>VD=!Z;AN'_BVS5SSDNB7!EOPD\"4E:NRF*D0NZM3;IA7=V;.H'J]L>)N3 6
M.S(YC:'6U8BBU]X5-U!^*M8?W^6;Z[+1TZ $5A/D@7;4<D641-RQ>IQ83V#,
M3.[Q%C3Q #MC/)"$*HK##(8P$<:_@P #D?IL3PGJ98FJNG(X+NEH25DS:4G/
M5IRR5$3M:J)&G'0]2LP%9>E&Y#2$I:,-19]=J^7YYI.0G9H,";8GA'!%%<=&
MA"%CY"'[-H+'K1-=;(A:AX0.TS[O 27.*TL,AB$%T%X!CU.+S/F9W9:'FEO1
MUTQI!F,N3G!.I-U):$;3G4LT79"?7MB=A@KU8\I31Z*[\]-4DQ[4[YQ&E%?&
M"(.88HAI!(US4@DMD14 ,Q153?YT*\XP[81BECA+,0,RY&_$.>I5D%I@4M_
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MI5":DY:;#_97K=-DYDO5H P.H$^7%Z1$%8HF<+S2$^]"A-XD\I&7O]I&91I
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M9<AA9J4%#<XPA3VC*CC)0C3@0DY^^ "=Y,:(TBRL@]D][OD<CS1::.TQ89@
M$=)(L'%"2!2T4#3DY,7!\,C8OZW<N<@&3_3M48PN3^\\.^SA L=>&*ZXM^ T
MB4J$T90K0'6 : !?EJ77)0F;/K&3*;ISFPY?1M4D*9PPF_\]MMUW0*:MKRRH
M#9X+SR1A 8SA.C!%XFI-HG,85U9T69;M!4R.3 F>S1P9W-%/8S$QG$F:TNTM
MLPIS097!V"-.J,V9*0,T[<]YIC0FQ)/]S(=C8SN&\.';LY-EJR&\*><ILC*Z
M*6<?'[J]#N6O,[-WN:<M?F41/7(<C ^<,P)>,P-$<2&9Q2Y0QW.\VB$&W;NG
M_L DV-F&[V3%E=C7%R'W7]./^XZ^UGM! 8K1N#:"0%Y L$('@:@C&+@D2%![
M88YP?ZJ[%7ETGBE=SK]4FVS'9T/X;3;]4B[B"%>(+58%[Q__/IT:_FVV_+_E
M\FTYGMU,[V?B.N2Y+^+3R?<78(D27(!RE@"DM#Q*G6*"!HJP"CF):/S'7!BX
M.,]^*JVO\XB^S^:C]!SN8TZ]V)$B*C&-K.'$$@X:0 D3@L),4<R-H3E91N+'
MY#H7N0[>Q]XH#_\U&H[5HER\FJZ'O4+HU70YKZ:+:OS?H\G=WKHC'7Q]04S$
M&J>3IU: #\H$[CUQUG@?)/"<;7KY8T8-6YJ=SJ-]CI?9X7AMAO[?*R6S'7<8
M5?/5:/>M2VU]91%DX, T)U'@0)DWJ;J5$(AH,$F!9<P7]6.^#$^"@U]KM@E#
MZ7+.U=[KU?)3.7__:33= +&*8M]KC3;6FR.[4'#D(BL,C>L\!6J"%!8DYY)3
M;)E7.>$"C'Y,HN&+]-(FU3_+ZN93LH._E//13;GZI1LMRWNM,X!9=["/!3;8
MZ\@O)50T'A"3%"DC)2)(.^E0UK3\L9%_"3(__WG[U"KH95H^[4*A- L2&Q4$
M1N"DT)9ZS:,4HMXDCF3E2?_($#@#D9Y]S/#A3>M&WZ/32TC^0)\*9J/)8A62
MW#)@AF@)5*9,1(^ >ZIRIMV/=(-SE/&E+6XK#/NU0/=UJ(#H<;OH+T0'04
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M+2I.X]AM1*4E0"5(RR6Q7#$E>?QG3AKI$*/"O:_.IR+?*7N.NK6%"6P#BRL
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M8D7:OTCS:MW;;2[(WICXRTT*!-Y[2!HX*&6U=Y3>JV(")*?.VP!-Y_:(U!#
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MM5#['05(@8F(P@]< G-6:<%4NM7>(HETG_E0!\=PW+V9I[PN3@Q!B#)>:2V
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M,"YX;6Q02P$"% ,4    " #[96-+LOG]^8<*  "59   $0
M@ ']G   ;FQN:RTR,#$W,#DS,"YX<V102P$"% ,4    " #[96-+C^/"*HP1
M  !QJ@  %0              @ &SIP  ;FQN:RTR,#$W,#DS,%]C86PN>&UL
M4$L! A0#%     @ ^V5C2R4)@G>3,   G%H" !4              ( !<KD
M &YL;FLM,C Q-S Y,S!?9&5F+GAM;%!+ 0(4 Q0    ( /ME8TOGB!GUSX8
M  *,!@ 5              "  3CJ  !N;&YK+3(P,3<P.3,P7VQA8BYX;6Q0
M2P$"% ,4    " #[96-+I- "]I=.  !&[P, %0              @ $Z<0$
K;FQN:RTR,#$W,#DS,%]P<F4N>&UL4$L%!@     &  8 B@$   3  0    $!

end
</TEXT>
</DOCUMENT>
</SEC-DOCUMENT>
